<SEC-DOCUMENT>0001729149-21-000137.txt : 20211102
<SEC-HEADER>0001729149-21-000137.hdr.sgml : 20211102
<ACCEPTANCE-DATETIME>20211101174405
ACCESSION NUMBER:		0001729149-21-000137
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		70
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211102
DATE AS OF CHANGE:		20211101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VIEMED HEALTHCARE, INC.
		CENTRAL INDEX KEY:			0001729149
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38973
		FILM NUMBER:		211368540

	BUSINESS ADDRESS:	
		STREET 1:		625 E. KALISTE SALOOM RD.
		CITY:			LAFAYETTE
		STATE:			LA
		ZIP:			70508
		BUSINESS PHONE:		337.504.3802

	MAIL ADDRESS:	
		STREET 1:		625 E. KALISTE SALOOM RD.
		CITY:			LAFAYETTE
		STATE:			LA
		ZIP:			70508
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vmd-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:fbb1b016-a19a-460d-bfda-ed9a0f837dc5,g:50e705b0-d493-4f83-95b4-caa6929c52c8,d:c737a9539ea24a1d98f7fd15a12e7af7--><html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:vmd="http://www.viemed.com/20210930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vmd-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180L2ZyYWc6YjQ5ODc5OGM2NThjNDBmODkzYmQ4MTE1OWIxNDYzMDUvdGFibGU6NGYzYmE1NTEyOTE2NDUzNzg0NzEwOTJjOTg2YjA3YmEvdGFibGVyYW5nZTo0ZjNiYTU1MTI5MTY0NTM3ODQ3MTA5MmM5ODZiMDdiYV8wLTEtMS0xLTE_1dfaf4ae-1a3f-498f-b1ad-f38a602f53a7">0001729149</ix:nonNumeric><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180L2ZyYWc6YjQ5ODc5OGM2NThjNDBmODkzYmQ4MTE1OWIxNDYzMDUvdGFibGU6NGYzYmE1NTEyOTE2NDUzNzg0NzEwOTJjOTg2YjA3YmEvdGFibGVyYW5nZTo0ZjNiYTU1MTI5MTY0NTM3ODQ3MTA5MmM5ODZiMDdiYV8xLTEtMS0xLTE_632b1c4b-087d-44e5-b2f5-d933b020dfb1">false</ix:nonNumeric><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180L2ZyYWc6YjQ5ODc5OGM2NThjNDBmODkzYmQ4MTE1OWIxNDYzMDUvdGFibGU6NGYzYmE1NTEyOTE2NDUzNzg0NzEwOTJjOTg2YjA3YmEvdGFibGVyYW5nZTo0ZjNiYTU1MTI5MTY0NTM3ODQ3MTA5MmM5ODZiMDdiYV8yLTEtMS0xLTE_ae929808-274a-4995-b116-8bb30400a0db">2021</ix:nonNumeric><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180L2ZyYWc6YjQ5ODc5OGM2NThjNDBmODkzYmQ4MTE1OWIxNDYzMDUvdGFibGU6NGYzYmE1NTEyOTE2NDUzNzg0NzEwOTJjOTg2YjA3YmEvdGFibGVyYW5nZTo0ZjNiYTU1MTI5MTY0NTM3ODQ3MTA5MmM5ODZiMDdiYV8zLTEtMS0xLTE_f3094da3-b736-4cf5-b5b1-65393a7b3bfa">Q3</ix:nonNumeric><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180L2ZyYWc6YjQ5ODc5OGM2NThjNDBmODkzYmQ4MTE1OWIxNDYzMDUvdGV4dHJlZ2lvbjpiNDk4Nzk4YzY1OGM0MGY4OTNiZDgxMTU5YjE0NjMwNV80NA_a81ac938-390b-49b6-b824-cdc4f0f63d5b">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i1afcee0f652943f8aad16dfbf102e536_D20210101-20210930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDIzNw_3068a39c-9f5a-4e15-9fea-67728d70b3a5">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i1afcee0f652943f8aad16dfbf102e536_D20210101-20210930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDM5ODA0NjUxODUwNg_2c114217-6a38-4569-b2f7-e925d2af2d45">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vmd-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie2c55bda39934f47aafd15467ea6d0a5_I20211023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if18d5f0f70ef493491936ce24033c80d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i976c03ac317a4dad950efc53136ca1d4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5d328191fd14b4b8c8177ad7a45c411_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78f4f7423ba64e63859d8515c428592c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ea5e57cd6a84244aa82b953943efc99_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a1ac0a3f55549f782851621e90eaa7c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90d795f6913c410caf28a7874f377029_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae414ee27046452e85105a8bd614cf93_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46db418aa76540aca2336dc096a0f9ed_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icde10966330448159a62ea1562b7a40c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf2dfa8d264844e19a4b600fd9dd036a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46dde1ac351f45b3905daa2f81146e8f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51b7b504524e4d5abf1313a033b40975_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6710f81bfc0f404287d6aa6655470fdb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e6a845ad54e4c62815896f2932bbbd3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic98b72a5b163495eb502663ae5631ff3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5be2a171f9354e10b04c4107daa2107f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0917a6724e5d4d2d84ae957241dc31d2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6486b80960f04e1daccfe12d493f4edd_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69698187989a40bc91ce9b1b21ee1349_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02af3a5a2bdd4b6786b29f8291d27eaa_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c5bb821fbb4572a29dd47fbc926156_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dcf0bfe379141e99b6c299ca2382485_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b6e39b815a0481b81048a6daf6dbe38_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32a8db59831844cf84a2c1297bb57c33_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i041aeccc8fca4dcbbfff6f4937474eaf_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9919bd0cd9a414385929c20caf931e1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b284b8a81064ddb96d6d70d6e5a89c1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc0e465557324a2ea8388615a3a390a7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4112591d4ceb45bb9e69695b1b461a72_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic33d050b9e874098924fdcfa31a8dad5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46d77374c8874d41b3947cf0b29e4b5e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i169b12543b7a4693955a72d78e570320_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a8950ebaa6d4023b4633983016fd884_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e735857f255494fa3f0fdeb61129073_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbd4539b888445aaa4a9f2e282cd287f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i697f499345304f75ba0a1a2f279da745_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d31ca92c88e48a9abe359674915ac36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9624c2e32e014ac3bacfe359b066e658_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia74bb5981805471fbf83349d5b020f16_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f43ebadddca443ab125057332efd25d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a781f027e5f4955901d37f1b4f38ded_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i464b82b483584d00a1b94e3674ba102f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib19f6e172d9b49cd9b5d8614f40a0e58_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id993d57472914822885303d1805d867f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a63aa35131e40bda35f8dedfa80bb16_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78c9f6db5b0d482a98e9ca413932fb50_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25c503eebf774a2abe26edc4ed510527_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i127e3aaec83d4f6d8f742e5114d5812c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e4a3b13e1894054b380ed7b2593deb5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c396414383b4e01919749fb5c6c1282_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68dbfdbb23794c9aa57688ded08012b4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b3e804780104f2c92291a6aab542159_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5b2ecbbe220415f99fcae20e610a16d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id00c330d28624a34b3fb015d48c87224_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i820eda4de0134410bc7323aa4f2359aa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a46a17ce83245f7bb8b1baf56327400_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd7126df3044d39a084ec7916656b51_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d2719e7ac624519adafa787168afc4c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfad155c822f4964b47061c31968d980_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8237e783d5184295a58fc1aa28006024_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7426e08cc52b45f197ca6891d552801b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24e84fd5360f4fd385f42eb20ba331d9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02d706f98718409cb5564654fd53deb2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac9ff3e2056a4a5f880103fc4356cd36_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f84494dae4e4eb7bb67d17f473a7c64_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e1a9a3cfd8e4e82bc8295ec950c8daa_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b274e0f2d945cebc379d707e4f5ea8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>vmd:state</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i9789ed0b93954ee49baa21647f388ef5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa9d483dc10645cbb1e0794af9dc1645_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeed513b2882441a875dcc01fbc0a501_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareAndMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ea450f7c474538bd7b5840ef6102d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareAndMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b429d6cb7cb45b3baf15962a80dda61_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32b248a3bb174a64841828130e70a17c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c40bc410d694b588140148c1dc03c0a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b7bf3629d3d438d8cc6edf60ac48177_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94f0a3d2683f4ff392518340e25d81aa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eca90250ea9417384566f7ebacc116b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46dcf7ac81934f2a98f642840bdfd97c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a4b30e32e7340a3b4b7cd8a1e99e3ae_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd7133079e94b92a73f8571b7906435_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareAndMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fdb1766786c4f3480910ae7b537fb05_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareAndMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76805b82fef445c8b00c89dac2de57b5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareAndMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i533015666e4b410e9c4fd427bd190a87_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareAndMedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd917d51157d466ba06d77882124fe90_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:VentilatorRentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21c590c6cb2c4aabab1faeddb85de476_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:VentilatorRentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i435b1dfb19324a3a80b71d9ec9b03097_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:VentilatorRentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b0c9015e90944a9a17d402213f296fc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:VentilatorRentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f1ecb80965642fbadc7233c55e2e25e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:OtherDurableMedicalEquipmentRentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7301bcb71cfa44948e8127d480f5130c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:OtherDurableMedicalEquipmentRentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63e996f926c5450fa282162205bc1bea_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:OtherDurableMedicalEquipmentRentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc18131a88214a2a81b395db3505d107_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:OtherDurableMedicalEquipmentRentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e78c9cea09846458e3dc27631212986_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:EquipmentSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc6492490bc4b1490392b2ed8be8db2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:EquipmentSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc9421ac4a184e8d91a81e460d2113cc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:EquipmentSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff19a29d6c2c4522a4f392e635400390_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:EquipmentSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8727827e5c84f4fa96f89fff0b8273c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:COVID19ResponseSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768c9291994346aab84e8a3706141a9e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:COVID19ResponseSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecce218d389d406eb3310f56da83c06e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:COVID19ResponseSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36805497dabe4b1ca576fc7081dd4b66_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:COVID19ResponseSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac0999e7702345499410c35dc62978eb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a4c357dacb453faeda00f5a03c85fd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69397aa140894aa59c5c17529168578a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f25b5934b1c4af683335208edd0f7bf_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i156a988ddacc42c782d87dff13bbeafa_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vmd:EquipmentMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ff889a5f20c48f0b14d11a61f24192a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vmd:EquipmentMedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fa701e0a3e54a9b9dd36ecc85c2307d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vmd:FurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79d9b33a1c5b4522a3fc544ec67f806d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vmd:FurnitureAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6b0c208bb684b35bbbd15d7eca58b2b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied68468793ac4161b8131a57412fe183_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff704998475b4b84afa049d983871456_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08badebcad9a46b2b8e8bfe2be733945_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53f44e1e3cce49638ad0ef4800be09eb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19004823fe6d4d70b445becfaf7cf907_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71dae52fc95540f0af34167cf33d9206_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90c97c3db0d745e2802b30d356846aa8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if94ef301d7e04a16834b80d74e605bda_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vmd:AssetsHeldUnderFinanceLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ad38a4d9ca54a5080a263d8110efa86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vmd:AssetsHeldUnderFinanceLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87fcc673b3034eaa9412181d84c0c71e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2c1e065140c48f584cc31eda13a9cc8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81a15ff7f25b45068f37929013eedd30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62a32ca8e15648e9b1241a1aae489574_I20190530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vmd:BuildingTermNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e7304b41d654a3d881976535714777c_D20190530-20190530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vmd:BuildingTermNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-30</xbrli:startDate><xbrli:endDate>2019-05-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0c674c148fc429ca571bcce37d330e5_I20190530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vmd:BuildingTermNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95649eeb9b3f4027bc486bde62cc4ae2_I20190919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vmd:TermNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3c6f22c80984ffcb2872cd478bf4368_D20191019-20191019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vmd:TermNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-19</xbrli:startDate><xbrli:endDate>2019-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie603f4248e314cdf811e9ec8560c574f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ee66bd47ddd42ec90cd24f18d4e553f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5485b5cf5d2b4b92a5935928e69064c0_I20150801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vmd:MonthlyRentalPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa3aec0aba44dc4bdc7a429c06c397f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vmd:MonthlyRentalPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic289ae73a55a46dfbf14b45d633afa0f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vmd:MonthlyRentalPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3279b51ac3584bafbc99103f6f86c88e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vmd:MonthlyRentalPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib14997b1010a40869c680e8e635ea4cd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vmd:MonthlyRentalPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8abf6fe7c8484bdcb2308cea38f75932_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b195c7493e8424bb8fd5536067a85e2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idea4ca441e78494680787bbcd4931142_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dbc8fd191ad4330a8f453ba42571847_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic76538552bd94126a41545b7ed1db49a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09ac0c6a09264cc5954537a0acda8d17_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94711e3a71c045bba46f486d3bd974f0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i336da365772c4ac388b46c52653f0063_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb901eb8035149c1915fc1b2307e3203_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ca70504217e48bf8c74635b2513864a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51c8148032c74773b49b36310c78a073_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8854bc148dc4d52b425355b31c2508a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1090d32a5c2b4309b916e12b4c123edc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ef9ec490070462eb08089125148bc55_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbca660f93914f07ace63ccfd0a4e058_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i266900fa2c164d91a01dddf36477fe2e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcb6a65153dd4f75bba69cc5b394f676_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00967b47876c44cd9989e4b0f712f2bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3bfc5ae6e62482f9bed49fbcbfabbbe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6da69231063840b48f20fac3ea629cd6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b09cd700c71469e82f19274c7204713_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eb813583e1d404cb010b4516417789f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb8b9626315448338619b019df225197_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec098e30f68048118c3feaeee0ec6ada_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="interestrateswap"><xbrli:measure>vmd:interestRateSwap</xbrli:measure></xbrli:unit><xbrli:context id="i93444cef350340c49a0041603bff9d22_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="classofstock"><xbrli:measure>vmd:classOfStock</xbrli:measure></xbrli:unit><xbrli:context id="ib6898be82ef3450d8af8019abc1d1fb6_I20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vmd:OmnibusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8114bd65eb746a5b3aaeaae80a4533d_D20200611-20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vmd:OmnibusPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d0af2de6c674c96b220f46c78c9e9ba_I20200611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vmd:OmnibusPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2dbd335dfd64d78885f580dba8cb8ba_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0187ebcaed44679c75f56be10857e9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1310db462e54e89b2b94af7bdd21af5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i795dccfd9203404ba393cb88b8244587_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3036198797724f58bf6c7bf4265403b6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dedb3f8a3514cc5a585e7453a724c8d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe99e45d98d34bfe97e7b979e75c259b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92da22dc12174d0da0397780472a1fbc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7697ee5e2a4842a0b54ef6b98b72541f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68e96bd771d5468da80ad750d5f5c11f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88bbd8e84fbf41e09eac6d65db435276_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia17494c399214eda9df7f117f9437b96_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd0c2762d894ddb8c72a023745c0b80_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad5f0e1d7d4d457f82377ac5c1601912_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1afcee0f652943f8aad16dfbf102e536_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2873c72b9da49babb2eb0a4aa374ba8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecdcfc455bed4a3ab837da5d7d3c93e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefa3109898274438af4768a1e85e1bab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44ffc467ff8a4229b2d74de1d78d1680_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a314a6d360248d9a6c6a44fcd3abb90_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5753dc4d89ed4578addb8f58e199c604_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4044ca35c71f4191b7fb20e6bf8ad931_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94ccb4b7c871492288b371e698ff505e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7eabec862824cb8beb06ebf1b6d9770_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6b1cbcf841f4955b15df2767b15477a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i118bddcb0f0f4367a8aef1f25a41b550_D20201228-20201228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-28</xbrli:startDate><xbrli:endDate>2020-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a5ccd697db64231a87cd517cfa2cfba_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001729149</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_1"></div><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:22.50pt 9.00pt 0.00pt 9.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQ1_dcf68893-4e4d-4ce7-9b95-405dd7629fa9">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:511.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OTM1ZDVkZWQxNmYxNDQ5Y2I3MDk3NzUzYTNhOTEyNDAvdGFibGVyYW5nZTo5MzVkNWRlZDE2ZjE0NDljYjcwOTc3NTNhM2E5MTI0MF8wLTAtMS0xLTE_1f58c8e1-c919-4d0b-9fcb-61b2507ec201">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xMjA_6343cee6-6744-4365-a8f5-f321eb30bbde">September 30, 2021</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:511.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6ZjdiYTVmODQxMmFiNGE3MGI3ZWMzZThlYjkzOGRjOWYvdGFibGVyYW5nZTpmN2JhNWY4NDEyYWI0YTcwYjdlYzNlOGViOTM4ZGM5Zl8wLTAtMS0xLTE_12846a22-4353-462c-b50d-7010bc5cfd6d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from _____ to _____</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission file number: <ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQ2_4491c9d1-7589-4a56-a929-b65482905ae9">001-38973</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQy_a1de1cec-ca64-4999-bc65-bd61ce9ac400">Viemed Healthcare, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">British Columbia, <ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF8wLTAtMS0xLTEvdGV4dHJlZ2lvbjozNjY2NTM1N2M1NTg0OGEwOGRlOTkzYjZmYmRiNDJkZV8yMg_f0a44d46-46c6-4f96-aabe-8787f4b71128">Canada</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification Number)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF8zLTEtMS0xLTEvdGV4dHJlZ2lvbjphYzY2NGY5OTI0ZmE0NzczYmEyZTg2YzE5MGZkZDhlYl80_95fb36ef-8606-4580-84be-e939ffcaed21">625 E. Kaliste Saloom Rd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF8zLTEtMS0xLTEvdGV4dHJlZ2lvbjphYzY2NGY5OTI0ZmE0NzczYmEyZTg2YzE5MGZkZDhlYl83_8b617f15-0512-4206-8eeb-5920ef15161f">Lafayette</ix:nonNumeric>, <ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF8zLTEtMS0xLTEvdGV4dHJlZ2lvbjphYzY2NGY5OTI0ZmE0NzczYmEyZTg2YzE5MGZkZDhlYl8xMQ_f52e00c2-27a6-4de3-9b34-797d1fd8dac6">LA</ix:nonNumeric> <ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF8zLTEtMS0xLTEvdGV4dHJlZ2lvbjphYzY2NGY5OTI0ZmE0NzczYmEyZTg2YzE5MGZkZDhlYl8xNA_dd276a6f-2e67-4cbf-af86-04ec2091924f">70508</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF82LTEtMS0xLTEvdGV4dHJlZ2lvbjphYTYzZDMwNTA0ODg0MjZkODUxMGQwYjQwMTI2YWFiNF81_bc49388c-196a-49ab-b352-2f8c3fe5784d">337</ix:nonNumeric>) <ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF82LTEtMS0xLTEvdGV4dHJlZ2lvbjphYTYzZDMwNTA0ODg0MjZkODUxMGQwYjQwMTI2YWFiNF85_2b9dd0d1-ee8c-4d56-a6a4-4e64e8f15a7e">504-3802</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6NTg2ZDUzZGRmOGZlNGY5Zjg1MTk1OWFjZDUxZjcwOWMvdGFibGVyYW5nZTo1ODZkNTNkZGY4ZmU0ZjlmODUxOTU5YWNkNTFmNzA5Y18yLTAtMS0xLTE_13fc080f-8892-49d7-bdfd-ed15b247c382">Common Shares, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6NTg2ZDUzZGRmOGZlNGY5Zjg1MTk1OWFjZDUxZjcwOWMvdGFibGVyYW5nZTo1ODZkNTNkZGY4ZmU0ZjlmODUxOTU5YWNkNTFmNzA5Y18yLTEtMS0xLTE_41c8c6a0-8f4e-4975-8e69-40499b739f0b">VMD</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6NTg2ZDUzZGRmOGZlNGY5Zjg1MTk1OWFjZDUxZjcwOWMvdGFibGVyYW5nZTo1ODZkNTNkZGY4ZmU0ZjlmODUxOTU5YWNkNTFmNzA5Y18yLTItMS0xLTE_677f9634-dc9b-4a82-b0aa-48a757fa9d89">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQ3_31d20fee-ec70-4ee8-a6b1-e6ed31059d8d">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#9744;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQ4_e9a591aa-1893-4cef-8f2f-caf3c0433556">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#9744;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> &#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6NzAyZGQ1NTNlYzdjNDE3MGFhNWZkZTU3NTNiZmQ1MzIvdGFibGVyYW5nZTo3MDJkZDU1M2VjN2M0MTcwYWE1ZmRlNTc1M2JmZDUzMl8wLTQtMS0xLTEvdGV4dHJlZ2lvbjpjMzA5ZTQ1YTA0MWE0MzdjYmViNGMwMTY4N2ExMTA0ZV80_c4a7ec0b-ee2d-47a2-a032-2c8db235831d">Non-Accelerated filer</ix:nonNumeric> &#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6NzAyZGQ1NTNlYzdjNDE3MGFhNWZkZTU3NTNiZmQ1MzIvdGFibGVyYW5nZTo3MDJkZDU1M2VjN2M0MTcwYWE1ZmRlNTc1M2JmZDUzMl8wLTYtMS0xLTEvdGV4dHJlZ2lvbjoxZTdmZjk0NjFiYTM0Nzc0ODI5NWM1MDEzOGQ3M2MxOF8zMQ_16b8b117-8c0b-49b0-835a-90193e45a85c">&#9746;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6NzAyZGQ1NTNlYzdjNDE3MGFhNWZkZTU3NTNiZmQ1MzIvdGFibGVyYW5nZTo3MDJkZDU1M2VjN2M0MTcwYWE1ZmRlNTc1M2JmZDUzMl8wLTYtMS0xLTEvdGV4dHJlZ2lvbjoxZTdmZjk0NjFiYTM0Nzc0ODI5NWM1MDEzOGQ3M2MxOF81OA_d9fe3133-ba3c-4f26-afc4-4fd9b250c5a4">&#9746;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQz_1fdfa471-33b8-4008-9904-1c69786971d6"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQz_fb2c1217-4cb4-4eb1-8d51-c0e331666074">&#9744;</ix:nonNumeric></ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQ0_dea7bcf3-afda-4111-8766-e8cf874c224c"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQ0_eefcf185-c3ee-429f-b3c5-36e827999efc">&#9744;</ix:nonNumeric></ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;23, 2021, there were <ix:nonFraction unitRef="shares" contextRef="ie2c55bda39934f47aafd15467ea6d0a5_I20211023" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xNzk2_3b7519f4-6fd2-456a-ad7d-d0f638ebd189">39,630,446</ix:nonFraction> common shares of the registrant outstanding.</span></div></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></div></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></td></tr></table></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_16">PART I - FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_16">3</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_16">Item 1. Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_16">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_16">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_19">Condensed Consolidated Statements of Income and Comprehensive Income</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_19">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_22">Condensed Consolidated Statements of Changes in Shareholders' Equity</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_25">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_28">Notes to the Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_28">8</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_82">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_82">24</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_85">Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_85">24</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_88">General Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_88">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_91">Overview</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_91">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_94">Trends Affecting Our Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_94">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_97">Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_97">28</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_100">Non-GAAP Financial Measures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_100">32</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_103">Liquidity and Capital Resources</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_103">34</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_106">Accounting and Disclosure Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_106">36</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_109">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_109">39</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_112">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_112">39</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_115">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_115">40</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_118">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_118">40</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_121">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_121">40</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_124">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_124">41</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_127">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_127">42</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_130">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_130">42</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_133">Item 5. Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_133">42</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_136">Item 6. Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic737a9539ea24a1d98f7fd15a12e7af7_136">42</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_16"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:328.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:79.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:79.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:29pt"><td colspan="18" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div></td></tr><tr style="height:15pt"><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Expressed in thousands of U.S. Dollars, except outstanding shares)</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At<br/>September 30, 2021</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">At<br/>December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(Audited)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNi0zLTEtMS0x_1a47e05e-3270-4695-9f1c-059e552214f1">26,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNi01LTEtMS0x_1ec456d7-3ea0-4534-aa96-e0e52b1c0767">30,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNy0wLTEtMS0xL3RleHRyZWdpb246ODYwNTI2YjVjY2ZhNDRmZGJiMjAxMjk1OTRlODRiNDJfNjc_e2733c57-8397-47f7-a02d-e8d8617dc28c">7,115</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNy0wLTEtMS0xL3RleHRyZWdpb246ODYwNTI2YjVjY2ZhNDRmZGJiMjAxMjk1OTRlODRiNDJfNzQ_819b7b99-ca64-41c0-b62a-85000cb05e9d">9,013</ix:nonFraction> at September 30, 2021 and December 31, 2020, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNy0zLTEtMS0x_0115ed63-1871-4c57-98e2-8f95d149fe70">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNy01LTEtMS0x_b1c42d22-fb81-4698-9a73-2275c6aa89c7">12,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory, net of inventory reserve of $<ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOC0wLTEtMS0xL3RleHRyZWdpb246ZjY1ZTViMGNjYWM5NDBlOGE4MjBlNTg0NDY0N2JhYzhfNDM_d6462bed-0c65-4998-b0d8-a38af655efa4">1,237</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOC0wLTEtMS0xL3RleHRyZWdpb246ZjY1ZTViMGNjYWM5NDBlOGE4MjBlNTg0NDY0N2JhYzhfNTA_eacd2fe7-7768-4b3a-b91f-813a6b629614">1,353</ix:nonFraction> at September 30, 2021 and December 31, 2020, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOC0zLTEtMS0x_0416796f-67bd-4783-848f-b0c063a6369a">2,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOC01LTEtMS0x_053fb3c0-5498-4c95-be03-7ac1131fc830">2,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOS0zLTEtMS0yMTQzNQ_0f9960e1-304d-4204-8d32-1612e38efcec">1,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOS01LTEtMS0yMTQzNQ_bef32be6-a8b0-42d4-9453-a292f57497e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOS0zLTEtMS0x_e8b640b0-0d85-48c4-aeda-b2117a68d083">3,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOS01LTEtMS0x_5d7243d9-ede1-4002-9760-6a49236ae88f">1,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTAtMy0xLTEtMQ_3e502aab-6666-4dea-a504-91cabbfde867">47,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTAtNS0xLTEtMQ_fccedfe7-51c5-4a76-b171-e64ef922d9fd">47,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTItMy0xLTEtMQ_9d554f69-ef8f-47fd-92d1-ad193c32ffea">59,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTItNS0xLTEtMQ_306b42a9-be62-4682-ac49-9f5a35427c2b">55,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTMtMy0xLTEtMQ_50f9fed5-691c-4c51-a876-9250bd6de2d9">1,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTMtNS0xLTEtMQ_79c2a770-99b4-4686-8e83-8e6a841cc241">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTQtMy0xLTEtMQ_32e4e4ae-87e8-493a-b832-55adcfda0d80">6,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTQtNS0xLTEtMQ_aa4bf731-a1a0-41a4-bf84-efbb728a3d07">8,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTUtMy0xLTEtMQ_2e683939-f4c8-472b-afad-8a5189018f86">861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTUtNS0xLTEtMQ_ec7523b5-c903-4aa1-9c59-2ca6767e961c">863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTYtMy0xLTEtMQ_7a42f96d-cf78-40a7-86ff-29bbe70d95ab">68,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTYtNS0xLTEtMQ_5679047e-3bef-402f-8f40-91990f6dbdc7">65,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTgtMy0xLTEtMQ_fc853db5-4b30-4831-a527-75f1a080e89c">115,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTgtNS0xLTEtMQ_3a69a10a-e5d1-4e33-9ce7-5c301496e362">112,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjItMy0xLTEtMQ_89531f58-99a2-4c26-9a03-914964e01cec">4,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjItNS0xLTEtMQ_b2add5bc-e34e-4a55-8fda-728fb3e572e8">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjMtMy0xLTEtMQ_09c6aef4-8f1b-40a7-864d-83597f1982bc">3,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjMtNS0xLTEtMQ_ffee5380-7b5d-4bf7-ba11-22f749089d32">3,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjQtMy0xLTEtMQ_4578f382-3faa-4579-b3da-3aabde850c0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjQtNS0xLTEtMQ_7cac1b16-0482-419f-8a56-a85ff15feb97">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjUtMy0xLTEtMQ_d1bd3775-145e-4ae6-b836-f9c764343561">9,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjUtNS0xLTEtMQ_9917223e-e790-4553-b707-ee9f285120f9">12,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" name="vmd:LeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjYtMy0xLTEtMQ_259e1ded-a4b9-4d4e-a5ad-78110c8a692c">481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="vmd:LeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjYtNS0xLTEtMQ_cecd2b03-8238-4bb7-8772-6e08730af739">2,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjctMy0xLTEtMQ_ba1d4caf-85fc-4480-b627-3a766d1051a3">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjctNS0xLTEtMQ_e9e741aa-143f-4446-a706-b8f9ee00f018">1,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjktMy0xLTEtMQ_5cf74c34-0061-47ec-8d4e-0609f4b2063b">20,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjktNS0xLTEtMQ_b188b700-dcbb-4d93-b32a-be4703b69368">23,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzEtMy0xLTEtMQ_11bb6441-956a-4025-8bae-6954ab3c36f5">730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzEtNS0xLTEtMQ_82f1e637-0bf5-4636-9a31-637f65306f7b">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" name="vmd:LeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzItMy0xLTEtMQ_36a4d51a-e173-497d-ab5c-201e89c7cf36">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" name="vmd:LeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzItNS0xLTEtMQ_de3332e0-7245-4867-8555-da0038564a90">762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzMtMy0xLTEtMQ_648b76d0-96b8-4ac9-94cd-d7e97ee12a1c">4,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzMtNS0xLTEtMQ_8addc88f-d2f4-4e99-a172-1c5f026877da">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzQtMy0xLTEtMQ_ae2def11-3f0f-4e16-ac0d-0a8ad99e3f2c">5,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzQtNS0xLTEtMQ_7c394369-cbb6-4387-8945-5b64576fd02d">7,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL LIABILITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzUtMy0xLTEtMQ_c2ae8615-6929-4c4a-9cf0-e4f8b63c8f13">26,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzUtNS0xLTEtMQ_717dcd1d-c045-461a-a7ce-907e7945af66">30,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitments and Contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzctMy0xLTEtMQ_d0ab40b1-13e8-43e9-85e7-0425a06757c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzctNS0xLTEtMQ_d3368304-cd09-4837-9651-fe2fb3dadce5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock - No par value: unlimited authorized; <ix:nonFraction unitRef="shares" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDAtMC0xLTEtMS90ZXh0cmVnaW9uOjZjZTE0ZTc2ZjAwOTRkZmE4ZTllOWVkNGI5MDI4NDBhXzU1_23bd00c6-532a-4728-b7dd-b49095ce310d"><ix:nonFraction unitRef="shares" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDAtMC0xLTEtMS90ZXh0cmVnaW9uOjZjZTE0ZTc2ZjAwOTRkZmE4ZTllOWVkNGI5MDI4NDBhXzU1_3c096ff8-cc3c-49af-a79e-edeb198deadf">39,630,446</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDAtMC0xLTEtMS90ZXh0cmVnaW9uOjZjZTE0ZTc2ZjAwOTRkZmE4ZTllOWVkNGI5MDI4NDBhXzYy_36b2ae3f-9a71-4760-ad27-ed0a2c420cb7"><ix:nonFraction unitRef="shares" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDAtMC0xLTEtMS90ZXh0cmVnaW9uOjZjZTE0ZTc2ZjAwOTRkZmE4ZTllOWVkNGI5MDI4NDBhXzYy_82bb926e-a6b0-488a-a48c-cfebf2da752f">39,185,182</ix:nonFraction></ix:nonFraction> issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDAtMy0xLTEtMQ_a3582f47-7d50-4de3-9416-f3fbaa60b8b8">13,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDAtNS0xLTEtMQ_ef02065a-69e5-479f-aa49-b93bbf87f451">9,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDEtMy0xLTEtMQ_94c842cc-14b1-41ec-9d70-d95c65867073">6,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDEtNS0xLTEtMQ_3af540ad-b45e-4347-9117-9cbf5297bba3">7,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDItMy0xLTEtMQ_e44ec6a9-f32e-4284-b6a4-a1456ab9dea3">330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDItNS0xLTEtMQ_abb0fa8a-a878-463b-8ee8-97c3b8c4849a">451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDMtMy0xLTEtMQ_f64c2845-7d85-4b5d-8a80-85d6076ae623">69,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDMtNS0xLTEtMQ_c75ab8ea-743d-434a-89be-d0dc4948a0eb">65,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDQtMy0xLTEtMQ_6aef7aa2-7748-4017-86dd-deb83b8aad52">89,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDQtNS0xLTEtMQ_1cd4bb8f-5dca-4657-a361-e0e1b4b201a8">81,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDYtMy0xLTEtMQ_ae10011d-3abc-4931-8b21-6d56d04323ef">115,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDYtNS0xLTEtMQ_3514e820-e2fc-4739-8e08-1d774c0bc446">112,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See accompanying notes to the condensed consolidated financial statements</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 3</span></div></td></tr></table></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_19"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:567.00pt"><tr><td style="width:1.0pt"></td><td style="width:565.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:29pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME</span></div></td></tr><tr style="height:23pt"><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Expressed in thousands of U.S. Dollars, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Unaudited)</span></div></td></tr></table></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:567.00pt"><tr><td style="width:1.0pt"></td><td style="width:292.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:24.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:6.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:6.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMi0zLTEtMS0x_7d2f5803-472c-4bfd-a484-02ea1d09b88a">29,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMi01LTEtMS0x_211ee8f4-0254-411c-a065-91a9b573d508">33,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMi03LTEtMS0x_92393056-f3ae-403a-8481-cfb142961e5d">85,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMi05LTEtMS0x_ad1771d1-e7f5-4e17-b725-87c79af19a0c">100,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNC0zLTEtMS0x_41820871-8960-440b-8e95-c72f69e28808">10,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNC01LTEtMS0x_d6553eca-fd46-40d0-8f34-2f7daa7fa411">13,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNC03LTEtMS0x_69b2ca42-1bd7-439f-9534-1e897382ca13">31,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNC05LTEtMS0x_b04f3f31-9dfd-411a-8d0f-9363f21f965a">39,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNi0zLTEtMS0x_ef3dfbb3-5d2e-4599-a9ef-ab9fb5e04519">18,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNi01LTEtMS0x_9b2c5471-7621-4508-8e80-ce4332fac941">19,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNi03LTEtMS0x_447043f0-a99e-46b7-89c3-ed6ec3d3bb60">53,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNi05LTEtMS0x_c8a851fb-a779-494e-bbf4-55eaa0668f12">60,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfOS0zLTEtMS0x_18fa4477-f279-4c2b-be63-3bf227b8ff8e">13,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfOS01LTEtMS0x_8349ab31-7398-4201-81d9-bd62e02460b2">13,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfOS03LTEtMS0x_2713dd3d-c8ab-4c85-bca0-243ac31eed0a">40,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfOS05LTEtMS0x_61330701-8c04-4481-9299-7845139e159c">40,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTAtMy0xLTEtMQ_1629ad4d-9181-4983-8d08-f2000f027f73">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTAtNS0xLTEtMQ_48861293-faa6-4319-8742-f36c8c824f1f">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTAtNy0xLTEtMQ_1681c690-d48e-48ad-936d-3e7b37eb7b3e">1,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTAtOS0xLTEtMQ_70e8fab2-4828-47d2-bf7e-90e1691a22b6">688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTEtMy0xLTEtMQ_29fe6c16-a0b4-47ba-bc29-12100164404c">1,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTEtNS0xLTEtMQ_c80e0072-3f22-429b-b5b6-4412011fc524">1,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTEtNy0xLTEtMQ_61678c09-3bfb-4716-830b-ae5d13f115bf">3,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTEtOS0xLTEtMQ_0eabce7f-097e-40fe-9de1-35a585ab9de2">3,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" name="us-gaap:DepreciationNonproduction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTItMy0xLTEtMQ_1c50b2ce-6cfa-4194-95ac-9dcd39870252">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" name="us-gaap:DepreciationNonproduction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTItNS0xLTEtMQ_716ad6a2-6c8d-472e-9a86-b05e2a75d95a">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationNonproduction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTItNy0xLTEtMQ_d18299be-ca5e-4d1c-b895-eb651136bbb4">618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationNonproduction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTItOS0xLTEtMQ_808e4872-efb4-4e36-b773-5936780bd9c9">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (gain) on disposal of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTMtMy0xLTEtMQ_6b2b56ad-9066-4aae-9bbf-c2584a32a1dc">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTMtNS0xLTEtMQ_04077bb4-6b5d-4077-b6d8-5533108cc762">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTMtNy0xLTEtMQ_3aee66e0-26e3-4bfd-8c35-6dca2394886a">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTMtOS0xLTEtMQ_28a78b22-b24c-4aaa-b265-0bd08998cacf">2,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other expense (income)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTQtMy0xLTEtMQ_00b897ea-b9df-47d9-8746-541cdb841e30">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTQtNS0xLTEtMQ_c3bcbc7f-c5e9-4744-a603-09bc2dcab34c">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTQtNy0xLTEtMQ_a9830296-4ced-431d-bbb5-5900516872cd">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTQtOS0xLTEtMQ_47713e0e-9ca7-4b54-a186-359a259060bd">3,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTUtMy0xLTEtMQ_86022a6c-95fb-4712-a8f9-89d41d18dca0">2,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTUtNS0xLTEtMQ_2e4ccfb6-016a-4320-8fe3-cd8a81286b46">4,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTUtNy0xLTEtMQ_c715a2ec-3a7e-4522-ab23-a926c93e8bc1">6,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTUtOS0xLTEtMQ_a0abb0f2-e751-4fb4-b327-d9380a9fc24e">21,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-operating income and expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTktMy0xLTEtMQ_1ab241cc-27c7-4f4d-8a30-649fa0ddb3dd">331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTktNS0xLTEtMQ_567ea430-0516-4ed5-8621-f37007ec60d9">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTktNy0xLTEtMQ_c7f15925-de7a-4348-87a2-16ca15e47d12">782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTktOS0xLTEtMQ_90f923fb-af70-4381-ba0c-12f6cdd00bb7">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net of interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjAtMy0xLTEtMQ_92b9e64f-ca7e-4ee1-8e7e-25f390fbb6fe">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjAtNS0xLTEtMQ_71875126-f6e5-4927-a2b9-093f1221a4d6">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjAtNy0xLTEtMQ_fd722672-ba8d-403d-a4a9-26d463f6db10">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjAtOS0xLTEtMQ_a43764d3-7c11-4601-907a-b8aaffd82346">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income before taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjItMy0xLTEtMQ_d032c7dc-3ae6-44a9-916e-b51b08caacd4">3,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjItNS0xLTEtMQ_426b2e9e-53ab-4fdc-91ce-af81332c277c">3,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjItNy0xLTEtMQ_e444a40c-d88b-4ea0-a3d0-17ea026244bc">7,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjItOS0xLTEtMQ_67001408-21ca-4d5c-9a22-071f687c5cff">21,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjMtMy0xLTEtMQ_fb0fbaf1-0059-48a2-87e4-4ef434f67219">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjMtNS0xLTEtMQ_5c2d215d-48d5-4008-86c1-9e6ac128f283">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjMtNy0xLTEtMQ_cc1a710b-d501-4c66-aafa-cd1c18eaefe5">2,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjMtOS0xLTEtMQ_36503325-5ddd-408c-b111-c11f11681cd6">5,318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjUtMy0xLTEtMQ_71f94573-7792-4090-9cc9-e950cac42d6b">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjUtNS0xLTEtMQ_72e06f0d-49fc-4dd7-aa17-ca9b77fb03f0">2,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjUtNy0xLTEtMQ_18a8b21a-e990-4c48-802a-e1bb3583bd80">5,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjUtOS0xLTEtMQ_50530932-3caa-4732-8669-ac159c9b5348">26,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in unrealized gain/loss on derivative instruments, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjgtMy0xLTEtMQ_4755e9e8-9d15-4e9b-aba1-82affecf4128">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjgtNS0xLTEtMQ_a1db7200-5c1f-4f7e-b670-92d626103588">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjgtNy0xLTEtMQ_511c5541-3318-4f36-83b9-2ee120afb87b">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjgtOS0xLTEtMQ_748ecaa7-a6ad-4dc5-8e25-450ea8c19b80">321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjktMy0xLTEtMQ_bcef684e-a72c-491f-9e32-ace5576e3963">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjktNS0xLTEtMQ_0f5114bf-1a0e-426f-a61e-bcdb20b72830">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjktNy0xLTEtMQ_f4edaa4f-2980-4550-a5ad-21a1fb55c177">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjktOS0xLTEtMQ_1a78876e-d8d0-4a4d-a3ec-2722f0ac7cd9">321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzEtMy0xLTEtMQ_0d408a23-41fa-4367-a74a-20cb44575d8d">1,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzEtNS0xLTEtMQ_23050498-6e7d-463a-b90f-092bae388aa5">2,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzEtNy0xLTEtMQ_53db2edb-b051-425e-afcd-3ba1a302ab29">5,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzEtOS0xLTEtMQ_3b077d8b-f23f-4e61-be7a-ab0e0c5f1d5a">26,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzQtMy0xLTEtMQ_61c0c0ed-6205-4813-97f2-6f3d81aeadcc">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzQtNS0xLTEtMQ_8e14e85a-553c-48f3-b302-5c84c0ddd0f2">0.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzQtNy0xLTEtMQ_d068e064-7dde-46c3-a5f9-0ec4bcee85ce">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzQtOS0xLTEtMQ_7166a582-56a8-474d-84a5-7bd22840304d">0.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzUtMy0xLTEtMQ_32bacb46-4844-48ea-8ae2-30fc7422ad26">0.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzUtNS0xLTEtMQ_91a45879-1ddf-40c8-a188-fa733e7c9540">0.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzUtNy0xLTEtMQ_376b3bff-f977-4ea6-8eca-89e9c3d67693">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzUtOS0xLTEtMQ_6414ba2e-dd63-4584-8e7d-1d694992456e">0.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzgtMy0xLTEtMQ_92ebcd98-8fe7-4063-9996-34b320b23859">39,607,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzgtNS0xLTEtMQ_78a43e2f-2721-4d28-b0b5-dd0ff650b62c">39,107,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzgtNy0xLTEtMQ_c0d760f8-dde0-4e73-8139-16976014f19d">39,442,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzgtOS0xLTEtMQ_cf07562a-6b26-4ea3-99b2-1aab80a16383">38,603,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzktMy0xLTEtMQ_38be7b5c-84ed-4446-b595-1f05df7b8edb">40,659,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzktNS0xLTEtMQ_25a2547d-5b55-4e50-9922-3eae04aca0ca">41,155,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzktNy0xLTEtMQ_95990a10-5fa6-4607-8c97-61cfa1417da9">40,716,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzktOS0xLTEtMQ_44c0a315-ffd8-4136-bb2f-73a02bd8f2ad">40,377,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See accompanying notes to the condensed consolidated financial statements</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 4</span></div></td></tr></table></div><div><span><br/></span></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_22"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</span></div></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Expressed in thousands of U.S. Dollars, except share and per share amounts)<br/>(Unaudited)</span></td></tr></table></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:567.00pt"><tr><td style="width:1.0pt"></td><td style="width:227.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders'<br/>equity</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained <br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' equity, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i976c03ac317a4dad950efc53136ca1d4_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMi0yLTEtMS0x_a0160b02-ca97-4bc1-b1a4-85387dcf2027">37,952,660</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i976c03ac317a4dad950efc53136ca1d4_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMi00LTEtMS0x_c2902632-9662-4747-8725-7af6237f2ef9">3,366</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d328191fd14b4b8c8177ad7a45c411_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMi02LTEtMS0x_b9e6d85f-c52d-4e10-8b0a-37abddefc8fe">6,377</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78f4f7423ba64e63859d8515c428592c_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMi04LTEtMS0x_d0916a60-950c-4849-aca1-2c5862d5d056">157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ea5e57cd6a84244aa82b953943efc99_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMi0xMC0xLTEtMQ_d1c9fed2-f9aa-4576-9c2f-d8819c95b625">34,113</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1ac0a3f55549f782851621e90eaa7c_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMi0xMi0xLTEtMQ_9ef38d8a-98f0-4232-923a-53d621bfcddf">43,699</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90d795f6913c410caf28a7874f377029_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMy02LTEtMS0x_103a7c82-4df6-42d4-9e24-ad1c400d346f">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae414ee27046452e85105a8bd614cf93_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMy0xMi0xLTEtMQ_62d12196-a54f-47b1-ad17-fedefb449a1a">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90d795f6913c410caf28a7874f377029_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNC02LTEtMS0x_0627f7d7-b11e-467f-922c-4b2663754b1e">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae414ee27046452e85105a8bd614cf93_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNC0xMi0xLTEtMQ_d1c8c172-dfd4-45a5-97c6-85dfa3ee3133">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46db418aa76540aca2336dc096a0f9ed_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNS0yLTEtMS0x_9394f549-5bf6-468e-b916-229fec00c9c0">4,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46db418aa76540aca2336dc096a0f9ed_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNS00LTEtMS0x_f4e22c63-6778-41d5-8369-362eea8d1faa">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae414ee27046452e85105a8bd614cf93_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNS0xMi0xLTEtMQ_c8059b0d-dfd1-4f8f-bdf6-6e68245d919e">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46db418aa76540aca2336dc096a0f9ed_D20200101-20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNi0yLTEtMS0x_71167d76-5503-4c32-8573-4e092d79c899">529,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46db418aa76540aca2336dc096a0f9ed_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNi00LTEtMS0x_9943ebc1-3b2c-4874-b66a-57243e5b1de9">3,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90d795f6913c410caf28a7874f377029_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNi02LTEtMS0x_e024f1a8-9cab-4033-a574-620f9f19689b">3,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae414ee27046452e85105a8bd614cf93_D20200101-20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNi0xMi0xLTEtMQ_15ffd0b6-61b6-4093-ad00-d865a0067edf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in accumulated other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icde10966330448159a62ea1562b7a40c_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfOC04LTEtMS0x_85b14353-da11-423a-9d87-16bdd045b664">312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae414ee27046452e85105a8bd614cf93_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfOC0xMi0xLTEtMQ_94cbb58c-3cd9-4a23-904f-1b458d3dff25">312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf2dfa8d264844e19a4b600fd9dd036a_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfOS0xMC0xLTEtMQ_4491eb53-c094-45bd-87c1-f64a4b7d54e4">4,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae414ee27046452e85105a8bd614cf93_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfOS0xMi0xLTEtMQ_28878ec4-9da2-4c42-8cab-c4c4c21ab8bf">4,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' equity, March 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46dde1ac351f45b3905daa2f81146e8f_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTAtMi0xLTEtMQ_54eb7dc3-5641-43a5-a0fe-e37b436231ba">38,486,772</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46dde1ac351f45b3905daa2f81146e8f_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTAtNC0xLTEtMQ_ea348403-76fa-4adf-86d3-060b7f77c4d6">6,657</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b7b504524e4d5abf1313a033b40975_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTAtNi0xLTEtMQ_e4307e78-58d4-4097-b85a-b68f65c7d16e">4,252</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6710f81bfc0f404287d6aa6655470fdb_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTAtOC0xLTEtMQ_f15e1d2e-b33b-41c2-b7df-743fe37f88c4">469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6a845ad54e4c62815896f2932bbbd3_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTAtMTAtMS0xLTE_7d252ec7-1169-4883-bb16-e1f88b729a17">38,356</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic98b72a5b163495eb502663ae5631ff3_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTAtMTItMS0xLTE_98682173-3e73-424d-aed7-9a6f6988d7ff">48,796</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5be2a171f9354e10b04c4107daa2107f_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTItNi0xLTEtMQ_20655734-680d-49cc-b9cf-bfca81489f1c">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0917a6724e5d4d2d84ae957241dc31d2_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTItMTItMS0xLTE_7b9acda7-6ba9-4199-ab4d-e39620a724d3">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation - restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5be2a171f9354e10b04c4107daa2107f_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTMtNi0xLTEtMQ_ca40b902-67bf-44de-8759-2efcc0402103">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0917a6724e5d4d2d84ae957241dc31d2_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTMtMTItMS0xLTE_1b39ff25-6769-4c61-b74f-16a432e4eb79">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6486b80960f04e1daccfe12d493f4edd_D20200401-20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTUtMi0xLTEtMQ_7c5ac3bb-a0bc-4ede-b04a-9efb54f14d8c">596,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6486b80960f04e1daccfe12d493f4edd_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTUtNC0xLTEtMQ_ac5c2803-7df8-4f33-9f49-95f2bcc674e3">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0917a6724e5d4d2d84ae957241dc31d2_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTUtMTItMS0xLTE_19303d54-18e8-4e94-a59c-81764e1de957">1,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in accumulated other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69698187989a40bc91ce9b1b21ee1349_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTctOC0xLTEtMQ_63ccce20-2468-40b7-9ae3-f41afa126fd9">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0917a6724e5d4d2d84ae957241dc31d2_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTctMTItMS0xLTE_4472e88b-53d8-4b46-b222-36ed494d18ec">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02af3a5a2bdd4b6786b29f8291d27eaa_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTgtMTAtMS0xLTE_3ad90a07-0a47-466a-b851-28abbe1d01e5">19,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0917a6724e5d4d2d84ae957241dc31d2_D20200401-20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTgtMTItMS0xLTE_01ade46d-e5f4-4d93-b099-131999858b67">19,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' equity, June 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15c5bb821fbb4572a29dd47fbc926156_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTktMi0xLTEtMQ_943d5786-90ff-4ad4-ba59-49ee056e1c61">39,082,932</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c5bb821fbb4572a29dd47fbc926156_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTktNC0xLTEtMQ_06e012b8-784c-440f-8ee7-68b74c519593">8,414</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dcf0bfe379141e99b6c299ca2382485_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTktNi0xLTEtMQ_3ccd2095-2b06-4588-8d46-0557750c9a25">5,448</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b6e39b815a0481b81048a6daf6dbe38_I20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTktOC0xLTEtMQ_da1f7065-71ff-4f72-9c53-29a1c8e91994">502</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32a8db59831844cf84a2c1297bb57c33_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTktMTAtMS0xLTE_41a1fd28-9c2a-49de-a83a-0b0625852b8f">57,768</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041aeccc8fca4dcbbfff6f4937474eaf_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTktMTItMS0xLTE_3c8b36bb-62a6-48a0-be22-fd54d247eaff">71,128</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9919bd0cd9a414385929c20caf931e1_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjEtNi0xLTEtMQ_f2bb1afb-dadb-4e57-912f-eca91e6f9b8a">945</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjEtMTItMS0xLTE_1301293d-e486-4be0-8705-4a882345997a">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - restricted stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9919bd0cd9a414385929c20caf931e1_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjItNi0xLTEtMQ_320541c6-d41d-411e-861e-c98c0c42c2da">289</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjItMTItMS0xLTE_bcf607b1-2c5b-4966-bceb-8769133db8fb">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b284b8a81064ddb96d6d70d6e5a89c1_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjQtMi0xLTEtMQ_37e3cbb7-5a9f-42d8-abcc-7829cff4906f">2,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b284b8a81064ddb96d6d70d6e5a89c1_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjQtNC0xLTEtMQ_0d809114-a660-48d7-a3b5-3d86ce1582a8">8</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjQtMTItMS0xLTE_b0d245ce-f13f-4886-8385-fc6c6e7dec1d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b284b8a81064ddb96d6d70d6e5a89c1_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjUtMi0xLTEtMQ_cca933db-e844-4996-9660-371d71a2a119">59,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b284b8a81064ddb96d6d70d6e5a89c1_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjUtNC0xLTEtMQ_cf972c5f-4aef-465d-818f-8bd388312b6e">663</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9919bd0cd9a414385929c20caf931e1_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjUtNi0xLTEtMQ_9b8fc921-6fb1-4827-ba5d-6ec20b9229fa">663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjUtMTItMS0xLTE_840dc258-9f3e-4589-9ad7-ffdc3cdc2674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in accumulated other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc0e465557324a2ea8388615a3a390a7_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjYtOC0xLTEtMQ_fa083a3d-d84f-468c-b9be-6f02e582d517">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjYtMTItMS0xLTE_376ee83d-93de-47de-bce5-91966006a33e">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4112591d4ceb45bb9e69695b1b461a72_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjctMTAtMS0xLTE_566edeea-773d-4282-aeee-55097190d610">2,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjctMTItMS0xLTE_51c4c1de-03b6-4602-8f23-ee748f6cd1f6">2,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' equity, September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic33d050b9e874098924fdcfa31a8dad5_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjgtMi0xLTEtMQ_e1cbc582-91f1-4f24-8a22-5eb66f34ee69">39,145,182</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33d050b9e874098924fdcfa31a8dad5_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjgtNC0xLTEtMQ_715481a7-5438-4b21-a270-48e80298b7f3">9,085</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46d77374c8874d41b3947cf0b29e4b5e_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjgtNi0xLTEtMQ_9c9f2b68-35eb-4fc2-b0ec-c6a1976f851f">6,019</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i169b12543b7a4693955a72d78e570320_I20200930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjgtOC0xLTEtMQ_14e0bd68-bb0b-47c5-9d3a-8a78339c19fe">478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a8950ebaa6d4023b4633983016fd884_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjgtMTAtMS0xLTE_988634ec-ba7a-46ca-9923-8d7e41d0a6a2">60,572</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e735857f255494fa3f0fdeb61129073_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjgtMTItMS0xLTE_6ea94076-d741-41ba-a090-a8f187c06508">75,198</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See accompanying notes to the condensed consolidated financial statements</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 5</span></div></td></tr></table></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</span></div></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Expressed in thousands of U.S. Dollars, except share and per share amounts)<br/>(Unaudited)</span></td></tr></table></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:567.00pt"><tr><td style="width:1.0pt"></td><td style="width:227.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:64.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders'<br/>equity</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained <br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' equity, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbd4539b888445aaa4a9f2e282cd287f_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTMtMi0xLTEtMQ_10c54987-99e5-4b07-ae61-cd2c831a5565">39,185,182</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbd4539b888445aaa4a9f2e282cd287f_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTMtNC0xLTEtMQ_75d0acd9-7c42-410f-b08e-0742e5569608">9,181</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i697f499345304f75ba0a1a2f279da745_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTMtNi0xLTEtMQ_ca603567-25e7-4703-8cfe-85b57c1f741b">7,320</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d31ca92c88e48a9abe359674915ac36_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTMtOC0xLTEtMQ_53fe9d0c-7fbc-461c-8189-f34bd0fa5d74">451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9624c2e32e014ac3bacfe359b066e658_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTMtMTAtMS0xLTE_2e19fa82-5861-46f9-a0b2-18006aca50e3">65,643</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTMtMTItMS0xLTE_fa330d3b-44fc-46af-92d4-799818c905c3">81,693</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia74bb5981805471fbf83349d5b020f16_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTQtNi0xLTEtMQ_86eb9fbc-bf74-4dc4-a2f7-dcea6363005a">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTQtMTItMS0xLTE_d698e4da-670b-4f11-8346-1cd715a198ae">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia74bb5981805471fbf83349d5b020f16_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTUtNi0xLTEtMQ_6f9e117d-0ea6-4b1b-9035-76cc2b4a9ec3">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTUtMTItMS0xLTE_e05079d0-fca8-48cd-8e14-f365c9d7efa7">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a781f027e5f4955901d37f1b4f38ded_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTctMi0xLTEtMQ_21bbc540-d4c9-4a0c-9aaa-46f9b5d00b29">16,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a781f027e5f4955901d37f1b4f38ded_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTctNC0xLTEtMQ_4a1f4e38-8f13-4c26-9cfe-4875d5e5c379">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTctMTItMS0xLTE_897e155c-6583-44f9-bf54-b83cf4c03652">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a781f027e5f4955901d37f1b4f38ded_D20210101-20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTgtMi0xLTEtMQ_eb1081d7-10ef-41fa-addb-deace6c3b9f3">556,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a781f027e5f4955901d37f1b4f38ded_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTgtNC0xLTEtMQ_d3a7d807-f1e2-4be6-9250-9a62d17b88d5">4,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia74bb5981805471fbf83349d5b020f16_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTgtNi0xLTEtMQ_9791f225-940f-4286-a1fc-8db86ca85264">4,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTgtMTItMS0xLTE_33cda269-e6b7-43fe-9171-2536f6e137a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares redeemed to pay income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i464b82b483584d00a1b94e3674ba102f_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTktMi0xLTEtMQ_42eea3de-5e08-4d92-846c-b36986a5bb82">181,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib19f6e172d9b49cd9b5d8614f40a0e58_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTktMTAtMS0xLTE_58a74e16-f22f-43c9-82d5-b65c4e73c811">1,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTktMTItMS0xLTE_bffade16-4dc0-4a5a-9313-a97bc8ba4dd9">1,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in accumulated other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id993d57472914822885303d1805d867f_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjAtOC0xLTEtMQ_01b5f291-eb20-4e6f-8894-abeef1d47b78">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjAtMTItMS0xLTE_90104c96-0735-4382-a36f-ca034187f68b">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19f6e172d9b49cd9b5d8614f40a0e58_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjEtMTAtMS0xLTE_b4b16356-20b1-427b-ba82-876e72b5e41b">1,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjEtMTItMS0xLTE_42396c00-ebe2-4dab-9d80-1fc326f4b9a5">1,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' equity, March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a63aa35131e40bda35f8dedfa80bb16_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjItMi0xLTEtMQ_36ec49b3-02f8-4dcb-9543-3aeb0f791707">39,577,288</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a63aa35131e40bda35f8dedfa80bb16_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjItNC0xLTEtMQ_559bd344-0ae5-4728-ad29-8e1b9cd5aa75">13,649</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c9f6db5b0d482a98e9ca413932fb50_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjItNi0xLTEtMQ_f3b7646e-d8e3-47ff-b737-9e9b773e9cab">4,224</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25c503eebf774a2abe26edc4ed510527_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjItOC0xLTEtMQ_a1ef2a0d-4883-4ccf-89b8-30e3600f7187">345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i127e3aaec83d4f6d8f742e5114d5812c_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjItMTAtMS0xLTE_2466f98d-a643-4e4e-b97f-7656e45720db">65,893</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e4a3b13e1894054b380ed7b2593deb5_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjItMTItMS0xLTE_b13ccbb8-ffb5-472a-8839-6eb11f661208">83,421</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c396414383b4e01919749fb5c6c1282_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjQtNi0xLTEtMQ_1e49fc00-69df-4a49-91ea-6c34127521a7">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68dbfdbb23794c9aa57688ded08012b4_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjQtMTItMS0xLTE_1eda6b13-b350-412f-bb4e-28bb3be3c394">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - restricted stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c396414383b4e01919749fb5c6c1282_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjUtNi0xLTEtMQ_7c112b09-ed13-464f-a8a1-5c87f151cab3">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68dbfdbb23794c9aa57688ded08012b4_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjUtMTItMS0xLTE_b9344eb0-06d1-484b-a4f8-9301c8ba2718">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b3e804780104f2c92291a6aab542159_D20210401-20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjYtMi0xLTEtMQ_520f606f-c409-4af2-8eca-b402da009193">11,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3e804780104f2c92291a6aab542159_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjYtNC0xLTEtMQ_dfbe5b9f-9b03-408a-afa6-869eb5b0343a">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68dbfdbb23794c9aa57688ded08012b4_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjYtMTItMS0xLTE_5f6c0754-b864-4bdd-b028-b1701cb85960">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in accumulated other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5b2ecbbe220415f99fcae20e610a16d_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjgtOC0xLTEtMQ_b123ed4a-1873-4992-b770-04e8d631ba5b">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68dbfdbb23794c9aa57688ded08012b4_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjgtMTItMS0xLTE_c29db3a4-445b-417b-8545-82c6b1a46add">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00c330d28624a34b3fb015d48c87224_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjktMTAtMS0xLTE_a456e59b-25a3-4555-8f89-f58c67027132">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68dbfdbb23794c9aa57688ded08012b4_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjktMTItMS0xLTE_74df9d73-bad8-4259-a05f-b1c5477349a4">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' equity, June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i820eda4de0134410bc7323aa4f2359aa_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzAtMi0xLTEtMQ_072e4800-249c-4aa2-8392-756ddcf1b289">39,588,299</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820eda4de0134410bc7323aa4f2359aa_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzAtNC0xLTEtMQ_cf1a67d4-faa3-490a-9377-2071f18a82c0">13,696</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a46a17ce83245f7bb8b1baf56327400_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzAtNi0xLTEtMQ_4e75e4af-00fe-47ae-b500-98318f289faa">5,460</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dd7126df3044d39a084ec7916656b51_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzAtOC0xLTEtMQ_738e7980-c47c-4f4e-b33b-496b133d582f">351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d2719e7ac624519adafa787168afc4c_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzAtMTAtMS0xLTE_7dbffa79-96d8-48c3-b4d7-18ea129e4776">67,459</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfad155c822f4964b47061c31968d980_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzAtMTItMS0xLTE_0a9e7c89-1cb7-43c6-b163-62d93c2e62d2">86,264</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8237e783d5184295a58fc1aa28006024_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzItNi0xLTEtMQ_a316a6b0-fa78-47ab-aa89-7411c0d5affc">1,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzItMTItMS0xLTE_826e8e28-8101-490b-b94e-dc787f403993">1,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation - restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8237e783d5184295a58fc1aa28006024_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzMtNi0xLTEtMQ_de33307a-7d19-4a1d-90b8-40b4201b31b4">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzMtMTItMS0xLTE_4f8d0f3c-5723-4743-a958-94eeded88f65">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7426e08cc52b45f197ca6891d552801b_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzYtMi0xLTEtMQ_b6d0b2fe-505a-49b1-bae9-5855d90884d8">42,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7426e08cc52b45f197ca6891d552801b_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzYtNC0xLTEtMQ_47f12f55-9e65-42e4-9dfa-ddcbf79bdcf9">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8237e783d5184295a58fc1aa28006024_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzYtNi0xLTEtMQ_c7a89a3b-4402-40bb-8ffd-acd4e5e922dc">261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzYtMTItMS0xLTE_511717df-c5ce-417a-abcf-19386dd4989f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in accumulated other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e84fd5360f4fd385f42eb20ba331d9_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzctOC0xLTEtMQ_95acca75-752a-46e4-acb3-133032953180">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzctMTItMS0xLTE_36aacb94-ea1a-4baa-b012-0502fb904384">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d706f98718409cb5564654fd53deb2_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzgtMTAtMS0xLTE_35dc501c-caa4-40a5-bad7-701d535e8fd8">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzgtMTItMS0xLTE_f24050ff-4339-4f7b-a747-c4d21a0076d9">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders' equity, September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac9ff3e2056a4a5f880103fc4356cd36_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzktMi0xLTEtMQ_f36873f6-87a7-47cb-bda2-f1ac58edc485">39,630,446</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac9ff3e2056a4a5f880103fc4356cd36_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzktNC0xLTEtMQ_408b7a2b-969a-48ce-b19f-6b2bb9ea952e">13,957</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f84494dae4e4eb7bb67d17f473a7c64_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzktNi0xLTEtMQ_0961e64a-7f00-45c2-bbcf-2be79325ce16">6,501</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e1a9a3cfd8e4e82bc8295ec950c8daa_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzktOC0xLTEtMQ_10e12ff7-ec2a-4e2f-8442-1f66c49db3a4">330</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b274e0f2d945cebc379d707e4f5ea8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzktMTAtMS0xLTE_1c74eac3-e555-442b-90e6-8e8f1c42eee6">69,248</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzktMTItMS0xLTE_8d021e9f-d01d-427b-ad63-f4436d868bd6">89,376</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See accompanying notes to the condensed consolidated financial statements</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 6</span></div></td></tr></table></div><div><span><br/></span></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_25"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:567.00pt"><tr><td style="width:1.0pt"></td><td style="width:565.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:29pt"><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-bottom:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Expressed in thousands of U.S. Dollars)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Unaudited)</span></div></td></tr></table></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:567.00pt"><tr><td style="width:1.0pt"></td><td style="width:376.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:25.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMy0zLTEtMS0x_5bee433f-5e35-454d-b1aa-000c9fd91204">5,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMy01LTEtMS0x_a163e5db-1158-46de-aa62-a6c9c1d6826a">26,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNS0zLTEtMS0x_63a53180-917a-4fa8-a3d8-b52d246b1b6a">8,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNS01LTEtMS0x_b4f4d9f8-9c7f-4fcc-9548-35d122311012">6,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNi0zLTEtMS0x_ad02e58b-3ca1-443b-a031-a8ccfe458280">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNi01LTEtMS0x_100b875e-34da-4ae4-8fd7-53d28af171a2">7,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in inventory reserve</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNy0zLTEtMS0x_0554daa8-1ee8-442a-847e-e43b16b567bd">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNy01LTEtMS0x_ac317936-9629-452a-b6da-6454293c7d7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfOC0zLTEtMS0x_ff5a10f4-d85c-4e58-a4f5-13409af4bb19">3,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfOC01LTEtMS0x_5793fb98-8fca-4f0b-be19-5cf4fe82e6b9">3,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions of earnings received from equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="vmd:DistributionsOfEarningsReceivedFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfOS0zLTEtMS0x_ce1e8b0c-2690-4f20-b9ca-28c98f5aaf98">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="vmd:DistributionsOfEarningsReceivedFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfOS01LTEtMS0x_4fa3c506-e650-424a-aa6c-66149dffdf2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTEtMy0xLTEtMQ_b4123c10-c2c0-4517-90d8-4faabd0fa5b2">782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTEtNS0xLTEtMQ_1a16f4ec-a4b0-4cbe-9958-cb5c6f6728f7">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (gain) on disposal of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTItMy0xLTEtMQ_fa7f2452-0b7e-4639-b7b5-92f6db1a6804">304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTItNS0xLTEtMQ_c415717c-01d9-44ed-8b1a-205c69eff06c">2,424</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax expense (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTMtMy0xLTEtMQ_6828c2c5-8c2d-40e2-9597-8812a74ff0ba">2,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTMtNS0xLTEtMQ_a859f8e3-ba00-4302-bb8f-88fca27b2d1d">7,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in working capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTUtMy0xLTEtMQ_758ca9f1-b706-4fdb-a241-20159b473e74">5,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTUtNS0xLTEtMQ_4335d208-8add-4efd-ad5c-ced37c4a423e">6,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTYtMy0xLTEtMQ_b45204e1-5637-479a-8e95-ee4b5022c15f">196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTYtNS0xLTEtMQ_77d989ca-8bb9-443d-a547-bc4811f8ffdb">1,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTctMy0xLTEtMQ_ecd0c2c5-3953-4611-9cb9-eb0ea9ea1542">2,259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTctNS0xLTEtMQ_c35914e7-ac4d-420c-8df0-121853c565f1">1,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in trade payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTgtMy0xLTEtMQ_9d2caee5-3bc5-4161-b500-ec24c40ce7de">2,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTgtNS0xLTEtMQ_349f0554-9227-40ba-965a-5d19d32bed9a">2,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTktMy0xLTEtMQ_9020c79b-d06c-4f05-8446-1a2e23fc8d39">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTktNS0xLTEtMQ_07cd13fd-46d1-4aa9-91a2-af4d8b8b28f7">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Decrease) increase in accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjAtMy0xLTEtMQ_4417aadd-78ca-4b0d-a645-cf445b962b39">3,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjAtNS0xLTEtMQ_ecc14a81-3c07-4991-b946-0f4ef8fad815">2,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in income tax payable/receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjEtMy0xLTEtMQ_474de3ae-d9b9-46bb-9169-84994adb35f2">1,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjEtNS0xLTEtMQ_a0e0a591-eff9-44e0-85c1-3b007b2d5485">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjItMy0xLTEtMQ_5fe85b74-5bf8-42fd-9cc2-6d97d65827f7">13,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjItNS0xLTEtMQ_0e1fcf9e-360b-4383-8bba-ee8d65399e63">29,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjUtMy0xLTEtMQ_ffcf21ad-dc00-490e-a7fa-1d681e21acf7">13,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjUtNS0xLTEtMQ_e7221d36-6e45-4cf1-b880-7fe684b2bfd4">8,204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjYtMy0xLTEtMQ_807922e4-8dbf-4a52-bdcd-1ff93ce4f7df">599</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjYtNS0xLTEtMQ_57990d40-05a1-4c54-bdbb-816e2dbac672">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjctMy0xLTEtMQ_f1610b6c-cbb3-4953-9526-92ee74d48fab">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjctNS0xLTEtMQ_40e8867d-b0d5-4862-818e-5948a8e7e936">5,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjgtMy0xLTEtMQ_69a60faa-89c1-48e5-9e54-fa97e64e97eb">13,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjgtNS0xLTEtMQ_665189e8-3245-4f91-8729-0d128efc5f6c">3,047</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzItMy0xLTEtMQ_d4db01c8-0f18-4fc8-b820-a0e3afd778d2">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzItNS0xLTEtMQ_10a14ce5-d335-44e1-9ca6-a40108cda8b7">1,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal payments on notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:RepaymentsOfOtherLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzYtMy0xLTEtMQ_c2aac97a-fe41-4733-ac63-2bdb4899f529">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" name="us-gaap:RepaymentsOfOtherLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzYtNS0xLTEtMQ_e6e53212-1582-4007-89c9-c7c6c5d0861e">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal payments on term note</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzctMy0xLTEtMQ_78ed606c-9b45-4d87-a720-b7d310125bc0">1,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfSecuredDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzctNS0xLTEtMQ_97c10c68-802e-4255-aae2-5f670f2dbe4c">1,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares redeemed to pay income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzgtMy0xLTEtMQ_939d8445-693f-41d7-848e-609fffe62212">1,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzgtNS0xLTEtMQ_c098a9f6-328d-4641-a07d-76bd346be9da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="vmd:LeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDAtMy0xLTEtMQ_1e65851e-f7e5-4dd9-8bd8-f8aceeabe8dd">2,080</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="vmd:LeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDAtNS0xLTEtMQ_f553746e-b9d7-4dc8-9438-a68bac0b15cd">7,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDItMy0xLTEtMQ_2facedd1-9dde-4134-8366-87a91ecbb852">4,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDItNS0xLTEtMQ_1fe42388-34f9-48d8-81cb-c135279b8299">7,231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDQtMy0xLTEtMQ_bd6b999f-c869-4187-8095-4c939b66ad41">4,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDQtNS0xLTEtMQ_0b3246fd-39bf-414f-9a97-f30dbc815188">19,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDUtMy0xLTEtMQ_8b51988f-45f9-442b-844e-94b7ff150978">30,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1ac0a3f55549f782851621e90eaa7c_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDUtNS0xLTEtMQ_906a9f4b-33f6-4ed7-9ec9-f0f4e693f2e6">13,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDYtMy0xLTEtMQ_52433884-60dd-49e1-85b0-482f1a540b0d">26,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e735857f255494fa3f0fdeb61129073_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDYtNS0xLTEtMQ_da8813fe-43dd-4e5a-a6e9-4da3d140b971">32,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the period for interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDktMy0xLTEtMQ_50fd8a5f-c46e-4f3d-a13f-7b6135551d1c">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDktNS0xLTEtMQ_23268373-85b0-4528-b1a5-6f6d310eeed7">437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the period for income taxes, net of refunds received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNTAtMy0xLTEtMQ_715d9a18-0bf6-4bb9-83e0-8cbe4763060b">1,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNTAtNS0xLTEtMQ_1218cfbc-75b6-4126-8ace-5c2230a0473f">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash transactions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net non-cash changes to finance lease balances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="vmd:NetNonCashChangesToFinanceLeaseBalances" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNTItMy0xLTEtMQ_42ef5566-d740-4d12-b8b6-0ab84ab909f0">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="vmd:NetNonCashChangesToFinanceLeaseBalances" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNTItNS0xLTEtMQ_f7c8a194-1162-4cce-bdd1-320b390fd548">3,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net non-cash changes to operating lease balances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="vmd:NetNonCashChangesToOperatingLeaseBalances" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNTMtMy0xLTEtMQ_75742b55-63dd-4d2e-b9ad-85894275efb0">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" name="vmd:NetNonCashChangesToOperatingLeaseBalances" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNTMtNS0xLTEtMQ_c33f56f2-6d40-4005-9df4-8be315a78370">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.238%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">See accompanying notes to the condensed consolidated financial statements</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 7</span></div></td></tr></table></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_28"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_31"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zMS9mcmFnOmE4MDc2MTE5YjllMDRkMWQ4NTRlOGZkYWMwM2VmMDkyL3RleHRyZWdpb246YTgwNzYxMTliOWUwNGQxZDg1NGU4ZmRhYzAzZWYwOTJfMTM2OA_5ebbdde8-4477-40d3-b8c6-37c55cbda5c4" continuedAt="i4324da3921d44a85a87f0c9f7b700cec" escape="true">Nature of Business and Operations</ix:nonNumeric></span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><ix:continuation id="i4324da3921d44a85a87f0c9f7b700cec"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Viemed Healthcare, Inc. (the "Company"), through its subsidiaries, is a provider of in-home durable medical equipment ("DME") and post-acute respiratory healthcare services in the United States. The Company&#8217;s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. The Company currently serves patients in <ix:nonFraction unitRef="state" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zMS9mcmFnOmE4MDc2MTE5YjllMDRkMWQ4NTRlOGZkYWMwM2VmMDkyL3RleHRyZWdpb246YTgwNzYxMTliOWUwNGQxZDg1NGU4ZmRhYzAzZWYwOTJfNDcz_3dfa8437-c16f-41c3-9d5c-18b51f4f078f">46</ix:nonFraction> states in the United States. The Company was incorporated under the Business Corporations Act (British Columbia) on December 14, 2016. The Company's registered and records office is located at Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2Z7 and its corporate office is located at 625 E. Kaliste Saloom Road, Lafayette, Louisiana 70508.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act (the "JOBS Act") and a "smaller reporting company" under Rule 12b-2 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), and, as such, has elected to comply with certain reduced U.S. public company reporting requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s common shares are traded in the U.S. on the Nasdaq Capital Market under the symbol VMD and in Canada on the Toronto Stock Exchange ("TSX") under the symbol VMD.TO.</span></div></ix:continuation><div style="padding-right:11.25pt;text-align:justify"><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_34"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.        <ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NTc_467a2e14-ac06-4c36-bfe9-c3211399face" continuedAt="i8dec2dd15c0e4b85ad635136f70a05fd" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div style="text-indent:-36pt"><span><br/></span></div><ix:continuation id="i8dec2dd15c0e4b85ad635136f70a05fd" continuedAt="i671621be56534a05ba132d30c223461c"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3Mzk_072f424e-5eb8-4482-8116-ad4102ce2fe4" continuedAt="i386f7853e5814fe0aefae2f7ac230836" escape="true">Principles of Presentation</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i386f7853e5814fe0aefae2f7ac230836">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. Our fiscal year ends on December 31. The Condensed Consolidated Balance Sheet as of December 31, 2020 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of our independent registered public accounting firm included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NTI_2613945d-1454-470b-823a-3a39f14f3681" continuedAt="i7cb3e59d6b5e43aca52b7d7b388fbbc4" escape="true">Basis of consolidation</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i7cb3e59d6b5e43aca52b7d7b388fbbc4">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3Mjc_f6e0a29e-c174-47c9-acb3-e186aceb4e07" continuedAt="i43bc2d47764b451a87b19438b572eeeb" escape="true">Use of estimates</ix:nonNumeric></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i43bc2d47764b451a87b19438b572eeeb">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates.</ix:continuation> </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NjM_7add8757-315f-4174-a514-07b5dbb24ac6" continuedAt="i232108d2f5c64c2285565ea6882ca0ce" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 8</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><ix:continuation id="i671621be56534a05ba132d30c223461c" continuedAt="i08d85bf16b104e34be76c7b9d8b0a8f9"><ix:continuation id="i232108d2f5c64c2285565ea6882ca0ce"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, our evaluation takes into consideration such factors as historical bad debt experience, national and local economic trends and conditions, industry and regulatory conditions, other collection indicators and information about disaggregated receivables. The complexity of many third-party billing arrangements, patient qualification for medical necessity of equipment and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded.</span></div></ix:continuation><div style="margin-bottom:0.1pt"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NDM_a4ca855f-1b91-416b-b9cd-165949de6956" escape="true"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimates and write-offs for the allowance for doubtful accounts for each reporting period were as follows:</span></div><div style="margin-bottom:0.1pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.568%"><tr><td style="width:1.0%"></td><td style="width:46.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfMS0yLTEtMS0x_99fd5af4-a3d3-4b22-99da-b07315090d2a">9,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1ac0a3f55549f782851621e90eaa7c_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfMS00LTEtMS0x_44e80b35-807b-4725-82b1-83b6c79fe2a6">7,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfMi0yLTEtMS0x_6f1a6299-df3e-413b-be05-ba188a95240a">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfMi00LTEtMS0x_c6be2cf9-08cf-42f4-a003-fe341b08967a">7,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts written off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfMy0yLTEtMS0x_0468df09-cd4b-4dea-900e-f75c8ec73920">7,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfMy00LTEtMS0x_46b62c8c-a0d7-4758-bb33-85ae3b34730a">6,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfNC0yLTEtMS0x_e2733c57-8397-47f7-a02d-e8d8617dc28c">7,115</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e735857f255494fa3f0fdeb61129073_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfNC00LTEtMS0x_0671c1ac-3e2b-47dc-8666-0dfce8f5a2c1">8,788</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:0.1pt;padding-left:27pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included in accounts receivable at September 30, 2021 are amounts due from Medicare and Medicaid which represent <ix:nonFraction unitRef="number" contextRef="i9789ed0b93954ee49baa21647f388ef5_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfNDIyOQ_a35f298b-dbc0-4540-a4a0-4625082f97d0">36</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ifa9d483dc10645cbb1e0794af9dc1645_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfNDIzNg_26e15cd0-6be4-460d-88c8-f54826894b32">10</ix:nonFraction>%, respectively, and <ix:nonFraction unitRef="number" contextRef="iaeed513b2882441a875dcc01fbc0a501_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfNDI1OA_52600533-6cee-4f3c-a809-2d3e736527c3">46</ix:nonFraction>% combined, of total outstanding receivables. As of December 31, 2020, <ix:nonFraction unitRef="number" contextRef="i68ea450f7c474538bd7b5840ef6102d0_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfNDMxNQ_46760175-3abd-4794-9f50-71014b7e5761">46</ix:nonFraction>% of total outstanding receivables were due from Medicare and Medicaid. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NjQ_557f0e47-a78f-4fc1-b04a-2de28d0ccbfa" escape="true"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and nine months ended September 30, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b429d6cb7cb45b3baf15962a80dda61_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMi0yLTEtMS0x_82371cdd-6592-42c8-9c42-ed68a6dbfdf9">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32b248a3bb174a64841828130e70a17c_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMi00LTEtMS0x_f6ca67f1-c4c9-4d12-8640-e33325db5c33">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c40bc410d694b588140148c1dc03c0a_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMi02LTEtMS0x_b71b4d91-58f0-43c6-b23f-53365c024555">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b7bf3629d3d438d8cc6edf60ac48177_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMi04LTEtMS0x_08b2b1c0-2a50-4ae4-97ef-38209b61574a">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i94f0a3d2683f4ff392518340e25d81aa_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMy0yLTEtMS0x_9a3bba1c-c90c-440d-ac52-479971e8fb33">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1eca90250ea9417384566f7ebacc116b_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMy00LTEtMS0x_de1a8048-870d-4a31-9cc8-fc09dabc0c54">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46dcf7ac81934f2a98f642840bdfd97c_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMy02LTEtMS0x_9b8d6480-d78e-47da-a20f-cd605782947d">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a4b30e32e7340a3b4b7cd8a1e99e3ae_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMy04LTEtMS0x_2ba188ef-23bd-4945-ae4f-af125defb5f8">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Medicare and Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcd7133079e94b92a73f8571b7906435_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfNC0yLTEtMS0x_97e5c436-76f0-40fb-940a-15a129b34c30">62</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6fdb1766786c4f3480910ae7b537fb05_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfNC00LTEtMS0x_9bd819ee-b63c-4b98-a179-66e180aad7b5">66</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i76805b82fef445c8b00c89dac2de57b5_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfNC02LTEtMS0x_2fe3d718-233e-4ec9-a97f-e6350aeca5b3">65</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i533015666e4b410e9c4fd427bd190a87_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfNC04LTEtMS0x_d7de3aa9-5e5a-47de-acd9-5e37571029d8">66</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NTM_aea344f2-87b4-44a8-88e5-a7e3094056f8" continuedAt="i756c1ef3ccb7433c948c80777524c120" escape="true">Inventory</ix:nonNumeric></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i756c1ef3ccb7433c948c80777524c120">Inventory represents non-serialized respiratory supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value.</ix:continuation> Inventory is presented net of a reserve balance of $<ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfNDk5MA_d6462bed-0c65-4998-b0d8-a38af655efa4">1,237,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryValuationReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfNDk5Nw_eacd2fe7-7768-4b3a-b91f-813a6b629614">1,353,000</ix:nonFraction> at September 30, 2021 and December 31, 2020, respectively, that relates to COVID-19 response supplies.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NDc_94a76c77-5612-4a6a-94ea-1449f2a05cea" continuedAt="i90667130be16493ca47634762b37084a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives. </span></div></ix:nonNumeric><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i90667130be16493ca47634762b37084a">Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been delivered to a patient and is put in use and continues through the useful life of the asset. Property and equipment with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.</ix:continuation> </span></div></ix:continuation><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><ix:continuation id="i08d85bf16b104e34be76c7b9d8b0a8f9" continuedAt="ibc910fef0c1f4eaa88bc29b2ddb5edca"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NTk_aa5e1055-0518-4eb1-859f-7f8cf0d2022f" continuedAt="i8031dc0b8bce4f658122c190f7a5d992" escape="true"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Equity investments</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity investments on the Condensed Consolidated Balance Sheets are comprised of an investment accounted for under the equity method and an equity investment without a readily determinable fair value which is accounted for under the measurement alternative described in ASC 321-10-35-2.</span></div></ix:nonNumeric><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3MzM_d577c01a-fe13-4e08-8c6f-61f4aa72b996" escape="true"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table details the Company&#8217;s equity investments:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.172%"><tr><td style="width:1.0%"></td><td style="width:47.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmZmOWUzYmJhZmU2MTQ0MmViNGRjMGM0NmExNGQwMmIwL3RhYmxlcmFuZ2U6ZmY5ZTNiYmFmZTYxNDQyZWI0ZGMwYzQ2YTE0ZDAyYjBfMS0yLTEtMS0x_555d324f-60c1-4507-ace2-24ceaf3c33ba">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmZmOWUzYmJhZmU2MTQ0MmViNGRjMGM0NmExNGQwMmIwL3RhYmxlcmFuZ2U6ZmY5ZTNiYmFmZTYxNDQyZWI0ZGMwYzQ2YTE0ZDAyYjBfMS00LTEtMS0x_5a036222-d2dd-45c9-a163-88549b3496ce">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmZmOWUzYmJhZmU2MTQ0MmViNGRjMGM0NmExNGQwMmIwL3RhYmxlcmFuZ2U6ZmY5ZTNiYmFmZTYxNDQyZWI0ZGMwYzQ2YTE0ZDAyYjBfMi0yLTEtMS0x_b92b8c2b-a5e6-4add-9080-2332a727959c">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" name="us-gaap:OtherInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmZmOWUzYmJhZmU2MTQ0MmViNGRjMGM0NmExNGQwMmIwL3RhYmxlcmFuZ2U6ZmY5ZTNiYmFmZTYxNDQyZWI0ZGMwYzQ2YTE0ZDAyYjBfMi00LTEtMS0x_15e720d0-e8a1-4748-ad7d-ad1d86951f47">599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmZmOWUzYmJhZmU2MTQ0MmViNGRjMGM0NmExNGQwMmIwL3RhYmxlcmFuZ2U6ZmY5ZTNiYmFmZTYxNDQyZWI0ZGMwYzQ2YTE0ZDAyYjBfMy0yLTEtMS0x_11e93ea6-89d6-474f-9337-1ca31858a9be">1,942</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmZmOWUzYmJhZmU2MTQ0MmViNGRjMGM0NmExNGQwMmIwL3RhYmxlcmFuZ2U6ZmY5ZTNiYmFmZTYxNDQyZWI0ZGMwYzQ2YTE0ZDAyYjBfMy00LTEtMS0x_f3804b37-9b82-4fbc-81bd-a6da5cad0a67">733</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><ix:continuation id="i8031dc0b8bce4f658122c190f7a5d992"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments accounted for under the equity method are investments in unconsolidated entities over whose operating and financial policies the Company has the ability to exercise significant influence but not control. Equity method investments are initially measured at cost in the Condensed Consolidated Balance Sheets with a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">y subsequent adjustments made to the carrying amount of the investment for the Company&#8217;s proportionate share of income or loss. The Company has recognized its share of income or loss on the gain (loss) from equity method investments within non-operating expenses in the Condensed Consolidated Statements of Income. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. No events or changes have occurred as of September 30, 2021 that would affect the carrying value of equity method investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other equity investments are investments without a readily determinable fair value which do not qualify for the practical expedient in ASC 820. For these investments, the Company has elected the measurement alternative which measures the investment at cost, less any impairment. ASU 2019-04 clarifies that if an entity identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it must measure its equity investment at fair value in accordance with ASC 820 as of the date that the observable transaction occurred. The Company was not aware of any impairment or observable price change adjustments that needed to be made as of September 30, 2021 on its investments in equity securities without a readily determinable fair value.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3MzQ_9334e857-4f45-49f8-966e-49a1bb6e0a1a" escape="true"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive income</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments, net of tax. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of the &#8220;backward tracing&#8221; prohibition in ASC 740, certain previously measured unrealized gains or losses have resulted in the existence of "dangling" amounts within other comprehensive income. The Company has elected the individual security approach to the release of these effects. Under the individual security approach, dangling amounts are tracked on a security-by-security basis and cleared out of the other comprehensive income balance upon sale of each individual security. During the periods presented, none of the individual securities associated with a dangling balance were sold.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NDk_6155d85e-953d-4cbf-9cf7-6059c698427e" continuedAt="i5eb78acadab74341b13ba37dd718460b" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue from a customer consists of any combination of the sale and rental of DME and/or patient medical services. Revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services. </span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 10</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><ix:continuation id="ibc910fef0c1f4eaa88bc29b2ddb5edca" continuedAt="i49c47cbcc142438f9dcc328ece60800f"><ix:continuation id="i5eb78acadab74341b13ba37dd718460b"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company&#8217;s products fall in the Medicare Fee-for-Service (&#8220;FFS&#8221;) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;). </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For commercial payors, DME companies must negotiate in-network pricing separately, though in general, the Company&#8217;s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with DME rentals, the Company recognizes revenue in accordance with ASC 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Leases,&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 842). For any DME sales and services, the Company recognizes revenue under FASB ASU 2014-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Revenue from Contracts with Customers,&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 606) and related amendments. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes equipment rental revenue over the non-cancelable lease term, which is <ix:nonNumeric contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" format="ixt-sec:durwordsen" name="us-gaap:LessorOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMTIwNDA_e8f5d04d-bee8-4514-9160-03935c91ffb1">one month</ix:nonNumeric>, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-bottom:0.1pt;padding-left:27pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3MzA_d65cb5ed-7f7b-4f28-9a4c-b37b35ffc0b5" escape="true"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The revenues from each major source are summarized in the following table:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from rentals </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Ventilator rentals, non-invasive and invasive</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd917d51157d466ba06d77882124fe90_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfMy0yLTEtMS0x_a614d679-f863-48ce-860c-c5bedaaf0897">21,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21c590c6cb2c4aabab1faeddb85de476_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfMy00LTEtMS0x_b64a3d30-0494-488f-a283-a8c6c796cea6">19,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i435b1dfb19324a3a80b71d9ec9b03097_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfMy02LTEtMS0x_2828bb65-21ac-4dc3-a414-4434356ce658">61,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b0c9015e90944a9a17d402213f296fc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfMy04LTEtMS0x_7c8951c3-62dd-4029-890e-484f23818472">58,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other durable medical equipment rentals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f1ecb80965642fbadc7233c55e2e25e_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNC0yLTEtMS0x_9295dc67-b098-45af-9d4b-5b293617798b">3,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7301bcb71cfa44948e8127d480f5130c_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNC00LTEtMS0x_e4e3cab1-9611-482d-bfbc-b7086dccd854">2,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e996f926c5450fa282162205bc1bea_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNC02LTEtMS0x_799d9145-efca-4be2-8a72-2ea253a0a7bc">9,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc18131a88214a2a81b395db3505d107_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNC04LTEtMS0x_88716b18-def4-4f9e-98cb-e69afc513a73">7,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from sales and services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Equipment and supply sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e78c9cea09846458e3dc27631212986_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNi0yLTEtMS0x_1d591c39-b414-4f1d-ae87-466fa9aecc35">2,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fc6492490bc4b1490392b2ed8be8db2_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNi00LTEtMS0x_93775ca1-d7ef-4b9a-8d41-87ad46b7a187">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc9421ac4a184e8d91a81e460d2113cc_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNi02LTEtMS0x_5b99323b-5619-402b-8310-761809c08c14">6,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff19a29d6c2c4522a4f392e635400390_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNi04LTEtMS0x_498c96ea-c6ef-4ab3-a481-52ac6df261b2">3,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COVID-19 response sales and services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8727827e5c84f4fa96f89fff0b8273c_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNy0yLTEtMS0x_83b94e2f-48ce-44fa-a057-e6676ce26edb">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768c9291994346aab84e8a3706141a9e_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNy00LTEtMS0x_5b4d4a90-9179-4ff3-a2e6-183d5cde352c">8,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecce218d389d406eb3310f56da83c06e_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNy02LTEtMS0x_863ed25f-52f9-4f9c-9704-7fd71b5f3564">5,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36805497dabe4b1ca576fc7081dd4b66_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNy04LTEtMS0x_3e86be6c-099e-4dd1-bae7-9832e5ed4a70">29,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac0999e7702345499410c35dc62978eb_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOC0yLTEtMS0x_93a02d01-98ae-4b65-9163-bd8bfdaa92e8">515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a4c357dacb453faeda00f5a03c85fd_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOC00LTEtMS0x_ccc7f47b-62ca-4852-beb7-c9f32b59c824">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69397aa140894aa59c5c17529168578a_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOC02LTEtMS0x_468c10ff-4306-4633-8f51-e8c472dd8fe5">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f25b5934b1c4af683335208edd0f7bf_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOC04LTEtMS0x_4e5efe30-f3d1-4f49-a061-460a114a9105">983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOS0yLTEtMS0x_7ed27b55-3c98-47c4-ab48-57c87a611451">29,285</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOS00LTEtMS0x_be01c5bb-5a23-4d69-be76-21597ee46daa">33,447</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOS02LTEtMS0x_d1ef67d0-3b27-4041-b1a6-12a17e0ae9b9">85,100</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOS04LTEtMS0x_a679a53a-51ce-4dec-8bea-65f057cd39d9">100,107</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:RevenueRecognitionLeases" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NjA_61872cc8-4015-4fe7-a2a0-b95e6888b646" continuedAt="i96857bd0eba340128c62b1de8cc6a243" escape="true"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 842</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company leases DME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company accounts for these rentals as operating leases.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under FASB ASC Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.</span></div></ix:nonNumeric><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i96857bd0eba340128c62b1de8cc6a243">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.</ix:continuation> </span></div></ix:continuation><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><ix:continuation id="i49c47cbcc142438f9dcc328ece60800f" continuedAt="i704500be20c94a63b0e2e88077807d6a"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NjY_0c6fb01f-a24b-46bb-8354-2114909ff2f0" escape="true"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 606</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company sells DME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also provides sleep study services to customers and recognizes revenue when the sleep study results are complete, satisfying the performance obligation. In response to the COVID-19 pandemic, the Company began offering contact and vaccine tracing services, which revenues are recognized in the period in which the service has been provided. The transaction price on equipment sales, sleep studies and contact and vaccine tracing is the amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the DME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The Company does not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Returns and refunds are not accepted on equipment sales, sleep study services or contact and vaccine tracing services. The Company does not offer warranties to customers in excess of the manufacturer&#8217;s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of September 30, 2021.</span></div></ix:nonNumeric><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3MzY_b8a38647-2e57-448f-93d4-f137438f6584" escape="true"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC 718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">, "Compensation&#8212;Stock Compensation"</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock&#8211;based compensation costs for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units ("RSUs") are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the Company&#8217;s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the equivalent Company's stock value at the end of each period and records a liability based on the percentage of requisite service.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NjI_5d32bb39-03f1-4882-8481-da2a467f8d21" continuedAt="if323dd80dca94f68a1a2c9e1a24291b4" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company utilizes an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the Term Note (as defined below).&#160;</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 12</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><ix:continuation id="i704500be20c94a63b0e2e88077807d6a" continuedAt="i437164c9291c4b05beaf6f25101b4009"><ix:continuation id="if323dd80dca94f68a1a2c9e1a24291b4"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk.&#160;These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company presents a positive ending period fair value of the interest rate swap contract in other long-term assets, as a component of long-term assets, and a negative ending period fair value of the interest rate swap contract in accrued liabilities, as a component of long-term liabilities on the Condensed Consolidated Balance Sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty&#160;as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets.&#160;To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3Mzc_0011a249-27e8-45b0-802e-152fe170d89a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to income taxes in numerous jurisdictions. Significant judgment is required in determining the provision for income taxes. The Company's income tax provisions reflect management&#8217;s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that we will receive refunds from or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact our effective tax rate as well as our business and operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted or substantively enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense.</span></div></ix:nonNumeric><div style="padding-right:45pt;text-align:justify;text-indent:27pt"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NTA_4919bec8-084e-465c-8dec-2a2118b41098" continuedAt="i1d628c44e00b42ad9367a468500543a0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#160;The new guidance simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The new guidance also improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending the existing guidance.&#160;The Company adopted this standard on January 1, 2020, which did not have any impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is an &#8220;emerging growth company&#8221; as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, our condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><ix:continuation id="i437164c9291c4b05beaf6f25101b4009"><ix:continuation id="i1d628c44e00b42ad9367a468500543a0"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2019, the FASB issued&#160;ASU 2019-11,&#160;Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which is intended to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets. The standard replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. Further, the FASB issued ASU 2019-04 and ASU 2019-05 to provide additional guidance on the credit losses standard. The standard is effective for fiscal years beginning after December 15, 2022 for smaller reporting companies, including interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the effect that this standard will have on its consolidated financial statements and related disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), which provides optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. Specifically, the guidance permits an entity, when certain criteria are met, to consider amendments to contracts made to comply with reference rate reform to meet the definition of a modification under GAAP. It further allows hedge accounting to be maintained and a one-time transfer or sale of qualifying held-to-maturity securities. The expedients and exceptions provided by the amendments are permitted to be adopted any time through December 31, 2022 and do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, except for certain optional expedients elected for certain hedging relationships existing as of December 31, 2022. The Company is currently evaluating the effect that this standard will have on its consolidated financial statements and related disclosures.</span></div></ix:continuation></ix:continuation><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_37"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNzYz_c8b86474-aac7-4d06-9fd1-1fb4f143e1d2" continuedAt="i52eac60616dc43d4aa6e03ed3f522184" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:-36pt"><span><br/></span></div><ix:continuation id="i52eac60616dc43d4aa6e03ed3f522184" continuedAt="i460a5ddbe34842b59b9baf7adcfee15a"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s fixed assets consist of its medical equipment held for rental, furniture and equipment, real property and related improvements, and vehicles and other various small equipment. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNzY1_858765f3-bd3a-4f54-9499-40bced918b33" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table details the Company&#8217;s fixed assets:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i156a988ddacc42c782d87dff13bbeafa_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfMS0yLTEtMS0x_f9ffbeb0-c5a2-42ee-827f-9ec893c786e4">72,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff889a5f20c48f0b14d11a61f24192a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfMS00LTEtMS0x_77d286b9-7987-473a-a1a7-30ca5ddba8d8">63,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fa701e0a3e54a9b9dd36ecc85c2307d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfMi0yLTEtMS0x_a9f1bd8a-74b8-4033-9aa8-6d80f87854d4">2,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d9b33a1c5b4522a3fc544ec67f806d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfMi00LTEtMS0x_a8bc23a6-ecff-4244-8239-32b055e979c5">2,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6b0c208bb684b35bbbd15d7eca58b2b_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfMy0yLTEtMS0x_671b3d8c-fa81-4af2-b87e-c904592b5c64">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied68468793ac4161b8131a57412fe183_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfMy00LTEtMS0x_b258c93d-0e53-40f1-b860-65f7e1ef45a0">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff704998475b4b84afa049d983871456_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNC0yLTEtMS0x_8a85cd15-dfca-4454-8c88-8453f6f66abb">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08badebcad9a46b2b8e8bfe2be733945_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNC00LTEtMS0x_61812006-99e9-4beb-8c4f-4c156c2523f0">5,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f44e1e3cce49638ad0ef4800be09eb_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNS0yLTEtMS0x_16e53225-72ac-4579-954a-d9dcb1ddd008">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19004823fe6d4d70b445becfaf7cf907_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNS00LTEtMS0x_857f6204-fd11-4247-952c-c33483fab781">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71dae52fc95540f0af34167cf33d9206_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNi0yLTEtMS0x_5f134d10-a469-491b-8467-256046f9f367">972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c97c3db0d745e2802b30d356846aa8_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNi00LTEtMS0x_bf898cfa-3e90-4502-801d-d763b70c9530">922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNy0yLTEtMS0x_46bfa0f6-3b45-4485-b468-eb2ce1ae58f7">25,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNy00LTEtMS0x_e72a3e11-88e6-415a-ab35-22b66f017ecf">20,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Property and equipment, net of accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfOC0yLTEtMS0x_849aa6a0-6c07-42b6-adc0-2614ab36da72">59,036</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfOC00LTEtMS0x_7a99587d-253b-4993-a48d-ed4561a51e30">55,056</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i460a5ddbe34842b59b9baf7adcfee15a">Depreciation in the amount of $<ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfMzE0_772ca4f4-61c2-4718-b998-343a9b323524">2,656,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfMzIx_d0b1fcbd-3c8e-4b0a-997c-29667b8086c8">2,224,000</ix:nonFraction> is included in cost of revenue for the three months ended September 30, 2021 and 2020, respectively, and in the amount of $<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNDI4_e89cc57d-aad6-420c-afff-8b3c8bb09e9a">7,574,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNDM1_f151e840-6a16-4a7a-8dbf-f445603b69b0">6,133,000</ix:nonFraction> for the nine months ended September 30, 2021 and 2020, respectively. Included in medical equipment above is equipment acquired under finance lease obligations whose cost and accumulated depreciation at September 30, 2021 total $<ix:nonFraction unitRef="usd" contextRef="if94ef301d7e04a16834b80d74e605bda_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNjEz_b2d1ba2e-0aa2-459d-b84d-327f09090a92">1,098,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if94ef301d7e04a16834b80d74e605bda_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNjIw_dee5eeee-3588-4e11-9778-26ce3a47a10c">222,000</ix:nonFraction>, respectively. At December 31, 2020, cost and accumulated depreciation on equipment acquired under finance lease obligations was $<ix:nonFraction unitRef="usd" contextRef="i3ad38a4d9ca54a5080a263d8110efa86_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNzM3_16d00f1c-af6f-4fff-baad-017cef6db8ab">6,900,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3ad38a4d9ca54a5080a263d8110efa86_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNzQ0_34836355-c863-48a0-b42c-1c5f657d5d86">885,000</ix:nonFraction>, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 14</span></div></td></tr></table></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_40"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RleHRyZWdpb246YTNjMTAwNzBkMDA0NDUxNTg4NDJhMDA0OWMzOTc3NGNfMTgx_8ff99b30-a4bb-42bb-bbb8-fa68885451d7" continuedAt="iddce72d919544ae39983e5b5153cb4b1" escape="true">Current Liabilities</ix:nonNumeric></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span><br/></span></div><ix:continuation id="iddce72d919544ae39983e5b5153cb4b1"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RleHRyZWdpb246YTNjMTAwNzBkMDA0NDUxNTg4NDJhMDA0OWMzOTc3NGNfMTgz_5becf1ea-03c3-433d-bcef-6524360832e8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s short-term accrued liabilities are included within current liabilities and consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"><tr><td style="width:1.0%"></td><td style="width:56.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued trade payables </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="vmd:AccruedTradePayablesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfMS0yLTEtMS0x_e9922b14-d3b9-401b-ade1-5dc72a7c3ac1">2,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="vmd:AccruedTradePayablesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfMS00LTEtMS0x_c1d709c1-8441-4384-864b-b3a6096c572b">1,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued commissions payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfMi0yLTEtMS0x_f459b75b-254d-4cec-ad12-778f5f30dafc">388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfMi00LTEtMS0x_a4dd141f-0ebe-4d8a-8eb7-8bdc0b395e94">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued bonuses payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfMy0yLTEtMS0x_69784a68-db97-4822-9be3-02e58ce64b67">2,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfMy00LTEtMS0x_a4c897e3-b10f-4978-9170-8ccff5739432">5,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued vacation and payroll</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNC0yLTEtMS0x_caca6307-980f-4a49-859b-1b9bd2ba0106">2,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNC00LTEtMS0x_fa23c063-53f5-4e77-98ef-1fe538068839">844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of phantom share liability </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNS0yLTEtMS0x_a8f087b2-b1b2-4e3b-b615-c5bd7815d4c2">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNS00LTEtMS0x_a4fd899f-c8b9-40ed-a3b6-33d3c111d7bd">4,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNi0yLTEtMS0x_8dfac32d-758a-4a55-8eec-18746345197d">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNi00LTEtMS0x_873bf6fa-4354-49e5-b3e5-ec0af9cd7213">546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNy0yLTEtMS0x_f67545e5-0dbd-48a3-8127-90aac72462bc">9,283</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNy00LTEtMS0x_0298c23f-988e-4550-b6e2-2260894344fe">12,595</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">                                   </span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_43"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="vmd:DebtandLeaseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTY0Ng_3dff3bf5-6fb1-4ff4-aa7d-59c75f11b7f7" continuedAt="i40f110468a6443d783bddfdeb2419da1" escape="true">Debt and Lease Liabilities</ix:nonNumeric></span></div><div style="padding-right:11.25pt;text-align:justify"><span><br/></span></div><ix:continuation id="i40f110468a6443d783bddfdeb2419da1" continuedAt="ia1f72cbfd0e047f1a48e8d8f303d9d0b"><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Senior Credit Facility </span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 20, 2018, the Company entered a Commercial Business Loan Agreement that provides for Term Loans and Line of Credit with Hancock Whitney Bank.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Line of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company maintains a line of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i87fcc673b3034eaa9412181d84c0c71e_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMjg5_35764e31-3395-41fa-aaae-69724755b1e0">10.0</ix:nonFraction> million that expires May 1, 2023 under the Commercial Business Loan Agreement. Any amounts advanced on this line will be subject to an interest rate equal to the WSJ prime rate plus a margin of <ix:nonFraction unitRef="number" contextRef="ia2c1e065140c48f584cc31eda13a9cc8_D20210101-20210930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDc4_4fca1cd7-f876-4562-8eca-c14480900af3">0.50</ix:nonFraction>%, with a <ix:nonFraction unitRef="number" contextRef="i87fcc673b3034eaa9412181d84c0c71e_I20210930" decimals="INF" name="vmd:DebtInstrumentInterestRateFloorRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDg5_6698cb1d-745a-48b5-991f-8d340150aa1b">3.50</ix:nonFraction>% interest rate floor and will be secured by substantially all of the Company's assets. There were <ix:nonFraction unitRef="usd" contextRef="i87fcc673b3034eaa9412181d84c0c71e_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:LineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTg5_60de9487-9446-4110-ad52-884632e7d6e0"><ix:nonFraction unitRef="usd" contextRef="i81a15ff7f25b45068f37929013eedd30_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:LineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTg5_d4ce773f-1104-4c1d-a47b-5b8d27930b05">no</ix:nonFraction></ix:nonFraction> borrowings against this line of credit at September 30, 2021 or December 31, 2020. </span></div><div style="text-align:center"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commercial Term Notes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 30, 2019, the Company entered into a term note (the &#8220;Building Term Note&#8221;) under the Commercial Business Loan Agreement in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="i62a32ca8e15648e9b1241a1aae489574_I20190530" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfODIy_1ef4e509-e113-4f42-98a7-8fe1d989730f">4.8</ix:nonFraction>&#160;million. The proceeds of the Building Term Note were used to purchase the Company's corporate headquarters. Beginning July 1, 2019, the Company began making monthly payments towards the outstanding balance. The Building Term Note matures on May 30, 2026 and is secured by substantially all of the assets of the borrower, including the real property acquired with the proceeds of the Building Term Note. The Building Term Note bears interest at a variable rate equal to the one month ICE LIBOR index plus a margin of <ix:nonFraction unitRef="number" contextRef="i9e7304b41d654a3d881976535714777c_D20190530-20190530" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMTMzMw_cd3b396b-5963-436c-9ac8-a5dde757031a">2.45</ix:nonFraction>% per annum. The Company is required to maintain a loan to value ratio of <ix:nonFraction unitRef="number" contextRef="i62a32ca8e15648e9b1241a1aae489574_I20190530" decimals="INF" name="vmd:DebtInstrumentCovenantLoanToValueRatio" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMTQwOA_9a18f804-ae7a-4f9f-bb90-628b1709cccf">85</ix:nonFraction>% with respect to the appraised value of the real property. In connection with the Building Term Note, the Company entered into an interest rate swap transaction (the "Interest Rate Swap Transaction") with Hancock Whitney Bank effectively fixing the interest rate for the Building Term Note at <ix:nonFraction unitRef="number" contextRef="id0c674c148fc429ca571bcce37d330e5_I20190530" decimals="INF" name="us-gaap:DerivativeFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMTcwMw_16691d53-4bde-4225-a050-e16b041da4e1">4.68</ix:nonFraction>%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On September 19, 2019, the Company entered into an additional loan agreement providing for a term note (the &#8220;Term Note") under the Commercial Business Loan Agreement in the principal amount of $<ix:nonFraction unitRef="usd" contextRef="i95649eeb9b3f4027bc486bde62cc4ae2_I20190919" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMTkwMQ_e4fd717a-26f2-4225-a409-598d5adfd5cf">5.0</ix:nonFraction> million. The proceeds of the Term Note were utilized for general corporate purposes. Beginning October 19, 2019, the Company started making monthly principal payments of $<ix:nonFraction unitRef="usd" contextRef="id3c6f22c80984ffcb2872cd478bf4368_D20191019-20191019" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMjA2Ng_605f532d-57a7-4a3d-930b-0a9d036a11d2">139,000</ix:nonFraction> towards the outstanding balance. The Term Note matures on September 19, 2022 and is secured by substantially all of the assets of the borrower. The Term Note bears interest at the rate of <ix:nonFraction unitRef="number" contextRef="i95649eeb9b3f4027bc486bde62cc4ae2_I20190919" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMjI1Nw_379c9582-4b19-46c2-a8fb-d97cd00db256">4.60</ix:nonFraction>% per annum.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company incurred immaterial financing costs related to the above term notes. These deferred financing costs are amortized over the term of the loans using the effective interest method.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><ix:continuation id="ia1f72cbfd0e047f1a48e8d8f303d9d0b"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTYzOQ_1588b0c0-8213-4ded-8393-f8e73df5d089" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The recorded balances associated with these term notes, which have terms greater than twelve months, are as follows:</span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"></td><td style="width:61.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie603f4248e314cdf811e9ec8560c574f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjg1MzkwODIwMjJmOTQ4YmQ4NDc0OTMyZmJjZWViMzM1L3RhYmxlcmFuZ2U6ODUzOTA4MjAyMmY5NDhiZDg0NzQ5MzJmYmNlZWIzMzVfMS0yLTEtMS0x_c162863e-34fb-4ff3-b932-a557db5ef32d">6,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ee66bd47ddd42ec90cd24f18d4e553f_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjg1MzkwODIwMjJmOTQ4YmQ4NDc0OTMyZmJjZWViMzM1L3RhYmxlcmFuZ2U6ODUzOTA4MjAyMmY5NDhiZDg0NzQ5MzJmYmNlZWIzMzVfMS00LTEtMS0x_639c2edb-222e-4a8f-8884-20285a098187">7,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie603f4248e314cdf811e9ec8560c574f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjg1MzkwODIwMjJmOTQ4YmQ4NDc0OTMyZmJjZWViMzM1L3RhYmxlcmFuZ2U6ODUzOTA4MjAyMmY5NDhiZDg0NzQ5MzJmYmNlZWIzMzVfMy0yLTEtMS0x_f2a0e32f-6078-41ad-83f2-6b208bdfe266">1,906</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ee66bd47ddd42ec90cd24f18d4e553f_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjg1MzkwODIwMjJmOTQ4YmQ4NDc0OTMyZmJjZWViMzM1L3RhYmxlcmFuZ2U6ODUzOTA4MjAyMmY5NDhiZDg0NzQ5MzJmYmNlZWIzMzVfMy00LTEtMS0x_970f619e-bee7-454b-9f8c-acf466844b9b">1,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net long-term notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie603f4248e314cdf811e9ec8560c574f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjg1MzkwODIwMjJmOTQ4YmQ4NDc0OTMyZmJjZWViMzM1L3RhYmxlcmFuZ2U6ODUzOTA4MjAyMmY5NDhiZDg0NzQ5MzJmYmNlZWIzMzVfNC0yLTEtMS0x_895e59a4-52a3-4d58-b7bb-88517d697acb">4,347</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ee66bd47ddd42ec90cd24f18d4e553f_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjg1MzkwODIwMjJmOTQ4YmQ4NDc0OTMyZmJjZWViMzM1L3RhYmxlcmFuZ2U6ODUzOTA4MjAyMmY5NDhiZDg0NzQ5MzJmYmNlZWIzMzVfNC00LTEtMS0x_9793b009-6eca-4baa-aee8-6351e6d96ee3">5,796</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Commercial Business Loan Agreement, the Company is subject to several restrictive covenants that, among other things, impose operating and financial restrictions on the Company. Financial covenants include a Total Debt to Adjusted EBITDA, a Loan-to-Value Ratio and a Fixed Charged Coverage Ratio, as defined in the Credit Agreement. The Credit Agreement also contains certain customary events of default, including, among other things, failure to make payments when due thereunder and failure to observe or perform certain covenants. The Company was in compliance with all covenants under the Commercial Business Term Loan Agreement in effect at September 30, 2021.</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="vmd:LiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTY0NA_cab01dca-1134-4946-908c-e386c08fe70c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has recognized finance lease liabilities for medical equipment and operating leases for land and buildings that have terms greater than twelve months, as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:60.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="vmd:LeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjY1NWVmZDhhYzU1NTQ3NzViMGE0ZTA2Y2Y2ZTc3YmZjL3RhYmxlcmFuZ2U6NjU1ZWZkOGFjNTU1NDc3NWIwYTRlMDZjZjZlNzdiZmNfMS0yLTEtMS0x_7a7a59a3-a139-4987-8ea3-082b85c2db07">1,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="vmd:LeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjY1NWVmZDhhYzU1NTQ3NzViMGE0ZTA2Y2Y2ZTc3YmZjL3RhYmxlcmFuZ2U6NjU1ZWZkOGFjNTU1NDc3NWIwYTRlMDZjZjZlNzdiZmNfMS00LTEtMS0x_070ca04f-4310-4e00-9548-74d501fab400">3,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" name="vmd:LeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjY1NWVmZDhhYzU1NTQ3NzViMGE0ZTA2Y2Y2ZTc3YmZjL3RhYmxlcmFuZ2U6NjU1ZWZkOGFjNTU1NDc3NWIwYTRlMDZjZjZlNzdiZmNfMy0yLTEtMS0x_be3180ee-53a4-45a9-97c7-5574b6bafb4d">481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="vmd:LeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjY1NWVmZDhhYzU1NTQ3NzViMGE0ZTA2Y2Y2ZTc3YmZjL3RhYmxlcmFuZ2U6NjU1ZWZkOGFjNTU1NDc3NWIwYTRlMDZjZjZlNzdiZmNfMy00LTEtMS0x_91c6b52a-1d1e-4e08-b91d-35ed07350473">2,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net long-term lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" name="vmd:LeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjY1NWVmZDhhYzU1NTQ3NzViMGE0ZTA2Y2Y2ZTc3YmZjL3RhYmxlcmFuZ2U6NjU1ZWZkOGFjNTU1NDc3NWIwYTRlMDZjZjZlNzdiZmNfNC0yLTEtMS0x_60588338-c818-4d09-88ca-cec093ce6dcd">834</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" name="vmd:LeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjY1NWVmZDhhYzU1NTQ3NzViMGE0ZTA2Y2Y2ZTc3YmZjL3RhYmxlcmFuZ2U6NjU1ZWZkOGFjNTU1NDc3NWIwYTRlMDZjZjZlNzdiZmNfNC00LTEtMS0x_451f4de7-5fcd-4cc5-8ca2-1fe4a6547038">762</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Finance lease liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has various finance leases for equipment with an implied interest rate at fixed rates up to <ix:nonFraction unitRef="number" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="INF" name="us-gaap:LesseeFinanceLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzU2MQ_f9ec9f6a-af2a-4dd9-a534-c1ff894353c6">9.61</ix:nonFraction>%, secured by equipment, due between 2021 and 2024. The Company's weighted average interest rate was <ix:nonFraction unitRef="number" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzY2Mw_e2334a80-a9e8-41a7-838b-ff607b46873e">3.74</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0e735857f255494fa3f0fdeb61129073_I20200930" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzY3MA_56275f6f-59b2-43f2-87a1-e82cd89349fa">3.17</ix:nonFraction>% for all finance lease liabilities outstanding as of September 30, 2021 and 2020, respectively. At September 30, 2021 and 2020, the weighted average lease term was approximately <ix:nonNumeric contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzgxNA_ed65fc84-52c5-40fb-b10e-43369c66426b">1.05</ix:nonNumeric> years and <ix:nonNumeric contextRef="i0e735857f255494fa3f0fdeb61129073_I20200930" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzgyMQ_b597aa18-0c5b-4361-be74-802a58b9eebb">0.73</ix:nonNumeric> years, respectively. Interest expense related to these finance lease obligations for the three and nine months ended September 30, 2021 amounted to $<ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzkzOA_641883e3-9025-4d5d-bacb-417d013a4c60">4,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzk0NQ_6b9e0caa-b5df-4248-b2d9-589df9e0f333">35,000</ix:nonFraction>, respectively. Interest expense related to these finance lease obligations for the three and nine months ended September 30, 2020 amount to $<ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDA2MA_0ab14822-2551-4524-aabc-62800449c043">34,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDA2Nw_8a1038ad-dc0e-49b6-b583-ce52eed7b529">128,000</ix:nonFraction>, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Operating lease liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has recognized operating lease liabilities that relate primarily to the lease of land and buildings. These leases contain renewal options that we have not included as part of the Company's assessment of the lease term as it is not reasonably certain that we will exercise these options. These lease liabilities are recorded at present value based on a discount rate of <ix:nonFraction unitRef="number" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="INF" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDQ5Ng_c8adff38-b1ef-4f08-abcd-1084c9d81e14">5.50</ix:nonFraction>%, which was based on the Company's incremental borrowing rate at the time of assessment. At September 30, 2021, the weighted average lease term was approximately <ix:nonNumeric contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDY0NA_244026c1-5ed3-4c2d-94a3-22db880d2b0f">3.39</ix:nonNumeric> years. Operating rental expenses were $<ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDY3OQ_585ff3e2-1160-4421-8e66-d8e4276cc42d">194,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDY4Ng_cee6af43-535c-4941-9770-c686d8cbb700">570,000</ix:nonFraction> for the three and nine months ended September 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDczNQ_61d2ef65-0870-43e6-85e3-a948cf0053a4">191,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDc0Mg_3ec35a26-5104-465c-b346-f9072e260964">575,000</ix:nonFraction> for the three and nine months ended September 30, 2020, respectively. The related assets for operating lease liabilities have been included with property and equipment on the Condensed Consolidated Balance Sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included within these operating lease liabilities are real property leases for real estate from a related party. On August 1, 2015, the Company entered <ix:nonNumeric contextRef="i5485b5cf5d2b4b92a5935928e69064c0_I20150801" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzI5ODUzNDg4OTE3OQ_060e56c8-1c77-4772-92ef-9ca41ad54fdd">ten-year</ix:nonNumeric> triple net lease agreements for office space with an entity that is affiliated with the Company's CEO, Casey Hoyt, and President, Michael Moore. Rental payments under these related party lease agreements are $<ix:nonFraction unitRef="usd" contextRef="iffa3aec0aba44dc4bdc7a429c06c397f_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTMwMA_d72154ee-fa55-40d2-a191-29f15d90b3f5">20,000</ix:nonFraction> per month, plus taxes, utilities and maintenance. Total rental payments for the use of these properties were $<ix:nonFraction unitRef="usd" contextRef="ic289ae73a55a46dfbf14b45d633afa0f_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTQxMg_44f2ff66-a6ff-4f46-90f1-10becd55a0c4">81,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iffa3aec0aba44dc4bdc7a429c06c397f_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTQxOQ_8da5d9a3-fafb-43e1-8eea-8b0537c92ff4">194,000</ix:nonFraction> for the three and nine months ended September 30, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i3279b51ac3584bafbc99103f6f86c88e_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTQ2OA_e38798d2-681c-4cd3-99e3-250b322dc524">58,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib14997b1010a40869c680e8e635ea4cd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTQ3NQ_297db7d0-b31b-4646-850d-148853eeecf1">180,000</ix:nonFraction> for the three and nine months ended September 30, 2020, respectively. The expense for these related party rents has been included within selling, general and administrative expenses.</span></div></ix:continuation><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 16</span></div></td></tr></table></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_46"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="padding-right:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RleHRyZWdpb246YjQ3NzA0YTc5YTVmNDUwOGE3N2FjNjc0Y2U4ZGRhZTVfNDE1OA_09309581-93c9-4d27-9538-e81d581b591e" continuedAt="icc9fa8269c4142388c421b77d8ea13e2" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><div style="padding-right:6.75pt;text-align:justify"><span><br/></span></div><ix:continuation id="icc9fa8269c4142388c421b77d8ea13e2" continuedAt="i81254a454c204991af53b6525f8d39bb"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under ASC Topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC Topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. There are three levels to the hierarchy based on the reliability of inputs, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value on a recurring basis. There were no transfers between fair value measurement levels during any presented period.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RleHRyZWdpb246YjQ3NzA0YTc5YTVmNDUwOGE3N2FjNjc0Y2U4ZGRhZTVfNDE1Nw_7c812134-9359-4c36-aad1-016db5d9efa6" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the Company's assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recurring Fair Value Measurements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8abf6fe7c8484bdcb2308cea38f75932_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfMy0yLTEtMS0x_185f0c9b-c944-4698-a4dd-cda070e64a86">21,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b195c7493e8424bb8fd5536067a85e2_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfMy00LTEtMS0x_b9b334f2-eba7-44eb-8e18-42cb1be9d54a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea4ca441e78494680787bbcd4931142_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfMy02LTEtMS0x_f39eba98-116f-4d50-91d6-e98a07685038">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dbc8fd191ad4330a8f453ba42571847_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfMy04LTEtMS0x_6517c9e1-fd80-4088-8d48-0a16abedbf1d">21,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic76538552bd94126a41545b7ed1db49a_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNC0yLTEtMS0x_7c8dba5d-c5f7-4d55-8dec-31bf9ef196f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09ac0c6a09264cc5954537a0acda8d17_I20210930" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNC00LTEtMS0x_76c5a1e8-04ff-4fa3-96e1-0b9274759e4b">270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94711e3a71c045bba46f486d3bd974f0_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNC02LTEtMS0x_336788f1-7384-4abe-8e8c-76a8ad77e64e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i336da365772c4ac388b46c52653f0063_I20210930" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNC04LTEtMS0x_f6034129-2e0e-4eeb-947f-af5291573628">270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb901eb8035149c1915fc1b2307e3203_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNS0yLTEtMS0x_68108e09-7023-4914-bd3b-e3d7b03c73d7">21,452</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ca70504217e48bf8c74635b2513864a_I20210930" decimals="-3" sign="-" name="vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNS00LTEtMS0x_c06a0eca-af14-46f0-878d-1413ab0fcf43">270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c8148032c74773b49b36310c78a073_I20210930" decimals="-3" format="ixt:fixed-zero" name="vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNS02LTEtMS0x_82fcc104-0a49-452e-99fd-a971b5f67448">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8854bc148dc4d52b425355b31c2508a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNS04LTEtMS0x_30477791-bd73-49ef-8c06-760fb33a9934">21,182</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recurring Fair Value Measurements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1090d32a5c2b4309b916e12b4c123edc_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfMy0yLTEtMS0x_81edc286-021c-4ab9-b06c-5989b85e98c0">25,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ef9ec490070462eb08089125148bc55_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfMy00LTEtMS0x_ea598483-8ff2-4ccd-aa05-b2d74cce8518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbca660f93914f07ace63ccfd0a4e058_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfMy02LTEtMS0x_42d8cafd-a27b-46df-b53a-e440b6e32fb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i266900fa2c164d91a01dddf36477fe2e_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfMy04LTEtMS0x_45bf7076-412c-4bc8-9987-bf04f7975788">25,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb6a65153dd4f75bba69cc5b394f676_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNC0yLTEtMS0x_d8785901-ad85-4da9-94f4-439eac881b32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00967b47876c44cd9989e4b0f712f2bc_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNC00LTEtMS0x_7bb51b2d-60a2-49be-9973-1405d89bb3d7">433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3bfc5ae6e62482f9bed49fbcbfabbbe_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNC02LTEtMS0x_0e8878df-5190-42c0-a27d-948c3242768f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6da69231063840b48f20fac3ea629cd6_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNC04LTEtMS0x_928921a9-b85d-4327-b0bf-e240066eb883">433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b09cd700c71469e82f19274c7204713_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNS0yLTEtMS0x_88224517-e6b8-45af-b1a1-75d0c1066b26">25,662</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8eb813583e1d404cb010b4516417789f_I20201231" decimals="-3" sign="-" name="vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNS00LTEtMS0x_8bd51d15-e4f4-4b47-949b-7a3a29d82bd5">433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb8b9626315448338619b019df225197_I20201231" decimals="-3" format="ixt:fixed-zero" name="vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNS02LTEtMS0x_70ff3951-d8c3-4e41-a430-3d714925a9a0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec098e30f68048118c3feaeee0ec6ada_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNS04LTEtMS0x_166b4038-d2f4-4035-b28b-3faa61503b2d">25,229</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Derivative instruments and hedging activities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes its interest rate swaps as either assets or liabilities in the accompanying Condensed Consolidated Balance Sheets at fair value. The valuation of these derivative instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. As of September 30, 2021, the Company holds <ix:nonFraction unitRef="interestrateswap" contextRef="i93444cef350340c49a0041603bff9d22_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RleHRyZWdpb246YjQ3NzA0YTc5YTVmNDUwOGE3N2FjNjc0Y2U4ZGRhZTVfMjI0Nw_50c040df-e410-4f03-ad5c-d660fc48de93">one</ix:nonFraction> interest rate swap contract which matures on May 30, 2026 and has a notional amount of $<ix:nonFraction unitRef="usd" contextRef="i93444cef350340c49a0041603bff9d22_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RleHRyZWdpb246YjQ3NzA0YTc5YTVmNDUwOGE3N2FjNjc0Y2U4ZGRhZTVfMjMzNw_c29ecbe5-c0c7-425d-8d77-f82528854f0b">4.5</ix:nonFraction> million. This contract is designated as a cash flow hedge. In the first nine months of 2021, ineffective portions of the hedge were immaterial. The fair value was $(<ix:nonFraction unitRef="usd" contextRef="i93444cef350340c49a0041603bff9d22_I20210930" decimals="-5" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RleHRyZWdpb246YjQ3NzA0YTc5YTVmNDUwOGE3N2FjNjc0Y2U4ZGRhZTVfMjQ5MQ_b2385627-d806-4657-b754-669b5e577578">0.3</ix:nonFraction>) million (determined based on Level 2 inputs) and is included in accrued liabilities, as a component of long-term liabilities as of September 30, 2021.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><ix:continuation id="i81254a454c204991af53b6525f8d39bb"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We measure certain assets and liabilities at fair value on a nonrecurring basis. These assets and liabilities include equity method investments and other equity investments. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. The Company's other equity investments are holdings in a privately-held company without a readily determinable market value. The Company remeasures equity securities without readily determinable fair value at fair value when an orderly transaction is identified for an identical or similar investment of the same issuer in accordance with Topic 820. ASU 2019-04 states that the measurement alternative is a nonrecurring fair value measurement. Accordingly, other equity investments without readily determinable fair value are classified within Level 3 in the fair value hierarchy because the Company estimates the value using a combination of observable and unobservable inputs, including valuation ascribed to the issuing company in subsequent financing rounds, volatility in the results of operations of the issuers and rights and obligations of the holdings we own.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company had no material adjustments of assets and liabilities measured at fair value on a nonrecurring basis during any of the periods presented. There were no transfers between fair value measurement levels during any presented period.</span></div></ix:continuation><div><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_58"></div><div style="padding-left:36pt;padding-right:6.75pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDM5ODA0NjUxODUxNw_7afd876a-10c9-408f-9d6b-f50b72833565" continuedAt="i1e8e66e5a92043d29ae1bd4d8a260f19" escape="true">Shareholders' Equity</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1e8e66e5a92043d29ae1bd4d8a260f19" continuedAt="i58fa07a42fd041be94a9f0489c6c2d8f"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Authorized share capital</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s authorized share capital consists of an unlimited number of common shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Issued and outstanding share capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has only <ix:nonFraction unitRef="classofstock" contextRef="iac9ff3e2056a4a5f880103fc4356cd36_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="vmd:NumberOfStockClasses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzI5ODUzNDg5MDU2Nw_646e6457-52f1-478a-8342-de268c9b4c3f">one</ix:nonFraction> class of stock outstanding, common shares. The authorized stock consists of an unlimited number of common shares with no stated par value, of which <ix:nonFraction unitRef="shares" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjE5OTAyMzI2MjgwNg_23bd00c6-532a-4728-b7dd-b49095ce310d"><ix:nonFraction unitRef="shares" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjE5OTAyMzI2MjgwNg_3c096ff8-cc3c-49af-a79e-edeb198deadf">39,630,446</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfOTM0NTg0ODg0MzUxMg_36b2ae3f-9a71-4760-ad27-ed0a2c420cb7"><ix:nonFraction unitRef="shares" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfOTM0NTg0ODg0MzUxMg_82bb926e-a6b0-488a-a48c-cfebf2da752f">39,185,182</ix:nonFraction></ix:nonFraction> shares were issued and outstanding as of September 30, 2021 and December 31, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, the Company repurchased and canceled <ix:nonFraction unitRef="shares" contextRef="i464b82b483584d00a1b94e3674ba102f_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDg0_42eea3de-5e08-4d92-846c-b36986a5bb82">181,320</ix:nonFraction> common shares at a cost of $<ix:nonFraction unitRef="usd" contextRef="i464b82b483584d00a1b94e3674ba102f_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNTE0_c301125a-06e7-4c5f-bdb3-604d12c34ab4">1.4</ix:nonFraction> million due to tax withholding for RSUs vesting. The Company&#8217;s retained earnings were reduced by the amount paid for the shares repurchased for cancellation.</span></div><div><span><br/></span></div><div style="padding-left:49.5pt;padding-right:6.75pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective June&#160;11, 2020 (the "Effective Date"), the Company&#8217;s shareholders approved the Company's 2020 Long Term Incentive Plan (the "Omnibus Plan"). Upon approval of the Omnibus Plan, no future awards are available to be made under the Company's previous RSU and Option Plans (collectively, the "Former Plan"), and the common shares that were not settled or awarded under the Former Plan as of the Effective Date are available for awards under the Omnibus Plan. The maximum number of common shares that are available for awards under the Omnibus Plan and under any other security-based compensation arrangements adopted by the Company, including the Former Plan, may not exceed <ix:nonFraction unitRef="shares" contextRef="ib6898be82ef3450d8af8019abc1d1fb6_I20200611" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMTM2Mg_cc718f1b-26ee-4a04-9fa7-3215d0e10735">7,758,211</ix:nonFraction> shares (equal to <ix:nonFraction unitRef="number" contextRef="id8114bd65eb746a5b3aaeaae80a4533d_D20200611-20200611" decimals="INF" name="vmd:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMTM4Mg_2790bbe0-5088-49fb-9243-215d3ab2d3e8">20</ix:nonFraction>% of the issued and outstanding common shares of the Company on the Effective Date). The maximum amount of the foregoing common shares that may be awarded under the Omnibus Plan as &#8220;incentive stock options&#8221; is <ix:nonFraction unitRef="shares" contextRef="i0d0af2de6c674c96b220f46c78c9e9ba_I20200611" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMTU5Mw_f6ce7ef2-084a-4ad7-8d2d-1da5765720bc">2,600,000</ix:nonFraction> common shares. As of September 30, 2021, the Company had outstanding options of <ix:nonFraction unitRef="shares" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMTY2MA_5bac8dcb-9292-428b-8228-355d74a42c14">3,772,000</ix:nonFraction> and RSUs of <ix:nonFraction unitRef="shares" contextRef="id2dbd335dfd64d78885f580dba8cb8ba_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMTY3NQ_39120077-70b7-41ed-8b65-534bba8f4ee5">219,000</ix:nonFraction> associated with common shares under the Omnibus Plan.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzIxNA_6ced9d93-5633-4566-82fa-2ce84c6c7cf8" continuedAt="i52486c9d94de4c06a6f7ef61e30e4a5f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation - options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0187ebcaed44679c75f56be10857e9_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMi0yLTEtMS0x_ec492639-54a4-4197-883b-19d1eba78bf5">1,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1310db462e54e89b2b94af7bdd21af5_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMi00LTEtMS0x_93cfc9f4-57e2-4d74-a8f3-410012631f41">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795dccfd9203404ba393cb88b8244587_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMi02LTEtMS0x_e281d36b-a584-4a98-9013-5854bece5fb2">3,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3036198797724f58bf6c7bf4265403b6_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMi04LTEtMS0x_3358788b-0af7-4f88-8b17-1c7594d4a3d4">2,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation - restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dedb3f8a3514cc5a585e7453a724c8d_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMy0yLTEtMS0x_ef5a2732-2b4f-41f0-8fa0-8e55d2ba7cb5">251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe99e45d98d34bfe97e7b979e75c259b_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMy00LTEtMS0x_dc43438f-d4cc-44a9-901d-db254eb0c022">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMy02LTEtMS0x_e82f46c0-a4ba-47c9-a610-ae3fb3705bb7">718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92da22dc12174d0da0397780472a1fbc_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMy04LTEtMS0x_0b8a3414-892a-44af-9cc7-2ee53915cace">812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfNC0yLTEtMS0x_0ce412cc-79cf-423e-aa54-fb815e904353">1,302</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfNC00LTEtMS0x_6f02573b-377e-4ed5-a695-0076584d39ac">1,234</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfNC02LTEtMS0x_7ec0b9eb-0ede-4b19-942c-7ae5de439739">3,845</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfNC04LTEtMS0x_b9656736-945a-4691-8d74-bcc7ef36052c">3,581</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:31.5pt"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 18</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><ix:continuation id="i58fa07a42fd041be94a9f0489c6c2d8f" continuedAt="ibd463eed60014cfbbe91e03b0a99d156"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At September 30, 2021, there was approximately $<ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMTg3Mw_9af1420d-ea16-4773-9cd1-2d6186c456ea">3,495,000</ix:nonFraction> of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized over a weighted-average period of&#160;<ix:nonNumeric contextRef="i795dccfd9203404ba393cb88b8244587_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjAzMw_0f9a6b19-63bb-4dbe-a281-8b8eb84c52c9">2.00</ix:nonNumeric> years. As of September 30, 2021, there was approximately $<ix:nonFraction unitRef="usd" contextRef="id2dbd335dfd64d78885f580dba8cb8ba_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjA3MQ_c39815a9-7db1-4f81-9688-e9497dcf5a06">852,000</ix:nonFraction> of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjI1MA_5a59a7b1-2691-4505-bff4-3ea20ab26dfb">0.90</ix:nonNumeric> years.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzIwMg_baa773c0-1b19-4a3f-a83e-7f6112bffffc" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the nine months ended September 30, 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of options<br/>&#160;(000's)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average exercise price</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMS0yLTEtMS0x_0e10ba6c-0377-4315-951a-fe42f72c69ed">3,057</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMS00LTEtMS0x_697acbd7-5c83-41b2-8200-ddb6bf2ca44a">4.37</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7697ee5e2a4842a0b54ef6b98b72541f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMS02LTEtMS0x_f74b8c9b-e33f-4823-bc40-f070fe041532">7.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMS04LTEtMS0x_bc5e72dd-aee8-4d00-9c2d-c70b5fcde741">10,362</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMi0yLTEtMS0x_b30f48ee-1b6d-405f-9912-4cdb038468ff">829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMi00LTEtMS0x_a9ee4b7a-e1e7-40b9-b176-5d236cc9f2d1">8.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMy0yLTEtMS0x_0986c319-bba7-46de-9851-32959eccf40d">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMy00LTEtMS0x_f0f2ebe5-c5b3-467a-ba40-d43f275a1540">3.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfNC0yLTEtMS0x_f523b83f-ebc7-4157-b52b-007614b0205a">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfNC00LTEtMS0x_5a93f1eb-0682-490f-8054-d4c1f734af29">8.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfNS0yLTEtMS0x_273e5d57-1a8a-4b6c-ae08-7ded9e47ecb9">3,772</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfNS00LTEtMS0x_57921123-261e-4a1a-bf7e-2e8ee3858aa9">5.21</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfNS02LTEtMS0x_6e12c79b-1c39-41d4-96c2-8cda5ae0a27d">7.7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfNS04LTEtMS0x_5c3d7ea5-9b66-4548-970d-1ae49b462c48">4,343</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For presentation purposes, stock options issued with a CAD exercise price have been translated to USD based on the prevailing exchange rate on the date of grant.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.</span></div></ix:nonNumeric><div style="padding-left:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding was $<ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjc2OQ_5c3d7ea5-9b66-4548-970d-1ae49b462c48">4,343,000</ix:nonFraction> and options exercisable were $<ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjgwMQ_0f67e0dd-3fab-4de4-9910-7505072d648d">3,798,000</ix:nonFraction> at September 30, 2021. For the nine months ended September 30, 2021, <ix:nonFraction unitRef="shares" contextRef="i68e96bd771d5468da80ad750d5f5c11f_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjgyMw_1fa2070b-8cff-494b-9638-7f13f9c0952c">27,597</ix:nonFraction> shares of common stock were issued pursuant to the exercise of stock options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At September 30, 2021, the Company had <ix:nonFraction unitRef="shares" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjkyOA_c41a1fb1-af5b-4e5a-8b1a-0e12fd30fee2">1,882,000</ix:nonFraction> exercisable stock options outstanding with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzAxMQ_5b8ade5a-0315-48ba-b2ee-8e47a66e8ff8">3.65</ix:nonFraction> and a weighted average remaining contractual life of <ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzA2Nw_4a90629a-033c-43d4-87c6-720fe3da09c0">6.8</ix:nonNumeric> years. At December 31, 2020, the Company had <ix:nonFraction unitRef="shares" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzA5NA_da48c1f5-f059-49b5-bfef-1bad077aeb32">971,000</ix:nonFraction> exercisable stock options outstanding with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzE3Nw_d06b8a90-79bd-4530-bbb9-84dead9240a9">3.09</ix:nonFraction> and a weighted average remaining contractual life of <ix:nonNumeric contextRef="i7697ee5e2a4842a0b54ef6b98b72541f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzIzMw_ea595b80-3f09-491d-b187-4312c5a2002a">6.9</ix:nonNumeric> years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC 718 &#8212; Compensation&#8212;Stock Compensation, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock&#8211;based compensation cost for stock options are determined at the grant date using the Black-Scholes option pricing model. <ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzE5Ng_b0a9a554-1308-44d5-9714-c5a9e5396f4f" continuedAt="i6c9e81eff48947a49a03cd302b569d76" escape="true">The assumptions used to determine the grant date fair value of the stock options granted during the nine months ended September 30, 2021 were as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i6c9e81eff48947a49a03cd302b569d76"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.775%"><tr><td style="width:1.0%"></td><td style="width:63.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.973%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.816%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i88bbd8e84fbf41e09eac6d65db435276_I20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfMi0yLTEtMS0xL3RleHRyZWdpb246OGQ5MDM3NjU1YzRlNDE2ZDk4ZjMzN2JkNGM5NjU4ZjNfNA_6a8eb2fd-735b-4773-af2a-6bd675676ec6">8.57</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ia17494c399214eda9df7f117f9437b96_I20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfMi0yLTEtMS0xL3RleHRyZWdpb246OGQ5MDM3NjU1YzRlNDE2ZDk4ZjMzN2JkNGM5NjU4ZjNfOQ_3c1b42d9-6983-4dad-ae16-365ebb3f9817">9.77</ix:nonFraction></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iffd0c2762d894ddb8c72a023745c0b80_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfMy0yLTEtMS0xL3RleHRyZWdpb246MjBkNmI5NzAzZDEyNDAzZGJjYjZlZTU3N2Q0MWFkZmRfNA_2038346a-d0a4-486d-85c9-d7b248e11836">0.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="iad5f0e1d7d4d457f82377ac5c1601912_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfMy0yLTEtMS0xL3RleHRyZWdpb246MjBkNmI5NzAzZDEyNDAzZGJjYjZlZTU3N2Q0MWFkZmRfOQ_ec23d191-a452-434b-85c1-8ac560c4bfb6">1.39</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iffd0c2762d894ddb8c72a023745c0b80_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNC0yLTEtMS0xL3RleHRyZWdpb246NzFkODcxMjA2Y2ZjNGQ0ZmExMjg4YjlhNjRhOTE4MzRfNA_ed704e67-0a82-4fed-a557-38db8876d396">64.55</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="iad5f0e1d7d4d457f82377ac5c1601912_D20210101-20210930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNC0yLTEtMS0xL3RleHRyZWdpb246NzFkODcxMjA2Y2ZjNGQ0ZmExMjg4YjlhNjRhOTE4MzRfOQ_4db090c1-c2d6-455f-b6be-c9ce8692db7e">67.57</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iffd0c2762d894ddb8c72a023745c0b80_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNS0yLTEtMS0xL3RleHRyZWdpb246ZTQ5MDFmZGFkNjAzNDI0M2EyM2M3MTBlZTE3ZDJiODBfNA_4b913b64-c4d9-4f36-a2c0-2c07ebe211e1">5.65</ix:nonNumeric> - <ix:nonNumeric contextRef="iad5f0e1d7d4d457f82377ac5c1601912_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNS0yLTEtMS0xL3RleHRyZWdpb246ZTQ5MDFmZGFkNjAzNDI0M2EyM2M3MTBlZTE3ZDJiODBfOQ_7913a5b4-dca7-4cb7-b520-b76914de53ec">5.76</ix:nonNumeric> years</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i795dccfd9203404ba393cb88b8244587_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNi0yLTEtMS0x_2d89379e-3001-402f-a51f-99ea09792eb4">Nil</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value on date of grant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i88bbd8e84fbf41e09eac6d65db435276_I20210930" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNy0yLTEtMS0xL3RleHRyZWdpb246MzMzODUzYjQ5OWEzNDdhYjk5NWRlYjBjNmQ4NTdlNjRfNA_bfdb5e22-b98e-40ab-aebe-b8ac4e580aa3">5.05</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="ia17494c399214eda9df7f117f9437b96_I20210930" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNy0yLTEtMS0xL3RleHRyZWdpb246MzMzODUzYjQ5OWEzNDdhYjk5NWRlYjBjNmQ4NTdlNjRfOQ_74cc61a4-b50e-4ffc-a3e5-cb1397e17b14">5.57</ix:nonFraction></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="padding-left:15.75pt;padding-right:15.75pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also grants RSUs to directors, officers, and employees. The Company accounts for RSUs using fair value as of the date of issuance. The fair value of the RSUs has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, based on the stock price on the date of grant.&#160;RSUs vest generally over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDIzNw_3068a39c-9f5a-4e15-9fea-67728d70b3a5">one</span> or <ix:nonNumeric contextRef="ib2873c72b9da49babb2eb0a4aa374ba8_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDM5ODA0NjUxODM1Mw_39d3e79e-768f-41f1-b4ee-41a852f65fc1">three-year</ix:nonNumeric> period. The Company accounts for forfeitures on RSUs under ASU 2016-09 and recognizes forfeitures in the period in which they occur.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><ix:continuation id="ibd463eed60014cfbbe91e03b0a99d156" continuedAt="i9206bc9d93894577a3a2ad299a95f627"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzIxNg_7653ed88-5b23-41d4-8013-aeafaa554e06" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for the nine months ended September 30, 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of RSUs (000's)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average grant price</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecdcfc455bed4a3ab837da5d7d3c93e3_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMS0yLTEtMS0x_4b227f45-a4c1-4176-952f-668aad136f3a">684</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iecdcfc455bed4a3ab837da5d7d3c93e3_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMS00LTEtMS0x_4bedad45-6e04-4706-b4e3-f1f4ca13e213">3.04</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iefa3109898274438af4768a1e85e1bab_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMS02LTEtMS0x_4e4e37ae-30e3-4627-959f-c5369493366c">0.22</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdcfc455bed4a3ab837da5d7d3c93e3_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMS04LTEtMS0x_562f6a9e-98bb-40a8-97d1-26ce855116ae">5,308</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMi0yLTEtMS0x_428ad42d-5a12-4bd9-a45d-d5e3d7c9a1f9">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMi00LTEtMS0x_cc733c9e-80da-413b-a928-ebef07260b5b">7.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMy0yLTEtMS0x_10f66d56-c9c9-4cf0-8a79-ce7746cdc00c">600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMy00LTEtMS0x_c648dd96-7927-4c62-981e-eaf67f190c43">2.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfNC0yLTEtMS0x_e76d1102-e262-4b84-b2ca-6cff9906c3ca">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfNC00LTEtMS0x_3e5fddba-2179-4e1d-89d8-6fa11b246515">6.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2dbd335dfd64d78885f580dba8cb8ba_I20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfNS0yLTEtMS0x_d031c510-ddb3-4668-b3f5-1cc8afe88879">219</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id2dbd335dfd64d78885f580dba8cb8ba_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfNS00LTEtMS0x_85da36e5-51f8-4e22-b59d-7166a79641be">6.72</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfNS02LTEtMS0x_2c498904-1112-43ed-92c1-b1cfed5ebf57">0.90</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2dbd335dfd64d78885f580dba8cb8ba_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfNS04LTEtMS0x_0208cc16-4ad5-4c71-a7d1-0fa9c8b0e00d">1,217</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All future equity grants will be awarded in USD, therefore, RSUs issued with a CAD grant price have been translated to USD based on the prevailing exchange rate on the date of grant for presentation purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate intrinsic value of time-based RSUs outstanding was based on our closing stock price on the last trading day of the period.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i9dedb3f8a3514cc5a585e7453a724c8d_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjE5OTAyMzI2MjgyNg_066390f9-8ca2-479c-932e-dec391f1dee0">81,394</ix:nonFraction> RSUs with a vesting term of <ix:nonNumeric contextRef="i9dedb3f8a3514cc5a585e7453a724c8d_D20210701-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzI5ODUzNDg5MDcyNA_2cfdb5c6-f02c-40d0-8d3a-4c6a570e6b58">one year</ix:nonNumeric> and a fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9dedb3f8a3514cc5a585e7453a724c8d_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjE5OTAyMzI2Mjg4NA_bac85181-acde-4755-9726-c0f96c62daae">6.38</ix:nonFraction> per share. During the nine months ended September 30, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDg5Nw_a54a49e3-32d6-4dbf-a86d-37e59d587282">144,700</ix:nonFraction> RSUs with a vesting term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDM5ODA0NjUxODUwNg_2c114217-6a38-4569-b2f7-e925d2af2d45">one</span> to <ix:nonNumeric contextRef="ib2873c72b9da49babb2eb0a4aa374ba8_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzI5ODUzNDg5MDc4Mg_e3a81fc8-7d94-48b3-90e1-5125c8e22554">three years</ix:nonNumeric> and a fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDk1MQ_b316bd4f-5921-419b-a8f7-0fe53b6054fb">7.34</ix:nonFraction> per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Phantom share units</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has a phantom share unit plan, which it uses for grants to directors, officers, and employees. Phantom share units granted under the plan are non-assignable and are settled in cash at vesting based on the fair value of the Company's common stock on the vesting date. Phantom share units vest annually over a <ix:nonNumeric contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzIwMA_1df742de-c080-4924-8cef-a1cbd6c513da">three-year</ix:nonNumeric> period. The cash-settled phantom share units are accounted for as liability awards and are re-measured at fair value each reporting period until they become vested with accrued liability and related expense being recognized over the requisite service period. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzE5NA_fb38e807-790d-4f67-a13a-4f72bdfb37f5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes phantom share unit activity for the nine months ended September 30, 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of phantom  share units (000's)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value of share equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44ffc467ff8a4229b2d74de1d78d1680_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfMS0yLTEtMS0x_f3e3d7a7-319c-48ae-94d8-27cf5d4fa3f3">985</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44ffc467ff8a4229b2d74de1d78d1680_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfMS00LTEtMS0x_da34df3a-4150-43d7-a70f-f31fe23ddf34">7,642</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfMi0yLTEtMS0x_2b169ef6-ca60-45bf-881e-ec47643ac934">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="vmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfMi00LTEtMS0x_9acb0fb3-d5d5-48bb-99f7-64a8b25f4d42">3,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfMy0yLTEtMS0x_8377f25d-7590-4d78-a945-5202802f2281">656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfMy00LTEtMS0x_80e548cc-8ca4-404c-99d4-6e4e23d76546">6,282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfNC0yLTEtMS0x_0ea7fc3e-1359-40fd-b9f6-6e67bebb1906">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930" decimals="-3" name="vmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfNC00LTEtMS0x_f340799f-fe28-410d-a6b8-f3017a0e6b8c">601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a314a6d360248d9a6c6a44fcd3abb90_I20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfNS0yLTEtMS0x_b3fb2d90-8421-4d09-ad65-22940ddb7017">614</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a314a6d360248d9a6c6a44fcd3abb90_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfNS00LTEtMS0x_a974c7c0-1907-48fa-b12f-27bf6ba05dbb">3,407</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The value of outstanding share equivalents at the beginning of the period is based on the market price of the Company&#8217;s stock at that time, the value of issued share equivalents is based on the market price of the Company&#8217;s stock at issuance, the value of vested share equivalents is based on the cash paid at the time of vesting, the values of expired/forfeited share equivalents and outstanding share equivalents at the end of the period and are based on the market price of the Company's stock at the end of the period. The market price of the Company's stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNjIyMA_7a382e56-fb98-418e-b940-75f0539e4bbd">5.55</ix:nonFraction> on September 30, 2021.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in fair value of the phantom share units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities. The total liability associated with phantom share units at September 30, 2021 is $<ix:nonFraction unitRef="usd" contextRef="i3a314a6d360248d9a6c6a44fcd3abb90_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNjUzNg_6e4df437-fb39-43c7-8552-45050b6ca11a">1,462,000</ix:nonFraction>, with $<ix:nonFraction unitRef="usd" contextRef="i3a314a6d360248d9a6c6a44fcd3abb90_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNjU0NQ_c32beafc-8dcb-484a-bff6-e0404bedef83">1,002,000</ix:nonFraction> of this amount included in current accrued liabilities and the remaining portion of $<ix:nonFraction unitRef="usd" contextRef="i3a314a6d360248d9a6c6a44fcd3abb90_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNjYzMg_27d15359-e4b5-4731-9f3f-a0215c256b67">460,000</ix:nonFraction> included in long-term accrued liabilities.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 20</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><ix:continuation id="i9206bc9d93894577a3a2ad299a95f627"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The impact associated with the fair value re-measurement of phantom share units is recorded in selling, general and administrative expenses within the unaudited Condensed Consolidated Statements of Income and Comprehensive Income. <ix:continuation id="i52486c9d94de4c06a6f7ef61e30e4a5f" continuedAt="i621ca1684e8642288c552447f203e948">The following table summarizes expense associated with the phantom share units for the three and nine months ended September 30, 2021 and 2020 (in thousands):</ix:continuation></span></div><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i621ca1684e8642288c552447f203e948"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.106%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.279%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5753dc4d89ed4578addb8f58e199c604_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmVlMTAzMjUyNzIzYzRmMTQ4MWM1Njc2NTU2NWEyZDM0L3RhYmxlcmFuZ2U6ZWUxMDMyNTI3MjNjNGYxNDgxYzU2NzY1NTY1YTJkMzRfMi0yLTEtMS0x_54e327ce-f68a-49e5-89ca-aa5c3d2fbcff">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4044ca35c71f4191b7fb20e6bf8ad931_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmVlMTAzMjUyNzIzYzRmMTQ4MWM1Njc2NTU2NWEyZDM0L3RhYmxlcmFuZ2U6ZWUxMDMyNTI3MjNjNGYxNDgxYzU2NzY1NTY1YTJkMzRfMi00LTEtMS0x_a4cdf2e3-3cfe-4b6e-a528-939070b09685">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ccb4b7c871492288b371e698ff505e_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmVlMTAzMjUyNzIzYzRmMTQ4MWM1Njc2NTU2NWEyZDM0L3RhYmxlcmFuZ2U6ZWUxMDMyNTI3MjNjNGYxNDgxYzU2NzY1NTY1YTJkMzRfMi02LTEtMS0x_24fa47d2-3088-4171-ad11-ccdc17d0b047">2,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7eabec862824cb8beb06ebf1b6d9770_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmVlMTAzMjUyNzIzYzRmMTQ4MWM1Njc2NTU2NWEyZDM0L3RhYmxlcmFuZ2U6ZWUxMDMyNTI3MjNjNGYxNDgxYzU2NzY1NTY1YTJkMzRfMi04LTEtMS0x_389bb14f-bd5c-4595-84ee-7690c527d3bb">4,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company paid cash settlements of $<ix:nonFraction unitRef="usd" contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzA4OQ_21ca260d-b9e3-45e9-8099-0bf5c502580a">6,282,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic6b1cbcf841f4955b15df2767b15477a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzA5Ng_54af0341-6e4b-4bbb-9d72-cd5b3a8fd588">4,201,000</ix:nonFraction> during the nine months ended September 30, 2021 and 2020, respectively, pertaining to vestings of cash-settled phantom share units.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_61"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182MS9mcmFnOjZkMmExYjExNDc0MjQ3MzFhYjZmODA1NDdkNzQ0YjFmL3RleHRyZWdpb246NmQyYTFiMTE0NzQyNDczMWFiNmY4MDU0N2Q3NDRiMWZfNjAzOQ_6e0dc2b9-d5c8-47dc-a643-2f87ddcd4c75" continuedAt="i1f414346be094f3e87512fed81118373" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1f414346be094f3e87512fed81118373" continuedAt="i1a3aa05e43944c7aad157557328499b3"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accrues estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450,&#160;Contingencies&#160;(&#8220;ASC 450&#8221;). No less than quarterly, we review the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, the Company (through its subsidiary Sleep Management LLC) submitted a purchase order (the &#8220;Purchase Order&#8221;) in March 2020 to Vyaire Medical, Inc. d/b/a CareFusion Respiratory Technologies (&#8220;Vyaire&#8221;) for respiratory equipment. The Company ultimately prepaid $<ix:nonFraction unitRef="usd" contextRef="ic98b72a5b163495eb502663ae5631ff3_I20200331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182MS9mcmFnOjZkMmExYjExNDc0MjQ3MzFhYjZmODA1NDdkNzQ0YjFmL3RleHRyZWdpb246NmQyYTFiMTE0NzQyNDczMWFiNmY4MDU0N2Q3NDRiMWZfMTQ0NQ_3757c944-65da-4320-abca-867e9b4baa33">1.4</ix:nonFraction>&#160;million towards the delivery of such respiratory equipment. Vyaire was unable or unwilling to deliver the vast majority of the respiratory equipment referenced in the Purchase Order, and also refused to refund the prepayment amount (less the amounts paid for equipment actually received). On July 29, 2020, the Company (through its subsidiary Sleep Management LLC) filed a lawsuit against Vyaire in the United States District Court for the Western District of Louisiana (the &#8220;Court&#8221;). This lawsuit was dismissed on December 8, 2020 in connection with the commencement of the lawsuit filed by the Company (through its subsidiary Sleep Management) on November 5, 2020, against Vyaire in the 15th Judicial District Court for the Parish of Lafayette, Louisiana (the &#8220;State Court&#8221;) seeking damages for breach of contract and seeking a declaratory judgment that the Company is not required to pay any further funds to Vyaire. On December 28, 2020, Vyaire filed its Answer, Affirmative Defenses, and Reconventional Demand (&#8220;Reconventional Demand&#8221;) with the State Court alleging breach of contract and seeking damages of $<ix:nonFraction unitRef="usd" contextRef="i118bddcb0f0f4367a8aef1f25a41b550_D20201228-20201228" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182MS9mcmFnOjZkMmExYjExNDc0MjQ3MzFhYjZmODA1NDdkNzQ0YjFmL3RleHRyZWdpb246NmQyYTFiMTE0NzQyNDczMWFiNmY4MDU0N2Q3NDRiMWZfMjU1Mw_4827f78c-88ae-4798-98fb-a37264b26c20">4.7</ix:nonFraction>&#160;million, purportedly for the improper cancellation of the Purchase Order. The Company filed its Answer to the Reconventional Demand on February 12, 2021 and the parties are currently engaged in discovery.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We continue to believe that we have valid legal and equitable grounds to recover our outstanding prepayment as a result of Vyaire&#8217;s failure to deliver the vast majority of the respiratory equipment referenced in the Purchase Order. We have determined that a loss related to the Reconventional Demand is not probable, and thus have not accrued a liability related to this claim. Although a loss may be reasonably possible, we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the Reconventional Demand given that the dispute is in the early stages of the legal process. As of September 30, 2021, outstanding funds in the amount of $<ix:nonFraction unitRef="usd" contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182MS9mcmFnOjZkMmExYjExNDc0MjQ3MzFhYjZmODA1NDdkNzQ0YjFmL3RleHRyZWdpb246NmQyYTFiMTE0NzQyNDczMWFiNmY4MDU0N2Q3NDRiMWZfMzQzMA_d04e7fa0-c137-4f0f-b009-fd88396084d7">0.9</ix:nonFraction> million related to undelivered respiratory equipment are included within other long-term assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Governmental and Regulatory Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time we are involved in various external governmental investigations, audits and reviews. Reviews, audits and investigations of this sort can lead to government actions, which can result in the assessment of recoupment of reimbursement, civil or criminal fines or penalties, or other sanctions, including restrictions or changes in the way we conduct business, loss of licensure or exclusion from participation in government healthcare programs.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 21</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><ix:continuation id="i1a3aa05e43944c7aad157557328499b3"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May of 2021, a final report and recommendation (&#8220;Report&#8221;) was issued by the U.S. Department of Health and Human Services Office of the Inspector General (&#8220;OIG&#8221;) regarding an audit by OIG of claims relating to one hundred (100) of the Company&#8217;s non-invasive ventilation at home (&#8220;NIVH&#8221;) patients. The OIG asserted that most of the sampled Medicare claims submitted for the monthly rental of non-invasive ventilators did not comply with Medicare requirements. The Company firmly believes that the Report ignores each patient&#8217;s diagnosis and supporting documentation of that diagnosis from treating and prescribing physicians and applies clinical guidelines that are contrary to CMS&#8217;s accepted standard of care. In late June of 2021, the Company received initial request letters from DME Medicare Administrative Contractors ("MACs") referencing the Report and requesting repayment of purported overpayments. The Company responded to each initial request by submitting a rebuttal and by filing a redetermination appeal as prescribed by the initial request letters and by statute. In September 2021, the MACs informed the Company of unfavorable decisions with respect to the redetermination appeals. The Company intends to continue to defend itself vigorously through the remaining appeals processes which include, in successive order, Reconsideration appeals, Administrative Law Judge appeals, Medicare Appeals Council review, and ultimately through Federal Court, if necess</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ary. The Reconsideration appeals are required to be submitted in writing to the designated Quality Independent Contractor ("QIC") within 180 days of receiving the redetermination appeals letter. The QIC has 60 days to render a reconsideration decision. The timing of additional appeals beyond reconsideration are subject to workload constraints of the reviewing body. Based on initial discussions with CMS, a review of the current facts and circumstances </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">as we understand them, and the nature of the requests, we have determined that a loss is not probable but may be reasonably possible. Accordingly, no related accrual has been recorded. The value of the population of associated claims within the 4-year reopening period prescribed by statute, including any potential interest, is approximately</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i6a5ccd697db64231a87cd517cfa2cfba_I20210531" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182MS9mcmFnOjZkMmExYjExNDc0MjQ3MzFhYjZmODA1NDdkNzQ0YjFmL3RleHRyZWdpb246NmQyYTFiMTE0NzQyNDczMWFiNmY4MDU0N2Q3NDRiMWZfNTcyNw_a1894c8f-5e54-48f1-886a-ad906a754d6c">9</ix:nonFraction>&#160;million. Man</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">agement estimates that a possible loss, if any, will not exceed this amount. It is possible that the ultimate resolution of this matter, if unfavorable, could materially and adversely affect the Company&#8217;s consolidated financial position, consolidated results of operations, or consolidated cash flows.</span></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_67"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182Ny9mcmFnOjkzYThiYjIzNmYyZjQwY2NiODJmMDNhZWYxYTFlYzQzL3RleHRyZWdpb246OTNhOGJiMjM2ZjJmNDBjY2I4MmYwM2FlZjFhMWVjNDNfMTgwOQ_38cf450c-11c5-47ab-967a-8874f1d64829" continuedAt="ic6da44e47a454b39abc420890a91f05e" escape="true">Income Taxes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic6da44e47a454b39abc420890a91f05e"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, the Company recorded income tax expense of $<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182Ny9mcmFnOjkzYThiYjIzNmYyZjQwY2NiODJmMDNhZWYxYTFlYzQzL3RleHRyZWdpb246OTNhOGJiMjM2ZjJmNDBjY2I4MmYwM2FlZjFhMWVjNDNfNzg_28920b91-27a8-482c-b2e8-5ba252a6f6d0">2.4</ix:nonFraction> million, which includes a discrete tax benefit of $<ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182Ny9mcmFnOjkzYThiYjIzNmYyZjQwY2NiODJmMDNhZWYxYTFlYzQzL3RleHRyZWdpb246OTNhOGJiMjM2ZjJmNDBjY2I4MmYwM2FlZjFhMWVjNDNfMTIz_3f6bd795-cef7-496b-96bb-3b84eff7e308">0.8</ix:nonFraction> million for excess tax benefits associated with stock-based compensation arrangements. Excluding the impact of the discrete tax benefit, the effective rate for the nine months ended September 30, 2021 is <ix:nonFraction unitRef="number" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182Ny9mcmFnOjkzYThiYjIzNmYyZjQwY2NiODJmMDNhZWYxYTFlYzQzL3RleHRyZWdpb246OTNhOGJiMjM2ZjJmNDBjY2I4MmYwM2FlZjFhMWVjNDNfMjg4_9f364289-5a4a-4197-96c3-c7f34468e131">43.4</ix:nonFraction>%. The effective rate differs from the amount computed by applying the statutory federal and state income tax rates to ordinary income before the provision for income taxes due to permanent non-deductible differences. Our effective tax rate is based on forecasted annual results which may fluctuate significantly through the rest of the year, in particular due to the uncertainty in our annual forecasts resulting from the unpredictable impact of the COVID-19 pandemic on our operating results. During the nine months ended September 30, 2020, the Company released a valuation allowance associated with deferred tax assets, resulting in a $<ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182Ny9mcmFnOjkzYThiYjIzNmYyZjQwY2NiODJmMDNhZWYxYTFlYzQzL3RleHRyZWdpb246OTNhOGJiMjM2ZjJmNDBjY2I4MmYwM2FlZjFhMWVjNDNfOTEw_1f598663-2c36-4654-b473-b2c8fdd40067">5.3</ix:nonFraction> million benefit during that period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At September 30, 2021 and 2020, the Company had no amounts recorded for uncertain tax positions and does not expect any material changes in uncertain tax benefits during the next 12 months. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company is subject to U.S. federal income tax as well as income tax in various states. The Company is generally not subject to examination by taxing authorities for years prior to 2016. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_73"></div><div style="padding-right:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RleHRyZWdpb246YjNjZjZhNmYwZGJmNDgxMWJkZTc1MjVkZWQ3ZmU2ZDJfODMz_43d73a20-e81c-494c-8f89-2a628a72a159" continuedAt="ibb90f30541a948f294993a4fa64ae329" escape="true">Earnings Per Share</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="ibb90f30541a948f294993a4fa64ae329" continuedAt="ie062f5fc9b4549019d041f83f0a98dd7"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income per common share is calculated using earnings for the year divided by the weighted average number of shares outstanding during the year</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Using the treasury stock method, diluted income per share amounts are calculated giving effect to the potential dilution that would occur if securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options and the vesting of RSUs are used to purchase common shares at the prevailing market rate. </span></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 22</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.<br/>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><ix:continuation id="ie062f5fc9b4549019d041f83f0a98dd7"><ix:nonNumeric contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RleHRyZWdpb246YjNjZjZhNmYwZGJmNDgxMWJkZTc1MjVkZWQ3ZmU2ZDJfODM3_c4fc2b8d-0ffb-4ba7-a106-bf4dbb8d00aa" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following reflects the earnings and share data used in the basic and diluted earnings per share computations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator - basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMy0yLTEtMS0x_27506ef4-9eb4-484f-85ac-6c5e05668640">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMy00LTEtMS0x_846b8156-4ec5-4018-b1bc-2ecfa5c798b1">2,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMy02LTEtMS0x_c5b3c7c1-f119-45c5-867c-a714a494ae80">5,039</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMy04LTEtMS0x_03260088-d962-4cbe-96cd-dcc2ab9d07ca">26,459</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNi0yLTEtMS0x_92ebcd98-8fe7-4063-9996-34b320b23859">39,607,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNi00LTEtMS0x_78a43e2f-2721-4d28-b0b5-dd0ff650b62c">39,107,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNi02LTEtMS0x_c0d760f8-dde0-4e73-8139-16976014f19d">39,442,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNi04LTEtMS0x_cf07562a-6b26-4ea3-99b2-1aab80a16383">38,603,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNy0yLTEtMS0x_38be7b5c-84ed-4446-b595-1f05df7b8edb">40,659,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNy00LTEtMS0x_25a2547d-5b55-4e50-9922-3eae04aca0ca">41,155,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNy02LTEtMS0x_95990a10-5fa6-4607-8c97-61cfa1417da9">40,716,747</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNy04LTEtMS0x_44c0a315-ffd8-4136-bb2f-73a02bd8f2ad">40,377,608</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfOS0yLTEtMS0x_61c0c0ed-6205-4813-97f2-6f3d81aeadcc">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfOS00LTEtMS0x_8e14e85a-553c-48f3-b302-5c84c0ddd0f2">0.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfOS02LTEtMS0x_d068e064-7dde-46c3-a5f9-0ec4bcee85ce">0.13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfOS04LTEtMS0x_7166a582-56a8-474d-84a5-7bd22840304d">0.69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTAtMi0xLTEtMQ_32bacb46-4844-48ea-8ae2-30fc7422ad26">0.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTAtNC0xLTEtMQ_91a45879-1ddf-40c8-a188-fa733e7c9540">0.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTAtNi0xLTEtMQ_376b3bff-f977-4ea6-8eca-89e9c3d67693">0.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTAtOC0xLTEtMQ_6414ba2e-dd63-4584-8e7d-1d694992456e">0.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator calculation from basic to diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTMtMi0xLTEtMQ_92ebcd98-8fe7-4063-9996-34b320b23859">39,607,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTMtNC0xLTEtMQ_78a43e2f-2721-4d28-b0b5-dd0ff650b62c">39,107,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTMtNi0xLTEtMQ_c0d760f8-dde0-4e73-8139-16976014f19d">39,442,088</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTMtOC0xLTEtMQ_cf07562a-6b26-4ea3-99b2-1aab80a16383">38,603,267</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options and other dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTQtMi0xLTEtMQ_eb23f443-8eea-4173-8fb7-cb68d1110375">1,051,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTQtNC0xLTEtMQ_b33f1410-f22a-4429-ac9e-8f7219011818">2,048,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTQtNi0xLTEtMQ_dbf1d182-384f-45fa-9322-879dffa59b3b">1,274,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTQtOC0xLTEtMQ_91351a3b-8a91-4533-85a2-1ae77c8e338b">1,774,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTUtMi0xLTEtMQ_b551b523-23d0-450d-914d-6f1b19558828">40,659,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTUtNC0xLTEtMQ_23d9aa48-9c13-4f75-83cb-25963f0e81f7">41,155,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTUtNi0xLTEtMQ_9abba4d1-b36f-40ea-9378-6846b45d0023">40,716,747</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTUtOC0xLTEtMQ_e7f81b12-c99d-4f6f-a00f-cfa41196d70a">40,377,608</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation consisted of dilutive employee stock options and RSUs that were de minimis in all periods presented.</span></div></ix:continuation><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 23</span></div></td></tr></table></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_82"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="padding-right:15.75pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with, and is qualified entirely by, our condensed consolidated financial statements (including Notes to the Condensed Consolidated Financial Statements) and the other consolidated financial information under Item 1 of this Quarterly Report on Form 10-Q. Some of the information in this discussion and analysis includes forward-looking statements that involve risk and uncertainties. Actual results and timing of events could differ from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">On March 11, 2020, the World Health Organization declared the outbreak of the novel coronavirus ("COVID-19") a pandemic. We are closely monitoring the impact of the COVID-19 pandemic on our business. The suspension of Medicare sequestration through December 31, 2021 (resulting in a 2% increase in Medicare payments to all providers) and regulatory guidance from CMS expanding telemedicine and reducing documentation requirements during the emergency period are expected to result in increased revenues for certain products and services. However, based on the duration and severity of the impacts of the COVID-19 pandemic, including but not limited to any negative economic conditions arising from the pandemic, our ability to assess potential patients in hospitals and set up and treat patients in the home, and the impacts of government actions and administrative regulations on the healthcare industry and broader economy, including through existing and any future stimulus efforts, we are uncertain of the ultimate impact COVID-19 could have on our business, financial condition and results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_85"></div><div style="padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</span></div><div style="padding-right:11.25pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain statements and information in this Quarterly Report on Form 10-Q may constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Any statements other than&#160;statements of historical information, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. These forward-looking statements are made as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except as required by applicable law.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management regarding future events, and include, but are not limited to, statements with respect to: operating results; profitability; financial condition and resources; anticipated needs for working capital; liquidity; capital resources; capital expenditures; milestones; licensing milestones; information with respect to future growth and growth strategies; anticipated trends in our industry; our future financing plans; timelines; currency fluctuations; government regulation; unanticipated expenses; commercial or governmental disputes or claims; limitations on insurance coverage or other reimbursement; and availability of cash flow to fund capital requirements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Often, but not always, forward-looking information can be identified by the use of words such as &#8220;plans&#8221;, &#8220;expects&#8221;, &#8220;is expected&#8221;, &#8220;budget&#8221;, &#8220;potential&#8221;, &#8220;scheduled&#8221;, &#8220;estimates&#8221;, &#8220;forecasts&#8221;, &#8220;intends&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;projects&#8221;, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results &#8220;will&#8221;, &#8220;should&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221; or &#8220;will be taken&#8221;, &#8220;occur&#8221; or &#8220;be achieved&#8221; or the negative of these terms or comparable terminology.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable. We cannot assure you, however, that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 24</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">By their nature, forward-looking statements involve numerous assumptions, inherent risks and uncertainties, both general and specific, including those identified under &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q and the other documents we file with the SEC, including under &#8220;Item 1A. Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December 31, 2020, and with the securities regulatory authorities in certain provinces of Canada, which contribute to the possibility that the predicted outcomes may not occur or may be delayed. The risks, uncertainties and other factors, many of which are beyond our control, that could influence actual results include, but are not limited to: the general business, market and economic conditions in the regions in which the we operate; the impact of the COVID-19 pandemic and of the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on our patient base, revenues, employees, and equipment and supplies; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; our novel business model; the risk that the clinical application of treatments that demonstrate positive results in a study may not be positively replicated or that such test results may not be predictive of actual treatment results or may not result in the adoption of such treatments by providers; the state of the capital markets; the availability of funds and resources to pursue operations; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers and the recall of certain Royal Philips BiPAP and CPAP devices and ventilators that we distribute and sell; granting of permits and licenses in a highly regulated business; competition; low profit market segments; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; the failure of third parties to comply with their obligations; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; our status as an emerging growth company and a smaller reporting company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the COVID-19 pandemic, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_88"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">General Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In this Quarterly Report on Form 10-Q, unless the context otherwise requires, the terms the "Company," "we," "us" and "our" refer to Viemed Healthcare, Inc. and its wholly-owned subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We were incorporated on December 14, 2016 pursuant to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Business Corporations Act</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (British Columbia). As of June 30, 2020, we determined that we no longer qualify as a "foreign private issuer," as defined in Rule 3b-4 of the Exchange Act, for the purposes of the informational requirements of the Exchange Act. As a result, effective January 1, 2021, we became subject to the proxy solicitation rules under Section 14 of the Exchange Act and Regulation FD, and our officers, directors, and principal shareholders became subject to the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. We will continue to file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K with the SEC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are an "emerging growth company," as defined in the JOBS Act and a "smaller reporting company" under Rule 12b-2 of the Exchange Act, and as such, we have elected to comply with certain reduced U.S. public company reporting requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless otherwise noted herein, all references to "$" or "USD" are to the currency of the United States and references to "CAD$" or "Canadian dollars" are to the currency of Canada.</span></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 25</span></div></td></tr></table></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_91"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We provide an array of home medical equipment, services and supplies, specializing in post-acute respiratory care services in the United States. Our primary objective is to focus on the organic growth of the business and thereby solidify our position as one of the United States&#8217; largest providers of in-home therapy for patients suffering from respiratory diseases. Our respiratory care programs are designed specifically for payors to have the ability to treat patients in the home for less total cost and with a superior quality of care. Our services include respiratory disease management (through the rental of various DME devices), in-home sleep testing and sleep apnea treatment, oxygen therapy, and the sale of associated supplies. We hold an approximate 10% equity interest in VeruStat, Inc, a company focusing on remote patient monitoring (&#8220;RPM&#8221;). The investment is part of an ongoing initiative to enable our salesforce to offer a new revenue source to its physician network around the country. RPM platforms allow physicians to bill for safely monitoring patients inside of the home that are struggling with chronic diseases. The VeruStat RPM solution can be placed in the home in conjunction with Viemed&#8217;s existing patient engagement platform (&#8220;PEP&#8221;). During the three months ended September 30, 2021, we formed Viemed Healthcare Staffing LLC, a healthcare staffing division. The underlying recruiting platform is expected to support internal resource fulfillment as well as external, contractual placement of allied health and nursing professionals.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We derive the majority of our revenue through the rental of non-invasive and invasive ventilators which represented 76.5% and 80.2% of our traditional revenue, excluding COVID-19 response sales and services, for the three months ended September 30, 2021 and 2020, respectively, and 77.9% and 82.9% for the nine months ended September 30, 2021 and 2020, respectively. We combine the benefits of home ventilation support with licensed Respiratory Therapists ("RTs") to drive improved patient outcomes and reduce costly hospital readmissions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We expect to grow through expansion of existing service areas as well as in new regions through a cost efficient launch that reduces location expenses. Our licensed RTs currently serve patients in 46 states. We expect to continue to employ more RTs in order to assure our high service model is accomplished in the home. As of September 30, 2021, we employed 280 licensed RTs, representing approximately 47% of our company-wide employee count. By focusing overhead costs on personnel that service the patient rather than physical location costs, we anticipate that we will efficiently scale our business in regions that are currently not being effectively serviced. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The continued trend of servicing patients in the home rather than in hospitals is aligned with our business objective and we anticipate that this trend will continue to offer growth opportunities for us. We expect to continue to be a solution to the rising health costs in the United States by offering more cost effective, home based solutions while increasing the quality of life for patients fighting serious respiratory diseases.</span></div><div><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_94"></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Trends Affecting our Business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. Various policies and initiatives have been implemented to reduce the transmission of COVID-19, including travel bans and restrictions, the postponement of non-essential medical surgeries, the limiting of access to medical facilities in certain areas, the promotion of social distancing and the adoption of remote working policies. Local, state and national governments continue to emphasize the importance of essential medical personnel and we remain open to meet the needs of our communities. Employee and patient safety is our first priority, and as a result, we put preparedness plans in place for our employees, especially our clinical personnel, and modified our clinical protocols to limit unnecessary patient encounters in order to ensure the safety of our employees as well as the safety of our patients. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These measures have not had a material adverse impact on our consolidated operating results for the three months ended September 30, 2021, but we have experienced curtailment of revenue growth in certain of our product categories due to the disruption in our access to physician and facility referral sources. This curtailment was slightly offset by revenue related to COVID-19 response sales and services. We cannot assure you that future governmental policies and initiatives will not significantly disrupt our operations or adversely affect our ability to provide services to our patients in the future. In addition, our current ability to assess potential patients in hospitals varies by hospital and city, but overall our business of setting up new patients in the home is continuing although at lower levels than in recent periods. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 26</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Act, which was signed into law on March 27, 2020, provides a substantial stimulus and assistance package intended to address the impact of the COVID-19 pandemic, including tax relief and government loans, grants and investments. The legislation provides for $175 billion in relief funds to hospitals and other healthcare providers on the front lines of the coronavirus response to support healthcare-related expenses or lost revenue attributable to COVID-19 and to ensure uninsured Americans can get testing and treatment for COVID-19. As a result, we received a payment from the Provider Relief Fund of $3.5 million in April 2020. Payments from the Provider Relief Fund are intended to compensate healthcare providers for lost revenues and incremental expenses incurred in response to the COVID-19 pandemic. The Department of Health and Human Services ("HHS") has stated that Provider Relief Fund payments are not loans and will not need to be repaid. However, as a condition to the receipt of funds, the Company and any other providers must agree to a detailed set of terms and conditions. CMS has indicated that the terms and conditions may be subject to ongoing changes and reporting. To the extent that reporting requirements and terms and conditions are modified, it may affect our ability to comply and may require the return of funds.&#160;In accordance with the terms of acceptance for the grant, we believe we have utilized these funds to prevent, prepare for, and respond to the COVID-19 pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The CARES Act also provides for a temporary suspension of the 2% payment sequestration adjustment currently applied to all Medicare fee-for-service claims. On Wednesday, April 14, 2021, the President signed H.R. 1868 into law, which further extended the suspension of Medicare sequestration until December 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are continuing to monitor any effects or requirements that may result from the CARES Act as many of the provisions in the CARES Act are temporary and may require us to modify our operations and compliance procedures. CMS and other federal agencies have and are likely to issue rules and regulations to implement the CARES Act. The impact of these rules and regulations are unknown and may affect us. To the extent these provisions will expire as stated in the CARES Act, we may experience adverse effects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2019, CMS announced the inclusion of noninvasive ventilator products on the list of products subject to the competitive bidding program for Round 2021, which covers the period of January 1, 2021 through December 31, 2023. Rental revenue from ventilator products represents a significant portion of our revenues (approximately 77.9% of total traditional revenue, excluding COVID-19 response sales and services, for the nine months ended September 30, 2021). On March 9, 2020, CMS announced that due to the COVID-19 pandemic, the United States President's exercise of the Defense Production Act, public concern regarding access to ventilators, and the non-invasive ventilators product category being new to the competitive bidding program, non-invasive ventilators were removed as a product category from Round 2021. On October 27, 2020, CMS announced that it had removed 13 of the 15 remaining product categories from Round 2021, including oxygen and PAP devices, because the payment amounts did not achieve expected savings. The next competitive bidding round is anticipated to begin no sooner than January 1, 2024. As a result of these announcements, we retain the ability to continue to furnish non-invasive ventilators and oxygen and PAP devices for all of our Medicare accredited areas, however, we are uncertain if non-invasive ventilators, oxygen, and PAP devices will be included in future competitive bidding programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The below table highlights summary financial and operational metrics for the last eight quarters.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"></td><td style="width:20.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of U.S. Dollars, except vent patients)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the quarter ended</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">March 31, 2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Profit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Profit %</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash (As of)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Assets (As of)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjusted EBITDA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vent Patients</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Refer to "Non-GAAP&#160;Financial Measures" section below for definition of Adjusted EBITDA.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.</span></div><div style="padding-left:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 27</span></div></td></tr></table></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_97"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Comparison of the Three Months Ended September 30, 2021 and 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended September 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ <br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% <br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,285</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33,447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,162)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,090)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,381</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">62.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">58.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,072)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,919</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,040</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,121)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(27.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-operating income and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1476.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,175</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,945</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(770)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,789</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,804</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,015)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(36.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="padding-right:20.25pt"><span><br/></span></div><div style="padding-right:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our revenue for the three months ended September 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ <br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% <br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Net revenue from rentals</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ventilator rentals, non-invasive and invasive</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other durable medical equipment rentals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Net revenue from sales and services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment and supply sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">COVID-19 response sales and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,285</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33,447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,162)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, net revenue totaled $29.3 million, a decrease of $4.2 million (or 12.4%) from the comparable period in 2020. Excluding COVID-19 response sales and services revenue, net revenue increased $2.9 million (or 11.8%) from the comparable period in 2020. The non-COVID-19 related net revenue growth was driven by an increase in ventilator rental revenue of $1.3 million&#160;(or&#160;6.7%) and rental revenue from other DME of&#160;$0.9 million&#160;(or&#160;35.8%) primarily associated with oxygen and PAP rentals. Non-COVID-19 related equipment sales and services combined increased by $0.6 million (or 28.3%) from the comparable three month period in 2020, primarily as a result of increasing demand for PAPs and respiratory supplies for our PAP patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 28</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, net revenue for COVID-19 response sales and services totaled $1.5 million, compared to $8.6 million during the comparable three month period in 2020 during the height of the pandemic. Current period COVID-19 response sales and services consist primarily of contact and vaccination tracing services. While we expect further COVID-19 response related revenue during the remainder of 2021, the impact of such revenue remains uncertain and dependent on the length and intensity of the COVID-19 pandemic and the availability of such equipment, supplies, and services from other suppliers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As we continue to expand geographically and further penetrate existing territories, we expect growth in our active ventilator patient base and ventilator rental revenue, as well as in our other growing respiratory offerings, though in the short term we anticipate growth to occur at a slightly slower rate than historically realized.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of revenue and gross profit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, cost of revenue totaled $10.9 million, a decrease of $3.1 million (or 22.1%) from the comparable period in 2020. For the three months ended September 30, 2021, COVID-19 response sales and services accounted for $0.9&#160;million (or 7.9%) of these costs, compared to $5.6&#160;million (or 39.8%) of these costs from the comparable period in 2020. Gross profit percentage increased from 58.2% in the three months ended September 30, 2020 to 62.8% in the three months ended September 30, 2021. The increase in overall gross profit percentage is due to declines in lower margin COVID-19 response sales and services as well as fluctuations in product and service mix. We expect our gross profit percentage for our normal operations (non-COVID-19 related) to remain relatively consistent with the current quarter through the end of 2021.</span></div><div style="margin-top:0.05pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expense</span></div><div style="margin-top:0.25pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, selling, general and administrative expenses totaled $13.3 million, a decrease of $0.3 million (or 2.1%) from the comparable prior period. Excluding COVID-19 related revenues, selling, general and administrative expenses as a percentage of revenue decreased to 47.6% for the three months ended September 30, 2021 compared to 52.4% for the three months ended September 30, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The decrease in overall selling, general and administrative expense as compared to the prior period is primarily attributable to a decrease in employee related expenses associated with variable and incentive based compensation. Phantom stock compensation expense also decreased by $0.4 million related to the impact from remeasurement of our phantom stock plan. As we continue to grow into new markets and increase our employee count, we expect selling, general and administrative expenses will grow proportionally as a percentage of revenue through the end of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, research and development expense totaled $0.6&#160;million, an increase of $0.3&#160;million (or 137.0%) from the comparable period in 2020. As we continue to invest in research and development related projects to support our technology initiatives, we expect that associated costs will continue to increase in 2021 relative to 2020 costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, stock-based compensation totaled $1.3 million, an increase of $0.1 million (or 5.5%) from the comparable period in 2020. We expect that as we continue to increase our employee count and utilize stock-based awards as an aspect of employee compensation, stock-based compensation expense will increase accordingly. Stock-based compensation as a percentage of revenue has historically remained near or below 5%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, net interest expense totaled $0.1 million, remaining consistent with the comparable period in 2020. We expect net interest expense to remain relatively consistent with the current quarter through the end of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Provision for income taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, the provision for income taxes was a $1.4 million expense, compared to a $1.1 million expense during the 2020 period, an increase of $0.2 million (or 21.5%). Excluding the benefit of discrete items, our annual estimated effective tax rate for 2021 is 43.4%.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the three months ended September 30, 2021, net income was $1.8 million, a decrease of $1.0 million (or 36.2%) from the comparable period in 2020. Net income as a percentage of net revenue decreased from 8.4% for the three months ended September 30, 2020 to 6.1% for the three months ended September 30, 2021, primarily due to the decrease in COVID-19 related activities and the increase in the provision for income taxes, as described above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Comparison of the Nine Months Ended September 30, 2021 and 2020:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the nine months ended September 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ <br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% <br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">85,100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100,107</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(15,007)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53,748</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">63.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">60,933</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">60.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7,185)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,424)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,915</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,514</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14,599)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(67.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-operating income and expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(782)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(746)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,448</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,141</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13,693)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(64.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision (benefit) for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,318)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,039</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">26,459</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">26.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(21,420)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(81.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 30</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="padding-right:20.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our revenue for the nine months ended September 30, 2021 and 2020:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ <br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% <br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Net revenue from rentals</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ventilator rentals, non-invasive and invasive</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other durable medical equipment rentals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Net revenue from sales and services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equipment and supply sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">COVID-19 response sales and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">85,100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100,107</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(15,007)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(15.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, revenue totaled $85.1 million, a decrease of $15.0 million (or 15.0%) from the comparable period in 2020. Non-COVID-19 related net revenue increased $8.8 million (or 12.4%) from the comparable period in 2020. Ventilator rental revenue increased $3.3 million (or 5.6%) due to our growth in active ventilator patient base. In addition to the ventilator rental revenue growth, rental revenue from other DME grew $2.6 million (or 36.9%) primarily from oxygen therapy and PAPs. In the short term, we anticipate our growth to occur at a slower rate than in historical periods as a result of the pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-COVID-19 related equipment sales and services combined increased by $2.8 million (or 57.0%) from the comparable period in 2020, primarily as a result of increasing demand for home sleep studies, PAPs, and associated supplies for our PAP patients.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of revenue and gross profit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, cost of revenue totaled $31.4&#160;million, a decrease of $7.8 million (or 20.0%) from the comparable period in 2020. For the nine months ended September 30, 2021, COVID-19 response sales and services accounted for $3.5&#160;million (or 11.1%) of these costs, compared to $15.3&#160;million (or 39.1%) of these costs from the comparable period in 2020. Gross profit percentage increased from 60.9% in the nine months ended September 30, 2020 to 63.2% in the nine months ended September 30, 2021. The increase in overall gross profit percentage is due to declines in lower margin COVID-19 response sales and services as well as fluctuations in product and service mix. We expect our gross profit percentage for our normal operations (non-COVID-19 related) to remain relatively consistent with the current quarter through the end of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, selling, general and administrative expenses totaled $40.7&#160;million, an increase of $0.1 million (or 0.2%) from the comparable period in 2020. Excluding COVID-19 related revenues, selling, general and administrative expenses as a percentage of net revenue decreased to 51.1% for the nine months ended September 30, 2021, compared to 56.6% for the nine months ended September 30, 2020. The decrease in selling, general and administrative expense as a percentage of non-COVID-19 related revenues as compared to the prior year period is attributable to lower variable and incentive based employee compensation partially offset by higher employee related expenses to accommodate the overall growth of the Company, as our full time employee count increased to 597 at September 30, 2021, compared to 499 at September 30, 2020, an increase of 19.6%. We expect selling, general and administrative expenses will grow proportionally as a percentage of revenue through the end of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, research and development expense totaled $1.5 million, an increase of $0.8 million (or 117.7%) from the comparable period in 2020. As we continue to invest in research and development related projects to support our technology initiatives, we expect that associated costs will continue to increase in 2021 relative to 2020 costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Loss on disposal of property and equipment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, we recorded a loss on disposal of property and equipment of $0.3&#160;million, compared to a gain of $2.4 million during the comparable period in 2020. As a result of our efforts for the COVID-19 response as described above, certain of our previously placed in service property and equipment was sold during the nine month period ended September 30, 2020. As a result, we recorded a net gain on disposal for related equipment during the prior comparable period. We expect disposals of equipment to generally remain consistent with historical trends, excluding COVID-19 related disposals, through the remainder of the year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other expense (income)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During nine months ended September 30, 2020, we recorded income from the receipt of Provider Relief Fund payments of $3.5 million in April 2020. Payments from the Provider Relief Fund are intended to compensate healthcare providers for lost revenues and incremental expenses incurred in response to the COVID-19 pandemic as described in detail above. There was no receipt of payments from the Provider Relief Fund during the nine months ended September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, stock-based compensation totaled $3.8&#160;million, an increase of $0.3 million (or 7.4%) from the comparable period in 2020. We expect that as we continue to increase our employee count and utilize stock-based awards as an aspect of employee compensation, stock-based compensation expense will increase accordingly. Stock-based compensation as a percentage of revenue has historically remained under 5%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest expense, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, net interest expense totaled $0.2&#160;million, a decrease of $0.2 million (or 39.1%) from the comparable period in 2020, as a result of declines in index rates associated with loans. We expect net interest expense to remain materially consistent through the end of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Provision (benefit) for income taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, the provision for income taxes was a $2.4&#160;million expense, compared to a $5.3 million benefit during the 2020 period. During the nine month period ended September 30, 2020, the Company determined it was more likely than not that deferred tax assets would be realized and made an adjustment to the deferred tax asset valuation allowance, which resulted in a net benefit for the period. Excluding the benefit of discrete items, our annual estimated effective tax rate for 2021 is 43.4%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net income</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, net income was $5.0 million, a decrease of $21.4 million (or 81.0%) from the comparable period in 2020. Net income as a percentage of revenue decreased from 26.4% for the nine months ended September 30, 2020 to 5.9% for the nine months ended September 30, 2021, driven by a decrease in COVID-19 related sales and the comparative benefit from income taxes in the prior period, as described above.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Non-GAAP&#160;Financial Measures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The Company uses Adjusted EBITDA, which is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States ("GAAP") to analyze its financial results and believes that it is useful to investors, as a supplement to U.S. GAAP measures. Management believes Adjusted EBITDA provides helpful information with respect to the Company&#8217;s operating performance as viewed by management, including a view of the Company&#8217;s business that is not dependent on the impact of the Company&#8217;s capitalization structure and items that are not part of the Company&#8217;s day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company&#8217;s operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company&#8217;s employees, (iii) for planning purposes, including the preparation of the Company&#8217;s internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company&#8217;s operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company&#8217;s operating performance in the same manner as management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 32</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In calculating Adjusted EBITDA, certain items (mostly non-cash) are excluded from net income including interest, taxes and depreciation of property and equipment. Set forth below are descriptions of the financial items that have been excluded from net income to calculate Adjusted EBITDA and the material limitations associated with using this non-GAAP financial measure as compared to net income.</span></div><div><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt">Depreciation may be useful for investors to consider because it generally represents the wear and tear on the property and equipment used in our operations. However, we do not believe these charges necessarily reflect the current and ongoing cash charges related to our operating costs.</span></div><div><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt">The amount of interest expense we incur or interest income we generate may be useful for investors to consider and may result in current cash inflows or outflows. However, we do not consider the amount of interest expense or interest income to be a representative component of the day-to-day operating performance of our business.</span></div><div style="padding-left:47.25pt;text-align:justify"><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt">Stock-based compensation may be useful for investors to consider because it is an estimate of the non-cash component of compensation received by the Company&#8217;s directors, officers, employees and consultants. However, stock-based compensation is being excluded from our operating expenses because the decisions which gave rise to these expenses were not made to increase revenue in a particular period, but were made for the Company&#8217;s long-term benefit over multiple periods. While strategic decisions, such as those to issue stock-based awards are made to further our long-term strategic objectives and do impact our earnings under GAAP, these items affect multiple periods and management is not able to change or affect these items within any period.</span></div><div style="padding-left:27pt;text-align:justify"><span><br/></span></div><div style="padding-left:27pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13pt">Income tax expense may be useful for investors to consider because it generally represents the taxes which may be payable for the period and the change in deferred income taxes and may reduce or increase the amount of funds otherwise available for use. However, we do not consider the amount of income tax expense to be a representative component of the day-to-day operating performance of our business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table is a reconciliation of Net income, the most directly comparable GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.967%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the quarter ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,388&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Add back:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,646)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,419</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,847</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,468</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,458</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,720</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,287</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,869</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,569</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Use of Non-GAAP Financial Measures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. It is not a measurement of our financial performance under GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with GAAP or as an alternative to cash flows from operating activities as a measure of the Company's liquidity, and may not be comparable to other similarly titled measures of other businesses. Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our operating results as reported under GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters we consider not to be indicative of ongoing operations; and other companies in our industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 33</span></div></td></tr></table></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_103"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Liquidity and Capital Resources</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents at&#160;September 30, 2021&#160;was $26.9 million, compared to $31.0 million&#160;at&#160;December 31, 2020. Based on our current plan of operations, we believe this amount, when combined with expected cash flows from operations and amounts available under our line of credit will be sufficient to fund our growth strategy and to meet our anticipated operating expenses, capital expenditures, and debt service obligations for at least the next 12 months from the date of this filing. The Company utilizes short term leases with a major supplier that could be extended over a longer term if there was a need for additional liquidity. Additionally, the Company maintains a $10.0 million line of credit with Hancock Whitney Bank which was fully undrawn as of September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:59.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,047)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,770)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4,114)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19,041</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Operating Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by operating activities during the nine months ended September 30, 2021 was $13.8 million, resulting from net income of $5.0 million and non-cash net income changes of $19.1 million, which was partially offset by a decrease in cash resulting from a change in operating assets and liabilities of $10.5 million. The non-cash net income changes primarily consisted of $5.3 million in change of allowance for doubtful accounts, $8.2 million of depreciation, $0.3 million of loss on disposal of property and equipment, $3.8 million of stock-based compensation, $0.8 million income from equity investments and $2.4 million of deferred income tax expense. The primary changes in operating assets and liabilities relate to an increase in accounts receivable of $5.6 million, an increase in prepaid expenses and other assets of $2.3 million, an increase in accounts payable of $2.6 million, a net increase in income taxes receivable/(payable) of $1.8 million, and a decrease in accrued liabilities of $3.7 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by operating activities during the nine months ended September 30, 2020 was $29.3 million, resulting from net income of $26.5 million, non-cash net income adjustments of $7.3 million, and an increase in net operating liabilities of $5.7 million, which was partially offset by an increase in net operating assets of $10.2 million. The non-cash net income adjustments primarily consisted of $7.0 million in change of allowance for doubtful accounts, $6.7 million of depreciation, $2.4 million of gains on disposal of property and equipment, change in deferred tax asset of $7.6 million and $3.6 million of stock-based compensation. The uses of cash related to changes in operating assets primarily consisted of an increase in accounts receivable of $7.0 million and an increase in inventory of $1.4 million. The changes in operating liabilities primarily consisted of an increase in accounts payable of $2.7 million and an increase in accrued liabilities of $2.4 million. The increase in our operating assets was primarily driven by accounts receivable related to COVID-19 response sales and services occurring during the period. Included in our operating cash flows for the period is the receipt of $3.5 million in Provider Relief Funds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in investing activities during the nine months ended September 30, 2021 was $13.2 million, consisting of $13.1 million of purchases of property and equipment and $0.6 million in equity investments, partially offset by $0.5 million of sales proceeds from the disposal of property and equipment. Purchases of property and equipment were primarily related to medical equipment rented to our patients. Combining cash purchases of property and equipment and equipment financed through finance leases, our total capital expenditures for the nine months ended September 30, 2021 were $13.1 million. This represents a $1.9 million, or 17.1%, increase year over year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 34</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in investing activities during the nine months ended September 30, 2020 was $3.0 million, consisting of $8.2 million of purchases of property and equipment, partially offset by $5.2 million of COVID-19 response sales proceeds from the disposal of property and equipment. Purchases of property and equipment were primarily related to medical equipment rented to our patients. Combining cash purchases of property and equipment of $8.2 million and equipment financed through finance leases of $3.0 million, our total capital expenditures for the nine months ended September 30, 2020 were $11.2 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Financing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in financing activities during the nine months ended September 30, 2021 was $4.8 million, consisting of $1.3 million in principal payments on the Term Note (as defined below), $2.1 million in repayments of finance lease liabilities, and $1.4 million for shares redeemed and canceled for tax withholding in connection with RSUs vested in the period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in financing activities during the nine months ended September 30, 2020 was $7.2 million, consisting of $1.2 million in principal payments on the Term Note and $7.7 million in repayments of finance lease liabilities, partially offset by $1.8 million of proceeds from the exercise of stock options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Line of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company maintains a line of credit in the amount of $10.0 million that expires May 1, 2023 under the Commercial Business Loan Agreement. Any amounts advanced on this line will be subject to an interest rate equal to the WSJ prime rate plus a margin of 0.50%, with a 3.50% interest rate floor and will be secured by substantially all of the Company's assets. There were no borrowings against this line of credit at September 30, 2021 or December 31, 2020. While we currently have no immediate plans to draw on this line of credit, the line of credit allows flexibility in funding our future operations subject to compliance with the covenants described above.</span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Commercial Business Loan Agreement, the Company is subject to several restrictive covenants that, among other things, impose operating and financial restrictions on the Company. Financial covenants include a Total Debt to Adjusted EBITDA, a Loan-to-Value Ratio and a Fixed Charged Coverage Ratio, as defined in the Credit Agreement. The Credit Agreement also contains certain customary events of default, including, among other things, failure to make payments when due thereunder and failure to observe or perform certain covenants. The Company was in compliance with all covenants under the Commercial Business Term Loan Agreement in effect at September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:115%">Commercial Term Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 30, 2019, the Company entered into an amendment to the loan agreement providing for a term note (the &#8220;Building Term Note&#8221;) in favor of Hancock Whitney Bank in the principal amount of $4.8 million. The proceeds of the Building Term Note were used to purchase a building to utilize as a new corporate headquarters for the Company. Beginning July 1, 2019, the Company makes monthly payments towards the outstanding balance. The Building Term Note matures on May 30, 2026 and is secured by substantially all of our assets, including the real property acquired with the proceeds of the Building Term Note. The Building Term Note bears interest at a variable rate equal to the one month ICE LIBOR index plus a margin of 2.45% per annum. The Company is required to maintain a loan to value ratio of 85% with respect to the appraised value of the real property. In connection with the Building Term Note, the Company entered into an interest rate swap transaction (the "Interest Rate Swap Transaction") with Hancock Whitney Bank effectively fixing the interest rate for the Building Term Note at 4.68%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On September 19, 2019, the Company entered into a third amendment to the loan agreement providing for a term note (the &#8220;Term Note") in favor of Hancock Whitney Bank in the principal amount of $5.0 million. The proceeds of the Term Note will be used for general corporate purposes. Beginning October 19, 2019, the Company makes monthly payments towards the outstanding balance. The Term Note matures on September 19, 2022 and is secured by substantially all of our assets. The Term Note bears interest at the rate of 4.60% per annum.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Off balance sheet arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has no material undisclosed off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its results of operations or financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 35</span></div></td></tr></table></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_106"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Accounting and Disclosure Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Critical Accounting Principles and Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. We evaluate our estimates on an ongoing basis, including those estimates related to allowance for doubtful accounts, inventory adjustments, impaired assets, income taxes, deferred tax valuation allowances and stock-based compensation costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We state these accounting policies in the notes to the consolidated financial statements and at relevant sections in the Management's Discussion and Analysis of Financial Condition and Results of Operations. The estimates are based on the information that is currently available to us and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We believe that the following critical accounting policies affect the more significant judgments and estimates used in the preparation of our consolidated financial statements:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Accounting under Topic 842</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We lease DME such as non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company considers these rentals to be operating leases.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under FASB ASC Topic 842, &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, we recognize rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which we operate, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Accounting under Topic 606</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We sell DME, replacement parts and supplies to customers and recognize revenue based on contractual payment rates as determined by the payors at the point in time when control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We also provide sleep study services to customers and recognize revenue when the sleep study results are complete, satisfying the performance obligation. In response to the COVID-19 pandemic, we began offering contact and vaccine tracing services, which revenues are recognized in the period in which the service has been provided. The transaction price on equipment sales, sleep studies and contact and vaccine tracing is the amount that we expect to receive in exchange for the goods and services provided. Due to the nature of the DME business, gross charges are retail charges and generally do not reflect what we are ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. We do not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We determine our estimates of contractual allowances and discounts based upon contractual agreements, our policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. We include in the transaction price only the amount that we expect to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 36</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which we operate, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Returns and refunds are not accepted on equipment sales, sleep study services or contact and vaccine tracing services. We do not offer warranties to customers in excess of the manufacturer&#8217;s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. We do not have any partially or unfilled performance obligations related to contracts with customers and as such, we have no contract liabilities as of September 30, 2021.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Allowance for doubtful accounts</span></div><div style="margin-top:0.4pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We estimate that a certain portion of receivables from customers may not be collected and maintain an allowance for doubtful accounts. We evaluate the net realizable value of accounts receivable as of the date of Consolidated Balance Sheets. Specifically, we consider historical realization data including current and historical cash collections, accounts receivable aging trends, other operating trends and relevant business conditions. Because of continuing changes in the healthcare industry and third-party reimbursement, it is possible that the estimates could change, which could have a material impact on the operations and cash flows. If circumstances related to certain customers change or actual results differ from expectations, our estimate of the recoverability of receivables could fluctuate from that provided for in our consolidated financial statements. A change in estimate could impact bad debt expense and accounts receivable. Our allowance for doubtful accounts was&#160;$7.1 million&#160;and&#160;$8.8 million&#160;as of&#160;September 30, 2021 and 2020, respectively, and based on our analysis, we believe the reserve is adequate for any exposure to credit losses.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We account for our stock-based compensation in accordance with ASC 718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock&#8211;based compensation cost for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation cost for RSUs are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the Company&#8217;s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the Company's stock at the end of each period and records a liability based on the percentage of requisite service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We utilize an interest rate swap contract to reduce our exposure to fluctuations in variable interest rates for future interest payments on Term Note.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For determining the fair value of our interest rate swap contract, we use significant other observable market data or assumptions (Level 2 inputs) that we believe market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk.&#160;Our fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company presents a positive ending period fair value of the interest rate swap contract in other long-term assets, as a component of long-term assets, and a negative ending period fair value of the interest rate swap contract in accrued liabilities, as a component of long-term liabilities on the Condensed Consolidated Balance Sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We recognize any differences between the variable interest rate payments and the fixed interest rate settlements from our swap counterparty&#160;as an adjustment to interest expense over the life of the swap. If determined to be effective cash flow hedges, we record the changes in the estimated fair value of the swaps to accumulated other comprehensive income or loss on our Condensed Consolidated Balance Sheets.&#160;To the extent our interest rate swaps are determined to be ineffective, we recognize the changes in the estimated fair value of our swaps in interest and other non-operating expenses, net on our Condensed Consolidated Statements of Income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 37</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Tabular amounts expressed in thousands of US Dollars, except per share amounts)</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are subject to income taxes in numerous jurisdictions. Significant judgment is required in determining the provision for income taxes. Our income tax provisions reflect management&#8217;s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. We recognize assets and liabilities for taxation when it is probable that we will receive refunds or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact our effective tax rate as well as our business and operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted or substantively enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 2 &#8211; Summary of Significant Account Policies&#160;of&#160;the&#160;Notes to Condensed Consolidated Financial Statements&#160;for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial positions and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 38</span></div></td></tr></table></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="padding-right:15.75pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="padding-right:15.75pt;text-align:justify"><span><br/></span></div><div style="padding-right:15.75pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This item is not applicable to smaller reporting companies.</span></div><div><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_112"></div><div style="padding-right:15.75pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-right:15.75pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, the Company's management, including its Chief Executive Officer and Chief Financial Officer, completed an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15 of the Exchange Act. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.51pt">that the Company's disclosure controls and procedures are designed to ensure (a) that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and (b) that such information is accumulated and communicated to the Company's management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure; and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.52pt">that the Company's disclosure controls and procedures are effective.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, there can be no assurance that the Company's disclosures controls and procedures will detect or uncover all failures of persons within the Company and its consolidated subsidiaries to disclose material information otherwise required to be set forth in the Company's periodic reports. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-right:15.75pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="padding-right:15.75pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no changes in the Company's internal control over financial reporting during the three months ended September 30, 2021 that have materially affected, or that are reasonably likely to materially affect, the Company's internal control over financial reporting.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 39</span></div></td></tr></table></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_118"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, we may be subject to various ongoing or threatened legal actions and other proceedings, including those that arise in the ordinary course of business, which may include employment matters, breach of contract disputes, as well as governmental and regulatory matters. Please read Note 8&#8212;Commitments and Contingencies to our condensed consolidated financial statements for more information. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. </span></div><div style="text-align:justify"><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_121"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in &#8220;Risk Factors&#8221; in our&#160;Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 3, 2021, which could materially affect our business, financial condition or future results. Except as set forth below, there have been no material changes in our risk factors from those disclosed in that Annual Report. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">The recall of certain Royal Philips BiPAP and CPAP and mechanical ventilator devices that we distribute and sell could have a significant negative impact on our business, reputation, results of operations, financial condition and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 14, 2021, Royal Philips (&#8220;Philips&#8221;), one of our largest suppliers of BiPAP (bi-level positive airway pressure) and CPAP (continuous positive airway pressure) and mechanical ventilator devices, initiated a voluntary recall notification with the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for certain Philips BiPAP and CPAP and mechanical ventilator devices that we distribute and sell. Philips initiated this recall to address potential health risks related to the polyester-based polyurethane (&#8220;PE-PUR&#8221;) sound abatement foam component in these devices. In July 2021, the FDA identified the Philips recall as a Class I recall, the most serious type of recall. As of September 1, 2021, the FDA has authorized Philips to rework affected first-generation DreamStation CPAP devices, which consists of replacing the PE-PUR sound abatement foam with a new material. In an October 18, 2021 press release, Philips stated that a total of approximately 750,000 repair kits and replacement devices have been produced, of which more than 250,000 have reached customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To date, Philips has produced millions of BiPAP and CPAP and mechanical ventilator devices using the PE-PUR sound abatement foam. Despite a complaint rate of 0.03% in 2020, Philips determined based on testing that there are possible health risks to users of the devices related to this type of foam, including that the foam may degrade into particles that may be ingested or inhaled by the user, and that the foam may off-gas certain chemicals. According to Philips, the potential risks of particulate exposure include headache, irritation, inflammation, respiratory issues, and possible toxic and carcinogenic effects, and the potential health risks of chemical exposure due to off-gassing include headache, irritation, hypersensitivity, nausea/vomiting, and possible toxic and carcinogenic effects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">While Philips produces alternative CPAP and mechanical ventilator devices that are not impacted by the recall, these alternative CPAP and mechanical ventilator devices are being used to replace recalled CPAP and mechanical ventilator devices rather than be sold to suppliers for placement with newly diagnosed patients. Depending on the time it takes for the FDA and Philips to resolve the issue, potential delays and shortages of BiPAP and CPAP and mechanical ventilator devices may occur in our industry, which could have a significant negative impact on our business, reputation, results of operations, financial condition and prospects if we are unable to procure replacement products at a reasonable cost on a timely basis or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, we do not currently know the full scope of potential risks that may arise as a result of the recall and replacement of BiPAP and CPAP and mechanical ventilator devices described above. Due to the volume of our patients currently using, or who in the past have used, the BiPAP and CPAP and mechanical ventilator devices affected by the recall described above as well as future users of any replacement devices, any litigation, class action or governmental enforcement actions (including, but not limited to, claims relating to product liability, negligence, patient harm including claims for personal injury or wrongful death, consumer protection, or fraud, overpayment or improper billing for services and products affected by the recall or replacement) that may involve us could have a significant negative impact on our business, reputation, results of operations, financial condition and prospects. At this time, several class action lawsuits have been filed against Philips in connection with the BiPAP and CPAP and mechanical ventilator devices affected by the recall. In addition, the reporting of product defects or voluntary recalls to the FDA or analogous regulatory bodies outside the United States could result in manufacturing audits, inspections and broader recalls or other disruptions to our and/or our suppliers&#8217; businesses. The recall described above and future recalls, whether voluntary or required, could result in significant costs to us and significant adverse publicity, which could harm our ability to market our products in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 40</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue we receive from third-party payors as well as Medicare and Medicaid is subject to potential retroactive reduction.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payments we receive from governmental healthcare programs, including Medicare and Medicaid, and private third-party payors can be retroactively adjusted after examination during the claims settlement process or as a result of post-payment audits and subsequent recoupment. Governmental healthcare programs and third-party payors may disallow, in whole or in part, our requests for reimbursement, or recoup amounts previously reimbursed, based on determinations by the payors or their third-party audit contractors that certain costs are not reimbursable because either adequate or additional documentation was not provided or because certain services were not covered or deemed to not be medically necessary. Significant adjustments, recoupments or repayments of our Medicare or Medicaid revenue, and the costs associated with complying with investigative audits by regulatory and governmental authorities, could materially and adversely affect our financial condition, results of operations and cash flows.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For example, in late June of 2021, we received initial request letters from DME Medicare Administrative Contractors referencing a previously disclosed U.S. Department of Health and Human Services Office of the Inspector General (&#8220;OIG&#8221;) report and recommendation regarding an audit by OIG of claims relating to one hundred of the Company&#8217;s non-invasive ventilation at home patients and requesting repayment of purported overpayments within the 4-year reopening period prescribed by statue. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2021, the MACs informed us of unfavorable decisions with respect to the redetermination appeals. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 8&#8212;Commitments and Contingencies to our condensed consolidated financial statements for more information. The ultimate resolution of this matter, if unfavorable, could materially and adversely affect our financial condition, results of operations, or cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, from time to time we become aware, either based on information provided by third parties and/or the results of internal audits, of payments from such payor sources that were either wholly or partially in excess of the amount that we should have been paid for the service provided. Overpayments may result from a variety of factors, including insufficient documentation supporting the services rendered or medical necessity of the services or other failures to document the satisfaction of the necessary conditions of payment. We are required by law in most instances to refund the full amount of the overpayment after becoming aware of it, and failure to do so within requisite time limits imposed by the law could lead to significant fines and penalties being imposed on us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furthermore, our initial billing of and payments for services that are unsupported by the requisite documentation and satisfaction of any other conditions of payment, regardless of our awareness of the failure at the time of the billing or payment, could expose us to significant fines and penalties. We could also be subject to exclusion from participation in the Medicare or Medicaid programs in some circumstances as well, in addition to any monetary or other fines, penalties or sanctions that we may incur under applicable federal and/or state law. Our repayment of any such amounts, as well as any fines, penalties or other sanctions that we may incur, could be significant and could have a material and adverse effect on our financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time we are also involved in various external governmental investigations, audits and reviews. Reviews, audits and investigations of this sort can lead to government actions, which can result in the assessment of recoupment of reimbursement, civil or criminal fines or penalties, or other sanctions, including restrictions or changes in the way we conduct business, loss of licensure or exclusion from participation in government healthcare programs. Failure to comply with applicable laws, regulations and rules could have a material and adverse effect on our financial condition, results of operations and cash flows. Furthermore, becoming subject to these governmental investigations, audits and reviews can also require us to incur significant legal and document production expenses as we cooperate with the government authorities, regardless of whether the particular investigation, audit or review leads to identification of underlying noncompliance or wrongdoing.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_124"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Company Repurchases of Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company did not repurchase any equity securities during the quarter ended&#160;September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have not declared or paid any cash or stock dividends on our common shares since our inception and do not anticipate declaring or paying any cash or stock dividends in the foreseeable future. Our subsidiaries are restricted from making distributions or dividend payments to us by the Loan Agreement, subject to certain exceptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 41</span></div></td></tr></table></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_130"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_133"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_136"></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 42</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The exhibits filed as part of this Quarterly Report on Form&#160;10-Q are set forth on the Exhibit&#160;Index below.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Title</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">#2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1729149/000114036119012755/ex2_1.htm">Share Purchase Agreement dated as of January 11, 2017 between PHM Logistics Corporation and Viemed, Inc. Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Registration Statement on Form 10 filed on July 10, 2019.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">#2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1729149/000114036119012755/ex2_2.htm">Asset Purchase Agreement dated as of January 11, 2017 between Patient Home Monitoring Corp. and Viemed Healthcare, Inc. Incorporated by reference to Exhibit 2.2 to the Company&#8217;s Registration Statement on Form 10 filed on July 10, 2019.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">#2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1729149/000114036119012755/ex2_3.htm">Arrangement Agreement dated as of January 11, 2017 between Patient Home Monitoring Corp. and Viemed Healthcare, Inc. Incorporated by reference to Exhibit 2.3 to the Company&#8217;s Registration Statement on Form 10 filed on July 10, 2019.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">#2.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1729149/000114036119012755/ex2_4.htm">Arrangement Agreement Amendment dated as of October 31, 2017 between Patient Home Monitoring Corp. and Viemed Healthcare, Inc. Incorporated by reference to Exhibit 2.4 to the Company&#8217;s Registration Statement on Form 10 filed on July 10, 2019.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1729149/000114036119012755/ex3_1.htm">Notice of Articles of Business Corporation Act of Viemed Healthcare, Inc. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Registration Statement on Form 10 filed on July 10, 2019.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1729149/000172914921000101/exhibit31.htm">Amended and Restated Business Corporation Act Articles of Viemed Healthcare, Inc. Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on June 10, 2021.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a101formofrestrictedstocku.htm">Form of Restricted Stock Unit Award</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a102non-employeedirectorsd.htm">Non-Employee Directors Deferred Compensation Plan</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q32021exhibit311.htm">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q32021exhibit312.htm">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q32021exhibit321.htm">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="q32021exhibit322.htm">Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">* Filed herewith.</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">** Furnished in accordance with Item 601(b)(32)(ii) of Regulation S-K.</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"># Schedules and similar attachments have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or similar attachment to the Securities and Exchange Commission upon request.</span></div></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 43</span></div></td></tr></table></div></div></div><div id="ic737a9539ea24a1d98f7fd15a12e7af7_139"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIEMED HEALTHCARE, INC.</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2021 and 2020</span></div></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange of Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VIEMED HEALTHCARE, INC.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Casey Hoyt</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Casey Hoyt</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Trae Fitzgerald</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trae Fitzgerald</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:174%">Date: November&#160;1, 2021</span></div><div><span><br/></span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:169.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 44</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a101formofrestrictedstocku.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if3180643816a4487a1db248d5bd834ba_58"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RESTRICTED STOCK UNITS AWARD AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS RESTRICTED STOCK UNITS AWARD AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into by and between Viemed Healthcare, Inc., a corporation duly incorporated under the laws of the Province of British Columbia (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and the &#8220;Participant&#8221; (identified in the award notice attached electronically hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Award Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)), an individual, on the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (identified in the Award Notice) pursuant to the Viemed Healthcare, Inc. 2020 Long Term Incentive Plan (effective June 11, 2020) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Plan is incorporated by reference herein in its entirety. Capitalized terms not otherwise defined in this Agreement shall have the meaning given to such terms in the Plan or, if applicable, the Award Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Participant is an Employee or Director, and in connection therewith, the Company desires to grant to Participant the number of restricted stock units identified in the Award Notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), subject to the terms and conditions of this Agreement and the Plan, with a view to increasing Participant&#8217;s interest in the Company&#8217;s welfare and growth&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Participant desires to have the opportunity to be a holder of the RSUs subject to the terms and conditions of this Agreement, the Award Notice and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the premises, mutual covenants and agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Grant of Company Stock and Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the restrictions, forfeiture provisions and other terms and conditions set forth herein and in the Plan and Award Notice, the Company grants to Participant an Award of the number of RSUs identified in the Award Notice, which after the applicable Vesting Date, as described below, shall entitle Participant to receive the number of shares of Company Stock equal to the number of RSUs that have become vested on the applicable Vesting Date. This Agreement the Award Notice of grant of RSUs are subject to the terms and conditions of the Plan, and the terms and conditions of the Plan shall control except to the extent otherwise permitted or authorized in the Plan and specifically addressed in this Agreement. The Plan, the Award Notice and this Agreement shall be administered by the Committee pursuant to the Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Vesting Dates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The RSUs shall vest on the dates provided in the Award Notice.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If Participant&#8217;s Employment or service as a Director is terminated by the Company and its Affiliates or Participant for any reason other than as described in the Award Notice prior to a Vesting Date, then Participant shall immediately forfeit all RSUs which are not vested. Any RSUs forfeited under this Agreement shall automatically revert to the Company and become canceled.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11202773v2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Settlement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Upon becoming vested pursuant to the Award Notice, the Company shall issue or cause to be issued a number of shares of Company Stock equal to the number of RSUs granted to Participant that have become vested on the applicable Vesting Date. All such shares of Company Stock shall be issued within 30 days of the Vesting Date. Notwithstanding the foregoing, the Participant may elect to defer the payment of such shares under the Viemed Healthcare, Inc. Non-Employee Directors Deferred Compensation Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Deferred Compensation Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), subject to the terms of such Deferred Compensation Plan. If such a deferral is made, the Company may credit dividend equivalents as provided in such Deferred Compensation Plan, but only on RSUs that are vested.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Tax Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This grant of RSUs is subject to and the Company shall have the power and the right to deduct or withhold from cash amounts payable to the Participant from the Company or an Affiliate or require the Participant to remit to the Company a cash amount sufficient to satisfy federal, state, and local taxes, domestic or foreign, required by law or regulation to be withheld with respect to any taxable event arising as a result of the RSUs granted, the Plan and this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.68pt">Certain Transfers Void</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any purported transfer of shares of Company Stock or RSUs in breach of any provision of this Agreement and Plan shall be void and ineffectual, and shall not operate to transfer any interest or title in the purported transferee.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt">No Fractional Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All provisions of this Agreement concern whole shares of Company Stock, and no fractional shares shall be issued.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.68pt">Not an Employment or Service Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement is not an employment agreement, and this Agreement shall not be, and no provision of this Agreement shall be construed or interpreted to create any right of Participant to continue Employment with or provide services to the Company, its Subsidiaries or any Affiliate.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any notice, instruction, authorization, request or demand required hereunder shall be in writing, and shall be delivered either by personal delivery, by telegram, telex, telecopy or similar facsimile or electronic means, by certified or registered mail, return receipt requested, or by courier or delivery service, addressed to the Company at the address indicated beneath its signature on the execution page of this Agreement, and to Participant at his address indicated on the Company&#8217;s stock records, or at such other address and number as a party shall have previously designated by written notice given to the other party in the manner hereinabove set forth. Notices shall be deemed given when received, if sent by facsimile or electronic means (confirmation of such receipt by confirmed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11202773v2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">facsimile or electronic transmission being deemed receipt of communications sent by facsimile or electronic means)&#59; and when delivered and receipted for (or upon the date of attempted delivery where delivery is refused), if hand-delivered, sent by express courier or delivery service, or sent by certified or registered mail, return receipt requested. Notwithstanding the foregoing, electronic signatures and delivery will only be permitted if it is acceptable under applicable law.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27.68pt">Amendment and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be amended, modified or superseded only by written instrument executed by the Company and, to the extent required under the Plan, by the Participant. Any waiver of the terms or conditions hereof shall be made only by a written instrument executed and delivered by the party waiving compliance. Any waiver granted by the Company shall be effective only if executed and delivered by a duly authorized executive officer of the Company other than Participant. The failure of any party at any time or times to require performance of any provisions hereof, shall in no manner effect the right to enforce the same. No waiver by any party of any term or condition, or the breach of any term or condition contained in this Agreement in one or more instances shall be deemed to be, or construed as, a further or continuing waiver of any such condition or breach or a waiver of any other condition or the breach of any other term or condition.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:29.01pt">Governing Law and Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. All questions arising with respect to the provisions of this Agreement shall be determined by application of the laws of Delaware, without giving any effect to any conflict of law provisions thereof, except to the extent Delaware state law is preempted by U.S. federal law, the laws of Canada or the laws of the Province of British Columbia. The obligation of the Company to sell and deliver Company Stock hereunder is subject to applicable laws and to the approval of any governmental authority required in connection with the authorization, issuance, sale, or delivery of such Company Stock.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the limitations which this Agreement and Plan impose upon transferability of shares of Company Stock, this Agreement shall bind, be enforceable by and inure to the benefit of the Company and its successors and assigns, and Participant, and Participant&#8217;s permitted assigns and upon death, estate and beneficiaries thereof (whether by will or the laws of descent and distribution), executors, administrators, agents, legal and personal representatives.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt">Community Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Each spouse individually is bound by, and such spouse&#8217;s interest, if any, in any RSUs is subject to, the terms of this Agreement. Nothing in this Agreement shall create a community property interest where none otherwise exists.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:29.67pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement together with the Award Notice and the Plan supersede any and all other prior understandings and agreements, either oral or in writing, between the parties with respect to the subject matter hereof and constitute the sole and only agreements between the parties with respect to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11202773v2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">said subject matter. All prior negotiations and agreements between the parties with respect to the subject matter hereof are merged into this Agreement. Each party to this Agreement acknowledges that no representations, inducements, promises, or agreements, orally or otherwise, have been made by any party or by anyone acting on behalf of any party, which are not embodied in this Agreement or the Plan and that any agreement, statement or promise that is not contained in this Agreement or the Plan shall not be valid or binding or of any force or effect.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:29.67pt">Compliance with Other Laws and Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement, the grant of RSUs and issuance of Company Stock shall be subject to all applicable U.S. federal and state and Canadian and Province of British Columbia or other foreign laws, rules, regulations and applicable rules and regulations of any exchanges on which such securities are traded or listed, and Company rules or policies. Any determination in which connection by the Committee shall be final, binding and conclusive on the parties hereto and on any third parties, including any individual or entity.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;padding-left:27pt">Independent Legal and Tax Advice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Participant has been advised and Participant hereby acknowledges that he has been advised to obtain independent legal and tax advice regarding this Agreement, grant of the RSUs and the disposition of such shares, including, without limitation, the impact of Code Section 409A.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Counterparts and Electronic Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement may be executed in multiple original counterparts, each of which shall be deemed an original, but all of which together shall constitute but one and the same instrument. Participant&#8217;s electronic acceptance of the Award Notice shall be deemed to be Participant&#8217;s execution and acceptance of this Agreement subject to the terms of the Award Notice and the Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">No Rights as Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Participant shall have no rights as a stockholder with respect to the shares of Company Stock underlying the RSUs and this Agreement until such RSUs are vested and shares of Company Stock have been issued to Participant.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Committee shall to the extent applicable interpret and construe this Award to comply with Code Section 409A and Section 24 of the Plan, and to the extent required a Change in Control shall be limited to a Change in Control that complies with Code Section 409A. The Committee may interpret or amend this Award to comply with Code Section 409A without the Participant&#8217;s consent even if such amendment would have an adverse effect on this Award. To the extent required under Code Section 409A, in the case of any Participant who is specified employee, a distribution on account of a separation from service may not be made before the date which is six months after the date of the Participant&#8217;s separation from service (or, if earlier, the date of the Participant&#8217;s death). For purposes of the foregoing and to the extent required by Code Section 409A with respect to an Award, the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">separation from service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">specified employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; all shall be defined in the same manner as those terms are defined for purposes of Section 409A of the Code, and the limitations set forth herein shall be applied in such manner </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11202773v2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(and only to the extent) as shall be necessary to comply with any requirements of Section 409A of the Code that are applicable to the Award as determined by the Committee. Furthermore, to the extent required under Code Section 409A, none of the Company, the Committee or Board shall have any discretion otherwise provided in the Plan or herein to the extent such discretion is prohibited under Code Section 409A for compliance with Code Section 409A with respect to deferred compensation including, without limitation, any discretion to accelerate or substitute as permitted under the Plan or determine an event is or is not a Change in Control. Notwithstanding the foregoing, none of the Company, any Affiliate or any officer, director, employee, shareholder or any agent of any of them guarantees or is responsible for the tax consequences to a Participant with respect to this Award under the Plan and the administration of the Plan, including without limitation, any excise or penalty tax or interest under Code Section 409A. Participant is advised to consult Participant&#8217;s tax advisor with respect to this Award and the tax consequences of this Award of RSUs and any payments hereunder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement is subject to any clawback policies that the Company, with the approval of the Board, may adopt from time to time, and as amended from time to time. Any such policy may subject the RSUs and Company Stock issued with respect to the RSUs under this Agreement to reduction, cancelation, forfeiture or recoupment if certain specified events or wrongful conduct occur, including but not limited to an accounting restatement due to the Company&#8217;s material noncompliance with financial reporting regulations or other events or wrongful conduct specified in any such clawback policy adopted to conform to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and rules promulgated thereunder by the Securities and Exchange Commission and that the Company determines should apply to this Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Participant&#8217;s Acknowledgments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Participant acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts this Agreement subject to all the terms and provisions of the Plan, the Award Notice and this Agreement. The Participant hereby agrees to accept as binding, conclusive, and final all decisions or interpretations of the Committee or the Board, as appropriate, upon any questions arising under the Plan or this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11202773v2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have caused this Agreement to be executed on the date as set out on the Award Notice.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COMPANY&#58;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">VIEMED HEALTHCARE, INC.</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PARTICIPANT&#58;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11202773v2</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a102non-employeedirectorsd.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2f7d2522317e49bc82542151248e1c1a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VIEMED HEALTHCARE, INC.<br>NON-EMPLOYEE DIRECTORS DEFERRED COMPENSATION PLAN</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The purpose of the Viemed Healthcare, Inc. Non-Employee Directors Deferred Compensation Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is to aid the Company in attracting and retaining experienced Non-Employee Directors by providing them with the opportunity to defer receipt, and thus taxation, of the shares of Stock issuable to them under their RSU Awards granted under the Viemed Healthcare, Inc. 2020 Long Term Incentive Plan (effective June 11, 2020). Capitalized terms used but not defined in this Plan have the respective meanings provided in the Appendix, and if not defined therein, shall have the meaning of such terms in the LTIP and RSU Award and in all events as required by Code Section 409A. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Participation and Participant Elections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Participation in the Plan is voluntary. Non-Employee Directors may elect to become Participants and to defer receipt of RSU Awards by filing a Participation Agreement&#47;Enrollment Form with the Committee in accordance with the terms and conditions of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Deferral of RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the terms and conditions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Participant may elect to defer, on a grant-by-grant basis for each Plan Year, the receipt of all or a portion of the shares of Stock (and any Account balance under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) that he or she will be entitled to receive upon vesting of his or her RSU Award for such Plan Year. Such deferral election must be made during the applicable </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> enrollment period for the Plan Year in which the RSU Award is granted. If a Participant elects to defer all or a part of his or her RSU Award for such Plan Year, the deferred portion of the RSU Award will be granted to him or her as restricted stock units under the applicable LTIP, subject to all terms and conditions applicable to such RSU Award (including vesting) but deferred in accordance with the applicable Participation Agreement&#47;Enrollment Form (such deferred restricted stock units, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">DSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). A Participant will be credited with one DSU with respect to each Restricted Stock Unit deferred which represents the right to receive one share of Stock, and each DSU shall be the equivalent of one share of Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Source of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Plan is not a separate source of shares of Stock&#59; rather, all grants of RSU Awards and issuance of shares of Stock in settlement of DSUs that are deferred as DSUs under this Plan, and amounts credited under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 3.1 and 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, will be made under, and subject to all of the terms and conditions of, the applicable LTIP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Election Timing  and Effective Dates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">A Participation Agreement&#47;Enrollment Form must be filed prior to the December 31st immediately preceding the Plan Year for which it is effective or by such earlier deadline as the Committee may prescribe.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Notwithstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.4(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a Participant who is newly eligible for the Plan may file a Participation Agreement&#47;Enrollment Form effective for the remainder of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11193096v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the initial Plan Year and applicable to compensation earned in the remainder of such Plan Year, but only if such election is made not more than 30 days after the Participant becomes eligible for the Plan. If the Non-Employee Director makes an initial election during such 30-day period but </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">after</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the Grant Date of the RSU Award, the portion of the RSU Award eligible for deferral will be equal to the total number of shares of Stock in such RSU Award multiplied by a fraction, the numerator of which is the number of days between the date on which the election is made and the first anniversary of the Grant Date, and the denominator of which is 365.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Contents of Participation Agreement&#47;Enrollment Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Committee will have the discretion to specify the contents of Participation Agreement&#47;Enrollment Forms. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, each Participation Agreement&#47;Enrollment Form will set forth&#58; (a) whether the Participant is electing to defer his or her RSU Award for that Plan Year (and whether it will be continued for all RSU Awards in subsequent years, an evergreen election in accordance with Code Section 409A, until the election is timely revoked by December 31 of the year prior to the year in which the revocation applies)&#59; (b) what portion, if any, of the RSU Award that the Participant wishes to defer for that Plan Year&#59; and (c) the period after which the issuance of the Stock underlying the RSUs, if applicable, is to be made (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Deferral Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Deferral Period shall end on the earlier of a specified date or upon the occurrence of a &#8220;separation of service&#8221; within the meaning of Code Section 409A (such as a Participant&#8217;s last day of Board service) or in accordance with such other terms that may be set forth in the Participation Agreement&#47;Enrollment Form&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Deferral Period that is a specified date may not exceed ten years from the Grant Date of the related RSU Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Cessation of Deferral Elections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Only to the extent permitted under Code Section 409A and in accordance with Code Section 409A, a Participant&#8217;s deferral election(s) in effect under the Plan for a Plan Year in which a Participant is granted an Unforeseeable Emergency distribution in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereof may be terminated by the Committee, effective as soon as practicable following the grant of such emergency distribution.  If a Participant&#8217;s deferral elections under the Plan are terminated in accordance with the foregoing sentence, such Participant shall be ineligible to make deferrals of compensation under the Plan as determined by the Committee in accordance with Code Section 409A and shall only be eligible again for deferrals as determined by the Committee in accordance with Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Modification or Revocation of Election by Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Participant may make an election to change the time of his or her payment from the Plan as set forth in an existing Participation Agreement&#47;Enrollment Form, but any such change must comply with Section 409A, including&#58; (a) lengthening of the Deferral Period by no less than five years from the original payment date under the Participation Agreement&#47;Enrollment Form (as in effect before such amendment)&#59; (b) filing such amended Participation Agreement&#47;Enrollment Form with the Committee at least 12 months prior to the date of the first scheduled payment under the Participation Agreement&#47;Enrollment Form (as in effect before such amendment)&#59; or (c) a 12-month delay in effectiveness of the requested amendment. Under no circumstances may a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11193096v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant&#8217;s Participation Agreement&#47;Enrollment Form be retroactively entered into, modified, or revoked.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Maintenance, Crediting, and Investment of Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Creation and Maintenance of Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Participant&#8217;s DSUs will be notionally credited by the Committee to the Participant&#8217;s Account as and when the RSUs would otherwise have been paid to the Participant, and each DSU shall be deemed to be the equivalent of one share of Stock. Separate Accounts will be maintained for each Participant. In addition, more than one Account may be maintained for a Participant as necessary to reflect separate Participation Agreement&#47;Enrollment Forms specifying different Deferral Periods. A Participant&#8217;s Accounts will be utilized solely as a device for the measurement and determination of the amounts to be paid to the Participant pursuant to this Plan and will not constitute or be treated as a trust fund of any kind.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Dividend Equivalents on Deferred Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The number of DSUs in the Participant&#8217;s Account that are based on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">vested</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> deferred RSUs shall be increased by the following calculations&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)  the number of DSUs that are based on vested RSUs in the Participant&#8217;s Account multiplied by any cash dividend (other than an extraordinary cash dividend that is subject to adjustment under the LTIP) declared by the Company on a share of Stock, divided by the Fair Market Value determined as of the related dividend payment date&#59; and&#47;or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)  the number of DSUs that are based on vested deferred RSUs in the Participant&#8217;s Account on the related Stock dividend payment date multiplied by any Stock dividend declared by the Company on a share of Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the avoidance of doubt, adjustments to DSUs in an Account in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> will be made only with respect to the deferred RSUs that are vested, and no amount will be credited for unvested portions of an RSU Award. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Vesting of Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the vesting and other terms of any RSU Award or the LTIP and after such RSUs are vested, each Participant will be 100% vested in his or her Accounts at all times.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Statement of Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  As soon as administratively feasible after the end of each Plan Year, the Committee will deliver to each Participant an annual statement of his or her Accounts in such form as the Committee deems appropriate, setting forth the balance to the credit of such Participant in his or her Accounts as of the end of the most recently-completed Plan Year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of any change in the number or kind of outstanding shares of Stock, including a stock split or consolidation or as otherwise provided in the LTIP (other than a stock dividend as provided above), an appropriate adjustment shall be made by the Committee in the number of DSUs credited to the Participant&#8217;s Account.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11193096v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Distribution of Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Time and Form of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the shares of Stock underlying a Participant&#8217;s DSUs (including any amount credited to an Account under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) will be distributed at the time or times elected by the Participant in the applicable Participation Agreement&#47;Enrollment Form and shall be paid in a lump sum only in shares of Stock&#59; provided that, fractional shares shall not be issued but shall be forfeited.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Early Payout Triggers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">All amounts in a Participant&#8217;s Account will be paid on the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">earliest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the following&#58;  the earliest date specified in the Participation Agreement&#47;Enrollment Form, a Change of Control, or a Participant&#8217;s death. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Unforeseeable Emergency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In accordance with Code Section 409A, if a Participant experiences an Unforeseeable Emergency, such Participant shall be permitted to withdraw all or a portion of his or her Account in the form of an immediate single-sum payment, subject to the limitations set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.19pt">A request for withdrawal shall be made to the Committee in writing and shall set forth the circumstances surrounding the Unforeseeable Emergency.  As a condition of and part of such request, the Participant shall provide to the Committee his or her written representation that (A) the emergency cannot be relieved by insurance or other reimbursement reasonably available to the Participant, (B) the emergency can only be relieved by liquidation of the Participant&#8217;s assets and any such liquidation would not itself result in severe damage or injury to the Participant, (C) the Participant has no reasonable borrowing capacity to relieve the emergency, and (D) the emergency cannot be relieved by cessation of the Participant&#8217;s deferrals under the Plan.  The Committee shall be entitled to request such additional information as may be reasonably required to determine whether an Unforeseeable Emergency exists or the amount of the emergency, and may establish additional conditions precedent to the review or granting of a request for a withdrawal on account of an Unforeseeable Emergency.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:7.86pt">If the Committee determines that an Unforeseeable Emergency exists, the Committee shall authorize the immediate distribution of the amount required to meet the financial need created by such Unforeseeable Emergency, including any taxes payable on such amount, and, if required, the cessation of the Participant&#8217;s deferrals to the Plan as permitted in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Issuance of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All shares of Stock or other securities delivered under the Plan and the applicable LTIP will be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under this Plan, the LTIP or the rules, regulations, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11193096v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other requirements of the Securities and Exchange Commission, any Stock Exchange on which such shares of Stock or other securities are then listed, and any applicable Canadian, U.S. federal, state, or local securities laws, and the Board may cause one or more legends to be put on any such certificates to make appropriate reference to such restrictions.  No Participant shall have any rights of ownership of Stock or a stockholder until such time as the shares of Stock are issued to the Participant pursuant to this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Rights of Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Once shares of Stock have been issued to a Participant in settlement of his or her DSUs and Accounts, the Participant is free to hold or dispose of such shares, subject to applicable securities laws and any internal policy of the Company then in effect and applicable to the Participant, including, but not limited to, the Company&#8217;s insider trading policies and any Director stock ownership guidelines. Notwithstanding the foregoing and except as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and the applicable LTIP, a DSU or the Participant&#8217;s Account balance, prior to settlement, will not entitle the Participant to any rights or privileges of ownership (including, without limitation, dividend and voting rights) in any share of Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Acceleration of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A Participant will have no right to compel any accelerated payment of any amounts due to him or her under the Plan. The Company may accelerate the payment of some or all of the amounts due to a Participant in a given year only in accordance with Section 409A and the terms of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Delay of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may delay the payment of some or all of the amounts due to a Participant in a given year only in accordance with Section 409A and the terms of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Beneficiary Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Right to Designate Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Participant has the right, at any time, to designate one or more Persons as his or her Beneficiary for his or her Account. A Beneficiary designation may be made, and may be amended, by the Participant by filing a written designation with the Committee, on such form and in accordance with such procedures as the Committee shall establish from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">No Beneficiary Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If a Participant fails to designate a Beneficiary as provided above, or if all designated Beneficiaries predecease the Participant, then the Participant will be deemed to have designated the surviving spouse of the Participant as the designated Beneficiary. If the Participant dies without a designated Beneficiary (or spouse as the deemed designated Beneficiary), the Participant&#8217;s estate will be deemed Beneficiary and all benefits remaining under this Plan and DSUs will be payable to the executor or personal representative of such estate. The payment of benefits under this Plan to a Beneficiary will fully and completely discharge the Company and the Committee from all further obligations under this Plan and Participant&#8217;s Account, DSUs and the LTIP and RSU Awards with respect to RSU Awards deferred under this Plan with respect to that Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11193096v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Plan will be administered by the Committee, which has the power to interpret the Plan and, subject to its provisions, to prescribe, amend, and rescind Plan rules and to make all determinations necessary for the Plan&#8217;s administration. Notwithstanding the foregoing, the Board has the authority to amend, discontinue, or terminate the Plan as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Authority and Limitations of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All rules, interpretations, and decisions of the Committee are conclusive and binding on all Persons, including, but not limited to, the Company, Participants, and Beneficiaries. No member of the Committee or the Board will be liable for any action or determination made in good faith by the Committee or the Board with respect to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Delegation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Committee may delegate any of its administrative duties and powers to any officer or employee of the Company as it deems appropriate, except for any duties that may not be delegated pursuant to applicable law or regulation. In administering the Plan, the Committee may employ attorneys, consultants, accountants, or other Persons, and the Company and the Committee will be entitled to rely on the advice or opinions of such Persons. All ordinary and reasonable expenses of this Plan will be paid by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Recusal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any member of the Committee who is due a benefit under the Plan must recuse himself or herself from any Committee deliberations that concern his or her benefits, including deliberations concerning such member&#8217;s eligibility for a benefit or his or her level of benefits&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that this limitation does not apply to deliberations that apply to Participants generally rather than the particular member at issue.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Amendment and Termination of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Board, in its sole discretion, may amend, suspend or discontinue the Plan or any deferral election at any time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that no such amendment, suspension, or discontinuance will reduce the accrued benefit under the Plan of any Participant except to the extent necessary to comply with any provision of federal, state, or other applicable law. The Board further has the right, without a Participant&#8217;s consent, to amend or modify the terms of the Plan and such Participant&#8217;s deferrals to the extent that the Committee deems it necessary to avoid adverse or unintended tax consequences to such Participant under Section 409A. In addition, the Committee has the authority to approve administrative and technical amendments to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Board, in its sole discretion, may terminate the Plan at any time, as long as such termination complies with then applicable tax and other requirements (including, but not limited to, Section 409A). Unless another provision of Code Section 409A provides otherwise, distributions of outstanding Account balances as of the date on which the Plan is terminated will be made in a lump sum payment 12 months after such termination, unless the right to receive a distribution in accordance with the terms of the Plan would occur before the end of such 12-month period, in which case distribution will be made in accordance with the terms of the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11193096v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Plan and the DSUs are intended to comply with Code Section 409A. If any provision of the Plan is capable of being interpreted in more than one manner, to the extent feasible, the provision will be interpreted in a manner that does not result in an excise tax under Code Section 409A.  This Plan and all Participation Agreement&#47;Enrollment Forms are intended to comply and shall be interpreted to comply with the requirements of Code Section 409A including, without limitation, to the extent required using applicable definitions from Code Section 409A.  In the case of any Participant who is a specified employee under Code Section 409A, a distribution on account of a separation from service may not be made before the date which is six (6) months after the date of the Participant&#8217;s separation from service (or, if earlier, the date of the Participant&#8217;s death).  For purposes of the foregoing, the terms &#8220;separation from service&#8221; and &#8220;specified employee&#8221;, all shall be defined in the same manner as those terms are defined for purposes of Code Section 409A, and the limitations set forth herein shall be applied in such manner (and only to the extent) as shall be necessary to comply with any requirements of Code Section 409A that are applicable to the Award as determined by the Committee.  Notwithstanding the foregoing, none of the Company, the Committee, any Company Affiliate or their directors, stockholders, members, officers, employees or agents of any of the foregoing guarantee or are responsible for the tax consequences to a Participant, designated Beneficiary or other Person with respect to the Plan, Accounts and DSUs including, without limitation, an excise tax under Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Unfunded Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Plan is intended to be an unfunded plan maintained primarily for the purpose of providing deferred compensation for Non-Employee Directors. All payments pursuant to the Plan will be made from the general funds of the Company and no special or separate fund will be established or other segregation of assets made to assure payment. No Participant or any other Person has under any circumstances any interest in any particular property or assets of the Company as a result of participating in the Plan. Notwithstanding the foregoing, the Company may (but is not obligated to) create one or more grantor trusts, the assets of which are subject to the claims of the Company&#8217;s creditors, to assist it in accumulating funds to pay its obligations under the Plan. In the event that such a trust is established, no Participant will have any right to compel the investment of any amounts deposited in such trust.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Nonassignability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as specifically set forth in the Plan with respect to the designation of Beneficiaries, neither a Participant nor any other Person has any right to commute, sell, assign, transfer, pledge, anticipate, mortgage, or otherwise encumber, transfer, hypothecate, or convey in advance of actual receipt the amounts, if any, payable under this Plan, which are, and all rights to which are, expressly declared to be unassignable and non-transferable. No part of the amounts payable will, prior to actual payment, be subject to seizure or sequestration for the payment of any debts, judgments, alimony, or separate maintenance owed by a Participant or any other Person, nor be transferable by operation of law in the event of a Participant&#8217;s or any other Person&#8217;s bankruptcy or insolvency.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11193096v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Validity and Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The invalidity or unenforceability of any provision of this Plan will not affect the validity or enforceability of any other provision of this Plan, which will remain in full force and effect, and any prohibition or unenforceability in any jurisdiction will not invalidate or render unenforceable such provision in any other jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The validity, interpretation, construction, and performance of this Plan shall in all respects be governed by the laws and provisions as provided in Section 19 of the LTIP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing in this Plan or any instrument executed pursuant to this Plan will confer upon any Participant any right to continue as a director of the Company or Company Affiliate or affect the right of the Company or Company Affiliate to terminate the services of any Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Underlying Plans and Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing in this Plan prevents the Company from modifying, amending or terminating the LTIP or any other plans and programs pursuant to which compensation is earned and which is deferred under this Plan.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">* * * * * * * * * * * * *</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As approved by the Compensation Committee on August ___, 2021 and adopted by the Board of Directors on August ___, 2021.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11193096v3</font></div></div></div><div id="i2f7d2522317e49bc82542151248e1c1a_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Appendix A<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise defined in this Plan, the following terms (and capitalized variants of such terms) have the meanings indicated, unless the context clearly indicates otherwise&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the bookkeeping accounts maintained by the Company for each Participant pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Person entitled receive any benefits payable under this Plan with respect to a given Participant pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a &#8220;Change of Control&#8221; as defined in the applicable LTIP, provided that such event constitutes a change in ownership or effective control of the Company or a change in ownership of a substantial portion of the Company&#8217;s assets, as such terms as defined in Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Committee as defined in the LTIP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Viemed Healthcare, Inc., a corporation duly incorporated under the laws of the Province of British Columbia, or any successor in interest.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Deferral Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">DSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning provided in the applicable LTIP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the date on which the RSU Award was granted to a given Participant under the LTIP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">LTIP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Viemed Healthcare, Inc. Long Term Incentive Plan (effective June 11, 2020) or any successor equity incentive plan under which shares of Stock may be granted to Non-Employee Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning of &#8220;Director&#8221; as defined in the LTIP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Non-Employee Director who elects to participate by filing a Participation Agreement&#47;Enrollment Form as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and any former Non-Employee Director who has outstanding deferred amounts under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Participation Agreement&#47;Enrollment Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the form completed by a Participant in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11193096v3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a natural person or company, and also means the group or syndicate created when two or more Persons act as a syndicate or other group (including, without limitation, a partnership or limited partnership).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means this Viemed Healthcare, Inc. Non-Employee Directors Deferred Compensation Plan, as it may be amended from time to time in accordance with its terms.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a twelve-month period beginning January 1 and ending the following December&#160;31.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RSU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a restricted stock unit granted under an Award under the LTIP, which is the right to receive one share of Stock upon vesting and payment of such Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the annual restricted stock units granted by the Company to a Non-Employee Director for his or her services as a member of the Board under the LTIP that by its terms is settled solely in shares of Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means Section 409A of the Internal Revenue Code of 1986, as amended, including all regulations and guidance issued under such section, or any successor provisions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Company&#8217;s common stock, as defined in the LTIP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Unforeseeable Emergency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to a Participant, his or her spouse, dependents (as defined in Code Section 152, without regard to Sections 152(b)(1), (b)(2), and (d)(1)(B)) or Beneficiary, a non-reimbursable severe financial hardship attributable to (i) a sudden and unexpected illness or accident or (ii) funeral expenses, and also means with respect to the Participant (x) a property loss due to casualty that is not otherwise covered by insurance, (y) imminent foreclosure or eviction from the Participant&#8217;s primary residence, or (z) a similar extraordinary and unforeseeable circumstance beyond the control of the Participant, as determined by the Committee and as defined in Code Section 409A.  For purposes of this Plan, the purchase of a home and the payment of college tuition are not Unforeseeable Emergencies.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11193096v3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>q32021exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib71a63edbcee410a95915a4f64b1b408_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a)&#47;15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Casey Hoyt, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this Quarterly Report on Form 10-Q of Viemed Healthcare, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;1, 2021</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Casey Hoyt</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:2.25pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Casey Hoyt</font></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div style="margin-bottom:1pt"><font><br></font></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>q32021exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5e3b10f6449043589a05173ab451e976_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#212121;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a)&#47;15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Trae Fitzgerald, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">I have reviewed this Quarterly Report on Form 10-Q of Viemed Healthcare, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.11pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;1, 2021</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Trae Fitzgerald</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:2.25pt"><font><br></font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trae Fitzgerald</font></div><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="margin-bottom:1pt"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>q32021exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1dd3761796384c36a33717329c355b9d_1"></div><div style="min-height:72pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Casey Hoyt, the Chief Executive Officer of Viemed Healthcare, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), hereby certify, that, to my knowledge&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The Quarterly Report on Form 10-Q for the period ended September 30, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;1, 2021</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Casey Hoyt</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Casey Hoyt</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>q32021exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7e21d0e85d954ba28d656244e0b04349_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Trae Fitzgerald, the Chief Financial Officer of Viemed Healthcare, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), hereby certify, that, to my knowledge&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The Quarterly Report on Form 10-Q for the period ended September 30, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;1, 2021</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Trae Fitzgerald</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trae Fitzgerald</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>vmd-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:fbb1b016-a19a-460d-bfda-ed9a0f837dc5,g:50e705b0-d493-4f83-95b4-caa6929c52c8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vmd="http://www.viemed.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.viemed.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vmd-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vmd-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vmd-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vmd-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.viemed.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandOperations" roleURI="http://www.viemed.com/role/NatureofBusinessandOperations">
        <link:definition>2101101 - Disclosure - Nature of Business and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandOperationsDetails" roleURI="http://www.viemed.com/role/NatureofBusinessandOperationsDetails">
        <link:definition>2402401 - Disclosure - Nature of Business and Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails" roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies (Customer Percentages) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies (Inventory and Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails" roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies (Equity investments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies (Revenue Recognition) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.viemed.com/role/PropertyandEquipment">
        <link:definition>2111103 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.viemed.com/role/PropertyandEquipmentTables">
        <link:definition>2312302 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofFixedAssetsDetails" roleURI="http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails">
        <link:definition>2413407 - Disclosure - Property and Equipment (Schedule of Fixed Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNarrativeDetails" roleURI="http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails">
        <link:definition>2414408 - Disclosure - Property and Equipment (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CurrentLiabilities" roleURI="http://www.viemed.com/role/CurrentLiabilities">
        <link:definition>2115104 - Disclosure - Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CurrentLiabilitiesTables" roleURI="http://www.viemed.com/role/CurrentLiabilitiesTables">
        <link:definition>2316303 - Disclosure - Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CurrentLiabilitiesDetails" roleURI="http://www.viemed.com/role/CurrentLiabilitiesDetails">
        <link:definition>2417409 - Disclosure - Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandLeaseLiabilities" roleURI="http://www.viemed.com/role/DebtandLeaseLiabilities">
        <link:definition>2118105 - Disclosure - Debt and Lease Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandLeaseLiabilitiesTables" roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesTables">
        <link:definition>2319304 - Disclosure - Debt and Lease Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandLeaseLiabilitiesLineofCreditNarrativeDetails" roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails">
        <link:definition>2420410 - Disclosure - Debt and Lease Liabilities (Line of Credit Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails" roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails">
        <link:definition>2421411 - Disclosure - Debt and Lease Liabilities (Commercial Term Notes Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandLeaseLiabilitiesScheduleofNotesPayableDetails" roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails">
        <link:definition>2422412 - Disclosure - Debt and Lease Liabilities (Schedule of Notes Payable) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandLeaseLiabilitiesLeaseLiabilitiesDetails" roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesLeaseLiabilitiesDetails">
        <link:definition>2423413 - Disclosure - Debt and Lease Liabilities (Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandLeaseLiabilitiesFinanceLeaseLiabilitiesDetails" roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesFinanceLeaseLiabilitiesDetails">
        <link:definition>2424414 - Disclosure - Debt and Lease Liabilities (Finance Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails" roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails">
        <link:definition>2425415 - Disclosure - Debt and Lease Liabilities (Operating Lease Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.viemed.com/role/FairValueMeasurement">
        <link:definition>2126106 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.viemed.com/role/FairValueMeasurementTables">
        <link:definition>2327305 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementRecurringBasisDetails" roleURI="http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails">
        <link:definition>2428416 - Disclosure - Fair Value Measurement (Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementNarrativeDetails" roleURI="http://www.viemed.com/role/FairValueMeasurementNarrativeDetails">
        <link:definition>2429417 - Disclosure - Fair Value Measurement (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.viemed.com/role/ShareholdersEquity">
        <link:definition>2130107 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.viemed.com/role/ShareholdersEquityTables">
        <link:definition>2331306 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityIssuedandOutstandingShareCapitalDetails" roleURI="http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails">
        <link:definition>2432418 - Disclosure - Shareholders' Equity (Issued and Outstanding Share Capital) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityStockbasedCompensationDetails" roleURI="http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails">
        <link:definition>2433419 - Disclosure - Shareholders' Equity (Stock-based Compensation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityOptionsStockOptionActivityDetails" roleURI="http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails">
        <link:definition>2434420 - Disclosure - Shareholders' Equity (Options, Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityOptionsNarrativeDetails" roleURI="http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails">
        <link:definition>2435421 - Disclosure - Shareholders' Equity (Options, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityOptionsFairValueAssumptionsDetails" roleURI="http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails">
        <link:definition>2436422 - Disclosure - Shareholders' Equity (Options, Fair Value Assumptions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityRestrictedStockUnitsDetails" roleURI="http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails">
        <link:definition>2437423 - Disclosure - Shareholders' Equity (Restricted Stock Units) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityPhantomShareUnitsDetails" roleURI="http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails">
        <link:definition>2438424 - Disclosure - Shareholders' Equity (Phantom Share Units) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.viemed.com/role/CommitmentsandContingencies">
        <link:definition>2139108 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.viemed.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2440425 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.viemed.com/role/IncomeTaxes">
        <link:definition>2141109 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.viemed.com/role/IncomeTaxesDetails">
        <link:definition>2442426 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.viemed.com/role/EarningsPerShare">
        <link:definition>2143110 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.viemed.com/role/EarningsPerShareTables">
        <link:definition>2344307 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.viemed.com/role/EarningsPerShareDetails">
        <link:definition>2445427 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vmd_LeaseLiabilityCurrent" abstract="false" name="LeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vmd_COVID19ResponseSalesMember" abstract="true" name="COVID19ResponseSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_TermNoteMember" abstract="true" name="TermNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_NetNonCashChangesToOperatingLeaseBalances" abstract="false" name="NetNonCashChangesToOperatingLeaseBalances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vmd_BuildingTermNoteMember" abstract="true" name="BuildingTermNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_DebtInstrumentCovenantLoanToValueRatio" abstract="false" name="DebtInstrumentCovenantLoanToValueRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vmd_OtherDurableMedicalEquipmentRentalsMember" abstract="true" name="OtherDurableMedicalEquipmentRentalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_AssetsHeldUnderFinanceLeasesMember" abstract="true" name="AssetsHeldUnderFinanceLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_LeasePayments" abstract="false" name="LeasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vmd_EquipmentSalesMember" abstract="true" name="EquipmentSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_EquipmentMedicalMember" abstract="true" name="EquipmentMedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_NumberOfStockClasses" abstract="false" name="NumberOfStockClasses" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vmd_DebtAndLeasesAbstract" abstract="true" name="DebtAndLeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vmd_DebtInstrumentInterestRateFloorRate" abstract="false" name="DebtInstrumentInterestRateFloorRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vmd_MonthlyRentalPaymentsMember" abstract="true" name="MonthlyRentalPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_LeaseLiabilityNoncurrent" abstract="false" name="LeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vmd_AccruedTradePayablesCurrent" abstract="false" name="AccruedTradePayablesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments" abstract="false" name="DistributionsOfEarningsReceivedFromEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="vmd_DebtandLeaseDisclosureTextBlock" abstract="false" name="DebtandLeaseDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vmd_OmnibusPlanMember" abstract="true" name="OmnibusPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_NetNonCashChangesToFinanceLeaseBalances" abstract="false" name="NetNonCashChangesToFinanceLeaseBalances" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vmd_MedicareAndMedicaidMember" abstract="true" name="MedicareAndMedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vmd_LiabilitiesLesseeTableTextBlock" abstract="false" name="LiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="vmd_FurnitureAndEquipmentMember" abstract="true" name="FurnitureAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vmd_VentilatorRentalMember" abstract="true" name="VentilatorRentalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" abstract="false" name="AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>vmd-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:fbb1b016-a19a-460d-bfda-ed9a0f837dc5,g:50e705b0-d493-4f83-95b4-caa6929c52c8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vmd-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ed345133-66b8-4ad7-becf-31c884203cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_d47f8ab5-5b30-43f5-b640-90be8bb89ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ed345133-66b8-4ad7-becf-31c884203cfd" xlink:to="loc_us-gaap_IncomeTaxesReceivable_d47f8ab5-5b30-43f5-b640-90be8bb89ad5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20c1516d-6121-4baf-be96-4ee41222625f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ed345133-66b8-4ad7-becf-31c884203cfd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20c1516d-6121-4baf-be96-4ee41222625f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_92103fbe-8708-4f83-b623-49f0821571ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ed345133-66b8-4ad7-becf-31c884203cfd" xlink:to="loc_us-gaap_InventoryNet_92103fbe-8708-4f83-b623-49f0821571ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c4106188-b789-4d10-9826-5d43c250ac88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ed345133-66b8-4ad7-becf-31c884203cfd" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c4106188-b789-4d10-9826-5d43c250ac88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0536737f-76a0-44a4-b5b0-645a7f66467e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_ed345133-66b8-4ad7-becf-31c884203cfd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0536737f-76a0-44a4-b5b0-645a7f66467e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_776fb49f-0a2d-4dae-ae95-8fabf5076453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a0106576-bdcd-4f56-97d1-e3cb77bd02e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_776fb49f-0a2d-4dae-ae95-8fabf5076453" xlink:to="loc_us-gaap_LiabilitiesCurrent_a0106576-bdcd-4f56-97d1-e3cb77bd02e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_f3e9d68e-25ff-4f6e-a49e-6f9e899b4df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_776fb49f-0a2d-4dae-ae95-8fabf5076453" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_f3e9d68e-25ff-4f6e-a49e-6f9e899b4df5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_21f11503-254a-4f8a-a713-b39abb8f8b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_898c56c0-6b74-4ecd-afcd-edae432aa899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21f11503-254a-4f8a-a713-b39abb8f8b95" xlink:to="loc_us-gaap_CommonStockValue_898c56c0-6b74-4ecd-afcd-edae432aa899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ba5591ba-ceec-4002-965f-88f0b28bef56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21f11503-254a-4f8a-a713-b39abb8f8b95" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ba5591ba-ceec-4002-965f-88f0b28bef56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_63726373-e735-47fd-ae14-4c71c2b0da89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21f11503-254a-4f8a-a713-b39abb8f8b95" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_63726373-e735-47fd-ae14-4c71c2b0da89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed52ca10-9785-40e8-802c-2e5b95694c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21f11503-254a-4f8a-a713-b39abb8f8b95" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ed52ca10-9785-40e8-802c-2e5b95694c19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0facd50d-b9c7-4ba4-8d67-cba76b435268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d922c8b3-e06d-4995-a336-08f9b95a63d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0facd50d-b9c7-4ba4-8d67-cba76b435268" xlink:to="loc_us-gaap_Liabilities_d922c8b3-e06d-4995-a336-08f9b95a63d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_468ff13d-22b3-4ccb-a7dd-ce567528fa50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0facd50d-b9c7-4ba4-8d67-cba76b435268" xlink:to="loc_us-gaap_StockholdersEquity_468ff13d-22b3-4ccb-a7dd-ce567528fa50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1c806d06-fd3b-4eaa-82af-d5f25a29445f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0facd50d-b9c7-4ba4-8d67-cba76b435268" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1c806d06-fd3b-4eaa-82af-d5f25a29445f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_0c0aa4b4-d3ab-4af0-94c5-49b0e8a63220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_30112ba2-558c-4c8d-ab43-2494e49d7c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0c0aa4b4-d3ab-4af0-94c5-49b0e8a63220" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_30112ba2-558c-4c8d-ab43-2494e49d7c7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_f1a23fd8-44d3-442e-be95-2ef2345b0e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0c0aa4b4-d3ab-4af0-94c5-49b0e8a63220" xlink:to="loc_us-gaap_Investments_f1a23fd8-44d3-442e-be95-2ef2345b0e3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_d5a0f25e-fd87-4dbe-a80a-a5cb2ae268b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0c0aa4b4-d3ab-4af0-94c5-49b0e8a63220" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_d5a0f25e-fd87-4dbe-a80a-a5cb2ae268b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_de068e71-afa9-47cc-b0a4-de7b0bab3318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_0c0aa4b4-d3ab-4af0-94c5-49b0e8a63220" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_de068e71-afa9-47cc-b0a4-de7b0bab3318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e1794a30-8be0-41f7-8aa9-0237637c8117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_80434a18-a79e-442a-ba61-c563f28517b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e1794a30-8be0-41f7-8aa9-0237637c8117" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_80434a18-a79e-442a-ba61-c563f28517b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_cb6c676d-0513-42d8-a96e-5a6bbc062fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e1794a30-8be0-41f7-8aa9-0237637c8117" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_cb6c676d-0513-42d8-a96e-5a6bbc062fa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3dffc0e4-15fe-49ab-8172-d01484092c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e1794a30-8be0-41f7-8aa9-0237637c8117" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3dffc0e4-15fe-49ab-8172-d01484092c90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeaseLiabilityCurrent_231ca339-50f0-496d-8059-9c5736f4a939" xlink:href="vmd-20210930.xsd#vmd_LeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e1794a30-8be0-41f7-8aa9-0237637c8117" xlink:to="loc_vmd_LeaseLiabilityCurrent_231ca339-50f0-496d-8059-9c5736f4a939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_4829b101-307e-40fb-919c-6c8f38a41dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e1794a30-8be0-41f7-8aa9-0237637c8117" xlink:to="loc_us-gaap_LongTermDebtCurrent_4829b101-307e-40fb-919c-6c8f38a41dc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_599e9c6a-a57d-4b1d-ab0f-f6191412b9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e1794a30-8be0-41f7-8aa9-0237637c8117" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_599e9c6a-a57d-4b1d-ab0f-f6191412b9e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_a20fbfce-4f79-4b9f-a394-aa7f96826556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeaseLiabilityNoncurrent_364538e1-f881-4f91-aefc-1441d39474b8" xlink:href="vmd-20210930.xsd#vmd_LeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_a20fbfce-4f79-4b9f-a394-aa7f96826556" xlink:to="loc_vmd_LeaseLiabilityNoncurrent_364538e1-f881-4f91-aefc-1441d39474b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b1ae9f29-e2cc-4355-9afc-fa3c7fcb6901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_a20fbfce-4f79-4b9f-a394-aa7f96826556" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b1ae9f29-e2cc-4355-9afc-fa3c7fcb6901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_dad70216-ffbe-406b-aa20-f1240c3e6269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_a20fbfce-4f79-4b9f-a394-aa7f96826556" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_dad70216-ffbe-406b-aa20-f1240c3e6269" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b0f5af9f-097f-44e9-871c-cfa46d8d4e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_94855b67-f92d-42e2-9824-3eebb5c30b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b0f5af9f-097f-44e9-871c-cfa46d8d4e2a" xlink:to="loc_us-gaap_AssetsCurrent_94855b67-f92d-42e2-9824-3eebb5c30b5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_257d165d-302a-4a80-8018-933ed7246cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b0f5af9f-097f-44e9-871c-cfa46d8d4e2a" xlink:to="loc_us-gaap_AssetsNoncurrent_257d165d-302a-4a80-8018-933ed7246cfd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="vmd-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ff4491b9-e783-42c6-9685-68500baf7ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f2d4a21c-c6fe-4dc7-8890-d5cf3c57fd36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ff4491b9-e783-42c6-9685-68500baf7ab5" xlink:to="loc_us-gaap_NetIncomeLoss_f2d4a21c-c6fe-4dc7-8890-d5cf3c57fd36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bd2a5723-d0ad-4e02-a879-1df9b58c3f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ff4491b9-e783-42c6-9685-68500baf7ab5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_bd2a5723-d0ad-4e02-a879-1df9b58c3f67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8272c217-b58f-4d1e-8700-b12de74503a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_16d017a4-bfd8-4026-a6aa-487a7861a4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8272c217-b58f-4d1e-8700-b12de74503a1" xlink:to="loc_us-gaap_OperatingIncomeLoss_16d017a4-bfd8-4026-a6aa-487a7861a4f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3a91e5cd-555b-4f11-bcfb-37f446a784d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8272c217-b58f-4d1e-8700-b12de74503a1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3a91e5cd-555b-4f11-bcfb-37f446a784d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_30036990-ef35-428d-baa1-9bd45fa58788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8272c217-b58f-4d1e-8700-b12de74503a1" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_30036990-ef35-428d-baa1-9bd45fa58788" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6803dbb6-c450-4a85-858c-f1d401913144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5db1f83a-ba37-43fd-81eb-85a82a897536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6803dbb6-c450-4a85-858c-f1d401913144" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5db1f83a-ba37-43fd-81eb-85a82a897536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2166ce06-8526-4133-bab1-f34f7787865e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6803dbb6-c450-4a85-858c-f1d401913144" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2166ce06-8526-4133-bab1-f34f7787865e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_a52e1c2a-e1ec-4606-9df1-4f398953388e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_60b042c9-95cd-4e80-9fab-869d61111662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_a52e1c2a-e1ec-4606-9df1-4f398953388e" xlink:to="loc_us-gaap_Revenues_60b042c9-95cd-4e80-9fab-869d61111662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_301aba60-332c-4f93-bd2a-9ef6a6faef23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_a52e1c2a-e1ec-4606-9df1-4f398953388e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_301aba60-332c-4f93-bd2a-9ef6a6faef23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8162ddef-d913-44c5-a655-96fa7ccbf976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d93f8473-3698-4ff8-b26f-e8a9d1182329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8162ddef-d913-44c5-a655-96fa7ccbf976" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_d93f8473-3698-4ff8-b26f-e8a9d1182329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7ec39396-253f-405e-905a-d23f97e5454f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_258c2c1f-3709-433f-a0bf-f593e4464c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7ec39396-253f-405e-905a-d23f97e5454f" xlink:to="loc_us-gaap_GrossProfit_258c2c1f-3709-433f-a0bf-f593e4464c5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_076f5b63-69b0-4fd4-8118-7a3936ba0010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7ec39396-253f-405e-905a-d23f97e5454f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_076f5b63-69b0-4fd4-8118-7a3936ba0010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c831f15c-d65a-4e2f-ae91-c3d7cbebe6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7ec39396-253f-405e-905a-d23f97e5454f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c831f15c-d65a-4e2f-ae91-c3d7cbebe6a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_39ca275d-d957-4630-b6e8-992c9cd42f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7ec39396-253f-405e-905a-d23f97e5454f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_39ca275d-d957-4630-b6e8-992c9cd42f4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationNonproduction_2a9a748d-538f-483a-a37f-331d1cc97bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationNonproduction"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7ec39396-253f-405e-905a-d23f97e5454f" xlink:to="loc_us-gaap_DepreciationNonproduction_2a9a748d-538f-483a-a37f-331d1cc97bfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_e5332727-cde7-4e1b-9429-50ef2c2a96ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7ec39396-253f-405e-905a-d23f97e5454f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_e5332727-cde7-4e1b-9429-50ef2c2a96ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b3b85138-c3fa-4158-849f-be5bfc5b707e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7ec39396-253f-405e-905a-d23f97e5454f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b3b85138-c3fa-4158-849f-be5bfc5b707e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vmd-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f325b0c-e70f-458c-8f6d-4b9c7185512b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4a7e3774-ee8a-48a5-861d-55c195343fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f325b0c-e70f-458c-8f6d-4b9c7185512b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4a7e3774-ee8a-48a5-861d-55c195343fb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11dd3751-a80f-43d0-aecf-9a811694bf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f325b0c-e70f-458c-8f6d-4b9c7185512b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_11dd3751-a80f-43d0-aecf-9a811694bf0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3412dee9-6b0b-4614-9cbc-75bf709cadd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f325b0c-e70f-458c-8f6d-4b9c7185512b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3412dee9-6b0b-4614-9cbc-75bf709cadd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_30a2670e-108b-4b3b-a067-e50662bf6e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_30a2670e-108b-4b3b-a067-e50662bf6e1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_bbd76dfe-8cfc-4d56-bdf1-ecf33ec4675f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_bbd76dfe-8cfc-4d56-bdf1-ecf33ec4675f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments_7c932a83-0227-4c4e-8c7f-b6bc7bb2230c" xlink:href="vmd-20210930.xsd#vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments_7c932a83-0227-4c4e-8c7f-b6bc7bb2230c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_45f69bed-95c4-441c-b06d-f036283f4c74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_45f69bed-95c4-441c-b06d-f036283f4c74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge_9250d273-3bfd-47d1-b1bb-aafbdaab785c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_InventoryLIFOReservePeriodCharge_9250d273-3bfd-47d1-b1bb-aafbdaab785c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3b4ab7b3-3fb1-421b-a498-08b0a9f6ae12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3b4ab7b3-3fb1-421b-a498-08b0a9f6ae12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_04caacb8-ebba-4ea7-bcad-5603e0a7747a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_NetIncomeLoss_04caacb8-ebba-4ea7-bcad-5603e0a7747a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_ebf2c0e6-f380-4bdf-942d-3af1118d6bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_ebf2c0e6-f380-4bdf-942d-3af1118d6bdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5b957d64-c2b6-42e0-a4da-9ddf7053831a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_ShareBasedCompensation_5b957d64-c2b6-42e0-a4da-9ddf7053831a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d27233c8-dec8-4684-a111-8d96624a26e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d27233c8-dec8-4684-a111-8d96624a26e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_34850f88-dc58-401a-b4fe-ea6d94b3d2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_34850f88-dc58-401a-b4fe-ea6d94b3d2e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_77ec50ca-8ee4-4143-aded-d97494bd3003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_77ec50ca-8ee4-4143-aded-d97494bd3003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_b7b492ab-5a09-44ec-8948-8f414de9814d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_b7b492ab-5a09-44ec-8948-8f414de9814d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_00af400d-6b21-4bde-aaba-eb5c1f3ebae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_00af400d-6b21-4bde-aaba-eb5c1f3ebae0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_998a9442-7700-49f9-acdf-a3133dbfbc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_998a9442-7700-49f9-acdf-a3133dbfbc0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_00886c26-aba7-45bb-8590-504c434c19a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dc03c975-d9c4-49b3-a203-7b58b8fadd2d" xlink:to="loc_us-gaap_Depreciation_00886c26-aba7-45bb-8590-504c434c19a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd66afae-abcc-4653-b3cf-262c6a4958f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a9847e43-1360-4f56-996b-17f6a84d30be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd66afae-abcc-4653-b3cf-262c6a4958f1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a9847e43-1360-4f56-996b-17f6a84d30be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_0a733bb6-ea5b-4286-830d-7c8a8cf64489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd66afae-abcc-4653-b3cf-262c6a4958f1" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_0a733bb6-ea5b-4286-830d-7c8a8cf64489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7e26b88c-97a9-4be0-98a0-5f2d7f520dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fd66afae-abcc-4653-b3cf-262c6a4958f1" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_7e26b88c-97a9-4be0-98a0-5f2d7f520dc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7dcba440-b8cc-42a3-95df-d3659ff2ae35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d13159e4-c0a4-4ab5-beab-d983941afbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7dcba440-b8cc-42a3-95df-d3659ff2ae35" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d13159e4-c0a4-4ab5-beab-d983941afbd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_c0eb1019-33d3-4ce2-b771-416342a1cef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7dcba440-b8cc-42a3-95df-d3659ff2ae35" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_c0eb1019-33d3-4ce2-b771-416342a1cef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeasePayments_77af20c2-231c-477b-a22e-155a7895d55e" xlink:href="vmd-20210930.xsd#vmd_LeasePayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7dcba440-b8cc-42a3-95df-d3659ff2ae35" xlink:to="loc_vmd_LeasePayments_77af20c2-231c-477b-a22e-155a7895d55e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_e645454a-35a2-490f-871a-120f66424c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7dcba440-b8cc-42a3-95df-d3659ff2ae35" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_e645454a-35a2-490f-871a-120f66424c4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_89ce6ef4-dea0-42f4-adf9-2850c661819b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7dcba440-b8cc-42a3-95df-d3659ff2ae35" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_89ce6ef4-dea0-42f4-adf9-2850c661819b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_1851d7dd-ed7a-428e-9b5a-5633f42c0264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b82abdbb-b7e5-481c-b58f-ee5c57e37ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_1851d7dd-ed7a-428e-9b5a-5633f42c0264" xlink:to="loc_us-gaap_EquityMethodInvestments_b82abdbb-b7e5-481c-b58f-ee5c57e37ddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_a5f16a95-be1a-418f-a17b-ed545fd7c801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_1851d7dd-ed7a-428e-9b5a-5633f42c0264" xlink:to="loc_us-gaap_OtherInvestments_a5f16a95-be1a-418f-a17b-ed545fd7c801" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:calculationLink xlink:role="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c633ffe5-19e0-49a7-9bc0-96367b562f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome_dd5a67e7-b292-49a6-8a13-7c59f9c16932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_c633ffe5-19e0-49a7-9bc0-96367b562f1e" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncome_dd5a67e7-b292-49a6-8a13-7c59f9c16932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ceae768d-a078-433a-8bf8-ff3724cd1fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_c633ffe5-19e0-49a7-9bc0-96367b562f1e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ceae768d-a078-433a-8bf8-ff3724cd1fc5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#PropertyandEquipmentScheduleofFixedAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e1140aa1-92e2-4ad8-a1d2-676d598147a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d7b81bf2-c819-4f90-aaf3-f5c9bc0a5733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e1140aa1-92e2-4ad8-a1d2-676d598147a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d7b81bf2-c819-4f90-aaf3-f5c9bc0a5733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac785fb6-e94e-4a8a-b2be-1b077208dd87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e1140aa1-92e2-4ad8-a1d2-676d598147a4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac785fb6-e94e-4a8a-b2be-1b077208dd87" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/CurrentLiabilitiesDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#CurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.viemed.com/role/CurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_decf0b5a-9e47-45ea-b230-6dd37fb4a75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_AccruedTradePayablesCurrent_6bf3c8ea-a139-4717-b8c3-83da83f9fcb4" xlink:href="vmd-20210930.xsd#vmd_AccruedTradePayablesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_decf0b5a-9e47-45ea-b230-6dd37fb4a75d" xlink:to="loc_vmd_AccruedTradePayablesCurrent_6bf3c8ea-a139-4717-b8c3-83da83f9fcb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_91af2624-546b-4650-a43a-9ceb76170679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_decf0b5a-9e47-45ea-b230-6dd37fb4a75d" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_91af2624-546b-4650-a43a-9ceb76170679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_a8bea903-512d-4bd6-9a25-047096c5585e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_decf0b5a-9e47-45ea-b230-6dd37fb4a75d" xlink:to="loc_us-gaap_AccruedBonusesCurrent_a8bea903-512d-4bd6-9a25-047096c5585e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_20bf89c2-6e34-4e77-bc24-90e0c28ae393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_decf0b5a-9e47-45ea-b230-6dd37fb4a75d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_20bf89c2-6e34-4e77-bc24-90e0c28ae393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_9e92048a-37b6-4cb7-9dd5-c224d1b13f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_decf0b5a-9e47-45ea-b230-6dd37fb4a75d" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_9e92048a-37b6-4cb7-9dd5-c224d1b13f1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ab72990e-fb39-4d66-ad14-2204986471ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_decf0b5a-9e47-45ea-b230-6dd37fb4a75d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ab72990e-fb39-4d66-ad14-2204986471ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilitiesScheduleofNotesPayableDetails"/>
  <link:calculationLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_7f32c830-3fbc-4c1f-a93e-7f26a818dd79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5bbb1828-a9db-485d-bba4-6de2ea531245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7f32c830-3fbc-4c1f-a93e-7f26a818dd79" xlink:to="loc_us-gaap_LongTermDebtCurrent_5bbb1828-a9db-485d-bba4-6de2ea531245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_b30e12a0-5b82-47e1-853e-72a47fd00fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7f32c830-3fbc-4c1f-a93e-7f26a818dd79" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_b30e12a0-5b82-47e1-853e-72a47fd00fff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilitiesLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilitiesLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeaseLiability_c7ff41ed-f244-48fb-b383-5c4d10af814a" xlink:href="vmd-20210930.xsd#vmd_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeaseLiabilityCurrent_e8aff1f9-4a5f-43b9-90f2-12e80cd83ca5" xlink:href="vmd-20210930.xsd#vmd_LeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vmd_LeaseLiability_c7ff41ed-f244-48fb-b383-5c4d10af814a" xlink:to="loc_vmd_LeaseLiabilityCurrent_e8aff1f9-4a5f-43b9-90f2-12e80cd83ca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeaseLiabilityNoncurrent_c1ffb1f4-a41f-4539-bad9-5fe151b540e5" xlink:href="vmd-20210930.xsd#vmd_LeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vmd_LeaseLiability_c7ff41ed-f244-48fb-b383-5c4d10af814a" xlink:to="loc_vmd_LeaseLiabilityNoncurrent_c1ffb1f4-a41f-4539-bad9-5fe151b540e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#FairValueMeasurementRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure_27f045ff-cf1e-4253-a5e2-06d2473c5e43" xlink:href="vmd-20210930.xsd#vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fcc15d6c-38a6-4cc2-b618-c553eecca48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure_27f045ff-cf1e-4253-a5e2-06d2473c5e43" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fcc15d6c-38a6-4cc2-b618-c553eecca48a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d9484d6b-d268-4ca9-8189-40c6eb65813c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure_27f045ff-cf1e-4253-a5e2-06d2473c5e43" xlink:to="loc_us-gaap_DerivativeLiabilities_d9484d6b-d268-4ca9-8189-40c6eb65813c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityPhantomShareUnitsDetails"/>
  <link:calculationLink xlink:role="http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_bff46836-8478-4b05-9246-6a70472eefe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_9b1c6e2a-216e-4e71-b094-f21b1e6f0c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_bff46836-8478-4b05-9246-6a70472eefe0" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_9b1c6e2a-216e-4e71-b094-f21b1e6f0c36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_f0c5529c-1697-490f-ab28-ceafd9b1fc18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_bff46836-8478-4b05-9246-6a70472eefe0" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_f0c5529c-1697-490f-ab28-ceafd9b1fc18" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.viemed.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_32c79f34-9548-41e7-a3aa-cb8ea26bd506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3f511f67-3482-4496-83db-1aa56e16d076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_32c79f34-9548-41e7-a3aa-cb8ea26bd506" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3f511f67-3482-4496-83db-1aa56e16d076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_baa5c324-96d2-41ef-a727-71408c887052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_32c79f34-9548-41e7-a3aa-cb8ea26bd506" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_baa5c324-96d2-41ef-a727-71408c887052" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>vmd-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:fbb1b016-a19a-460d-bfda-ed9a0f837dc5,g:50e705b0-d493-4f83-95b4-caa6929c52c8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="vmd-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended" id="i77ee6e3aff56480893f0d30764d56972_CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0025c6a9-5d20-4a9b-8dd0-bd2cc24df88e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0025c6a9-5d20-4a9b-8dd0-bd2cc24df88e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cbe15160-41d4-426c-a682-53331b31f598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cbe15160-41d4-426c-a682-53331b31f598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0f53885d-0775-4147-ab8c-7069d2336699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockholdersEquity_0f53885d-0775-4147-ab8c-7069d2336699" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_9feb7de6-2f67-43fb-b1a9-5305b12153f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_9feb7de6-2f67-43fb-b1a9-5305b12153f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_261d2341-894d-4f20-9c5b-d02bd8091559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_261d2341-894d-4f20-9c5b-d02bd8091559" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e1b5091-2424-4b71-91cc-fc386bd9bb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e1b5091-2424-4b71-91cc-fc386bd9bb0c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_797ac78b-df1f-42fa-95bc-cb235f7b748c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_797ac78b-df1f-42fa-95bc-cb235f7b748c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ea691bbc-8ae8-46da-b9e5-84949aa8d4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ea691bbc-8ae8-46da-b9e5-84949aa8d4e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_501f4dff-2b7c-45ec-887e-3067f5968d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_501f4dff-2b7c-45ec-887e-3067f5968d40" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8ec31015-ef3b-49f5-813a-479416207bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8ec31015-ef3b-49f5-813a-479416207bae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_75fe8180-cac8-4413-9a3d-56a6fd61495c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_75fe8180-cac8-4413-9a3d-56a6fd61495c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c83ab5dd-53dc-47ca-b4a4-e0bda2df8632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c83ab5dd-53dc-47ca-b4a4-e0bda2df8632" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_59a20ed3-891a-4df9-b958-01eedf93d108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_NetIncomeLoss_59a20ed3-891a-4df9-b958-01eedf93d108" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a316f606-983a-4a8a-b7b2-c698101bc968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e24cfd1a-f648-4b8e-bc90-c78114352e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_065ebe07-c5ce-4802-8dc3-96aa1264d1da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0025c6a9-5d20-4a9b-8dd0-bd2cc24df88e" xlink:to="loc_us-gaap_StatementTable_065ebe07-c5ce-4802-8dc3-96aa1264d1da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_30d7b90d-2896-4b97-bf6f-4391d83f9b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_065ebe07-c5ce-4802-8dc3-96aa1264d1da" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_30d7b90d-2896-4b97-bf6f-4391d83f9b02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_30d7b90d-2896-4b97-bf6f-4391d83f9b02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30d7b90d-2896-4b97-bf6f-4391d83f9b02" xlink:to="loc_us-gaap_EquityComponentDomain_30d7b90d-2896-4b97-bf6f-4391d83f9b02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e9cfeffc-7a24-42ef-b9a4-191b8ec794dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30d7b90d-2896-4b97-bf6f-4391d83f9b02" xlink:to="loc_us-gaap_EquityComponentDomain_e9cfeffc-7a24-42ef-b9a4-191b8ec794dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c770f355-67e4-4c68-8ba7-c907d8e2aa1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e9cfeffc-7a24-42ef-b9a4-191b8ec794dc" xlink:to="loc_us-gaap_CommonStockMember_c770f355-67e4-4c68-8ba7-c907d8e2aa1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_27d29cf8-030d-4de9-9a64-8ee1f29fa94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e9cfeffc-7a24-42ef-b9a4-191b8ec794dc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_27d29cf8-030d-4de9-9a64-8ee1f29fa94d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a286d36c-c42c-494f-ba30-1af36473d5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e9cfeffc-7a24-42ef-b9a4-191b8ec794dc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a286d36c-c42c-494f-ba30-1af36473d5e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fac811e7-3878-4044-af42-cd22854d48f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e9cfeffc-7a24-42ef-b9a4-191b8ec794dc" xlink:to="loc_us-gaap_RetainedEarningsMember_fac811e7-3878-4044-af42-cd22854d48f4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" xlink:type="extended" id="id991502e6e8543b3953fc7ec212dca17_SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7a332d3a-f733-4098-b340-c160de2a853f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f643a2ce-ffe3-467d-af04-d196dad4976e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7a332d3a-f733-4098-b340-c160de2a853f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f643a2ce-ffe3-467d-af04-d196dad4976e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_e31ece7c-94c5-40ec-9322-b50a43f7f9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7a332d3a-f733-4098-b340-c160de2a853f" xlink:to="loc_us-gaap_ConcentrationRiskTable_e31ece7c-94c5-40ec-9322-b50a43f7f9b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3ea90b94-9aee-450f-b201-a0384d1f315b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e31ece7c-94c5-40ec-9322-b50a43f7f9b6" xlink:to="loc_srt_MajorCustomersAxis_3ea90b94-9aee-450f-b201-a0384d1f315b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3ea90b94-9aee-450f-b201-a0384d1f315b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3ea90b94-9aee-450f-b201-a0384d1f315b" xlink:to="loc_srt_NameOfMajorCustomerDomain_3ea90b94-9aee-450f-b201-a0384d1f315b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_60645ca7-be3c-41a4-8c81-dabdedb6e975" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3ea90b94-9aee-450f-b201-a0384d1f315b" xlink:to="loc_srt_NameOfMajorCustomerDomain_60645ca7-be3c-41a4-8c81-dabdedb6e975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_MedicareAndMedicaidMember_c67a7e42-14f8-4cbe-a6cd-559ae6ba8f63" xlink:href="vmd-20210930.xsd#vmd_MedicareAndMedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_60645ca7-be3c-41a4-8c81-dabdedb6e975" xlink:to="loc_vmd_MedicareAndMedicaidMember_c67a7e42-14f8-4cbe-a6cd-559ae6ba8f63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_MedicareMember_e4520941-5ecc-4172-89e9-c78d31ed414b" xlink:href="vmd-20210930.xsd#vmd_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vmd_MedicareAndMedicaidMember_c67a7e42-14f8-4cbe-a6cd-559ae6ba8f63" xlink:to="loc_vmd_MedicareMember_e4520941-5ecc-4172-89e9-c78d31ed414b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_MedicaidMember_c512488a-460d-4abd-9950-29b087dd1f18" xlink:href="vmd-20210930.xsd#vmd_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vmd_MedicareAndMedicaidMember_c67a7e42-14f8-4cbe-a6cd-559ae6ba8f63" xlink:to="loc_vmd_MedicaidMember_c512488a-460d-4abd-9950-29b087dd1f18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5b925eb2-2982-4cc5-85b6-5344e1bcd79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e31ece7c-94c5-40ec-9322-b50a43f7f9b6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5b925eb2-2982-4cc5-85b6-5344e1bcd79e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5b925eb2-2982-4cc5-85b6-5344e1bcd79e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5b925eb2-2982-4cc5-85b6-5344e1bcd79e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5b925eb2-2982-4cc5-85b6-5344e1bcd79e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bf76a3c3-7a21-4dda-82d4-db3c641b957f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5b925eb2-2982-4cc5-85b6-5344e1bcd79e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bf76a3c3-7a21-4dda-82d4-db3c641b957f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e142ffc0-cd34-414e-8d5f-fb018f1f8b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_bf76a3c3-7a21-4dda-82d4-db3c641b957f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e142ffc0-cd34-414e-8d5f-fb018f1f8b9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_326bd596-5097-40c6-8cbd-f636b675716e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_e31ece7c-94c5-40ec-9322-b50a43f7f9b6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_326bd596-5097-40c6-8cbd-f636b675716e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_326bd596-5097-40c6-8cbd-f636b675716e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_326bd596-5097-40c6-8cbd-f636b675716e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_326bd596-5097-40c6-8cbd-f636b675716e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec65a6cb-6c0c-4842-932d-0690f3b31a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_326bd596-5097-40c6-8cbd-f636b675716e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec65a6cb-6c0c-4842-932d-0690f3b31a96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_c3edf732-0aae-49e1-a7ab-3e5c3b649548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec65a6cb-6c0c-4842-932d-0690f3b31a96" xlink:to="loc_us-gaap_AccountsReceivableMember_c3edf732-0aae-49e1-a7ab-3e5c3b649548" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_96a1238e-dbce-4c97-9653-4836facbf798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec65a6cb-6c0c-4842-932d-0690f3b31a96" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_96a1238e-dbce-4c97-9653-4836facbf798" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended" id="ied91df7d067f4d1e83e1fbc3a71a2e22_SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_76629f99-b01b-41a1-91ae-ad14b5edbd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_67787680-211a-40c5-b8a3-c4de2c3179cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_76629f99-b01b-41a1-91ae-ad14b5edbd12" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_67787680-211a-40c5-b8a3-c4de2c3179cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome_61ca92b7-a4a4-4448-a6a2-52650b5b725f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_76629f99-b01b-41a1-91ae-ad14b5edbd12" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncome_61ca92b7-a4a4-4448-a6a2-52650b5b725f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6effe936-3a40-40c9-b441-e003f4d463bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_76629f99-b01b-41a1-91ae-ad14b5edbd12" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6effe936-3a40-40c9-b441-e003f4d463bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3cb2f4ec-374e-445a-a09a-eaabe84b954c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_76629f99-b01b-41a1-91ae-ad14b5edbd12" xlink:to="loc_us-gaap_Revenues_3cb2f4ec-374e-445a-a09a-eaabe84b954c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b7abb5c9-b400-41a8-8e6d-92fc7f458231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_76629f99-b01b-41a1-91ae-ad14b5edbd12" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b7abb5c9-b400-41a8-8e6d-92fc7f458231" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c211a8ba-47af-4d15-a7ca-a5ed0c26da82" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b7abb5c9-b400-41a8-8e6d-92fc7f458231" xlink:to="loc_srt_ProductOrServiceAxis_c211a8ba-47af-4d15-a7ca-a5ed0c26da82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c211a8ba-47af-4d15-a7ca-a5ed0c26da82_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c211a8ba-47af-4d15-a7ca-a5ed0c26da82" xlink:to="loc_srt_ProductsAndServicesDomain_c211a8ba-47af-4d15-a7ca-a5ed0c26da82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c211a8ba-47af-4d15-a7ca-a5ed0c26da82" xlink:to="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_VentilatorRentalMember_be614ac7-2380-4841-a828-eaa2edbdd679" xlink:href="vmd-20210930.xsd#vmd_VentilatorRentalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:to="loc_vmd_VentilatorRentalMember_be614ac7-2380-4841-a828-eaa2edbdd679" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_OtherDurableMedicalEquipmentRentalsMember_6e38e27c-1f4f-4310-b0b2-e14a9e79ac09" xlink:href="vmd-20210930.xsd#vmd_OtherDurableMedicalEquipmentRentalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:to="loc_vmd_OtherDurableMedicalEquipmentRentalsMember_6e38e27c-1f4f-4310-b0b2-e14a9e79ac09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_EquipmentSalesMember_8372c12a-d7ad-4ec6-a4a6-6b051ab07c7f" xlink:href="vmd-20210930.xsd#vmd_EquipmentSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:to="loc_vmd_EquipmentSalesMember_8372c12a-d7ad-4ec6-a4a6-6b051ab07c7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_COVID19ResponseSalesMember_3846971a-5f73-446c-b387-612962b66515" xlink:href="vmd-20210930.xsd#vmd_COVID19ResponseSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:to="loc_vmd_COVID19ResponseSalesMember_3846971a-5f73-446c-b387-612962b66515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_c405425a-968b-442d-850e-2ce47141bec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:to="loc_us-gaap_ServiceMember_c405425a-968b-442d-850e-2ce47141bec0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#PropertyandEquipmentScheduleofFixedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" xlink:type="extended" id="i2ed3b00f85c045f38fcf62050d127506_PropertyandEquipmentScheduleofFixedAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8e3ead9a-4a81-4d4c-9e8e-cb1b05c1c219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f169a69d-13b9-49f4-9d7f-7af6484977c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8e3ead9a-4a81-4d4c-9e8e-cb1b05c1c219" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f169a69d-13b9-49f4-9d7f-7af6484977c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d1945ea3-d6f2-4971-83f5-9ac406769e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8e3ead9a-4a81-4d4c-9e8e-cb1b05c1c219" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d1945ea3-d6f2-4971-83f5-9ac406769e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9f650351-1741-4dc4-966c-a22a96515f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8e3ead9a-4a81-4d4c-9e8e-cb1b05c1c219" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9f650351-1741-4dc4-966c-a22a96515f45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9bee72f1-834e-416a-8ab0-cd8dfe668599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8e3ead9a-4a81-4d4c-9e8e-cb1b05c1c219" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9bee72f1-834e-416a-8ab0-cd8dfe668599" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_da376e58-d79f-4cf8-b2c4-a35ccf03e1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9bee72f1-834e-416a-8ab0-cd8dfe668599" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_da376e58-d79f-4cf8-b2c4-a35ccf03e1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da376e58-d79f-4cf8-b2c4-a35ccf03e1a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_da376e58-d79f-4cf8-b2c4-a35ccf03e1a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_da376e58-d79f-4cf8-b2c4-a35ccf03e1a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_da376e58-d79f-4cf8-b2c4-a35ccf03e1a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_EquipmentMedicalMember_cec053da-a623-4abf-9377-3486dd6f9dfe" xlink:href="vmd-20210930.xsd#vmd_EquipmentMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:to="loc_vmd_EquipmentMedicalMember_cec053da-a623-4abf-9377-3486dd6f9dfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_FurnitureAndEquipmentMember_cf1fd562-1752-43cd-8164-280fd6a43a3c" xlink:href="vmd-20210930.xsd#vmd_FurnitureAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:to="loc_vmd_FurnitureAndEquipmentMember_cf1fd562-1752-43cd-8164-280fd6a43a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_02d1b9d9-b849-4dd5-8c6c-d7f58b88582c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:to="loc_us-gaap_LandMember_02d1b9d9-b849-4dd5-8c6c-d7f58b88582c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_334bc8ef-3aec-4f3d-86f4-d302f17f6d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:to="loc_us-gaap_BuildingMember_334bc8ef-3aec-4f3d-86f4-d302f17f6d80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c5372711-cbba-4dda-a162-89b27bf723b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c5372711-cbba-4dda-a162-89b27bf723b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_bf6319b3-5ee3-444a-9fe8-cdb53c7ba252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:to="loc_us-gaap_VehiclesMember_bf6319b3-5ee3-444a-9fe8-cdb53c7ba252" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended" id="i91969a5a6d3646339e48e2e46e43a0cb_PropertyandEquipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6df60c2-de45-4890-88ee-7c467c11be8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation_4f79ad8d-41a4-4a70-8789-92237ac8d633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6df60c2-de45-4890-88ee-7c467c11be8b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation_4f79ad8d-41a4-4a70-8789-92237ac8d633" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_242ee25b-a4d0-4fd1-a44b-b760b5064852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6df60c2-de45-4890-88ee-7c467c11be8b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_242ee25b-a4d0-4fd1-a44b-b760b5064852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_15f96411-b36e-4ba6-af7b-34bb9be662b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6df60c2-de45-4890-88ee-7c467c11be8b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_15f96411-b36e-4ba6-af7b-34bb9be662b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c88256d6-8756-47cb-bb63-a8b37bf27b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6df60c2-de45-4890-88ee-7c467c11be8b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c88256d6-8756-47cb-bb63-a8b37bf27b0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f406c7-9fc3-4488-8b4d-efa5416cd8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c88256d6-8756-47cb-bb63-a8b37bf27b0b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f406c7-9fc3-4488-8b4d-efa5416cd8b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_17f406c7-9fc3-4488-8b4d-efa5416cd8b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f406c7-9fc3-4488-8b4d-efa5416cd8b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_17f406c7-9fc3-4488-8b4d-efa5416cd8b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3980c772-0a57-49b4-bfe0-94584ad655e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f406c7-9fc3-4488-8b4d-efa5416cd8b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3980c772-0a57-49b4-bfe0-94584ad655e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_AssetsHeldUnderFinanceLeasesMember_5f2e5119-46c0-43bf-a63e-2d5932daa759" xlink:href="vmd-20210930.xsd#vmd_AssetsHeldUnderFinanceLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3980c772-0a57-49b4-bfe0-94584ad655e5" xlink:to="loc_vmd_AssetsHeldUnderFinanceLeasesMember_5f2e5119-46c0-43bf-a63e-2d5932daa759" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails" xlink:type="extended" id="i790c69221fb24bd88fb13418ed605c99_DebtandLeaseLiabilitiesLineofCreditNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_486fefe1-ec5e-43ff-a017-3b9bb89006ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6efd2958-3c3f-4871-8fce-a6396f34a39d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_486fefe1-ec5e-43ff-a017-3b9bb89006ee" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6efd2958-3c3f-4871-8fce-a6396f34a39d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7971425c-84ce-4e3b-8857-40428b37e61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_486fefe1-ec5e-43ff-a017-3b9bb89006ee" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7971425c-84ce-4e3b-8857-40428b37e61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtInstrumentInterestRateFloorRate_afc6bef5-babe-4c8a-9c86-c6f2a4f5ae94" xlink:href="vmd-20210930.xsd#vmd_DebtInstrumentInterestRateFloorRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_486fefe1-ec5e-43ff-a017-3b9bb89006ee" xlink:to="loc_vmd_DebtInstrumentInterestRateFloorRate_afc6bef5-babe-4c8a-9c86-c6f2a4f5ae94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_51c25492-331c-4309-81e1-e2a56b5d1f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_486fefe1-ec5e-43ff-a017-3b9bb89006ee" xlink:to="loc_us-gaap_LineOfCredit_51c25492-331c-4309-81e1-e2a56b5d1f2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_c6166926-7fe6-4afd-81ce-ed4214920212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_486fefe1-ec5e-43ff-a017-3b9bb89006ee" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_c6166926-7fe6-4afd-81ce-ed4214920212" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9850c216-468c-4809-a080-852c970b9a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c6166926-7fe6-4afd-81ce-ed4214920212" xlink:to="loc_us-gaap_CreditFacilityAxis_9850c216-468c-4809-a080-852c970b9a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9850c216-468c-4809-a080-852c970b9a33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_9850c216-468c-4809-a080-852c970b9a33" xlink:to="loc_us-gaap_CreditFacilityDomain_9850c216-468c-4809-a080-852c970b9a33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_de68c2cd-85d6-4bcc-a739-358c2d1e8584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_9850c216-468c-4809-a080-852c970b9a33" xlink:to="loc_us-gaap_CreditFacilityDomain_de68c2cd-85d6-4bcc-a739-358c2d1e8584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6b4149fb-0125-4552-aa2d-24bf98745c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_de68c2cd-85d6-4bcc-a739-358c2d1e8584" xlink:to="loc_us-gaap_LineOfCreditMember_6b4149fb-0125-4552-aa2d-24bf98745c90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_72cdfc59-e498-41df-9f4a-a8b9591ec598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c6166926-7fe6-4afd-81ce-ed4214920212" xlink:to="loc_us-gaap_VariableRateAxis_72cdfc59-e498-41df-9f4a-a8b9591ec598" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_72cdfc59-e498-41df-9f4a-a8b9591ec598_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_72cdfc59-e498-41df-9f4a-a8b9591ec598" xlink:to="loc_us-gaap_VariableRateDomain_72cdfc59-e498-41df-9f4a-a8b9591ec598_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_56b4b774-79e4-4919-a4f4-0a35ffe52882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_72cdfc59-e498-41df-9f4a-a8b9591ec598" xlink:to="loc_us-gaap_VariableRateDomain_56b4b774-79e4-4919-a4f4-0a35ffe52882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_41a4ceb9-adf6-4adb-b8ef-2996ea13cb21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_56b4b774-79e4-4919-a4f4-0a35ffe52882" xlink:to="loc_us-gaap_PrimeRateMember_41a4ceb9-adf6-4adb-b8ef-2996ea13cb21" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails" xlink:type="extended" id="i6ceacab4d9d74abdb85225a7a3c677c2_DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2c619ae0-f36c-49a4-a26c-90cc06d3823e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2c619ae0-f36c-49a4-a26c-90cc06d3823e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba89fddd-ed4e-44b9-90ce-2f1485907e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba89fddd-ed4e-44b9-90ce-2f1485907e52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtInstrumentCovenantLoanToValueRatio_6d8c376b-543b-4148-8b2e-d1667b5c2dc1" xlink:href="vmd-20210930.xsd#vmd_DebtInstrumentCovenantLoanToValueRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:to="loc_vmd_DebtInstrumentCovenantLoanToValueRatio_6d8c376b-543b-4148-8b2e-d1667b5c2dc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_c66791d1-8be0-4c30-9ea6-a5368a14d43f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_c66791d1-8be0-4c30-9ea6-a5368a14d43f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_b3b70867-308f-4b92-b3ed-3743bc8b1d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_b3b70867-308f-4b92-b3ed-3743bc8b1d04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5daf2def-a66b-4b6c-9fb4-3b8f529b3177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5daf2def-a66b-4b6c-9fb4-3b8f529b3177" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c853021f-f272-4b76-8cad-ee7e286785a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:to="loc_us-gaap_DebtInstrumentTable_c853021f-f272-4b76-8cad-ee7e286785a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5899069b-5911-446e-977b-5e0bfbcbd7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c853021f-f272-4b76-8cad-ee7e286785a2" xlink:to="loc_us-gaap_DebtInstrumentAxis_5899069b-5911-446e-977b-5e0bfbcbd7f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5899069b-5911-446e-977b-5e0bfbcbd7f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5899069b-5911-446e-977b-5e0bfbcbd7f7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5899069b-5911-446e-977b-5e0bfbcbd7f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_84e71691-6207-4568-b984-37b2f1e5e35b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5899069b-5911-446e-977b-5e0bfbcbd7f7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_84e71691-6207-4568-b984-37b2f1e5e35b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_BuildingTermNoteMember_d12a5165-fed4-4e46-b881-5e443c22b734" xlink:href="vmd-20210930.xsd#vmd_BuildingTermNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84e71691-6207-4568-b984-37b2f1e5e35b" xlink:to="loc_vmd_BuildingTermNoteMember_d12a5165-fed4-4e46-b881-5e443c22b734" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_TermNoteMember_847610b0-d90a-4d1e-99e8-3f76e53410ab" xlink:href="vmd-20210930.xsd#vmd_TermNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84e71691-6207-4568-b984-37b2f1e5e35b" xlink:to="loc_vmd_TermNoteMember_847610b0-d90a-4d1e-99e8-3f76e53410ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c34e2f58-c136-439f-b0fe-40862a846514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c853021f-f272-4b76-8cad-ee7e286785a2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c34e2f58-c136-439f-b0fe-40862a846514" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c34e2f58-c136-439f-b0fe-40862a846514_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c34e2f58-c136-439f-b0fe-40862a846514" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c34e2f58-c136-439f-b0fe-40862a846514_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1326329d-f25f-488b-96bd-741a8a4d3593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c34e2f58-c136-439f-b0fe-40862a846514" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1326329d-f25f-488b-96bd-741a8a4d3593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_19a40cf4-4031-454d-8a68-3c0920a45805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1326329d-f25f-488b-96bd-741a8a4d3593" xlink:to="loc_us-gaap_NotesPayableToBanksMember_19a40cf4-4031-454d-8a68-3c0920a45805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2b701920-9a6c-4f34-9b49-55bdf7baa79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c853021f-f272-4b76-8cad-ee7e286785a2" xlink:to="loc_us-gaap_VariableRateAxis_2b701920-9a6c-4f34-9b49-55bdf7baa79f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_2b701920-9a6c-4f34-9b49-55bdf7baa79f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_2b701920-9a6c-4f34-9b49-55bdf7baa79f" xlink:to="loc_us-gaap_VariableRateDomain_2b701920-9a6c-4f34-9b49-55bdf7baa79f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_945aa524-27a4-4a70-8ad6-bbe4871b5ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_2b701920-9a6c-4f34-9b49-55bdf7baa79f" xlink:to="loc_us-gaap_VariableRateDomain_945aa524-27a4-4a70-8ad6-bbe4871b5ae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d905bf06-f570-40c5-a0cf-741cfb688507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_945aa524-27a4-4a70-8ad6-bbe4871b5ae0" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d905bf06-f570-40c5-a0cf-741cfb688507" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5c888107-b28b-439a-86ed-a80de53cb892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_c853021f-f272-4b76-8cad-ee7e286785a2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5c888107-b28b-439a-86ed-a80de53cb892" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5c888107-b28b-439a-86ed-a80de53cb892_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5c888107-b28b-439a-86ed-a80de53cb892" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5c888107-b28b-439a-86ed-a80de53cb892_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e2ce39d5-0b16-4079-8056-6dcf3c5cc83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5c888107-b28b-439a-86ed-a80de53cb892" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e2ce39d5-0b16-4079-8056-6dcf3c5cc83b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8d27d51c-40f0-42fe-a162-6a0cdf671610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e2ce39d5-0b16-4079-8056-6dcf3c5cc83b" xlink:to="loc_us-gaap_InterestRateSwapMember_8d27d51c-40f0-42fe-a162-6a0cdf671610" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilitiesScheduleofNotesPayableDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails" xlink:type="extended" id="i662e7ec936c646c5b54a025d7cf38373_DebtandLeaseLiabilitiesScheduleofNotesPayableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_112f76bf-c6fd-433f-966e-de3c88b6b979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4ae838aa-7b8b-4619-a47f-2959d9e368ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112f76bf-c6fd-433f-966e-de3c88b6b979" xlink:to="loc_us-gaap_LongTermDebt_4ae838aa-7b8b-4619-a47f-2959d9e368ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_bfb8bc25-3a37-46d5-899a-0456d577bf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112f76bf-c6fd-433f-966e-de3c88b6b979" xlink:to="loc_us-gaap_LongTermDebtCurrent_bfb8bc25-3a37-46d5-899a-0456d577bf4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c321086f-0e02-4653-a1f9-ce793ef4fe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112f76bf-c6fd-433f-966e-de3c88b6b979" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c321086f-0e02-4653-a1f9-ce793ef4fe2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_03684eac-a564-48b2-bfad-d70cc1303c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112f76bf-c6fd-433f-966e-de3c88b6b979" xlink:to="loc_us-gaap_DebtInstrumentTable_03684eac-a564-48b2-bfad-d70cc1303c90" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9d83fb6d-4b17-4d2a-a424-c43e9126854d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_03684eac-a564-48b2-bfad-d70cc1303c90" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9d83fb6d-4b17-4d2a-a424-c43e9126854d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9d83fb6d-4b17-4d2a-a424-c43e9126854d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9d83fb6d-4b17-4d2a-a424-c43e9126854d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9d83fb6d-4b17-4d2a-a424-c43e9126854d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a706b5f0-0ec0-4b04-9d2c-3eaff11020bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9d83fb6d-4b17-4d2a-a424-c43e9126854d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a706b5f0-0ec0-4b04-9d2c-3eaff11020bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_93fa0516-fd15-455d-968b-ee2ab89c64bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a706b5f0-0ec0-4b04-9d2c-3eaff11020bb" xlink:to="loc_us-gaap_NotesPayableToBanksMember_93fa0516-fd15-455d-968b-ee2ab89c64bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails" xlink:type="extended" id="ieaf32f7a642b4052aebcc326960746ff_DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_d040a4eb-e30e-4cdf-82b0-d2863be264f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_d040a4eb-e30e-4cdf-82b0-d2863be264f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ac9d0207-af2f-4c0d-9e4d-e19cc7a6db48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ac9d0207-af2f-4c0d-9e4d-e19cc7a6db48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_80a9e691-595b-4c48-9711-739dc1bd52b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:to="loc_us-gaap_LeaseCost_80a9e691-595b-4c48-9711-739dc1bd52b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b67c2d41-7fd7-4296-8090-12663555e4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b67c2d41-7fd7-4296-8090-12663555e4f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_19c94cea-c708-487a-ad8b-c999871b5a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_19c94cea-c708-487a-ad8b-c999871b5a77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_b2a098a1-4d79-4d3f-8884-ff3c6266f034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_b2a098a1-4d79-4d3f-8884-ff3c6266f034" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_fe43b956-42a2-4b85-a0a4-98f972c4385f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_fe43b956-42a2-4b85-a0a4-98f972c4385f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_cd05dbb6-91ef-4678-9984-e32f0be8a17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fe43b956-42a2-4b85-a0a4-98f972c4385f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_cd05dbb6-91ef-4678-9984-e32f0be8a17f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_cd05dbb6-91ef-4678-9984-e32f0be8a17f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_cd05dbb6-91ef-4678-9984-e32f0be8a17f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_cd05dbb6-91ef-4678-9984-e32f0be8a17f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d34b7f82-7689-4327-9cab-88835bb5f283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_cd05dbb6-91ef-4678-9984-e32f0be8a17f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d34b7f82-7689-4327-9cab-88835bb5f283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_MonthlyRentalPaymentsMember_f00ba1f4-4b15-455f-840f-2fb65c4f0d4d" xlink:href="vmd-20210930.xsd#vmd_MonthlyRentalPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d34b7f82-7689-4327-9cab-88835bb5f283" xlink:to="loc_vmd_MonthlyRentalPaymentsMember_f00ba1f4-4b15-455f-840f-2fb65c4f0d4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f8fcabe-52f1-41ce-9e66-2ddb66f7be13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fe43b956-42a2-4b85-a0a4-98f972c4385f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f8fcabe-52f1-41ce-9e66-2ddb66f7be13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4f8fcabe-52f1-41ce-9e66-2ddb66f7be13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f8fcabe-52f1-41ce-9e66-2ddb66f7be13" xlink:to="loc_us-gaap_RelatedPartyDomain_4f8fcabe-52f1-41ce-9e66-2ddb66f7be13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ef6cfb39-4ac0-4dc3-bff3-014c58413959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f8fcabe-52f1-41ce-9e66-2ddb66f7be13" xlink:to="loc_us-gaap_RelatedPartyDomain_ef6cfb39-4ac0-4dc3-bff3-014c58413959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_df2d854b-cf32-459f-8aa9-25dbecdc73b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_ef6cfb39-4ac0-4dc3-bff3-014c58413959" xlink:to="loc_srt_AffiliatedEntityMember_df2d854b-cf32-459f-8aa9-25dbecdc73b2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#FairValueMeasurementRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" xlink:type="extended" id="i771160345f4b46dd8ecb202a57326f3f_FairValueMeasurementRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b38928d1-2791-41bf-8622-e4f7043decfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_26bd558f-31e9-4fc9-b6d6-3b41a4f6b883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b38928d1-2791-41bf-8622-e4f7043decfa" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_26bd558f-31e9-4fc9-b6d6-3b41a4f6b883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_e62cf20c-7bdf-4f1d-aa75-9e2ac8467779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b38928d1-2791-41bf-8622-e4f7043decfa" xlink:to="loc_us-gaap_DerivativeLiabilities_e62cf20c-7bdf-4f1d-aa75-9e2ac8467779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure_ade78d90-6511-4774-8d78-c51c1b9eb7d2" xlink:href="vmd-20210930.xsd#vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b38928d1-2791-41bf-8622-e4f7043decfa" xlink:to="loc_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure_ade78d90-6511-4774-8d78-c51c1b9eb7d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1a8725a8-d7cd-4c8c-b519-9fe0fe96faa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b38928d1-2791-41bf-8622-e4f7043decfa" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1a8725a8-d7cd-4c8c-b519-9fe0fe96faa1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_98f13594-71d8-4907-90d5-328c56f82314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1a8725a8-d7cd-4c8c-b519-9fe0fe96faa1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_98f13594-71d8-4907-90d5-328c56f82314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_98f13594-71d8-4907-90d5-328c56f82314_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_98f13594-71d8-4907-90d5-328c56f82314" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_98f13594-71d8-4907-90d5-328c56f82314_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e05b8425-6b82-4fd1-9af5-834ccd2bbec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_98f13594-71d8-4907-90d5-328c56f82314" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e05b8425-6b82-4fd1-9af5-834ccd2bbec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7faf2b19-f1a1-4f32-bfc6-7acc6a40b6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e05b8425-6b82-4fd1-9af5-834ccd2bbec4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7faf2b19-f1a1-4f32-bfc6-7acc6a40b6f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fade4d96-a0bd-407c-87bb-9fc744771c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1a8725a8-d7cd-4c8c-b519-9fe0fe96faa1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fade4d96-a0bd-407c-87bb-9fc744771c4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fade4d96-a0bd-407c-87bb-9fc744771c4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fade4d96-a0bd-407c-87bb-9fc744771c4b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fade4d96-a0bd-407c-87bb-9fc744771c4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9874f5e2-c683-4342-be5d-91b32dcafecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fade4d96-a0bd-407c-87bb-9fc744771c4b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9874f5e2-c683-4342-be5d-91b32dcafecc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_158c136d-c4c5-4d4a-8fc1-061a96b2f498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9874f5e2-c683-4342-be5d-91b32dcafecc" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_158c136d-c4c5-4d4a-8fc1-061a96b2f498" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a2287939-91a1-461f-a5b7-0eee7ff852d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9874f5e2-c683-4342-be5d-91b32dcafecc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a2287939-91a1-461f-a5b7-0eee7ff852d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_43e5a082-2854-4af2-9e47-0e08735ca892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9874f5e2-c683-4342-be5d-91b32dcafecc" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_43e5a082-2854-4af2-9e47-0e08735ca892" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_0183ccf1-4a17-4706-b17d-af4665a8e07d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1a8725a8-d7cd-4c8c-b519-9fe0fe96faa1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_0183ccf1-4a17-4706-b17d-af4665a8e07d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0183ccf1-4a17-4706-b17d-af4665a8e07d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_0183ccf1-4a17-4706-b17d-af4665a8e07d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0183ccf1-4a17-4706-b17d-af4665a8e07d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1745b950-bfab-43e3-bd27-846d52146002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_0183ccf1-4a17-4706-b17d-af4665a8e07d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1745b950-bfab-43e3-bd27-846d52146002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d1b3dac6-6b55-4306-85e5-fb16f34464b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1745b950-bfab-43e3-bd27-846d52146002" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d1b3dac6-6b55-4306-85e5-fb16f34464b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a6c2b312-aa7c-4766-acac-8fd5689a5ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1a8725a8-d7cd-4c8c-b519-9fe0fe96faa1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a6c2b312-aa7c-4766-acac-8fd5689a5ec7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a6c2b312-aa7c-4766-acac-8fd5689a5ec7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a6c2b312-aa7c-4766-acac-8fd5689a5ec7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a6c2b312-aa7c-4766-acac-8fd5689a5ec7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1d238c3a-fc88-41eb-8d0d-c07b405b25bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a6c2b312-aa7c-4766-acac-8fd5689a5ec7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1d238c3a-fc88-41eb-8d0d-c07b405b25bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_ce94b359-d877-40f1-a921-9e4437bd7933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1d238c3a-fc88-41eb-8d0d-c07b405b25bc" xlink:to="loc_us-gaap_InterestRateSwapMember_ce94b359-d877-40f1-a921-9e4437bd7933" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended" id="i9be7b2ad97ec4bcf8d326b5d25a708f5_FairValueMeasurementNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b2352bf8-22fa-4a4c-96db-90e45d0ee09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_b48b05e2-2f74-4f16-92a1-5bfe83672b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b2352bf8-22fa-4a4c-96db-90e45d0ee09b" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_b48b05e2-2f74-4f16-92a1-5bfe83672b19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_38dd22ad-6a98-4758-9116-be7482732888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b2352bf8-22fa-4a4c-96db-90e45d0ee09b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_38dd22ad-6a98-4758-9116-be7482732888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_f9fe439c-43c4-4e98-b2de-b9a400d1dd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b2352bf8-22fa-4a4c-96db-90e45d0ee09b" xlink:to="loc_us-gaap_DerivativeLiabilities_f9fe439c-43c4-4e98-b2de-b9a400d1dd15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9d1887bf-8a64-4fe4-b024-2b2155bf9b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b2352bf8-22fa-4a4c-96db-90e45d0ee09b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9d1887bf-8a64-4fe4-b024-2b2155bf9b24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b1a1fa99-41b5-4b76-b6b1-1b3622805c60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9d1887bf-8a64-4fe4-b024-2b2155bf9b24" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b1a1fa99-41b5-4b76-b6b1-1b3622805c60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b1a1fa99-41b5-4b76-b6b1-1b3622805c60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b1a1fa99-41b5-4b76-b6b1-1b3622805c60" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b1a1fa99-41b5-4b76-b6b1-1b3622805c60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2fee6238-9044-4b7f-b196-5541cad2bd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b1a1fa99-41b5-4b76-b6b1-1b3622805c60" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2fee6238-9044-4b7f-b196-5541cad2bd88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5570f692-1782-4eab-84d4-d10babe35e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2fee6238-9044-4b7f-b196-5541cad2bd88" xlink:to="loc_us-gaap_InterestRateSwapMember_5570f692-1782-4eab-84d4-d10babe35e39" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityIssuedandOutstandingShareCapitalDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails" xlink:type="extended" id="i9fcddd4390b74b14905c1e5b6a2d1590_ShareholdersEquityIssuedandOutstandingShareCapitalDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_NumberOfStockClasses_4007d499-afb4-4434-807d-aaff735cd424" xlink:href="vmd-20210930.xsd#vmd_NumberOfStockClasses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:to="loc_vmd_NumberOfStockClasses_4007d499-afb4-4434-807d-aaff735cd424" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8bdaea2e-3c5c-4cc8-a3d3-9a0f266eafa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8bdaea2e-3c5c-4cc8-a3d3-9a0f266eafa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2c226f77-7dc6-4edd-86fc-1626e29415bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:to="loc_us-gaap_CommonStockSharesIssued_2c226f77-7dc6-4edd-86fc-1626e29415bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6cb06928-79af-4477-880b-8743f26ce3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6cb06928-79af-4477-880b-8743f26ce3a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_cf08806a-0e20-40dc-8cf3-b582b8bf955b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_cf08806a-0e20-40dc-8cf3-b582b8bf955b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_996e3996-b81c-4956-82a8-336e200bac80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_996e3996-b81c-4956-82a8-336e200bac80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_99ee33c1-5b26-493c-bdc8-543445a21509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_996e3996-b81c-4956-82a8-336e200bac80" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_99ee33c1-5b26-493c-bdc8-543445a21509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_99ee33c1-5b26-493c-bdc8-543445a21509_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99ee33c1-5b26-493c-bdc8-543445a21509" xlink:to="loc_us-gaap_EquityComponentDomain_99ee33c1-5b26-493c-bdc8-543445a21509_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a9c957f1-15e0-4b62-99f2-8fcd22acbd27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99ee33c1-5b26-493c-bdc8-543445a21509" xlink:to="loc_us-gaap_EquityComponentDomain_a9c957f1-15e0-4b62-99f2-8fcd22acbd27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ff746c7e-4c03-429b-8200-a8a6749ff619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a9c957f1-15e0-4b62-99f2-8fcd22acbd27" xlink:to="loc_us-gaap_CommonStockMember_ff746c7e-4c03-429b-8200-a8a6749ff619" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityStockbasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" xlink:type="extended" id="if20ac0c6ce3b43d185621fe745bd1ea9_ShareholdersEquityStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c68a7f2f-665f-4fb8-b851-50ff215733e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c68a7f2f-665f-4fb8-b851-50ff215733e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding_eef5d2b1-76e9-4e94-8e5c-fda1d36e6dc1" xlink:href="vmd-20210930.xsd#vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding_eef5d2b1-76e9-4e94-8e5c-fda1d36e6dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99de59e9-db28-4a38-9994-d9b246b8a326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99de59e9-db28-4a38-9994-d9b246b8a326" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e9f39bd2-e74b-4839-bbf7-dcfdbd0263a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e9f39bd2-e74b-4839-bbf7-dcfdbd0263a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9ec77de3-b83f-41a3-85f6-276b852b9ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9ec77de3-b83f-41a3-85f6-276b852b9ba7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_23c39cbb-906e-4d25-9964-ed25f192cd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_23c39cbb-906e-4d25-9964-ed25f192cd9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_517a5048-0aec-4dc9-83ed-7f07e7d46af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_517a5048-0aec-4dc9-83ed-7f07e7d46af5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0f24dd65-ae7d-4501-87a7-4014b09a3b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0f24dd65-ae7d-4501-87a7-4014b09a3b56" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_41e93934-397a-4ed5-959e-6f78297e01b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_41e93934-397a-4ed5-959e-6f78297e01b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c2d43402-e712-4ac2-9512-427e65589130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_41e93934-397a-4ed5-959e-6f78297e01b4" xlink:to="loc_us-gaap_AwardTypeAxis_c2d43402-e712-4ac2-9512-427e65589130" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2d43402-e712-4ac2-9512-427e65589130_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c2d43402-e712-4ac2-9512-427e65589130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2d43402-e712-4ac2-9512-427e65589130_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_749a67b9-86f5-4d02-859c-184af6cab737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c2d43402-e712-4ac2-9512-427e65589130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_749a67b9-86f5-4d02-859c-184af6cab737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e43e5997-47a8-4e7c-9d8c-09e27eef0a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_749a67b9-86f5-4d02-859c-184af6cab737" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e43e5997-47a8-4e7c-9d8c-09e27eef0a5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7e253239-7347-40a0-b4fc-b10a2a3b32a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_749a67b9-86f5-4d02-859c-184af6cab737" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7e253239-7347-40a0-b4fc-b10a2a3b32a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fb5e4ff3-f77a-45fa-b909-667468db31c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_41e93934-397a-4ed5-959e-6f78297e01b4" xlink:to="loc_us-gaap_PlanNameAxis_fb5e4ff3-f77a-45fa-b909-667468db31c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fb5e4ff3-f77a-45fa-b909-667468db31c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_fb5e4ff3-f77a-45fa-b909-667468db31c3" xlink:to="loc_us-gaap_PlanNameDomain_fb5e4ff3-f77a-45fa-b909-667468db31c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e09b0f01-4cd6-4884-a0ae-4a8936c04d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_fb5e4ff3-f77a-45fa-b909-667468db31c3" xlink:to="loc_us-gaap_PlanNameDomain_e09b0f01-4cd6-4884-a0ae-4a8936c04d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_OmnibusPlanMember_0226f571-740f-4baf-bbfe-bb71ff961a51" xlink:href="vmd-20210930.xsd#vmd_OmnibusPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e09b0f01-4cd6-4884-a0ae-4a8936c04d2d" xlink:to="loc_vmd_OmnibusPlanMember_0226f571-740f-4baf-bbfe-bb71ff961a51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_38fd99a0-4d73-4791-8626-6a22bab2eb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_41e93934-397a-4ed5-959e-6f78297e01b4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_38fd99a0-4d73-4791-8626-6a22bab2eb2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_38fd99a0-4d73-4791-8626-6a22bab2eb2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_38fd99a0-4d73-4791-8626-6a22bab2eb2d" xlink:to="loc_us-gaap_ClassOfStockDomain_38fd99a0-4d73-4791-8626-6a22bab2eb2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8d1baffd-36c9-43a1-93b3-639d6757112f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_38fd99a0-4d73-4791-8626-6a22bab2eb2d" xlink:to="loc_us-gaap_ClassOfStockDomain_8d1baffd-36c9-43a1-93b3-639d6757112f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a28f9eb9-1897-4d3a-a32a-eac469f7cfef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8d1baffd-36c9-43a1-93b3-639d6757112f" xlink:to="loc_us-gaap_CommonStockMember_a28f9eb9-1897-4d3a-a32a-eac469f7cfef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityOptionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails" xlink:type="extended" id="ifab28ae6955f4a7dacfaae2970be6c6e_ShareholdersEquityOptionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_81959f3a-d94a-46a9-b5b0-3ecfbe51aa69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_81959f3a-d94a-46a9-b5b0-3ecfbe51aa69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_866a2256-b367-4e30-8a27-13c12be64f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_866a2256-b367-4e30-8a27-13c12be64f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a3705ccf-c9ef-426a-9872-414e4bee0bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a3705ccf-c9ef-426a-9872-414e4bee0bb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_71b0009a-50a7-41a5-bdb7-b1796573b245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_71b0009a-50a7-41a5-bdb7-b1796573b245" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1c69ad3c-af5a-4e2b-b099-7509258b4d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1c69ad3c-af5a-4e2b-b099-7509258b4d0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7a17c59-d02f-46d7-b45b-ae04083a6785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7a17c59-d02f-46d7-b45b-ae04083a6785" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c477baa0-c940-42c8-b61c-d313b26169d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c477baa0-c940-42c8-b61c-d313b26169d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9e0d4d73-5473-44b6-82aa-000d4bf6e31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c477baa0-c940-42c8-b61c-d313b26169d4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9e0d4d73-5473-44b6-82aa-000d4bf6e31a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9e0d4d73-5473-44b6-82aa-000d4bf6e31a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9e0d4d73-5473-44b6-82aa-000d4bf6e31a" xlink:to="loc_us-gaap_ClassOfStockDomain_9e0d4d73-5473-44b6-82aa-000d4bf6e31a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6bb861ac-aea3-4662-a125-840014728486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9e0d4d73-5473-44b6-82aa-000d4bf6e31a" xlink:to="loc_us-gaap_ClassOfStockDomain_6bb861ac-aea3-4662-a125-840014728486" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d48b43f7-8ffe-42e1-8ba6-1a20a02b165e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6bb861ac-aea3-4662-a125-840014728486" xlink:to="loc_us-gaap_CommonStockMember_d48b43f7-8ffe-42e1-8ba6-1a20a02b165e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityOptionsFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails" xlink:type="extended" id="ib3500d5dbfea4cc6816d22ab647b38df_ShareholdersEquityOptionsFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_47276d40-20b1-444d-9bcd-93858e0a160e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_47276d40-20b1-444d-9bcd-93858e0a160e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_db2bec6c-8b83-44b2-a273-451e9d2f5d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_db2bec6c-8b83-44b2-a273-451e9d2f5d70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dc869d78-8b54-4362-9760-f853e29c04e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dc869d78-8b54-4362-9760-f853e29c04e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_86d321b8-3cf1-494c-b891-ae28667f0156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_86d321b8-3cf1-494c-b891-ae28667f0156" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fadcb719-7bfa-4983-be1f-9864bf5b855f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fadcb719-7bfa-4983-be1f-9864bf5b855f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_305feb29-9953-4350-800d-3749164156e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:to="loc_us-gaap_SharePrice_305feb29-9953-4350-800d-3749164156e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_295c6f46-87fb-4fe3-8df9-d9650215ef88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_295c6f46-87fb-4fe3-8df9-d9650215ef88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0aae8f10-11ba-4f96-8d20-7a800c2393e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_295c6f46-87fb-4fe3-8df9-d9650215ef88" xlink:to="loc_us-gaap_AwardTypeAxis_0aae8f10-11ba-4f96-8d20-7a800c2393e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aae8f10-11ba-4f96-8d20-7a800c2393e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0aae8f10-11ba-4f96-8d20-7a800c2393e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0aae8f10-11ba-4f96-8d20-7a800c2393e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dcd9a986-5fcb-4467-992e-f964602a9fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0aae8f10-11ba-4f96-8d20-7a800c2393e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dcd9a986-5fcb-4467-992e-f964602a9fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_24fe0ee9-a522-47a0-b4df-0aba1ea52af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dcd9a986-5fcb-4467-992e-f964602a9fdf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_24fe0ee9-a522-47a0-b4df-0aba1ea52af0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_01006728-c9a0-4c41-9da3-74333be6a1c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_295c6f46-87fb-4fe3-8df9-d9650215ef88" xlink:to="loc_srt_RangeAxis_01006728-c9a0-4c41-9da3-74333be6a1c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_01006728-c9a0-4c41-9da3-74333be6a1c9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_01006728-c9a0-4c41-9da3-74333be6a1c9" xlink:to="loc_srt_RangeMember_01006728-c9a0-4c41-9da3-74333be6a1c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a30d973c-2766-4fa1-a400-17d3fb071e9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_01006728-c9a0-4c41-9da3-74333be6a1c9" xlink:to="loc_srt_RangeMember_a30d973c-2766-4fa1-a400-17d3fb071e9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dfacc38f-9bd9-480d-afdd-4f9fc9760333" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a30d973c-2766-4fa1-a400-17d3fb071e9d" xlink:to="loc_srt_MinimumMember_dfacc38f-9bd9-480d-afdd-4f9fc9760333" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8375b4f6-b86a-4992-b599-6e3bd37d05f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a30d973c-2766-4fa1-a400-17d3fb071e9d" xlink:to="loc_srt_MaximumMember_8375b4f6-b86a-4992-b599-6e3bd37d05f4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" xlink:type="extended" id="ia74f90d96f964b7e98eccc51ba504d08_ShareholdersEquityRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c032553e-6d31-4c72-81f1-6d6d91c30953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c032553e-6d31-4c72-81f1-6d6d91c30953" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e44cf35-ad3f-41e5-81bd-e0b4c1f7b134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e44cf35-ad3f-41e5-81bd-e0b4c1f7b134" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4570dbb7-e51e-458a-af37-2f352336e408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e44cf35-ad3f-41e5-81bd-e0b4c1f7b134" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4570dbb7-e51e-458a-af37-2f352336e408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2d5f4928-2a2c-4c7b-b86e-95a359869202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e44cf35-ad3f-41e5-81bd-e0b4c1f7b134" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2d5f4928-2a2c-4c7b-b86e-95a359869202" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4b185bab-6827-4064-937a-4a6abf770308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e44cf35-ad3f-41e5-81bd-e0b4c1f7b134" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4b185bab-6827-4064-937a-4a6abf770308" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1ded9648-30a1-4500-9d02-93a883f1a96f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e44cf35-ad3f-41e5-81bd-e0b4c1f7b134" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1ded9648-30a1-4500-9d02-93a883f1a96f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4aab10b1-73dc-48f2-848f-ba7b5b583ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_147c0d02-1378-4fcb-ad80-1fe3b139a2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_147c0d02-1378-4fcb-ad80-1fe3b139a2e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_45e92b72-a655-4e0f-8dfc-82661c0218ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_147c0d02-1378-4fcb-ad80-1fe3b139a2e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_45e92b72-a655-4e0f-8dfc-82661c0218ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8cb83911-e80c-4748-a7de-ad09c8ca1514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_147c0d02-1378-4fcb-ad80-1fe3b139a2e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8cb83911-e80c-4748-a7de-ad09c8ca1514" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6f3d1259-5bcd-4a78-8f0e-ced089d09ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_147c0d02-1378-4fcb-ad80-1fe3b139a2e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6f3d1259-5bcd-4a78-8f0e-ced089d09ba8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_dbbdbe7f-0eb6-42a5-bf62-88c1858f36bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_147c0d02-1378-4fcb-ad80-1fe3b139a2e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_dbbdbe7f-0eb6-42a5-bf62-88c1858f36bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fdf134c7-d4c4-42b5-b220-cd2870a7bfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e4343a56-62e6-4180-b6d3-895c71c0a350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e4343a56-62e6-4180-b6d3-895c71c0a350" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_97d95cc9-e933-41d9-ab36-f0207b5916a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e4343a56-62e6-4180-b6d3-895c71c0a350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_97d95cc9-e933-41d9-ab36-f0207b5916a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_8361415a-7bad-4c9b-b227-8359729a84b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_8361415a-7bad-4c9b-b227-8359729a84b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_aaee9f7f-7d81-4d75-af6a-21f25c2677a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_8361415a-7bad-4c9b-b227-8359729a84b3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_aaee9f7f-7d81-4d75-af6a-21f25c2677a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_910286cc-3a31-4c82-b1b2-c38aa19e4eed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_910286cc-3a31-4c82-b1b2-c38aa19e4eed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b1143fec-b46b-4e66-8b89-041e834286d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_910286cc-3a31-4c82-b1b2-c38aa19e4eed" xlink:to="loc_us-gaap_AwardTypeAxis_b1143fec-b46b-4e66-8b89-041e834286d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1143fec-b46b-4e66-8b89-041e834286d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b1143fec-b46b-4e66-8b89-041e834286d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1143fec-b46b-4e66-8b89-041e834286d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31c95e53-555a-4237-958a-7b6789b9da43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b1143fec-b46b-4e66-8b89-041e834286d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31c95e53-555a-4237-958a-7b6789b9da43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_79ba794b-f14f-416a-b5bc-2abbd9c0ffd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31c95e53-555a-4237-958a-7b6789b9da43" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_79ba794b-f14f-416a-b5bc-2abbd9c0ffd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9435f3ad-7f1b-4389-99a4-0709b19dc627" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_910286cc-3a31-4c82-b1b2-c38aa19e4eed" xlink:to="loc_srt_RangeAxis_9435f3ad-7f1b-4389-99a4-0709b19dc627" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9435f3ad-7f1b-4389-99a4-0709b19dc627_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9435f3ad-7f1b-4389-99a4-0709b19dc627" xlink:to="loc_srt_RangeMember_9435f3ad-7f1b-4389-99a4-0709b19dc627_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50a196be-04d7-4b58-88fb-9682b9a2b30e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9435f3ad-7f1b-4389-99a4-0709b19dc627" xlink:to="loc_srt_RangeMember_50a196be-04d7-4b58-88fb-9682b9a2b30e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_706a4aeb-79db-4726-90eb-63ec38651659" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50a196be-04d7-4b58-88fb-9682b9a2b30e" xlink:to="loc_srt_MinimumMember_706a4aeb-79db-4726-90eb-63ec38651659" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd772213-6fb7-46d2-ba27-95972ba70847" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50a196be-04d7-4b58-88fb-9682b9a2b30e" xlink:to="loc_srt_MaximumMember_bd772213-6fb7-46d2-ba27-95972ba70847" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityPhantomShareUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" xlink:type="extended" id="i8c8e320a66ad4692931878ad65afc464_ShareholdersEquityPhantomShareUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f1744f29-e1da-42ec-9f08-bb4ca33dc471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f1744f29-e1da-42ec-9f08-bb4ca33dc471" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f62aa813-5a03-4509-9991-b176edba64af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f62aa813-5a03-4509-9991-b176edba64af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_526e446c-71db-4585-b87c-608e258a7c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f62aa813-5a03-4509-9991-b176edba64af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_526e446c-71db-4585-b87c-608e258a7c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cd0c99c4-0e78-44c6-a51f-c950c833c313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f62aa813-5a03-4509-9991-b176edba64af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cd0c99c4-0e78-44c6-a51f-c950c833c313" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ee1ce996-d8a7-471e-a9d3-9b250382f850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f62aa813-5a03-4509-9991-b176edba64af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ee1ce996-d8a7-471e-a9d3-9b250382f850" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_264f501c-560b-46e3-bd15-d1a1e42e9527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f62aa813-5a03-4509-9991-b176edba64af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_264f501c-560b-46e3-bd15-d1a1e42e9527" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f8f3a537-083a-41ef-aacf-1279e7d2a586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_960951bc-0311-4c23-b7d5-bd9225f18793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_960951bc-0311-4c23-b7d5-bd9225f18793" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_37e6d4e7-e32b-455e-95ad-ce4738c002a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_960951bc-0311-4c23-b7d5-bd9225f18793" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_37e6d4e7-e32b-455e-95ad-ce4738c002a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued_84c629bb-2976-40f9-af99-679e26eb7c8c" xlink:href="vmd-20210930.xsd#vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_960951bc-0311-4c23-b7d5-bd9225f18793" xlink:to="loc_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued_84c629bb-2976-40f9-af99-679e26eb7c8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6429c03a-fb05-47a1-a8b3-7b1cd3ccac23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_960951bc-0311-4c23-b7d5-bd9225f18793" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6429c03a-fb05-47a1-a8b3-7b1cd3ccac23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_314669c1-787f-4794-8379-f5fe89e220ab" xlink:href="vmd-20210930.xsd#vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_960951bc-0311-4c23-b7d5-bd9225f18793" xlink:to="loc_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_314669c1-787f-4794-8379-f5fe89e220ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_f6996362-d228-4ad3-b1f7-f873fd6361dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_3475a6dc-27a0-43c1-a690-d3a7849ac334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_SharePrice_3475a6dc-27a0-43c1-a690-d3a7849ac334" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_055bad7f-f833-44a4-b49b-a197096a2547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_055bad7f-f833-44a4-b49b-a197096a2547" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_b44d4688-73f7-426e-b1a6-019518ea8601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_b44d4688-73f7-426e-b1a6-019518ea8601" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_644d76d5-3ec2-4186-ae5c-b475c858e4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_644d76d5-3ec2-4186-ae5c-b475c858e4f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb53282e-a750-48fa-bcf1-dc6c56500399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb53282e-a750-48fa-bcf1-dc6c56500399" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1dcc9374-d360-432e-85eb-c5ffe1c1b42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1dcc9374-d360-432e-85eb-c5ffe1c1b42d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8ab92fa-98dd-46fa-b403-492c06927d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8ab92fa-98dd-46fa-b403-492c06927d6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_995bdce2-7562-4490-9a2f-24fdecacad93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8ab92fa-98dd-46fa-b403-492c06927d6c" xlink:to="loc_us-gaap_AwardTypeAxis_995bdce2-7562-4490-9a2f-24fdecacad93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_995bdce2-7562-4490-9a2f-24fdecacad93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_995bdce2-7562-4490-9a2f-24fdecacad93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_995bdce2-7562-4490-9a2f-24fdecacad93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bebe3741-c1e5-4f55-b7bc-10310a7bc192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_995bdce2-7562-4490-9a2f-24fdecacad93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bebe3741-c1e5-4f55-b7bc-10310a7bc192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_a1940453-51ab-45fd-80c6-1c78b49d8ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bebe3741-c1e5-4f55-b7bc-10310a7bc192" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_a1940453-51ab-45fd-80c6-1c78b49d8ea1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5ea63eda-0d6d-402b-b579-2c406232b10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8ab92fa-98dd-46fa-b403-492c06927d6c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5ea63eda-0d6d-402b-b579-2c406232b10a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5ea63eda-0d6d-402b-b579-2c406232b10a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5ea63eda-0d6d-402b-b579-2c406232b10a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5ea63eda-0d6d-402b-b579-2c406232b10a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7378afc1-33be-4e96-84fe-6d9903402d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5ea63eda-0d6d-402b-b579-2c406232b10a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7378afc1-33be-4e96-84fe-6d9903402d75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_80373cfa-6757-4426-a92d-e635b5ce715f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7378afc1-33be-4e96-84fe-6d9903402d75" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_80373cfa-6757-4426-a92d-e635b5ce715f" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>vmd-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:fbb1b016-a19a-460d-bfda-ed9a0f837dc5,g:50e705b0-d493-4f83-95b4-caa6929c52c8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_0d64b230-fdf4-47fd-aebf-43a9f083262b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_303d8927-915f-4e5b-92c4-9aa3070d610d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_75f0caed-60ef-460c-accf-65b5743d31bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b04e7855-ae32-46ce-a727-3e1e105f1256_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_058c22bf-907d-4202-aa77-f006ab239d39_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a9ef9bfe-f532-4f06-979e-5e8aec49fcc5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6c5bb202-ed3f-4530-b370-e205647a7855_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a7f406e0-ba70-48ad-8291-dce4c32e3b29_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_bc7961ec-5a04-41a6-9f87-7952bfbea7fc_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c16a9312-c069-481b-8d02-a9b3fe43f7f0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued vacation and payroll</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_41b287a7-fb2e-406f-a250-c6f2b22f2a49_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssets_beb3abcc-9b9b-4e05-be33-cc0c1eae2431_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding deposit</link:label>
    <link:label id="lab_us-gaap_DepositsAssets_label_en-US" xlink:label="lab_us-gaap_DepositsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssets" xlink:to="lab_us-gaap_DepositsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0cba3da0-ad77-430e-8d13-439283281096_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e739a251-aed9-46d4-b8a0-ddd4da2b226d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_BuildingTermNoteMember_94332a62-9788-4f68-8335-6c1e8ce08eed_terseLabel_en-US" xlink:label="lab_vmd_BuildingTermNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building Term Note</link:label>
    <link:label id="lab_vmd_BuildingTermNoteMember_label_en-US" xlink:label="lab_vmd_BuildingTermNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building Term Note [Member]</link:label>
    <link:label id="lab_vmd_BuildingTermNoteMember_documentation_en-US" xlink:label="lab_vmd_BuildingTermNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building Term Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_BuildingTermNoteMember" xlink:href="vmd-20210930.xsd#vmd_BuildingTermNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_BuildingTermNoteMember" xlink:to="lab_vmd_BuildingTermNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_9e981398-9b3c-4e08-b0d0-fa4eefeaaee7_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_ba51769e-3fdc-4d03-a488-c84fd8156bba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_45a5fa81-1598-498c-a9f2-4a7793cf1a85_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_dd57798d-e21e-4fd1-b846-1e240306e2fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired / Forfeited (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_cdfe8be4-026b-4cdf-b163-fabce2f9d48c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d394e220-41c4-4bd0-a0da-7ba028d7ab8f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b6f4b9eb-d57e-4331-bf0d-633934ec6673_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1c79f903-047d-4f21-838f-359b54a014be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5e6a1b06-59d2-4a35-b412-54151ed73cff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_bff4a515-a73f-4525-be3c-ccced6e98196_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a7f23de4-5c2e-4609-90e2-dc0522698bca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6d7d4d05-d2f8-43ae-a6f8-6914a7c3204a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares in Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cb71d067-6c80-47e7-bfe8-95edd1800684_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ab24a798-830d-41ad-a7bb-a2c8ec4a5cd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncome_83fafdd4-dfc4-4f94-b30d-49122e4eac0b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from rentals</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncome_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncome" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c16ddf93-205f-49a4-9c07-432d98aeb43d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total rental payments</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_a915353d-ab83-4c6e-b811-e6bcfe081f2c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired / Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_62543507-1021-461f-99b6-7611430ca9e5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_ca379627-f1a5-4981-b255-f519b012fae5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued bonuses payable</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_cde78314-87eb-45ec-9766-d719f14ecf07_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67471823-86d8-4657-9722-999d521c4f0f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_cd7f1ea0-bb2b-4e88-8e76-96a3128447c5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_4de940a6-f975-4985-808f-eda70e53683c_verboseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_cf526ae8-4c15-4bf3-ae9e-7c46042e8b18_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states in which entity provides DME and health care solutions</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb99daef-c8ef-4102-ab7a-f19f0fdafcc5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0130ee94-c661-4dfd-acf6-528f130ed6a2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_93caad20-f7d9-4f0e-ae5e-d1d43c12cf68_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_a83d0b42-dfd7-430a-b291-5348137d17ef_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fade6a94-8122-455c-8ebd-db22a7840f04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_370ce085-ac33-4e8f-9575-eb2d8fa9bddc_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bee80093-c752-44fe-8ad9-c02ee8fa8814_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c3862a7a-c6a4-4df2-9186-8ed18bdd7f14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1ea0ec3d-2e05-46e5-b18b-bdd2fe912590_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_43dfe88d-7fe9-4c78-9073-ba0c71d158b8_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_55a0e62a-6ceb-4aa0-9d9c-17855eb38c6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a4c7001c-2146-43c4-994c-b49329a494b2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_608f9fe5-e2d3-4846-8f4c-92ba56cb7c88_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aaf81ed8-0ef9-4bcb-95db-3382b555adb6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cfe56874-1646-4939-bebf-1f86e0519fb8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2cc3b7f9-238a-4f78-97a5-d78437cf9441_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f5facc1e-91ac-49b4-b042-010c8b07c56e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_59fdd1ed-a819-4168-b1fe-d0d71da6dd9e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_4eeb2826-4b76-454c-8450-19044ca4da28_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5258a7be-f5c4-44ad-a56f-ed1d0f90c069_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_d073669f-6816-4254-ac0b-b2fc94f8486c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f509a124-33fa-4108-b458-49d4c0d0de7c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_AssetsHeldUnderFinanceLeasesMember_68b3ff14-ca28-48cf-94d5-9033d98fc2f6_terseLabel_en-US" xlink:label="lab_vmd_AssetsHeldUnderFinanceLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital lease</link:label>
    <link:label id="lab_vmd_AssetsHeldUnderFinanceLeasesMember_label_en-US" xlink:label="lab_vmd_AssetsHeldUnderFinanceLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held Under Finance Leases [Member]</link:label>
    <link:label id="lab_vmd_AssetsHeldUnderFinanceLeasesMember_documentation_en-US" xlink:label="lab_vmd_AssetsHeldUnderFinanceLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held Under Finance Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_AssetsHeldUnderFinanceLeasesMember" xlink:href="vmd-20210930.xsd#vmd_AssetsHeldUnderFinanceLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_AssetsHeldUnderFinanceLeasesMember" xlink:to="lab_vmd_AssetsHeldUnderFinanceLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cabc5b6b-fd1d-4600-a6f6-96fabc1a8ab1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_84ba2cf6-49a6-4576-b621-6d927b014589_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_287ffda2-8a6c-41b5-82ca-07fc2fde2a25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares redeemed to pay income tax</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_a3c82254-d6e4-4161-ba9f-54e5e6d92280_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares redeemed to pay income tax</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0fe35e8a-64ac-4682-8ed1-28da552189fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_693e21de-0363-44ac-9add-0973635ea5fc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8e110148-dbd5-4fe3-a017-f3ba3cae7826_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_OmnibusPlanMember_5706147a-4e35-4499-8259-bbc9278775e5_terseLabel_en-US" xlink:label="lab_vmd_OmnibusPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Plan</link:label>
    <link:label id="lab_vmd_OmnibusPlanMember_label_en-US" xlink:label="lab_vmd_OmnibusPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Plan [Member]</link:label>
    <link:label id="lab_vmd_OmnibusPlanMember_documentation_en-US" xlink:label="lab_vmd_OmnibusPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_OmnibusPlanMember" xlink:href="vmd-20210930.xsd#vmd_OmnibusPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_OmnibusPlanMember" xlink:to="lab_vmd_OmnibusPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_86d7ff31-5fb6-4d8f-b92b-c22633d878d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5fbd453c-104f-40af-add8-d04d46558770_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_ccff7dca-0ed0-4d67-bbed-85a5b6f36b9a_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4c66bd71-ff8e-4e14-9459-eee9d626ea87_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_761789bf-9bcf-4501-beff-f9fe54fad1b8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed interest rate</link:label>
    <link:label id="lab_us-gaap_DerivativeFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_DerivativeFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Fixed Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFixedInterestRate" xlink:to="lab_us-gaap_DerivativeFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_50cc2e0d-2e8c-444a-92ab-2c213e0398ee_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8d475319-2528-48e9-81e7-8b314934881f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_de3c8b55-2101-4603-a518-c01657aa82e3_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from equity method investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_LeaseLiabilityCurrent_3f4a50fb-8dab-407d-b4e7-bd544c1b348f_terseLabel_en-US" xlink:label="lab_vmd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_vmd_LeaseLiabilityCurrent_c8c19b4d-09d4-4258-a408-a7ea4e3537c4_negatedTerseLabel_en-US" xlink:label="lab_vmd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_vmd_LeaseLiabilityCurrent_label_en-US" xlink:label="lab_vmd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:label id="lab_vmd_LeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_vmd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeaseLiabilityCurrent" xlink:href="vmd-20210930.xsd#vmd_LeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_LeaseLiabilityCurrent" xlink:to="lab_vmd_LeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_992bccf2-6f4a-4ab2-bb61-3e051b23e4b4_terseLabel_en-US" xlink:label="lab_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_label_en-US" xlink:label="lab_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:href="vmd-20210930.xsd#vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:to="lab_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_d390198c-dbef-468f-a59f-abc85919094f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cfd647be-1b44-413e-805a-08653b049529_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_608d9c8a-cfca-4e96-b042-a8b2dc56d456_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9adf9104-5280-41b4-ba89-16c70dabd75b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6a3eb076-b980-43f0-a072-9a909140ebfd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued_8c645edd-8c04-4731-84b8-c9e954fdd1f4_terseLabel_en-US" xlink:label="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued</link:label>
    <link:label id="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued_label_en-US" xlink:label="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Issued</link:label>
    <link:label id="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued_documentation_en-US" xlink:label="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" xlink:href="vmd-20210930.xsd#vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" xlink:to="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_134b8cb1-e61b-49b3-a2f5-2024057479c9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Source</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments_aebad5fd-4196-49f2-8d29-0bfa5dc12c05_terseLabel_en-US" xlink:label="lab_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions of earnings received from equity method investments</link:label>
    <link:label id="lab_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments_label_en-US" xlink:label="lab_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions Of Earnings Received From Equity Method Investments</link:label>
    <link:label id="lab_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments_documentation_en-US" xlink:label="lab_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions Of Earnings Received From Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments" xlink:href="vmd-20210930.xsd#vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments" xlink:to="lab_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7aac527-a1ed-4f49-9c89-65e90d5d420b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs (000's)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_342dcca2-3eca-4924-a555-6fb8f8d73b25_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of phantom share units (000's)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7144e6df-431e-4403-9418-8b06dc949c36_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_0246065a-fe61-44b7-ac2b-a56a6081a1d1_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_dc856070-72c2-4f54-838d-7f1aa352a1d3_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_fcd87de1-9864-4586-a9f1-def92d49a908_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_dd058e42-72ac-4182-8448-42906f94ac3c_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_dc907f64-7df3-4a83-b4c8-d39eae8d62d7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of phantom share liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_524a6aac-c8e4-49d6-bb59-34554dc107f9_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b2d54749-5f08-4a7d-9c18-ebb539db8ab3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38fbbfb8-3c67-49d1-a5c1-e2345b176da4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_AccruedTradePayablesCurrent_d9f057c4-ecf6-42c3-8ed4-c9589e2dff5b_terseLabel_en-US" xlink:label="lab_vmd_AccruedTradePayablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued trade payables</link:label>
    <link:label id="lab_vmd_AccruedTradePayablesCurrent_label_en-US" xlink:label="lab_vmd_AccruedTradePayablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Trade Payables, Current</link:label>
    <link:label id="lab_vmd_AccruedTradePayablesCurrent_documentation_en-US" xlink:label="lab_vmd_AccruedTradePayablesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Trade Payables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_AccruedTradePayablesCurrent" xlink:href="vmd-20210930.xsd#vmd_AccruedTradePayablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_AccruedTradePayablesCurrent" xlink:to="lab_vmd_AccruedTradePayablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_52e1190f-13ba-4474-b012-beaf8458a53a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_51fed402-e753-4e22-9ef3-2c3583e45d5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c9e85795-894c-48bb-9cf5-f4996a811c02_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_d2f59c40-0e35-4815-bb33-e790dd498345_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_80d607fd-f451-42fc-b047-57a3d2e9e9eb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized gain/loss on derivative instruments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_88a7798d-62f4-4f76-b25e-7a4a93516ac3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_230b59b7-cc21-493d-9507-1345f41255cf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in equity investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a76b54e3-e829-4ed3-abba-d4ecb74f5f23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_357bfb85-7937-4929-a11f-19809ef144c8_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e8ebfe2c-9f07-43c9-b33c-15b8a4e8a5c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_040182c8-c066-4eca-95a6-19796c6fceff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_812d33e9-03a8-4d47-a8ae-719b95661dd5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_c6dd7fd7-693c-46dd-9b39-c0932a3a3f04_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_359a83ea-460d-42ba-930b-7a2de5581d60_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_37636463-3129-4c92-a381-25a214eafcaa_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition period</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_caf53d0a-5a85-450b-a789-a78b02e9f451_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_797a3a85-4f91-4371-9f2b-2b564ac2da26_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settlement</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cash Used to Settle Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4646abf1-dc00-4a36-9541-2b426369ded9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_351b60ce-5db8-49fe-9b83-6a503569a979_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ffde3113-a5fe-4e69-a49a-d2d4e579ccb4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_FurnitureAndEquipmentMember_340075b3-2177-4924-8534-8c907d7566d9_terseLabel_en-US" xlink:label="lab_vmd_FurnitureAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_vmd_FurnitureAndEquipmentMember_label_en-US" xlink:label="lab_vmd_FurnitureAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Equipment [Member]</link:label>
    <link:label id="lab_vmd_FurnitureAndEquipmentMember_documentation_en-US" xlink:label="lab_vmd_FurnitureAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_FurnitureAndEquipmentMember" xlink:href="vmd-20210930.xsd#vmd_FurnitureAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_FurnitureAndEquipmentMember" xlink:to="lab_vmd_FurnitureAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7b7d2b76-b3cd-437e-bd2a-3453d0bdbccd_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business and Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_e3059ea8-1399-481a-993b-2e8a7004c0e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_d1c21da2-cf91-4634-a5f6-0492fb7d5e33_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_a574c28a-5a1e-4518-9082-c294dbf00dcb_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_c547cf1b-3e9e-4f2a-9f7a-ea21b4a63719_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings against facility</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_8b2a51cf-b5ed-467e-b3a6-14187799bbb7_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_913c73d1-dd16-47a7-a4a2-b37435c028fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired / Forfeited (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_8901be12-0e46-47b8-b7e6-def03a6072cf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c168a194-135d-4344-b265-6be5ed7540ca_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_077f9c10-d6ad-4370-b947-2da231ed8c1c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_NumberOfStockClasses_3c93b18b-e856-44dd-84cf-6a8f9a7e9b9a_terseLabel_en-US" xlink:label="lab_vmd_NumberOfStockClasses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock classes</link:label>
    <link:label id="lab_vmd_NumberOfStockClasses_label_en-US" xlink:label="lab_vmd_NumberOfStockClasses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stock Classes</link:label>
    <link:label id="lab_vmd_NumberOfStockClasses_documentation_en-US" xlink:label="lab_vmd_NumberOfStockClasses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stock Classes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_NumberOfStockClasses" xlink:href="vmd-20210930.xsd#vmd_NumberOfStockClasses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_NumberOfStockClasses" xlink:to="lab_vmd_NumberOfStockClasses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_b9e50ceb-83dc-47f9-9faa-b27a3012533d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e3489670-740a-418b-a902-8804c381e447_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_ce45fe30-b34c-4d40-9209-a2bc7c6cefb6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c208e220-e844-47a8-9027-63fdad3936b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_5f149092-0921-493e-8ba1-d2e2f54257f7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_MonthlyRentalPaymentsMember_6f42fe4d-59f0-40a7-892b-8fc475a535e0_terseLabel_en-US" xlink:label="lab_vmd_MonthlyRentalPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly Rental Payments</link:label>
    <link:label id="lab_vmd_MonthlyRentalPaymentsMember_label_en-US" xlink:label="lab_vmd_MonthlyRentalPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly Rental Payments [Member]</link:label>
    <link:label id="lab_vmd_MonthlyRentalPaymentsMember_documentation_en-US" xlink:label="lab_vmd_MonthlyRentalPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly Rental Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_MonthlyRentalPaymentsMember" xlink:href="vmd-20210930.xsd#vmd_MonthlyRentalPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_MonthlyRentalPaymentsMember" xlink:to="lab_vmd_MonthlyRentalPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_0f73eba7-18ea-42c1-be35-030239c4d83b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_23f6d265-9280-4e35-9ae2-df3a48b97e19_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2fc1416f-8e18-46cc-911b-70fe924bba6e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0c35ab15-f441-4414-b4e1-0c0f0af7cd0d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_fef89bad-3b7f-4ed1-8a7c-dd0c9c12a13f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_51ae9753-ec5c-446e-81e4-9079357e1fff_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_9d01c97d-0025-4446-8857-9403e810b638_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_3f0906bf-82b5-41f3-8430-dcfe468e584d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - No par value: unlimited authorized; 39,630,446 and 39,185,182 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_31ab63bf-b994-4cb9-8eb7-f35a1638a5c1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_124c3e05-7346-4f01-b2cb-bde5173c76cf_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2308ecd7-68ab-4702-81c7-57c6a4640b0d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period of recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_62fa9ae8-3dac-4004-9f63-43538268fcfb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3eaa1a73-c73d-474f-ab90-ca072d3cba3d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_fc2246df-c9c6-4188-8502-fe69ea7d0156_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f394b223-d20d-4d4f-9ab8-3401c4572bb2_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_fbce9a66-4e64-4efb-ae35-7f6745cd5b09_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_bd23309e-1455-4849-9112-d45ad9b74f20_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_116521eb-65e9-4b25-ace0-ed64eb4a1a4f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_c76694d1-80a1-4440-a28c-2e4f2f805750_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4490e561-feef-4642-9ee8-aefbc07d24c8_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_74ea5a57-a1d0-482d-bb3a-66198857e098_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestments_c5b2db19-18ee-49b2-9cf8-51a7449df224_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other equity investments</link:label>
    <link:label id="lab_us-gaap_OtherInvestments_label_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestments" xlink:to="lab_us-gaap_OtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_MedicareMember_5825e743-f1b3-4e0f-9229-21ee5507f744_terseLabel_en-US" xlink:label="lab_vmd_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare revenues</link:label>
    <link:label id="lab_vmd_MedicareMember_label_en-US" xlink:label="lab_vmd_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_vmd_MedicareMember_documentation_en-US" xlink:label="lab_vmd_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_MedicareMember" xlink:href="vmd-20210930.xsd#vmd_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_MedicareMember" xlink:to="lab_vmd_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_8ad62b2d-8c38-4b63-b1bd-f7370b0f13aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_b7464a50-5952-4d21-a936-e1e0223ba690_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Phantom Share Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_1b5a4866-3592-4cb2-9963-48814fc94e72_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_bee0da41-bbae-4309-a023-622ae5d00847_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly principal payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_f96177e9-68fe-4fa0-90d2-a867de6962d3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_001855ce-8a2a-42c7-a2f9-e4f7800790b5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_3f5b3170-64f6-40ad-8401-922cc9bdf77a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_LeaseLiabilityNoncurrent_8788a013-a5fd-40e3-a069-5e696684653f_terseLabel_en-US" xlink:label="lab_vmd_LeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_vmd_LeaseLiabilityNoncurrent_2f7073e6-503a-4ed3-a4d6-3259ae629524_verboseLabel_en-US" xlink:label="lab_vmd_LeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net long-term lease liabilities</link:label>
    <link:label id="lab_vmd_LeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_vmd_LeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_vmd_LeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_vmd_LeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeaseLiabilityNoncurrent" xlink:href="vmd-20210930.xsd#vmd_LeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_LeaseLiabilityNoncurrent" xlink:to="lab_vmd_LeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDiscountRate_abfbcb9c-c2dd-4868-a89f-2082867e8e6d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9f0850a8-5e2c-4f28-94a0-ef32fb4ac151_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fbb18f05-6bbd-4920-8ac9-09129982f914_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d14e90eb-45f9-420e-a69e-8599762950f7_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_072f2473-f61f-4b67-aa3c-e2bab6826cb9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_89de7e77-7cfc-46f6-9c13-020328d86285_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73e42f71-a5eb-44e2-ae00-4609c6dbe59c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from sales and services</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_8b4a5a89-ba72-4799-9b72-365a688e9d29_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in income tax payable/receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3e1d9665-4c8d-49ce-89e2-d5559cc43801_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3e890858-ae0d-4c5e-96a9-0f766a816b9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_347a1815-74ab-4abd-8759-bf98930d3e3d_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0d5b133d-c242-4772-a9d1-8c2357429138_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_a6f122cb-2c9d-47f4-bcd9-227409f024a9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_861aefae-0d3c-4b0f-af56-9b1d5b9b6df6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average lease term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2319fb5c-0e22-456c-87d3-a3ed24a75f05_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ebe4df2-1f60-43a2-8436-e32dd45bc6b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_EquipmentMedicalMember_2a23048f-72d5-469d-a6da-cec2ef9f944d_terseLabel_en-US" xlink:label="lab_vmd_EquipmentMedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical equipment</link:label>
    <link:label id="lab_vmd_EquipmentMedicalMember_label_en-US" xlink:label="lab_vmd_EquipmentMedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment, Medical [Member]</link:label>
    <link:label id="lab_vmd_EquipmentMedicalMember_documentation_en-US" xlink:label="lab_vmd_EquipmentMedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment, Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_EquipmentMedicalMember" xlink:href="vmd-20210930.xsd#vmd_EquipmentMedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_EquipmentMedicalMember" xlink:to="lab_vmd_EquipmentMedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_568fa029-4f9a-4af6-b306-5eb7abed9999_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_87eab188-c71d-4ddd-afd5-dd211962ee4f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_dc06dd14-f8e1-43b5-b998-e0ce0287213f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_f6bde0dc-9cb3-4736-b0ae-cc97a4266598_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_39673e04-80c9-4f23-93f4-c05edc279101_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1d9693b0-4309-4a26-b439-12a10cf60a90_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_f1348919-8615-4708-b39f-0bd3ec3f5f7b_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_f8434488-17fe-45a1-a905-68919f8d5050_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental payments</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_14cf5b10-6f7f-48d7-9e61-16e03a691250_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_f3601c25-4938-40c8-af52-0e9ab07f91f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_267db44e-fb5d-454d-870f-3c8a7478e036_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f8638dd3-97bb-4728-b2a0-4c61ccc37e75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_acf55201-f2dd-493f-83e8-bf356a7a8643_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_0123dd82-7c6c-4cb0-a641-7946ae4d9c3e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation - restricted stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4d135dbc-d55d-46f4-b435-0e6666794e76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_a250a5bb-9051-42da-9863-bc1226e80b55_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares redeemed to pay income tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_1420ff51-281f-4970-ad7f-9573dff51446_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares redeemed to pay income tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cd5b1a21-5e5b-465c-9e87-487eb040d8a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_LeasePayments_fac467a0-04f6-45f3-a2e8-03461fe7b7f5_negatedTerseLabel_en-US" xlink:label="lab_vmd_LeasePayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of lease liabilities</link:label>
    <link:label id="lab_vmd_LeasePayments_label_en-US" xlink:label="lab_vmd_LeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Payments</link:label>
    <link:label id="lab_vmd_LeasePayments_documentation_en-US" xlink:label="lab_vmd_LeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeasePayments" xlink:href="vmd-20210930.xsd#vmd_LeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_LeasePayments" xlink:to="lab_vmd_LeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_bfa9b18e-eff4-437a-b21a-3ed4bd9d7bab_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1da4b7a3-99fe-4174-93f5-9b645dd2e2aa_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c48ff131-314e-4d9b-99af-186680f690e1_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_714ee86f-dacf-453f-a612-aceea0e8ad85_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a95b0774-6b78-4127-8baf-13ad1756f69c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_LeaseLiability_6e0a2705-7c3e-490a-89b1-7b1dfc829a33_totalLabel_en-US" xlink:label="lab_vmd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_vmd_LeaseLiability_label_en-US" xlink:label="lab_vmd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_vmd_LeaseLiability_documentation_en-US" xlink:label="lab_vmd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeaseLiability" xlink:href="vmd-20210930.xsd#vmd_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_LeaseLiability" xlink:to="lab_vmd_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_TermNoteMember_bf456eec-b216-4df7-bcb6-fff1686df1be_terseLabel_en-US" xlink:label="lab_vmd_TermNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Note</link:label>
    <link:label id="lab_vmd_TermNoteMember_label_en-US" xlink:label="lab_vmd_TermNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Note [Member]</link:label>
    <link:label id="lab_vmd_TermNoteMember_documentation_en-US" xlink:label="lab_vmd_TermNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Note [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_TermNoteMember" xlink:href="vmd-20210930.xsd#vmd_TermNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_TermNoteMember" xlink:to="lab_vmd_TermNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_beaabdd6-b9ee-4f08-892d-b73b433d7f3e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_39624173-0433-4b0f-b70e-3f4c79b591f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cc640b30-bdb1-419b-9702-104d3a854224_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4233169c-5f89-42ce-bc97-0417618bf3b8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_4225093d-e3de-4764-b7cb-1d905fffd32a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_54460061-f86e-4234-9c7a-e3f200c75174_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3fbd7c38-678f-4167-87b3-8ff495586db4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1ac69f16-4907-4fae-bf90-e2596dd83b6e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4fa06f79-c12e-4ff9-a01b-c681f941a910_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares redeemed to pay income tax</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_75ee48ab-399c-4f85-98b7-87a3c2b5c9a9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_f5ee6902-0360-46ee-9fb4-749ec12e701d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash transactions</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_a7c4fef9-9ca9-4722-bc24-0b584d0c4574_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_025f11bc-c03d-4265-bf71-9b3af4f88411_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_1e59db02-4486-4b2a-be96-fcf056e9fcfd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_NetNonCashChangesToOperatingLeaseBalances_7df6d3a3-2ddf-4220-8b0b-4341570ad714_terseLabel_en-US" xlink:label="lab_vmd_NetNonCashChangesToOperatingLeaseBalances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net non-cash changes to operating lease balances</link:label>
    <link:label id="lab_vmd_NetNonCashChangesToOperatingLeaseBalances_label_en-US" xlink:label="lab_vmd_NetNonCashChangesToOperatingLeaseBalances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Non-Cash Changes To Operating Lease Balances</link:label>
    <link:label id="lab_vmd_NetNonCashChangesToOperatingLeaseBalances_documentation_en-US" xlink:label="lab_vmd_NetNonCashChangesToOperatingLeaseBalances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Non-Cash Changes To Operating Lease Balances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_NetNonCashChangesToOperatingLeaseBalances" xlink:href="vmd-20210930.xsd#vmd_NetNonCashChangesToOperatingLeaseBalances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_NetNonCashChangesToOperatingLeaseBalances" xlink:to="lab_vmd_NetNonCashChangesToOperatingLeaseBalances" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1d77f866-c1d0-472e-b3c5-dd2d2cbbdfa7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_5af5090a-8a9d-4033-8457-7c578d973fe6_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value on date of grant (USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_e65c7d44-6987-4f6b-80d7-e70e40bcfb00_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price(USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5cafd346-7bbc-4385-ad69-05eba87e6cd4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_a4afaee1-6867-49a2-9fad-e1142da5b450_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_49b61b49-df0d-49eb-8f99-e1a9cbde862f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f1e628b8-9ed7-45ff-b0f3-859ccc44faff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_464203fd-1d6f-43b0-a1ef-83dc9d949239_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding_c06b0922-b3c8-4be0-b713-30dd3b03cb85_terseLabel_en-US" xlink:label="lab_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of issued and outstanding shares</link:label>
    <link:label id="lab_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding_label_en-US" xlink:label="lab_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Grant, Percent Of Stock Outstanding</link:label>
    <link:label id="lab_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding_documentation_en-US" xlink:label="lab_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Grant, Percent Of Stock Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding" xlink:href="vmd-20210930.xsd#vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding" xlink:to="lab_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_06a8e831-cadf-4a4f-ae69-07f0f0a7a9dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_d7c301a9-9006-4c11-a9ce-99ba553a302d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_05457f23-7058-4e8a-bcab-e00ad5b2c852_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f43363ce-7d34-49f6-bec5-a0ed7ca31559_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_fe4e8788-2705-431c-a985-e42c264eb77d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_90196281-207a-4d7c-86e7-94524fec33ab_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_4a4dd08d-cbb8-40f2-a9a9-9027fd3fafa5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_27c97f7f-146e-4119-8ba7-bf35b68e2742_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_31fdb88c-84b0-4e2b-914b-a11bca21d70c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_dd7504c1-d399-43d1-8b87-720a0a507fe1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision (benefit) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2587d13b-79e7-44b5-b4b3-04c2942ebf72_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1e090680-0978-402b-b64d-eb9d92f757a0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $7,115 and $9,013 at September 30, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_cfd54274-699a-42fe-a9ef-8f237910d04e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_458d0525-6ddc-44ad-a20e-4ae8413f4e5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a91fbb43-6c3e-4493-bcd1-bc677a0689a2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_744724bf-13f6-4518-b3ae-01f3863f0300_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_722526db-d78e-4b85-bdb2-a8a0cdee2448_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_819b458d-befc-47f3-9310-d81c2bfa0437_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b7cf51fd-fc2e-4d6f-9dd8-a97de432de86_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_938aabbd-a7db-404d-8bed-edc1c8d0f37b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired / Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_5bd8c7f8-9566-4670-8e22-f10abf0f3ac8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net of inventory reserve of $1,237 and $1,353 at September 30, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f3c9e64a-508f-413c-b687-e60c65bac6c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisional income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_OtherDurableMedicalEquipmentRentalsMember_3558bac7-03b7-4aed-8d8b-6da110198f95_terseLabel_en-US" xlink:label="lab_vmd_OtherDurableMedicalEquipmentRentalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other durable medical equipment rentals</link:label>
    <link:label id="lab_vmd_OtherDurableMedicalEquipmentRentalsMember_label_en-US" xlink:label="lab_vmd_OtherDurableMedicalEquipmentRentalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Durable Medical Equipment Rentals [Member]</link:label>
    <link:label id="lab_vmd_OtherDurableMedicalEquipmentRentalsMember_documentation_en-US" xlink:label="lab_vmd_OtherDurableMedicalEquipmentRentalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Durable Medical Equipment Rentals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_OtherDurableMedicalEquipmentRentalsMember" xlink:href="vmd-20210930.xsd#vmd_OtherDurableMedicalEquipmentRentalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_OtherDurableMedicalEquipmentRentalsMember" xlink:to="lab_vmd_OtherDurableMedicalEquipmentRentalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d8229b5c-4c33-43d6-9774-d802545b49e3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_55a2e3ef-9329-4202-88fe-b2f695cc95aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_276f7d40-194c-41c0-ad22-421c7422226d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_1aaa5a95-6613-4fb8-b45e-0792af8887cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, valuation allowance released</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fc74e60c-9cb4-46b6-8b03-d8241f6bdd33_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized pre-tax stock option expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_ebaccab6-b02a-48f1-a18c-d62647f753b5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_57baa30e-b013-4678-9614-e19f7ff7abbf_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3ec346b9-de1d-421f-b986-a317f08df7c7_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae149bac-c36f-4ec8-89e3-4be4f42dfecb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_COVID19ResponseSalesMember_dc30981b-8172-47d1-bd39-560704de46d4_terseLabel_en-US" xlink:label="lab_vmd_COVID19ResponseSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 response sales and services</link:label>
    <link:label id="lab_vmd_COVID19ResponseSalesMember_label_en-US" xlink:label="lab_vmd_COVID19ResponseSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Response Sales [Member]</link:label>
    <link:label id="lab_vmd_COVID19ResponseSalesMember_documentation_en-US" xlink:label="lab_vmd_COVID19ResponseSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Response Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_COVID19ResponseSalesMember" xlink:href="vmd-20210930.xsd#vmd_COVID19ResponseSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_COVID19ResponseSalesMember" xlink:to="lab_vmd_COVID19ResponseSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f6c15533-668f-4c81-bc65-6b7a2f490353_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_0b90f4b6-bb2d-4a65-88a8-d14cd38023db_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_908c6ebf-dfe7-461d-8281-82bf10519fa7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_82c32821-e029-49fc-9ad8-55c63fb417a2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized pre-tax compensation expense, restricted stock units</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_bc916eda-d394-4eb1-a767-4bf8b2dfc73f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_5f6316ee-80fd-4424-8ed1-21c1b2aab0ba_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember" xlink:to="lab_us-gaap_NotesPayableToBanksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_efc282f3-0625-4f1f-a6c6-503c1ccbc906_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_86ec821e-54ed-4034-9f30-29ff734a7981_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ad9679a8-ab6b-4fa2-a7d0-18cc1800e5ef_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_MedicaidMember_b4573448-566d-4eea-a07d-a1d015fcf048_terseLabel_en-US" xlink:label="lab_vmd_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid revenues</link:label>
    <link:label id="lab_vmd_MedicaidMember_label_en-US" xlink:label="lab_vmd_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_vmd_MedicaidMember_documentation_en-US" xlink:label="lab_vmd_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_MedicaidMember" xlink:href="vmd-20210930.xsd#vmd_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_MedicaidMember" xlink:to="lab_vmd_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_940201e2-a5bd-4de8-b5e6-9ef6d8e5f9b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_6076666c-9072-4d4a-8d53-b25be3e7b733_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_a733924e-433a-4558-b5eb-33d45bb5b1d6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_02a63c6e-492e-456b-991d-b34572c9f69d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_5264470c-e85b-49bf-a05f-0b9cdeeea3de_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments</link:label>
    <link:label id="lab_us-gaap_Investments_67fef08d-56b9-47d1-90d4-a0967def7885_totalLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_d813f013-4034-4035-af7b-7050920f7b18_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_DebtInstrumentInterestRateFloorRate_db1a7d7c-d949-48ec-bad9-181e3b3dc2f2_terseLabel_en-US" xlink:label="lab_vmd_DebtInstrumentInterestRateFloorRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floor rate</link:label>
    <link:label id="lab_vmd_DebtInstrumentInterestRateFloorRate_label_en-US" xlink:label="lab_vmd_DebtInstrumentInterestRateFloorRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Floor Rate</link:label>
    <link:label id="lab_vmd_DebtInstrumentInterestRateFloorRate_documentation_en-US" xlink:label="lab_vmd_DebtInstrumentInterestRateFloorRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Floor Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtInstrumentInterestRateFloorRate" xlink:href="vmd-20210930.xsd#vmd_DebtInstrumentInterestRateFloorRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_DebtInstrumentInterestRateFloorRate" xlink:to="lab_vmd_DebtInstrumentInterestRateFloorRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0aed29ec-ce82-4192-88bb-c1f06f30da33_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0b061ddf-0759-4080-a2a4-ea8453ee842c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_54816c94-0467-4b68-b80d-187f6976d045_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3e23c2f4-47f7-4019-8650-7b975b825727_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_54eee133-e9a7-4831-aeb8-5d4f3e44afe5_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_7c997d27-eee3-4e42-a8cb-a892fbf473d6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_b63e5c76-2505-42bb-a74f-4b43d32b4c1a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_a9383da9-1e7e-4b96-912e-13ae2d5f83c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in trade payables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_142bb1b7-def3-47ea-bbbb-f5f7a7dce2dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b6fb7fd2-5446-443a-93b9-9a19a434f76a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ca98dc6c-64a3-4013-9518-a1890e36d35a_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2887665c-03fd-4684-bf7d-df3f1aabc858_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_01b4e751-10ab-48c0-af8e-39394b17fbc9_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3de15d09-ee0a-4fb7-8daa-af50ad8ab56b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in accumulated other comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_cc4ee64f-eeb5-4e11-859d-3d5aafede526_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_34057af6-bbf3-4e49-bde4-3f01e80e17aa_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_08dc11d0-2778-4337-8323-02130b0377bd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_4e8803e3-650e-462d-b355-a44966a4687e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_fba6aa34-0993-43ad-8c2d-ff43e42b5107_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on term note</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_ad433688-7731-49a1-8a82-7e8d209ce42a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_3a89988e-40c1-433b-9a10-e2956d0c96e2_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_08449e3c-4686-4335-a365-1e9653325cc0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_3b6ff98c-4241-4c83-bfed-05fde63b3a28_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_561b80c1-d8b3-40ef-a3a4-0a0ba7d17d1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable, Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_a6af72d3-d3a4-4086-978c-4bff5bac184a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_63c9c0b7-3495-44f8-9bce-2538078533f6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_74b7793a-aa62-4db8-9e33-db08b56c20be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_7aee402d-37d8-45df-a2d6-381753b990c6_negatedTerseLabel_en-US" xlink:label="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired / Forfeited</link:label>
    <link:label id="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_label_en-US" xlink:label="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited</link:label>
    <link:label id="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_documentation_en-US" xlink:label="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:href="vmd-20210930.xsd#vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:to="lab_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2dd45e78-08cb-4961-9a89-47dd7ccb7a68_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_e10abc0d-68ef-4b79-b730-61f49d8eb52e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ae74867-3e4d-4636-9537-9ae07cd4cd81_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1ec2da3a-ffd1-4fc1-9557-bd983b0a5e57_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0615d3e9-c3b0-4a60-923e-425376115e83_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f4744c54-ce93-4333-a2a5-ae9d81a8ad70_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average number of common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_729d638c-b31f-4a93-ba9d-3591c08a3dea_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8deecfd0-8594-4a1e-9e67-0fa0f99c3ebe_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_2a3d7fb7-b20e-4969-95e4-46e89c5c67fc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator calculation from basic to diluted:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d303c019-259b-4d97-83ef-9c2fb67f2301_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and other dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_f022269e-5ee0-4b64-8a5e-8e934feaca46_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for income taxes, net of refunds received</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_DebtAndLeasesAbstract_be1ab22e-a709-4853-a265-d3052a669d2c_terseLabel_en-US" xlink:label="lab_vmd_DebtAndLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt And Leases [Abstract]</link:label>
    <link:label id="lab_vmd_DebtAndLeasesAbstract_label_en-US" xlink:label="lab_vmd_DebtAndLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt And Leases [Abstract]</link:label>
    <link:label id="lab_vmd_DebtAndLeasesAbstract_documentation_en-US" xlink:label="lab_vmd_DebtAndLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt And Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtAndLeasesAbstract" xlink:href="vmd-20210930.xsd#vmd_DebtAndLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_DebtAndLeasesAbstract" xlink:to="lab_vmd_DebtAndLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_059648ec-4948-4109-8b10-cb6a34513ed0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_36908f1a-55af-4f5d-85bc-3f7564cad612_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_64a903ee-d21e-4538-ae98-30e2cbd6632f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_c909ecfb-7e1b-49f0-a3d0-83e247e2d79d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e36c5823-9cc6-4e26-8e5a-78638f6b9fdb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_e0414dda-27a5-47ff-81ec-a20860a6dbec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1c417233-b457-48e9-aa69-6a31353d0e22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_fb10d0ce-fd01-4f1d-9956-0c9ec7e7b467_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b0886ee4-d468-4914-acb3-197c6f1ec293_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9d135fa8-0097-49d6-ac7e-ac2647f7f30d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_2fe8aae4-249c-4d91-8f24-ca0f4b0a4c26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_511e2906-474e-42f2-8887-49699d881619_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7152d58f-b28d-45a0-a08e-b95e390c414e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e73cbcd9-681a-4dfe-9b3d-f1739b23b9f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_68cd8c8f-741b-4259-8b64-260f9c9ac215_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationNonproduction_bf4a8c64-9443-4822-95c1-95585c4b6627_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationNonproduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationNonproduction_label_en-US" xlink:label="lab_us-gaap_DepreciationNonproduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationNonproduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationNonproduction" xlink:to="lab_us-gaap_DepreciationNonproduction" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_DebtandLeaseDisclosureTextBlock_ce3c6b92-f400-4cc2-89bf-d38fd9648aa5_terseLabel_en-US" xlink:label="lab_vmd_DebtandLeaseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lease Liabilities</link:label>
    <link:label id="lab_vmd_DebtandLeaseDisclosureTextBlock_label_en-US" xlink:label="lab_vmd_DebtandLeaseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lease Disclosure [Text Block]</link:label>
    <link:label id="lab_vmd_DebtandLeaseDisclosureTextBlock_documentation_en-US" xlink:label="lab_vmd_DebtandLeaseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lease Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtandLeaseDisclosureTextBlock" xlink:href="vmd-20210930.xsd#vmd_DebtandLeaseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_DebtandLeaseDisclosureTextBlock" xlink:to="lab_vmd_DebtandLeaseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ac0e929e-97c3-4a91-9c3c-577c94422b98_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a10e96ae-78f7-4046-b8f4-78aa9030ef0c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciation_0fb4ff2a-c395-4d6c-be85-6c03aea42677_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciation_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f70c0beb-af5b-4ba1-acb6-41abf209b107_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options (000's)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_df40bfeb-fc68-4e00-9bc4-ed8a2713519a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating rental expenses</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_8d6c17c1-5041-49cc-ac3c-77e25c762b54_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5f7c42e9-6c3a-4312-9eca-9ac1721f16be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionLeases_f74ea115-a099-4650-a5a4-f789d7a3c4ba_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Accounting under Topic 842</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionLeases_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionLeases" xlink:to="lab_us-gaap_RevenueRecognitionLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c966468e-9e53-4b1f-959e-9acc192e4337_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_721b97d5-733d-4128-a423-0919d1ca5c71_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_acfb086c-e3bb-4769-b0d7-7bb19db40d1a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_088f9d2f-87fb-4557-a8db-55221c586a1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_b8ef04b3-220d-4e30-bca7-e65afccfbc7b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notes Payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_db8e4b69-76e5-4fb4-96d5-f12d6d1c2fe5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_fa07c0c0-9308-4c0b-9861-67158706f756_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5fe3b087-0389-4ee5-ac94-8b6b18983ca3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_dd187511-d77b-455f-a5dc-1e362d44e0c8_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Other Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_EquipmentSalesMember_45ca73cb-0131-4441-a7b8-c80fa0a1b5dc_terseLabel_en-US" xlink:label="lab_vmd_EquipmentSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment and supply sales</link:label>
    <link:label id="lab_vmd_EquipmentSalesMember_label_en-US" xlink:label="lab_vmd_EquipmentSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Sales [Member]</link:label>
    <link:label id="lab_vmd_EquipmentSalesMember_documentation_en-US" xlink:label="lab_vmd_EquipmentSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_EquipmentSalesMember" xlink:href="vmd-20210930.xsd#vmd_EquipmentSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_EquipmentSalesMember" xlink:to="lab_vmd_EquipmentSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8c6fd67a-b284-400c-a3bf-0fa68cae52b8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_3c02ef8f-1d8b-4fa2-b3d2-37447604ec57_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_17a6e3d1-005d-49fa-a82b-ac82d79126a2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_0d3ba608-e6a3-49e5-a649-c916abb3da07_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_8dfec252-eec6-4c60-bfa2-cee9f00a57b0_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_cf7b53e5-d6a6-43ee-9b08-ac84cffe453e_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_DebtInstrumentCovenantLoanToValueRatio_115de1e5-ec2f-444a-8efc-d5dd9dc76966_terseLabel_en-US" xlink:label="lab_vmd_DebtInstrumentCovenantLoanToValueRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required loan to value ratio</link:label>
    <link:label id="lab_vmd_DebtInstrumentCovenantLoanToValueRatio_label_en-US" xlink:label="lab_vmd_DebtInstrumentCovenantLoanToValueRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Loan To Value Ratio</link:label>
    <link:label id="lab_vmd_DebtInstrumentCovenantLoanToValueRatio_documentation_en-US" xlink:label="lab_vmd_DebtInstrumentCovenantLoanToValueRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Loan To Value Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtInstrumentCovenantLoanToValueRatio" xlink:href="vmd-20210930.xsd#vmd_DebtInstrumentCovenantLoanToValueRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_DebtInstrumentCovenantLoanToValueRatio" xlink:to="lab_vmd_DebtInstrumentCovenantLoanToValueRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_b94c595c-c031-4a9d-955a-7ccb1a177db7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7f936a44-fa84-41a4-bc74-95b78e8f0e85_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d4aca5a3-bf0b-4faf-a495-d93ca71582fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_36db7327-bdd6-4643-81d2-2edbcbfefa16_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_47dc3a5d-de9e-41a5-9d9f-3205a1dcd2a2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_1788b2d2-4435-4c4d-accd-eac7802c4b83_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net long-term notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_4e8b70c9-8989-4d10-96f3-eed05dd53bc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_31ccc7be-4c7f-4c4f-93dd-984eb70b3f79_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f46dcb65-b6ef-4d8c-9cd4-e2b4f45bd82f_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation, expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e2e3ec8a-6e79-4028-8140-d38f043a4d33_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_281970db-68af-44c4-9fe7-4074f43d07fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4bc015cd-fb23-4009-be22-524c136f3e5e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_62efb208-37fe-4b83-92ef-88ce3539b91f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_8486b869-804b-4621-b923-dab00431adff_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_501787ab-ac6c-407f-abc7-54bb11662226_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_30507ae6-85c1-4e2b-88aa-21bd0a1b9a42_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory reserve</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8cde563c-c3e7-4e0b-90a3-6a9becb04e2e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4842ccd5-71da-45c9-972f-bde246dbda69_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_e400cf86-4eb9-4e5b-8c86-a2ca64605761_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Revenue by Customer</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8161a521-04c2-4512-ba07-f2c2c9a41583_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_72b82e8c-8715-4a7c-8b85-1c468368319b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_114ef198-e2a9-4e0d-abb8-93555611378b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_38ee6df5-d83c-4eaa-84d8-6b859de05e34_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_e92fa760-1f1e-4955-9b4a-09e95f5e70aa_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICE LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ae435b7d-48e3-4b15-96f3-caa00a4b9508_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f4813506-a661-4e20-a393-6823aff6262d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market mutual funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_3ec81794-ca6c-4a50-9796-a4baa4ae6778_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Accounting under Topic 606</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_18db33b8-0985-4b1f-8d62-d4f0d59e487d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_77314c16-489b-43f7-afb5-93b22fe9de1f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a4601277-eabf-4c78-8c70-2f851378b994_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued pursuant to stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_aec1948b-151f-4db9-a0e0-2825c72471e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d1f5a0f9-dc9c-4a34-9acf-c73ebc469a42_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2d1ddb03-ff8a-4286-ae3d-a753fc76f993_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_NetNonCashChangesToFinanceLeaseBalances_670bc3dc-88c0-42c8-b7bb-2facad8ea6b7_terseLabel_en-US" xlink:label="lab_vmd_NetNonCashChangesToFinanceLeaseBalances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net non-cash changes to finance lease balances</link:label>
    <link:label id="lab_vmd_NetNonCashChangesToFinanceLeaseBalances_label_en-US" xlink:label="lab_vmd_NetNonCashChangesToFinanceLeaseBalances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Non-Cash Changes To Finance Lease Balances</link:label>
    <link:label id="lab_vmd_NetNonCashChangesToFinanceLeaseBalances_documentation_en-US" xlink:label="lab_vmd_NetNonCashChangesToFinanceLeaseBalances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Non-Cash Changes To Finance Lease Balances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_NetNonCashChangesToFinanceLeaseBalances" xlink:href="vmd-20210930.xsd#vmd_NetNonCashChangesToFinanceLeaseBalances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_NetNonCashChangesToFinanceLeaseBalances" xlink:to="lab_vmd_NetNonCashChangesToFinanceLeaseBalances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_728a3e7d-d65f-4cfe-ba83-659b6978512a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_09e5caa4-cb1f-4b7d-bb73-591b0b7a24b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_ba07cc9a-42a2-4040-94bb-07ba68d2fc04_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_888ee9de-36c9-45cc-aeb1-21329f06ac6d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e3202589-ee33-40e0-99a2-3e7c4830fbd6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_926388a6-7fd9-4cb9-9b45-7c911d7985db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_88fab41b-7d88-4648-bc04-87f3e181f623_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_957ddb50-bcd5-4c9d-809e-4e86787a6a11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts written off</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_75fd8729-a56b-4e5f-a97a-552990f1d8be_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_c126d144-a2d7-428e-9771-f559b0d33732_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income and expenses</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_10e49b3e-8438-4eea-a7d4-a460b1c101d6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_MedicareAndMedicaidMember_832c9dd0-8b13-4446-ab87-711716cb9f0e_terseLabel_en-US" xlink:label="lab_vmd_MedicareAndMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Medicare and Medicaid</link:label>
    <link:label id="lab_vmd_MedicareAndMedicaidMember_label_en-US" xlink:label="lab_vmd_MedicareAndMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare And Medicaid [Member]</link:label>
    <link:label id="lab_vmd_MedicareAndMedicaidMember_documentation_en-US" xlink:label="lab_vmd_MedicareAndMedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare And Medicaid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_MedicareAndMedicaidMember" xlink:href="vmd-20210930.xsd#vmd_MedicareAndMedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_MedicareAndMedicaidMember" xlink:to="lab_vmd_MedicareAndMedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_9c3ca732-663d-4c62-9ec5-50ad83aa0ce2_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_d5cdb57e-447b-468e-ad30-45f6dd41837c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_5bad9f9b-7cfe-455e-b7e4-91f1aa298f2c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_52e8c7c4-6445-4f83-8583-ab956b4c5bf8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in working capital</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ebaace9e-c46f-41d4-ab70-900f98e2b486_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_47161f9a-121f-44cd-b4ec-35da98434f95_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_393cbc23-1bb1-4b88-98cb-332e235f4dd0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a7a3ec7b-cff4-4b49-9e90-65e38704d943_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_a1f36c0a-07e4-4ae5-a1cf-b3cf8ca15101_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_49585908-2ad1-42d8-8b86-62368bcf321f_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_368baf47-a863-4a87-aa26-9be935ee9058_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_e21a8e8b-a2a9-4a2a-b891-048222da8c02_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_ed73c519-048a-4ecd-875a-ad7ddd9dd45e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation - options</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8d4fcf0c-a86b-4ad6-85f7-b3dd656e9357_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_108edb38-5aa9-4fdd-917b-fe07a2df4046_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_70154764-2846-4fb6-ab82-d76e6074586c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade payables</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f3189946-1bf9-4a78-a275-f85339ebd146_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_5e8361dc-f031-413f-8abd-f39b1ba64718_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued commissions payable</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Commission, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_VentilatorRentalMember_a9a57979-da18-421e-973e-2386bcec645c_terseLabel_en-US" xlink:label="lab_vmd_VentilatorRentalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ventilator rentals, non-invasive and invasive</link:label>
    <link:label id="lab_vmd_VentilatorRentalMember_label_en-US" xlink:label="lab_vmd_VentilatorRentalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ventilator Rental [Member]</link:label>
    <link:label id="lab_vmd_VentilatorRentalMember_documentation_en-US" xlink:label="lab_vmd_VentilatorRentalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ventilator Rental [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_VentilatorRentalMember" xlink:href="vmd-20210930.xsd#vmd_VentilatorRentalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_VentilatorRentalMember" xlink:to="lab_vmd_VentilatorRentalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_05d8b043-7c80-4a14-bc82-de6e42a6f72d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_0911d004-4ca5-4d72-a06b-a02e3a48a05f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_de2ba3c9-8990-4c2c-94f3-559d38a8ca27_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure_42e1a59e-eb94-4ff0-9c67-aa05521bd3f0_totalLabel_en-US" xlink:label="lab_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Fair Value Disclosure And Liabilities Fair Value Disclosure</link:label>
    <link:label id="lab_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure_documentation_en-US" xlink:label="lab_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Fair Value Disclosure And Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" xlink:href="vmd-20210930.xsd#vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" xlink:to="lab_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d100aab2-342a-45c5-bbca-09e8d69dbdb5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_85eb9238-8f4c-4191-b0d2-e3a48f4702fb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently adopted accounting pronouncements and Recently issued accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_f5e01286-aad1-4680-be4f-1e79d5432fd9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of share equivalents</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c285c2cd-6b41-429a-b88c-98ac8372adfe_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_ee1e5c4e-e1b4-474e-a966-0c9814e07e1a_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5a8a81f3-c215-4a12-bdf2-fda5b74a1c2a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_fb10756a-5bdd-480f-9ffc-fb2f87f909e9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_8414f51c-6bfd-402f-a67a-535b580125d4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_26f7b337-314e-42d5-9445-61f6e5f30788_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PhantomShareUnitsPSUsMember_c00d68df-a95f-43c3-9c59-e3a44bd25c63_terseLabel_en-US" xlink:label="lab_us-gaap_PhantomShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phantom Share Units</link:label>
    <link:label id="lab_us-gaap_PhantomShareUnitsPSUsMember_label_en-US" xlink:label="lab_us-gaap_PhantomShareUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phantom Share Units (PSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PhantomShareUnitsPSUsMember" xlink:to="lab_us-gaap_PhantomShareUnitsPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_584d531c-3035-42dc-8309-0ea6247d789c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_6a7097f5-2b08-40b3-882e-e77aea84bf18_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vmd_LiabilitiesLesseeTableTextBlock_3b302af1-a049-4436-994b-a4827483280e_terseLabel_en-US" xlink:label="lab_vmd_LiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Liabilities</link:label>
    <link:label id="lab_vmd_LiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_vmd_LiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_vmd_LiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_vmd_LiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LiabilitiesLesseeTableTextBlock" xlink:href="vmd-20210930.xsd#vmd_LiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vmd_LiabilitiesLesseeTableTextBlock" xlink:to="lab_vmd_LiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_ac6954be-2528-41f1-83d9-e36c7fc6d3c3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLIFOReservePeriodCharge_2639fce3-a400-416c-bc82-eecb81bba1b1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReservePeriodCharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in inventory reserve</link:label>
    <link:label id="lab_us-gaap_InventoryLIFOReservePeriodCharge_label_en-US" xlink:label="lab_us-gaap_InventoryLIFOReservePeriodCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, LIFO Reserve, Period Charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="lab_us-gaap_InventoryLIFOReservePeriodCharge" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>vmd-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:fbb1b016-a19a-460d-bfda-ed9a0f837dc5,g:50e705b0-d493-4f83-95b4-caa6929c52c8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.viemed.com/role/Cover" xlink:type="simple" xlink:href="vmd-20210930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_51a93484-97ab-4705-b723-68afa4447908" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_DocumentType_51a93484-97ab-4705-b723-68afa4447908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_62c6197c-87d5-4c1b-ad52-6329d31ff74d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_DocumentQuarterlyReport_62c6197c-87d5-4c1b-ad52-6329d31ff74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f327a920-70b2-49b3-ae6c-51d448c76689" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_DocumentPeriodEndDate_f327a920-70b2-49b3-ae6c-51d448c76689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8360fda4-dbcf-4d22-8e26-9e7bcca5df70" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_DocumentTransitionReport_8360fda4-dbcf-4d22-8e26-9e7bcca5df70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9eb78e3f-e0bf-4d46-85b0-ddafa0d8135d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityFileNumber_9eb78e3f-e0bf-4d46-85b0-ddafa0d8135d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8d59671b-ba57-418b-b136-653a92bc84cb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityRegistrantName_8d59671b-ba57-418b-b136-653a92bc84cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2dc865fd-269f-43d9-b168-6519bfc67122" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2dc865fd-269f-43d9-b168-6519bfc67122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_657cdd81-810a-4938-b4fe-be4ad6f7bf13" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityAddressAddressLine1_657cdd81-810a-4938-b4fe-be4ad6f7bf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cab96ba4-fae5-45af-83ec-11601bdafb91" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityAddressCityOrTown_cab96ba4-fae5-45af-83ec-11601bdafb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_117ea7be-dd38-4064-b571-09baee9037a1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityAddressStateOrProvince_117ea7be-dd38-4064-b571-09baee9037a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ebbc7d61-11ee-4312-88f1-3381e4147781" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityAddressPostalZipCode_ebbc7d61-11ee-4312-88f1-3381e4147781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0e63a876-337b-4030-852b-79e48cc7cd65" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_CityAreaCode_0e63a876-337b-4030-852b-79e48cc7cd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a39e19af-8342-4c66-bbb7-28011fd70b42" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_LocalPhoneNumber_a39e19af-8342-4c66-bbb7-28011fd70b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c05f584f-1825-4de2-bd32-7b0989b2e8ac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_Security12bTitle_c05f584f-1825-4de2-bd32-7b0989b2e8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_eb975515-b5c8-49b8-8c1a-9da87c222e39" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_TradingSymbol_eb975515-b5c8-49b8-8c1a-9da87c222e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b58ae1c3-4e49-4d41-8d6e-77560332f456" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_SecurityExchangeName_b58ae1c3-4e49-4d41-8d6e-77560332f456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_0b62d956-4d89-4ec2-bb74-95aa451ca7cd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityCurrentReportingStatus_0b62d956-4d89-4ec2-bb74-95aa451ca7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0f4d86e4-887f-43cb-86b7-bbe8555e9c3b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityInteractiveDataCurrent_0f4d86e4-887f-43cb-86b7-bbe8555e9c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_4ba3753c-5cac-4f7e-a29d-43b81f1ce533" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityFilerCategory_4ba3753c-5cac-4f7e-a29d-43b81f1ce533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_bba6dd96-f129-44a3-b1c6-5871a79b072e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntitySmallBusiness_bba6dd96-f129-44a3-b1c6-5871a79b072e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b8243dec-3751-4994-8ba1-bbcba8471bbb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityEmergingGrowthCompany_b8243dec-3751-4994-8ba1-bbcba8471bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_906e0f5c-5001-49a8-acc5-56d3ea47782f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityExTransitionPeriod_906e0f5c-5001-49a8-acc5-56d3ea47782f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_1e697d8b-bde3-437b-8e83-c0d426f7d72a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityShellCompany_1e697d8b-bde3-437b-8e83-c0d426f7d72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9a4da821-674d-494f-889a-53feb08ce38d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9a4da821-674d-494f-889a-53feb08ce38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8e0dc677-479e-46b1-a317-a1effc2ce867" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_EntityCentralIndexKey_8e0dc677-479e-46b1-a317-a1effc2ce867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1aac08ac-9806-4a85-acda-78d943b1d4c4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_AmendmentFlag_1aac08ac-9806-4a85-acda-78d943b1d4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9c17cac8-2ddb-431d-ae04-534074fa8eb4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_DocumentFiscalYearFocus_9c17cac8-2ddb-431d-ae04-534074fa8eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0cddfebf-8012-48f0-aad8-7423588ee0b6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0cddfebf-8012-48f0-aad8-7423588ee0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_65edea20-f8fd-4137-9ce2-d0c8b72cf71e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9c3f414b-c0f8-4354-bb5c-27801590e79b" xlink:to="loc_dei_CurrentFiscalYearEndDate_65edea20-f8fd-4137-9ce2-d0c8b72cf71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="vmd-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_77b54871-09a3-40ba-9dac-270884cabdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ef820ea7-788c-4ae9-a2c4-3352d51503a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_77b54871-09a3-40ba-9dac-270884cabdeb" xlink:to="loc_us-gaap_AssetsAbstract_ef820ea7-788c-4ae9-a2c4-3352d51503a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_734469b0-9039-465b-8be7-b7d77ba48af1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ef820ea7-788c-4ae9-a2c4-3352d51503a1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_734469b0-9039-465b-8be7-b7d77ba48af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e1a8a1ad-40c9-4c43-b513-a10749f1193f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_734469b0-9039-465b-8be7-b7d77ba48af1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e1a8a1ad-40c9-4c43-b513-a10749f1193f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cd5cfcc2-ed28-444d-ac08-d279c6493971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_734469b0-9039-465b-8be7-b7d77ba48af1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cd5cfcc2-ed28-444d-ac08-d279c6493971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4e6e0073-be4c-4733-b2c0-2f763bdbd21a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_734469b0-9039-465b-8be7-b7d77ba48af1" xlink:to="loc_us-gaap_InventoryNet_4e6e0073-be4c-4733-b2c0-2f763bdbd21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_e994e5ed-2464-447a-816a-e1e60882d176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_734469b0-9039-465b-8be7-b7d77ba48af1" xlink:to="loc_us-gaap_IncomeTaxesReceivable_e994e5ed-2464-447a-816a-e1e60882d176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a67b103a-f1dc-43a5-8252-319821a6737a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_734469b0-9039-465b-8be7-b7d77ba48af1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a67b103a-f1dc-43a5-8252-319821a6737a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6783219d-1f5c-474d-bde6-3759ee4c0e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_734469b0-9039-465b-8be7-b7d77ba48af1" xlink:to="loc_us-gaap_AssetsCurrent_6783219d-1f5c-474d-bde6-3759ee4c0e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_12bdce1a-60a1-44be-9c82-0958589e5c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ef820ea7-788c-4ae9-a2c4-3352d51503a1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_12bdce1a-60a1-44be-9c82-0958589e5c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3aab2457-9349-4a37-b7c6-07d72c70f63c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_12bdce1a-60a1-44be-9c82-0958589e5c95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3aab2457-9349-4a37-b7c6-07d72c70f63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_34cecb7b-1ab1-483a-aeea-46042e11782c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_12bdce1a-60a1-44be-9c82-0958589e5c95" xlink:to="loc_us-gaap_Investments_34cecb7b-1ab1-483a-aeea-46042e11782c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_969158ac-f9c1-4d68-b8bd-7c0457b7418d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_12bdce1a-60a1-44be-9c82-0958589e5c95" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_969158ac-f9c1-4d68-b8bd-7c0457b7418d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_37f94574-30e4-41c1-99eb-6464c413f4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_12bdce1a-60a1-44be-9c82-0958589e5c95" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_37f94574-30e4-41c1-99eb-6464c413f4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_72ac99d4-1379-49a5-9b4c-bbb81d3f5aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_12bdce1a-60a1-44be-9c82-0958589e5c95" xlink:to="loc_us-gaap_AssetsNoncurrent_72ac99d4-1379-49a5-9b4c-bbb81d3f5aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6e567818-c90b-40f2-b119-47a20cf003ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ef820ea7-788c-4ae9-a2c4-3352d51503a1" xlink:to="loc_us-gaap_Assets_6e567818-c90b-40f2-b119-47a20cf003ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_0fc37602-88bf-4457-8226-d4823f0fe318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_77b54871-09a3-40ba-9dac-270884cabdeb" xlink:to="loc_us-gaap_LiabilitiesAbstract_0fc37602-88bf-4457-8226-d4823f0fe318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f4a51848-2694-4e7c-9b95-82839992e47d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0fc37602-88bf-4457-8226-d4823f0fe318" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f4a51848-2694-4e7c-9b95-82839992e47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_86c4c729-16f1-485d-a4e9-254c646640ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f4a51848-2694-4e7c-9b95-82839992e47d" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_86c4c729-16f1-485d-a4e9-254c646640ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_951b58fa-7df3-4117-aecb-2556ef89be45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f4a51848-2694-4e7c-9b95-82839992e47d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_951b58fa-7df3-4117-aecb-2556ef89be45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_c40d2506-46c5-46a6-8ce7-9c23d87dba7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f4a51848-2694-4e7c-9b95-82839992e47d" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_c40d2506-46c5-46a6-8ce7-9c23d87dba7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1ae32e4c-8ad7-4f52-a207-be3b412752bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f4a51848-2694-4e7c-9b95-82839992e47d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1ae32e4c-8ad7-4f52-a207-be3b412752bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeaseLiabilityCurrent_ffda4eff-e808-442e-84f4-3c328ab3590d" xlink:href="vmd-20210930.xsd#vmd_LeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f4a51848-2694-4e7c-9b95-82839992e47d" xlink:to="loc_vmd_LeaseLiabilityCurrent_ffda4eff-e808-442e-84f4-3c328ab3590d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_88482b84-b05d-4068-ac69-38273f28bd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f4a51848-2694-4e7c-9b95-82839992e47d" xlink:to="loc_us-gaap_LongTermDebtCurrent_88482b84-b05d-4068-ac69-38273f28bd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4465dc6c-3633-4e32-8fbb-429adf8dfeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f4a51848-2694-4e7c-9b95-82839992e47d" xlink:to="loc_us-gaap_LiabilitiesCurrent_4465dc6c-3633-4e32-8fbb-429adf8dfeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_f27b1daf-42b0-43b9-bef8-7eb76da53ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0fc37602-88bf-4457-8226-d4823f0fe318" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_f27b1daf-42b0-43b9-bef8-7eb76da53ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_76e7d691-e98e-4ee6-a797-f5607f9ab385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f27b1daf-42b0-43b9-bef8-7eb76da53ecf" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_76e7d691-e98e-4ee6-a797-f5607f9ab385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeaseLiabilityNoncurrent_0a035d60-c113-4af1-8661-c0a435b8e553" xlink:href="vmd-20210930.xsd#vmd_LeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f27b1daf-42b0-43b9-bef8-7eb76da53ecf" xlink:to="loc_vmd_LeaseLiabilityNoncurrent_0a035d60-c113-4af1-8661-c0a435b8e553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_902ad94d-bd0e-461d-9291-3f73d3c88ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f27b1daf-42b0-43b9-bef8-7eb76da53ecf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_902ad94d-bd0e-461d-9291-3f73d3c88ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_797f2442-1508-4762-9090-10fe4abe988a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f27b1daf-42b0-43b9-bef8-7eb76da53ecf" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_797f2442-1508-4762-9090-10fe4abe988a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4358c3e5-c31e-4967-b463-df78cfb65ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0fc37602-88bf-4457-8226-d4823f0fe318" xlink:to="loc_us-gaap_Liabilities_4358c3e5-c31e-4967-b463-df78cfb65ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a91fd177-21ab-4a1c-a151-5a5afcf2a955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_77b54871-09a3-40ba-9dac-270884cabdeb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a91fd177-21ab-4a1c-a151-5a5afcf2a955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_eb5a3eb3-49dd-40c4-ae54-422f41eee6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_77b54871-09a3-40ba-9dac-270884cabdeb" xlink:to="loc_us-gaap_StockholdersEquityAbstract_eb5a3eb3-49dd-40c4-ae54-422f41eee6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b6ecb7bb-8af8-4b47-8ac5-2cfb1aaceb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eb5a3eb3-49dd-40c4-ae54-422f41eee6a5" xlink:to="loc_us-gaap_CommonStockValue_b6ecb7bb-8af8-4b47-8ac5-2cfb1aaceb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_668691df-e231-48be-998e-cd4820336357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eb5a3eb3-49dd-40c4-ae54-422f41eee6a5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_668691df-e231-48be-998e-cd4820336357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bd6ee046-23cc-4942-a7f9-b92266718689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eb5a3eb3-49dd-40c4-ae54-422f41eee6a5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bd6ee046-23cc-4942-a7f9-b92266718689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9d5b7f6f-522a-4241-98d8-dfa0b6d3d9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eb5a3eb3-49dd-40c4-ae54-422f41eee6a5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9d5b7f6f-522a-4241-98d8-dfa0b6d3d9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_84e77aad-1849-4404-960a-78d24f8ee622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eb5a3eb3-49dd-40c4-ae54-422f41eee6a5" xlink:to="loc_us-gaap_StockholdersEquity_84e77aad-1849-4404-960a-78d24f8ee622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_23acb014-417a-4055-bef1-0e455edbbe98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_77b54871-09a3-40ba-9dac-270884cabdeb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_23acb014-417a-4055-bef1-0e455edbbe98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="vmd-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4ace16c6-203a-401b-895b-504b9832ad54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_43d4fede-9713-4c01-a2b2-2eab2a6623b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4ace16c6-203a-401b-895b-504b9832ad54" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_43d4fede-9713-4c01-a2b2-2eab2a6623b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_d11ca7bf-08fe-4e5c-94ea-bdb0a3e420ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4ace16c6-203a-401b-895b-504b9832ad54" xlink:to="loc_us-gaap_InventoryValuationReserves_d11ca7bf-08fe-4e5c-94ea-bdb0a3e420ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b66f1919-7aa2-4a54-9708-6baab8288cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4ace16c6-203a-401b-895b-504b9832ad54" xlink:to="loc_us-gaap_CommonStockSharesIssued_b66f1919-7aa2-4a54-9708-6baab8288cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c256af20-3c38-49b2-8eca-29b3b3fddd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4ace16c6-203a-401b-895b-504b9832ad54" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c256af20-3c38-49b2-8eca-29b3b3fddd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="vmd-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_961f9439-e085-4e89-a210-a3aac75fb11b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0fb7e057-eaf6-4155-a506-33a459c6891b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_961f9439-e085-4e89-a210-a3aac75fb11b" xlink:to="loc_us-gaap_Revenues_0fb7e057-eaf6-4155-a506-33a459c6891b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_23818ab6-9af1-4440-bb2c-0539cfc14c17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_961f9439-e085-4e89-a210-a3aac75fb11b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_23818ab6-9af1-4440-bb2c-0539cfc14c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_6f9bac0f-6697-4139-a47d-0e90857f0e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_961f9439-e085-4e89-a210-a3aac75fb11b" xlink:to="loc_us-gaap_GrossProfit_6f9bac0f-6697-4139-a47d-0e90857f0e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3b3c2410-ec1c-4fbc-a437-8fd550c3a03f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_961f9439-e085-4e89-a210-a3aac75fb11b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3b3c2410-ec1c-4fbc-a437-8fd550c3a03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dd535ea6-bcc0-4776-a2cf-972535851982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3b3c2410-ec1c-4fbc-a437-8fd550c3a03f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dd535ea6-bcc0-4776-a2cf-972535851982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9c04ee02-e9ac-423d-a2f8-0ccd5d4039af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3b3c2410-ec1c-4fbc-a437-8fd550c3a03f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9c04ee02-e9ac-423d-a2f8-0ccd5d4039af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_15483b0f-f954-4a18-bc81-e96cea7874e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3b3c2410-ec1c-4fbc-a437-8fd550c3a03f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_15483b0f-f954-4a18-bc81-e96cea7874e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationNonproduction_4287572b-e9c5-4e89-8fec-17f21799a030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationNonproduction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3b3c2410-ec1c-4fbc-a437-8fd550c3a03f" xlink:to="loc_us-gaap_DepreciationNonproduction_4287572b-e9c5-4e89-8fec-17f21799a030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_4c5efa23-9fec-483a-840b-2e10a1a70085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3b3c2410-ec1c-4fbc-a437-8fd550c3a03f" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_4c5efa23-9fec-483a-840b-2e10a1a70085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a3be8d22-7462-4c94-ba37-7a227e63c5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3b3c2410-ec1c-4fbc-a437-8fd550c3a03f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a3be8d22-7462-4c94-ba37-7a227e63c5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_25c44db6-f624-4fb1-9ba9-972ff89e2264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3b3c2410-ec1c-4fbc-a437-8fd550c3a03f" xlink:to="loc_us-gaap_OperatingIncomeLoss_25c44db6-f624-4fb1-9ba9-972ff89e2264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d4a39c26-3734-4171-b439-32bdb2972061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_961f9439-e085-4e89-a210-a3aac75fb11b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d4a39c26-3734-4171-b439-32bdb2972061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_7041f5d3-4766-4080-882d-005db284f03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d4a39c26-3734-4171-b439-32bdb2972061" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_7041f5d3-4766-4080-882d-005db284f03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_8ac39617-07a8-4eee-8186-2c110976a29c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_d4a39c26-3734-4171-b439-32bdb2972061" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_8ac39617-07a8-4eee-8186-2c110976a29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_05e43393-90ac-4d99-a4f7-c6bb522ac523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_961f9439-e085-4e89-a210-a3aac75fb11b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_05e43393-90ac-4d99-a4f7-c6bb522ac523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_71662c91-d052-4329-94dc-10a1cac163eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_961f9439-e085-4e89-a210-a3aac75fb11b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_71662c91-d052-4329-94dc-10a1cac163eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0a9ea0fe-2251-46c9-a86b-eeb06c547e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_961f9439-e085-4e89-a210-a3aac75fb11b" xlink:to="loc_us-gaap_NetIncomeLoss_0a9ea0fe-2251-46c9-a86b-eeb06c547e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2c61fc34-f502-4a6c-bf04-04aed9bacdeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_961f9439-e085-4e89-a210-a3aac75fb11b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2c61fc34-f502-4a6c-bf04-04aed9bacdeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8491042e-19ac-4d7b-a085-c7359e197f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2c61fc34-f502-4a6c-bf04-04aed9bacdeb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_8491042e-19ac-4d7b-a085-c7359e197f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_14ef795b-7c3c-4c2e-a56e-68c8335b93f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_2c61fc34-f502-4a6c-bf04-04aed9bacdeb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_14ef795b-7c3c-4c2e-a56e-68c8335b93f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9f8ed454-6a6f-40fb-bf0e-33b9c051f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_961f9439-e085-4e89-a210-a3aac75fb11b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9f8ed454-6a6f-40fb-bf0e-33b9c051f8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d3ff228e-8737-4cec-a0ab-5eba3be02968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_961f9439-e085-4e89-a210-a3aac75fb11b" xlink:to="loc_us-gaap_EarningsPerShareAbstract_d3ff228e-8737-4cec-a0ab-5eba3be02968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b86c751b-df64-4386-99c4-16f384543325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d3ff228e-8737-4cec-a0ab-5eba3be02968" xlink:to="loc_us-gaap_EarningsPerShareBasic_b86c751b-df64-4386-99c4-16f384543325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_99a74dfe-1d86-48aa-a5e8-ec0cadb9244c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d3ff228e-8737-4cec-a0ab-5eba3be02968" xlink:to="loc_us-gaap_EarningsPerShareDiluted_99a74dfe-1d86-48aa-a5e8-ec0cadb9244c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a62f2b62-889d-4fa9-a7ca-7ccfdda6c79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_961f9439-e085-4e89-a210-a3aac75fb11b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a62f2b62-889d-4fa9-a7ca-7ccfdda6c79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fe594ea4-d81f-4481-badb-c7ad24163456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a62f2b62-889d-4fa9-a7ca-7ccfdda6c79a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fe594ea4-d81f-4481-badb-c7ad24163456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2dcc1e3f-2792-48c7-ace9-fadacafef6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a62f2b62-889d-4fa9-a7ca-7ccfdda6c79a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2dcc1e3f-2792-48c7-ace9-fadacafef6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="vmd-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_57455da8-5b01-4d7e-b2c4-6f75d4d6decb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_065ebe07-c5ce-4802-8dc3-96aa1264d1da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_57455da8-5b01-4d7e-b2c4-6f75d4d6decb" xlink:to="loc_us-gaap_StatementTable_065ebe07-c5ce-4802-8dc3-96aa1264d1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_30d7b90d-2896-4b97-bf6f-4391d83f9b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_065ebe07-c5ce-4802-8dc3-96aa1264d1da" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_30d7b90d-2896-4b97-bf6f-4391d83f9b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e9cfeffc-7a24-42ef-b9a4-191b8ec794dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30d7b90d-2896-4b97-bf6f-4391d83f9b02" xlink:to="loc_us-gaap_EquityComponentDomain_e9cfeffc-7a24-42ef-b9a4-191b8ec794dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c770f355-67e4-4c68-8ba7-c907d8e2aa1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e9cfeffc-7a24-42ef-b9a4-191b8ec794dc" xlink:to="loc_us-gaap_CommonStockMember_c770f355-67e4-4c68-8ba7-c907d8e2aa1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_27d29cf8-030d-4de9-9a64-8ee1f29fa94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e9cfeffc-7a24-42ef-b9a4-191b8ec794dc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_27d29cf8-030d-4de9-9a64-8ee1f29fa94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a286d36c-c42c-494f-ba30-1af36473d5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e9cfeffc-7a24-42ef-b9a4-191b8ec794dc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a286d36c-c42c-494f-ba30-1af36473d5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fac811e7-3878-4044-af42-cd22854d48f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e9cfeffc-7a24-42ef-b9a4-191b8ec794dc" xlink:to="loc_us-gaap_RetainedEarningsMember_fac811e7-3878-4044-af42-cd22854d48f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0025c6a9-5d20-4a9b-8dd0-bd2cc24df88e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_065ebe07-c5ce-4802-8dc3-96aa1264d1da" xlink:to="loc_us-gaap_StatementLineItems_0025c6a9-5d20-4a9b-8dd0-bd2cc24df88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0025c6a9-5d20-4a9b-8dd0-bd2cc24df88e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cbe15160-41d4-426c-a682-53331b31f598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cbe15160-41d4-426c-a682-53331b31f598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0f53885d-0775-4147-ab8c-7069d2336699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockholdersEquity_0f53885d-0775-4147-ab8c-7069d2336699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_9feb7de6-2f67-43fb-b1a9-5305b12153f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_9feb7de6-2f67-43fb-b1a9-5305b12153f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_261d2341-894d-4f20-9c5b-d02bd8091559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_261d2341-894d-4f20-9c5b-d02bd8091559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e1b5091-2424-4b71-91cc-fc386bd9bb0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6e1b5091-2424-4b71-91cc-fc386bd9bb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_797ac78b-df1f-42fa-95bc-cb235f7b748c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_797ac78b-df1f-42fa-95bc-cb235f7b748c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ea691bbc-8ae8-46da-b9e5-84949aa8d4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ea691bbc-8ae8-46da-b9e5-84949aa8d4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_501f4dff-2b7c-45ec-887e-3067f5968d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_501f4dff-2b7c-45ec-887e-3067f5968d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8ec31015-ef3b-49f5-813a-479416207bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_8ec31015-ef3b-49f5-813a-479416207bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_75fe8180-cac8-4413-9a3d-56a6fd61495c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_75fe8180-cac8-4413-9a3d-56a6fd61495c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c83ab5dd-53dc-47ca-b4a4-e0bda2df8632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c83ab5dd-53dc-47ca-b4a4-e0bda2df8632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_59a20ed3-891a-4df9-b958-01eedf93d108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_NetIncomeLoss_59a20ed3-891a-4df9-b958-01eedf93d108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a316f606-983a-4a8a-b7b2-c698101bc968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a316f606-983a-4a8a-b7b2-c698101bc968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e24cfd1a-f648-4b8e-bc90-c78114352e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3b96cc87-1f88-4ae5-b37d-f3ff60aa642c" xlink:to="loc_us-gaap_StockholdersEquity_e24cfd1a-f648-4b8e-bc90-c78114352e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="vmd-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8f41fc16-ff73-42d5-a438-8f9289f8f2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_946d1e4c-7274-406c-87e6-0a4da9cb1364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8f41fc16-ff73-42d5-a438-8f9289f8f2bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_946d1e4c-7274-406c-87e6-0a4da9cb1364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c3e421c1-bc12-4874-b419-25790192bf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_946d1e4c-7274-406c-87e6-0a4da9cb1364" xlink:to="loc_us-gaap_NetIncomeLoss_c3e421c1-bc12-4874-b419-25790192bf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7cb5ad6d-3777-4ea8-a1f2-884bf7dc7e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_946d1e4c-7274-406c-87e6-0a4da9cb1364" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7cb5ad6d-3777-4ea8-a1f2-884bf7dc7e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c81e4879-53c9-4483-87e4-93762e9cd925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7cb5ad6d-3777-4ea8-a1f2-884bf7dc7e8d" xlink:to="loc_us-gaap_Depreciation_c81e4879-53c9-4483-87e4-93762e9cd925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_cea56079-8b0f-425e-8cf0-0a93eee20c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7cb5ad6d-3777-4ea8-a1f2-884bf7dc7e8d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_cea56079-8b0f-425e-8cf0-0a93eee20c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge_973f7b80-f402-4601-90b3-e41abefdc567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7cb5ad6d-3777-4ea8-a1f2-884bf7dc7e8d" xlink:to="loc_us-gaap_InventoryLIFOReservePeriodCharge_973f7b80-f402-4601-90b3-e41abefdc567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4e9c7d90-08ec-4159-bde3-eaca2a121c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7cb5ad6d-3777-4ea8-a1f2-884bf7dc7e8d" xlink:to="loc_us-gaap_ShareBasedCompensation_4e9c7d90-08ec-4159-bde3-eaca2a121c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments_6f2cf416-4728-420d-be78-449020116e03" xlink:href="vmd-20210930.xsd#vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7cb5ad6d-3777-4ea8-a1f2-884bf7dc7e8d" xlink:to="loc_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments_6f2cf416-4728-420d-be78-449020116e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_cbfb683c-e0ee-4711-b766-019b91a8fee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7cb5ad6d-3777-4ea8-a1f2-884bf7dc7e8d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_cbfb683c-e0ee-4711-b766-019b91a8fee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_795afe66-b3b6-4cde-abef-78e40c9bddb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7cb5ad6d-3777-4ea8-a1f2-884bf7dc7e8d" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_795afe66-b3b6-4cde-abef-78e40c9bddb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_171b3c86-4eab-46a8-8fd3-6bf4917d0492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7cb5ad6d-3777-4ea8-a1f2-884bf7dc7e8d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_171b3c86-4eab-46a8-8fd3-6bf4917d0492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6747f68-1894-44bd-b192-5b8d468e53a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_946d1e4c-7274-406c-87e6-0a4da9cb1364" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6747f68-1894-44bd-b192-5b8d468e53a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6055e6c1-491b-46e6-b555-7720e9089ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6747f68-1894-44bd-b192-5b8d468e53a4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_6055e6c1-491b-46e6-b555-7720e9089ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_21bfdd3b-bb00-4d58-97f5-245c7a9339dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6747f68-1894-44bd-b192-5b8d468e53a4" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_21bfdd3b-bb00-4d58-97f5-245c7a9339dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d2481cb6-9d01-4dde-a582-69a32bf29c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6747f68-1894-44bd-b192-5b8d468e53a4" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d2481cb6-9d01-4dde-a582-69a32bf29c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0b85b59e-e109-466d-86f6-b51c6e0a6e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6747f68-1894-44bd-b192-5b8d468e53a4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_0b85b59e-e109-466d-86f6-b51c6e0a6e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c02a9e28-03d8-4648-a01f-b03ba45078dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6747f68-1894-44bd-b192-5b8d468e53a4" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c02a9e28-03d8-4648-a01f-b03ba45078dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_71588014-0989-403e-9ecb-d72aaae1f2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6747f68-1894-44bd-b192-5b8d468e53a4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_71588014-0989-403e-9ecb-d72aaae1f2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_d9b4edb2-a5d5-4755-b1af-dca329165501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6747f68-1894-44bd-b192-5b8d468e53a4" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_d9b4edb2-a5d5-4755-b1af-dca329165501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49146ef2-80d8-4fb1-8add-61a92b5b94ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_946d1e4c-7274-406c-87e6-0a4da9cb1364" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_49146ef2-80d8-4fb1-8add-61a92b5b94ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e76bae00-53b1-447f-a76c-11b799b9424a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8f41fc16-ff73-42d5-a438-8f9289f8f2bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e76bae00-53b1-447f-a76c-11b799b9424a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fe3fb207-f5e8-4c59-9e56-35eb4bab9592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e76bae00-53b1-447f-a76c-11b799b9424a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fe3fb207-f5e8-4c59-9e56-35eb4bab9592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_d8bfa780-5c43-4888-9ba1-56438a48010c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e76bae00-53b1-447f-a76c-11b799b9424a" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_d8bfa780-5c43-4888-9ba1-56438a48010c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_20b0e6a5-1799-4c47-a1cb-23a8ccd3e921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e76bae00-53b1-447f-a76c-11b799b9424a" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_20b0e6a5-1799-4c47-a1cb-23a8ccd3e921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ed4e44f-4ea0-4e2e-9cb9-b88ddb034a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e76bae00-53b1-447f-a76c-11b799b9424a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7ed4e44f-4ea0-4e2e-9cb9-b88ddb034a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f5fd987-26e7-4fcc-b9dd-56adfaec9bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8f41fc16-ff73-42d5-a438-8f9289f8f2bd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f5fd987-26e7-4fcc-b9dd-56adfaec9bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a7a58597-298c-45ab-a18a-29bd6a784c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f5fd987-26e7-4fcc-b9dd-56adfaec9bec" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a7a58597-298c-45ab-a18a-29bd6a784c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_274518b2-303b-4d47-8518-826b6fa6a1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f5fd987-26e7-4fcc-b9dd-56adfaec9bec" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_274518b2-303b-4d47-8518-826b6fa6a1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_4c8b1115-e313-4d03-b6af-9db3c3755c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f5fd987-26e7-4fcc-b9dd-56adfaec9bec" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_4c8b1115-e313-4d03-b6af-9db3c3755c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_18fdb72e-c169-40ee-b02d-f519dad97113" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f5fd987-26e7-4fcc-b9dd-56adfaec9bec" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_18fdb72e-c169-40ee-b02d-f519dad97113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeasePayments_40b0bfee-b42c-4d72-86bc-d6242f86e782" xlink:href="vmd-20210930.xsd#vmd_LeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f5fd987-26e7-4fcc-b9dd-56adfaec9bec" xlink:to="loc_vmd_LeasePayments_40b0bfee-b42c-4d72-86bc-d6242f86e782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a54749a-6bda-4521-8d43-a4fa54556d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f5fd987-26e7-4fcc-b9dd-56adfaec9bec" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a54749a-6bda-4521-8d43-a4fa54556d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ddfc9eb9-f5ab-4e12-af5a-859a965a964d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8f41fc16-ff73-42d5-a438-8f9289f8f2bd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ddfc9eb9-f5ab-4e12-af5a-859a965a964d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3d1d4885-993e-4d21-a45e-ee814ca75b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8f41fc16-ff73-42d5-a438-8f9289f8f2bd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3d1d4885-993e-4d21-a45e-ee814ca75b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6ab6703c-4104-495b-a855-f9943af74f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8f41fc16-ff73-42d5-a438-8f9289f8f2bd" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6ab6703c-4104-495b-a855-f9943af74f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cea42de-c858-4be4-b4b2-5c6f7ec7ad51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8f41fc16-ff73-42d5-a438-8f9289f8f2bd" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cea42de-c858-4be4-b4b2-5c6f7ec7ad51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_5e35a71d-299a-4286-9d1e-9860811760b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cea42de-c858-4be4-b4b2-5c6f7ec7ad51" xlink:to="loc_us-gaap_InterestPaidNet_5e35a71d-299a-4286-9d1e-9860811760b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_c2c0ef6f-80e7-44d7-ae62-5a59e6e5d608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cea42de-c858-4be4-b4b2-5c6f7ec7ad51" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_c2c0ef6f-80e7-44d7-ae62-5a59e6e5d608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_fc8a47c9-1817-4db9-8177-92def944dde7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8f41fc16-ff73-42d5-a438-8f9289f8f2bd" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_fc8a47c9-1817-4db9-8177-92def944dde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_NetNonCashChangesToFinanceLeaseBalances_a7f61b11-3627-4532-ba88-288540bb6ce0" xlink:href="vmd-20210930.xsd#vmd_NetNonCashChangesToFinanceLeaseBalances"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_fc8a47c9-1817-4db9-8177-92def944dde7" xlink:to="loc_vmd_NetNonCashChangesToFinanceLeaseBalances_a7f61b11-3627-4532-ba88-288540bb6ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_NetNonCashChangesToOperatingLeaseBalances_ee554700-f22f-49f8-9d39-1725dfa8802f" xlink:href="vmd-20210930.xsd#vmd_NetNonCashChangesToOperatingLeaseBalances"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_fc8a47c9-1817-4db9-8177-92def944dde7" xlink:to="loc_vmd_NetNonCashChangesToOperatingLeaseBalances_ee554700-f22f-49f8-9d39-1725dfa8802f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/NatureofBusinessandOperations" xlink:type="simple" xlink:href="vmd-20210930.xsd#NatureofBusinessandOperations"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/NatureofBusinessandOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20893daa-6fae-4f1c-9524-82477aa5e8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bb23a52e-0b94-4682-ad51-8a50f6a60901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20893daa-6fae-4f1c-9524-82477aa5e8e7" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bb23a52e-0b94-4682-ad51-8a50f6a60901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/NatureofBusinessandOperationsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#NatureofBusinessandOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/NatureofBusinessandOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5bae15d8-fcaf-43c7-9d04-cd027c088396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_1cbdc0bc-7c96-42c7-89a0-bf20d94e2073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5bae15d8-fcaf-43c7-9d04-cd027c088396" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_1cbdc0bc-7c96-42c7-89a0-bf20d94e2073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vmd-20210930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a5cbb6aa-0ee5-4576-95e2-9f5c6cfaa206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_90512578-1755-4408-ad38-3be35c355f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a5cbb6aa-0ee5-4576-95e2-9f5c6cfaa206" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_90512578-1755-4408-ad38-3be35c355f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vmd-20210930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d5000390-21be-497b-b876-3a0d9a007b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d5000390-21be-497b-b876-3a0d9a007b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_9b9d2bf9-16c3-42ac-b49f-faf22ac0efe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_9b9d2bf9-16c3-42ac-b49f-faf22ac0efe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b645b2b8-9f93-43e5-9c26-6e7470d06b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_UseOfEstimates_b645b2b8-9f93-43e5-9c26-6e7470d06b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_27ac45d3-8986-4720-a895-2c3b62cabb57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_27ac45d3-8986-4720-a895-2c3b62cabb57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_187cb047-1d92-4ada-a211-fb75622f607f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_187cb047-1d92-4ada-a211-fb75622f607f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_23ff452d-7fb5-45a9-88ea-2e3cfd57f673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_23ff452d-7fb5-45a9-88ea-2e3cfd57f673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_29d72c18-8bec-4ada-86c2-3663c15b321c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_29d72c18-8bec-4ada-86c2-3663c15b321c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_349c0119-6e55-45ab-93d9-46f5da22dc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_349c0119-6e55-45ab-93d9-46f5da22dc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_c458fd56-4b2a-40bf-8fa8-df0982fd1092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_c458fd56-4b2a-40bf-8fa8-df0982fd1092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionLeases_a5d8a316-f3b8-4aa7-b360-6929c4d83701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionLeases"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_RevenueRecognitionLeases_a5d8a316-f3b8-4aa7-b360-6929c4d83701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e8c9a7c8-5819-4bd3-9b35-6fe0b7efcd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e8c9a7c8-5819-4bd3-9b35-6fe0b7efcd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0e6adc49-cb6f-4a67-9a84-554274e28b36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0e6adc49-cb6f-4a67-9a84-554274e28b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_49805994-8b76-422d-aa5c-b19e09a03db8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_49805994-8b76-422d-aa5c-b19e09a03db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_eabf1585-a874-41e7-b24f-6aeefb5b8524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_eabf1585-a874-41e7-b24f-6aeefb5b8524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d3fbe895-af55-48fd-bd58-45c8e49e68f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_738b897a-995d-42d0-a23f-e1f7116f7e11" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d3fbe895-af55-48fd-bd58-45c8e49e68f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="vmd-20210930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a425d41c-ef5f-4cd3-89c3-ad6e4950a7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_9b6664da-0d70-47c9-9fc3-1295dad213c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a425d41c-ef5f-4cd3-89c3-ad6e4950a7d0" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_9b6664da-0d70-47c9-9fc3-1295dad213c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_38502b5e-639a-4e07-bdd3-c346ad0fc41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a425d41c-ef5f-4cd3-89c3-ad6e4950a7d0" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_38502b5e-639a-4e07-bdd3-c346ad0fc41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_d1671379-110b-4f1b-ab91-27f135b4990d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a425d41c-ef5f-4cd3-89c3-ad6e4950a7d0" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_d1671379-110b-4f1b-ab91-27f135b4990d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_97cb40fe-534e-409a-a6e3-4a631841b153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a425d41c-ef5f-4cd3-89c3-ad6e4950a7d0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_97cb40fe-534e-409a-a6e3-4a631841b153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c4429ebf-c874-4d68-bd7e-0294d81bc312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4cf3ab37-a160-4fca-92b8-dec0f1240b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c4429ebf-c874-4d68-bd7e-0294d81bc312" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4cf3ab37-a160-4fca-92b8-dec0f1240b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1bddfb25-8150-43f4-87c7-a414ddff4bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4cf3ab37-a160-4fca-92b8-dec0f1240b49" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1bddfb25-8150-43f4-87c7-a414ddff4bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_c3b0ba0e-37fc-4a88-852f-5d803da5d076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4cf3ab37-a160-4fca-92b8-dec0f1240b49" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_c3b0ba0e-37fc-4a88-852f-5d803da5d076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_19297fd8-2cae-4316-8821-04f0cf2f67de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4cf3ab37-a160-4fca-92b8-dec0f1240b49" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_19297fd8-2cae-4316-8821-04f0cf2f67de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1390c095-7d5c-403b-9447-0f0623706592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_4cf3ab37-a160-4fca-92b8-dec0f1240b49" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1390c095-7d5c-403b-9447-0f0623706592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_90e4e6fa-980a-492a-8ea7-a90f5e1ad158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_e31ece7c-94c5-40ec-9322-b50a43f7f9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_90e4e6fa-980a-492a-8ea7-a90f5e1ad158" xlink:to="loc_us-gaap_ConcentrationRiskTable_e31ece7c-94c5-40ec-9322-b50a43f7f9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3ea90b94-9aee-450f-b201-a0384d1f315b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e31ece7c-94c5-40ec-9322-b50a43f7f9b6" xlink:to="loc_srt_MajorCustomersAxis_3ea90b94-9aee-450f-b201-a0384d1f315b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_60645ca7-be3c-41a4-8c81-dabdedb6e975" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3ea90b94-9aee-450f-b201-a0384d1f315b" xlink:to="loc_srt_NameOfMajorCustomerDomain_60645ca7-be3c-41a4-8c81-dabdedb6e975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_MedicareAndMedicaidMember_c67a7e42-14f8-4cbe-a6cd-559ae6ba8f63" xlink:href="vmd-20210930.xsd#vmd_MedicareAndMedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_60645ca7-be3c-41a4-8c81-dabdedb6e975" xlink:to="loc_vmd_MedicareAndMedicaidMember_c67a7e42-14f8-4cbe-a6cd-559ae6ba8f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_MedicareMember_e4520941-5ecc-4172-89e9-c78d31ed414b" xlink:href="vmd-20210930.xsd#vmd_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_MedicareAndMedicaidMember_c67a7e42-14f8-4cbe-a6cd-559ae6ba8f63" xlink:to="loc_vmd_MedicareMember_e4520941-5ecc-4172-89e9-c78d31ed414b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_MedicaidMember_c512488a-460d-4abd-9950-29b087dd1f18" xlink:href="vmd-20210930.xsd#vmd_MedicaidMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_MedicareAndMedicaidMember_c67a7e42-14f8-4cbe-a6cd-559ae6ba8f63" xlink:to="loc_vmd_MedicaidMember_c512488a-460d-4abd-9950-29b087dd1f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5b925eb2-2982-4cc5-85b6-5344e1bcd79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e31ece7c-94c5-40ec-9322-b50a43f7f9b6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5b925eb2-2982-4cc5-85b6-5344e1bcd79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bf76a3c3-7a21-4dda-82d4-db3c641b957f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5b925eb2-2982-4cc5-85b6-5344e1bcd79e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bf76a3c3-7a21-4dda-82d4-db3c641b957f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_e142ffc0-cd34-414e-8d5f-fb018f1f8b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_bf76a3c3-7a21-4dda-82d4-db3c641b957f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_e142ffc0-cd34-414e-8d5f-fb018f1f8b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_326bd596-5097-40c6-8cbd-f636b675716e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e31ece7c-94c5-40ec-9322-b50a43f7f9b6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_326bd596-5097-40c6-8cbd-f636b675716e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec65a6cb-6c0c-4842-932d-0690f3b31a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_326bd596-5097-40c6-8cbd-f636b675716e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec65a6cb-6c0c-4842-932d-0690f3b31a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_c3edf732-0aae-49e1-a7ab-3e5c3b649548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec65a6cb-6c0c-4842-932d-0690f3b31a96" xlink:to="loc_us-gaap_AccountsReceivableMember_c3edf732-0aae-49e1-a7ab-3e5c3b649548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_96a1238e-dbce-4c97-9653-4836facbf798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ec65a6cb-6c0c-4842-932d-0690f3b31a96" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_96a1238e-dbce-4c97-9653-4836facbf798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7a332d3a-f733-4098-b340-c160de2a853f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_e31ece7c-94c5-40ec-9322-b50a43f7f9b6" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_7a332d3a-f733-4098-b340-c160de2a853f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f643a2ce-ffe3-467d-af04-d196dad4976e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7a332d3a-f733-4098-b340-c160de2a853f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f643a2ce-ffe3-467d-af04-d196dad4976e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b35c28e8-4a50-47e6-8a47-cc77f6206f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_f9d81ab9-49d0-4718-8ff6-21ce1ffd3cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b35c28e8-4a50-47e6-8a47-cc77f6206f10" xlink:to="loc_us-gaap_InventoryValuationReserves_f9d81ab9-49d0-4718-8ff6-21ce1ffd3cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7cf3c4cb-da91-4d30-93ef-818c7011bfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_7db60291-e3e4-483c-ad88-44c468d348db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7cf3c4cb-da91-4d30-93ef-818c7011bfd8" xlink:to="loc_us-gaap_EquityMethodInvestments_7db60291-e3e4-483c-ad88-44c468d348db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_b6a4b4d7-b94f-41d9-9156-a80ee9c38abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7cf3c4cb-da91-4d30-93ef-818c7011bfd8" xlink:to="loc_us-gaap_OtherInvestments_b6a4b4d7-b94f-41d9-9156-a80ee9c38abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_1f091fc3-4a23-45fd-89c0-7c8ed2e30900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7cf3c4cb-da91-4d30-93ef-818c7011bfd8" xlink:to="loc_us-gaap_Investments_1f091fc3-4a23-45fd-89c0-7c8ed2e30900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0770cd3c-c0c6-49fd-91ea-597e4570f716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b7abb5c9-b400-41a8-8e6d-92fc7f458231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0770cd3c-c0c6-49fd-91ea-597e4570f716" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b7abb5c9-b400-41a8-8e6d-92fc7f458231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c211a8ba-47af-4d15-a7ca-a5ed0c26da82" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b7abb5c9-b400-41a8-8e6d-92fc7f458231" xlink:to="loc_srt_ProductOrServiceAxis_c211a8ba-47af-4d15-a7ca-a5ed0c26da82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c211a8ba-47af-4d15-a7ca-a5ed0c26da82" xlink:to="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_VentilatorRentalMember_be614ac7-2380-4841-a828-eaa2edbdd679" xlink:href="vmd-20210930.xsd#vmd_VentilatorRentalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:to="loc_vmd_VentilatorRentalMember_be614ac7-2380-4841-a828-eaa2edbdd679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_OtherDurableMedicalEquipmentRentalsMember_6e38e27c-1f4f-4310-b0b2-e14a9e79ac09" xlink:href="vmd-20210930.xsd#vmd_OtherDurableMedicalEquipmentRentalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:to="loc_vmd_OtherDurableMedicalEquipmentRentalsMember_6e38e27c-1f4f-4310-b0b2-e14a9e79ac09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_EquipmentSalesMember_8372c12a-d7ad-4ec6-a4a6-6b051ab07c7f" xlink:href="vmd-20210930.xsd#vmd_EquipmentSalesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:to="loc_vmd_EquipmentSalesMember_8372c12a-d7ad-4ec6-a4a6-6b051ab07c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_COVID19ResponseSalesMember_3846971a-5f73-446c-b387-612962b66515" xlink:href="vmd-20210930.xsd#vmd_COVID19ResponseSalesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:to="loc_vmd_COVID19ResponseSalesMember_3846971a-5f73-446c-b387-612962b66515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_c405425a-968b-442d-850e-2ce47141bec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a25bbf7-c62a-4e51-a523-db6c73241707" xlink:to="loc_us-gaap_ServiceMember_c405425a-968b-442d-850e-2ce47141bec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_76629f99-b01b-41a1-91ae-ad14b5edbd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b7abb5c9-b400-41a8-8e6d-92fc7f458231" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_76629f99-b01b-41a1-91ae-ad14b5edbd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_67787680-211a-40c5-b8a3-c4de2c3179cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_76629f99-b01b-41a1-91ae-ad14b5edbd12" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_67787680-211a-40c5-b8a3-c4de2c3179cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome_61ca92b7-a4a4-4448-a6a2-52650b5b725f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_76629f99-b01b-41a1-91ae-ad14b5edbd12" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncome_61ca92b7-a4a4-4448-a6a2-52650b5b725f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6effe936-3a40-40c9-b441-e003f4d463bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_76629f99-b01b-41a1-91ae-ad14b5edbd12" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6effe936-3a40-40c9-b441-e003f4d463bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_3cb2f4ec-374e-445a-a09a-eaabe84b954c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_76629f99-b01b-41a1-91ae-ad14b5edbd12" xlink:to="loc_us-gaap_Revenues_3cb2f4ec-374e-445a-a09a-eaabe84b954c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="vmd-20210930.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d8c800d5-a29a-4127-90e9-13358e045af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_245946f5-b74a-4747-93b3-5d28c816cb48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d8c800d5-a29a-4127-90e9-13358e045af5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_245946f5-b74a-4747-93b3-5d28c816cb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="vmd-20210930.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1eac3d4f-1655-44c2-b10f-d9ad98171502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ad2b00fd-fa5d-418c-8380-cca7ed00bdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1eac3d4f-1655-44c2-b10f-d9ad98171502" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ad2b00fd-fa5d-418c-8380-cca7ed00bdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#PropertyandEquipmentScheduleofFixedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ed08164d-ab7c-4e13-913a-0c1a04d57d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9bee72f1-834e-416a-8ab0-cd8dfe668599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ed08164d-ab7c-4e13-913a-0c1a04d57d40" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9bee72f1-834e-416a-8ab0-cd8dfe668599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_da376e58-d79f-4cf8-b2c4-a35ccf03e1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9bee72f1-834e-416a-8ab0-cd8dfe668599" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_da376e58-d79f-4cf8-b2c4-a35ccf03e1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_da376e58-d79f-4cf8-b2c4-a35ccf03e1a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_EquipmentMedicalMember_cec053da-a623-4abf-9377-3486dd6f9dfe" xlink:href="vmd-20210930.xsd#vmd_EquipmentMedicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:to="loc_vmd_EquipmentMedicalMember_cec053da-a623-4abf-9377-3486dd6f9dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_FurnitureAndEquipmentMember_cf1fd562-1752-43cd-8164-280fd6a43a3c" xlink:href="vmd-20210930.xsd#vmd_FurnitureAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:to="loc_vmd_FurnitureAndEquipmentMember_cf1fd562-1752-43cd-8164-280fd6a43a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_02d1b9d9-b849-4dd5-8c6c-d7f58b88582c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:to="loc_us-gaap_LandMember_02d1b9d9-b849-4dd5-8c6c-d7f58b88582c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_334bc8ef-3aec-4f3d-86f4-d302f17f6d80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:to="loc_us-gaap_BuildingMember_334bc8ef-3aec-4f3d-86f4-d302f17f6d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c5372711-cbba-4dda-a162-89b27bf723b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c5372711-cbba-4dda-a162-89b27bf723b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_bf6319b3-5ee3-444a-9fe8-cdb53c7ba252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_52bb0372-92f4-4735-95a7-4de5037707c8" xlink:to="loc_us-gaap_VehiclesMember_bf6319b3-5ee3-444a-9fe8-cdb53c7ba252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8e3ead9a-4a81-4d4c-9e8e-cb1b05c1c219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9bee72f1-834e-416a-8ab0-cd8dfe668599" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8e3ead9a-4a81-4d4c-9e8e-cb1b05c1c219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f169a69d-13b9-49f4-9d7f-7af6484977c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8e3ead9a-4a81-4d4c-9e8e-cb1b05c1c219" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f169a69d-13b9-49f4-9d7f-7af6484977c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d1945ea3-d6f2-4971-83f5-9ac406769e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8e3ead9a-4a81-4d4c-9e8e-cb1b05c1c219" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d1945ea3-d6f2-4971-83f5-9ac406769e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9f650351-1741-4dc4-966c-a22a96515f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8e3ead9a-4a81-4d4c-9e8e-cb1b05c1c219" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9f650351-1741-4dc4-966c-a22a96515f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#PropertyandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c46120e0-8cb3-4b03-acaa-69cf72b75140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c88256d6-8756-47cb-bb63-a8b37bf27b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c46120e0-8cb3-4b03-acaa-69cf72b75140" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c88256d6-8756-47cb-bb63-a8b37bf27b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f406c7-9fc3-4488-8b4d-efa5416cd8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c88256d6-8756-47cb-bb63-a8b37bf27b0b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f406c7-9fc3-4488-8b4d-efa5416cd8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3980c772-0a57-49b4-bfe0-94584ad655e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17f406c7-9fc3-4488-8b4d-efa5416cd8b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3980c772-0a57-49b4-bfe0-94584ad655e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_AssetsHeldUnderFinanceLeasesMember_5f2e5119-46c0-43bf-a63e-2d5932daa759" xlink:href="vmd-20210930.xsd#vmd_AssetsHeldUnderFinanceLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3980c772-0a57-49b4-bfe0-94584ad655e5" xlink:to="loc_vmd_AssetsHeldUnderFinanceLeasesMember_5f2e5119-46c0-43bf-a63e-2d5932daa759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6df60c2-de45-4890-88ee-7c467c11be8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c88256d6-8756-47cb-bb63-a8b37bf27b0b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6df60c2-de45-4890-88ee-7c467c11be8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation_4f79ad8d-41a4-4a70-8789-92237ac8d633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6df60c2-de45-4890-88ee-7c467c11be8b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciation_4f79ad8d-41a4-4a70-8789-92237ac8d633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_242ee25b-a4d0-4fd1-a44b-b760b5064852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6df60c2-de45-4890-88ee-7c467c11be8b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_242ee25b-a4d0-4fd1-a44b-b760b5064852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_15f96411-b36e-4ba6-af7b-34bb9be662b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c6df60c2-de45-4890-88ee-7c467c11be8b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_15f96411-b36e-4ba6-af7b-34bb9be662b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/CurrentLiabilities" xlink:type="simple" xlink:href="vmd-20210930.xsd#CurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/CurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_583feea6-6cd4-4404-a843-9394def9d6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_06330670-561c-4aa7-9adb-81ea0a6723a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_583feea6-6cd4-4404-a843-9394def9d6c0" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_06330670-561c-4aa7-9adb-81ea0a6723a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/CurrentLiabilitiesTables" xlink:type="simple" xlink:href="vmd-20210930.xsd#CurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/CurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6c93bf3b-c6aa-44ae-a050-a9206229107a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_eebaf2ab-d287-4f8b-8417-1ed2c8d8fc05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6c93bf3b-c6aa-44ae-a050-a9206229107a" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_eebaf2ab-d287-4f8b-8417-1ed2c8d8fc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/CurrentLiabilitiesDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#CurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/CurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_932201f0-6598-4404-8b38-405507d95a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_AccruedTradePayablesCurrent_c793111e-5b8b-4487-8071-fe1cceb0a7b4" xlink:href="vmd-20210930.xsd#vmd_AccruedTradePayablesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_932201f0-6598-4404-8b38-405507d95a33" xlink:to="loc_vmd_AccruedTradePayablesCurrent_c793111e-5b8b-4487-8071-fe1cceb0a7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_bd2f8a50-7d63-4bc7-a4d8-065b3f083da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_932201f0-6598-4404-8b38-405507d95a33" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_bd2f8a50-7d63-4bc7-a4d8-065b3f083da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_c79d26f0-8446-4cd7-ba29-9dd9fe842e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_932201f0-6598-4404-8b38-405507d95a33" xlink:to="loc_us-gaap_AccruedBonusesCurrent_c79d26f0-8446-4cd7-ba29-9dd9fe842e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6a914d1f-7550-4b02-831e-483400eb39c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_932201f0-6598-4404-8b38-405507d95a33" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6a914d1f-7550-4b02-831e-483400eb39c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_36aee395-f377-4612-a41d-00dba0d1476b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_932201f0-6598-4404-8b38-405507d95a33" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_36aee395-f377-4612-a41d-00dba0d1476b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1a85417d-e2eb-448f-90c7-7b7b3de3bc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_932201f0-6598-4404-8b38-405507d95a33" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1a85417d-e2eb-448f-90c7-7b7b3de3bc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ec1fe69e-27d7-4f51-9a6a-9fe7d22b0472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_932201f0-6598-4404-8b38-405507d95a33" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ec1fe69e-27d7-4f51-9a6a-9fe7d22b0472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilities" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilities"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtAndLeasesAbstract_1eff3bc5-89a2-4fcc-962c-ddd29839c285" xlink:href="vmd-20210930.xsd#vmd_DebtAndLeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtandLeaseDisclosureTextBlock_7ebfcdbe-2faa-4e5b-8b29-d9bc3111fa3b" xlink:href="vmd-20210930.xsd#vmd_DebtandLeaseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_1eff3bc5-89a2-4fcc-962c-ddd29839c285" xlink:to="loc_vmd_DebtandLeaseDisclosureTextBlock_7ebfcdbe-2faa-4e5b-8b29-d9bc3111fa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesTables" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtAndLeasesAbstract_54b22f93-8ce3-4e19-a2e3-e1dc728be6b7" xlink:href="vmd-20210930.xsd#vmd_DebtAndLeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_4d0c1e02-8db4-4aa6-9251-a40acb1bc028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_54b22f93-8ce3-4e19-a2e3-e1dc728be6b7" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_4d0c1e02-8db4-4aa6-9251-a40acb1bc028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LiabilitiesLesseeTableTextBlock_1c13dd92-14ae-4150-8ddb-efe434e344eb" xlink:href="vmd-20210930.xsd#vmd_LiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_54b22f93-8ce3-4e19-a2e3-e1dc728be6b7" xlink:to="loc_vmd_LiabilitiesLesseeTableTextBlock_1c13dd92-14ae-4150-8ddb-efe434e344eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtAndLeasesAbstract_dae1824a-7545-471d-aff8-c29117c4082f" xlink:href="vmd-20210930.xsd#vmd_DebtAndLeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_c6166926-7fe6-4afd-81ce-ed4214920212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_dae1824a-7545-471d-aff8-c29117c4082f" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_c6166926-7fe6-4afd-81ce-ed4214920212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9850c216-468c-4809-a080-852c970b9a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c6166926-7fe6-4afd-81ce-ed4214920212" xlink:to="loc_us-gaap_CreditFacilityAxis_9850c216-468c-4809-a080-852c970b9a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_de68c2cd-85d6-4bcc-a739-358c2d1e8584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_9850c216-468c-4809-a080-852c970b9a33" xlink:to="loc_us-gaap_CreditFacilityDomain_de68c2cd-85d6-4bcc-a739-358c2d1e8584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6b4149fb-0125-4552-aa2d-24bf98745c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_de68c2cd-85d6-4bcc-a739-358c2d1e8584" xlink:to="loc_us-gaap_LineOfCreditMember_6b4149fb-0125-4552-aa2d-24bf98745c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_72cdfc59-e498-41df-9f4a-a8b9591ec598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c6166926-7fe6-4afd-81ce-ed4214920212" xlink:to="loc_us-gaap_VariableRateAxis_72cdfc59-e498-41df-9f4a-a8b9591ec598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_56b4b774-79e4-4919-a4f4-0a35ffe52882" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_72cdfc59-e498-41df-9f4a-a8b9591ec598" xlink:to="loc_us-gaap_VariableRateDomain_56b4b774-79e4-4919-a4f4-0a35ffe52882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_41a4ceb9-adf6-4adb-b8ef-2996ea13cb21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_56b4b774-79e4-4919-a4f4-0a35ffe52882" xlink:to="loc_us-gaap_PrimeRateMember_41a4ceb9-adf6-4adb-b8ef-2996ea13cb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_486fefe1-ec5e-43ff-a017-3b9bb89006ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_c6166926-7fe6-4afd-81ce-ed4214920212" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_486fefe1-ec5e-43ff-a017-3b9bb89006ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6efd2958-3c3f-4871-8fce-a6396f34a39d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_486fefe1-ec5e-43ff-a017-3b9bb89006ee" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6efd2958-3c3f-4871-8fce-a6396f34a39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7971425c-84ce-4e3b-8857-40428b37e61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_486fefe1-ec5e-43ff-a017-3b9bb89006ee" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7971425c-84ce-4e3b-8857-40428b37e61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtInstrumentInterestRateFloorRate_afc6bef5-babe-4c8a-9c86-c6f2a4f5ae94" xlink:href="vmd-20210930.xsd#vmd_DebtInstrumentInterestRateFloorRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_486fefe1-ec5e-43ff-a017-3b9bb89006ee" xlink:to="loc_vmd_DebtInstrumentInterestRateFloorRate_afc6bef5-babe-4c8a-9c86-c6f2a4f5ae94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_51c25492-331c-4309-81e1-e2a56b5d1f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_486fefe1-ec5e-43ff-a017-3b9bb89006ee" xlink:to="loc_us-gaap_LineOfCredit_51c25492-331c-4309-81e1-e2a56b5d1f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtAndLeasesAbstract_938aad48-cc04-4a33-9cd7-399d4d179fe5" xlink:href="vmd-20210930.xsd#vmd_DebtAndLeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_c853021f-f272-4b76-8cad-ee7e286785a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_938aad48-cc04-4a33-9cd7-399d4d179fe5" xlink:to="loc_us-gaap_DebtInstrumentTable_c853021f-f272-4b76-8cad-ee7e286785a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5899069b-5911-446e-977b-5e0bfbcbd7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c853021f-f272-4b76-8cad-ee7e286785a2" xlink:to="loc_us-gaap_DebtInstrumentAxis_5899069b-5911-446e-977b-5e0bfbcbd7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_84e71691-6207-4568-b984-37b2f1e5e35b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5899069b-5911-446e-977b-5e0bfbcbd7f7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_84e71691-6207-4568-b984-37b2f1e5e35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_BuildingTermNoteMember_d12a5165-fed4-4e46-b881-5e443c22b734" xlink:href="vmd-20210930.xsd#vmd_BuildingTermNoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84e71691-6207-4568-b984-37b2f1e5e35b" xlink:to="loc_vmd_BuildingTermNoteMember_d12a5165-fed4-4e46-b881-5e443c22b734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_TermNoteMember_847610b0-d90a-4d1e-99e8-3f76e53410ab" xlink:href="vmd-20210930.xsd#vmd_TermNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_84e71691-6207-4568-b984-37b2f1e5e35b" xlink:to="loc_vmd_TermNoteMember_847610b0-d90a-4d1e-99e8-3f76e53410ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c34e2f58-c136-439f-b0fe-40862a846514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c853021f-f272-4b76-8cad-ee7e286785a2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c34e2f58-c136-439f-b0fe-40862a846514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1326329d-f25f-488b-96bd-741a8a4d3593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c34e2f58-c136-439f-b0fe-40862a846514" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1326329d-f25f-488b-96bd-741a8a4d3593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_19a40cf4-4031-454d-8a68-3c0920a45805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1326329d-f25f-488b-96bd-741a8a4d3593" xlink:to="loc_us-gaap_NotesPayableToBanksMember_19a40cf4-4031-454d-8a68-3c0920a45805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2b701920-9a6c-4f34-9b49-55bdf7baa79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c853021f-f272-4b76-8cad-ee7e286785a2" xlink:to="loc_us-gaap_VariableRateAxis_2b701920-9a6c-4f34-9b49-55bdf7baa79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_945aa524-27a4-4a70-8ad6-bbe4871b5ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_2b701920-9a6c-4f34-9b49-55bdf7baa79f" xlink:to="loc_us-gaap_VariableRateDomain_945aa524-27a4-4a70-8ad6-bbe4871b5ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d905bf06-f570-40c5-a0cf-741cfb688507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_945aa524-27a4-4a70-8ad6-bbe4871b5ae0" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_d905bf06-f570-40c5-a0cf-741cfb688507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5c888107-b28b-439a-86ed-a80de53cb892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c853021f-f272-4b76-8cad-ee7e286785a2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5c888107-b28b-439a-86ed-a80de53cb892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e2ce39d5-0b16-4079-8056-6dcf3c5cc83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5c888107-b28b-439a-86ed-a80de53cb892" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e2ce39d5-0b16-4079-8056-6dcf3c5cc83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_8d27d51c-40f0-42fe-a162-6a0cdf671610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e2ce39d5-0b16-4079-8056-6dcf3c5cc83b" xlink:to="loc_us-gaap_InterestRateSwapMember_8d27d51c-40f0-42fe-a162-6a0cdf671610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_c853021f-f272-4b76-8cad-ee7e286785a2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2c619ae0-f36c-49a4-a26c-90cc06d3823e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2c619ae0-f36c-49a4-a26c-90cc06d3823e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba89fddd-ed4e-44b9-90ce-2f1485907e52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba89fddd-ed4e-44b9-90ce-2f1485907e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtInstrumentCovenantLoanToValueRatio_6d8c376b-543b-4148-8b2e-d1667b5c2dc1" xlink:href="vmd-20210930.xsd#vmd_DebtInstrumentCovenantLoanToValueRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:to="loc_vmd_DebtInstrumentCovenantLoanToValueRatio_6d8c376b-543b-4148-8b2e-d1667b5c2dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFixedInterestRate_c66791d1-8be0-4c30-9ea6-a5368a14d43f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:to="loc_us-gaap_DerivativeFixedInterestRate_c66791d1-8be0-4c30-9ea6-a5368a14d43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_b3b70867-308f-4b92-b3ed-3743bc8b1d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_b3b70867-308f-4b92-b3ed-3743bc8b1d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5daf2def-a66b-4b6c-9fb4-3b8f529b3177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e242e526-ba53-493c-babe-081674451f01" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5daf2def-a66b-4b6c-9fb4-3b8f529b3177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilitiesScheduleofNotesPayableDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtAndLeasesAbstract_fb400a81-f4be-415e-a39f-17b97769c724" xlink:href="vmd-20210930.xsd#vmd_DebtAndLeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_03684eac-a564-48b2-bfad-d70cc1303c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_fb400a81-f4be-415e-a39f-17b97769c724" xlink:to="loc_us-gaap_DebtInstrumentTable_03684eac-a564-48b2-bfad-d70cc1303c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9d83fb6d-4b17-4d2a-a424-c43e9126854d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_03684eac-a564-48b2-bfad-d70cc1303c90" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9d83fb6d-4b17-4d2a-a424-c43e9126854d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a706b5f0-0ec0-4b04-9d2c-3eaff11020bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9d83fb6d-4b17-4d2a-a424-c43e9126854d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a706b5f0-0ec0-4b04-9d2c-3eaff11020bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableToBanksMember_93fa0516-fd15-455d-968b-ee2ab89c64bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBanksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_a706b5f0-0ec0-4b04-9d2c-3eaff11020bb" xlink:to="loc_us-gaap_NotesPayableToBanksMember_93fa0516-fd15-455d-968b-ee2ab89c64bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_112f76bf-c6fd-433f-966e-de3c88b6b979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_03684eac-a564-48b2-bfad-d70cc1303c90" xlink:to="loc_us-gaap_DebtInstrumentLineItems_112f76bf-c6fd-433f-966e-de3c88b6b979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4ae838aa-7b8b-4619-a47f-2959d9e368ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112f76bf-c6fd-433f-966e-de3c88b6b979" xlink:to="loc_us-gaap_LongTermDebt_4ae838aa-7b8b-4619-a47f-2959d9e368ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_bfb8bc25-3a37-46d5-899a-0456d577bf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112f76bf-c6fd-433f-966e-de3c88b6b979" xlink:to="loc_us-gaap_LongTermDebtCurrent_bfb8bc25-3a37-46d5-899a-0456d577bf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c321086f-0e02-4653-a1f9-ce793ef4fe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112f76bf-c6fd-433f-966e-de3c88b6b979" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c321086f-0e02-4653-a1f9-ce793ef4fe2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilitiesLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilitiesLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtAndLeasesAbstract_df46c384-8d85-4aea-9914-2b27e19aff99" xlink:href="vmd-20210930.xsd#vmd_DebtAndLeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeaseLiability_6c856a44-1f79-48d6-a1d8-70a6cf54dbb8" xlink:href="vmd-20210930.xsd#vmd_LeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_df46c384-8d85-4aea-9914-2b27e19aff99" xlink:to="loc_vmd_LeaseLiability_6c856a44-1f79-48d6-a1d8-70a6cf54dbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeaseLiabilityCurrent_2c26c8e8-fd65-4b6a-9b7e-68b48f285d86" xlink:href="vmd-20210930.xsd#vmd_LeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_df46c384-8d85-4aea-9914-2b27e19aff99" xlink:to="loc_vmd_LeaseLiabilityCurrent_2c26c8e8-fd65-4b6a-9b7e-68b48f285d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_LeaseLiabilityNoncurrent_ea2521aa-72b1-4979-b3bd-3e64971573d4" xlink:href="vmd-20210930.xsd#vmd_LeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_df46c384-8d85-4aea-9914-2b27e19aff99" xlink:to="loc_vmd_LeaseLiabilityNoncurrent_ea2521aa-72b1-4979-b3bd-3e64971573d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilitiesFinanceLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilitiesFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtAndLeasesAbstract_a2711316-1bb9-4cb2-b0e7-e7ee33f900d3" xlink:href="vmd-20210930.xsd#vmd_DebtAndLeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDiscountRate_ec6f4e04-feb2-469c-8134-8905f9a40f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_a2711316-1bb9-4cb2-b0e7-e7ee33f900d3" xlink:to="loc_us-gaap_LesseeFinanceLeaseDiscountRate_ec6f4e04-feb2-469c-8134-8905f9a40f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_cef6a07b-681d-49d9-82f0-ac604d81f905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_a2711316-1bb9-4cb2-b0e7-e7ee33f900d3" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_cef6a07b-681d-49d9-82f0-ac604d81f905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_4bd6bd21-8210-46ee-80fb-6fd0798ac6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_a2711316-1bb9-4cb2-b0e7-e7ee33f900d3" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_4bd6bd21-8210-46ee-80fb-6fd0798ac6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_01fe1273-2615-4e4b-bc9c-2b10b5a3d301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_a2711316-1bb9-4cb2-b0e7-e7ee33f900d3" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_01fe1273-2615-4e4b-bc9c-2b10b5a3d301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_vmd_DebtAndLeasesAbstract_54e86405-cb67-460f-bab4-a8e84a421cf9" xlink:href="vmd-20210930.xsd#vmd_DebtAndLeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_fe43b956-42a2-4b85-a0a4-98f972c4385f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_DebtAndLeasesAbstract_54e86405-cb67-460f-bab4-a8e84a421cf9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_fe43b956-42a2-4b85-a0a4-98f972c4385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_cd05dbb6-91ef-4678-9984-e32f0be8a17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fe43b956-42a2-4b85-a0a4-98f972c4385f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_cd05dbb6-91ef-4678-9984-e32f0be8a17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_d34b7f82-7689-4327-9cab-88835bb5f283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_cd05dbb6-91ef-4678-9984-e32f0be8a17f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_d34b7f82-7689-4327-9cab-88835bb5f283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_MonthlyRentalPaymentsMember_f00ba1f4-4b15-455f-840f-2fb65c4f0d4d" xlink:href="vmd-20210930.xsd#vmd_MonthlyRentalPaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_d34b7f82-7689-4327-9cab-88835bb5f283" xlink:to="loc_vmd_MonthlyRentalPaymentsMember_f00ba1f4-4b15-455f-840f-2fb65c4f0d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f8fcabe-52f1-41ce-9e66-2ddb66f7be13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fe43b956-42a2-4b85-a0a4-98f972c4385f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f8fcabe-52f1-41ce-9e66-2ddb66f7be13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ef6cfb39-4ac0-4dc3-bff3-014c58413959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f8fcabe-52f1-41ce-9e66-2ddb66f7be13" xlink:to="loc_us-gaap_RelatedPartyDomain_ef6cfb39-4ac0-4dc3-bff3-014c58413959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_df2d854b-cf32-459f-8aa9-25dbecdc73b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_ef6cfb39-4ac0-4dc3-bff3-014c58413959" xlink:to="loc_srt_AffiliatedEntityMember_df2d854b-cf32-459f-8aa9-25dbecdc73b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_fe43b956-42a2-4b85-a0a4-98f972c4385f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_d040a4eb-e30e-4cdf-82b0-d2863be264f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_d040a4eb-e30e-4cdf-82b0-d2863be264f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ac9d0207-af2f-4c0d-9e4d-e19cc7a6db48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ac9d0207-af2f-4c0d-9e4d-e19cc7a6db48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_80a9e691-595b-4c48-9711-739dc1bd52b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:to="loc_us-gaap_LeaseCost_80a9e691-595b-4c48-9711-739dc1bd52b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b67c2d41-7fd7-4296-8090-12663555e4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_b67c2d41-7fd7-4296-8090-12663555e4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_19c94cea-c708-487a-ad8b-c999871b5a77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_19c94cea-c708-487a-ad8b-c999871b5a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_b2a098a1-4d79-4d3f-8884-ff3c6266f034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3134f6ed-90ea-4c66-aa1a-1b02929d95fe" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_b2a098a1-4d79-4d3f-8884-ff3c6266f034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="vmd-20210930.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6c16ead3-388e-41fd-8ac7-f3492381c0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8e7a5676-f575-4c91-b1cb-f475d9401192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6c16ead3-388e-41fd-8ac7-f3492381c0d9" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_8e7a5676-f575-4c91-b1cb-f475d9401192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="vmd-20210930.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_14ec4fd5-fe33-4393-833c-73a5f72f179f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_633f6281-db6b-4fed-9a83-a6f619402dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_14ec4fd5-fe33-4393-833c-73a5f72f179f" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_633f6281-db6b-4fed-9a83-a6f619402dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#FairValueMeasurementRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b99f1797-0da0-44cb-8f36-73f02f3f9948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1a8725a8-d7cd-4c8c-b519-9fe0fe96faa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b99f1797-0da0-44cb-8f36-73f02f3f9948" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1a8725a8-d7cd-4c8c-b519-9fe0fe96faa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_98f13594-71d8-4907-90d5-328c56f82314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1a8725a8-d7cd-4c8c-b519-9fe0fe96faa1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_98f13594-71d8-4907-90d5-328c56f82314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e05b8425-6b82-4fd1-9af5-834ccd2bbec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_98f13594-71d8-4907-90d5-328c56f82314" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e05b8425-6b82-4fd1-9af5-834ccd2bbec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7faf2b19-f1a1-4f32-bfc6-7acc6a40b6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e05b8425-6b82-4fd1-9af5-834ccd2bbec4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7faf2b19-f1a1-4f32-bfc6-7acc6a40b6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fade4d96-a0bd-407c-87bb-9fc744771c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1a8725a8-d7cd-4c8c-b519-9fe0fe96faa1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fade4d96-a0bd-407c-87bb-9fc744771c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9874f5e2-c683-4342-be5d-91b32dcafecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fade4d96-a0bd-407c-87bb-9fc744771c4b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9874f5e2-c683-4342-be5d-91b32dcafecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_158c136d-c4c5-4d4a-8fc1-061a96b2f498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9874f5e2-c683-4342-be5d-91b32dcafecc" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_158c136d-c4c5-4d4a-8fc1-061a96b2f498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a2287939-91a1-461f-a5b7-0eee7ff852d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9874f5e2-c683-4342-be5d-91b32dcafecc" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a2287939-91a1-461f-a5b7-0eee7ff852d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_43e5a082-2854-4af2-9e47-0e08735ca892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9874f5e2-c683-4342-be5d-91b32dcafecc" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_43e5a082-2854-4af2-9e47-0e08735ca892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_0183ccf1-4a17-4706-b17d-af4665a8e07d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1a8725a8-d7cd-4c8c-b519-9fe0fe96faa1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_0183ccf1-4a17-4706-b17d-af4665a8e07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1745b950-bfab-43e3-bd27-846d52146002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_0183ccf1-4a17-4706-b17d-af4665a8e07d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1745b950-bfab-43e3-bd27-846d52146002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d1b3dac6-6b55-4306-85e5-fb16f34464b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1745b950-bfab-43e3-bd27-846d52146002" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d1b3dac6-6b55-4306-85e5-fb16f34464b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a6c2b312-aa7c-4766-acac-8fd5689a5ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1a8725a8-d7cd-4c8c-b519-9fe0fe96faa1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a6c2b312-aa7c-4766-acac-8fd5689a5ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1d238c3a-fc88-41eb-8d0d-c07b405b25bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a6c2b312-aa7c-4766-acac-8fd5689a5ec7" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1d238c3a-fc88-41eb-8d0d-c07b405b25bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_ce94b359-d877-40f1-a921-9e4437bd7933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_1d238c3a-fc88-41eb-8d0d-c07b405b25bc" xlink:to="loc_us-gaap_InterestRateSwapMember_ce94b359-d877-40f1-a921-9e4437bd7933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b38928d1-2791-41bf-8622-e4f7043decfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_1a8725a8-d7cd-4c8c-b519-9fe0fe96faa1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b38928d1-2791-41bf-8622-e4f7043decfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_26bd558f-31e9-4fc9-b6d6-3b41a4f6b883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b38928d1-2791-41bf-8622-e4f7043decfa" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_26bd558f-31e9-4fc9-b6d6-3b41a4f6b883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_e62cf20c-7bdf-4f1d-aa75-9e2ac8467779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b38928d1-2791-41bf-8622-e4f7043decfa" xlink:to="loc_us-gaap_DerivativeLiabilities_e62cf20c-7bdf-4f1d-aa75-9e2ac8467779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure_ade78d90-6511-4774-8d78-c51c1b9eb7d2" xlink:href="vmd-20210930.xsd#vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b38928d1-2791-41bf-8622-e4f7043decfa" xlink:to="loc_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure_ade78d90-6511-4774-8d78-c51c1b9eb7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_51965415-b4bb-4680-a861-e7a260c2f910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9d1887bf-8a64-4fe4-b024-2b2155bf9b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_51965415-b4bb-4680-a861-e7a260c2f910" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9d1887bf-8a64-4fe4-b024-2b2155bf9b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b1a1fa99-41b5-4b76-b6b1-1b3622805c60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9d1887bf-8a64-4fe4-b024-2b2155bf9b24" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b1a1fa99-41b5-4b76-b6b1-1b3622805c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2fee6238-9044-4b7f-b196-5541cad2bd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b1a1fa99-41b5-4b76-b6b1-1b3622805c60" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2fee6238-9044-4b7f-b196-5541cad2bd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5570f692-1782-4eab-84d4-d10babe35e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2fee6238-9044-4b7f-b196-5541cad2bd88" xlink:to="loc_us-gaap_InterestRateSwapMember_5570f692-1782-4eab-84d4-d10babe35e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b2352bf8-22fa-4a4c-96db-90e45d0ee09b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9d1887bf-8a64-4fe4-b024-2b2155bf9b24" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b2352bf8-22fa-4a4c-96db-90e45d0ee09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_b48b05e2-2f74-4f16-92a1-5bfe83672b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b2352bf8-22fa-4a4c-96db-90e45d0ee09b" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_b48b05e2-2f74-4f16-92a1-5bfe83672b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_38dd22ad-6a98-4758-9116-be7482732888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b2352bf8-22fa-4a4c-96db-90e45d0ee09b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_38dd22ad-6a98-4758-9116-be7482732888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_f9fe439c-43c4-4e98-b2de-b9a400d1dd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_b2352bf8-22fa-4a4c-96db-90e45d0ee09b" xlink:to="loc_us-gaap_DerivativeLiabilities_f9fe439c-43c4-4e98-b2de-b9a400d1dd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93bc9659-12aa-4c36-9fcf-f099190bb22f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_b618c6e2-7b1c-451a-bfe9-67f79df75830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93bc9659-12aa-4c36-9fcf-f099190bb22f" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_b618c6e2-7b1c-451a-bfe9-67f79df75830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_550859e1-8690-4253-bb98-48f53fdf68c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_80793483-aec3-4a69-8e18-06eaf5e47587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_550859e1-8690-4253-bb98-48f53fdf68c3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_80793483-aec3-4a69-8e18-06eaf5e47587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4fdaf62a-32a6-4b51-9dde-29a82e7d27c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_550859e1-8690-4253-bb98-48f53fdf68c3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4fdaf62a-32a6-4b51-9dde-29a82e7d27c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6eee08d1-1ba4-47a9-aef2-ecdd5ae20cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_550859e1-8690-4253-bb98-48f53fdf68c3" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6eee08d1-1ba4-47a9-aef2-ecdd5ae20cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e2c56e62-e9de-4390-8a90-d7efc52ea2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_550859e1-8690-4253-bb98-48f53fdf68c3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e2c56e62-e9de-4390-8a90-d7efc52ea2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_8cb777cf-6da1-4359-ac8d-c4ea321649e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_550859e1-8690-4253-bb98-48f53fdf68c3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_8cb777cf-6da1-4359-ac8d-c4ea321649e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityIssuedandOutstandingShareCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb2d213a-cfb7-4020-add7-106077ceba35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_996e3996-b81c-4956-82a8-336e200bac80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb2d213a-cfb7-4020-add7-106077ceba35" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_996e3996-b81c-4956-82a8-336e200bac80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_99ee33c1-5b26-493c-bdc8-543445a21509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_996e3996-b81c-4956-82a8-336e200bac80" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_99ee33c1-5b26-493c-bdc8-543445a21509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a9c957f1-15e0-4b62-99f2-8fcd22acbd27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99ee33c1-5b26-493c-bdc8-543445a21509" xlink:to="loc_us-gaap_EquityComponentDomain_a9c957f1-15e0-4b62-99f2-8fcd22acbd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ff746c7e-4c03-429b-8200-a8a6749ff619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a9c957f1-15e0-4b62-99f2-8fcd22acbd27" xlink:to="loc_us-gaap_CommonStockMember_ff746c7e-4c03-429b-8200-a8a6749ff619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_996e3996-b81c-4956-82a8-336e200bac80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_NumberOfStockClasses_4007d499-afb4-4434-807d-aaff735cd424" xlink:href="vmd-20210930.xsd#vmd_NumberOfStockClasses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:to="loc_vmd_NumberOfStockClasses_4007d499-afb4-4434-807d-aaff735cd424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8bdaea2e-3c5c-4cc8-a3d3-9a0f266eafa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8bdaea2e-3c5c-4cc8-a3d3-9a0f266eafa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2c226f77-7dc6-4edd-86fc-1626e29415bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:to="loc_us-gaap_CommonStockSharesIssued_2c226f77-7dc6-4edd-86fc-1626e29415bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6cb06928-79af-4477-880b-8743f26ce3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_6cb06928-79af-4477-880b-8743f26ce3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_cf08806a-0e20-40dc-8cf3-b582b8bf955b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_190815e3-3a6d-4ef0-b14c-d0bd13952861" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_cf08806a-0e20-40dc-8cf3-b582b8bf955b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityStockbasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab151f2a-143c-4b85-97dc-f09c92dd9a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_41e93934-397a-4ed5-959e-6f78297e01b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab151f2a-143c-4b85-97dc-f09c92dd9a12" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_41e93934-397a-4ed5-959e-6f78297e01b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c2d43402-e712-4ac2-9512-427e65589130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_41e93934-397a-4ed5-959e-6f78297e01b4" xlink:to="loc_us-gaap_AwardTypeAxis_c2d43402-e712-4ac2-9512-427e65589130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_749a67b9-86f5-4d02-859c-184af6cab737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c2d43402-e712-4ac2-9512-427e65589130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_749a67b9-86f5-4d02-859c-184af6cab737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e43e5997-47a8-4e7c-9d8c-09e27eef0a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_749a67b9-86f5-4d02-859c-184af6cab737" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e43e5997-47a8-4e7c-9d8c-09e27eef0a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7e253239-7347-40a0-b4fc-b10a2a3b32a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_749a67b9-86f5-4d02-859c-184af6cab737" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7e253239-7347-40a0-b4fc-b10a2a3b32a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fb5e4ff3-f77a-45fa-b909-667468db31c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_41e93934-397a-4ed5-959e-6f78297e01b4" xlink:to="loc_us-gaap_PlanNameAxis_fb5e4ff3-f77a-45fa-b909-667468db31c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e09b0f01-4cd6-4884-a0ae-4a8936c04d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_fb5e4ff3-f77a-45fa-b909-667468db31c3" xlink:to="loc_us-gaap_PlanNameDomain_e09b0f01-4cd6-4884-a0ae-4a8936c04d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_OmnibusPlanMember_0226f571-740f-4baf-bbfe-bb71ff961a51" xlink:href="vmd-20210930.xsd#vmd_OmnibusPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e09b0f01-4cd6-4884-a0ae-4a8936c04d2d" xlink:to="loc_vmd_OmnibusPlanMember_0226f571-740f-4baf-bbfe-bb71ff961a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_38fd99a0-4d73-4791-8626-6a22bab2eb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_41e93934-397a-4ed5-959e-6f78297e01b4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_38fd99a0-4d73-4791-8626-6a22bab2eb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8d1baffd-36c9-43a1-93b3-639d6757112f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_38fd99a0-4d73-4791-8626-6a22bab2eb2d" xlink:to="loc_us-gaap_ClassOfStockDomain_8d1baffd-36c9-43a1-93b3-639d6757112f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a28f9eb9-1897-4d3a-a32a-eac469f7cfef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8d1baffd-36c9-43a1-93b3-639d6757112f" xlink:to="loc_us-gaap_CommonStockMember_a28f9eb9-1897-4d3a-a32a-eac469f7cfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_41e93934-397a-4ed5-959e-6f78297e01b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c68a7f2f-665f-4fb8-b851-50ff215733e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c68a7f2f-665f-4fb8-b851-50ff215733e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding_eef5d2b1-76e9-4e94-8e5c-fda1d36e6dc1" xlink:href="vmd-20210930.xsd#vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding_eef5d2b1-76e9-4e94-8e5c-fda1d36e6dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99de59e9-db28-4a38-9994-d9b246b8a326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99de59e9-db28-4a38-9994-d9b246b8a326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e9f39bd2-e74b-4839-bbf7-dcfdbd0263a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e9f39bd2-e74b-4839-bbf7-dcfdbd0263a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9ec77de3-b83f-41a3-85f6-276b852b9ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9ec77de3-b83f-41a3-85f6-276b852b9ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_23c39cbb-906e-4d25-9964-ed25f192cd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_23c39cbb-906e-4d25-9964-ed25f192cd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_517a5048-0aec-4dc9-83ed-7f07e7d46af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_517a5048-0aec-4dc9-83ed-7f07e7d46af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0f24dd65-ae7d-4501-87a7-4014b09a3b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c1fae1a-1b8c-4c5f-9e89-02c3c53cb457" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_0f24dd65-ae7d-4501-87a7-4014b09a3b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityOptionsStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aef86abd-c509-48e2-bb1e-32d570ae1a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_01ca7529-bc18-4247-bdcd-fe64336b1756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aef86abd-c509-48e2-bb1e-32d570ae1a7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_01ca7529-bc18-4247-bdcd-fe64336b1756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dbe99bdd-f347-44c4-9d87-d09bcdd58114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_01ca7529-bc18-4247-bdcd-fe64336b1756" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dbe99bdd-f347-44c4-9d87-d09bcdd58114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3f0c06f0-c943-4470-aa57-fc09f166b472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_01ca7529-bc18-4247-bdcd-fe64336b1756" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3f0c06f0-c943-4470-aa57-fc09f166b472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_05666686-38bc-4ab4-b6c9-d7fe8d77c1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_01ca7529-bc18-4247-bdcd-fe64336b1756" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_05666686-38bc-4ab4-b6c9-d7fe8d77c1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ac4e3cd7-843f-4e3a-8b4c-90f419043555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_01ca7529-bc18-4247-bdcd-fe64336b1756" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ac4e3cd7-843f-4e3a-8b4c-90f419043555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ca66849-868d-479a-9b47-cc53d9c8142e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_01ca7529-bc18-4247-bdcd-fe64336b1756" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ca66849-868d-479a-9b47-cc53d9c8142e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df1651f2-5768-4924-80f8-93fd36c33ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aef86abd-c509-48e2-bb1e-32d570ae1a7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df1651f2-5768-4924-80f8-93fd36c33ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3e594a9c-34a5-4c0b-ae99-58b79ea81322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df1651f2-5768-4924-80f8-93fd36c33ba2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3e594a9c-34a5-4c0b-ae99-58b79ea81322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_aa886f04-69e4-4e17-b83f-4635f91e277b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df1651f2-5768-4924-80f8-93fd36c33ba2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_aa886f04-69e4-4e17-b83f-4635f91e277b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e9c09242-1ba1-464b-9846-863f8d110dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df1651f2-5768-4924-80f8-93fd36c33ba2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e9c09242-1ba1-464b-9846-863f8d110dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c57e23dd-260d-4497-b1b0-05cb76d8faa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df1651f2-5768-4924-80f8-93fd36c33ba2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c57e23dd-260d-4497-b1b0-05cb76d8faa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ca4aeabe-d22a-4ba5-bc31-b6591faf7478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_df1651f2-5768-4924-80f8-93fd36c33ba2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ca4aeabe-d22a-4ba5-bc31-b6591faf7478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3a6472dd-1407-4f3f-b949-070ceddf9d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aef86abd-c509-48e2-bb1e-32d570ae1a7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3a6472dd-1407-4f3f-b949-070ceddf9d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f0d62810-acc4-4dad-b663-4ec9b6a84ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3a6472dd-1407-4f3f-b949-070ceddf9d8c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f0d62810-acc4-4dad-b663-4ec9b6a84ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_3d29794a-196f-4771-908f-ed9616275030" xlink:href="vmd-20210930.xsd#vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aef86abd-c509-48e2-bb1e-32d570ae1a7e" xlink:to="loc_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_3d29794a-196f-4771-908f-ed9616275030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0c3ad96a-dc06-4668-b032-1f4fd79ff046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract_3d29794a-196f-4771-908f-ed9616275030" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0c3ad96a-dc06-4668-b032-1f4fd79ff046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityOptionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3327db83-51d1-4416-87b8-e18e855cc7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c477baa0-c940-42c8-b61c-d313b26169d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3327db83-51d1-4416-87b8-e18e855cc7cf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c477baa0-c940-42c8-b61c-d313b26169d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9e0d4d73-5473-44b6-82aa-000d4bf6e31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c477baa0-c940-42c8-b61c-d313b26169d4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9e0d4d73-5473-44b6-82aa-000d4bf6e31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6bb861ac-aea3-4662-a125-840014728486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9e0d4d73-5473-44b6-82aa-000d4bf6e31a" xlink:to="loc_us-gaap_ClassOfStockDomain_6bb861ac-aea3-4662-a125-840014728486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d48b43f7-8ffe-42e1-8ba6-1a20a02b165e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6bb861ac-aea3-4662-a125-840014728486" xlink:to="loc_us-gaap_CommonStockMember_d48b43f7-8ffe-42e1-8ba6-1a20a02b165e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c477baa0-c940-42c8-b61c-d313b26169d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_81959f3a-d94a-46a9-b5b0-3ecfbe51aa69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_81959f3a-d94a-46a9-b5b0-3ecfbe51aa69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_866a2256-b367-4e30-8a27-13c12be64f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_866a2256-b367-4e30-8a27-13c12be64f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a3705ccf-c9ef-426a-9872-414e4bee0bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a3705ccf-c9ef-426a-9872-414e4bee0bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_71b0009a-50a7-41a5-bdb7-b1796573b245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_71b0009a-50a7-41a5-bdb7-b1796573b245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1c69ad3c-af5a-4e2b-b099-7509258b4d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1c69ad3c-af5a-4e2b-b099-7509258b4d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7a17c59-d02f-46d7-b45b-ae04083a6785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_365c7197-a790-4878-aa15-76fce279eaae" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a7a17c59-d02f-46d7-b45b-ae04083a6785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityOptionsFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eecdaa7d-28fa-4e71-ad23-87e02b49a61f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_295c6f46-87fb-4fe3-8df9-d9650215ef88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eecdaa7d-28fa-4e71-ad23-87e02b49a61f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_295c6f46-87fb-4fe3-8df9-d9650215ef88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0aae8f10-11ba-4f96-8d20-7a800c2393e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_295c6f46-87fb-4fe3-8df9-d9650215ef88" xlink:to="loc_us-gaap_AwardTypeAxis_0aae8f10-11ba-4f96-8d20-7a800c2393e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dcd9a986-5fcb-4467-992e-f964602a9fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0aae8f10-11ba-4f96-8d20-7a800c2393e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dcd9a986-5fcb-4467-992e-f964602a9fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_24fe0ee9-a522-47a0-b4df-0aba1ea52af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dcd9a986-5fcb-4467-992e-f964602a9fdf" xlink:to="loc_us-gaap_EmployeeStockOptionMember_24fe0ee9-a522-47a0-b4df-0aba1ea52af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_01006728-c9a0-4c41-9da3-74333be6a1c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_295c6f46-87fb-4fe3-8df9-d9650215ef88" xlink:to="loc_srt_RangeAxis_01006728-c9a0-4c41-9da3-74333be6a1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a30d973c-2766-4fa1-a400-17d3fb071e9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_01006728-c9a0-4c41-9da3-74333be6a1c9" xlink:to="loc_srt_RangeMember_a30d973c-2766-4fa1-a400-17d3fb071e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dfacc38f-9bd9-480d-afdd-4f9fc9760333" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a30d973c-2766-4fa1-a400-17d3fb071e9d" xlink:to="loc_srt_MinimumMember_dfacc38f-9bd9-480d-afdd-4f9fc9760333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8375b4f6-b86a-4992-b599-6e3bd37d05f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a30d973c-2766-4fa1-a400-17d3fb071e9d" xlink:to="loc_srt_MaximumMember_8375b4f6-b86a-4992-b599-6e3bd37d05f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_295c6f46-87fb-4fe3-8df9-d9650215ef88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_47276d40-20b1-444d-9bcd-93858e0a160e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_47276d40-20b1-444d-9bcd-93858e0a160e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_db2bec6c-8b83-44b2-a273-451e9d2f5d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_db2bec6c-8b83-44b2-a273-451e9d2f5d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dc869d78-8b54-4362-9760-f853e29c04e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dc869d78-8b54-4362-9760-f853e29c04e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_86d321b8-3cf1-494c-b891-ae28667f0156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_86d321b8-3cf1-494c-b891-ae28667f0156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fadcb719-7bfa-4983-be1f-9864bf5b855f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fadcb719-7bfa-4983-be1f-9864bf5b855f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_305feb29-9953-4350-800d-3749164156e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852f8886-c243-4a65-91fb-a5d35eede854" xlink:to="loc_us-gaap_SharePrice_305feb29-9953-4350-800d-3749164156e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c80a3475-9f58-4a99-bc4c-635f85f5bc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_910286cc-3a31-4c82-b1b2-c38aa19e4eed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c80a3475-9f58-4a99-bc4c-635f85f5bc3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_910286cc-3a31-4c82-b1b2-c38aa19e4eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b1143fec-b46b-4e66-8b89-041e834286d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_910286cc-3a31-4c82-b1b2-c38aa19e4eed" xlink:to="loc_us-gaap_AwardTypeAxis_b1143fec-b46b-4e66-8b89-041e834286d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31c95e53-555a-4237-958a-7b6789b9da43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b1143fec-b46b-4e66-8b89-041e834286d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31c95e53-555a-4237-958a-7b6789b9da43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_79ba794b-f14f-416a-b5bc-2abbd9c0ffd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_31c95e53-555a-4237-958a-7b6789b9da43" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_79ba794b-f14f-416a-b5bc-2abbd9c0ffd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9435f3ad-7f1b-4389-99a4-0709b19dc627" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_910286cc-3a31-4c82-b1b2-c38aa19e4eed" xlink:to="loc_srt_RangeAxis_9435f3ad-7f1b-4389-99a4-0709b19dc627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50a196be-04d7-4b58-88fb-9682b9a2b30e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9435f3ad-7f1b-4389-99a4-0709b19dc627" xlink:to="loc_srt_RangeMember_50a196be-04d7-4b58-88fb-9682b9a2b30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_706a4aeb-79db-4726-90eb-63ec38651659" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50a196be-04d7-4b58-88fb-9682b9a2b30e" xlink:to="loc_srt_MinimumMember_706a4aeb-79db-4726-90eb-63ec38651659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd772213-6fb7-46d2-ba27-95972ba70847" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50a196be-04d7-4b58-88fb-9682b9a2b30e" xlink:to="loc_srt_MaximumMember_bd772213-6fb7-46d2-ba27-95972ba70847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_910286cc-3a31-4c82-b1b2-c38aa19e4eed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c032553e-6d31-4c72-81f1-6d6d91c30953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c032553e-6d31-4c72-81f1-6d6d91c30953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e44cf35-ad3f-41e5-81bd-e0b4c1f7b134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e44cf35-ad3f-41e5-81bd-e0b4c1f7b134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4570dbb7-e51e-458a-af37-2f352336e408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e44cf35-ad3f-41e5-81bd-e0b4c1f7b134" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4570dbb7-e51e-458a-af37-2f352336e408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2d5f4928-2a2c-4c7b-b86e-95a359869202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e44cf35-ad3f-41e5-81bd-e0b4c1f7b134" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2d5f4928-2a2c-4c7b-b86e-95a359869202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4b185bab-6827-4064-937a-4a6abf770308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e44cf35-ad3f-41e5-81bd-e0b4c1f7b134" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4b185bab-6827-4064-937a-4a6abf770308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1ded9648-30a1-4500-9d02-93a883f1a96f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e44cf35-ad3f-41e5-81bd-e0b4c1f7b134" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1ded9648-30a1-4500-9d02-93a883f1a96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4aab10b1-73dc-48f2-848f-ba7b5b583ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e44cf35-ad3f-41e5-81bd-e0b4c1f7b134" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4aab10b1-73dc-48f2-848f-ba7b5b583ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_147c0d02-1378-4fcb-ad80-1fe3b139a2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_147c0d02-1378-4fcb-ad80-1fe3b139a2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_45e92b72-a655-4e0f-8dfc-82661c0218ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_147c0d02-1378-4fcb-ad80-1fe3b139a2e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_45e92b72-a655-4e0f-8dfc-82661c0218ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8cb83911-e80c-4748-a7de-ad09c8ca1514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_147c0d02-1378-4fcb-ad80-1fe3b139a2e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8cb83911-e80c-4748-a7de-ad09c8ca1514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6f3d1259-5bcd-4a78-8f0e-ced089d09ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_147c0d02-1378-4fcb-ad80-1fe3b139a2e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6f3d1259-5bcd-4a78-8f0e-ced089d09ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_dbbdbe7f-0eb6-42a5-bf62-88c1858f36bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_147c0d02-1378-4fcb-ad80-1fe3b139a2e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_dbbdbe7f-0eb6-42a5-bf62-88c1858f36bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fdf134c7-d4c4-42b5-b220-cd2870a7bfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_147c0d02-1378-4fcb-ad80-1fe3b139a2e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fdf134c7-d4c4-42b5-b220-cd2870a7bfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e4343a56-62e6-4180-b6d3-895c71c0a350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e4343a56-62e6-4180-b6d3-895c71c0a350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_97d95cc9-e933-41d9-ab36-f0207b5916a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e4343a56-62e6-4180-b6d3-895c71c0a350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_97d95cc9-e933-41d9-ab36-f0207b5916a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_8361415a-7bad-4c9b-b227-8359729a84b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b3d85c4-835c-46d6-99ea-833e541cdb53" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_8361415a-7bad-4c9b-b227-8359729a84b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_aaee9f7f-7d81-4d75-af6a-21f25c2677a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_8361415a-7bad-4c9b-b227-8359729a84b3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_aaee9f7f-7d81-4d75-af6a-21f25c2677a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#ShareholdersEquityPhantomShareUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d6d1e41-35c7-4da0-9c8f-7af0bf2356e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8ab92fa-98dd-46fa-b403-492c06927d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d6d1e41-35c7-4da0-9c8f-7af0bf2356e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8ab92fa-98dd-46fa-b403-492c06927d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_995bdce2-7562-4490-9a2f-24fdecacad93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8ab92fa-98dd-46fa-b403-492c06927d6c" xlink:to="loc_us-gaap_AwardTypeAxis_995bdce2-7562-4490-9a2f-24fdecacad93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bebe3741-c1e5-4f55-b7bc-10310a7bc192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_995bdce2-7562-4490-9a2f-24fdecacad93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bebe3741-c1e5-4f55-b7bc-10310a7bc192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PhantomShareUnitsPSUsMember_a1940453-51ab-45fd-80c6-1c78b49d8ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PhantomShareUnitsPSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bebe3741-c1e5-4f55-b7bc-10310a7bc192" xlink:to="loc_us-gaap_PhantomShareUnitsPSUsMember_a1940453-51ab-45fd-80c6-1c78b49d8ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5ea63eda-0d6d-402b-b579-2c406232b10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8ab92fa-98dd-46fa-b403-492c06927d6c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5ea63eda-0d6d-402b-b579-2c406232b10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7378afc1-33be-4e96-84fe-6d9903402d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5ea63eda-0d6d-402b-b579-2c406232b10a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7378afc1-33be-4e96-84fe-6d9903402d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_80373cfa-6757-4426-a92d-e635b5ce715f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7378afc1-33be-4e96-84fe-6d9903402d75" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_80373cfa-6757-4426-a92d-e635b5ce715f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8ab92fa-98dd-46fa-b403-492c06927d6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f1744f29-e1da-42ec-9f08-bb4ca33dc471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f1744f29-e1da-42ec-9f08-bb4ca33dc471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f62aa813-5a03-4509-9991-b176edba64af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f62aa813-5a03-4509-9991-b176edba64af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_526e446c-71db-4585-b87c-608e258a7c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f62aa813-5a03-4509-9991-b176edba64af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_526e446c-71db-4585-b87c-608e258a7c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cd0c99c4-0e78-44c6-a51f-c950c833c313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f62aa813-5a03-4509-9991-b176edba64af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cd0c99c4-0e78-44c6-a51f-c950c833c313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ee1ce996-d8a7-471e-a9d3-9b250382f850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f62aa813-5a03-4509-9991-b176edba64af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ee1ce996-d8a7-471e-a9d3-9b250382f850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_264f501c-560b-46e3-bd15-d1a1e42e9527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f62aa813-5a03-4509-9991-b176edba64af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_264f501c-560b-46e3-bd15-d1a1e42e9527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f8f3a537-083a-41ef-aacf-1279e7d2a586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f62aa813-5a03-4509-9991-b176edba64af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f8f3a537-083a-41ef-aacf-1279e7d2a586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_960951bc-0311-4c23-b7d5-bd9225f18793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_960951bc-0311-4c23-b7d5-bd9225f18793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_37e6d4e7-e32b-455e-95ad-ce4738c002a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_960951bc-0311-4c23-b7d5-bd9225f18793" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_37e6d4e7-e32b-455e-95ad-ce4738c002a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued_84c629bb-2976-40f9-af99-679e26eb7c8c" xlink:href="vmd-20210930.xsd#vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_960951bc-0311-4c23-b7d5-bd9225f18793" xlink:to="loc_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued_84c629bb-2976-40f9-af99-679e26eb7c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6429c03a-fb05-47a1-a8b3-7b1cd3ccac23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_960951bc-0311-4c23-b7d5-bd9225f18793" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6429c03a-fb05-47a1-a8b3-7b1cd3ccac23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_314669c1-787f-4794-8379-f5fe89e220ab" xlink:href="vmd-20210930.xsd#vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_960951bc-0311-4c23-b7d5-bd9225f18793" xlink:to="loc_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited_314669c1-787f-4794-8379-f5fe89e220ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_f6996362-d228-4ad3-b1f7-f873fd6361dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_960951bc-0311-4c23-b7d5-bd9225f18793" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_f6996362-d228-4ad3-b1f7-f873fd6361dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_3475a6dc-27a0-43c1-a690-d3a7849ac334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_SharePrice_3475a6dc-27a0-43c1-a690-d3a7849ac334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_055bad7f-f833-44a4-b49b-a197096a2547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_055bad7f-f833-44a4-b49b-a197096a2547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_b44d4688-73f7-426e-b1a6-019518ea8601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_b44d4688-73f7-426e-b1a6-019518ea8601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_644d76d5-3ec2-4186-ae5c-b475c858e4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_644d76d5-3ec2-4186-ae5c-b475c858e4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb53282e-a750-48fa-bcf1-dc6c56500399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb53282e-a750-48fa-bcf1-dc6c56500399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1dcc9374-d360-432e-85eb-c5ffe1c1b42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9d6ff1d-e78c-4609-8422-c54b30ba10bc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_1dcc9374-d360-432e-85eb-c5ffe1c1b42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vmd-20210930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_15c7fb0c-5955-48ba-a177-e9499885fabe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e39985b8-3389-4a7f-9ad6-846c9b5d9284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_15c7fb0c-5955-48ba-a177-e9499885fabe" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e39985b8-3389-4a7f-9ad6-846c9b5d9284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75595826-cbbd-490b-bae1-05a76150d9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_333f2a3a-df30-4ea0-b45e-bdb9bc6613f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75595826-cbbd-490b-bae1-05a76150d9a0" xlink:to="loc_us-gaap_PurchaseObligation_333f2a3a-df30-4ea0-b45e-bdb9bc6613f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_db78a2b6-37e8-4dae-930d-3a92212de7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75595826-cbbd-490b-bae1-05a76150d9a0" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_db78a2b6-37e8-4dae-930d-3a92212de7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssets_d40d4016-9eab-434c-a3ac-59d82ec25161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75595826-cbbd-490b-bae1-05a76150d9a0" xlink:to="loc_us-gaap_DepositsAssets_d40d4016-9eab-434c-a3ac-59d82ec25161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5f8e3311-bb52-4c0f-a0c2-591ef1e1a680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_75595826-cbbd-490b-bae1-05a76150d9a0" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_5f8e3311-bb52-4c0f-a0c2-591ef1e1a680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/IncomeTaxes" xlink:type="simple" xlink:href="vmd-20210930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ab0821a9-8090-4958-8d1c-752ac957350d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_87e4d8e8-2430-44f7-aeee-5115e34b7c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ab0821a9-8090-4958-8d1c-752ac957350d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_87e4d8e8-2430-44f7-aeee-5115e34b7c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_633e371d-150d-4475-a5a4-b1e1d42a5db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bed8778d-bafe-4bf7-ae6c-7b61d86392df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_633e371d-150d-4475-a5a4-b1e1d42a5db7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bed8778d-bafe-4bf7-ae6c-7b61d86392df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_b021d42a-852a-46b4-8670-b09878570c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_633e371d-150d-4475-a5a4-b1e1d42a5db7" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_b021d42a-852a-46b4-8670-b09878570c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1b169b19-5ea8-450b-9ea6-599acff6594a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_633e371d-150d-4475-a5a4-b1e1d42a5db7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1b169b19-5ea8-450b-9ea6-599acff6594a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_75b35692-3951-425a-bf23-feaa82e98dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_633e371d-150d-4475-a5a4-b1e1d42a5db7" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_75b35692-3951-425a-bf23-feaa82e98dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/EarningsPerShare" xlink:type="simple" xlink:href="vmd-20210930.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7fa2bf7b-1d3a-4144-9591-6b0b13dc604b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_88b747af-e868-4485-ad5e-2aab6706f544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7fa2bf7b-1d3a-4144-9591-6b0b13dc604b" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_88b747af-e868-4485-ad5e-2aab6706f544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="vmd-20210930.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e97bdce3-9b34-4e95-a933-e1259ff4f11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4029e0c9-06ce-443f-8850-bf3a794a8be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e97bdce3-9b34-4e95-a933-e1259ff4f11d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4029e0c9-06ce-443f-8850-bf3a794a8be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.viemed.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="vmd-20210930.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.viemed.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_785361c1-d096-4c52-8f43-62512d6f06cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7f29a6d4-147c-48b7-aa3b-f2b43803fa44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_785361c1-d096-4c52-8f43-62512d6f06cf" xlink:to="loc_us-gaap_NetIncomeLoss_7f29a6d4-147c-48b7-aa3b-f2b43803fa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a481abd1-66af-4aa3-bc5a-5cc01393e1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_785361c1-d096-4c52-8f43-62512d6f06cf" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a481abd1-66af-4aa3-bc5a-5cc01393e1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ecb7ce27-b45d-4889-9d84-4554cfa74427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a481abd1-66af-4aa3-bc5a-5cc01393e1c4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ecb7ce27-b45d-4889-9d84-4554cfa74427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_996b002f-f7b9-4efa-82cb-c14dbe814f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_a481abd1-66af-4aa3-bc5a-5cc01393e1c4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_996b002f-f7b9-4efa-82cb-c14dbe814f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_17afab74-2ef9-47f1-b884-32df139e0e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_785361c1-d096-4c52-8f43-62512d6f06cf" xlink:to="loc_us-gaap_EarningsPerShareBasic_17afab74-2ef9-47f1-b884-32df139e0e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b32ed30c-9101-47eb-94c2-f1a6c3011f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_785361c1-d096-4c52-8f43-62512d6f06cf" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b32ed30c-9101-47eb-94c2-f1a6c3011f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_27815f30-c0c0-43a7-b0e3-857d3668c43c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_785361c1-d096-4c52-8f43-62512d6f06cf" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_27815f30-c0c0-43a7-b0e3-857d3668c43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_46fae80a-b503-4833-92b7-af371ded2221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_27815f30-c0c0-43a7-b0e3-857d3668c43c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_46fae80a-b503-4833-92b7-af371ded2221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d7df041a-20be-45fc-8041-13ec6c015da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_27815f30-c0c0-43a7-b0e3-857d3668c43c" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d7df041a-20be-45fc-8041-13ec6c015da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_664ba65d-b49f-4180-9bb6-b1ed4ea6f3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_27815f30-c0c0-43a7-b0e3-857d3668c43c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_664ba65d-b49f-4180-9bb6-b1ed4ea6f3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>vmd-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:vmd="http://www.viemed.com/20210930"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vmd-20210930.xsd" xlink:type="simple"/>
    <context id="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie2c55bda39934f47aafd15467ea6d0a5_I20211023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <instant>2021-10-23</instant>
        </period>
    </context>
    <context id="if18d5f0f70ef493491936ce24033c80d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i976c03ac317a4dad950efc53136ca1d4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic5d328191fd14b4b8c8177ad7a45c411_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i78f4f7423ba64e63859d8515c428592c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5ea5e57cd6a84244aa82b953943efc99_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a1ac0a3f55549f782851621e90eaa7c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i90d795f6913c410caf28a7874f377029_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iae414ee27046452e85105a8bd614cf93_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i46db418aa76540aca2336dc096a0f9ed_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icde10966330448159a62ea1562b7a40c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icf2dfa8d264844e19a4b600fd9dd036a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i46dde1ac351f45b3905daa2f81146e8f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i51b7b504524e4d5abf1313a033b40975_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6710f81bfc0f404287d6aa6655470fdb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5e6a845ad54e4c62815896f2932bbbd3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic98b72a5b163495eb502663ae5631ff3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5be2a171f9354e10b04c4107daa2107f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0917a6724e5d4d2d84ae957241dc31d2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6486b80960f04e1daccfe12d493f4edd_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i69698187989a40bc91ce9b1b21ee1349_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i02af3a5a2bdd4b6786b29f8291d27eaa_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i15c5bb821fbb4572a29dd47fbc926156_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4dcf0bfe379141e99b6c299ca2382485_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5b6e39b815a0481b81048a6daf6dbe38_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i32a8db59831844cf84a2c1297bb57c33_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i041aeccc8fca4dcbbfff6f4937474eaf_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id9919bd0cd9a414385929c20caf931e1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9b284b8a81064ddb96d6d70d6e5a89c1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifc0e465557324a2ea8388615a3a390a7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4112591d4ceb45bb9e69695b1b461a72_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic33d050b9e874098924fdcfa31a8dad5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i46d77374c8874d41b3947cf0b29e4b5e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i169b12543b7a4693955a72d78e570320_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9a8950ebaa6d4023b4633983016fd884_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0e735857f255494fa3f0fdeb61129073_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icbd4539b888445aaa4a9f2e282cd287f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i697f499345304f75ba0a1a2f279da745_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d31ca92c88e48a9abe359674915ac36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9624c2e32e014ac3bacfe359b066e658_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia74bb5981805471fbf83349d5b020f16_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5f43ebadddca443ab125057332efd25d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4a781f027e5f4955901d37f1b4f38ded_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i464b82b483584d00a1b94e3674ba102f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib19f6e172d9b49cd9b5d8614f40a0e58_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id993d57472914822885303d1805d867f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5a63aa35131e40bda35f8dedfa80bb16_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i78c9f6db5b0d482a98e9ca413932fb50_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i25c503eebf774a2abe26edc4ed510527_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i127e3aaec83d4f6d8f742e5114d5812c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6e4a3b13e1894054b380ed7b2593deb5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9c396414383b4e01919749fb5c6c1282_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i68dbfdbb23794c9aa57688ded08012b4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1b3e804780104f2c92291a6aab542159_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib5b2ecbbe220415f99fcae20e610a16d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id00c330d28624a34b3fb015d48c87224_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i820eda4de0134410bc7323aa4f2359aa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1a46a17ce83245f7bb8b1baf56327400_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4dd7126df3044d39a084ec7916656b51_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0d2719e7ac624519adafa787168afc4c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibfad155c822f4964b47061c31968d980_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8237e783d5184295a58fc1aa28006024_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7426e08cc52b45f197ca6891d552801b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i24e84fd5360f4fd385f42eb20ba331d9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i02d706f98718409cb5564654fd53deb2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac9ff3e2056a4a5f880103fc4356cd36_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1f84494dae4e4eb7bb67d17f473a7c64_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4e1a9a3cfd8e4e82bc8295ec950c8daa_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i86b274e0f2d945cebc379d707e4f5ea8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9789ed0b93954ee49baa21647f388ef5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa9d483dc10645cbb1e0794af9dc1645_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaeed513b2882441a875dcc01fbc0a501_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareAndMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i68ea450f7c474538bd7b5840ef6102d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareAndMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b429d6cb7cb45b3baf15962a80dda61_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i32b248a3bb174a64841828130e70a17c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3c40bc410d694b588140148c1dc03c0a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2b7bf3629d3d438d8cc6edf60ac48177_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i94f0a3d2683f4ff392518340e25d81aa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1eca90250ea9417384566f7ebacc116b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i46dcf7ac81934f2a98f642840bdfd97c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2a4b30e32e7340a3b4b7cd8a1e99e3ae_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibcd7133079e94b92a73f8571b7906435_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareAndMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6fdb1766786c4f3480910ae7b537fb05_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareAndMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i76805b82fef445c8b00c89dac2de57b5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareAndMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i533015666e4b410e9c4fd427bd190a87_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">vmd:MedicareAndMedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icd917d51157d466ba06d77882124fe90_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:VentilatorRentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i21c590c6cb2c4aabab1faeddb85de476_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:VentilatorRentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i435b1dfb19324a3a80b71d9ec9b03097_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:VentilatorRentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5b0c9015e90944a9a17d402213f296fc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:VentilatorRentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1f1ecb80965642fbadc7233c55e2e25e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:OtherDurableMedicalEquipmentRentalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7301bcb71cfa44948e8127d480f5130c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:OtherDurableMedicalEquipmentRentalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i63e996f926c5450fa282162205bc1bea_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:OtherDurableMedicalEquipmentRentalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idc18131a88214a2a81b395db3505d107_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:OtherDurableMedicalEquipmentRentalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3e78c9cea09846458e3dc27631212986_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:EquipmentSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7fc6492490bc4b1490392b2ed8be8db2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:EquipmentSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibc9421ac4a184e8d91a81e460d2113cc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:EquipmentSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff19a29d6c2c4522a4f392e635400390_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:EquipmentSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id8727827e5c84f4fa96f89fff0b8273c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:COVID19ResponseSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i768c9291994346aab84e8a3706141a9e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:COVID19ResponseSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iecce218d389d406eb3310f56da83c06e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:COVID19ResponseSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i36805497dabe4b1ca576fc7081dd4b66_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vmd:COVID19ResponseSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iac0999e7702345499410c35dc62978eb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06a4c357dacb453faeda00f5a03c85fd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i69397aa140894aa59c5c17529168578a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2f25b5934b1c4af683335208edd0f7bf_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i156a988ddacc42c782d87dff13bbeafa_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vmd:EquipmentMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6ff889a5f20c48f0b14d11a61f24192a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vmd:EquipmentMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2fa701e0a3e54a9b9dd36ecc85c2307d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vmd:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i79d9b33a1c5b4522a3fc544ec67f806d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vmd:FurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6b0c208bb684b35bbbd15d7eca58b2b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ied68468793ac4161b8131a57412fe183_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff704998475b4b84afa049d983871456_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i08badebcad9a46b2b8e8bfe2be733945_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53f44e1e3cce49638ad0ef4800be09eb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i19004823fe6d4d70b445becfaf7cf907_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71dae52fc95540f0af34167cf33d9206_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i90c97c3db0d745e2802b30d356846aa8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if94ef301d7e04a16834b80d74e605bda_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vmd:AssetsHeldUnderFinanceLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3ad38a4d9ca54a5080a263d8110efa86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vmd:AssetsHeldUnderFinanceLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i87fcc673b3034eaa9412181d84c0c71e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia2c1e065140c48f584cc31eda13a9cc8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i81a15ff7f25b45068f37929013eedd30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62a32ca8e15648e9b1241a1aae489574_I20190530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vmd:BuildingTermNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-30</instant>
        </period>
    </context>
    <context id="i9e7304b41d654a3d881976535714777c_D20190530-20190530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vmd:BuildingTermNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-30</startDate>
            <endDate>2019-05-30</endDate>
        </period>
    </context>
    <context id="id0c674c148fc429ca571bcce37d330e5_I20190530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vmd:BuildingTermNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-30</instant>
        </period>
    </context>
    <context id="i95649eeb9b3f4027bc486bde62cc4ae2_I20190919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vmd:TermNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-19</instant>
        </period>
    </context>
    <context id="id3c6f22c80984ffcb2872cd478bf4368_D20191019-20191019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vmd:TermNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-19</startDate>
            <endDate>2019-10-19</endDate>
        </period>
    </context>
    <context id="ie603f4248e314cdf811e9ec8560c574f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1ee66bd47ddd42ec90cd24f18d4e553f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5485b5cf5d2b4b92a5935928e69064c0_I20150801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vmd:MonthlyRentalPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-01</instant>
        </period>
    </context>
    <context id="iffa3aec0aba44dc4bdc7a429c06c397f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vmd:MonthlyRentalPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic289ae73a55a46dfbf14b45d633afa0f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vmd:MonthlyRentalPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3279b51ac3584bafbc99103f6f86c88e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vmd:MonthlyRentalPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib14997b1010a40869c680e8e635ea4cd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vmd:MonthlyRentalPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8abf6fe7c8484bdcb2308cea38f75932_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0b195c7493e8424bb8fd5536067a85e2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idea4ca441e78494680787bbcd4931142_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2dbc8fd191ad4330a8f453ba42571847_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic76538552bd94126a41545b7ed1db49a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i09ac0c6a09264cc5954537a0acda8d17_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i94711e3a71c045bba46f486d3bd974f0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i336da365772c4ac388b46c52653f0063_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibb901eb8035149c1915fc1b2307e3203_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1ca70504217e48bf8c74635b2513864a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i51c8148032c74773b49b36310c78a073_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic8854bc148dc4d52b425355b31c2508a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1090d32a5c2b4309b916e12b4c123edc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ef9ec490070462eb08089125148bc55_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbca660f93914f07ace63ccfd0a4e058_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i266900fa2c164d91a01dddf36477fe2e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibcb6a65153dd4f75bba69cc5b394f676_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00967b47876c44cd9989e4b0f712f2bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3bfc5ae6e62482f9bed49fbcbfabbbe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6da69231063840b48f20fac3ea629cd6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b09cd700c71469e82f19274c7204713_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8eb813583e1d404cb010b4516417789f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb8b9626315448338619b019df225197_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec098e30f68048118c3feaeee0ec6ada_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93444cef350340c49a0041603bff9d22_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib6898be82ef3450d8af8019abc1d1fb6_I20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vmd:OmnibusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="id8114bd65eb746a5b3aaeaae80a4533d_D20200611-20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vmd:OmnibusPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="i0d0af2de6c674c96b220f46c78c9e9ba_I20200611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vmd:OmnibusPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="id2dbd335dfd64d78885f580dba8cb8ba_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iaa0187ebcaed44679c75f56be10857e9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia1310db462e54e89b2b94af7bdd21af5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i795dccfd9203404ba393cb88b8244587_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3036198797724f58bf6c7bf4265403b6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9dedb3f8a3514cc5a585e7453a724c8d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibe99e45d98d34bfe97e7b979e75c259b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i92da22dc12174d0da0397780472a1fbc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7697ee5e2a4842a0b54ef6b98b72541f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i68e96bd771d5468da80ad750d5f5c11f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i88bbd8e84fbf41e09eac6d65db435276_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia17494c399214eda9df7f117f9437b96_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iffd0c2762d894ddb8c72a023745c0b80_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iad5f0e1d7d4d457f82377ac5c1601912_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1afcee0f652943f8aad16dfbf102e536_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib2873c72b9da49babb2eb0a4aa374ba8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iecdcfc455bed4a3ab837da5d7d3c93e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefa3109898274438af4768a1e85e1bab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i44ffc467ff8a4229b2d74de1d78d1680_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a314a6d360248d9a6c6a44fcd3abb90_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5753dc4d89ed4578addb8f58e199c604_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4044ca35c71f4191b7fb20e6bf8ad931_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i94ccb4b7c871492288b371e698ff505e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie7eabec862824cb8beb06ebf1b6d9770_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic6b1cbcf841f4955b15df2767b15477a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PhantomShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i118bddcb0f0f4367a8aef1f25a41b550_D20201228-20201228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <startDate>2020-12-28</startDate>
            <endDate>2020-12-28</endDate>
        </period>
    </context>
    <context id="i6a5ccd697db64231a87cd517cfa2cfba_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001729149</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="state">
        <measure>vmd:state</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="interestrateswap">
        <measure>vmd:interestRateSwap</measure>
    </unit>
    <unit id="classofstock">
        <measure>vmd:classOfStock</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180L2ZyYWc6YjQ5ODc5OGM2NThjNDBmODkzYmQ4MTE1OWIxNDYzMDUvdGFibGU6NGYzYmE1NTEyOTE2NDUzNzg0NzEwOTJjOTg2YjA3YmEvdGFibGVyYW5nZTo0ZjNiYTU1MTI5MTY0NTM3ODQ3MTA5MmM5ODZiMDdiYV8wLTEtMS0xLTE_1dfaf4ae-1a3f-498f-b1ad-f38a602f53a7">0001729149</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180L2ZyYWc6YjQ5ODc5OGM2NThjNDBmODkzYmQ4MTE1OWIxNDYzMDUvdGFibGU6NGYzYmE1NTEyOTE2NDUzNzg0NzEwOTJjOTg2YjA3YmEvdGFibGVyYW5nZTo0ZjNiYTU1MTI5MTY0NTM3ODQ3MTA5MmM5ODZiMDdiYV8xLTEtMS0xLTE_632b1c4b-087d-44e5-b2f5-d933b020dfb1">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180L2ZyYWc6YjQ5ODc5OGM2NThjNDBmODkzYmQ4MTE1OWIxNDYzMDUvdGFibGU6NGYzYmE1NTEyOTE2NDUzNzg0NzEwOTJjOTg2YjA3YmEvdGFibGVyYW5nZTo0ZjNiYTU1MTI5MTY0NTM3ODQ3MTA5MmM5ODZiMDdiYV8yLTEtMS0xLTE_ae929808-274a-4995-b116-8bb30400a0db">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180L2ZyYWc6YjQ5ODc5OGM2NThjNDBmODkzYmQ4MTE1OWIxNDYzMDUvdGFibGU6NGYzYmE1NTEyOTE2NDUzNzg0NzEwOTJjOTg2YjA3YmEvdGFibGVyYW5nZTo0ZjNiYTU1MTI5MTY0NTM3ODQ3MTA5MmM5ODZiMDdiYV8zLTEtMS0xLTE_f3094da3-b736-4cf5-b5b1-65393a7b3bfa">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180L2ZyYWc6YjQ5ODc5OGM2NThjNDBmODkzYmQ4MTE1OWIxNDYzMDUvdGV4dHJlZ2lvbjpiNDk4Nzk4YzY1OGM0MGY4OTNiZDgxMTU5YjE0NjMwNV80NA_a81ac938-390b-49b6-b824-cdc4f0f63d5b">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1afcee0f652943f8aad16dfbf102e536_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDIzNw_3068a39c-9f5a-4e15-9fea-67728d70b3a5">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1afcee0f652943f8aad16dfbf102e536_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDM5ODA0NjUxODUwNg_2c114217-6a38-4569-b2f7-e925d2af2d45">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQ1_dcf68893-4e4d-4ce7-9b95-405dd7629fa9">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OTM1ZDVkZWQxNmYxNDQ5Y2I3MDk3NzUzYTNhOTEyNDAvdGFibGVyYW5nZTo5MzVkNWRlZDE2ZjE0NDljYjcwOTc3NTNhM2E5MTI0MF8wLTAtMS0xLTE_1f58c8e1-c919-4d0b-9fcb-61b2507ec201">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xMjA_6343cee6-6744-4365-a8f5-f321eb30bbde">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6ZjdiYTVmODQxMmFiNGE3MGI3ZWMzZThlYjkzOGRjOWYvdGFibGVyYW5nZTpmN2JhNWY4NDEyYWI0YTcwYjdlYzNlOGViOTM4ZGM5Zl8wLTAtMS0xLTE_12846a22-4353-462c-b50d-7010bc5cfd6d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQ2_4491c9d1-7589-4a56-a929-b65482905ae9">001-38973</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQy_a1de1cec-ca64-4999-bc65-bd61ce9ac400">Viemed Healthcare, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF8wLTAtMS0xLTEvdGV4dHJlZ2lvbjozNjY2NTM1N2M1NTg0OGEwOGRlOTkzYjZmYmRiNDJkZV8yMg_f0a44d46-46c6-4f96-aabe-8787f4b71128">Z4</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF8zLTEtMS0xLTEvdGV4dHJlZ2lvbjphYzY2NGY5OTI0ZmE0NzczYmEyZTg2YzE5MGZkZDhlYl80_95fb36ef-8606-4580-84be-e939ffcaed21">625 E. Kaliste Saloom Rd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF8zLTEtMS0xLTEvdGV4dHJlZ2lvbjphYzY2NGY5OTI0ZmE0NzczYmEyZTg2YzE5MGZkZDhlYl83_8b617f15-0512-4206-8eeb-5920ef15161f">Lafayette</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF8zLTEtMS0xLTEvdGV4dHJlZ2lvbjphYzY2NGY5OTI0ZmE0NzczYmEyZTg2YzE5MGZkZDhlYl8xMQ_f52e00c2-27a6-4de3-9b34-797d1fd8dac6">LA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF8zLTEtMS0xLTEvdGV4dHJlZ2lvbjphYzY2NGY5OTI0ZmE0NzczYmEyZTg2YzE5MGZkZDhlYl8xNA_dd276a6f-2e67-4cbf-af86-04ec2091924f">70508</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF82LTEtMS0xLTEvdGV4dHJlZ2lvbjphYTYzZDMwNTA0ODg0MjZkODUxMGQwYjQwMTI2YWFiNF81_bc49388c-196a-49ab-b352-2f8c3fe5784d">337</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6OWUyMDJiMTFjYmI4NDg3YWJjZmQ5NGE2YmU4MGMyNzgvdGFibGVyYW5nZTo5ZTIwMmIxMWNiYjg0ODdhYmNmZDk0YTZiZTgwYzI3OF82LTEtMS0xLTEvdGV4dHJlZ2lvbjphYTYzZDMwNTA0ODg0MjZkODUxMGQwYjQwMTI2YWFiNF85_2b9dd0d1-ee8c-4d56-a6a4-4e64e8f15a7e">504-3802</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6NTg2ZDUzZGRmOGZlNGY5Zjg1MTk1OWFjZDUxZjcwOWMvdGFibGVyYW5nZTo1ODZkNTNkZGY4ZmU0ZjlmODUxOTU5YWNkNTFmNzA5Y18yLTAtMS0xLTE_13fc080f-8892-49d7-bdfd-ed15b247c382">Common Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6NTg2ZDUzZGRmOGZlNGY5Zjg1MTk1OWFjZDUxZjcwOWMvdGFibGVyYW5nZTo1ODZkNTNkZGY4ZmU0ZjlmODUxOTU5YWNkNTFmNzA5Y18yLTEtMS0xLTE_41c8c6a0-8f4e-4975-8e69-40499b739f0b">VMD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6NTg2ZDUzZGRmOGZlNGY5Zjg1MTk1OWFjZDUxZjcwOWMvdGFibGVyYW5nZTo1ODZkNTNkZGY4ZmU0ZjlmODUxOTU5YWNkNTFmNzA5Y18yLTItMS0xLTE_677f9634-dc9b-4a82-b0aa-48a757fa9d89">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQ3_31d20fee-ec70-4ee8-a6b1-e6ed31059d8d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQ4_e9a591aa-1893-4cef-8f2f-caf3c0433556">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6NzAyZGQ1NTNlYzdjNDE3MGFhNWZkZTU3NTNiZmQ1MzIvdGFibGVyYW5nZTo3MDJkZDU1M2VjN2M0MTcwYWE1ZmRlNTc1M2JmZDUzMl8wLTQtMS0xLTEvdGV4dHJlZ2lvbjpjMzA5ZTQ1YTA0MWE0MzdjYmViNGMwMTY4N2ExMTA0ZV80_c4a7ec0b-ee2d-47a2-a032-2c8db235831d">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6NzAyZGQ1NTNlYzdjNDE3MGFhNWZkZTU3NTNiZmQ1MzIvdGFibGVyYW5nZTo3MDJkZDU1M2VjN2M0MTcwYWE1ZmRlNTc1M2JmZDUzMl8wLTYtMS0xLTEvdGV4dHJlZ2lvbjoxZTdmZjk0NjFiYTM0Nzc0ODI5NWM1MDEzOGQ3M2MxOF8zMQ_16b8b117-8c0b-49b0-835a-90193e45a85c">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGFibGU6NzAyZGQ1NTNlYzdjNDE3MGFhNWZkZTU3NTNiZmQ1MzIvdGFibGVyYW5nZTo3MDJkZDU1M2VjN2M0MTcwYWE1ZmRlNTc1M2JmZDUzMl8wLTYtMS0xLTEvdGV4dHJlZ2lvbjoxZTdmZjk0NjFiYTM0Nzc0ODI5NWM1MDEzOGQ3M2MxOF81OA_d9fe3133-ba3c-4f26-afc4-4fd9b250c5a4">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQz_1fdfa471-33b8-4008-9904-1c69786971d6">false</dei:EntityExTransitionPeriod>
    <dei:EntityExTransitionPeriod
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQz_fb2c1217-4cb4-4eb1-8d51-c0e331666074">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQ0_dea7bcf3-afda-4111-8766-e8cf874c224c">false</dei:EntityShellCompany>
    <dei:EntityShellCompany
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xODQ0_eefcf185-c3ee-429f-b3c5-36e827999efc">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie2c55bda39934f47aafd15467ea6d0a5_I20211023"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xL2ZyYWc6NTJkNDc1MWU3YmE1NGNjZDhhY2RiZWFlNGI3ZDBjMTIvdGV4dHJlZ2lvbjo1MmQ0NzUxZTdiYTU0Y2NkOGFjZGJlYWU0YjdkMGMxMl8xNzk2_3b7519f4-6fd2-456a-ad7d-d0f638ebd189"
      unitRef="shares">39630446</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNi0zLTEtMS0x_1a47e05e-3270-4695-9f1c-059e552214f1"
      unitRef="usd">26867000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNi01LTEtMS0x_1ec456d7-3ea0-4534-aa96-e0e52b1c0767"
      unitRef="usd">30981000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNy0wLTEtMS0xL3RleHRyZWdpb246ODYwNTI2YjVjY2ZhNDRmZGJiMjAxMjk1OTRlODRiNDJfNjc_e2733c57-8397-47f7-a02d-e8d8617dc28c"
      unitRef="usd">7115000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNy0wLTEtMS0xL3RleHRyZWdpb246ODYwNTI2YjVjY2ZhNDRmZGJiMjAxMjk1OTRlODRiNDJfNzQ_819b7b99-ca64-41c0-b62a-85000cb05e9d"
      unitRef="usd">9013000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNy0zLTEtMS0x_0115ed63-1871-4c57-98e2-8f95d149fe70"
      unitRef="usd">12696000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNy01LTEtMS0x_b1c42d22-fb81-4698-9a73-2275c6aa89c7"
      unitRef="usd">12373000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryValuationReserves
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOC0wLTEtMS0xL3RleHRyZWdpb246ZjY1ZTViMGNjYWM5NDBlOGE4MjBlNTg0NDY0N2JhYzhfNDM_d6462bed-0c65-4998-b0d8-a38af655efa4"
      unitRef="usd">1237000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOC0wLTEtMS0xL3RleHRyZWdpb246ZjY1ZTViMGNjYWM5NDBlOGE4MjBlNTg0NDY0N2JhYzhfNTA_eacd2fe7-7768-4b3a-b91f-813a6b629614"
      unitRef="usd">1353000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOC0zLTEtMS0x_0416796f-67bd-4783-848f-b0c063a6369a"
      unitRef="usd">2622000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOC01LTEtMS0x_053fb3c0-5498-4c95-be03-7ac1131fc830"
      unitRef="usd">2310000</us-gaap:InventoryNet>
    <us-gaap:IncomeTaxesReceivable
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOS0zLTEtMS0yMTQzNQ_0f9960e1-304d-4204-8d32-1612e38efcec"
      unitRef="usd">1420000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOS01LTEtMS0yMTQzNQ_bef32be6-a8b0-42d4-9453-a292f57497e3"
      unitRef="usd">0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOS0zLTEtMS0x_e8b640b0-0d85-48c4-aeda-b2117a68d083"
      unitRef="usd">3761000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfOS01LTEtMS0x_5d7243d9-ede1-4002-9760-6a49236ae88f"
      unitRef="usd">1511000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTAtMy0xLTEtMQ_3e502aab-6666-4dea-a504-91cabbfde867"
      unitRef="usd">47366000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTAtNS0xLTEtMQ_fccedfe7-51c5-4a76-b171-e64ef922d9fd"
      unitRef="usd">47175000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTItMy0xLTEtMQ_9d554f69-ef8f-47fd-92d1-ad193c32ffea"
      unitRef="usd">59036000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTItNS0xLTEtMQ_306b42a9-be62-4682-ac49-9f5a35427c2b"
      unitRef="usd">55056000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Investments
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTMtMy0xLTEtMQ_50f9fed5-691c-4c51-a876-9250bd6de2d9"
      unitRef="usd">1942000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTMtNS0xLTEtMQ_79c2a770-99b4-4686-8e83-8e6a841cc241"
      unitRef="usd">733000</us-gaap:Investments>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTQtMy0xLTEtMQ_32e4e4ae-87e8-493a-b832-55adcfda0d80"
      unitRef="usd">6281000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTQtNS0xLTEtMQ_aa4bf731-a1a0-41a4-bf84-efbb728a3d07"
      unitRef="usd">8733000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTUtMy0xLTEtMQ_2e683939-f4c8-472b-afad-8a5189018f86"
      unitRef="usd">861000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTUtNS0xLTEtMQ_ec7523b5-c903-4aa1-9c59-2ca6767e961c"
      unitRef="usd">863000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTYtMy0xLTEtMQ_7a42f96d-cf78-40a7-86ff-29bbe70d95ab"
      unitRef="usd">68120000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTYtNS0xLTEtMQ_5679047e-3bef-402f-8f40-91990f6dbdc7"
      unitRef="usd">65385000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTgtMy0xLTEtMQ_fc853db5-4b30-4831-a527-75f1a080e89c"
      unitRef="usd">115486000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMTgtNS0xLTEtMQ_3a69a10a-e5d1-4e33-9ce7-5c301496e362"
      unitRef="usd">112560000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjItMy0xLTEtMQ_89531f58-99a2-4c26-9a03-914964e01cec"
      unitRef="usd">4734000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjItNS0xLTEtMQ_b2add5bc-e34e-4a55-8fda-728fb3e572e8"
      unitRef="usd">2096000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjMtMy0xLTEtMQ_09c6aef4-8f1b-40a7-864d-83597f1982bc"
      unitRef="usd">3795000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjMtNS0xLTEtMQ_ffee5380-7b5d-4bf7-ba11-22f749089d32"
      unitRef="usd">3409000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjQtMy0xLTEtMQ_4578f382-3faa-4579-b3da-3aabde850c0c"
      unitRef="usd">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjQtNS0xLTEtMQ_7cac1b16-0482-419f-8a56-a85ff15feb97"
      unitRef="usd">340000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjUtMy0xLTEtMQ_d1bd3775-145e-4ae6-b836-f9c764343561"
      unitRef="usd">9283000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjUtNS0xLTEtMQ_9917223e-e790-4553-b707-ee9f285120f9"
      unitRef="usd">12595000</us-gaap:AccruedLiabilitiesCurrent>
    <vmd:LeaseLiabilityCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjYtMy0xLTEtMQ_259e1ded-a4b9-4d4e-a5ad-78110c8a692c"
      unitRef="usd">481000</vmd:LeaseLiabilityCurrent>
    <vmd:LeaseLiabilityCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjYtNS0xLTEtMQ_cecd2b03-8238-4bb7-8772-6e08730af739"
      unitRef="usd">2741000</vmd:LeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjctMy0xLTEtMQ_ba1d4caf-85fc-4480-b627-3a766d1051a3"
      unitRef="usd">1906000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjctNS0xLTEtMQ_e9e741aa-143f-4446-a706-b8f9ee00f018"
      unitRef="usd">1836000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjktMy0xLTEtMQ_5cf74c34-0061-47ec-8d4e-0609f4b2063b"
      unitRef="usd">20199000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMjktNS0xLTEtMQ_b188b700-dcbb-4d93-b32a-be4703b69368"
      unitRef="usd">23017000</us-gaap:LiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzEtMy0xLTEtMQ_11bb6441-956a-4025-8bae-6954ab3c36f5"
      unitRef="usd">730000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzEtNS0xLTEtMQ_82f1e637-0bf5-4636-9a31-637f65306f7b"
      unitRef="usd">1292000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <vmd:LeaseLiabilityNoncurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzItMy0xLTEtMQ_36a4d51a-e173-497d-ab5c-201e89c7cf36"
      unitRef="usd">834000</vmd:LeaseLiabilityNoncurrent>
    <vmd:LeaseLiabilityNoncurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzItNS0xLTEtMQ_de3332e0-7245-4867-8555-da0038564a90"
      unitRef="usd">762000</vmd:LeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzMtMy0xLTEtMQ_648b76d0-96b8-4ac9-94cd-d7e97ee12a1c"
      unitRef="usd">4347000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzMtNS0xLTEtMQ_8addc88f-d2f4-4e99-a172-1c5f026877da"
      unitRef="usd">5796000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzQtMy0xLTEtMQ_ae2def11-3f0f-4e16-ac0d-0a8ad99e3f2c"
      unitRef="usd">5911000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzQtNS0xLTEtMQ_7c394369-cbb6-4387-8945-5b64576fd02d"
      unitRef="usd">7850000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzUtMy0xLTEtMQ_c2ae8615-6929-4c4a-9cf0-e4f8b63c8f13"
      unitRef="usd">26110000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzUtNS0xLTEtMQ_717dcd1d-c045-461a-a7ce-907e7945af66"
      unitRef="usd">30867000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzctMy0xLTEtMQ_d0ab40b1-13e8-43e9-85e7-0425a06757c7"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfMzctNS0xLTEtMQ_d3368304-cd09-4837-9651-fe2fb3dadce5"
      unitRef="usd">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommonStockSharesIssued
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDAtMC0xLTEtMS90ZXh0cmVnaW9uOjZjZTE0ZTc2ZjAwOTRkZmE4ZTllOWVkNGI5MDI4NDBhXzU1_23bd00c6-532a-4728-b7dd-b49095ce310d"
      unitRef="shares">39630446</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDAtMC0xLTEtMS90ZXh0cmVnaW9uOjZjZTE0ZTc2ZjAwOTRkZmE4ZTllOWVkNGI5MDI4NDBhXzU1_3c096ff8-cc3c-49af-a79e-edeb198deadf"
      unitRef="shares">39630446</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDAtMC0xLTEtMS90ZXh0cmVnaW9uOjZjZTE0ZTc2ZjAwOTRkZmE4ZTllOWVkNGI5MDI4NDBhXzYy_36b2ae3f-9a71-4760-ad27-ed0a2c420cb7"
      unitRef="shares">39185182</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDAtMC0xLTEtMS90ZXh0cmVnaW9uOjZjZTE0ZTc2ZjAwOTRkZmE4ZTllOWVkNGI5MDI4NDBhXzYy_82bb926e-a6b0-488a-a48c-cfebf2da752f"
      unitRef="shares">39185182</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDAtMy0xLTEtMQ_a3582f47-7d50-4de3-9416-f3fbaa60b8b8"
      unitRef="usd">13957000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDAtNS0xLTEtMQ_ef02065a-69e5-479f-aa49-b93bbf87f451"
      unitRef="usd">9181000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDEtMy0xLTEtMQ_94c842cc-14b1-41ec-9d70-d95c65867073"
      unitRef="usd">6501000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDEtNS0xLTEtMQ_3af540ad-b45e-4347-9117-9cbf5297bba3"
      unitRef="usd">7320000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDItMy0xLTEtMQ_e44ec6a9-f32e-4284-b6a4-a1456ab9dea3"
      unitRef="usd">-330000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDItNS0xLTEtMQ_abb0fa8a-a878-463b-8ee8-97c3b8c4849a"
      unitRef="usd">-451000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDMtMy0xLTEtMQ_f64c2845-7d85-4b5d-8a80-85d6076ae623"
      unitRef="usd">69248000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDMtNS0xLTEtMQ_c75ab8ea-743d-434a-89be-d0dc4948a0eb"
      unitRef="usd">65643000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDQtMy0xLTEtMQ_6aef7aa2-7748-4017-86dd-deb83b8aad52"
      unitRef="usd">89376000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDQtNS0xLTEtMQ_1cd4bb8f-5dca-4657-a361-e0e1b4b201a8"
      unitRef="usd">81693000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDYtMy0xLTEtMQ_ae10011d-3abc-4931-8b21-6d56d04323ef"
      unitRef="usd">115486000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xNi9mcmFnOjkzMWE4OTlhNzM2NjQ4YzdhYzYzYjQzYjY1ZTVhZTkyL3RhYmxlOjRiYmQ1YTVjZDM4YzRiMGNhYzk1MWFlMTlkMTg1OTllL3RhYmxlcmFuZ2U6NGJiZDVhNWNkMzhjNGIwY2FjOTUxYWUxOWQxODU5OWVfNDYtNS0xLTEtMQ_3514e820-e2fc-4739-8e08-1d774c0bc446"
      unitRef="usd">112560000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMi0zLTEtMS0x_7d2f5803-472c-4bfd-a484-02ea1d09b88a"
      unitRef="usd">29285000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMi01LTEtMS0x_211ee8f4-0254-411c-a065-91a9b573d508"
      unitRef="usd">33447000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMi03LTEtMS0x_92393056-f3ae-403a-8481-cfb142961e5d"
      unitRef="usd">85100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMi05LTEtMS0x_ad1771d1-e7f5-4e17-b725-87c79af19a0c"
      unitRef="usd">100107000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNC0zLTEtMS0x_41820871-8960-440b-8e95-c72f69e28808"
      unitRef="usd">10904000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNC01LTEtMS0x_d6553eca-fd46-40d0-8f34-2f7daa7fa411"
      unitRef="usd">13994000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNC03LTEtMS0x_69b2ca42-1bd7-439f-9534-1e897382ca13"
      unitRef="usd">31352000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNC05LTEtMS0x_b04f3f31-9dfd-411a-8d0f-9363f21f965a"
      unitRef="usd">39174000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNi0zLTEtMS0x_ef3dfbb3-5d2e-4599-a9ef-ab9fb5e04519"
      unitRef="usd">18381000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNi01LTEtMS0x_9b2c5471-7621-4508-8e80-ce4332fac941"
      unitRef="usd">19453000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNi03LTEtMS0x_447043f0-a99e-46b7-89c3-ed6ec3d3bb60"
      unitRef="usd">53748000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfNi05LTEtMS0x_c8a851fb-a779-494e-bbf4-55eaa0668f12"
      unitRef="usd">60933000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfOS0zLTEtMS0x_18fa4477-f279-4c2b-be63-3bf227b8ff8e"
      unitRef="usd">13260000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfOS01LTEtMS0x_8349ab31-7398-4201-81d9-bd62e02460b2"
      unitRef="usd">13550000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfOS03LTEtMS0x_2713dd3d-c8ab-4c85-bca0-243ac31eed0a"
      unitRef="usd">40653000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfOS05LTEtMS0x_61330701-8c04-4481-9299-7845139e159c"
      unitRef="usd">40555000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTAtMy0xLTEtMQ_1629ad4d-9181-4983-8d08-f2000f027f73"
      unitRef="usd">576000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTAtNS0xLTEtMQ_48861293-faa6-4319-8742-f36c8c824f1f"
      unitRef="usd">243000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTAtNy0xLTEtMQ_1681c690-d48e-48ad-936d-3e7b37eb7b3e"
      unitRef="usd">1498000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTAtOS0xLTEtMQ_70e8fab2-4828-47d2-bf7e-90e1691a22b6"
      unitRef="usd">688000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTEtMy0xLTEtMQ_29fe6c16-a0b4-47ba-bc29-12100164404c"
      unitRef="usd">1302000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTEtNS0xLTEtMQ_c80e0072-3f22-429b-b5b6-4412011fc524"
      unitRef="usd">1234000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTEtNy0xLTEtMQ_61678c09-3bfb-4716-830b-ae5d13f115bf"
      unitRef="usd">3845000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTEtOS0xLTEtMQ_0eabce7f-097e-40fe-9de1-35a585ab9de2"
      unitRef="usd">3581000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationNonproduction
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTItMy0xLTEtMQ_1c50b2ce-6cfa-4194-95ac-9dcd39870252"
      unitRef="usd">211000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTItNS0xLTEtMQ_716ad6a2-6c8d-472e-9a86-b05e2a75d95a"
      unitRef="usd">202000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTItNy0xLTEtMQ_d18299be-ca5e-4d1c-b895-eb651136bbb4"
      unitRef="usd">618000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTItOS0xLTEtMQ_808e4872-efb4-4e36-b773-5936780bd9c9"
      unitRef="usd">612000</us-gaap:DepreciationNonproduction>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTMtMy0xLTEtMQ_6b2b56ad-9066-4aae-9bbf-c2584a32a1dc"
      unitRef="usd">-145000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTMtNS0xLTEtMQ_04077bb4-6b5d-4077-b6d8-5533108cc762"
      unitRef="usd">-203000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTMtNy0xLTEtMQ_3aee66e0-26e3-4bfd-8c35-6dca2394886a"
      unitRef="usd">-304000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTMtOS0xLTEtMQ_28a78b22-b24c-4aaa-b265-0bd08998cacf"
      unitRef="usd">2424000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTQtMy0xLTEtMQ_00b897ea-b9df-47d9-8746-541cdb841e30"
      unitRef="usd">32000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTQtNS0xLTEtMQ_c3bcbc7f-c5e9-4744-a603-09bc2dcab34c"
      unitRef="usd">19000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTQtNy0xLTEtMQ_a9830296-4ced-431d-bbb5-5900516872cd"
      unitRef="usd">85000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTQtOS0xLTEtMQ_47713e0e-9ca7-4b54-a186-359a259060bd"
      unitRef="usd">3593000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTUtMy0xLTEtMQ_86022a6c-95fb-4712-a8f9-89d41d18dca0"
      unitRef="usd">2919000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTUtNS0xLTEtMQ_2e4ccfb6-016a-4320-8fe3-cd8a81286b46"
      unitRef="usd">4040000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTUtNy0xLTEtMQ_c715a2ec-3a7e-4522-ab23-a926c93e8bc1"
      unitRef="usd">6915000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTUtOS0xLTEtMQ_a0abb0f2-e751-4fb4-b327-d9380a9fc24e"
      unitRef="usd">21514000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTktMy0xLTEtMQ_1ab241cc-27c7-4f4d-8a30-649fa0ddb3dd"
      unitRef="usd">331000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTktNS0xLTEtMQ_567ea430-0516-4ed5-8621-f37007ec60d9"
      unitRef="usd">21000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTktNy0xLTEtMQ_c7f15925-de7a-4348-87a2-16ca15e47d12"
      unitRef="usd">782000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMTktOS0xLTEtMQ_90f923fb-af70-4381-ba0c-12f6cdd00bb7"
      unitRef="usd">36000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjAtMy0xLTEtMQ_92b9e64f-ca7e-4ee1-8e7e-25f390fbb6fe"
      unitRef="usd">-75000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjAtNS0xLTEtMQ_71875126-f6e5-4927-a2b9-093f1221a4d6"
      unitRef="usd">-116000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjAtNy0xLTEtMQ_fd722672-ba8d-403d-a4a9-26d463f6db10"
      unitRef="usd">-249000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjAtOS0xLTEtMQ_a43764d3-7c11-4601-907a-b8aaffd82346"
      unitRef="usd">-409000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjItMy0xLTEtMQ_d032c7dc-3ae6-44a9-916e-b51b08caacd4"
      unitRef="usd">3175000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjItNS0xLTEtMQ_426b2e9e-53ab-4fdc-91ce-af81332c277c"
      unitRef="usd">3945000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjItNy0xLTEtMQ_e444a40c-d88b-4ea0-a3d0-17ea026244bc"
      unitRef="usd">7448000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjItOS0xLTEtMQ_67001408-21ca-4d5c-9a22-071f687c5cff"
      unitRef="usd">21141000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjMtMy0xLTEtMQ_fb0fbaf1-0059-48a2-87e4-4ef434f67219"
      unitRef="usd">1386000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjMtNS0xLTEtMQ_5c2d215d-48d5-4008-86c1-9e6ac128f283"
      unitRef="usd">1141000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjMtNy0xLTEtMQ_cc1a710b-d501-4c66-aafa-cd1c18eaefe5"
      unitRef="usd">2409000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjMtOS0xLTEtMQ_36503325-5ddd-408c-b111-c11f11681cd6"
      unitRef="usd">-5318000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjUtMy0xLTEtMQ_71f94573-7792-4090-9cc9-e950cac42d6b"
      unitRef="usd">1789000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjUtNS0xLTEtMQ_72e06f0d-49fc-4dd7-aa17-ca9b77fb03f0"
      unitRef="usd">2804000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjUtNy0xLTEtMQ_18a8b21a-e990-4c48-802a-e1bb3583bd80"
      unitRef="usd">5039000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjUtOS0xLTEtMQ_50530932-3caa-4732-8669-ac159c9b5348"
      unitRef="usd">26459000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjgtMy0xLTEtMQ_4755e9e8-9d15-4e9b-aba1-82affecf4128"
      unitRef="usd">21000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjgtNS0xLTEtMQ_a1db7200-5c1f-4f7e-b670-92d626103588"
      unitRef="usd">24000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjgtNy0xLTEtMQ_511c5541-3318-4f36-83b9-2ee120afb87b"
      unitRef="usd">121000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjgtOS0xLTEtMQ_748ecaa7-a6ad-4dc5-8e25-450ea8c19b80"
      unitRef="usd">-321000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjktMy0xLTEtMQ_bcef684e-a72c-491f-9e32-ace5576e3963"
      unitRef="usd">21000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjktNS0xLTEtMQ_0f5114bf-1a0e-426f-a61e-bcdb20b72830"
      unitRef="usd">24000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjktNy0xLTEtMQ_f4edaa4f-2980-4550-a5ad-21a1fb55c177"
      unitRef="usd">121000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMjktOS0xLTEtMQ_1a78876e-d8d0-4a4d-a3ec-2722f0ac7cd9"
      unitRef="usd">-321000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzEtMy0xLTEtMQ_0d408a23-41fa-4367-a74a-20cb44575d8d"
      unitRef="usd">1810000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzEtNS0xLTEtMQ_23050498-6e7d-463a-b90f-092bae388aa5"
      unitRef="usd">2828000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzEtNy0xLTEtMQ_53db2edb-b051-425e-afcd-3ba1a302ab29"
      unitRef="usd">5160000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzEtOS0xLTEtMQ_3b077d8b-f23f-4e61-be7a-ab0e0c5f1d5a"
      unitRef="usd">26138000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzQtMy0xLTEtMQ_61c0c0ed-6205-4813-97f2-6f3d81aeadcc"
      unitRef="usdPerShare">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzQtNS0xLTEtMQ_8e14e85a-553c-48f3-b302-5c84c0ddd0f2"
      unitRef="usdPerShare">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzQtNy0xLTEtMQ_d068e064-7dde-46c3-a5f9-0ec4bcee85ce"
      unitRef="usdPerShare">0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzQtOS0xLTEtMQ_7166a582-56a8-474d-84a5-7bd22840304d"
      unitRef="usdPerShare">0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzUtMy0xLTEtMQ_32bacb46-4844-48ea-8ae2-30fc7422ad26"
      unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzUtNS0xLTEtMQ_91a45879-1ddf-40c8-a188-fa733e7c9540"
      unitRef="usdPerShare">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzUtNy0xLTEtMQ_376b3bff-f977-4ea6-8eca-89e9c3d67693"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzUtOS0xLTEtMQ_6414ba2e-dd63-4584-8e7d-1d694992456e"
      unitRef="usdPerShare">0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzgtMy0xLTEtMQ_92ebcd98-8fe7-4063-9996-34b320b23859"
      unitRef="shares">39607540</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzgtNS0xLTEtMQ_78a43e2f-2721-4d28-b0b5-dd0ff650b62c"
      unitRef="shares">39107640</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzgtNy0xLTEtMQ_c0d760f8-dde0-4e73-8139-16976014f19d"
      unitRef="shares">39442088</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzgtOS0xLTEtMQ_cf07562a-6b26-4ea3-99b2-1aab80a16383"
      unitRef="shares">38603267</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzktMy0xLTEtMQ_38be7b5c-84ed-4446-b595-1f05df7b8edb"
      unitRef="shares">40659353</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzktNS0xLTEtMQ_25a2547d-5b55-4e50-9922-3eae04aca0ca"
      unitRef="shares">41155668</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzktNy0xLTEtMQ_95990a10-5fa6-4607-8c97-61cfa1417da9"
      unitRef="shares">40716747</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18xOS9mcmFnOjZjMDRjODc0Y2FjMTRjMDQ5OWJiOWY4NGUwODE5NTEyL3RhYmxlOmRiMDQ3MDhhNDVlYjRhODk4NDQ0MTQ5NmM5ZmM3NjY5L3RhYmxlcmFuZ2U6ZGIwNDcwOGE0NWViNGE4OTg0NDQxNDk2YzlmYzc2NjlfMzktOS0xLTEtMQ_44c0a315-ffd8-4136-bb2f-73a02bd8f2ad"
      unitRef="shares">40377608</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i976c03ac317a4dad950efc53136ca1d4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMi0yLTEtMS0x_a0160b02-ca97-4bc1-b1a4-85387dcf2027"
      unitRef="shares">37952660</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i976c03ac317a4dad950efc53136ca1d4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMi00LTEtMS0x_c2902632-9662-4747-8725-7af6237f2ef9"
      unitRef="usd">3366000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5d328191fd14b4b8c8177ad7a45c411_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMi02LTEtMS0x_b9e6d85f-c52d-4e10-8b0a-37abddefc8fe"
      unitRef="usd">6377000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78f4f7423ba64e63859d8515c428592c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMi04LTEtMS0x_d0916a60-950c-4849-aca1-2c5862d5d056"
      unitRef="usd">-157000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5ea5e57cd6a84244aa82b953943efc99_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMi0xMC0xLTEtMQ_d1c9fed2-f9aa-4576-9c2f-d8819c95b625"
      unitRef="usd">34113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7a1ac0a3f55549f782851621e90eaa7c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMi0xMi0xLTEtMQ_9ef38d8a-98f0-4232-923a-53d621bfcddf"
      unitRef="usd">43699000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i90d795f6913c410caf28a7874f377029_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMy02LTEtMS0x_103a7c82-4df6-42d4-9e24-ad1c400d346f"
      unitRef="usd">891000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="iae414ee27046452e85105a8bd614cf93_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMy0xMi0xLTEtMQ_62d12196-a54f-47b1-ad17-fedefb449a1a"
      unitRef="usd">891000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="i90d795f6913c410caf28a7874f377029_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNC02LTEtMS0x_0627f7d7-b11e-467f-922c-4b2663754b1e"
      unitRef="usd">260000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="iae414ee27046452e85105a8bd614cf93_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNC0xMi0xLTEtMQ_d1c8c172-dfd4-45a5-97c6-85dfa3ee3133"
      unitRef="usd">260000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i46db418aa76540aca2336dc096a0f9ed_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNS0yLTEtMS0x_9394f549-5bf6-468e-b916-229fec00c9c0"
      unitRef="shares">4737</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i46db418aa76540aca2336dc096a0f9ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNS00LTEtMS0x_f4e22c63-6778-41d5-8369-362eea8d1faa"
      unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iae414ee27046452e85105a8bd614cf93_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNS0xMi0xLTEtMQ_c8059b0d-dfd1-4f8f-bdf6-6e68245d919e"
      unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i46db418aa76540aca2336dc096a0f9ed_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNi0yLTEtMS0x_71167d76-5503-4c32-8573-4e092d79c899"
      unitRef="shares">529375</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i46db418aa76540aca2336dc096a0f9ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNi00LTEtMS0x_9943ebc1-3b2c-4874-b66a-57243e5b1de9"
      unitRef="usd">3276000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i90d795f6913c410caf28a7874f377029_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNi02LTEtMS0x_e024f1a8-9cab-4033-a574-620f9f19689b"
      unitRef="usd">-3276000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="iae414ee27046452e85105a8bd614cf93_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNi0xMi0xLTEtMQ_15ffd0b6-61b6-4093-ad00-d865a0067edf"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icde10966330448159a62ea1562b7a40c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfOC04LTEtMS0x_85b14353-da11-423a-9d87-16bdd045b664"
      unitRef="usd">-312000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iae414ee27046452e85105a8bd614cf93_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfOC0xMi0xLTEtMQ_94cbb58c-3cd9-4a23-904f-1b458d3dff25"
      unitRef="usd">-312000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="icf2dfa8d264844e19a4b600fd9dd036a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfOS0xMC0xLTEtMQ_4491eb53-c094-45bd-87c1-f64a4b7d54e4"
      unitRef="usd">4243000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iae414ee27046452e85105a8bd614cf93_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfOS0xMi0xLTEtMQ_28878ec4-9da2-4c42-8cab-c4c4c21ab8bf"
      unitRef="usd">4243000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i46dde1ac351f45b3905daa2f81146e8f_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTAtMi0xLTEtMQ_54eb7dc3-5641-43a5-a0fe-e37b436231ba"
      unitRef="shares">38486772</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i46dde1ac351f45b3905daa2f81146e8f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTAtNC0xLTEtMQ_ea348403-76fa-4adf-86d3-060b7f77c4d6"
      unitRef="usd">6657000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i51b7b504524e4d5abf1313a033b40975_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTAtNi0xLTEtMQ_e4307e78-58d4-4097-b85a-b68f65c7d16e"
      unitRef="usd">4252000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6710f81bfc0f404287d6aa6655470fdb_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTAtOC0xLTEtMQ_f15e1d2e-b33b-41c2-b7df-743fe37f88c4"
      unitRef="usd">-469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e6a845ad54e4c62815896f2932bbbd3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTAtMTAtMS0xLTE_7d252ec7-1169-4883-bb16-e1f88b729a17"
      unitRef="usd">38356000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic98b72a5b163495eb502663ae5631ff3_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTAtMTItMS0xLTE_98682173-3e73-424d-aed7-9a6f6988d7ff"
      unitRef="usd">48796000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i5be2a171f9354e10b04c4107daa2107f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTItNi0xLTEtMQ_20655734-680d-49cc-b9cf-bfca81489f1c"
      unitRef="usd">933000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i0917a6724e5d4d2d84ae957241dc31d2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTItMTItMS0xLTE_7b9acda7-6ba9-4199-ab4d-e39620a724d3"
      unitRef="usd">933000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="i5be2a171f9354e10b04c4107daa2107f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTMtNi0xLTEtMQ_ca40b902-67bf-44de-8759-2efcc0402103"
      unitRef="usd">263000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="i0917a6724e5d4d2d84ae957241dc31d2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTMtMTItMS0xLTE_1b39ff25-6769-4c61-b74f-16a432e4eb79"
      unitRef="usd">263000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6486b80960f04e1daccfe12d493f4edd_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTUtMi0xLTEtMQ_7c5ac3bb-a0bc-4ede-b04a-9efb54f14d8c"
      unitRef="shares">596160</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6486b80960f04e1daccfe12d493f4edd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTUtNC0xLTEtMQ_ac5c2803-7df8-4f33-9f49-95f2bcc674e3"
      unitRef="usd">1757000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0917a6724e5d4d2d84ae957241dc31d2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTUtMTItMS0xLTE_19303d54-18e8-4e94-a59c-81764e1de957"
      unitRef="usd">1757000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i69698187989a40bc91ce9b1b21ee1349_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTctOC0xLTEtMQ_63ccce20-2468-40b7-9ae3-f41afa126fd9"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0917a6724e5d4d2d84ae957241dc31d2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTctMTItMS0xLTE_4472e88b-53d8-4b46-b222-36ed494d18ec"
      unitRef="usd">-33000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i02af3a5a2bdd4b6786b29f8291d27eaa_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTgtMTAtMS0xLTE_3ad90a07-0a47-466a-b851-28abbe1d01e5"
      unitRef="usd">19412000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0917a6724e5d4d2d84ae957241dc31d2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTgtMTItMS0xLTE_01ade46d-e5f4-4d93-b099-131999858b67"
      unitRef="usd">19412000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i15c5bb821fbb4572a29dd47fbc926156_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTktMi0xLTEtMQ_943d5786-90ff-4ad4-ba59-49ee056e1c61"
      unitRef="shares">39082932</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i15c5bb821fbb4572a29dd47fbc926156_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTktNC0xLTEtMQ_06e012b8-784c-440f-8ee7-68b74c519593"
      unitRef="usd">8414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4dcf0bfe379141e99b6c299ca2382485_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTktNi0xLTEtMQ_3ccd2095-2b06-4588-8d46-0557750c9a25"
      unitRef="usd">5448000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b6e39b815a0481b81048a6daf6dbe38_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTktOC0xLTEtMQ_da1f7065-71ff-4f72-9c53-29a1c8e91994"
      unitRef="usd">-502000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i32a8db59831844cf84a2c1297bb57c33_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTktMTAtMS0xLTE_41a1fd28-9c2a-49de-a83a-0b0625852b8f"
      unitRef="usd">57768000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i041aeccc8fca4dcbbfff6f4937474eaf_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMTktMTItMS0xLTE_3c8b36bb-62a6-48a0-be22-fd54d247eaff"
      unitRef="usd">71128000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="id9919bd0cd9a414385929c20caf931e1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjEtNi0xLTEtMQ_f2bb1afb-dadb-4e57-912f-eca91e6f9b8a"
      unitRef="usd">945000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjEtMTItMS0xLTE_1301293d-e486-4be0-8705-4a882345997a"
      unitRef="usd">945000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="id9919bd0cd9a414385929c20caf931e1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjItNi0xLTEtMQ_320541c6-d41d-411e-861e-c98c0c42c2da"
      unitRef="usd">289000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjItMTItMS0xLTE_bcf607b1-2c5b-4966-bceb-8769133db8fb"
      unitRef="usd">289000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9b284b8a81064ddb96d6d70d6e5a89c1_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjQtMi0xLTEtMQ_37e3cbb7-5a9f-42d8-abcc-7829cff4906f"
      unitRef="shares">2400</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9b284b8a81064ddb96d6d70d6e5a89c1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjQtNC0xLTEtMQ_0d809114-a660-48d7-a3b5-3d86ce1582a8"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjQtMTItMS0xLTE_b0d245ce-f13f-4886-8385-fc6c6e7dec1d"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i9b284b8a81064ddb96d6d70d6e5a89c1_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjUtMi0xLTEtMQ_cca933db-e844-4996-9660-371d71a2a119"
      unitRef="shares">59850</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i9b284b8a81064ddb96d6d70d6e5a89c1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjUtNC0xLTEtMQ_cf972c5f-4aef-465d-818f-8bd388312b6e"
      unitRef="usd">663000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="id9919bd0cd9a414385929c20caf931e1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjUtNi0xLTEtMQ_9b8fc921-6fb1-4827-ba5d-6ec20b9229fa"
      unitRef="usd">-663000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjUtMTItMS0xLTE_840dc258-9f3e-4589-9ad7-ffdc3cdc2674"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifc0e465557324a2ea8388615a3a390a7_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjYtOC0xLTEtMQ_fa083a3d-d84f-468c-b9be-6f02e582d517"
      unitRef="usd">24000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjYtMTItMS0xLTE_376ee83d-93de-47de-bce5-91966006a33e"
      unitRef="usd">24000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i4112591d4ceb45bb9e69695b1b461a72_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjctMTAtMS0xLTE_566edeea-773d-4282-aeee-55097190d610"
      unitRef="usd">2804000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjctMTItMS0xLTE_51c4c1de-03b6-4602-8f23-ee748f6cd1f6"
      unitRef="usd">2804000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic33d050b9e874098924fdcfa31a8dad5_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjgtMi0xLTEtMQ_e1cbc582-91f1-4f24-8a22-5eb66f34ee69"
      unitRef="shares">39145182</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic33d050b9e874098924fdcfa31a8dad5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjgtNC0xLTEtMQ_715481a7-5438-4b21-a270-48e80298b7f3"
      unitRef="usd">9085000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i46d77374c8874d41b3947cf0b29e4b5e_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjgtNi0xLTEtMQ_9c9f2b68-35eb-4fc2-b0ec-c6a1976f851f"
      unitRef="usd">6019000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i169b12543b7a4693955a72d78e570320_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjgtOC0xLTEtMQ_14e0bd68-bb0b-47c5-9d3a-8a78339c19fe"
      unitRef="usd">-478000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a8950ebaa6d4023b4633983016fd884_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjgtMTAtMS0xLTE_988634ec-ba7a-46ca-9923-8d7e41d0a6a2"
      unitRef="usd">60572000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e735857f255494fa3f0fdeb61129073_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfMjgtMTItMS0xLTE_6ea94076-d741-41ba-a090-a8f187c06508"
      unitRef="usd">75198000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="icbd4539b888445aaa4a9f2e282cd287f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTMtMi0xLTEtMQ_10c54987-99e5-4b07-ae61-cd2c831a5565"
      unitRef="shares">39185182</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icbd4539b888445aaa4a9f2e282cd287f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTMtNC0xLTEtMQ_75d0acd9-7c42-410f-b08e-0742e5569608"
      unitRef="usd">9181000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i697f499345304f75ba0a1a2f279da745_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTMtNi0xLTEtMQ_ca603567-25e7-4703-8cfe-85b57c1f741b"
      unitRef="usd">7320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6d31ca92c88e48a9abe359674915ac36_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTMtOC0xLTEtMQ_53fe9d0c-7fbc-461c-8189-f34bd0fa5d74"
      unitRef="usd">-451000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9624c2e32e014ac3bacfe359b066e658_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTMtMTAtMS0xLTE_2e19fa82-5861-46f9-a0b2-18006aca50e3"
      unitRef="usd">65643000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTMtMTItMS0xLTE_fa330d3b-44fc-46af-92d4-799818c905c3"
      unitRef="usd">81693000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ia74bb5981805471fbf83349d5b020f16_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTQtNi0xLTEtMQ_86eb9fbc-bf74-4dc4-a2f7-dcea6363005a"
      unitRef="usd">1078000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTQtMTItMS0xLTE_d698e4da-670b-4f11-8346-1cd715a198ae"
      unitRef="usd">1078000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="ia74bb5981805471fbf83349d5b020f16_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTUtNi0xLTEtMQ_6f9e117d-0ea6-4b1b-9035-76cc2b4a9ec3"
      unitRef="usd">229000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTUtMTItMS0xLTE_e05079d0-fca8-48cd-8e14-f365c9d7efa7"
      unitRef="usd">229000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4a781f027e5f4955901d37f1b4f38ded_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTctMi0xLTEtMQ_21bbc540-d4c9-4a0c-9aaa-46f9b5d00b29"
      unitRef="shares">16586</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4a781f027e5f4955901d37f1b4f38ded_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTctNC0xLTEtMQ_4a1f4e38-8f13-4c26-9cfe-4875d5e5c379"
      unitRef="usd">65000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTctMTItMS0xLTE_897e155c-6583-44f9-bf54-b83cf4c03652"
      unitRef="usd">65000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i4a781f027e5f4955901d37f1b4f38ded_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTgtMi0xLTEtMQ_eb1081d7-10ef-41fa-addb-deace6c3b9f3"
      unitRef="shares">556840</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i4a781f027e5f4955901d37f1b4f38ded_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTgtNC0xLTEtMQ_d3a7d807-f1e2-4be6-9250-9a62d17b88d5"
      unitRef="usd">4403000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ia74bb5981805471fbf83349d5b020f16_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTgtNi0xLTEtMQ_9791f225-940f-4286-a1fc-8db86ca85264"
      unitRef="usd">-4403000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTgtMTItMS0xLTE_33cda269-e6b7-43fe-9171-2536f6e137a1"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i464b82b483584d00a1b94e3674ba102f_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTktMi0xLTEtMQ_42eea3de-5e08-4d92-846c-b36986a5bb82"
      unitRef="shares">181320</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ib19f6e172d9b49cd9b5d8614f40a0e58_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTktMTAtMS0xLTE_58a74e16-f22f-43c9-82d5-b65c4e73c811"
      unitRef="usd">1434000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNTktMTItMS0xLTE_bffade16-4dc0-4a5a-9313-a97bc8ba4dd9"
      unitRef="usd">1434000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id993d57472914822885303d1805d867f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjAtOC0xLTEtMQ_01b5f291-eb20-4e6f-8894-abeef1d47b78"
      unitRef="usd">106000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjAtMTItMS0xLTE_90104c96-0735-4382-a36f-ca034187f68b"
      unitRef="usd">106000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ib19f6e172d9b49cd9b5d8614f40a0e58_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjEtMTAtMS0xLTE_b4b16356-20b1-427b-ba82-876e72b5e41b"
      unitRef="usd">1684000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5f43ebadddca443ab125057332efd25d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjEtMTItMS0xLTE_42396c00-ebe2-4dab-9d80-1fc326f4b9a5"
      unitRef="usd">1684000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5a63aa35131e40bda35f8dedfa80bb16_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjItMi0xLTEtMQ_36ec49b3-02f8-4dcb-9543-3aeb0f791707"
      unitRef="shares">39577288</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5a63aa35131e40bda35f8dedfa80bb16_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjItNC0xLTEtMQ_559bd344-0ae5-4728-ad29-8e1b9cd5aa75"
      unitRef="usd">13649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78c9f6db5b0d482a98e9ca413932fb50_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjItNi0xLTEtMQ_f3b7646e-d8e3-47ff-b737-9e9b773e9cab"
      unitRef="usd">4224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i25c503eebf774a2abe26edc4ed510527_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjItOC0xLTEtMQ_a1ef2a0d-4883-4ccf-89b8-30e3600f7187"
      unitRef="usd">-345000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i127e3aaec83d4f6d8f742e5114d5812c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjItMTAtMS0xLTE_2466f98d-a643-4e4e-b97f-7656e45720db"
      unitRef="usd">65893000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6e4a3b13e1894054b380ed7b2593deb5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjItMTItMS0xLTE_b13ccbb8-ffb5-472a-8839-6eb11f661208"
      unitRef="usd">83421000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i9c396414383b4e01919749fb5c6c1282_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjQtNi0xLTEtMQ_1e49fc00-69df-4a49-91ea-6c34127521a7"
      unitRef="usd">998000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i68dbfdbb23794c9aa57688ded08012b4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjQtMTItMS0xLTE_1eda6b13-b350-412f-bb4e-28bb3be3c394"
      unitRef="usd">998000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="i9c396414383b4e01919749fb5c6c1282_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjUtNi0xLTEtMQ_7c112b09-ed13-464f-a8a1-5c87f151cab3"
      unitRef="usd">238000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="i68dbfdbb23794c9aa57688ded08012b4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjUtMTItMS0xLTE_b9344eb0-06d1-484b-a4f8-9301c8ba2718"
      unitRef="usd">238000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1b3e804780104f2c92291a6aab542159_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjYtMi0xLTEtMQ_520f606f-c409-4af2-8eca-b402da009193"
      unitRef="shares">11011</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1b3e804780104f2c92291a6aab542159_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjYtNC0xLTEtMQ_dfbe5b9f-9b03-408a-afa6-869eb5b0343a"
      unitRef="usd">47000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i68dbfdbb23794c9aa57688ded08012b4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjYtMTItMS0xLTE_5f6c0754-b864-4bdd-b028-b1701cb85960"
      unitRef="usd">47000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib5b2ecbbe220415f99fcae20e610a16d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjgtOC0xLTEtMQ_b123ed4a-1873-4992-b770-04e8d631ba5b"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i68dbfdbb23794c9aa57688ded08012b4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjgtMTItMS0xLTE_c29db3a4-445b-417b-8545-82c6b1a46add"
      unitRef="usd">-6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="id00c330d28624a34b3fb015d48c87224_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjktMTAtMS0xLTE_a456e59b-25a3-4555-8f89-f58c67027132"
      unitRef="usd">1566000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i68dbfdbb23794c9aa57688ded08012b4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNjktMTItMS0xLTE_74df9d73-bad8-4259-a05f-b1c5477349a4"
      unitRef="usd">1566000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i820eda4de0134410bc7323aa4f2359aa_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzAtMi0xLTEtMQ_072e4800-249c-4aa2-8392-756ddcf1b289"
      unitRef="shares">39588299</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i820eda4de0134410bc7323aa4f2359aa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzAtNC0xLTEtMQ_cf1a67d4-faa3-490a-9377-2071f18a82c0"
      unitRef="usd">13696000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a46a17ce83245f7bb8b1baf56327400_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzAtNi0xLTEtMQ_4e75e4af-00fe-47ae-b500-98318f289faa"
      unitRef="usd">5460000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4dd7126df3044d39a084ec7916656b51_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzAtOC0xLTEtMQ_738e7980-c47c-4f4e-b33b-496b133d582f"
      unitRef="usd">-351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d2719e7ac624519adafa787168afc4c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzAtMTAtMS0xLTE_7dbffa79-96d8-48c3-b4d7-18ea129e4776"
      unitRef="usd">67459000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibfad155c822f4964b47061c31968d980_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzAtMTItMS0xLTE_0a9e7c89-1cb7-43c6-b163-62d93c2e62d2"
      unitRef="usd">86264000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i8237e783d5184295a58fc1aa28006024_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzItNi0xLTEtMQ_a316a6b0-fa78-47ab-aa89-7411c0d5affc"
      unitRef="usd">1051000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzItMTItMS0xLTE_826e8e28-8101-490b-b94e-dc787f403993"
      unitRef="usd">1051000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="i8237e783d5184295a58fc1aa28006024_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzMtNi0xLTEtMQ_de33307a-7d19-4a1d-90b8-40b4201b31b4"
      unitRef="usd">251000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzMtMTItMS0xLTE_4f8d0f3c-5723-4743-a958-94eeded88f65"
      unitRef="usd">251000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i7426e08cc52b45f197ca6891d552801b_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzYtMi0xLTEtMQ_b6d0b2fe-505a-49b1-bae9-5855d90884d8"
      unitRef="shares">42147</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i7426e08cc52b45f197ca6891d552801b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzYtNC0xLTEtMQ_47f12f55-9e65-42e4-9dfa-ddcbf79bdcf9"
      unitRef="usd">261000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i8237e783d5184295a58fc1aa28006024_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzYtNi0xLTEtMQ_c7a89a3b-4402-40bb-8ffd-acd4e5e922dc"
      unitRef="usd">-261000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzYtMTItMS0xLTE_511717df-c5ce-417a-abcf-19386dd4989f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i24e84fd5360f4fd385f42eb20ba331d9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzctOC0xLTEtMQ_95acca75-752a-46e4-acb3-133032953180"
      unitRef="usd">21000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzctMTItMS0xLTE_36aacb94-ea1a-4baa-b012-0502fb904384"
      unitRef="usd">21000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i02d706f98718409cb5564654fd53deb2_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzgtMTAtMS0xLTE_35dc501c-caa4-40a5-bad7-701d535e8fd8"
      unitRef="usd">1789000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzgtMTItMS0xLTE_f24050ff-4339-4f7b-a747-c4d21a0076d9"
      unitRef="usd">1789000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iac9ff3e2056a4a5f880103fc4356cd36_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzktMi0xLTEtMQ_f36873f6-87a7-47cb-bda2-f1ac58edc485"
      unitRef="shares">39630446</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iac9ff3e2056a4a5f880103fc4356cd36_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzktNC0xLTEtMQ_408b7a2b-969a-48ce-b19f-6b2bb9ea952e"
      unitRef="usd">13957000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f84494dae4e4eb7bb67d17f473a7c64_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzktNi0xLTEtMQ_0961e64a-7f00-45c2-bbcf-2be79325ce16"
      unitRef="usd">6501000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e1a9a3cfd8e4e82bc8295ec950c8daa_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzktOC0xLTEtMQ_10e12ff7-ec2a-4e2f-8442-1f66c49db3a4"
      unitRef="usd">-330000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i86b274e0f2d945cebc379d707e4f5ea8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzktMTAtMS0xLTE_1c74eac3-e555-442b-90e6-8e8f1c42eee6"
      unitRef="usd">69248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yMi9mcmFnOjg5OWJlZWNhNjNiNzQ3NDU5NWRjNjA1Y2ZmODU1YmU0L3RhYmxlOjQzNDhiNmNlM2YwNzQ1MWRhZGJhNTAxNzc4MTBmOWZiL3RhYmxlcmFuZ2U6NDM0OGI2Y2UzZjA3NDUxZGFkYmE1MDE3NzgxMGY5ZmJfNzktMTItMS0xLTE_8d021e9f-d01d-427b-ad63-f4436d868bd6"
      unitRef="usd">89376000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMy0zLTEtMS0x_5bee433f-5e35-454d-b1aa-000c9fd91204"
      unitRef="usd">5039000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMy01LTEtMS0x_a163e5db-1158-46de-aa62-a6c9c1d6826a"
      unitRef="usd">26459000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNS0zLTEtMS0x_63a53180-917a-4fa8-a3d8-b52d246b1b6a"
      unitRef="usd">8192000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNS01LTEtMS0x_b4f4d9f8-9c7f-4fcc-9548-35d122311012"
      unitRef="usd">6745000</us-gaap:Depreciation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNi0zLTEtMS0x_ad02e58b-3ca1-443b-a031-a8ccfe458280"
      unitRef="usd">5250000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNi01LTEtMS0x_100b875e-34da-4ae4-8fd7-53d28af171a2"
      unitRef="usd">7031000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryLIFOReservePeriodCharge
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNy0zLTEtMS0x_0554daa8-1ee8-442a-847e-e43b16b567bd"
      unitRef="usd">-116000</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNy01LTEtMS0x_ac317936-9629-452a-b6da-6454293c7d7f"
      unitRef="usd">0</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:ShareBasedCompensation
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfOC0zLTEtMS0x_ff5a10f4-d85c-4e58-a4f5-13409af4bb19"
      unitRef="usd">3845000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfOC01LTEtMS0x_5793fb98-8fca-4f0b-be19-5cf4fe82e6b9"
      unitRef="usd">3581000</us-gaap:ShareBasedCompensation>
    <vmd:DistributionsOfEarningsReceivedFromEquityMethodInvestments
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfOS0zLTEtMS0x_ce1e8b0c-2690-4f20-b9ca-28c98f5aaf98"
      unitRef="usd">172000</vmd:DistributionsOfEarningsReceivedFromEquityMethodInvestments>
    <vmd:DistributionsOfEarningsReceivedFromEquityMethodInvestments
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfOS01LTEtMS0x_4fa3c506-e650-424a-aa6c-66149dffdf2b"
      unitRef="usd">0</vmd:DistributionsOfEarningsReceivedFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTEtMy0xLTEtMQ_b4123c10-c2c0-4517-90d8-4faabd0fa5b2"
      unitRef="usd">782000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTEtNS0xLTEtMQ_1a16f4ec-a4b0-4cbe-9958-cb5c6f6728f7"
      unitRef="usd">36000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTItMy0xLTEtMQ_fa7f2452-0b7e-4639-b7b5-92f6db1a6804"
      unitRef="usd">-304000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTItNS0xLTEtMQ_c415717c-01d9-44ed-8b1a-205c69eff06c"
      unitRef="usd">2424000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTMtMy0xLTEtMQ_6828c2c5-8c2d-40e2-9597-8812a74ff0ba"
      unitRef="usd">2410000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTMtNS0xLTEtMQ_a859f8e3-ba00-4302-bb8f-88fca27b2d1d"
      unitRef="usd">-7593000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTUtMy0xLTEtMQ_758ca9f1-b706-4fdb-a241-20159b473e74"
      unitRef="usd">5573000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTUtNS0xLTEtMQ_4335d208-8add-4efd-ad5c-ced37c4a423e"
      unitRef="usd">6986000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTYtMy0xLTEtMQ_b45204e1-5637-479a-8e95-ee4b5022c15f"
      unitRef="usd">196000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTYtNS0xLTEtMQ_77d989ca-8bb9-443d-a547-bc4811f8ffdb"
      unitRef="usd">1402000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTctMy0xLTEtMQ_ecd0c2c5-3953-4611-9cb9-eb0ea9ea1542"
      unitRef="usd">2259000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTctNS0xLTEtMQ_c35914e7-ac4d-420c-8df0-121853c565f1"
      unitRef="usd">1771000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTgtMy0xLTEtMQ_9d2caee5-3bc5-4161-b500-ec24c40ce7de"
      unitRef="usd">2638000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTgtNS0xLTEtMQ_349f0554-9227-40ba-965a-5d19d32bed9a"
      unitRef="usd">2739000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTktMy0xLTEtMQ_9020c79b-d06c-4f05-8446-1a2e23fc8d39"
      unitRef="usd">386000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMTktNS0xLTEtMQ_07cd13fd-46d1-4aa9-91a2-af4d8b8b28f7"
      unitRef="usd">297000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjAtMy0xLTEtMQ_4417aadd-78ca-4b0d-a645-cf445b962b39"
      unitRef="usd">-3711000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjAtNS0xLTEtMQ_ecc14a81-3c07-4991-b946-0f4ef8fad815"
      unitRef="usd">2397000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjEtMy0xLTEtMQ_474de3ae-d9b9-46bb-9169-84994adb35f2"
      unitRef="usd">-1760000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjEtNS0xLTEtMQ_a0e0a591-eff9-44e0-85c1-3b007b2d5485"
      unitRef="usd">282000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjItMy0xLTEtMQ_5fe85b74-5bf8-42fd-9cc2-6d97d65827f7"
      unitRef="usd">13839000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjItNS0xLTEtMQ_0e1fcf9e-360b-4383-8bba-ee8d65399e63"
      unitRef="usd">29319000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjUtMy0xLTEtMQ_ffcf21ad-dc00-490e-a7fa-1d681e21acf7"
      unitRef="usd">13080000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjUtNS0xLTEtMQ_e7221d36-6e45-4cf1-b880-7fe684b2bfd4"
      unitRef="usd">8204000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjYtMy0xLTEtMQ_807922e4-8dbf-4a52-bdcd-1ff93ce4f7df"
      unitRef="usd">599000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjYtNS0xLTEtMQ_57990d40-05a1-4c54-bdbb-816e2dbac672"
      unitRef="usd">30000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjctMy0xLTEtMQ_f1610b6c-cbb3-4953-9526-92ee74d48fab"
      unitRef="usd">496000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjctNS0xLTEtMQ_40e8867d-b0d5-4862-818e-5948a8e7e936"
      unitRef="usd">5187000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjgtMy0xLTEtMQ_69a60faa-89c1-48e5-9e54-fa97e64e97eb"
      unitRef="usd">-13183000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMjgtNS0xLTEtMQ_665189e8-3245-4f91-8729-0d128efc5f6c"
      unitRef="usd">-3047000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzItMy0xLTEtMQ_d4db01c8-0f18-4fc8-b820-a0e3afd778d2"
      unitRef="usd">112000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzItNS0xLTEtMQ_10a14ce5-d335-44e1-9ca6-a40108cda8b7"
      unitRef="usd">1780000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzYtMy0xLTEtMQ_c2aac97a-fe41-4733-ac63-2bdb4899f529"
      unitRef="usd">113000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzYtNS0xLTEtMQ_e6e53212-1582-4007-89c9-c7c6c5d0861e"
      unitRef="usd">104000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzctMy0xLTEtMQ_78ed606c-9b45-4d87-a720-b7d310125bc0"
      unitRef="usd">1255000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzctNS0xLTEtMQ_97c10c68-802e-4255-aae2-5f670f2dbe4c"
      unitRef="usd">1199000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzgtMy0xLTEtMQ_939d8445-693f-41d7-848e-609fffe62212"
      unitRef="usd">1434000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfMzgtNS0xLTEtMQ_c098a9f6-328d-4641-a07d-76bd346be9da"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <vmd:LeasePayments
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDAtMy0xLTEtMQ_1e65851e-f7e5-4dd9-8bd8-f8aceeabe8dd"
      unitRef="usd">2080000</vmd:LeasePayments>
    <vmd:LeasePayments
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDAtNS0xLTEtMQ_f553746e-b9d7-4dc8-9438-a68bac0b15cd"
      unitRef="usd">7708000</vmd:LeasePayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDItMy0xLTEtMQ_2facedd1-9dde-4134-8366-87a91ecbb852"
      unitRef="usd">-4770000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDItNS0xLTEtMQ_1fe42388-34f9-48d8-81cb-c135279b8299"
      unitRef="usd">-7231000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDQtMy0xLTEtMQ_bd6b999f-c869-4187-8095-4c939b66ad41"
      unitRef="usd">-4114000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDQtNS0xLTEtMQ_0b3246fd-39bf-414f-9a97-f30dbc815188"
      unitRef="usd">19041000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDUtMy0xLTEtMQ_8b51988f-45f9-442b-844e-94b7ff150978"
      unitRef="usd">30981000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7a1ac0a3f55549f782851621e90eaa7c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDUtNS0xLTEtMQ_906a9f4b-33f6-4ed7-9ec9-f0f4e693f2e6"
      unitRef="usd">13355000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDYtMy0xLTEtMQ_52433884-60dd-49e1-85b0-482f1a540b0d"
      unitRef="usd">26867000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0e735857f255494fa3f0fdeb61129073_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDYtNS0xLTEtMQ_da8813fe-43dd-4e5a-a6e9-4da3d140b971"
      unitRef="usd">32396000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDktMy0xLTEtMQ_50fd8a5f-c46e-4f3d-a13f-7b6135551d1c"
      unitRef="usd">278000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNDktNS0xLTEtMQ_23268373-85b0-4528-b1a5-6f6d310eeed7"
      unitRef="usd">437000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNTAtMy0xLTEtMQ_715d9a18-0bf6-4bb9-83e0-8cbe4763060b"
      unitRef="usd">1760000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNTAtNS0xLTEtMQ_1218cfbc-75b6-4126-8ace-5c2230a0473f"
      unitRef="usd">1975000</us-gaap:IncomeTaxesPaidNet>
    <vmd:NetNonCashChangesToFinanceLeaseBalances
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNTItMy0xLTEtMQ_42ef5566-d740-4d12-b8b6-0ab84ab909f0"
      unitRef="usd">42000</vmd:NetNonCashChangesToFinanceLeaseBalances>
    <vmd:NetNonCashChangesToFinanceLeaseBalances
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNTItNS0xLTEtMQ_f7c8a194-1162-4cce-bdd1-320b390fd548"
      unitRef="usd">3002000</vmd:NetNonCashChangesToFinanceLeaseBalances>
    <vmd:NetNonCashChangesToOperatingLeaseBalances
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNTMtMy0xLTEtMQ_75742b55-63dd-4d2e-b9ad-85894275efb0"
      unitRef="usd">372000</vmd:NetNonCashChangesToOperatingLeaseBalances>
    <vmd:NetNonCashChangesToOperatingLeaseBalances
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18yNS9mcmFnOjRkODEwZTgxMmE4MjRkMzZiYzE1ZDZkYWRjMTAyZjNkL3RhYmxlOmEzNWQwNTVkMTA2OTRhM2U5ZTk4MzRlMGFhNWIzZWFlL3RhYmxlcmFuZ2U6YTM1ZDA1NWQxMDY5NGEzZTllOTgzNGUwYWE1YjNlYWVfNTMtNS0xLTEtMQ_c33f56f2-6d40-4005-9df4-8be315a78370"
      unitRef="usd">57000</vmd:NetNonCashChangesToOperatingLeaseBalances>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zMS9mcmFnOmE4MDc2MTE5YjllMDRkMWQ4NTRlOGZkYWMwM2VmMDkyL3RleHRyZWdpb246YTgwNzYxMTliOWUwNGQxZDg1NGU4ZmRhYzAzZWYwOTJfMTM2OA_5ebbdde8-4477-40d3-b8c6-37c55cbda5c4">Nature of Business and Operations&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;Viemed Healthcare, Inc. (the "Company"), through its subsidiaries, is a provider of in-home durable medical equipment ("DME") and post-acute respiratory healthcare services in the United States. The Company&#x2019;s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. The Company currently serves patients in 46 states in the United States. The Company was incorporated under the Business Corporations Act (British Columbia) on December 14, 2016. The Company's registered and records office is located at Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2Z7 and its corporate office is located at 625 E. Kaliste Saloom Road, Lafayette, Louisiana 70508.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act (the "JOBS Act") and a "smaller reporting company" under Rule 12b-2 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), and, as such, has elected to comply with certain reduced U.S. public company reporting requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s common shares are traded in the U.S. on the Nasdaq Capital Market under the symbol VMD and in Canada on the Toronto Stock Exchange ("TSX") under the symbol VMD.TO.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zMS9mcmFnOmE4MDc2MTE5YjllMDRkMWQ4NTRlOGZkYWMwM2VmMDkyL3RleHRyZWdpb246YTgwNzYxMTliOWUwNGQxZDg1NGU4ZmRhYzAzZWYwOTJfNDcz_3dfa8437-c16f-41c3-9d5c-18b51f4f078f"
      unitRef="state">46</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NTc_467a2e14-ac06-4c36-bfe9-c3211399face">Summary of Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Principles of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders&#x2019; Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. Our fiscal year ends on December 31. The Condensed Consolidated Balance Sheet as of December 31, 2020 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of our independent registered public accounting firm included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2021, our evaluation takes into consideration such factors as historical bad debt experience, national and local economic trends and conditions, industry and regulatory conditions, other collection indicators and information about disaggregated receivables. The complexity of many third-party billing arrangements, patient qualification for medical necessity of equipment and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The estimates and write-offs for the allowance for doubtful accounts for each reporting period were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amounts written off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,788&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:27pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Included in accounts receivable at September 30, 2021 are amounts due from Medicare and Medicaid which represent 36% and 10%, respectively, and 46% combined, of total outstanding receivables. As of December 31, 2020, 46% of total outstanding receivables were due from Medicare and Medicaid. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and nine months ended September 30, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Medicare and Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventory represents non-serialized respiratory supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value. Inventory is presented net of a reserve balance of $1,237,000 and $1,353,000 at September 30, 2021 and December 31, 2020, respectively, that relates to COVID-19 response supplies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been delivered to a patient and is put in use and continues through the useful life of the asset. Property and equipment with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity investments on the Condensed Consolidated Balance Sheets are comprised of an investment accounted for under the equity method and an equity investment without a readily determinable fair value which is accounted for under the measurement alternative described in ASC 321-10-35-2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table details the Company&#x2019;s equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.172%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,942&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;733&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments accounted for under the equity method are investments in unconsolidated entities over whose operating and financial policies the Company has the ability to exercise significant influence but not control. Equity method investments are initially measured at cost in the Condensed Consolidated Balance Sheets with a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;n&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;y subsequent adjustments made to the carrying amount of the investment for the Company&#x2019;s proportionate share of income or loss. The Company has recognized its share of income or loss on the gain (loss) from equity method investments within non-operating expenses in the Condensed Consolidated Statements of Income. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. No events or changes have occurred as of September 30, 2021 that would affect the carrying value of equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other equity investments are investments without a readily determinable fair value which do not qualify for the practical expedient in ASC 820. For these investments, the Company has elected the measurement alternative which measures the investment at cost, less any impairment. ASU 2019-04 clarifies that if an entity identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it must measure its equity investment at fair value in accordance with ASC 820 as of the date that the observable transaction occurred. The Company was not aware of any impairment or observable price change adjustments that needed to be made as of September 30, 2021 on its investments in equity securities without a readily determinable fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments, net of tax. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As a result of the &#x201c;backward tracing&#x201d; prohibition in ASC 740, certain previously measured unrealized gains or losses have resulted in the existence of "dangling" amounts within other comprehensive income. The Company has elected the individual security approach to the release of these effects. Under the individual security approach, dangling amounts are tracked on a security-by-security basis and cleared out of the other comprehensive income balance upon sale of each individual security. During the periods presented, none of the individual securities associated with a dangling balance were sold.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Revenue from a customer consists of any combination of the sale and rental of DME and/or patient medical services. Revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company&#x2019;s products fall in the Medicare Fee-for-Service (&#x201c;FFS&#x201d;) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare &amp;amp; Medicaid Services (&#x201c;CMS&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For commercial payors, DME companies must negotiate in-network pricing separately, though in general, the Company&#x2019;s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with DME rentals, the Company recognizes revenue in accordance with ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Leases,&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (Topic 842). For any DME sales and services, the Company recognizes revenue under FASB ASU 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Revenue from Contracts with Customers,&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (Topic 606) and related amendments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;padding-left:27pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The revenues from each major source are summarized in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenue from rentals &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Ventilator rentals, non-invasive and invasive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other durable medical equipment rentals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenue from sales and services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;Equipment and supply sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;COVID-19 response sales and services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;29,285&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;33,447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;85,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;100,107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Accounting under Topic 842&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company leases DME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company accounts for these rentals as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under FASB ASC Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Accounting under Topic 606&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company sells DME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company also provides sleep study services to customers and recognizes revenue when the sleep study results are complete, satisfying the performance obligation. In response to the COVID-19 pandemic, the Company began offering contact and vaccine tracing services, which revenues are recognized in the period in which the service has been provided. The transaction price on equipment sales, sleep studies and contact and vaccine tracing is the amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the DME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The Company does not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Returns and refunds are not accepted on equipment sales, sleep study services or contact and vaccine tracing services. The Company does not offer warranties to customers in excess of the manufacturer&#x2019;s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company accounts for its stock-based compensation in accordance with ASC 718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;, "Compensation&#x2014;Stock Compensation"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock&#x2013;based compensation costs for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units ("RSUs") are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the Company&#x2019;s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the equivalent Company's stock value at the end of each period and records a liability based on the percentage of requisite service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company utilizes an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the Term Note (as defined below).&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk.&#160;These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company presents a positive ending period fair value of the interest rate swap contract in other long-term assets, as a component of long-term assets, and a negative ending period fair value of the interest rate swap contract in accrued liabilities, as a component of long-term liabilities on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty&#160;as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets.&#160;To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is subject to income taxes in numerous jurisdictions. Significant judgment is required in determining the provision for income taxes. The Company's income tax provisions reflect management&#x2019;s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that we will receive refunds from or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact our effective tax rate as well as our business and operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted or substantively enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:45pt;text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12,&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#160;The new guidance simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The new guidance also improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending the existing guidance.&#160;The Company adopted this standard on January 1, 2020, which did not have any impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is an &#x201c;emerging growth company&#x201d; as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, our condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In November 2019, the FASB issued&#160;ASU 2019-11,&#160;Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which is intended to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets. The standard replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. Further, the FASB issued ASU 2019-04 and ASU 2019-05 to provide additional guidance on the credit losses standard. The standard is effective for fiscal years beginning after December 15, 2022 for smaller reporting companies, including interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the effect that this standard will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), which provides optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. Specifically, the guidance permits an entity, when certain criteria are met, to consider amendments to contracts made to comply with reference rate reform to meet the definition of a modification under GAAP. It further allows hedge accounting to be maintained and a one-time transfer or sale of qualifying held-to-maturity securities. The expedients and exceptions provided by the amendments are permitted to be adopted any time through December 31, 2022 and do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, except for certain optional expedients elected for certain hedging relationships existing as of December 31, 2022. The Company is currently evaluating the effect that this standard will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3Mzk_072f424e-5eb8-4482-8116-ad4102ce2fe4">Principles of PresentationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders&#x2019; Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. Our fiscal year ends on December 31. The Condensed Consolidated Balance Sheet as of December 31, 2020 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of our independent registered public accounting firm included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NTI_2613945d-1454-470b-823a-3a39f14f3681">Basis of consolidationThese consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3Mjc_f6e0a29e-c174-47c9-acb3-e186aceb4e07">Use of estimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NjM_7add8757-315f-4174-a514-07b5dbb24ac6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2021, our evaluation takes into consideration such factors as historical bad debt experience, national and local economic trends and conditions, industry and regulatory conditions, other collection indicators and information about disaggregated receivables. The complexity of many third-party billing arrangements, patient qualification for medical necessity of equipment and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NDM_a4ca855f-1b91-416b-b9cd-165949de6956">&lt;div style="margin-bottom:0.1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The estimates and write-offs for the allowance for doubtful accounts for each reporting period were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amounts written off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;8,788&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfMS0yLTEtMS0x_99fd5af4-a3d3-4b22-99da-b07315090d2a"
      unitRef="usd">9013000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i7a1ac0a3f55549f782851621e90eaa7c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfMS00LTEtMS0x_44e80b35-807b-4725-82b1-83b6c79fe2a6"
      unitRef="usd">7782000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfMi0yLTEtMS0x_6f1a6299-df3e-413b-be05-ba188a95240a"
      unitRef="usd">5250000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfMi00LTEtMS0x_c6be2cf9-08cf-42f4-a003-fe341b08967a"
      unitRef="usd">7031000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfMy0yLTEtMS0x_0468df09-cd4b-4dea-900e-f75c8ec73920"
      unitRef="usd">7148000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfMy00LTEtMS0x_46b62c8c-a0d7-4758-bb33-85ae3b34730a"
      unitRef="usd">6025000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfNC0yLTEtMS0x_e2733c57-8397-47f7-a02d-e8d8617dc28c"
      unitRef="usd">7115000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i0e735857f255494fa3f0fdeb61129073_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjViZmU5NWFkMTMzMjRmMjk4YTdhZGU4NGI1YzY5ZjNhL3RhYmxlcmFuZ2U6NWJmZTk1YWQxMzMyNGYyOThhN2FkZTg0YjVjNjlmM2FfNC00LTEtMS0x_0671c1ac-3e2b-47dc-8666-0dfce8f5a2c1"
      unitRef="usd">8788000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9789ed0b93954ee49baa21647f388ef5_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfNDIyOQ_a35f298b-dbc0-4540-a4a0-4625082f97d0"
      unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifa9d483dc10645cbb1e0794af9dc1645_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfNDIzNg_26e15cd0-6be4-460d-88c8-f54826894b32"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaeed513b2882441a875dcc01fbc0a501_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfNDI1OA_52600533-6cee-4f3c-a809-2d3e736527c3"
      unitRef="number">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i68ea450f7c474538bd7b5840ef6102d0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfNDMxNQ_46760175-3abd-4794-9f50-71014b7e5761"
      unitRef="number">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NjQ_557f0e47-a78f-4fc1-b04a-2de28d0ccbfa">&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and nine months ended September 30, 2021 and 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Medicare and Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8b429d6cb7cb45b3baf15962a80dda61_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMi0yLTEtMS0x_82371cdd-6592-42c8-9c42-ed68a6dbfdf9"
      unitRef="number">0.53</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i32b248a3bb174a64841828130e70a17c_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMi00LTEtMS0x_f6ca67f1-c4c9-4d12-8640-e33325db5c33"
      unitRef="number">0.57</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3c40bc410d694b588140148c1dc03c0a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMi02LTEtMS0x_b71b4d91-58f0-43c6-b23f-53365c024555"
      unitRef="number">0.56</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2b7bf3629d3d438d8cc6edf60ac48177_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMi04LTEtMS0x_08b2b1c0-2a50-4ae4-97ef-38209b61574a"
      unitRef="number">0.58</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i94f0a3d2683f4ff392518340e25d81aa_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMy0yLTEtMS0x_9a3bba1c-c90c-440d-ac52-479971e8fb33"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1eca90250ea9417384566f7ebacc116b_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMy00LTEtMS0x_de1a8048-870d-4a31-9cc8-fc09dabc0c54"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i46dcf7ac81934f2a98f642840bdfd97c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMy02LTEtMS0x_9b8d6480-d78e-47da-a20f-cd605782947d"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2a4b30e32e7340a3b4b7cd8a1e99e3ae_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfMy04LTEtMS0x_2ba188ef-23bd-4945-ae4f-af125defb5f8"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibcd7133079e94b92a73f8571b7906435_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfNC0yLTEtMS0x_97e5c436-76f0-40fb-940a-15a129b34c30"
      unitRef="number">0.62</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6fdb1766786c4f3480910ae7b537fb05_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfNC00LTEtMS0x_9bd819ee-b63c-4b98-a179-66e180aad7b5"
      unitRef="number">0.66</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i76805b82fef445c8b00c89dac2de57b5_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfNC02LTEtMS0x_2fe3d718-233e-4ec9-a97f-e6350aeca5b3"
      unitRef="number">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i533015666e4b410e9c4fd427bd190a87_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOjEyMDY3NWIzMGYwZjQ3Yjg5N2ExMWY5MDg0ZTFkODU2L3RhYmxlcmFuZ2U6MTIwNjc1YjMwZjBmNDdiODk3YTExZjkwODRlMWQ4NTZfNC04LTEtMS0x_d7de3aa9-5e5a-47de-acd9-5e37571029d8"
      unitRef="number">0.66</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NTM_aea344f2-87b4-44a8-88e5-a7e3094056f8">InventoryInventory represents non-serialized respiratory supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfNDk5MA_d6462bed-0c65-4998-b0d8-a38af655efa4"
      unitRef="usd">1237000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfNDk5Nw_eacd2fe7-7768-4b3a-b91f-813a6b629614"
      unitRef="usd">1353000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NDc_94a76c77-5612-4a6a-94ea-1449f2a05cea">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives. &lt;/span&gt;&lt;/div&gt;Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been delivered to a patient and is put in use and continues through the useful life of the asset. Property and equipment with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NTk_aa5e1055-0518-4eb1-859f-7f8cf0d2022f">&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Equity investments on the Condensed Consolidated Balance Sheets are comprised of an investment accounted for under the equity method and an equity investment without a readily determinable fair value which is accounted for under the measurement alternative described in ASC 321-10-35-2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Investments accounted for under the equity method are investments in unconsolidated entities over whose operating and financial policies the Company has the ability to exercise significant influence but not control. Equity method investments are initially measured at cost in the Condensed Consolidated Balance Sheets with a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;n&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;y subsequent adjustments made to the carrying amount of the investment for the Company&#x2019;s proportionate share of income or loss. The Company has recognized its share of income or loss on the gain (loss) from equity method investments within non-operating expenses in the Condensed Consolidated Statements of Income. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. No events or changes have occurred as of September 30, 2021 that would affect the carrying value of equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other equity investments are investments without a readily determinable fair value which do not qualify for the practical expedient in ASC 820. For these investments, the Company has elected the measurement alternative which measures the investment at cost, less any impairment. ASU 2019-04 clarifies that if an entity identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it must measure its equity investment at fair value in accordance with ASC 820 as of the date that the observable transaction occurred. The Company was not aware of any impairment or observable price change adjustments that needed to be made as of September 30, 2021 on its investments in equity securities without a readily determinable fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3MzM_d577c01a-fe13-4e08-8c6f-61f4aa72b996">&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table details the Company&#x2019;s equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.172%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,942&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;733&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmZmOWUzYmJhZmU2MTQ0MmViNGRjMGM0NmExNGQwMmIwL3RhYmxlcmFuZ2U6ZmY5ZTNiYmFmZTYxNDQyZWI0ZGMwYzQ2YTE0ZDAyYjBfMS0yLTEtMS0x_555d324f-60c1-4507-ace2-24ceaf3c33ba"
      unitRef="usd">744000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmZmOWUzYmJhZmU2MTQ0MmViNGRjMGM0NmExNGQwMmIwL3RhYmxlcmFuZ2U6ZmY5ZTNiYmFmZTYxNDQyZWI0ZGMwYzQ2YTE0ZDAyYjBfMS00LTEtMS0x_5a036222-d2dd-45c9-a163-88549b3496ce"
      unitRef="usd">134000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherInvestments
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmZmOWUzYmJhZmU2MTQ0MmViNGRjMGM0NmExNGQwMmIwL3RhYmxlcmFuZ2U6ZmY5ZTNiYmFmZTYxNDQyZWI0ZGMwYzQ2YTE0ZDAyYjBfMi0yLTEtMS0x_b92b8c2b-a5e6-4add-9080-2332a727959c"
      unitRef="usd">1198000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmZmOWUzYmJhZmU2MTQ0MmViNGRjMGM0NmExNGQwMmIwL3RhYmxlcmFuZ2U6ZmY5ZTNiYmFmZTYxNDQyZWI0ZGMwYzQ2YTE0ZDAyYjBfMi00LTEtMS0x_15e720d0-e8a1-4748-ad7d-ad1d86951f47"
      unitRef="usd">599000</us-gaap:OtherInvestments>
    <us-gaap:Investments
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmZmOWUzYmJhZmU2MTQ0MmViNGRjMGM0NmExNGQwMmIwL3RhYmxlcmFuZ2U6ZmY5ZTNiYmFmZTYxNDQyZWI0ZGMwYzQ2YTE0ZDAyYjBfMy0yLTEtMS0x_11e93ea6-89d6-474f-9337-1ca31858a9be"
      unitRef="usd">1942000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmZmOWUzYmJhZmU2MTQ0MmViNGRjMGM0NmExNGQwMmIwL3RhYmxlcmFuZ2U6ZmY5ZTNiYmFmZTYxNDQyZWI0ZGMwYzQ2YTE0ZDAyYjBfMy00LTEtMS0x_f3804b37-9b82-4fbc-81bd-a6da5cad0a67"
      unitRef="usd">733000</us-gaap:Investments>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3MzQ_9334e857-4f45-49f8-966e-49a1bb6e0a1a">&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments, net of tax. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As a result of the &#x201c;backward tracing&#x201d; prohibition in ASC 740, certain previously measured unrealized gains or losses have resulted in the existence of "dangling" amounts within other comprehensive income. The Company has elected the individual security approach to the release of these effects. Under the individual security approach, dangling amounts are tracked on a security-by-security basis and cleared out of the other comprehensive income balance upon sale of each individual security. During the periods presented, none of the individual securities associated with a dangling balance were sold.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NDk_6155d85e-953d-4cbf-9cf7-6059c698427e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Revenue from a customer consists of any combination of the sale and rental of DME and/or patient medical services. Revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company&#x2019;s products fall in the Medicare Fee-for-Service (&#x201c;FFS&#x201d;) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare &amp;amp; Medicaid Services (&#x201c;CMS&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For commercial payors, DME companies must negotiate in-network pricing separately, though in general, the Company&#x2019;s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with DME rentals, the Company recognizes revenue in accordance with ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Leases,&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (Topic 842). For any DME sales and services, the Company recognizes revenue under FASB ASU 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Revenue from Contracts with Customers,&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (Topic 606) and related amendments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMTIwNDA_e8f5d04d-bee8-4514-9160-03935c91ffb1">P1M</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3MzA_d65cb5ed-7f7b-4f28-9a4c-b37b35ffc0b5">&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The revenues from each major source are summarized in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenue from rentals &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Ventilator rentals, non-invasive and invasive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Other durable medical equipment rentals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenue from sales and services &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;Equipment and supply sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;COVID-19 response sales and services&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:2pt;margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;29,285&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;33,447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;85,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;100,107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="icd917d51157d466ba06d77882124fe90_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfMy0yLTEtMS0x_a614d679-f863-48ce-860c-c5bedaaf0897"
      unitRef="usd">21305000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="i21c590c6cb2c4aabab1faeddb85de476_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfMy00LTEtMS0x_b64a3d30-0494-488f-a283-a8c6c796cea6"
      unitRef="usd">19962000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="i435b1dfb19324a3a80b71d9ec9b03097_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfMy02LTEtMS0x_2828bb65-21ac-4dc3-a414-4434356ce658"
      unitRef="usd">61962000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="i5b0c9015e90944a9a17d402213f296fc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfMy04LTEtMS0x_7c8951c3-62dd-4029-890e-484f23818472"
      unitRef="usd">58672000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="i1f1ecb80965642fbadc7233c55e2e25e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNC0yLTEtMS0x_9295dc67-b098-45af-9d4b-5b293617798b"
      unitRef="usd">3598000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="i7301bcb71cfa44948e8127d480f5130c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNC00LTEtMS0x_e4e3cab1-9611-482d-bfbc-b7086dccd854"
      unitRef="usd">2649000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="i63e996f926c5450fa282162205bc1bea_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNC02LTEtMS0x_799d9145-efca-4be2-8a72-2ea253a0a7bc"
      unitRef="usd">9833000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="idc18131a88214a2a81b395db3505d107_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNC04LTEtMS0x_88716b18-def4-4f9e-98cb-e69afc513a73"
      unitRef="usd">7184000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e78c9cea09846458e3dc27631212986_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNi0yLTEtMS0x_1d591c39-b414-4f1d-ae87-466fa9aecc35"
      unitRef="usd">2415000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fc6492490bc4b1490392b2ed8be8db2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNi00LTEtMS0x_93775ca1-d7ef-4b9a-8d41-87ad46b7a187"
      unitRef="usd">1890000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc9421ac4a184e8d91a81e460d2113cc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNi02LTEtMS0x_5b99323b-5619-402b-8310-761809c08c14"
      unitRef="usd">6258000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff19a29d6c2c4522a4f392e635400390_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNi04LTEtMS0x_498c96ea-c6ef-4ab3-a481-52ac6df261b2"
      unitRef="usd">3962000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8727827e5c84f4fa96f89fff0b8273c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNy0yLTEtMS0x_83b94e2f-48ce-44fa-a057-e6676ce26edb"
      unitRef="usd">1452000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i768c9291994346aab84e8a3706141a9e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNy00LTEtMS0x_5b4d4a90-9179-4ff3-a2e6-183d5cde352c"
      unitRef="usd">8553000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iecce218d389d406eb3310f56da83c06e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNy02LTEtMS0x_863ed25f-52f9-4f9c-9704-7fd71b5f3564"
      unitRef="usd">5542000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36805497dabe4b1ca576fc7081dd4b66_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfNy04LTEtMS0x_3e86be6c-099e-4dd1-bae7-9832e5ed4a70"
      unitRef="usd">29306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac0999e7702345499410c35dc62978eb_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOC0yLTEtMS0x_93a02d01-98ae-4b65-9163-bd8bfdaa92e8"
      unitRef="usd">515000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06a4c357dacb453faeda00f5a03c85fd_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOC00LTEtMS0x_ccc7f47b-62ca-4852-beb7-c9f32b59c824"
      unitRef="usd">393000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69397aa140894aa59c5c17529168578a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOC02LTEtMS0x_468c10ff-4306-4633-8f51-e8c472dd8fe5"
      unitRef="usd">1505000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f25b5934b1c4af683335208edd0f7bf_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOC04LTEtMS0x_4e5efe30-f3d1-4f49-a061-460a114a9105"
      unitRef="usd">983000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOS0yLTEtMS0x_7ed27b55-3c98-47c4-ab48-57c87a611451"
      unitRef="usd">29285000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOS00LTEtMS0x_be01c5bb-5a23-4d69-be76-21597ee46daa"
      unitRef="usd">33447000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOS02LTEtMS0x_d1ef67d0-3b27-4041-b1a6-12a17e0ae9b9"
      unitRef="usd">85100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RhYmxlOmE1YjEyYmE0NjY5YTRmN2Y5YWVlMmZkMjdmZWM5N2U0L3RhYmxlcmFuZ2U6YTViMTJiYTQ2NjlhNGY3ZjlhZWUyZmQyN2ZlYzk3ZTRfOS04LTEtMS0x_a679a53a-51ce-4dec-8bea-65f057cd39d9"
      unitRef="usd">100107000</us-gaap:Revenues>
    <us-gaap:RevenueRecognitionLeases
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NjA_61872cc8-4015-4fe7-a2a0-b95e6888b646">&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Accounting under Topic 842&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company leases DME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company accounts for these rentals as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under FASB ASC Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.&lt;/span&gt;&lt;/div&gt;Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.</us-gaap:RevenueRecognitionLeases>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NjY_0c6fb01f-a24b-46bb-8354-2114909ff2f0">&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Accounting under Topic 606&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company sells DME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company also provides sleep study services to customers and recognizes revenue when the sleep study results are complete, satisfying the performance obligation. In response to the COVID-19 pandemic, the Company began offering contact and vaccine tracing services, which revenues are recognized in the period in which the service has been provided. The transaction price on equipment sales, sleep studies and contact and vaccine tracing is the amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the DME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The Company does not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Returns and refunds are not accepted on equipment sales, sleep study services or contact and vaccine tracing services. The Company does not offer warranties to customers in excess of the manufacturer&#x2019;s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of September 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3MzY_b8a38647-2e57-448f-93d4-f137438f6584">&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company accounts for its stock-based compensation in accordance with ASC 718&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;, "Compensation&#x2014;Stock Compensation"&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock&#x2013;based compensation costs for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units ("RSUs") are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the Company&#x2019;s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the equivalent Company's stock value at the end of each period and records a liability based on the percentage of requisite service.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NjI_5d32bb39-03f1-4882-8481-da2a467f8d21">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company utilizes an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the Term Note (as defined below).&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk.&#160;These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company presents a positive ending period fair value of the interest rate swap contract in other long-term assets, as a component of long-term assets, and a negative ending period fair value of the interest rate swap contract in accrued liabilities, as a component of long-term liabilities on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty&#160;as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets.&#160;To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3Mzc_0011a249-27e8-45b0-802e-152fe170d89a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is subject to income taxes in numerous jurisdictions. Significant judgment is required in determining the provision for income taxes. The Company's income tax provisions reflect management&#x2019;s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that we will receive refunds from or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact our effective tax rate as well as our business and operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted or substantively enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNC9mcmFnOjczYzIzNzYzN2M1MDQ0M2Y4ZWJmM2RkNWQ5MTVhZjM0L3RleHRyZWdpb246NzNjMjM3NjM3YzUwNDQzZjhlYmYzZGQ1ZDkxNWFmMzRfMjY3NTA_4919bec8-084e-465c-8dec-2a2118b41098">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12,&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#160;The new guidance simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The new guidance also improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending the existing guidance.&#160;The Company adopted this standard on January 1, 2020, which did not have any impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is an &#x201c;emerging growth company&#x201d; as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, our condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In November 2019, the FASB issued&#160;ASU 2019-11,&#160;Codification Improvements to Topic 326, Financial Instruments &#x2013; Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which is intended to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets. The standard replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. Further, the FASB issued ASU 2019-04 and ASU 2019-05 to provide additional guidance on the credit losses standard. The standard is effective for fiscal years beginning after December 15, 2022 for smaller reporting companies, including interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the effect that this standard will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), which provides optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. Specifically, the guidance permits an entity, when certain criteria are met, to consider amendments to contracts made to comply with reference rate reform to meet the definition of a modification under GAAP. It further allows hedge accounting to be maintained and a one-time transfer or sale of qualifying held-to-maturity securities. The expedients and exceptions provided by the amendments are permitted to be adopted any time through December 31, 2022 and do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, except for certain optional expedients elected for certain hedging relationships existing as of December 31, 2022. The Company is currently evaluating the effect that this standard will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNzYz_c8b86474-aac7-4d06-9fd1-1fb4f143e1d2">Property and Equipment&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s fixed assets consist of its medical equipment held for rental, furniture and equipment, real property and related improvements, and vehicles and other various small equipment. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table details the Company&#x2019;s fixed assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"&gt;Property and equipment, net of accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;59,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;55,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation in the amount of $2,656,000 and $2,224,000 is included in cost of revenue for the three months ended September 30, 2021 and 2020, respectively, and in the amount of $7,574,000 and $6,133,000 for the nine months ended September 30, 2021 and 2020, respectively. Included in medical equipment above is equipment acquired under finance lease obligations whose cost and accumulated depreciation at September 30, 2021 total $1,098,000 and $222,000, respectively. At December 31, 2020, cost and accumulated depreciation on equipment acquired under finance lease obligations was $6,900,000 and $885,000, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNzY1_858765f3-bd3a-4f54-9499-40bced918b33">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table details the Company&#x2019;s fixed assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%"&gt;Property and equipment, net of accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;59,036&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;55,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i156a988ddacc42c782d87dff13bbeafa_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfMS0yLTEtMS0x_f9ffbeb0-c5a2-42ee-827f-9ec893c786e4"
      unitRef="usd">72795000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6ff889a5f20c48f0b14d11a61f24192a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfMS00LTEtMS0x_77d286b9-7987-473a-a1a7-30ca5ddba8d8"
      unitRef="usd">63307000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2fa701e0a3e54a9b9dd36ecc85c2307d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfMi0yLTEtMS0x_a9f1bd8a-74b8-4033-9aa8-6d80f87854d4"
      unitRef="usd">2410000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i79d9b33a1c5b4522a3fc544ec67f806d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfMi00LTEtMS0x_a8bc23a6-ecff-4244-8239-32b055e979c5"
      unitRef="usd">2722000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie6b0c208bb684b35bbbd15d7eca58b2b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfMy0yLTEtMS0x_671b3d8c-fa81-4af2-b87e-c904592b5c64"
      unitRef="usd">2138000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ied68468793ac4161b8131a57412fe183_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfMy00LTEtMS0x_b258c93d-0e53-40f1-b860-65f7e1ef45a0"
      unitRef="usd">2138000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iff704998475b4b84afa049d983871456_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNC0yLTEtMS0x_8a85cd15-dfca-4454-8c88-8453f6f66abb"
      unitRef="usd">5863000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i08badebcad9a46b2b8e8bfe2be733945_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNC00LTEtMS0x_61812006-99e9-4beb-8c4f-4c156c2523f0"
      unitRef="usd">5966000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i53f44e1e3cce49638ad0ef4800be09eb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNS0yLTEtMS0x_16e53225-72ac-4579-954a-d9dcb1ddd008"
      unitRef="usd">296000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i19004823fe6d4d70b445becfaf7cf907_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNS00LTEtMS0x_857f6204-fd11-4247-952c-c33483fab781"
      unitRef="usd">290000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i71dae52fc95540f0af34167cf33d9206_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNi0yLTEtMS0x_5f134d10-a469-491b-8467-256046f9f367"
      unitRef="usd">972000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i90c97c3db0d745e2802b30d356846aa8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNi00LTEtMS0x_bf898cfa-3e90-4502-801d-d763b70c9530"
      unitRef="usd">922000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNy0yLTEtMS0x_46bfa0f6-3b45-4485-b468-eb2ce1ae58f7"
      unitRef="usd">25438000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfNy00LTEtMS0x_e72a3e11-88e6-415a-ab35-22b66f017ecf"
      unitRef="usd">20289000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfOC0yLTEtMS0x_849aa6a0-6c07-42b6-adc0-2614ab36da72"
      unitRef="usd">59036000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RhYmxlOjM4ZWMwNzQzZjNkMTQyZTRiYWFhMWVlZjczYmU4ZmU1L3RhYmxlcmFuZ2U6MzhlYzA3NDNmM2QxNDJlNGJhYWExZWVmNzNiZThmZTVfOC00LTEtMS0x_7a99587d-253b-4993-a48d-ed4561a51e30"
      unitRef="usd">55056000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfMzE0_772ca4f4-61c2-4718-b998-343a9b323524"
      unitRef="usd">2656000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfMzIx_d0b1fcbd-3c8e-4b0a-997c-29667b8086c8"
      unitRef="usd">2224000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNDI4_e89cc57d-aad6-420c-afff-8b3c8bb09e9a"
      unitRef="usd">7574000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciation
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNDM1_f151e840-6a16-4a7a-8dbf-f445603b69b0"
      unitRef="usd">6133000</us-gaap:CostOfGoodsAndServicesSoldDepreciation>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if94ef301d7e04a16834b80d74e605bda_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNjEz_b2d1ba2e-0aa2-459d-b84d-327f09090a92"
      unitRef="usd">1098000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if94ef301d7e04a16834b80d74e605bda_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNjIw_dee5eeee-3588-4e11-9778-26ce3a47a10c"
      unitRef="usd">222000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3ad38a4d9ca54a5080a263d8110efa86_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNzM3_16d00f1c-af6f-4fff-baad-017cef6db8ab"
      unitRef="usd">6900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3ad38a4d9ca54a5080a263d8110efa86_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN18zNy9mcmFnOmVhMmM2ODM4Y2RmNDQ1NGFhZmY1MzJiMzU4Yzk2NWEwL3RleHRyZWdpb246ZWEyYzY4MzhjZGY0NDU0YWFmZjUzMmIzNThjOTY1YTBfNzQ0_34836355-c863-48a0-b42c-1c5f657d5d86"
      unitRef="usd">885000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RleHRyZWdpb246YTNjMTAwNzBkMDA0NDUxNTg4NDJhMDA0OWMzOTc3NGNfMTgx_8ff99b30-a4bb-42bb-bbb8-fa68885451d7">Current Liabilities&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term accrued liabilities are included within current liabilities and consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued trade payables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued commissions payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued bonuses payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued vacation and payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current portion of phantom share liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,595&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RleHRyZWdpb246YTNjMTAwNzBkMDA0NDUxNTg4NDJhMDA0OWMzOTc3NGNfMTgz_5becf1ea-03c3-433d-bcef-6524360832e8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s short-term accrued liabilities are included within current liabilities and consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.260%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued trade payables &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued commissions payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued bonuses payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued vacation and payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current portion of phantom share liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9,283&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12,595&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <vmd:AccruedTradePayablesCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfMS0yLTEtMS0x_e9922b14-d3b9-401b-ade1-5dc72a7c3ac1"
      unitRef="usd">2265000</vmd:AccruedTradePayablesCurrent>
    <vmd:AccruedTradePayablesCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfMS00LTEtMS0x_c1d709c1-8441-4384-864b-b3a6096c572b"
      unitRef="usd">1252000</vmd:AccruedTradePayablesCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfMi0yLTEtMS0x_f459b75b-254d-4cec-ad12-778f5f30dafc"
      unitRef="usd">388000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfMi00LTEtMS0x_a4dd141f-0ebe-4d8a-8eb7-8bdc0b395e94"
      unitRef="usd">278000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfMy0yLTEtMS0x_69784a68-db97-4822-9be3-02e58ce64b67"
      unitRef="usd">2912000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfMy00LTEtMS0x_a4c897e3-b10f-4978-9170-8ccff5739432"
      unitRef="usd">5190000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNC0yLTEtMS0x_caca6307-980f-4a49-859b-1b9bd2ba0106"
      unitRef="usd">2027000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNC00LTEtMS0x_fa23c063-53f5-4e77-98ef-1fe538068839"
      unitRef="usd">844000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNS0yLTEtMS0x_a8f087b2-b1b2-4e3b-b615-c5bd7815d4c2"
      unitRef="usd">1002000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNS00LTEtMS0x_a4fd899f-c8b9-40ed-a3b6-33d3c111d7bd"
      unitRef="usd">4485000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNi0yLTEtMS0x_8dfac32d-758a-4a55-8eec-18746345197d"
      unitRef="usd">689000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNi00LTEtMS0x_873bf6fa-4354-49e5-b3e5-ec0af9cd7213"
      unitRef="usd">546000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNy0yLTEtMS0x_f67545e5-0dbd-48a3-8127-90aac72462bc"
      unitRef="usd">9283000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180MC9mcmFnOmEzYzEwMDcwZDAwNDQ1MTU4ODQyYTAwNDljMzk3NzRjL3RhYmxlOmY0MDYzMGJkN2ZlNjQzNDNiMDk5YzEzZGM3YjdjNDllL3RhYmxlcmFuZ2U6ZjQwNjMwYmQ3ZmU2NDM0M2IwOTljMTNkYzdiN2M0OWVfNy00LTEtMS0x_0298c23f-988e-4550-b6e2-2260894344fe"
      unitRef="usd">12595000</us-gaap:AccruedLiabilitiesCurrent>
    <vmd:DebtandLeaseDisclosureTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTY0Ng_3dff3bf5-6fb1-4ff4-aa7d-59c75f11b7f7">Debt and Lease Liabilities&lt;div style="padding-right:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Senior Credit Facility &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On February 20, 2018, the Company entered a Commercial Business Loan Agreement that provides for Term Loans and Line of Credit with Hancock Whitney Bank.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Line of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The Company maintains a line of credit in the amount of $10.0 million that expires May 1, 2023 under the Commercial Business Loan Agreement. Any amounts advanced on this line will be subject to an interest rate equal to the WSJ prime rate plus a margin of 0.50%, with a 3.50% interest rate floor and will be secured by substantially all of the Company's assets. There were no borrowings against this line of credit at September 30, 2021 or December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commercial Term Notes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On May 30, 2019, the Company entered into a term note (the &#x201c;Building Term Note&#x201d;) under the Commercial Business Loan Agreement in the principal amount of $4.8&#160;million. The proceeds of the Building Term Note were used to purchase the Company's corporate headquarters. Beginning July 1, 2019, the Company began making monthly payments towards the outstanding balance. The Building Term Note matures on May 30, 2026 and is secured by substantially all of the assets of the borrower, including the real property acquired with the proceeds of the Building Term Note. The Building Term Note bears interest at a variable rate equal to the one month ICE LIBOR index plus a margin of 2.45% per annum. The Company is required to maintain a loan to value ratio of 85% with respect to the appraised value of the real property. In connection with the Building Term Note, the Company entered into an interest rate swap transaction (the "Interest Rate Swap Transaction") with Hancock Whitney Bank effectively fixing the interest rate for the Building Term Note at 4.68%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On September 19, 2019, the Company entered into an additional loan agreement providing for a term note (the &#x201c;Term Note") under the Commercial Business Loan Agreement in the principal amount of $5.0 million. The proceeds of the Term Note were utilized for general corporate purposes. Beginning October 19, 2019, the Company started making monthly principal payments of $139,000 towards the outstanding balance. The Term Note matures on September 19, 2022 and is secured by substantially all of the assets of the borrower. The Term Note bears interest at the rate of 4.60% per annum.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company incurred immaterial financing costs related to the above term notes. These deferred financing costs are amortized over the term of the loans using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The recorded balances associated with these term notes, which have terms greater than twelve months, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net long-term notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,796&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under the Commercial Business Loan Agreement, the Company is subject to several restrictive covenants that, among other things, impose operating and financial restrictions on the Company. Financial covenants include a Total Debt to Adjusted EBITDA, a Loan-to-Value Ratio and a Fixed Charged Coverage Ratio, as defined in the Credit Agreement. The Credit Agreement also contains certain customary events of default, including, among other things, failure to make payments when due thereunder and failure to observe or perform certain covenants. The Company was in compliance with all covenants under the Commercial Business Term Loan Agreement in effect at September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:4.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-right:11.25pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has recognized finance lease liabilities for medical equipment and operating leases for land and buildings that have terms greater than twelve months, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net long-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;834&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has various finance leases for equipment with an implied interest rate at fixed rates up to 9.61%, secured by equipment, due between 2021 and 2024. The Company's weighted average interest rate was 3.74% and 3.17% for all finance lease liabilities outstanding as of September 30, 2021 and 2020, respectively. At September 30, 2021 and 2020, the weighted average lease term was approximately 1.05 years and 0.73 years, respectively. Interest expense related to these finance lease obligations for the three and nine months ended September 30, 2021 amounted to $4,000 and $35,000, respectively. Interest expense related to these finance lease obligations for the three and nine months ended September 30, 2020 amount to $34,000 and $128,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has recognized operating lease liabilities that relate primarily to the lease of land and buildings. These leases contain renewal options that we have not included as part of the Company's assessment of the lease term as it is not reasonably certain that we will exercise these options. These lease liabilities are recorded at present value based on a discount rate of 5.50%, which was based on the Company's incremental borrowing rate at the time of assessment. At September 30, 2021, the weighted average lease term was approximately 3.39 years. Operating rental expenses were $194,000 and $570,000 for the three and nine months ended September 30, 2021, respectively, and $191,000 and $575,000 for the three and nine months ended September 30, 2020, respectively. The related assets for operating lease liabilities have been included with property and equipment on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Included within these operating lease liabilities are real property leases for real estate from a related party. On August 1, 2015, the Company entered ten-year triple net lease agreements for office space with an entity that is affiliated with the Company's CEO, Casey Hoyt, and President, Michael Moore. Rental payments under these related party lease agreements are $20,000 per month, plus taxes, utilities and maintenance. Total rental payments for the use of these properties were $81,000 and $194,000 for the three and nine months ended September 30, 2021, respectively, and $58,000 and $180,000 for the three and nine months ended September 30, 2020, respectively. The expense for these related party rents has been included within selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;</vmd:DebtandLeaseDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i87fcc673b3034eaa9412181d84c0c71e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMjg5_35764e31-3395-41fa-aaae-69724755b1e0"
      unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia2c1e065140c48f584cc31eda13a9cc8_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDc4_4fca1cd7-f876-4562-8eca-c14480900af3"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <vmd:DebtInstrumentInterestRateFloorRate
      contextRef="i87fcc673b3034eaa9412181d84c0c71e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDg5_6698cb1d-745a-48b5-991f-8d340150aa1b"
      unitRef="number">0.0350</vmd:DebtInstrumentInterestRateFloorRate>
    <us-gaap:LineOfCredit
      contextRef="i87fcc673b3034eaa9412181d84c0c71e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTg5_60de9487-9446-4110-ad52-884632e7d6e0"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i81a15ff7f25b45068f37929013eedd30_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTg5_d4ce773f-1104-4c1d-a47b-5b8d27930b05"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i62a32ca8e15648e9b1241a1aae489574_I20190530"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfODIy_1ef4e509-e113-4f42-98a7-8fe1d989730f"
      unitRef="usd">4800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9e7304b41d654a3d881976535714777c_D20190530-20190530"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMTMzMw_cd3b396b-5963-436c-9ac8-a5dde757031a"
      unitRef="number">0.0245</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <vmd:DebtInstrumentCovenantLoanToValueRatio
      contextRef="i62a32ca8e15648e9b1241a1aae489574_I20190530"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMTQwOA_9a18f804-ae7a-4f9f-bb90-628b1709cccf"
      unitRef="number">0.85</vmd:DebtInstrumentCovenantLoanToValueRatio>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="id0c674c148fc429ca571bcce37d330e5_I20190530"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMTcwMw_16691d53-4bde-4225-a050-e16b041da4e1"
      unitRef="number">0.0468</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i95649eeb9b3f4027bc486bde62cc4ae2_I20190919"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMTkwMQ_e4fd717a-26f2-4225-a409-598d5adfd5cf"
      unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="id3c6f22c80984ffcb2872cd478bf4368_D20191019-20191019"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMjA2Ng_605f532d-57a7-4a3d-930b-0a9d036a11d2"
      unitRef="usd">139000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i95649eeb9b3f4027bc486bde62cc4ae2_I20190919"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMjI1Nw_379c9582-4b19-46c2-a8fb-d97cd00db256"
      unitRef="number">0.0460</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTYzOQ_1588b0c0-8213-4ded-8393-f8e73df5d089">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The recorded balances associated with these term notes, which have terms greater than twelve months, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,906)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net long-term notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,796&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebt
      contextRef="ie603f4248e314cdf811e9ec8560c574f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjg1MzkwODIwMjJmOTQ4YmQ4NDc0OTMyZmJjZWViMzM1L3RhYmxlcmFuZ2U6ODUzOTA4MjAyMmY5NDhiZDg0NzQ5MzJmYmNlZWIzMzVfMS0yLTEtMS0x_c162863e-34fb-4ff3-b932-a557db5ef32d"
      unitRef="usd">6253000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1ee66bd47ddd42ec90cd24f18d4e553f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjg1MzkwODIwMjJmOTQ4YmQ4NDc0OTMyZmJjZWViMzM1L3RhYmxlcmFuZ2U6ODUzOTA4MjAyMmY5NDhiZDg0NzQ5MzJmYmNlZWIzMzVfMS00LTEtMS0x_639c2edb-222e-4a8f-8884-20285a098187"
      unitRef="usd">7632000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ie603f4248e314cdf811e9ec8560c574f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjg1MzkwODIwMjJmOTQ4YmQ4NDc0OTMyZmJjZWViMzM1L3RhYmxlcmFuZ2U6ODUzOTA4MjAyMmY5NDhiZDg0NzQ5MzJmYmNlZWIzMzVfMy0yLTEtMS0x_f2a0e32f-6078-41ad-83f2-6b208bdfe266"
      unitRef="usd">1906000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i1ee66bd47ddd42ec90cd24f18d4e553f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjg1MzkwODIwMjJmOTQ4YmQ4NDc0OTMyZmJjZWViMzM1L3RhYmxlcmFuZ2U6ODUzOTA4MjAyMmY5NDhiZDg0NzQ5MzJmYmNlZWIzMzVfMy00LTEtMS0x_970f619e-bee7-454b-9f8c-acf466844b9b"
      unitRef="usd">1836000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie603f4248e314cdf811e9ec8560c574f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjg1MzkwODIwMjJmOTQ4YmQ4NDc0OTMyZmJjZWViMzM1L3RhYmxlcmFuZ2U6ODUzOTA4MjAyMmY5NDhiZDg0NzQ5MzJmYmNlZWIzMzVfNC0yLTEtMS0x_895e59a4-52a3-4d58-b7bb-88517d697acb"
      unitRef="usd">4347000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1ee66bd47ddd42ec90cd24f18d4e553f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjg1MzkwODIwMjJmOTQ4YmQ4NDc0OTMyZmJjZWViMzM1L3RhYmxlcmFuZ2U6ODUzOTA4MjAyMmY5NDhiZDg0NzQ5MzJmYmNlZWIzMzVfNC00LTEtMS0x_9793b009-6eca-4baa-aee8-6351e6d96ee3"
      unitRef="usd">5796000</us-gaap:LongTermDebtNoncurrent>
    <vmd:LiabilitiesLesseeTableTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTY0NA_cab01dca-1134-4946-908c-e386c08fe70c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has recognized finance lease liabilities for medical equipment and operating leases for land and buildings that have terms greater than twelve months, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.670%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net long-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;834&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vmd:LiabilitiesLesseeTableTextBlock>
    <vmd:LeaseLiability
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjY1NWVmZDhhYzU1NTQ3NzViMGE0ZTA2Y2Y2ZTc3YmZjL3RhYmxlcmFuZ2U6NjU1ZWZkOGFjNTU1NDc3NWIwYTRlMDZjZjZlNzdiZmNfMS0yLTEtMS0x_7a7a59a3-a139-4987-8ea3-082b85c2db07"
      unitRef="usd">1315000</vmd:LeaseLiability>
    <vmd:LeaseLiability
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjY1NWVmZDhhYzU1NTQ3NzViMGE0ZTA2Y2Y2ZTc3YmZjL3RhYmxlcmFuZ2U6NjU1ZWZkOGFjNTU1NDc3NWIwYTRlMDZjZjZlNzdiZmNfMS00LTEtMS0x_070ca04f-4310-4e00-9548-74d501fab400"
      unitRef="usd">3503000</vmd:LeaseLiability>
    <vmd:LeaseLiabilityCurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjY1NWVmZDhhYzU1NTQ3NzViMGE0ZTA2Y2Y2ZTc3YmZjL3RhYmxlcmFuZ2U6NjU1ZWZkOGFjNTU1NDc3NWIwYTRlMDZjZjZlNzdiZmNfMy0yLTEtMS0x_be3180ee-53a4-45a9-97c7-5574b6bafb4d"
      unitRef="usd">481000</vmd:LeaseLiabilityCurrent>
    <vmd:LeaseLiabilityCurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjY1NWVmZDhhYzU1NTQ3NzViMGE0ZTA2Y2Y2ZTc3YmZjL3RhYmxlcmFuZ2U6NjU1ZWZkOGFjNTU1NDc3NWIwYTRlMDZjZjZlNzdiZmNfMy00LTEtMS0x_91c6b52a-1d1e-4e08-b91d-35ed07350473"
      unitRef="usd">2741000</vmd:LeaseLiabilityCurrent>
    <vmd:LeaseLiabilityNoncurrent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjY1NWVmZDhhYzU1NTQ3NzViMGE0ZTA2Y2Y2ZTc3YmZjL3RhYmxlcmFuZ2U6NjU1ZWZkOGFjNTU1NDc3NWIwYTRlMDZjZjZlNzdiZmNfNC0yLTEtMS0x_60588338-c818-4d09-88ca-cec093ce6dcd"
      unitRef="usd">834000</vmd:LeaseLiabilityNoncurrent>
    <vmd:LeaseLiabilityNoncurrent
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RhYmxlOjY1NWVmZDhhYzU1NTQ3NzViMGE0ZTA2Y2Y2ZTc3YmZjL3RhYmxlcmFuZ2U6NjU1ZWZkOGFjNTU1NDc3NWIwYTRlMDZjZjZlNzdiZmNfNC00LTEtMS0x_451f4de7-5fcd-4cc5-8ca2-1fe4a6547038"
      unitRef="usd">762000</vmd:LeaseLiabilityNoncurrent>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzU2MQ_f9ec9f6a-af2a-4dd9-a534-c1ff894353c6"
      unitRef="number">0.0961</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzY2Mw_e2334a80-a9e8-41a7-838b-ff607b46873e"
      unitRef="number">0.0374</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i0e735857f255494fa3f0fdeb61129073_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzY3MA_56275f6f-59b2-43f2-87a1-e82cd89349fa"
      unitRef="number">0.0317</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzgxNA_ed65fc84-52c5-40fb-b10e-43369c66426b">P1Y18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i0e735857f255494fa3f0fdeb61129073_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzgyMQ_b597aa18-0c5b-4361-be74-802a58b9eebb">P0Y8M23D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzkzOA_641883e3-9025-4d5d-bacb-417d013a4c60"
      unitRef="usd">4000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzk0NQ_6b9e0caa-b5df-4248-b2d9-589df9e0f333"
      unitRef="usd">35000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDA2MA_0ab14822-2551-4524-aabc-62800449c043"
      unitRef="usd">34000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDA2Nw_8a1038ad-dc0e-49b6-b583-ce52eed7b529"
      unitRef="usd">128000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDQ5Ng_c8adff38-b1ef-4f08-abcd-1084c9d81e14"
      unitRef="number">0.0550</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDY0NA_244026c1-5ed3-4c2d-94a3-22db880d2b0f">P3Y4M20D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCost
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDY3OQ_585ff3e2-1160-4421-8e66-d8e4276cc42d"
      unitRef="usd">194000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDY4Ng_cee6af43-535c-4941-9770-c686d8cbb700"
      unitRef="usd">570000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDczNQ_61d2ef65-0870-43e6-85e3-a948cf0053a4"
      unitRef="usd">191000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNDc0Mg_3ec35a26-5104-465c-b346-f9072e260964"
      unitRef="usd">575000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i5485b5cf5d2b4b92a5935928e69064c0_I20150801"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfMzI5ODUzNDg4OTE3OQ_060e56c8-1c77-4772-92ef-9ca41ad54fdd">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="iffa3aec0aba44dc4bdc7a429c06c397f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTMwMA_d72154ee-fa55-40d2-a191-29f15d90b3f5"
      unitRef="usd">20000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ic289ae73a55a46dfbf14b45d633afa0f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTQxMg_44f2ff66-a6ff-4f46-90f1-10becd55a0c4"
      unitRef="usd">81000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="iffa3aec0aba44dc4bdc7a429c06c397f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTQxOQ_8da5d9a3-fafb-43e1-8eea-8b0537c92ff4"
      unitRef="usd">194000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i3279b51ac3584bafbc99103f6f86c88e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTQ2OA_e38798d2-681c-4cd3-99e3-250b322dc524"
      unitRef="usd">58000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ib14997b1010a40869c680e8e635ea4cd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180My9mcmFnOmUxYjhlZTg1YjQxODRkODI5MTEwMzhhYmY1OWU2ZTFhL3RleHRyZWdpb246ZTFiOGVlODViNDE4NGQ4MjkxMTAzOGFiZjU5ZTZlMWFfNTQ3NQ_297db7d0-b31b-4646-850d-148853eeecf1"
      unitRef="usd">180000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RleHRyZWdpb246YjQ3NzA0YTc5YTVmNDUwOGE3N2FjNjc0Y2U4ZGRhZTVfNDE1OA_09309581-93c9-4d27-9538-e81d581b591e">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC Topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. There are three levels to the hierarchy based on the reliability of inputs, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company measures certain assets and liabilities at fair value on a recurring basis. There were no transfers between fair value measurement levels during any presented period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:0.1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Recurring Fair Value Measurements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21,452&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21,182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Recurring Fair Value Measurements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25,662&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25,229&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative instruments and hedging activities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes its interest rate swaps as either assets or liabilities in the accompanying Condensed Consolidated Balance Sheets at fair value. The valuation of these derivative instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. As of September 30, 2021, the Company holds one interest rate swap contract which matures on May 30, 2026 and has a notional amount of $4.5 million. This contract is designated as a cash flow hedge. In the first nine months of 2021, ineffective portions of the hedge were immaterial. The fair value was $(0.3) million (determined based on Level 2 inputs) and is included in accrued liabilities, as a component of long-term liabilities as of September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;We measure certain assets and liabilities at fair value on a nonrecurring basis. These assets and liabilities include equity method investments and other equity investments. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. The Company's other equity investments are holdings in a privately-held company without a readily determinable market value. The Company remeasures equity securities without readily determinable fair value at fair value when an orderly transaction is identified for an identical or similar investment of the same issuer in accordance with Topic 820. ASU 2019-04 states that the measurement alternative is a nonrecurring fair value measurement. Accordingly, other equity investments without readily determinable fair value are classified within Level 3 in the fair value hierarchy because the Company estimates the value using a combination of observable and unobservable inputs, including valuation ascribed to the issuing company in subsequent financing rounds, volatility in the results of operations of the issuers and rights and obligations of the holdings we own.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company had no material adjustments of assets and liabilities measured at fair value on a nonrecurring basis during any of the periods presented. There were no transfers between fair value measurement levels during any presented period.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RleHRyZWdpb246YjQ3NzA0YTc5YTVmNDUwOGE3N2FjNjc0Y2U4ZGRhZTVfNDE1Nw_7c812134-9359-4c36-aad1-016db5d9efa6">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Recurring Fair Value Measurements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21,452&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;21,182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;At December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Recurring Fair Value Measurements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Money market mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25,662&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;25,229&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8abf6fe7c8484bdcb2308cea38f75932_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfMy0yLTEtMS0x_185f0c9b-c944-4698-a4dd-cda070e64a86"
      unitRef="usd">21452000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0b195c7493e8424bb8fd5536067a85e2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfMy00LTEtMS0x_b9b334f2-eba7-44eb-8e18-42cb1be9d54a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idea4ca441e78494680787bbcd4931142_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfMy02LTEtMS0x_f39eba98-116f-4d50-91d6-e98a07685038"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2dbc8fd191ad4330a8f453ba42571847_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfMy04LTEtMS0x_6517c9e1-fd80-4088-8d48-0a16abedbf1d"
      unitRef="usd">21452000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ic76538552bd94126a41545b7ed1db49a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNC0yLTEtMS0x_7c8dba5d-c5f7-4d55-8dec-31bf9ef196f6"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i09ac0c6a09264cc5954537a0acda8d17_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNC00LTEtMS0x_76c5a1e8-04ff-4fa3-96e1-0b9274759e4b"
      unitRef="usd">270000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i94711e3a71c045bba46f486d3bd974f0_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNC02LTEtMS0x_336788f1-7384-4abe-8e8c-76a8ad77e64e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i336da365772c4ac388b46c52653f0063_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNC04LTEtMS0x_f6034129-2e0e-4eeb-947f-af5291573628"
      unitRef="usd">270000</us-gaap:DerivativeLiabilities>
    <vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure
      contextRef="ibb901eb8035149c1915fc1b2307e3203_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNS0yLTEtMS0x_68108e09-7023-4914-bd3b-e3d7b03c73d7"
      unitRef="usd">21452000</vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure>
    <vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure
      contextRef="i1ca70504217e48bf8c74635b2513864a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNS00LTEtMS0x_c06a0eca-af14-46f0-878d-1413ab0fcf43"
      unitRef="usd">-270000</vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure>
    <vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure
      contextRef="i51c8148032c74773b49b36310c78a073_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNS02LTEtMS0x_82fcc104-0a49-452e-99fd-a971b5f67448"
      unitRef="usd">0</vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure>
    <vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure
      contextRef="ic8854bc148dc4d52b425355b31c2508a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOmNiY2Y2ODljNWRlNTQwMjRhODhhYjE5NjY5ODQwZDAzL3RhYmxlcmFuZ2U6Y2JjZjY4OWM1ZGU1NDAyNGE4OGFiMTk2Njk4NDBkMDNfNS04LTEtMS0x_30477791-bd73-49ef-8c06-760fb33a9934"
      unitRef="usd">21182000</vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1090d32a5c2b4309b916e12b4c123edc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfMy0yLTEtMS0x_81edc286-021c-4ab9-b06c-5989b85e98c0"
      unitRef="usd">25662000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1ef9ec490070462eb08089125148bc55_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfMy00LTEtMS0x_ea598483-8ff2-4ccd-aa05-b2d74cce8518"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifbca660f93914f07ace63ccfd0a4e058_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfMy02LTEtMS0x_42d8cafd-a27b-46df-b53a-e440b6e32fb1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i266900fa2c164d91a01dddf36477fe2e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfMy04LTEtMS0x_45bf7076-412c-4bc8-9987-bf04f7975788"
      unitRef="usd">25662000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ibcb6a65153dd4f75bba69cc5b394f676_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNC0yLTEtMS0x_d8785901-ad85-4da9-94f4-439eac881b32"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i00967b47876c44cd9989e4b0f712f2bc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNC00LTEtMS0x_7bb51b2d-60a2-49be-9973-1405d89bb3d7"
      unitRef="usd">433000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic3bfc5ae6e62482f9bed49fbcbfabbbe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNC02LTEtMS0x_0e8878df-5190-42c0-a27d-948c3242768f"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6da69231063840b48f20fac3ea629cd6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNC04LTEtMS0x_928921a9-b85d-4327-b0bf-e240066eb883"
      unitRef="usd">433000</us-gaap:DerivativeLiabilities>
    <vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure
      contextRef="i5b09cd700c71469e82f19274c7204713_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNS0yLTEtMS0x_88224517-e6b8-45af-b1a1-75d0c1066b26"
      unitRef="usd">25662000</vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure>
    <vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure
      contextRef="i8eb813583e1d404cb010b4516417789f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNS00LTEtMS0x_8bd51d15-e4f4-4b47-949b-7a3a29d82bd5"
      unitRef="usd">-433000</vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure>
    <vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure
      contextRef="ibb8b9626315448338619b019df225197_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNS02LTEtMS0x_70ff3951-d8c3-4e41-a430-3d714925a9a0"
      unitRef="usd">0</vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure>
    <vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure
      contextRef="iec098e30f68048118c3feaeee0ec6ada_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RhYmxlOjRhZDA2OTAxMGJkYzQ3NWU5MzAzNzEyYWUyYmI0OTY3L3RhYmxlcmFuZ2U6NGFkMDY5MDEwYmRjNDc1ZTkzMDM3MTJhZTJiYjQ5NjdfNS04LTEtMS0x_166b4038-d2f4-4035-b28b-3faa61503b2d"
      unitRef="usd">25229000</vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="i93444cef350340c49a0041603bff9d22_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RleHRyZWdpb246YjQ3NzA0YTc5YTVmNDUwOGE3N2FjNjc0Y2U4ZGRhZTVfMjI0Nw_50c040df-e410-4f03-ad5c-d660fc48de93"
      unitRef="interestrateswap">1</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i93444cef350340c49a0041603bff9d22_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RleHRyZWdpb246YjQ3NzA0YTc5YTVmNDUwOGE3N2FjNjc0Y2U4ZGRhZTVfMjMzNw_c29ecbe5-c0c7-425d-8d77-f82528854f0b"
      unitRef="usd">4500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i93444cef350340c49a0041603bff9d22_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN180Ni9mcmFnOmI0NzcwNGE3OWE1ZjQ1MDhhNzdhYzY3NGNlOGRkYWU1L3RleHRyZWdpb246YjQ3NzA0YTc5YTVmNDUwOGE3N2FjNjc0Y2U4ZGRhZTVfMjQ5MQ_b2385627-d806-4657-b754-669b5e577578"
      unitRef="usd">300000</us-gaap:DerivativeLiabilities>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDM5ODA0NjUxODUxNw_7afd876a-10c9-408f-9d6b-f50b72833565">Shareholders' Equity&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Authorized share capital&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s authorized share capital consists of an unlimited number of common shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Issued and outstanding share capital&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has only one class of stock outstanding, common shares. The authorized stock consists of an unlimited number of common shares with no stated par value, of which 39,630,446 and 39,185,182 shares were issued and outstanding as of September 30, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2021, the Company repurchased and canceled 181,320 common shares at a cost of $1.4 million due to tax withholding for RSUs vesting. The Company&#x2019;s retained earnings were reduced by the amount paid for the shares repurchased for cancellation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:49.5pt;padding-right:6.75pt;text-align:justify;text-indent:-49.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effective June&#160;11, 2020 (the "Effective Date"), the Company&#x2019;s shareholders approved the Company's 2020 Long Term Incentive Plan (the "Omnibus Plan"). Upon approval of the Omnibus Plan, no future awards are available to be made under the Company's previous RSU and Option Plans (collectively, the "Former Plan"), and the common shares that were not settled or awarded under the Former Plan as of the Effective Date are available for awards under the Omnibus Plan. The maximum number of common shares that are available for awards under the Omnibus Plan and under any other security-based compensation arrangements adopted by the Company, including the Former Plan, may not exceed 7,758,211 shares (equal to 20% of the issued and outstanding common shares of the Company on the Effective Date). The maximum amount of the foregoing common shares that may be awarded under the Omnibus Plan as &#x201c;incentive stock options&#x201d; is 2,600,000 common shares. As of September 30, 2021, the Company had outstanding options of 3,772,000 and RSUs of 219,000 associated with common shares under the Omnibus Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation - options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation - restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,845&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At September 30, 2021, there was approximately $3,495,000 of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized over a weighted-average period of&#160;2.00 years. As of September 30, 2021, there was approximately $852,000 of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 0.90 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the nine months ended September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of options&lt;br/&gt;&#160;(000's)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,057&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4.37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10,362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,772&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,343&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For presentation purposes, stock options issued with a CAD exercise price have been translated to USD based on the prevailing exchange rate on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options outstanding was $4,343,000 and options exercisable were $3,798,000 at September 30, 2021. For the nine months ended September 30, 2021, 27,597 shares of common stock were issued pursuant to the exercise of stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At September 30, 2021, the Company had 1,882,000 exercisable stock options outstanding with a weighted average exercise price of $3.65 and a weighted average remaining contractual life of 6.8 years. At December 31, 2020, the Company had 971,000 exercisable stock options outstanding with a weighted average exercise price of $3.09 and a weighted average remaining contractual life of 6.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company accounts for its stock-based compensation in accordance with ASC 718 &#x2014; Compensation&#x2014;Stock Compensation, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock&#x2013;based compensation cost for stock options are determined at the grant date using the Black-Scholes option pricing model. The assumptions used to determine the grant date fair value of the stock options granted during the nine months ended September 30, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.775%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$8.57 - $9.77&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.60% - 1.39%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.55% - 67.57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.65 - 5.76 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value on date of grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$5.05 - $5.57&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:15.75pt;padding-right:15.75pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company also grants RSUs to directors, officers, and employees. The Company accounts for RSUs using fair value as of the date of issuance. The fair value of the RSUs has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, based on the stock price on the date of grant.&#160;RSUs vest generally over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDIzNw_3068a39c-9f5a-4e15-9fea-67728d70b3a5"&gt;one&lt;/span&gt; or three-year period. The Company accounts for forfeitures on RSUs under ASU 2016-09 and recognizes forfeitures in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity for the nine months ended September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of RSUs (000's)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted average grant price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.04&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.22 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,308&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.90 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;All future equity grants will be awarded in USD, therefore, RSUs issued with a CAD grant price have been translated to USD based on the prevailing exchange rate on the date of grant for presentation purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of time-based RSUs outstanding was based on our closing stock price on the last trading day of the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;During the three months ended September 30, 2021, the Company issued 81,394 RSUs with a vesting term of one year and a fair value of $6.38 per share. During the nine months ended September 30, 2021, the Company issued 144,700 RSUs with a vesting term of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDM5ODA0NjUxODUwNg_2c114217-6a38-4569-b2f7-e925d2af2d45"&gt;one&lt;/span&gt; to three years and a fair value of $7.34 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Phantom share units&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has a phantom share unit plan, which it uses for grants to directors, officers, and employees. Phantom share units granted under the plan are non-assignable and are settled in cash at vesting based on the fair value of the Company's common stock on the vesting date. Phantom share units vest annually over a three-year period. The cash-settled phantom share units are accounted for as liability awards and are re-measured at fair value each reporting period until they become vested with accrued liability and related expense being recognized over the requisite service period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes phantom share unit activity for the nine months ended September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of phantom  share units (000's)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value of share equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,407&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;The value of outstanding share equivalents at the beginning of the period is based on the market price of the Company&#x2019;s stock at that time, the value of issued share equivalents is based on the market price of the Company&#x2019;s stock at issuance, the value of vested share equivalents is based on the cash paid at the time of vesting, the values of expired/forfeited share equivalents and outstanding share equivalents at the end of the period and are based on the market price of the Company's stock at the end of the period. The market price of the Company's stock was $5.55 on September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change in fair value of the phantom share units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities. The total liability associated with phantom share units at September 30, 2021 is $1,462,000, with $1,002,000 of this amount included in current accrued liabilities and the remaining portion of $460,000 included in long-term accrued liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The impact associated with the fair value re-measurement of phantom share units is recorded in selling, general and administrative expenses within the unaudited Condensed Consolidated Statements of Income and Comprehensive Income. The following table summarizes expense associated with the phantom share units for the three and nine months ended September 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company paid cash settlements of $6,282,000 and $4,201,000 during the nine months ended September 30, 2021 and 2020, respectively, pertaining to vestings of cash-settled phantom share units.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <vmd:NumberOfStockClasses
      contextRef="iac9ff3e2056a4a5f880103fc4356cd36_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzI5ODUzNDg5MDU2Nw_646e6457-52f1-478a-8342-de268c9b4c3f"
      unitRef="classofstock">1</vmd:NumberOfStockClasses>
    <us-gaap:CommonStockSharesIssued
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjE5OTAyMzI2MjgwNg_23bd00c6-532a-4728-b7dd-b49095ce310d"
      unitRef="shares">39630446</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjE5OTAyMzI2MjgwNg_3c096ff8-cc3c-49af-a79e-edeb198deadf"
      unitRef="shares">39630446</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfOTM0NTg0ODg0MzUxMg_36b2ae3f-9a71-4760-ad27-ed0a2c420cb7"
      unitRef="shares">39185182</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfOTM0NTg0ODg0MzUxMg_82bb926e-a6b0-488a-a48c-cfebf2da752f"
      unitRef="shares">39185182</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i464b82b483584d00a1b94e3674ba102f_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDg0_42eea3de-5e08-4d92-846c-b36986a5bb82"
      unitRef="shares">181320</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="i464b82b483584d00a1b94e3674ba102f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNTE0_c301125a-06e7-4c5f-bdb3-604d12c34ab4"
      unitRef="usd">1400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ib6898be82ef3450d8af8019abc1d1fb6_I20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMTM2Mg_cc718f1b-26ee-4a04-9fa7-3215d0e10735"
      unitRef="shares">7758211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <vmd:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding
      contextRef="id8114bd65eb746a5b3aaeaae80a4533d_D20200611-20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMTM4Mg_2790bbe0-5088-49fb-9243-215d3ab2d3e8"
      unitRef="number">0.20</vmd:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i0d0af2de6c674c96b220f46c78c9e9ba_I20200611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMTU5Mw_f6ce7ef2-084a-4ad7-8d2d-1da5765720bc"
      unitRef="shares">2600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMTY2MA_5bac8dcb-9292-428b-8228-355d74a42c14"
      unitRef="shares">3772000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id2dbd335dfd64d78885f580dba8cb8ba_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMTY3NQ_39120077-70b7-41ed-8b65-534bba8f4ee5"
      unitRef="shares">219000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzIxNA_6ced9d93-5633-4566-82fa-2ce84c6c7cf8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation - options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation - restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,845&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table summarizes expense associated with the phantom share units for the three and nine months ended September 30, 2021 and 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaa0187ebcaed44679c75f56be10857e9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMi0yLTEtMS0x_ec492639-54a4-4197-883b-19d1eba78bf5"
      unitRef="usd">1051000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia1310db462e54e89b2b94af7bdd21af5_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMi00LTEtMS0x_93cfc9f4-57e2-4d74-a8f3-410012631f41"
      unitRef="usd">945000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i795dccfd9203404ba393cb88b8244587_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMi02LTEtMS0x_e281d36b-a584-4a98-9013-5854bece5fb2"
      unitRef="usd">3127000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3036198797724f58bf6c7bf4265403b6_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMi04LTEtMS0x_3358788b-0af7-4f88-8b17-1c7594d4a3d4"
      unitRef="usd">2769000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9dedb3f8a3514cc5a585e7453a724c8d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMy0yLTEtMS0x_ef5a2732-2b4f-41f0-8fa0-8e55d2ba7cb5"
      unitRef="usd">251000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibe99e45d98d34bfe97e7b979e75c259b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMy00LTEtMS0x_dc43438f-d4cc-44a9-901d-db254eb0c022"
      unitRef="usd">289000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMy02LTEtMS0x_e82f46c0-a4ba-47c9-a610-ae3fb3705bb7"
      unitRef="usd">718000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i92da22dc12174d0da0397780472a1fbc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfMy04LTEtMS0x_0b8a3414-892a-44af-9cc7-2ee53915cace"
      unitRef="usd">812000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfNC0yLTEtMS0x_0ce412cc-79cf-423e-aa54-fb815e904353"
      unitRef="usd">1302000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfNC00LTEtMS0x_6f02573b-377e-4ed5-a695-0076584d39ac"
      unitRef="usd">1234000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfNC02LTEtMS0x_7ec0b9eb-0ede-4b19-942c-7ae5de439739"
      unitRef="usd">3845000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjBlNDcwOWQ2OGRkYTQ1ZGZhYjIzMjQzZjIxZjJjMmY1L3RhYmxlcmFuZ2U6MGU0NzA5ZDY4ZGRhNDVkZmFiMjMyNDNmMjFmMmMyZjVfNC04LTEtMS0x_b9656736-945a-4691-8d74-bcc7ef36052c"
      unitRef="usd">3581000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMTg3Mw_9af1420d-ea16-4773-9cd1-2d6186c456ea"
      unitRef="usd">3495000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i795dccfd9203404ba393cb88b8244587_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjAzMw_0f9a6b19-63bb-4dbe-a281-8b8eb84c52c9">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="id2dbd335dfd64d78885f580dba8cb8ba_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjA3MQ_c39815a9-7db1-4f81-9688-e9497dcf5a06"
      unitRef="usd">852000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjI1MA_5a59a7b1-2691-4505-bff4-3ea20ab26dfb">P0Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzIwMg_baa773c0-1b19-4a3f-a83e-7f6112bffffc">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the nine months ended September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.491%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of options&lt;br/&gt;&#160;(000's)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,057&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4.37&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;10,362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,772&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5.21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;4,343&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For presentation purposes, stock options issued with a CAD exercise price have been translated to USD based on the prevailing exchange rate on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMS0yLTEtMS0x_0e10ba6c-0377-4315-951a-fe42f72c69ed"
      unitRef="shares">3057000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMS00LTEtMS0x_697acbd7-5c83-41b2-8200-ddb6bf2ca44a"
      unitRef="usdPerShare">4.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7697ee5e2a4842a0b54ef6b98b72541f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMS02LTEtMS0x_f74b8c9b-e33f-4823-bc40-f070fe041532">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMS04LTEtMS0x_bc5e72dd-aee8-4d00-9c2d-c70b5fcde741"
      unitRef="usd">10362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMi0yLTEtMS0x_b30f48ee-1b6d-405f-9912-4cdb038468ff"
      unitRef="shares">829000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMi00LTEtMS0x_a9ee4b7a-e1e7-40b9-b176-5d236cc9f2d1"
      unitRef="usdPerShare">8.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMy0yLTEtMS0x_0986c319-bba7-46de-9851-32959eccf40d"
      unitRef="shares">28000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfMy00LTEtMS0x_f0f2ebe5-c5b3-467a-ba40-d43f275a1540"
      unitRef="usdPerShare">3.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfNC0yLTEtMS0x_f523b83f-ebc7-4157-b52b-007614b0205a"
      unitRef="shares">86000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfNC00LTEtMS0x_5a93f1eb-0682-490f-8054-d4c1f734af29"
      unitRef="usdPerShare">8.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfNS0yLTEtMS0x_273e5d57-1a8a-4b6c-ae08-7ded9e47ecb9"
      unitRef="shares">3772000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfNS00LTEtMS0x_57921123-261e-4a1a-bf7e-2e8ee3858aa9"
      unitRef="usdPerShare">5.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfNS02LTEtMS0x_6e12c79b-1c39-41d4-96c2-8cda5ae0a27d">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmY0MzlhMDc4Y2JhOTQ3MTM4NmNjZjFhNDI1YjA5NzhjL3RhYmxlcmFuZ2U6ZjQzOWEwNzhjYmE5NDcxMzg2Y2NmMWE0MjViMDk3OGNfNS04LTEtMS0x_5c3d7ea5-9b66-4548-970d-1ae49b462c48"
      unitRef="usd">4343000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjc2OQ_5c3d7ea5-9b66-4548-970d-1ae49b462c48"
      unitRef="usd">4343000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjgwMQ_0f67e0dd-3fab-4de4-9910-7505072d648d"
      unitRef="usd">3798000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i68e96bd771d5468da80ad750d5f5c11f_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjgyMw_1fa2070b-8cff-494b-9638-7f13f9c0952c"
      unitRef="shares">27597</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjkyOA_c41a1fb1-af5b-4e5a-8b1a-0e12fd30fee2"
      unitRef="shares">1882000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzAxMQ_5b8ade5a-0315-48ba-b2ee-8e47a66e8ff8"
      unitRef="usdPerShare">3.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzA2Nw_4a90629a-033c-43d4-87c6-720fe3da09c0">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzA5NA_da48c1f5-f059-49b5-bfef-1bad077aeb32"
      unitRef="shares">971000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzE3Nw_d06b8a90-79bd-4530-bbb9-84dead9240a9"
      unitRef="usdPerShare">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i7697ee5e2a4842a0b54ef6b98b72541f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzIzMw_ea595b80-3f09-491d-b187-4312c5a2002a">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzE5Ng_b0a9a554-1308-44d5-9714-c5a9e5396f4f">The assumptions used to determine the grant date fair value of the stock options granted during the nine months ended September 30, 2021 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.775%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.973%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$8.57 - $9.77&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.60% - 1.39%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.55% - 67.57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.65 - 5.76 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value on date of grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$5.05 - $5.57&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i88bbd8e84fbf41e09eac6d65db435276_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfMi0yLTEtMS0xL3RleHRyZWdpb246OGQ5MDM3NjU1YzRlNDE2ZDk4ZjMzN2JkNGM5NjU4ZjNfNA_6a8eb2fd-735b-4773-af2a-6bd675676ec6"
      unitRef="usdPerShare">8.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ia17494c399214eda9df7f117f9437b96_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfMi0yLTEtMS0xL3RleHRyZWdpb246OGQ5MDM3NjU1YzRlNDE2ZDk4ZjMzN2JkNGM5NjU4ZjNfOQ_3c1b42d9-6983-4dad-ae16-365ebb3f9817"
      unitRef="usdPerShare">9.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iffd0c2762d894ddb8c72a023745c0b80_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfMy0yLTEtMS0xL3RleHRyZWdpb246MjBkNmI5NzAzZDEyNDAzZGJjYjZlZTU3N2Q0MWFkZmRfNA_2038346a-d0a4-486d-85c9-d7b248e11836"
      unitRef="number">0.0060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iad5f0e1d7d4d457f82377ac5c1601912_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfMy0yLTEtMS0xL3RleHRyZWdpb246MjBkNmI5NzAzZDEyNDAzZGJjYjZlZTU3N2Q0MWFkZmRfOQ_ec23d191-a452-434b-85c1-8ac560c4bfb6"
      unitRef="number">0.0139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iffd0c2762d894ddb8c72a023745c0b80_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNC0yLTEtMS0xL3RleHRyZWdpb246NzFkODcxMjA2Y2ZjNGQ0ZmExMjg4YjlhNjRhOTE4MzRfNA_ed704e67-0a82-4fed-a557-38db8876d396"
      unitRef="number">0.6455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iad5f0e1d7d4d457f82377ac5c1601912_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNC0yLTEtMS0xL3RleHRyZWdpb246NzFkODcxMjA2Y2ZjNGQ0ZmExMjg4YjlhNjRhOTE4MzRfOQ_4db090c1-c2d6-455f-b6be-c9ce8692db7e"
      unitRef="number">0.6757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iffd0c2762d894ddb8c72a023745c0b80_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNS0yLTEtMS0xL3RleHRyZWdpb246ZTQ5MDFmZGFkNjAzNDI0M2EyM2M3MTBlZTE3ZDJiODBfNA_4b913b64-c4d9-4f36-a2c0-2c07ebe211e1">P5Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iad5f0e1d7d4d457f82377ac5c1601912_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNS0yLTEtMS0xL3RleHRyZWdpb246ZTQ5MDFmZGFkNjAzNDI0M2EyM2M3MTBlZTE3ZDJiODBfOQ_7913a5b4-dca7-4cb7-b520-b76914de53ec">P5Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i795dccfd9203404ba393cb88b8244587_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNi0yLTEtMS0x_2d89379e-3001-402f-a51f-99ea09792eb4"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharePrice
      contextRef="i88bbd8e84fbf41e09eac6d65db435276_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNy0yLTEtMS0xL3RleHRyZWdpb246MzMzODUzYjQ5OWEzNDdhYjk5NWRlYjBjNmQ4NTdlNjRfNA_bfdb5e22-b98e-40ab-aebe-b8ac4e580aa3"
      unitRef="usdPerShare">5.05</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="ia17494c399214eda9df7f117f9437b96_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmE3ZjQxMTNiZTJmNzQxZDliZDRjMDc2ZDNhNzEwY2M1L3RhYmxlcmFuZ2U6YTdmNDExM2JlMmY3NDFkOWJkNGMwNzZkM2E3MTBjYzVfNy0yLTEtMS0xL3RleHRyZWdpb246MzMzODUzYjQ5OWEzNDdhYjk5NWRlYjBjNmQ4NTdlNjRfOQ_74cc61a4-b50e-4ffc-a3e5-cb1397e17b14"
      unitRef="usdPerShare">5.57</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib2873c72b9da49babb2eb0a4aa374ba8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDM5ODA0NjUxODM1Mw_39d3e79e-768f-41f1-b4ee-41a852f65fc1">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzIxNg_7653ed88-5b23-41d4-8013-aeafaa554e06">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity for the nine months ended September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of RSUs (000's)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted average grant price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted average remaining contractual life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;684&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3.04&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.22 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5,308&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;6.72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;0.90 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1,217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;All future equity grants will be awarded in USD, therefore, RSUs issued with a CAD grant price have been translated to USD based on the prevailing exchange rate on the date of grant for presentation purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of time-based RSUs outstanding was based on our closing stock price on the last trading day of the period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iecdcfc455bed4a3ab837da5d7d3c93e3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMS0yLTEtMS0x_4b227f45-a4c1-4176-952f-668aad136f3a"
      unitRef="shares">684000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iecdcfc455bed4a3ab837da5d7d3c93e3_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMS00LTEtMS0x_4bedad45-6e04-4706-b4e3-f1f4ca13e213"
      unitRef="usdPerShare">3.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="iefa3109898274438af4768a1e85e1bab_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMS02LTEtMS0x_4e4e37ae-30e3-4627-959f-c5369493366c">P0Y2M19D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="iecdcfc455bed4a3ab837da5d7d3c93e3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMS04LTEtMS0x_562f6a9e-98bb-40a8-97d1-26ce855116ae"
      unitRef="usd">5308000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMi0yLTEtMS0x_428ad42d-5a12-4bd9-a45d-d5e3d7c9a1f9"
      unitRef="shares">145000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMi00LTEtMS0x_cc733c9e-80da-413b-a928-ebef07260b5b"
      unitRef="usdPerShare">7.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMy0yLTEtMS0x_10f66d56-c9c9-4cf0-8a79-ce7746cdc00c"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfMy00LTEtMS0x_c648dd96-7927-4c62-981e-eaf67f190c43"
      unitRef="usdPerShare">2.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfNC0yLTEtMS0x_e76d1102-e262-4b84-b2ca-6cff9906c3ca"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfNC00LTEtMS0x_3e5fddba-2179-4e1d-89d8-6fa11b246515"
      unitRef="usdPerShare">6.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id2dbd335dfd64d78885f580dba8cb8ba_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfNS0yLTEtMS0x_d031c510-ddb3-4668-b3f5-1cc8afe88879"
      unitRef="shares">219000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id2dbd335dfd64d78885f580dba8cb8ba_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfNS00LTEtMS0x_85da36e5-51f8-4e22-b59d-7166a79641be"
      unitRef="usdPerShare">6.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfNS02LTEtMS0x_2c498904-1112-43ed-92c1-b1cfed5ebf57">P0Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="id2dbd335dfd64d78885f580dba8cb8ba_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOjU0MDdkZTlkZmNkODQ2YWViZTMxNGI3YWE0YmVkOTViL3RhYmxlcmFuZ2U6NTQwN2RlOWRmY2Q4NDZhZWJlMzE0YjdhYTRiZWQ5NWJfNS04LTEtMS0x_0208cc16-4ad5-4c71-a7d1-0fa9c8b0e00d"
      unitRef="usd">1217000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9dedb3f8a3514cc5a585e7453a724c8d_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjE5OTAyMzI2MjgyNg_066390f9-8ca2-479c-932e-dec391f1dee0"
      unitRef="shares">81394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9dedb3f8a3514cc5a585e7453a724c8d_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzI5ODUzNDg5MDcyNA_2cfdb5c6-f02c-40d0-8d3a-4c6a570e6b58">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9dedb3f8a3514cc5a585e7453a724c8d_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMjE5OTAyMzI2Mjg4NA_bac85181-acde-4755-9726-c0f96c62daae"
      unitRef="usdPerShare">6.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDg5Nw_a54a49e3-32d6-4dbf-a86d-37e59d587282"
      unitRef="shares">144700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ib2873c72b9da49babb2eb0a4aa374ba8_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfMzI5ODUzNDg5MDc4Mg_e3a81fc8-7d94-48b3-90e1-5125c8e22554">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i886f33580f4447e1b7c66e0f0ec1c80d_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDk1MQ_b316bd4f-5921-419b-a8f7-0fe53b6054fb"
      unitRef="usdPerShare">7.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzIwMA_1df742de-c080-4924-8cef-a1cbd6c513da">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzE5NA_fb38e807-790d-4f67-a13a-4f72bdfb37f5">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes phantom share unit activity for the nine months ended September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.299%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of phantom  share units (000's)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value of share equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;7,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired / Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,407&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;The value of outstanding share equivalents at the beginning of the period is based on the market price of the Company&#x2019;s stock at that time, the value of issued share equivalents is based on the market price of the Company&#x2019;s stock at issuance, the value of vested share equivalents is based on the cash paid at the time of vesting, the values of expired/forfeited share equivalents and outstanding share equivalents at the end of the period and are based on the market price of the Company's stock at the end of the period. The market price of the Company's stock was $5.55 on September 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i44ffc467ff8a4229b2d74de1d78d1680_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfMS0yLTEtMS0x_f3e3d7a7-319c-48ae-94d8-27cf5d4fa3f3"
      unitRef="shares">985000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i44ffc467ff8a4229b2d74de1d78d1680_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfMS00LTEtMS0x_da34df3a-4150-43d7-a70f-f31fe23ddf34"
      unitRef="usd">7642000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfMi0yLTEtMS0x_2b169ef6-ca60-45bf-881e-ec47643ac934"
      unitRef="shares">394000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <vmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued
      contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfMi00LTEtMS0x_9acb0fb3-d5d5-48bb-99f7-64a8b25f4d42"
      unitRef="usd">3766000</vmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfMy0yLTEtMS0x_8377f25d-7590-4d78-a945-5202802f2281"
      unitRef="shares">656000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfMy00LTEtMS0x_80e548cc-8ca4-404c-99d4-6e4e23d76546"
      unitRef="usd">6282000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfNC0yLTEtMS0x_0ea7fc3e-1359-40fd-b9f6-6e67bebb1906"
      unitRef="shares">109000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <vmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited
      contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfNC00LTEtMS0x_f340799f-fe28-410d-a6b8-f3017a0e6b8c"
      unitRef="usd">601000</vmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i3a314a6d360248d9a6c6a44fcd3abb90_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfNS0yLTEtMS0x_b3fb2d90-8421-4d09-ad65-22940ddb7017"
      unitRef="shares">614000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i3a314a6d360248d9a6c6a44fcd3abb90_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmM5NzcwMzg5MmQyZjQ1OWFhMzUyNDNhZjI3YTNiMGRjL3RhYmxlcmFuZ2U6Yzk3NzAzODkyZDJmNDU5YWEzNTI0M2FmMjdhM2IwZGNfNS00LTEtMS0x_a974c7c0-1907-48fa-b12f-27bf6ba05dbb"
      unitRef="usd">3407000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharePrice
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNjIyMA_7a382e56-fb98-418e-b940-75f0539e4bbd"
      unitRef="usdPerShare">5.55</us-gaap:SharePrice>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i3a314a6d360248d9a6c6a44fcd3abb90_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNjUzNg_6e4df437-fb39-43c7-8552-45050b6ca11a"
      unitRef="usd">1462000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i3a314a6d360248d9a6c6a44fcd3abb90_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNjU0NQ_c32beafc-8dcb-484a-bff6-e0404bedef83"
      unitRef="usd">1002000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="i3a314a6d360248d9a6c6a44fcd3abb90_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNjYzMg_27d15359-e4b5-4731-9f3f-a0215c256b67"
      unitRef="usd">460000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5753dc4d89ed4578addb8f58e199c604_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmVlMTAzMjUyNzIzYzRmMTQ4MWM1Njc2NTU2NWEyZDM0L3RhYmxlcmFuZ2U6ZWUxMDMyNTI3MjNjNGYxNDgxYzU2NzY1NTY1YTJkMzRfMi0yLTEtMS0x_54e327ce-f68a-49e5-89ca-aa5c3d2fbcff"
      unitRef="usd">41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4044ca35c71f4191b7fb20e6bf8ad931_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmVlMTAzMjUyNzIzYzRmMTQ4MWM1Njc2NTU2NWEyZDM0L3RhYmxlcmFuZ2U6ZWUxMDMyNTI3MjNjNGYxNDgxYzU2NzY1NTY1YTJkMzRfMi00LTEtMS0x_a4cdf2e3-3cfe-4b6e-a528-939070b09685"
      unitRef="usd">459000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i94ccb4b7c871492288b371e698ff505e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmVlMTAzMjUyNzIzYzRmMTQ4MWM1Njc2NTU2NWEyZDM0L3RhYmxlcmFuZ2U6ZWUxMDMyNTI3MjNjNGYxNDgxYzU2NzY1NTY1YTJkMzRfMi02LTEtMS0x_24fa47d2-3088-4171-ad11-ccdc17d0b047"
      unitRef="usd">2400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7eabec862824cb8beb06ebf1b6d9770_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RhYmxlOmVlMTAzMjUyNzIzYzRmMTQ4MWM1Njc2NTU2NWEyZDM0L3RhYmxlcmFuZ2U6ZWUxMDMyNTI3MjNjNGYxNDgxYzU2NzY1NTY1YTJkMzRfMi04LTEtMS0x_389bb14f-bd5c-4595-84ee-7690c527d3bb"
      unitRef="usd">4070000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzA4OQ_21ca260d-b9e3-45e9-8099-0bf5c502580a"
      unitRef="usd">6282000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
      contextRef="ic6b1cbcf841f4955b15df2767b15477a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNzA5Ng_54af0341-6e4b-4bbb-9d72-cd5b3a8fd588"
      unitRef="usd">4201000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182MS9mcmFnOjZkMmExYjExNDc0MjQ3MzFhYjZmODA1NDdkNzQ0YjFmL3RleHRyZWdpb246NmQyYTFiMTE0NzQyNDczMWFiNmY4MDU0N2Q3NDRiMWZfNjAzOQ_6e0dc2b9-d5c8-47dc-a643-2f87ddcd4c75">Commitments and Contingencies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company accrues estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450,&#160;Contingencies&#160;(&#x201c;ASC 450&#x201d;). No less than quarterly, we review the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, the Company (through its subsidiary Sleep Management LLC) submitted a purchase order (the &#x201c;Purchase Order&#x201d;) in March 2020 to Vyaire Medical, Inc. d/b/a CareFusion Respiratory Technologies (&#x201c;Vyaire&#x201d;) for respiratory equipment. The Company ultimately prepaid $1.4&#160;million towards the delivery of such respiratory equipment. Vyaire was unable or unwilling to deliver the vast majority of the respiratory equipment referenced in the Purchase Order, and also refused to refund the prepayment amount (less the amounts paid for equipment actually received). On July 29, 2020, the Company (through its subsidiary Sleep Management LLC) filed a lawsuit against Vyaire in the United States District Court for the Western District of Louisiana (the &#x201c;Court&#x201d;). This lawsuit was dismissed on December 8, 2020 in connection with the commencement of the lawsuit filed by the Company (through its subsidiary Sleep Management) on November 5, 2020, against Vyaire in the 15th Judicial District Court for the Parish of Lafayette, Louisiana (the &#x201c;State Court&#x201d;) seeking damages for breach of contract and seeking a declaratory judgment that the Company is not required to pay any further funds to Vyaire. On December 28, 2020, Vyaire filed its Answer, Affirmative Defenses, and Reconventional Demand (&#x201c;Reconventional Demand&#x201d;) with the State Court alleging breach of contract and seeking damages of $4.7&#160;million, purportedly for the improper cancellation of the Purchase Order. The Company filed its Answer to the Reconventional Demand on February 12, 2021 and the parties are currently engaged in discovery.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;We continue to believe that we have valid legal and equitable grounds to recover our outstanding prepayment as a result of Vyaire&#x2019;s failure to deliver the vast majority of the respiratory equipment referenced in the Purchase Order. We have determined that a loss related to the Reconventional Demand is not probable, and thus have not accrued a liability related to this claim. Although a loss may be reasonably possible, we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the Reconventional Demand given that the dispute is in the early stages of the legal process. As of September 30, 2021, outstanding funds in the amount of $0.9 million related to undelivered respiratory equipment are included within other long-term assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%"&gt;Governmental and Regulatory Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;From time to time we are involved in various external governmental investigations, audits and reviews. Reviews, audits and investigations of this sort can lead to government actions, which can result in the assessment of recoupment of reimbursement, civil or criminal fines or penalties, or other sanctions, including restrictions or changes in the way we conduct business, loss of licensure or exclusion from participation in government healthcare programs.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In May of 2021, a final report and recommendation (&#x201c;Report&#x201d;) was issued by the U.S. Department of Health and Human Services Office of the Inspector General (&#x201c;OIG&#x201d;) regarding an audit by OIG of claims relating to one hundred (100) of the Company&#x2019;s non-invasive ventilation at home (&#x201c;NIVH&#x201d;) patients. The OIG asserted that most of the sampled Medicare claims submitted for the monthly rental of non-invasive ventilators did not comply with Medicare requirements. The Company firmly believes that the Report ignores each patient&#x2019;s diagnosis and supporting documentation of that diagnosis from treating and prescribing physicians and applies clinical guidelines that are contrary to CMS&#x2019;s accepted standard of care. In late June of 2021, the Company received initial request letters from DME Medicare Administrative Contractors ("MACs") referencing the Report and requesting repayment of purported overpayments. The Company responded to each initial request by submitting a rebuttal and by filing a redetermination appeal as prescribed by the initial request letters and by statute. In September 2021, the MACs informed the Company of unfavorable decisions with respect to the redetermination appeals. The Company intends to continue to defend itself vigorously through the remaining appeals processes which include, in successive order, Reconsideration appeals, Administrative Law Judge appeals, Medicare Appeals Council review, and ultimately through Federal Court, if necess&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ary. The Reconsideration appeals are required to be submitted in writing to the designated Quality Independent Contractor ("QIC") within 180 days of receiving the redetermination appeals letter. The QIC has 60 days to render a reconsideration decision. The timing of additional appeals beyond reconsideration are subject to workload constraints of the reviewing body. Based on initial discussions with CMS, a review of the current facts and circumstances &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;as we understand them, and the nature of the requests, we have determined that a loss is not probable but may be reasonably possible. Accordingly, no related accrual has been recorded. The value of the population of associated claims within the 4-year reopening period prescribed by statute, including any potential interest, is approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; $9&#160;million. Man&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;agement estimates that a possible loss, if any, will not exceed this amount. It is possible that the ultimate resolution of this matter, if unfavorable, could materially and adversely affect the Company&#x2019;s consolidated financial position, consolidated results of operations, or consolidated cash flows.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="ic98b72a5b163495eb502663ae5631ff3_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182MS9mcmFnOjZkMmExYjExNDc0MjQ3MzFhYjZmODA1NDdkNzQ0YjFmL3RleHRyZWdpb246NmQyYTFiMTE0NzQyNDczMWFiNmY4MDU0N2Q3NDRiMWZfMTQ0NQ_3757c944-65da-4320-abca-867e9b4baa33"
      unitRef="usd">1400000</us-gaap:PurchaseObligation>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i118bddcb0f0f4367a8aef1f25a41b550_D20201228-20201228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182MS9mcmFnOjZkMmExYjExNDc0MjQ3MzFhYjZmODA1NDdkNzQ0YjFmL3RleHRyZWdpb246NmQyYTFiMTE0NzQyNDczMWFiNmY4MDU0N2Q3NDRiMWZfMjU1Mw_4827f78c-88ae-4798-98fb-a37264b26c20"
      unitRef="usd">4700000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:DepositsAssets
      contextRef="if18d5f0f70ef493491936ce24033c80d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182MS9mcmFnOjZkMmExYjExNDc0MjQ3MzFhYjZmODA1NDdkNzQ0YjFmL3RleHRyZWdpb246NmQyYTFiMTE0NzQyNDczMWFiNmY4MDU0N2Q3NDRiMWZfMzQzMA_d04e7fa0-c137-4f0f-b009-fd88396084d7"
      unitRef="usd">900000</us-gaap:DepositsAssets>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i6a5ccd697db64231a87cd517cfa2cfba_I20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182MS9mcmFnOjZkMmExYjExNDc0MjQ3MzFhYjZmODA1NDdkNzQ0YjFmL3RleHRyZWdpb246NmQyYTFiMTE0NzQyNDczMWFiNmY4MDU0N2Q3NDRiMWZfNTcyNw_a1894c8f-5e54-48f1-886a-ad906a754d6c"
      unitRef="usd">9000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182Ny9mcmFnOjkzYThiYjIzNmYyZjQwY2NiODJmMDNhZWYxYTFlYzQzL3RleHRyZWdpb246OTNhOGJiMjM2ZjJmNDBjY2I4MmYwM2FlZjFhMWVjNDNfMTgwOQ_38cf450c-11c5-47ab-967a-8874f1d64829">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2021, the Company recorded income tax expense of $2.4 million, which includes a discrete tax benefit of $0.8 million for excess tax benefits associated with stock-based compensation arrangements. Excluding the impact of the discrete tax benefit, the effective rate for the nine months ended September 30, 2021 is 43.4%. The effective rate differs from the amount computed by applying the statutory federal and state income tax rates to ordinary income before the provision for income taxes due to permanent non-deductible differences. Our effective tax rate is based on forecasted annual results which may fluctuate significantly through the rest of the year, in particular due to the uncertainty in our annual forecasts resulting from the unpredictable impact of the COVID-19 pandemic on our operating results. During the nine months ended September 30, 2020, the Company released a valuation allowance associated with deferred tax assets, resulting in a $5.3 million benefit during that period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At September 30, 2021 and 2020, the Company had no amounts recorded for uncertain tax positions and does not expect any material changes in uncertain tax benefits during the next 12 months. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company is subject to U.S. federal income tax as well as income tax in various states. The Company is generally not subject to examination by taxing authorities for years prior to 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182Ny9mcmFnOjkzYThiYjIzNmYyZjQwY2NiODJmMDNhZWYxYTFlYzQzL3RleHRyZWdpb246OTNhOGJiMjM2ZjJmNDBjY2I4MmYwM2FlZjFhMWVjNDNfNzg_28920b91-27a8-482c-b2e8-5ba252a6f6d0"
      unitRef="usd">2400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182Ny9mcmFnOjkzYThiYjIzNmYyZjQwY2NiODJmMDNhZWYxYTFlYzQzL3RleHRyZWdpb246OTNhOGJiMjM2ZjJmNDBjY2I4MmYwM2FlZjFhMWVjNDNfMTIz_3f6bd795-cef7-496b-96bb-3b84eff7e308"
      unitRef="usd">800000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182Ny9mcmFnOjkzYThiYjIzNmYyZjQwY2NiODJmMDNhZWYxYTFlYzQzL3RleHRyZWdpb246OTNhOGJiMjM2ZjJmNDBjY2I4MmYwM2FlZjFhMWVjNDNfMjg4_9f364289-5a4a-4197-96c3-c7f34468e131"
      unitRef="number">0.434</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN182Ny9mcmFnOjkzYThiYjIzNmYyZjQwY2NiODJmMDNhZWYxYTFlYzQzL3RleHRyZWdpb246OTNhOGJiMjM2ZjJmNDBjY2I4MmYwM2FlZjFhMWVjNDNfOTEw_1f598663-2c36-4654-b473-b2c8fdd40067"
      unitRef="usd">-5300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RleHRyZWdpb246YjNjZjZhNmYwZGJmNDgxMWJkZTc1MjVkZWQ3ZmU2ZDJfODMz_43d73a20-e81c-494c-8f89-2a628a72a159">Earnings Per Share&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Income per common share is calculated using earnings for the year divided by the weighted average number of shares outstanding during the year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Using the treasury stock method, diluted income per share amounts are calculated giving effect to the potential dilution that would occur if securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options and the vesting of RSUs are used to purchase common shares at the prevailing market rate. &lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following reflects the earnings and share data used in the basic and diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Numerator - basic and diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic weighted-average number of common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,607,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,107,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,442,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,603,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,659,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,155,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,716,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,377,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Denominator calculation from basic to diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic weighted-average number of common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,607,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,107,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,442,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,603,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options and other dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,051,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,048,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,274,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,774,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,659,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,155,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,716,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,377,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares excluded from the calculation consisted of dilutive employee stock options and RSUs that were de minimis in all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RleHRyZWdpb246YjNjZjZhNmYwZGJmNDgxMWJkZTc1MjVkZWQ3ZmU2ZDJfODM3_c4fc2b8d-0ffb-4ba7-a106-bf4dbb8d00aa">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following reflects the earnings and share data used in the basic and diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.831%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.698%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Numerator - basic and diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic weighted-average number of common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,607,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,107,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,442,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,603,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,659,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,155,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,716,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,377,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Denominator calculation from basic to diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic weighted-average number of common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,607,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,107,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,442,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,603,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options and other dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,051,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,048,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,274,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,774,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted weighted-average number of shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,659,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,155,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,716,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,377,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMy0yLTEtMS0x_27506ef4-9eb4-484f-85ac-6c5e05668640"
      unitRef="usd">1789000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMy00LTEtMS0x_846b8156-4ec5-4018-b1bc-2ecfa5c798b1"
      unitRef="usd">2804000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMy02LTEtMS0x_c5b3c7c1-f119-45c5-867c-a714a494ae80"
      unitRef="usd">5039000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMy04LTEtMS0x_03260088-d962-4cbe-96cd-dcc2ab9d07ca"
      unitRef="usd">26459000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNi0yLTEtMS0x_92ebcd98-8fe7-4063-9996-34b320b23859"
      unitRef="shares">39607540</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNi00LTEtMS0x_78a43e2f-2721-4d28-b0b5-dd0ff650b62c"
      unitRef="shares">39107640</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNi02LTEtMS0x_c0d760f8-dde0-4e73-8139-16976014f19d"
      unitRef="shares">39442088</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNi04LTEtMS0x_cf07562a-6b26-4ea3-99b2-1aab80a16383"
      unitRef="shares">38603267</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNy0yLTEtMS0x_38be7b5c-84ed-4446-b595-1f05df7b8edb"
      unitRef="shares">40659353</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNy00LTEtMS0x_25a2547d-5b55-4e50-9922-3eae04aca0ca"
      unitRef="shares">41155668</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNy02LTEtMS0x_95990a10-5fa6-4607-8c97-61cfa1417da9"
      unitRef="shares">40716747</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfNy04LTEtMS0x_44c0a315-ffd8-4136-bb2f-73a02bd8f2ad"
      unitRef="shares">40377608</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfOS0yLTEtMS0x_61c0c0ed-6205-4813-97f2-6f3d81aeadcc"
      unitRef="usdPerShare">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfOS00LTEtMS0x_8e14e85a-553c-48f3-b302-5c84c0ddd0f2"
      unitRef="usdPerShare">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfOS02LTEtMS0x_d068e064-7dde-46c3-a5f9-0ec4bcee85ce"
      unitRef="usdPerShare">0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfOS04LTEtMS0x_7166a582-56a8-474d-84a5-7bd22840304d"
      unitRef="usdPerShare">0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTAtMi0xLTEtMQ_32bacb46-4844-48ea-8ae2-30fc7422ad26"
      unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTAtNC0xLTEtMQ_91a45879-1ddf-40c8-a188-fa733e7c9540"
      unitRef="usdPerShare">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTAtNi0xLTEtMQ_376b3bff-f977-4ea6-8eca-89e9c3d67693"
      unitRef="usdPerShare">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTAtOC0xLTEtMQ_6414ba2e-dd63-4584-8e7d-1d694992456e"
      unitRef="usdPerShare">0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTMtMi0xLTEtMQ_92ebcd98-8fe7-4063-9996-34b320b23859"
      unitRef="shares">39607540</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTMtNC0xLTEtMQ_78a43e2f-2721-4d28-b0b5-dd0ff650b62c"
      unitRef="shares">39107640</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTMtNi0xLTEtMQ_c0d760f8-dde0-4e73-8139-16976014f19d"
      unitRef="shares">39442088</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTMtOC0xLTEtMQ_cf07562a-6b26-4ea3-99b2-1aab80a16383"
      unitRef="shares">38603267</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTQtMi0xLTEtMQ_eb23f443-8eea-4173-8fb7-cb68d1110375"
      unitRef="shares">1051813</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTQtNC0xLTEtMQ_b33f1410-f22a-4429-ac9e-8f7219011818"
      unitRef="shares">2048028</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTQtNi0xLTEtMQ_dbf1d182-384f-45fa-9322-879dffa59b3b"
      unitRef="shares">1274659</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTQtOC0xLTEtMQ_91351a3b-8a91-4533-85a2-1ae77c8e338b"
      unitRef="shares">1774341</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0f164680a52c4595a2825372313c0fdd_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTUtMi0xLTEtMQ_b551b523-23d0-450d-914d-6f1b19558828"
      unitRef="shares">40659353</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if95c9629a44d4ac49c9fc212f81f8524_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTUtNC0xLTEtMQ_23d9aa48-9c13-4f75-83cb-25963f0e81f7"
      unitRef="shares">41155668</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTUtNi0xLTEtMQ_9abba4d1-b36f-40ea-9378-6846b45d0023"
      unitRef="shares">40716747</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3d924ac1c35f457f905ace180bbf4957_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN183My9mcmFnOmIzY2Y2YTZmMGRiZjQ4MTFiZGU3NTI1ZGVkN2ZlNmQyL3RhYmxlOmY1OThjMmQwNmQ5NTRjMjBiNjBkZjAyNzM2MTYwYWY5L3RhYmxlcmFuZ2U6ZjU5OGMyZDA2ZDk1NGMyMGI2MGRmMDI3MzYxNjBhZjlfMTUtOC0xLTEtMQ_e7f81b12-c99d-4f6f-a00f-cfa41196d70a"
      unitRef="shares">40377608</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445346713272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Viemed Healthcare, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">Z4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">625 E. Kaliste Saloom Rd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lafayette<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">LA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">70508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">504-3802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,630,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001729149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445342435448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,867<span></span>
</td>
<td class="nump">$ 30,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $7,115 and $9,013 at September 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">12,696<span></span>
</td>
<td class="nump">12,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net of inventory reserve of $1,237 and $1,353 at September 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">2,622<span></span>
</td>
<td class="nump">2,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">3,761<span></span>
</td>
<td class="nump">1,511<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">47,366<span></span>
</td>
<td class="nump">47,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Long-term assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">59,036<span></span>
</td>
<td class="nump">55,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Equity investments</a></td>
<td class="nump">1,942<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">6,281<span></span>
</td>
<td class="nump">8,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total long-term assets</a></td>
<td class="nump">68,120<span></span>
</td>
<td class="nump">65,385<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">115,486<span></span>
</td>
<td class="nump">112,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">4,734<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">3,795<span></span>
</td>
<td class="nump">3,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">9,283<span></span>
</td>
<td class="nump">12,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_LeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">2,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">1,906<span></span>
</td>
<td class="nump">1,836<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">20,199<span></span>
</td>
<td class="nump">23,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Accrued liabilities</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_LeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">834<span></span>
</td>
<td class="nump">762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">4,347<span></span>
</td>
<td class="nump">5,796<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">5,911<span></span>
</td>
<td class="nump">7,850<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">26,110<span></span>
</td>
<td class="nump">30,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - No par value: unlimited authorized; 39,630,446 and 39,185,182 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">13,957<span></span>
</td>
<td class="nump">9,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">6,501<span></span>
</td>
<td class="nump">7,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(330)<span></span>
</td>
<td class="num">(451)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">69,248<span></span>
</td>
<td class="nump">65,643<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL SHAREHOLDERS' EQUITY</a></td>
<td class="nump">89,376<span></span>
</td>
<td class="nump">81,693<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</a></td>
<td class="nump">$ 115,486<span></span>
</td>
<td class="nump">$ 112,560<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_LeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_LeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445426847928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 7,115<span></span>
</td>
<td class="nump">$ 9,013<span></span>
</td>
<td class="nump">$ 8,788<span></span>
</td>
<td class="nump">$ 7,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="nump">$ 1,237<span></span>
</td>
<td class="nump">$ 1,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued (in shares)</a></td>
<td class="nump">39,630,446<span></span>
</td>
<td class="nump">39,185,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Outstanding (in shares)</a></td>
<td class="nump">39,630,446<span></span>
</td>
<td class="nump">39,185,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445342418312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 29,285<span></span>
</td>
<td class="nump">$ 33,447<span></span>
</td>
<td class="nump">$ 85,100<span></span>
</td>
<td class="nump">$ 100,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">10,904<span></span>
</td>
<td class="nump">13,994<span></span>
</td>
<td class="nump">31,352<span></span>
</td>
<td class="nump">39,174<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">18,381<span></span>
</td>
<td class="nump">19,453<span></span>
</td>
<td class="nump">53,748<span></span>
</td>
<td class="nump">60,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">13,260<span></span>
</td>
<td class="nump">13,550<span></span>
</td>
<td class="nump">40,653<span></span>
</td>
<td class="nump">40,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">1,234<span></span>
</td>
<td class="nump">3,845<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss (gain) on disposal of property and equipment</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="num">(2,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income)</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="num">(3,593)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">2,919<span></span>
</td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">6,915<span></span>
</td>
<td class="nump">21,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income and expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income from equity method investments</a></td>
<td class="num">(331)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(782)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net of interest income</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income before taxes</a></td>
<td class="nump">3,175<span></span>
</td>
<td class="nump">3,945<span></span>
</td>
<td class="nump">7,448<span></span>
</td>
<td class="nump">21,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">2,409<span></span>
</td>
<td class="num">(5,318)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">1,789<span></span>
</td>
<td class="nump">2,804<span></span>
</td>
<td class="nump">5,039<span></span>
</td>
<td class="nump">26,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Change in unrealized gain/loss on derivative instruments, net of tax</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 1,810<span></span>
</td>
<td class="nump">$ 2,828<span></span>
</td>
<td class="nump">$ 5,160<span></span>
</td>
<td class="nump">$ 26,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">39,607,540<span></span>
</td>
<td class="nump">39,107,640<span></span>
</td>
<td class="nump">39,442,088<span></span>
</td>
<td class="nump">38,603,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">40,659,353<span></span>
</td>
<td class="nump">41,155,668<span></span>
</td>
<td class="nump">40,716,747<span></span>
</td>
<td class="nump">40,377,608<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445341862584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Retained earnings</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,952,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 43,699<span></span>
</td>
<td class="nump">$ 3,366<span></span>
</td>
<td class="nump">$ 6,377<span></span>
</td>
<td class="num">$ (157)<span></span>
</td>
<td class="nump">$ 34,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation - options</a></td>
<td class="nump">891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Stock-based compensation - restricted stock</a></td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,276<span></span>
</td>
<td class="num">(3,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Change in accumulated other comprehensive loss, net of tax</a></td>
<td class="num">(312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">4,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,243<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,486,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, ending balance at Mar. 31, 2020</a></td>
<td class="nump">48,796<span></span>
</td>
<td class="nump">$ 6,657<span></span>
</td>
<td class="nump">4,252<span></span>
</td>
<td class="num">(469)<span></span>
</td>
<td class="nump">38,356<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,952,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, beginning balance at Dec. 31, 2019</a></td>
<td class="nump">43,699<span></span>
</td>
<td class="nump">$ 3,366<span></span>
</td>
<td class="nump">6,377<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="nump">34,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Change in accumulated other comprehensive loss, net of tax</a></td>
<td class="num">(321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">26,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,145,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, ending balance at Sep. 30, 2020</a></td>
<td class="nump">75,198<span></span>
</td>
<td class="nump">$ 9,085<span></span>
</td>
<td class="nump">6,019<span></span>
</td>
<td class="num">(478)<span></span>
</td>
<td class="nump">60,572<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,486,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, beginning balance at Mar. 31, 2020</a></td>
<td class="nump">48,796<span></span>
</td>
<td class="nump">$ 6,657<span></span>
</td>
<td class="nump">4,252<span></span>
</td>
<td class="num">(469)<span></span>
</td>
<td class="nump">38,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation - options</a></td>
<td class="nump">933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Stock-based compensation - restricted stock</a></td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">1,757<span></span>
</td>
<td class="nump">$ 1,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Change in accumulated other comprehensive loss, net of tax</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">19,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,412<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,082,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, ending balance at Jun. 30, 2020</a></td>
<td class="nump">71,128<span></span>
</td>
<td class="nump">$ 8,414<span></span>
</td>
<td class="nump">5,448<span></span>
</td>
<td class="num">(502)<span></span>
</td>
<td class="nump">57,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation - options</a></td>
<td class="nump">945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Stock-based compensation - restricted stock</a></td>
<td class="nump">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 663<span></span>
</td>
<td class="num">(663)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Change in accumulated other comprehensive loss, net of tax</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">2,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,804<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,145,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 75,198<span></span>
</td>
<td class="nump">$ 9,085<span></span>
</td>
<td class="nump">6,019<span></span>
</td>
<td class="num">(478)<span></span>
</td>
<td class="nump">60,572<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">39,185,182<span></span>
</td>
<td class="nump">39,185,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 81,693<span></span>
</td>
<td class="nump">$ 9,181<span></span>
</td>
<td class="nump">7,320<span></span>
</td>
<td class="num">(451)<span></span>
</td>
<td class="nump">65,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation - options</a></td>
<td class="nump">1,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Stock-based compensation - restricted stock</a></td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 4,403<span></span>
</td>
<td class="num">(4,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Shares redeemed to pay income tax</a></td>
<td class="num">(1,434)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Change in accumulated other comprehensive loss, net of tax</a></td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">1,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,684<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,577,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 83,421<span></span>
</td>
<td class="nump">$ 13,649<span></span>
</td>
<td class="nump">4,224<span></span>
</td>
<td class="num">(345)<span></span>
</td>
<td class="nump">65,893<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">39,185,182<span></span>
</td>
<td class="nump">39,185,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 81,693<span></span>
</td>
<td class="nump">$ 9,181<span></span>
</td>
<td class="nump">7,320<span></span>
</td>
<td class="num">(451)<span></span>
</td>
<td class="nump">65,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares redeemed to pay income tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Shares redeemed to pay income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Change in accumulated other comprehensive loss, net of tax</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 5,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">39,630,446<span></span>
</td>
<td class="nump">39,630,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 89,376<span></span>
</td>
<td class="nump">$ 13,957<span></span>
</td>
<td class="nump">6,501<span></span>
</td>
<td class="num">(330)<span></span>
</td>
<td class="nump">69,248<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,577,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, beginning balance at Mar. 31, 2021</a></td>
<td class="nump">83,421<span></span>
</td>
<td class="nump">$ 13,649<span></span>
</td>
<td class="nump">4,224<span></span>
</td>
<td class="num">(345)<span></span>
</td>
<td class="nump">65,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation - options</a></td>
<td class="nump">998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Stock-based compensation - restricted stock</a></td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Change in accumulated other comprehensive loss, net of tax</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">1,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,588,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, ending balance at Jun. 30, 2021</a></td>
<td class="nump">86,264<span></span>
</td>
<td class="nump">$ 13,696<span></span>
</td>
<td class="nump">5,460<span></span>
</td>
<td class="num">(351)<span></span>
</td>
<td class="nump">67,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation - options</a></td>
<td class="nump">1,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Stock-based compensation - restricted stock</a></td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Change in accumulated other comprehensive loss, net of tax</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 1,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,789<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shareholders' equity, ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="nump">39,630,446<span></span>
</td>
<td class="nump">39,630,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity, ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 89,376<span></span>
</td>
<td class="nump">$ 13,957<span></span>
</td>
<td class="nump">$ 6,501<span></span>
</td>
<td class="num">$ (330)<span></span>
</td>
<td class="nump">$ 69,248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445342228232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 5,039<span></span>
</td>
<td class="nump">$ 26,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">8,192<span></span>
</td>
<td class="nump">6,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Change in allowance for doubtful accounts</a></td>
<td class="nump">5,250<span></span>
</td>
<td class="nump">7,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Change in inventory reserve</a></td>
<td class="num">(116)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,845<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments', window );">Distributions of earnings received from equity method investments</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Income from equity method investments</a></td>
<td class="num">(782)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss (gain) on disposal of property and equipment</a></td>
<td class="nump">304<span></span>
</td>
<td class="num">(2,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="nump">2,410<span></span>
</td>
<td class="num">(7,593)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net change in working capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="num">(5,573)<span></span>
</td>
<td class="num">(6,986)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventory</a></td>
<td class="num">(196)<span></span>
</td>
<td class="num">(1,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Increase in prepaid expenses and other assets</a></td>
<td class="num">(2,259)<span></span>
</td>
<td class="num">(1,771)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase in trade payables</a></td>
<td class="nump">2,638<span></span>
</td>
<td class="nump">2,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase in deferred revenue</a></td>
<td class="nump">386<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">(Decrease) increase in accrued liabilities</a></td>
<td class="num">(3,711)<span></span>
</td>
<td class="nump">2,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable', window );">Change in income tax payable/receivable</a></td>
<td class="num">(1,760)<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">13,839<span></span>
</td>
<td class="nump">29,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(13,080)<span></span>
</td>
<td class="num">(8,204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Investment in equity investments</a></td>
<td class="num">(599)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">5,187<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(13,183)<span></span>
</td>
<td class="num">(3,047)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">1,780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Principal payments on notes payable</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Principal payments on term note</a></td>
<td class="num">(1,255)<span></span>
</td>
<td class="num">(1,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Shares redeemed to pay income tax</a></td>
<td class="num">(1,434)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_LeasePayments', window );">Repayments of lease liabilities</a></td>
<td class="num">(2,080)<span></span>
</td>
<td class="num">(7,708)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(4,770)<span></span>
</td>
<td class="num">(7,231)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(4,114)<span></span>
</td>
<td class="nump">19,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">30,981<span></span>
</td>
<td class="nump">13,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">26,867<span></span>
</td>
<td class="nump">32,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid during the period for income taxes, net of refunds received</a></td>
<td class="nump">1,760<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_NetNonCashChangesToFinanceLeaseBalances', window );">Net non-cash changes to finance lease balances</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">3,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_NetNonCashChangesToOperatingLeaseBalances', window );">Net non-cash changes to operating lease balances</a></td>
<td class="nump">$ 372<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e99989-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Distributions Of Earnings Received From Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_LeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_LeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_NetNonCashChangesToFinanceLeaseBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Non-Cash Changes To Finance Lease Balances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_NetNonCashChangesToFinanceLeaseBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_NetNonCashChangesToOperatingLeaseBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Non-Cash Changes To Operating Lease Balances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_NetNonCashChangesToOperatingLeaseBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445338966600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business and Operations</a></td>
<td class="text">Nature of Business and Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Viemed Healthcare, Inc. (the "Company"), through its subsidiaries, is a provider of in-home durable medical equipment ("DME") and post-acute respiratory healthcare services in the United States. The Company&#8217;s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. The Company currently serves patients in 46 states in the United States. The Company was incorporated under the Business Corporations Act (British Columbia) on December 14, 2016. The Company's registered and records office is located at Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2Z7 and its corporate office is located at 625 E. Kaliste Saloom Road, Lafayette, Louisiana 70508.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act (the "JOBS Act") and a "smaller reporting company" under Rule 12b-2 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), and, as such, has elected to comply with certain reduced U.S. public company reporting requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s common shares are traded in the U.S. on the Nasdaq Capital Market under the symbol VMD and in Canada on the Toronto Stock Exchange ("TSX") under the symbol VMD.TO.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445338651384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Principles of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. Our fiscal year ends on December 31. The Condensed Consolidated Balance Sheet as of December 31, 2020 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of our independent registered public accounting firm included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, our evaluation takes into consideration such factors as historical bad debt experience, national and local economic trends and conditions, industry and regulatory conditions, other collection indicators and information about disaggregated receivables. The complexity of many third-party billing arrangements, patient qualification for medical necessity of equipment and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded.</span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimates and write-offs for the allowance for doubtful accounts for each reporting period were as follows:</span></div><div style="margin-bottom:0.1pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.568%"><tr><td style="width:1.0%"/><td style="width:46.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts written off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,115</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,788</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:0.1pt;padding-left:27pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included in accounts receivable at September 30, 2021 are amounts due from Medicare and Medicaid which represent 36% and 10%, respectively, and 46% combined, of total outstanding receivables. As of December 31, 2020, 46% of total outstanding receivables were due from Medicare and Medicaid. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and nine months ended September 30, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Medicare and Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory represents non-serialized respiratory supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value. Inventory is presented net of a reserve balance of $1,237,000 and $1,353,000 at September 30, 2021 and December 31, 2020, respectively, that relates to COVID-19 response supplies.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been delivered to a patient and is put in use and continues through the useful life of the asset. Property and equipment with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Equity investments</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity investments on the Condensed Consolidated Balance Sheets are comprised of an investment accounted for under the equity method and an equity investment without a readily determinable fair value which is accounted for under the measurement alternative described in ASC 321-10-35-2.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table details the Company&#8217;s equity investments:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.172%"><tr><td style="width:1.0%"/><td style="width:47.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,942</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">733</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments accounted for under the equity method are investments in unconsolidated entities over whose operating and financial policies the Company has the ability to exercise significant influence but not control. Equity method investments are initially measured at cost in the Condensed Consolidated Balance Sheets with a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">y subsequent adjustments made to the carrying amount of the investment for the Company&#8217;s proportionate share of income or loss. The Company has recognized its share of income or loss on the gain (loss) from equity method investments within non-operating expenses in the Condensed Consolidated Statements of Income. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. No events or changes have occurred as of September 30, 2021 that would affect the carrying value of equity method investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other equity investments are investments without a readily determinable fair value which do not qualify for the practical expedient in ASC 820. For these investments, the Company has elected the measurement alternative which measures the investment at cost, less any impairment. ASU 2019-04 clarifies that if an entity identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it must measure its equity investment at fair value in accordance with ASC 820 as of the date that the observable transaction occurred. The Company was not aware of any impairment or observable price change adjustments that needed to be made as of September 30, 2021 on its investments in equity securities without a readily determinable fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive income</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments, net of tax. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of the &#8220;backward tracing&#8221; prohibition in ASC 740, certain previously measured unrealized gains or losses have resulted in the existence of "dangling" amounts within other comprehensive income. The Company has elected the individual security approach to the release of these effects. Under the individual security approach, dangling amounts are tracked on a security-by-security basis and cleared out of the other comprehensive income balance upon sale of each individual security. During the periods presented, none of the individual securities associated with a dangling balance were sold.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue from a customer consists of any combination of the sale and rental of DME and/or patient medical services. Revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company&#8217;s products fall in the Medicare Fee-for-Service (&#8220;FFS&#8221;) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;). </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For commercial payors, DME companies must negotiate in-network pricing separately, though in general, the Company&#8217;s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with DME rentals, the Company recognizes revenue in accordance with ASC 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Leases,&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 842). For any DME sales and services, the Company recognizes revenue under FASB ASU 2014-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Revenue from Contracts with Customers,&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 606) and related amendments. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:0.1pt;padding-left:27pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The revenues from each major source are summarized in the following table:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from rentals </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Ventilator rentals, non-invasive and invasive</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other durable medical equipment rentals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from sales and services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Equipment and supply sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COVID-19 response sales and services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29,285</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33,447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">85,100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">100,107</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 842</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company leases DME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company accounts for these rentals as operating leases.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under FASB ASC Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 606</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company sells DME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also provides sleep study services to customers and recognizes revenue when the sleep study results are complete, satisfying the performance obligation. In response to the COVID-19 pandemic, the Company began offering contact and vaccine tracing services, which revenues are recognized in the period in which the service has been provided. The transaction price on equipment sales, sleep studies and contact and vaccine tracing is the amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the DME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The Company does not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Returns and refunds are not accepted on equipment sales, sleep study services or contact and vaccine tracing services. The Company does not offer warranties to customers in excess of the manufacturer&#8217;s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of September 30, 2021.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC 718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">, "Compensation&#8212;Stock Compensation"</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock&#8211;based compensation costs for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units ("RSUs") are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the Company&#8217;s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the equivalent Company's stock value at the end of each period and records a liability based on the percentage of requisite service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company utilizes an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the Term Note (as defined below).&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk.&#160;These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company presents a positive ending period fair value of the interest rate swap contract in other long-term assets, as a component of long-term assets, and a negative ending period fair value of the interest rate swap contract in accrued liabilities, as a component of long-term liabilities on the Condensed Consolidated Balance Sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty&#160;as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets.&#160;To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to income taxes in numerous jurisdictions. Significant judgment is required in determining the provision for income taxes. The Company's income tax provisions reflect management&#8217;s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that we will receive refunds from or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact our effective tax rate as well as our business and operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted or substantively enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense.</span></div><div style="padding-right:45pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#160;The new guidance simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The new guidance also improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending the existing guidance.&#160;The Company adopted this standard on January 1, 2020, which did not have any impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is an &#8220;emerging growth company&#8221; as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, our condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2019, the FASB issued&#160;ASU 2019-11,&#160;Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which is intended to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets. The standard replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. Further, the FASB issued ASU 2019-04 and ASU 2019-05 to provide additional guidance on the credit losses standard. The standard is effective for fiscal years beginning after December 15, 2022 for smaller reporting companies, including interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the effect that this standard will have on its consolidated financial statements and related disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), which provides optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. Specifically, the guidance permits an entity, when certain criteria are met, to consider amendments to contracts made to comply with reference rate reform to meet the definition of a modification under GAAP. It further allows hedge accounting to be maintained and a one-time transfer or sale of qualifying held-to-maturity securities. The expedients and exceptions provided by the amendments are permitted to be adopted any time through December 31, 2022 and do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, except for certain optional expedients elected for certain hedging relationships existing as of December 31, 2022. The Company is currently evaluating the effect that this standard will have on its consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445430480888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s fixed assets consist of its medical equipment held for rental, furniture and equipment, real property and related improvements, and vehicles and other various small equipment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table details the Company&#8217;s fixed assets:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,438)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Property and equipment, net of accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59,036</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation in the amount of $2,656,000 and $2,224,000 is included in cost of revenue for the three months ended September 30, 2021 and 2020, respectively, and in the amount of $7,574,000 and $6,133,000 for the nine months ended September 30, 2021 and 2020, respectively. Included in medical equipment above is equipment acquired under finance lease obligations whose cost and accumulated depreciation at September 30, 2021 total $1,098,000 and $222,000, respectively. At December 31, 2020, cost and accumulated depreciation on equipment acquired under finance lease obligations was $6,900,000 and $885,000, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445340992568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Current Liabilities</a></td>
<td class="text">Current Liabilities<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s short-term accrued liabilities are included within current liabilities and consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"><tr><td style="width:1.0%"/><td style="width:56.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued trade payables </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued commissions payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued bonuses payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued vacation and payroll</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of phantom share liability </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,595</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445430480888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Lease Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_DebtAndLeasesAbstract', window );"><strong>Debt And Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_DebtandLeaseDisclosureTextBlock', window );">Debt and Lease Liabilities</a></td>
<td class="text">Debt and Lease Liabilities<div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Senior Credit Facility </span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 20, 2018, the Company entered a Commercial Business Loan Agreement that provides for Term Loans and Line of Credit with Hancock Whitney Bank.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Line of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Company maintains a line of credit in the amount of $10.0 million that expires May 1, 2023 under the Commercial Business Loan Agreement. Any amounts advanced on this line will be subject to an interest rate equal to the WSJ prime rate plus a margin of 0.50%, with a 3.50% interest rate floor and will be secured by substantially all of the Company's assets. There were no borrowings against this line of credit at September 30, 2021 or December 31, 2020. </span></div><div style="text-align:center"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Commercial Term Notes</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 30, 2019, the Company entered into a term note (the &#8220;Building Term Note&#8221;) under the Commercial Business Loan Agreement in the principal amount of $4.8&#160;million. The proceeds of the Building Term Note were used to purchase the Company's corporate headquarters. Beginning July 1, 2019, the Company began making monthly payments towards the outstanding balance. The Building Term Note matures on May 30, 2026 and is secured by substantially all of the assets of the borrower, including the real property acquired with the proceeds of the Building Term Note. The Building Term Note bears interest at a variable rate equal to the one month ICE LIBOR index plus a margin of 2.45% per annum. The Company is required to maintain a loan to value ratio of 85% with respect to the appraised value of the real property. In connection with the Building Term Note, the Company entered into an interest rate swap transaction (the "Interest Rate Swap Transaction") with Hancock Whitney Bank effectively fixing the interest rate for the Building Term Note at 4.68%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On September 19, 2019, the Company entered into an additional loan agreement providing for a term note (the &#8220;Term Note") under the Commercial Business Loan Agreement in the principal amount of $5.0 million. The proceeds of the Term Note were utilized for general corporate purposes. Beginning October 19, 2019, the Company started making monthly principal payments of $139,000 towards the outstanding balance. The Term Note matures on September 19, 2022 and is secured by substantially all of the assets of the borrower. The Term Note bears interest at the rate of 4.60% per annum.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company incurred immaterial financing costs related to the above term notes. These deferred financing costs are amortized over the term of the loans using the effective interest method.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The recorded balances associated with these term notes, which have terms greater than twelve months, are as follows:</span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"/><td style="width:61.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.813%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.813%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.412%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,906)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net long-term notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,347</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,796</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Commercial Business Loan Agreement, the Company is subject to several restrictive covenants that, among other things, impose operating and financial restrictions on the Company. Financial covenants include a Total Debt to Adjusted EBITDA, a Loan-to-Value Ratio and a Fixed Charged Coverage Ratio, as defined in the Credit Agreement. The Credit Agreement also contains certain customary events of default, including, among other things, failure to make payments when due thereunder and failure to observe or perform certain covenants. The Company was in compliance with all covenants under the Commercial Business Term Loan Agreement in effect at September 30, 2021.</span></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has recognized finance lease liabilities for medical equipment and operating leases for land and buildings that have terms greater than twelve months, as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:60.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net long-term lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">834</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">762</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Finance lease liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has various finance leases for equipment with an implied interest rate at fixed rates up to 9.61%, secured by equipment, due between 2021 and 2024. The Company's weighted average interest rate was 3.74% and 3.17% for all finance lease liabilities outstanding as of September 30, 2021 and 2020, respectively. At September 30, 2021 and 2020, the weighted average lease term was approximately 1.05 years and 0.73 years, respectively. Interest expense related to these finance lease obligations for the three and nine months ended September 30, 2021 amounted to $4,000 and $35,000, respectively. Interest expense related to these finance lease obligations for the three and nine months ended September 30, 2020 amount to $34,000 and $128,000, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Operating lease liabilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has recognized operating lease liabilities that relate primarily to the lease of land and buildings. These leases contain renewal options that we have not included as part of the Company's assessment of the lease term as it is not reasonably certain that we will exercise these options. These lease liabilities are recorded at present value based on a discount rate of 5.50%, which was based on the Company's incremental borrowing rate at the time of assessment. At September 30, 2021, the weighted average lease term was approximately 3.39 years. Operating rental expenses were $194,000 and $570,000 for the three and nine months ended September 30, 2021, respectively, and $191,000 and $575,000 for the three and nine months ended September 30, 2020, respectively. The related assets for operating lease liabilities have been included with property and equipment on the Condensed Consolidated Balance Sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included within these operating lease liabilities are real property leases for real estate from a related party. On August 1, 2015, the Company entered ten-year triple net lease agreements for office space with an entity that is affiliated with the Company's CEO, Casey Hoyt, and President, Michael Moore. Rental payments under these related party lease agreements are $20,000 per month, plus taxes, utilities and maintenance. Total rental payments for the use of these properties were $81,000 and $194,000 for the three and nine months ended September 30, 2021, respectively, and $58,000 and $180,000 for the three and nine months ended September 30, 2020, respectively. The expense for these related party rents has been included within selling, general and administrative expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_DebtAndLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt And Leases [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_DebtAndLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_DebtandLeaseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt and Lease Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_DebtandLeaseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445340992568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under ASC Topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC Topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. There are three levels to the hierarchy based on the reliability of inputs, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value on a recurring basis. There were no transfers between fair value measurement levels during any presented period.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the Company's assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.129%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recurring Fair Value Measurements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,452</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(270)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,182</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.129%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recurring Fair Value Measurements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25,662</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(433)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25,229</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Derivative instruments and hedging activities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes its interest rate swaps as either assets or liabilities in the accompanying Condensed Consolidated Balance Sheets at fair value. The valuation of these derivative instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. As of September 30, 2021, the Company holds one interest rate swap contract which matures on May 30, 2026 and has a notional amount of $4.5 million. This contract is designated as a cash flow hedge. In the first nine months of 2021, ineffective portions of the hedge were immaterial. The fair value was $(0.3) million (determined based on Level 2 inputs) and is included in accrued liabilities, as a component of long-term liabilities as of September 30, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We measure certain assets and liabilities at fair value on a nonrecurring basis. These assets and liabilities include equity method investments and other equity investments. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. The Company's other equity investments are holdings in a privately-held company without a readily determinable market value. The Company remeasures equity securities without readily determinable fair value at fair value when an orderly transaction is identified for an identical or similar investment of the same issuer in accordance with Topic 820. ASU 2019-04 states that the measurement alternative is a nonrecurring fair value measurement. Accordingly, other equity investments without readily determinable fair value are classified within Level 3 in the fair value hierarchy because the Company estimates the value using a combination of observable and unobservable inputs, including valuation ascribed to the issuing company in subsequent financing rounds, volatility in the results of operations of the issuers and rights and obligations of the holdings we own.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company had no material adjustments of assets and liabilities measured at fair value on a nonrecurring basis during any of the periods presented. There were no transfers between fair value measurement levels during any presented period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445430480888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders' Equity<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Authorized share capital</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s authorized share capital consists of an unlimited number of common shares</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Issued and outstanding share capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has only one class of stock outstanding, common shares. The authorized stock consists of an unlimited number of common shares with no stated par value, of which 39,630,446 and 39,185,182 shares were issued and outstanding as of September 30, 2021 and December 31, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, the Company repurchased and canceled 181,320 common shares at a cost of $1.4 million due to tax withholding for RSUs vesting. The Company&#8217;s retained earnings were reduced by the amount paid for the shares repurchased for cancellation.</span></div><div><span><br/></span></div><div style="padding-left:49.5pt;padding-right:6.75pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective June&#160;11, 2020 (the "Effective Date"), the Company&#8217;s shareholders approved the Company's 2020 Long Term Incentive Plan (the "Omnibus Plan"). Upon approval of the Omnibus Plan, no future awards are available to be made under the Company's previous RSU and Option Plans (collectively, the "Former Plan"), and the common shares that were not settled or awarded under the Former Plan as of the Effective Date are available for awards under the Omnibus Plan. The maximum number of common shares that are available for awards under the Omnibus Plan and under any other security-based compensation arrangements adopted by the Company, including the Former Plan, may not exceed 7,758,211 shares (equal to 20% of the issued and outstanding common shares of the Company on the Effective Date). The maximum amount of the foregoing common shares that may be awarded under the Omnibus Plan as &#8220;incentive stock options&#8221; is 2,600,000 common shares. As of September 30, 2021, the Company had outstanding options of 3,772,000 and RSUs of 219,000 associated with common shares under the Omnibus Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.118%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation - options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation - restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,302</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,234</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,845</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,581</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At September 30, 2021, there was approximately $3,495,000 of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized over a weighted-average period of&#160;2.00 years. As of September 30, 2021, there was approximately $852,000 of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 0.90 years.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the nine months ended September 30, 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of options<br/>&#160;(000's)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average exercise price</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,057</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.37</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,362</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,772</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,343</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For presentation purposes, stock options issued with a CAD exercise price have been translated to USD based on the prevailing exchange rate on the date of grant.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding was $4,343,000 and options exercisable were $3,798,000 at September 30, 2021. For the nine months ended September 30, 2021, 27,597 shares of common stock were issued pursuant to the exercise of stock options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At September 30, 2021, the Company had 1,882,000 exercisable stock options outstanding with a weighted average exercise price of $3.65 and a weighted average remaining contractual life of 6.8 years. At December 31, 2020, the Company had 971,000 exercisable stock options outstanding with a weighted average exercise price of $3.09 and a weighted average remaining contractual life of 6.9 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC 718 &#8212; Compensation&#8212;Stock Compensation, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock&#8211;based compensation cost for stock options are determined at the grant date using the Black-Scholes option pricing model. The assumptions used to determine the grant date fair value of the stock options granted during the nine months ended September 30, 2021 were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.775%"><tr><td style="width:1.0%"/><td style="width:63.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.816%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8.57 - $9.77</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.60% - 1.39%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.55% - 67.57%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.65 - 5.76 years</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value on date of grant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5.05 - $5.57</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:15.75pt;padding-right:15.75pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also grants RSUs to directors, officers, and employees. The Company accounts for RSUs using fair value as of the date of issuance. The fair value of the RSUs has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, based on the stock price on the date of grant.&#160;RSUs vest generally over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDIzNw_3068a39c-9f5a-4e15-9fea-67728d70b3a5">one</span> or three-year period. The Company accounts for forfeitures on RSUs under ASU 2016-09 and recognizes forfeitures in the period in which they occur.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for the nine months ended September 30, 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of RSUs (000's)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average grant price</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.04</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.22 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,308</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.72</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.90 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,217</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All future equity grants will be awarded in USD, therefore, RSUs issued with a CAD grant price have been translated to USD based on the prevailing exchange rate on the date of grant for presentation purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate intrinsic value of time-based RSUs outstanding was based on our closing stock price on the last trading day of the period.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021, the Company issued 81,394 RSUs with a vesting term of one year and a fair value of $6.38 per share. During the nine months ended September 30, 2021, the Company issued 144,700 RSUs with a vesting term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmM3MzdhOTUzOWVhMjRhMWQ5OGY3ZmQxNWExMmU3YWY3L3NlYzpjNzM3YTk1MzllYTI0YTFkOThmN2ZkMTVhMTJlN2FmN181OC9mcmFnOjNmMDliZmMzOWI4ZTQxZjk4MDczMWY4MmEzZjAxNWQyL3RleHRyZWdpb246M2YwOWJmYzM5YjhlNDFmOTgwNzMxZjgyYTNmMDE1ZDJfNDM5ODA0NjUxODUwNg_2c114217-6a38-4569-b2f7-e925d2af2d45">one</span> to three years and a fair value of $7.34 per share.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Phantom share units</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has a phantom share unit plan, which it uses for grants to directors, officers, and employees. Phantom share units granted under the plan are non-assignable and are settled in cash at vesting based on the fair value of the Company's common stock on the vesting date. Phantom share units vest annually over a three-year period. The cash-settled phantom share units are accounted for as liability awards and are re-measured at fair value each reporting period until they become vested with accrued liability and related expense being recognized over the requisite service period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes phantom share unit activity for the nine months ended September 30, 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of phantom  share units (000's)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value of share equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">985</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,642</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(601)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">614</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,407</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The value of outstanding share equivalents at the beginning of the period is based on the market price of the Company&#8217;s stock at that time, the value of issued share equivalents is based on the market price of the Company&#8217;s stock at issuance, the value of vested share equivalents is based on the cash paid at the time of vesting, the values of expired/forfeited share equivalents and outstanding share equivalents at the end of the period and are based on the market price of the Company's stock at the end of the period. The market price of the Company's stock was $5.55 on September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in fair value of the phantom share units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities. The total liability associated with phantom share units at September 30, 2021 is $1,462,000, with $1,002,000 of this amount included in current accrued liabilities and the remaining portion of $460,000 included in long-term accrued liabilities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The impact associated with the fair value re-measurement of phantom share units is recorded in selling, general and administrative expenses within the unaudited Condensed Consolidated Statements of Income and Comprehensive Income. The following table summarizes expense associated with the phantom share units for the three and nine months ended September 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.279%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company paid cash settlements of $6,282,000 and $4,201,000 during the nine months ended September 30, 2021 and 2020, respectively, pertaining to vestings of cash-settled phantom share units.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445338934104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accrues estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450,&#160;Contingencies&#160;(&#8220;ASC 450&#8221;). No less than quarterly, we review the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, the Company (through its subsidiary Sleep Management LLC) submitted a purchase order (the &#8220;Purchase Order&#8221;) in March 2020 to Vyaire Medical, Inc. d/b/a CareFusion Respiratory Technologies (&#8220;Vyaire&#8221;) for respiratory equipment. The Company ultimately prepaid $1.4&#160;million towards the delivery of such respiratory equipment. Vyaire was unable or unwilling to deliver the vast majority of the respiratory equipment referenced in the Purchase Order, and also refused to refund the prepayment amount (less the amounts paid for equipment actually received). On July 29, 2020, the Company (through its subsidiary Sleep Management LLC) filed a lawsuit against Vyaire in the United States District Court for the Western District of Louisiana (the &#8220;Court&#8221;). This lawsuit was dismissed on December 8, 2020 in connection with the commencement of the lawsuit filed by the Company (through its subsidiary Sleep Management) on November 5, 2020, against Vyaire in the 15th Judicial District Court for the Parish of Lafayette, Louisiana (the &#8220;State Court&#8221;) seeking damages for breach of contract and seeking a declaratory judgment that the Company is not required to pay any further funds to Vyaire. On December 28, 2020, Vyaire filed its Answer, Affirmative Defenses, and Reconventional Demand (&#8220;Reconventional Demand&#8221;) with the State Court alleging breach of contract and seeking damages of $4.7&#160;million, purportedly for the improper cancellation of the Purchase Order. The Company filed its Answer to the Reconventional Demand on February 12, 2021 and the parties are currently engaged in discovery.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We continue to believe that we have valid legal and equitable grounds to recover our outstanding prepayment as a result of Vyaire&#8217;s failure to deliver the vast majority of the respiratory equipment referenced in the Purchase Order. We have determined that a loss related to the Reconventional Demand is not probable, and thus have not accrued a liability related to this claim. Although a loss may be reasonably possible, we do not have sufficient information to determine the amount or range of reasonably possible loss with respect to the Reconventional Demand given that the dispute is in the early stages of the legal process. As of September 30, 2021, outstanding funds in the amount of $0.9 million related to undelivered respiratory equipment are included within other long-term assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Governmental and Regulatory Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time we are involved in various external governmental investigations, audits and reviews. Reviews, audits and investigations of this sort can lead to government actions, which can result in the assessment of recoupment of reimbursement, civil or criminal fines or penalties, or other sanctions, including restrictions or changes in the way we conduct business, loss of licensure or exclusion from participation in government healthcare programs.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May of 2021, a final report and recommendation (&#8220;Report&#8221;) was issued by the U.S. Department of Health and Human Services Office of the Inspector General (&#8220;OIG&#8221;) regarding an audit by OIG of claims relating to one hundred (100) of the Company&#8217;s non-invasive ventilation at home (&#8220;NIVH&#8221;) patients. The OIG asserted that most of the sampled Medicare claims submitted for the monthly rental of non-invasive ventilators did not comply with Medicare requirements. The Company firmly believes that the Report ignores each patient&#8217;s diagnosis and supporting documentation of that diagnosis from treating and prescribing physicians and applies clinical guidelines that are contrary to CMS&#8217;s accepted standard of care. In late June of 2021, the Company received initial request letters from DME Medicare Administrative Contractors ("MACs") referencing the Report and requesting repayment of purported overpayments. The Company responded to each initial request by submitting a rebuttal and by filing a redetermination appeal as prescribed by the initial request letters and by statute. In September 2021, the MACs informed the Company of unfavorable decisions with respect to the redetermination appeals. The Company intends to continue to defend itself vigorously through the remaining appeals processes which include, in successive order, Reconsideration appeals, Administrative Law Judge appeals, Medicare Appeals Council review, and ultimately through Federal Court, if necess</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ary. The Reconsideration appeals are required to be submitted in writing to the designated Quality Independent Contractor ("QIC") within 180 days of receiving the redetermination appeals letter. The QIC has 60 days to render a reconsideration decision. The timing of additional appeals beyond reconsideration are subject to workload constraints of the reviewing body. Based on initial discussions with CMS, a review of the current facts and circumstances </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">as we understand them, and the nature of the requests, we have determined that a loss is not probable but may be reasonably possible. Accordingly, no related accrual has been recorded. The value of the population of associated claims within the 4-year reopening period prescribed by statute, including any potential interest, is approximately</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> $9&#160;million. Man</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">agement estimates that a possible loss, if any, will not exceed this amount. It is possible that the ultimate resolution of this matter, if unfavorable, could materially and adversely affect the Company&#8217;s consolidated financial position, consolidated results of operations, or consolidated cash flows.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445341626024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, the Company recorded income tax expense of $2.4 million, which includes a discrete tax benefit of $0.8 million for excess tax benefits associated with stock-based compensation arrangements. Excluding the impact of the discrete tax benefit, the effective rate for the nine months ended September 30, 2021 is 43.4%. The effective rate differs from the amount computed by applying the statutory federal and state income tax rates to ordinary income before the provision for income taxes due to permanent non-deductible differences. Our effective tax rate is based on forecasted annual results which may fluctuate significantly through the rest of the year, in particular due to the uncertainty in our annual forecasts resulting from the unpredictable impact of the COVID-19 pandemic on our operating results. During the nine months ended September 30, 2020, the Company released a valuation allowance associated with deferred tax assets, resulting in a $5.3 million benefit during that period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At September 30, 2021 and 2020, the Company had no amounts recorded for uncertain tax positions and does not expect any material changes in uncertain tax benefits during the next 12 months. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company is subject to U.S. federal income tax as well as income tax in various states. The Company is generally not subject to examination by taxing authorities for years prior to 2016. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445340460728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income per common share is calculated using earnings for the year divided by the weighted average number of shares outstanding during the year</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Using the treasury stock method, diluted income per share amounts are calculated giving effect to the potential dilution that would occur if securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options and the vesting of RSUs are used to purchase common shares at the prevailing market rate. </span><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following reflects the earnings and share data used in the basic and diluted earnings per share computations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator - basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,039&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,607,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,107,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,442,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,603,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,659,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,155,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,716,747&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,377,608&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator calculation from basic to diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,607,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,107,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,442,088&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,603,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options and other dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,051,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,048,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,274,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,774,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,659,353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,155,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,716,747&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,377,608&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation consisted of dilutive employee stock options and RSUs that were de minimis in all periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445432568248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Principles of Presentation</a></td>
<td class="text">Principles of PresentationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. Our fiscal year ends on December 31. The Condensed Consolidated Balance Sheet as of December 31, 2020 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of our independent registered public accounting firm included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of consolidation</a></td>
<td class="text">Basis of consolidationThese consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text">Use of estimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, our evaluation takes into consideration such factors as historical bad debt experience, national and local economic trends and conditions, industry and regulatory conditions, other collection indicators and information about disaggregated receivables. The complexity of many third-party billing arrangements, patient qualification for medical necessity of equipment and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">InventoryInventory represents non-serialized respiratory supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives. </span></div>Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been delivered to a patient and is put in use and continues through the useful life of the asset. Property and equipment with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity investments</a></td>
<td class="text"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Equity investments</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity investments on the Condensed Consolidated Balance Sheets are comprised of an investment accounted for under the equity method and an equity investment without a readily determinable fair value which is accounted for under the measurement alternative described in ASC 321-10-35-2.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments accounted for under the equity method are investments in unconsolidated entities over whose operating and financial policies the Company has the ability to exercise significant influence but not control. Equity method investments are initially measured at cost in the Condensed Consolidated Balance Sheets with a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">n</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">y subsequent adjustments made to the carrying amount of the investment for the Company&#8217;s proportionate share of income or loss. The Company has recognized its share of income or loss on the gain (loss) from equity method investments within non-operating expenses in the Condensed Consolidated Statements of Income. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. No events or changes have occurred as of September 30, 2021 that would affect the carrying value of equity method investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other equity investments are investments without a readily determinable fair value which do not qualify for the practical expedient in ASC 820. For these investments, the Company has elected the measurement alternative which measures the investment at cost, less any impairment. ASU 2019-04 clarifies that if an entity identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it must measure its equity investment at fair value in accordance with ASC 820 as of the date that the observable transaction occurred. The Company was not aware of any impairment or observable price change adjustments that needed to be made as of September 30, 2021 on its investments in equity securities without a readily determinable fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive income</a></td>
<td class="text"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive income</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments, net of tax. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of the &#8220;backward tracing&#8221; prohibition in ASC 740, certain previously measured unrealized gains or losses have resulted in the existence of "dangling" amounts within other comprehensive income. The Company has elected the individual security approach to the release of these effects. Under the individual security approach, dangling amounts are tracked on a security-by-security basis and cleared out of the other comprehensive income balance upon sale of each individual security. During the periods presented, none of the individual securities associated with a dangling balance were sold.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue from a customer consists of any combination of the sale and rental of DME and/or patient medical services. Revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company&#8217;s products fall in the Medicare Fee-for-Service (&#8220;FFS&#8221;) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;). </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For commercial payors, DME companies must negotiate in-network pricing separately, though in general, the Company&#8217;s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with DME rentals, the Company recognizes revenue in accordance with ASC 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Leases,&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 842). For any DME sales and services, the Company recognizes revenue under FASB ASU 2014-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Revenue from Contracts with Customers,&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 606) and related amendments. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionLeases', window );">Revenue Accounting under Topic 842</a></td>
<td class="text"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 842</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company leases DME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company accounts for these rentals as operating leases.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under FASB ASC Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date products are delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.</span></div>Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Accounting under Topic 606</a></td>
<td class="text"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 606</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company sells DME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also provides sleep study services to customers and recognizes revenue when the sleep study results are complete, satisfying the performance obligation. In response to the COVID-19 pandemic, the Company began offering contact and vaccine tracing services, which revenues are recognized in the period in which the service has been provided. The transaction price on equipment sales, sleep studies and contact and vaccine tracing is the amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the DME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The Company does not generally contract with uninsured customers. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Returns and refunds are not accepted on equipment sales, sleep study services or contact and vaccine tracing services. The Company does not offer warranties to customers in excess of the manufacturer&#8217;s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of September 30, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC 718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">, "Compensation&#8212;Stock Compensation"</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock&#8211;based compensation costs for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units ("RSUs") are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the Company&#8217;s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the equivalent Company's stock value at the end of each period and records a liability based on the percentage of requisite service.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Interest rate swaps</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company utilizes an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the Term Note (as defined below).&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk.&#160;These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company presents a positive ending period fair value of the interest rate swap contract in other long-term assets, as a component of long-term assets, and a negative ending period fair value of the interest rate swap contract in accrued liabilities, as a component of long-term liabilities on the Condensed Consolidated Balance Sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty&#160;as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets.&#160;To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to income taxes in numerous jurisdictions. Significant judgment is required in determining the provision for income taxes. The Company's income tax provisions reflect management&#8217;s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that we will receive refunds from or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact our effective tax rate as well as our business and operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted or substantively enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted accounting pronouncements and Recently issued accounting pronouncements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,&#160;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.&#160;The new guidance simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The new guidance also improves consistent application of and simplifies GAAP for other areas of Topic 740 by clarifying and amending the existing guidance.&#160;The Company adopted this standard on January 1, 2020, which did not have any impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is an &#8220;emerging growth company&#8221; as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, our condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2019, the FASB issued&#160;ASU 2019-11,&#160;Codification Improvements to Topic 326, Financial Instruments &#8211; Credit Losses. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which is intended to improve financial reporting by requiring earlier recognition of credit losses on certain financial assets. The standard replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. Further, the FASB issued ASU 2019-04 and ASU 2019-05 to provide additional guidance on the credit losses standard. The standard is effective for fiscal years beginning after December 15, 2022 for smaller reporting companies, including interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the effect that this standard will have on its consolidated financial statements and related disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), which provides optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. Specifically, the guidance permits an entity, when certain criteria are met, to consider amendments to contracts made to comply with reference rate reform to meet the definition of a modification under GAAP. It further allows hedge accounting to be maintained and a one-time transfer or sale of qualifying held-to-maturity securities. The expedients and exceptions provided by the amendments are permitted to be adopted any time through December 31, 2022 and do not apply to contract modifications made and hedging relationships entered into or evaluated after December 31, 2022, except for certain optional expedients elected for certain hedging relationships existing as of December 31, 2022. The Company is currently evaluating the effect that this standard will have on its consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition for leases entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445337600680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable, Allowance for Doubtful Accounts</a></td>
<td class="text"><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimates and write-offs for the allowance for doubtful accounts for each reporting period were as follows:</span></div><div style="margin-bottom:0.1pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.568%"><tr><td style="width:1.0%"/><td style="width:46.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.304%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts written off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,115</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,788</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Revenue by Customer</a></td>
<td class="text"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and nine months ended September 30, 2021 and 2020 were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.704%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Medicare and Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investments</a></td>
<td class="text"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table details the Company&#8217;s equity investments:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.172%"><tr><td style="width:1.0%"/><td style="width:47.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.516%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,942</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">733</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue by Source</a></td>
<td class="text"><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The revenues from each major source are summarized in the following table:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from rentals </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Ventilator rentals, non-invasive and invasive</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other durable medical equipment rentals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from sales and services </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Equipment and supply sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;COVID-19 response sales and services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29,285</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33,447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">85,100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">100,107</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445338881688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table details the Company&#8217;s fixed assets:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,307&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,438)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Property and equipment, net of accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59,036</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445338978648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Current Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s short-term accrued liabilities are included within current liabilities and consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"><tr><td style="width:1.0%"/><td style="width:56.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.260%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued trade payables </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued commissions payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued bonuses payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued vacation and payroll</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of phantom share liability </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,595</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445340521896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Lease Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_DebtAndLeasesAbstract', window );"><strong>Debt And Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Notes Payable</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The recorded balances associated with these term notes, which have terms greater than twelve months, are as follows:</span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"/><td style="width:61.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.813%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.410%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.813%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.412%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,906)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net long-term notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,347</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,796</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_LiabilitiesLesseeTableTextBlock', window );">Schedule of Lease Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has recognized finance lease liabilities for medical equipment and operating leases for land and buildings that have terms greater than twelve months, as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"/><td style="width:60.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.670%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,741)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net long-term lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">834</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">762</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_DebtAndLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt And Leases [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_DebtAndLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_LiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_LiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445338882808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the Company's assets and liabilities measured at fair value on a recurring basis as of September 30, 2021 and December 31, 2020:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.129%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recurring Fair Value Measurements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,452</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(270)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,182</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.129%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recurring Fair Value Measurements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25,662</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(433)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25,229</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445345993176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense for the three and nine months ended September 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.118%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation - options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation - restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,302</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,234</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,845</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,581</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The following table summarizes expense associated with the phantom share units for the three and nine months ended September 30, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.279%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the nine months ended September 30, 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.491%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of options<br/>&#160;(000's)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average exercise price</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,057</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.37</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,362</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,772</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,343</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For presentation purposes, stock options issued with a CAD exercise price have been translated to USD based on the prevailing exchange rate on the date of grant.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options, Valuation Assumptions</a></td>
<td class="text">The assumptions used to determine the grant date fair value of the stock options granted during the nine months ended September 30, 2021 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.775%"><tr><td style="width:1.0%"/><td style="width:63.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.973%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.816%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8.57 - $9.77</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.60% - 1.39%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.55% - 67.57%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.65 - 5.76 years</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value on date of grant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5.05 - $5.57</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for the nine months ended September 30, 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.417%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.380%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.122%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of RSUs (000's)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average grant price</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.04</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.22 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,308</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.72</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.90 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,217</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All future equity grants will be awarded in USD, therefore, RSUs issued with a CAD grant price have been translated to USD based on the prevailing exchange rate on the date of grant for presentation purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate intrinsic value of time-based RSUs outstanding was based on our closing stock price on the last trading day of the period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Phantom Share Units</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes phantom share unit activity for the nine months ended September 30, 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.667%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of phantom  share units (000's)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value of share equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">985</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,642</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,282)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(601)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">614</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,407</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The value of outstanding share equivalents at the beginning of the period is based on the market price of the Company&#8217;s stock at that time, the value of issued share equivalents is based on the market price of the Company&#8217;s stock at issuance, the value of vested share equivalents is based on the cash paid at the time of vesting, the values of expired/forfeited share equivalents and outstanding share equivalents at the end of the period and are based on the market price of the Company's stock at the end of the period. The market price of the Company's stock was $5.55 on September 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445340474264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following reflects the earnings and share data used in the basic and diluted earnings per share computations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.831%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.698%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator - basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,039&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,607,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,107,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,442,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,603,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,659,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,155,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,716,747&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,377,608&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator calculation from basic to diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,607,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,107,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,442,088&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,603,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options and other dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,051,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,048,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,274,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,774,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,659,353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,155,668&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,716,747&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,377,608&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445338924104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business and Operations (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>state</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity provides DME and health care solutions</a></td>
<td class="nump">46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445345902744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Allowance for Doubtful Accounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance, beginning of year</a></td>
<td class="nump">$ 9,013<span></span>
</td>
<td class="nump">$ 7,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Change in allowance for doubtful accounts</a></td>
<td class="nump">5,250<span></span>
</td>
<td class="nump">7,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Amounts written off</a></td>
<td class="num">(7,148)<span></span>
</td>
<td class="num">(6,025)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance, end of period</a></td>
<td class="nump">$ 7,115<span></span>
</td>
<td class="nump">$ 8,788<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445342753688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Customer Percentages) (Details) - Customer Concentration<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vmd_MedicareAndMedicaidMember', window );">Total Medicare and Medicaid | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vmd_MedicareAndMedicaidMember', window );">Total Medicare and Medicaid | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">62.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vmd_MedicareMember', window );">Medicare revenues | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vmd_MedicareMember', window );">Medicare revenues | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vmd_MedicaidMember', window );">Medicaid revenues | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=vmd_MedicaidMember', window );">Medicaid revenues | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vmd_MedicareAndMedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vmd_MedicareAndMedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vmd_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vmd_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=vmd_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=vmd_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445340303080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Inventory and Property and Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve</a></td>
<td class="nump">$ 1,237<span></span>
</td>
<td class="nump">$ 1,353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445338730760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Equity investments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investments</a></td>
<td class="nump">$ 744<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other equity investments</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Balance, end of period</a></td>
<td class="nump">$ 1,942<span></span>
</td>
<td class="nump">$ 733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f,g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445341907240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Revenue Recognition) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Recognition period</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 29,285<span></span>
</td>
<td class="nump">$ 33,447<span></span>
</td>
<td class="nump">$ 85,100<span></span>
</td>
<td class="nump">$ 100,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vmd_VentilatorRentalMember', window );">Ventilator rentals, non-invasive and invasive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncome', window );">Revenue from rentals</a></td>
<td class="nump">21,305<span></span>
</td>
<td class="nump">19,962<span></span>
</td>
<td class="nump">61,962<span></span>
</td>
<td class="nump">58,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vmd_OtherDurableMedicalEquipmentRentalsMember', window );">Other durable medical equipment rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncome', window );">Revenue from rentals</a></td>
<td class="nump">3,598<span></span>
</td>
<td class="nump">2,649<span></span>
</td>
<td class="nump">9,833<span></span>
</td>
<td class="nump">7,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vmd_EquipmentSalesMember', window );">Equipment and supply sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from sales and services</a></td>
<td class="nump">2,415<span></span>
</td>
<td class="nump">1,890<span></span>
</td>
<td class="nump">6,258<span></span>
</td>
<td class="nump">3,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vmd_COVID19ResponseSalesMember', window );">COVID-19 response sales and services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from sales and services</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="nump">8,553<span></span>
</td>
<td class="nump">5,542<span></span>
</td>
<td class="nump">29,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from sales and services</a></td>
<td class="nump">$ 515<span></span>
</td>
<td class="nump">$ 393<span></span>
</td>
<td class="nump">$ 1,505<span></span>
</td>
<td class="nump">$ 983<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123420820&amp;loc=SL77919311-209978<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vmd_VentilatorRentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vmd_VentilatorRentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vmd_OtherDurableMedicalEquipmentRentalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vmd_OtherDurableMedicalEquipmentRentalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vmd_EquipmentSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vmd_EquipmentSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vmd_COVID19ResponseSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vmd_COVID19ResponseSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445342792456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Fixed Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">$ (25,438)<span></span>
</td>
<td class="num">$ (20,289)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization</a></td>
<td class="nump">59,036<span></span>
</td>
<td class="nump">55,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vmd_EquipmentMedicalMember', window );">Medical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">72,795<span></span>
</td>
<td class="nump">63,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vmd_FurnitureAndEquipmentMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,410<span></span>
</td>
<td class="nump">2,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,138<span></span>
</td>
<td class="nump">2,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,863<span></span>
</td>
<td class="nump">5,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 972<span></span>
</td>
<td class="nump">$ 922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vmd_EquipmentMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vmd_EquipmentMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vmd_FurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vmd_FurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445432566632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciation', window );">Depreciation</a></td>
<td class="nump">$ 2,656<span></span>
</td>
<td class="nump">$ 2,224<span></span>
</td>
<td class="nump">$ 7,574<span></span>
</td>
<td class="nump">$ 6,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">25,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vmd_AssetsHeldUnderFinanceLeasesMember', window );">Capital lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 885<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vmd_AssetsHeldUnderFinanceLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vmd_AssetsHeldUnderFinanceLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445342281960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_AccruedTradePayablesCurrent', window );">Accrued trade payables</a></td>
<td class="nump">$ 2,265<span></span>
</td>
<td class="nump">$ 1,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrent', window );">Accrued commissions payable</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonuses payable</a></td>
<td class="nump">2,912<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued vacation and payroll</a></td>
<td class="nump">2,027<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Current portion of phantom share liability</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">4,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other liabilities</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 9,283<span></span>
</td>
<td class="nump">$ 12,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_AccruedTradePayablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Trade Payables, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_AccruedTradePayablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445339073080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Lease Liabilities (Line of Credit Narrative) (Details) - Line of Credit - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_DebtInstrumentInterestRateFloorRate', window );">Floor rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Borrowings against facility</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_DebtInstrumentInterestRateFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Floor Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_DebtInstrumentInterestRateFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445342544984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Lease Liabilities (Commercial Term Notes Narrative) (Details) - Notes Payable - USD ($)<br></strong></div></th>
<th class="th"><div>Oct. 19, 2019</div></th>
<th class="th"><div>May 30, 2019</div></th>
<th class="th"><div>Sep. 19, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vmd_BuildingTermNoteMember', window );">Building Term Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_DebtInstrumentCovenantLoanToValueRatio', window );">Required loan to value ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vmd_BuildingTermNoteMember', window );">Building Term Note | Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Fixed interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vmd_BuildingTermNoteMember', window );">Building Term Note | ICE LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vmd_TermNoteMember', window );">Term Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Monthly principal payments</a></td>
<td class="nump">$ 139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_DebtInstrumentCovenantLoanToValueRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Loan To Value Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_DebtInstrumentCovenantLoanToValueRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vmd_BuildingTermNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vmd_BuildingTermNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vmd_TermNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vmd_TermNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445342565560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Lease Liabilities (Schedule of Notes Payable) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of notes payable</a></td>
<td class="num">$ (1,906)<span></span>
</td>
<td class="num">$ (1,836)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Net long-term notes payable</a></td>
<td class="nump">4,347<span></span>
</td>
<td class="nump">5,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember', window );">Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">6,253<span></span>
</td>
<td class="nump">7,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of notes payable</a></td>
<td class="num">(1,906)<span></span>
</td>
<td class="num">(1,836)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Net long-term notes payable</a></td>
<td class="nump">$ 4,347<span></span>
</td>
<td class="nump">$ 5,796<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445337535032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Lease Liabilities (Lease Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_DebtAndLeasesAbstract', window );"><strong>Debt And Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_LeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 1,315<span></span>
</td>
<td class="nump">$ 3,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_LeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="num">(481)<span></span>
</td>
<td class="num">(2,741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_LeaseLiabilityNoncurrent', window );">Net long-term lease liabilities</a></td>
<td class="nump">$ 834<span></span>
</td>
<td class="nump">$ 762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_DebtAndLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt And Leases [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_DebtAndLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_LeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_LeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445340281704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Lease Liabilities (Finance Lease Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_DebtAndLeasesAbstract', window );"><strong>Debt And Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Interest rate</a></td>
<td class="nump">9.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average interest rate</a></td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.17%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average lease term</a></td>
<td class="text">1 year 18 days<span></span>
</td>
<td class="text">8 months 23 days<span></span>
</td>
<td class="text">1 year 18 days<span></span>
</td>
<td class="text">8 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_DebtAndLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt And Leases [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_DebtAndLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445342511656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Lease Liabilities (Operating Lease Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Aug. 01, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average lease term</a></td>
<td class="text">3 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Operating rental expenses</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">$ 570<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=vmd_MonthlyRentalPaymentsMember', window );">Monthly Rental Payments | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Rental payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Total rental payments</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vmd_MonthlyRentalPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vmd_MonthlyRentalPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445342279096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement (Recurring Basis) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swap</a></td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">21,182<span></span>
</td>
<td class="nump">$ 25,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swap</a></td>
<td class="num">(270)<span></span>
</td>
<td class="num">(433)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market mutual funds</a></td>
<td class="nump">21,452<span></span>
</td>
<td class="nump">25,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">21,452<span></span>
</td>
<td class="nump">25,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 1 | Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swap</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market mutual funds</a></td>
<td class="nump">21,452<span></span>
</td>
<td class="nump">25,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="num">(270)<span></span>
</td>
<td class="num">(433)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 2 | Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swap</a></td>
<td class="num">(270)<span></span>
</td>
<td class="num">(433)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 2 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market mutual funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 3 | Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swap</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair Value, Inputs, Level 3 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market mutual funds</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets Fair Value Disclosure And Liabilities Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445347131624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement (Narrative) (Details) - Interest Rate<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>interestRateSwap</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of interest rate swaps | interestRateSwap</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value</a></td>
<td class="num">$ (0.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445342401096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Issued and Outstanding Share Capital) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>classOfStock </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,630,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,185,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,630,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,185,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Shares redeemed to pay income tax | $</a></td>
<td class="nump">$ 1,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_NumberOfStockClasses', window );">Number of stock classes | classOfStock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">39,577,288<span></span>
</td>
<td class="nump">39,630,446<span></span>
</td>
<td class="nump">39,588,299<span></span>
</td>
<td class="nump">39,185,182<span></span>
</td>
<td class="nump">39,145,182<span></span>
</td>
<td class="nump">39,082,932<span></span>
</td>
<td class="nump">38,486,772<span></span>
</td>
<td class="nump">37,952,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Shares redeemed to pay income tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(181,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Shares redeemed to pay income tax | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_NumberOfStockClasses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Stock Classes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_NumberOfStockClasses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445341060872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Stock-based Compensation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 11, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,772,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,772,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,057,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="nump">$ 1,234<span></span>
</td>
<td class="nump">$ 3,845<span></span>
</td>
<td class="nump">$ 3,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized pre-tax stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vmd_OmnibusPlanMember', window );">Omnibus Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Maximum shares in Plan (in shares)</a></td>
<td class="nump">7,758,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding', window );">Percent of issued and outstanding shares</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vmd_OmnibusPlanMember', window );">Omnibus Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Maximum shares in Plan (in shares)</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,051<span></span>
</td>
<td class="nump">945<span></span>
</td>
<td class="nump">$ 3,127<span></span>
</td>
<td class="nump">2,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 251<span></span>
</td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
<td class="nump">$ 812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized pre-tax compensation expense, restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Grant, Percent Of Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vmd_OmnibusPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vmd_OmnibusPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445342250088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Options, Stock Option Activity) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options (000's)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">3,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Issued (in shares)</a></td>
<td class="nump">829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired / Forfeited (in shares)</a></td>
<td class="num">(86)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">3,772<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average grant price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (USD per share)</a></td>
<td class="nump">$ 4.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Issued (USD per share)</a></td>
<td class="nump">8.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (USD per share)</a></td>
<td class="nump">3.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired / Forfeited (USD per share)</a></td>
<td class="nump">8.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (USD per share)</a></td>
<td class="nump">$ 5.21<span></span>
</td>
<td class="nump">$ 4.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value (USD per share)</a></td>
<td class="nump">$ 4,343<span></span>
</td>
<td class="nump">$ 10,362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445430939288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Options, Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value (USD per share)</a></td>
<td class="nump">$ 4,343<span></span>
</td>
<td class="nump">$ 10,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 3,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued pursuant to stock options (in shares)</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">1,882,000<span></span>
</td>
<td class="nump">971,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price (USD per share)</a></td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued pursuant to stock options (in shares)</a></td>
<td class="nump">27,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445426803960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Options, Fair Value Assumptions) (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value on date of grant (USD per share)</a></td>
<td class="nump">$ 5.55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (USD per share)</a></td>
<td class="nump">$ 8.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">64.55%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value on date of grant (USD per share)</a></td>
<td class="nump">$ 5.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (USD per share)</a></td>
<td class="nump">$ 9.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">67.57%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value on date of grant (USD per share)</a></td>
<td class="nump">$ 5.57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445340622728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Restricted Stock Units) (Details) - Restricted Stock Units - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs (000's)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares)</a></td>
<td class="nump">81,394<span></span>
</td>
<td class="nump">144,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Expired / Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">219,000<span></span>
</td>
<td class="nump">219,000<span></span>
</td>
<td class="nump">684,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted average grant price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Issued (USD per share)</a></td>
<td class="nump">$ 6.38<span></span>
</td>
<td class="nump">7.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Expired / Forfeited (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (USD per share)</a></td>
<td class="nump">$ 6.72<span></span>
</td>
<td class="nump">$ 6.72<span></span>
</td>
<td class="nump">$ 3.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">2 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1,217<span></span>
</td>
<td class="nump">$ 1,217<span></span>
</td>
<td class="nump">$ 5,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445426058712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Phantom Share Units) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Value of share equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price(USD per share)</a></td>
<td class="nump">$ 5.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Current accrued liabilities</a></td>
<td class="nump">$ 1,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="nump">$ 1,234<span></span>
</td>
<td class="nump">$ 3,845<span></span>
</td>
<td class="nump">$ 3,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember', window );">Phantom Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of phantom share units (000's)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(656)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Expired / Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Value of share equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited', window );">Expired / Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(601)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Ending balance</a></td>
<td class="nump">$ 3,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Total liability</a></td>
<td class="nump">1,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Current accrued liabilities</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Long-term accrued liabilities</a></td>
<td class="nump">460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,282<span></span>
</td>
<td class="nump">4,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember', window );">Phantom Share Units | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Value of share equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 4,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PhantomShareUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445338633608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 28, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Outstanding deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445341320584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="nump">$ 1,141<span></span>
</td>
<td class="nump">$ 2,409<span></span>
</td>
<td class="num">$ (5,318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Provisional income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets, valuation allowance released</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140445342774264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to shareholders</a></td>
<td class="nump">$ 1,789<span></span>
</td>
<td class="nump">$ 1,566<span></span>
</td>
<td class="nump">$ 1,684<span></span>
</td>
<td class="nump">$ 2,804<span></span>
</td>
<td class="nump">$ 19,412<span></span>
</td>
<td class="nump">$ 4,243<span></span>
</td>
<td class="nump">$ 5,039<span></span>
</td>
<td class="nump">$ 26,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average number of common shares (in shares)</a></td>
<td class="nump">39,607,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,107,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,442,088<span></span>
</td>
<td class="nump">38,603,267<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average number of shares (in shares)</a></td>
<td class="nump">40,659,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,155,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,716,747<span></span>
</td>
<td class="nump">40,377,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Denominator calculation from basic to diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average number of common shares (in shares)</a></td>
<td class="nump">39,607,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,107,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,442,088<span></span>
</td>
<td class="nump">38,603,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Stock options and other dilutive securities (in shares)</a></td>
<td class="nump">1,051,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,048,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,274,659<span></span>
</td>
<td class="nump">1,774,341<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average number of shares (in shares)</a></td>
<td class="nump">40,659,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,155,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,716,747<span></span>
</td>
<td class="nump">40,377,608<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>65
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M'G:[B?/(=P+/?.(8H4CJ!+[U;((B79<YH2FB,&3H.YSY'6]?>:LB>+^*.,S
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M?SR\J8KU[OLJOA1552QW+^=9JCJR%JC_WQ9%]?--_148AV]AN?@?4$L#!!0
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MI#13I;4575F5]^B36J@U>P\4GVRCG59&T?YP;WCP-*6![X82](TL0R&7Z/-
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M[._O)23MTZ)=>%O'ZWQN/1X'\1,#$UB# ,X7UOK-(CC8ON^._P)02P,$%
M  @ ?8UA4VJ[B6^:(P  C7(  !@   !X;"]W;W)K<VAE971S+W-H965T."YX
M;6SM/6ESX[B5?X7EG21V%>76X7.N*K=G>K>SZ9FN<4_R86L_0"0D<9J' I"6
ME5^_[\)!BK+=V:0J'U*5],@4 3R\^P+T[:XQG^U&ZS9YJLK:?G>R:=OMUV_>
MV&RC*V7/FZVNX9M58RK5PI]F_<9NC58Y#:K*-_/I].I-I8KZY/MOZ=E'\_VW
M3=>61:T_FL1V5:7,_JTNF]UW)[,3]^"78KUI\<&;[[_=JK5^T.VOVX\&_GKC
M9\F+2M>V:.K$Z-5W)W>SK]]>X/OTPI\+O;/1YP1WLFR:S_C'^_R[DRD"I$N=
MM3B#@O\\ZGM=EC@1@/%7F?/$+XD#X\]N]G>T=]C+4EE]WY1_*?)V\]W)S4F2
MZY7JRO:79O=?6O9SB?-E36GIWV3'[UXL3I*LLVU3R6" H"IJ_J]Z$CQ$ VZF
M1P;,9<"<X.:%",H?5*N^_]8TN\3@VS ;?J"MTF@ KJB1* ^M@6\+&-=^_\#$
M2)I5\E"LZV)59*IND[LL:[JZ+>IU\K$IBZS0]MLW+:R'H]YD,O=;GGM^9.[;
MY$-3MQN;_%CG.N^/?P-P>F#G#MBW\V<G?-#;\V0Q39/Y=#Y[9KZ%W_R"YEL<
MF6]DE\G_W"UM:X!9_O>9!2[\ A>TP,4_!;O_J+F3CZ:HLV);PD=X^Z/15M>M
M(JGXM-$@&5E3;56]QT%=K;J\:'6>9 V0K;;\R<)<N<+'JZ)6,)LJ$PMS:!#0
MUB8;]:B3I=9U JIAJPR\5]0TL<GA;0U<W6[H;X%M&T!:ZUH;599[_%YO6Q[;
M F"_U@3( ZY#H-]5VL VD]/?_\?-?#[]YC_O[C[2Q]DW9PEH*!C8PAM5!&11
ML^8B%5#GR;8SMD-$M0VM83J$ ;\Q>MV5]"*MA5\^Z*PS15O(&S\^91M5KW5R
MWU1584DQG>)[)P\_WI^<G1/R30[[*_<I3K!/\B:IFQ:@R,HN!U27I9M["-BJ
M:5IX%98R^J]=@2A<[A/<(>T,253J5H_B__R0CE]"/:!7H'N:++L6]2TJ3@)8
MY;^!(N)7<;+"$@EA'S7NH(27 4T&GP$(IE.E39/=IL@VJ:-DLRUJW"B,J50-
MVAYG2VGA6F?:6N1DH,B6>3-9J<( 0S2= 5R[C=S'&WFK2F*L!U1]L-Z1UQ["
M+F'M]S5@2!.Z@82PV ;-"[ N?_'*6>Z)"2SN[6$#6]@T9:Z-14:<77^3_ C4
M:_>RR&NF4W:3O /K:(G0S!O,QEOXM\FM0XO.SY.? 26KPF: ]KU6)M$U? ^8
M_0'06"VU218SYH;7X"U1!$$TEG3K--G!%[ G0 VPC&FJ)%(*+S 3<D_> 'J&
M?)\#U&5C.S/"X@2RU5_$M7;3="7, #(,W@A2 \;\UM5L[DGA("Y570-'OD8*
M@& X@(40/AD-'.F>@EIK3(O80J8L $SPBW+D5= ;(!$:=[/MEJ!R8SVW*DSE
ML.#UVCV+J3",3>X8Q%]DB3I!AR.932?_[3G"T1HF.: 6T[M6+:#6 ;CL+-@+
M"TP*B.HR1(5J92,6/!:B.\ P8#60SCT1;HE,F(.N1:?)J2PW%- "W^NG+6@(
MQ*; ",@ FA*HY\!GH"=P8$"\V!LF\PO$<(S3BE[K1%@B]!%I"GB\ P$L]Y-F
M5\-LMEO:(B^4 :4-"KDL>8>B&1,P[;55&6OY8+5T68!SI4C"?K6T80U:KB+#
M@]AEL\9[Z&WJ^ ;P)53QJ R(&TF7"^?;2 \B/BOU64=+XM:4!4]YRY 2]=1J
MA2HY<".LK2J/&GA?"QN7A5H693!<0?0$>.1-7/G8&%X%M^>0_GKY&8/-Z$==
M=P(-,@[(.&B8CHQ&&$2> 3'B>?(AX ?=;I)(^QR.NBW09@.BV*"/4-(RP 6@
M[%+X+$8+!WVN@562K#!95P'\\ +8#]6U&QC8,L/W/)6FAL]9M,L&E0/8J R6
M$MI$U%P",\%VG9B <K)-K9:E/N\Y:@J_$'9P6.B8]:+)PG:-+I$<,*D@$\UN
M _/A[M,@)/!4%X^X7D21DL@&6KC9D?9'D<V;;MFNNM(/16M-]K%53[CMQP(]
M',0-NB=@D9-'578$8>Q?@;O<B1=RE[4=^0.L)S)2T'D!?&O8C QH>.[<U1[8
M8\_04V '#?T"P "$9Z)Z( 1"5X6YE[6"JJ.]%C01^&7P/F O:QZUZ"L! VP(
MV(]<+X6\,%&)%*F:G(A%[!5<K#'0O(%&[=V^TOJ"B=2MDZ\7:'.>O&]Q)]L&
MW$Y<U>OSP"&OFTFHPIZL^&GRC/2A2G V0[0%G9F104*3TH XB7N,6,K0;5FA
MV^+\#=:P.Q B F85(0F5M&;,E,5G$)!-T_2HAWJ5"%6!]66.\R/<S%ZPHC%Z
M!9/T A#8*W"(?MHH<%J1Z<E*Q"Y)JVOBA%P_PF+@WN8D0\RXL-.,?3O5@F;;
MD@X@MJ$U>:^TQPELD7UGP*59XU)KA>+P.GJ^$ZM9@YT&5J- F0W\ P9!;.$E
MUDV) !K%CTU0"^8"@23 P(7-A31LZYUF OT2Z4/'Y#W%6"O9.IF AO0FS-A4
MX,:TAIQ+(C:P,R&)E$0.F#7[.&AJX,_X'=:0,6W9F2"HD"!Q\+-LT&4LK%JO
M83J2DXAS&.,<_CRA@+."!%.^*4P^ :L,SYS(*F.0K4D=I<D6%D E^E=02EZ2
MB1Z5S@DG''S(K*B*MZ1UG>)$M6]:("J_8'11+2%^9-7LS!MQ,;^66&T>"^0?
MTG;NZ5;M<>/H6[%J)/:*HBKT,YVQ-,4:E&M)6HZU%F.@;_@B#G3NUTMRCT^U
M O88VMID!\XK,LNJP2GLUR,<>/AHZI09!(S@ =>UQ(3DJ7Z5W*;3V0+^>YU>
MW\PE9*)MOP#E93J_G,*HZ6(&X3X_P\V"T))..;U.9Q<W9\GI53J=7YX%(%"H
M87G9$BX\FUW"?V\ @!L,\+P+/JK$V[%-HW [PN1@^8BJ'XAW#)M7_J/(18\"
M:B6"75S]CEZ837^7(M715P;/ A,#^/@"O@:>7H+P0\2-FKMI@1]!$M CP11"
M7P;NQ@.UE"9Z:3@3^/D-G$/X(3[:,[L$)@$$9Y@^6NNA0_X'B^YUI$S930%=
MH55ET0E#&B!L]S__^?T/D]DM(084!KRD7!K&B5#J&;O=&,UPO$97THL<Q [9
M^A--%"<E!^-_POF?^9[FI[G#)X\H[^->+I+?)9?7^,\5_G,#_W@,^K=NX:G[
M/[[QB2@XCO:K.;QPA9-=7;I/[VN8B!1O^.39#TU=/;%DQHN_D4*UV\*PHK;=
M=EL66CQ7R>CT%2!J5:  ?M=5Q$.I\[<;</M018.#F'?@'?C92*];Y]WG+H@
MK44N(U(8M!OZN'V'@9Q*-&9N%S(0: 9HIW@%P3/D+0$KP89(9&G<>?+S$MPK
M3(SA^ETM[$-ON"D).B,C"+#@^HU/&E!:1-D7YZ\I1">L QZ'^'/P\*M9.E^
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M&;RU/OX1G2#4+G^&H59A>!#$/1JQB):"/$()UCBI%*<MG%L==@UH!_-AJ 3
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M\",^>0.<Y>)/%_RZM&>4AT528&%#0E8*2UU!Q26O77^.RQNF/FF8]@HDP,_
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M/%%P4*Y7VAPE2:!!PD";7J\%(:BB,BG;8D(0GY/CS"V+[Z#V\$]J:.BQLE,
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MIR.E/A! 6+#@?GX?!^S)Y:BD0$;^77Q<A%<GKNQC6];TV?PQA53N7ZM0EGR
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M A76O)/^DSG^AB<^DX!7&NGB"L?>=TP9R\YYHT[!I"NA^W_^<#J'BX!Y_DP
M.P6P6'>?*%;YCGN^7EIS!!N\"2T(D6J,IN*$#I=R[RWM"HKSZZVE^[7^$;BN
MX/VW3K1TXGZ9><(.'EEYPMGT..P9G 7<&>T;!^]UA=73^(QJ&@ICY\(V[$7
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M@S8XT'YMC#\K(<'P'5O_"U!+ P04    " !]C6%3B<M!:]<"   H!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RE55%OVC 0_BNGK-H3:X))(#!
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M01 JDS5=$3TR5PA%#ZRE?H$CB3)-76<=Z"TXBK35DII7J-T$Z&8<EALTW?7
M)\R.EGYCB5J%*0J)FR-4)_&O@/78,*%OO\<2UL$R79;"^C:W)S ,TA38*.TP
M&ZUJB\_GK#?N,TAZ_?%SN$>>\;;5J00"&DJ;@!$;01K'<-*Q(ID\BHJK"JZH
MPT@ZK\Y)A0/E%T4,XEZ<)AV[)B7,"Z6&Z1B2> CWVG'YJN97,.ZQ=. K9KUD
MG,!K#RT\Z]X2S:Z94994J95K&[FS=F-PT7;_,[R=H3?<[ 2I*'%+KM'U* G
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M:+3"@F*F0%JS/T$DPAN8#^W(E\X+*[T2ZFN!1?"&EOUR\RL<!]X*[_*T(.M
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M9>&JPQRGJJU)ZHB9M@!=1<]/#)C)M"5^^C?B<6^\5"FOE+CC9\N.H,2R&R6
MM%-IREU!=;[!"2/.$IW0-Q=NORJ"Z>W[_'+8^JB%*GW!G^XHKX!FP_>M^FG]
M=? \?!1KAH=/BQ_YN,\!&G-,13TRZ0@;/M>%&V]R_D0V,QZ=#O^DXUME:0#>
MSPU:U/*&%JB_F9[]#U!+ P04    " !]C6%3224'I"L(  #&%@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q,BYX;6R]6%UO&S<6_2N$-MC:@"S)LI,Z6=N
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MZ&(D2EK*5OL/9O,3)7N>,UYAM M_Q2;N/3L?B:)UWM3I,#2H51/_RX?DA^S
MQ>S @7DZ, ]Z1T%!RS?2R^M+:S;"\FZ@\8]@:C@-Y53#0;GS%JL*Y_SUCU)9
M\9O4+8EW)%UK"1[WEU,/;-XQ+1+.;<29'\!Y*=Z9QE=._-"45&Z?GT*G7K%Y
MI]CM_*N =[2>B+/96,QG\].OX)WUAIX%O+,_-_2-<H4V;*L3_[Q9.&^1&__Z
MBHSS7L9YD''^7SOS6W#$)[C6BIN[U^*C6:M"7,SAGB7OO0][E>-\!%8II!.^
M(K&VJB#\DA[%T>I2+ B55! *H13>"%2'%A*UX1SJWUBQEBHLP"6-6T*:%%K)
MA=+*/PK5\%YCH85^C%MDK*T%^0U1@\2TGP&TEM:K0JUEXYV ;%:ES@PII2=Q
MI"8T&3,B/2@?53V>;)LGR'FYT KY#2!1*;+2%M6C !M!G74+?&C+YLN@B*>B
M:M27%MM;!QNA<A2LFE7NJN 2E)&JU;\I^@K[A5D*LW!D[R&4.@&R*;GRGFYM
MFZ>;%X]P\)=6!8%!2C#>.+\'>4%1RTT%W\E[J32O3L3'BBP):5E/2R0TW9,.
MEC+8X 6FHU*PV17'=8@4E(LBQIP)2Z/!O>Z5^)EQQ*DX$;\^T27H"D9DNA1?
M6N.!'&+BQ%';R/(/<!&5Q]'S):*H"JECXCC.G$ZXP@'5L6U*"#=)HN<0_3;*
M,]#9LM1F1YIJ"MV6,7:=PD$Y]D?F0U:$[>YSMS=_+$@%]%(AV3UR-61+]S0H
MDTQ/$G?T8'R'H&MI_ZJ98][Q%&5PUU-(3JX=S 0V&-T8GP1UJI_!CY_V9-]A
MGX2D CVL.)^0'G^TY2K4(CV0+13G$5*7S[XV-0HW5'M)GBRG_G;Q@&< @QI&
M4L="!(6VC.9$@=<K8U$J60#/4-:#N3]GYB9Z*YDE,M;C=BT^4-':4$>WTD'F
MQTRYQ":01]9+U1QR)V SQ0.L[6$7#-M5VX:"IWOF<SVI90 YB:6B+".WL%*8
MBAQ6./ADE2FCSV/U!3K@4+DT_\!#N;N_<X=,J#,7_8DM7.R(+5JGIWJ! NCZ
M9P!] ^*/;T_#V]DK<>/W;3YZRXQB6H=3[K@OPJYJNA3\:#Q2>HC2_JX%VL%D
M0(]=;ZA;W^+8L@6V>";FI^/SYW/\^/O?+N:G\W]L_4J+;^%3R\EFN6^XC5SW
M>X[FW\^.=YZB7AET?+T#?'HQ9_.?..7_:_WS\8L7!ZV/BU^S_OSL['CGJ;>^
M@XZO=X#G\Y<PW:I[&?@KKV!.E8K*5<AJ9IV8AGGU(>W,J@GM4 7^W-4P9&(B
MX8/<&8BJ*"(F2WMM,. T3$7XY8Q6/">4J'XM&XPQ=SSD[I1T++&A_R/[ >N8
MZ?8:%T:D2&I ;AV+Q<!-Z!%0A4NAW#M-C%.3X/TEQD?3ACHOI*O$$N4-KTG]
MR"68NC$]K-%L\BVA-$D65:8;J\]EVQU._3=.&04&:IY,.6%899>LR\YOZ14&
MOD \/"G@P@)FXF;( <68X?+F&=/Q) X0W:@P0&U'%"E^3S$Q5+W6BGUD-!2(
ML61RWT\[XZV&4AE=LG]H3\+TQF(64G!1T)Z"-]_)QP[P14Q.R;,@FB)"Q"-(
MS<%@!9Z=3YYC4M,:"\FS/6P(O%.K)J140!B"Q^F.6+R-H5LJ"]70]'AN"W<:
M8$=S\&ZYI-CSU\:R!GU4 DAL(PH$#PN5U*D%#+2]@>AG1[,)2C)I*HZRC.PG
MNNT1Y3@Z?WLX0L+:EK::Q3A9!H_#S]$KVC2K$Q:PW1@/A.R;.O4OIK$[S?KW
MOEE^0XMN<KRA2SLZ/#7%"8XG;\_3 0B<?82T]0.KQ9$S[<D6)^*'P^=@ $5&
M@.UAVD$V*QM& )[;$2=@WH?-6"TPT*XBOQ7*%FV-"TP3Q]I2\7 T7 H*:6W@
MO61Y3*-<>(W4IX>"^+*VE4:3G(Z_<P<M"^ISW4%,G%=Y+@5W@/!.*L*%,-$O
M2)![G@\SA2P5^+#+RHPO]@@7W.?2+);D.PY=C$N'NA<SB_IV#L3KT/Z;)M=
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M"IH+G7K%.9$>[$>!A&IPT=%<P[MNN960VVU9W&*;ULQGVA+]1P%]_*K*C?@
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M'0]$:3]OLS>FV/(G98O"@#6^7"N)!)8F8'Q9%*:^H0V:;PQ?_P=02P,$%
M  @ ?8UA4X55M=)P#   YAX  !D   !X;"]W;W)K<VAE971S+W-H965T,30N
M>&ULM5E=<]LV%OTK&&UF)YE19%EQVK1-,N,X3>-.G*1QVC[L[ -$0A):DF
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MXXGRZ:UJ^A)=*V\RERY&5\M'$&#D"1?@^<HA$/(7'C"\VG[^'U!+ P04
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MG9>).1IR4QF6$GTI[A:EW]]F="KKD]I@Q"0U44;@5HNET.JG'1PBZ!+.;F1
M4_;<96 VNEI5[+?I AD0 S1:>\L:W@YWU,OV:O9U>WO!?4]^J]%XAC<PG6<_
MOYPHWUX:VT5T=;JHK5W$M2\]EKAGLY<-^+YQ+O8+<3#<W"_^ 5!+ P04
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M"_.1J/08Z7=->:ELES6GZ^7UPP+)S0O5R%^0\7//$0XN>&1UMJ-,$!"*J)^
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M,T#G"QKAL3 5M0704?J=WM]!;=E*J'#+I*YDK_=(V-AO$ _3<9*.T@=_-O6
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MG^?37_JFI3\DMFSZOJGHQXT%+G?X 'R/?_)(?\$)PI^6^^'_ 5!+ P04
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M%K*K-9<K8$+^IY:)%R8^<OE1P"[J[HR,M2 1?<G>3+P@SD[9F]3SP^3T60E
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M4JZ=H5-!?FZ^-'2_QCT!5P6<W3>BIHH[V+_A*XGV8)HX"N)-DWP'N&@!V0>
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M5EAGZ(+\?2-%.J9(^Q3I:R53WU2=1- K>,'=ETQ]D]"WY:EM>8F+@/K.HGG
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MAS6]Y6@\@/976KO]Q"<8_QV6_P%02P,$%     @ ?8UA4ZE0P8XN P  B0<
M !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULE57;;MPX#/T5PLA#"GCC
MV]P2S R02Q>[0%H$37?WH>B#;'-LH;+D2G+<[-<O)7O<Z28S:!]L211Y1.J0
MU+I7^HNI$2U\:X0TFZ"VMKV*(E/4V#!SH5J4M+-3NF&6EKJ*3*N1E=ZH$5$:
MQXNH85P&V[67/>CM6G56<(D/&DS7-$P_WZ!0_29(@KW@ Z]JZP31=MVR"A_1
M_M4^:%I%$TK)&Y2&*PD:=YO@.KFZF3M]K_ WQ]X<S,%%DBOUQ2W^+#=![!Q"
M@85U"(R&)[Q%(1P0N?%UQ RF(YWAX7R/_KN/G6+)F<%;)?[AI:TWP2J $G>L
M$_:#ZO_ ,1[O8*&$\7_H!]UL$4#1&:N:T9@\:+@<1O9MO(<#@U5\Q" =#5+O
M]W"0]_*.6;9=:]6#=MJ$YB8^5&]-SG'I2'FTFG8YV=GM'>86F"SA'BDVN.<L
MYX);C@;./[)<H'FSCBP=Y-2C8@2]&4#3(Z"7\$Y)6QMX*TLL?[2/R,')RW3O
MY4UZ$O 1VPO(XA#2.$U.X&53U)G'RTY%?;V/VL"GZ]Q831GR^03X; *?>?#9
M,6>I<,I.(*@=O%>6X!_8L[O*UR[R))2KR"O3L@(W 96<0?V$P?9CC50.A=)T
MMY21@LF"SF#&J((S2[*>VQIL3?I@43<@G1,A]#4O:JC9TR V4%$5TXQ4F03;
MHZ"=QA,7 M-(D+!3@LK67 $Q8+')27M/ ]QA,4H2+XG':-LA6CB#19C.,QJ7
MX2)+Z:X- =UV6J.TT"KMRY(N2?Y@=IZ$E_'BC1M7&8WOJ3,)):O?OL=R<,0L
MS&9+&N?A\G(!)]B;3^S-?YJ]%S7Q&H,GX8XS>*N:ELEGXL-X-BO)_R7N=EPZ
M/D'XH\5!.5(#A@9+7C !^+7C;>.NT94N=6C-+)?58#6H"K?COKSCHJ1-XWBV
M/\W_KW)__\+A,TC"+)G3F(7S.#O._\M8SV>KA#(@#9>SY/\9\%+[#%;9S*79
M(GTU Z*#]MB@KOPC8*!0G;1#IYRDTSMS/;37[^K#(_6.Z8I+0T[LR#2^6!+[
M>FC\P\*JUC?;7%EJW7Y:TUN)VBG0_DY1 H\+=\#T^F[_ U!+ P04    " !]
MC6%3PP#Z;/@"   Q!P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6R]
M55%OVS@,_BN$;]A:H*@=)>VZ+ F0M#>LP H4;;=[&/:@V'0B5)8\B6[6^_5'
MR8Z7=6WV=B^62)$?/U(F-=E8=^_7B 0_*FW\-%D3U>,T]?D:*^F/;8V&3TKK
M*DDLNE7J:X>RB$Z53D66G::55":93:+NVLTFMB&M#%X[\$U52?>X0&TWTV20
M;!4W:K6FH$AGDUJN\!;I<WWM6$I[E$)5:+RR!AR6TV0^&"]&P3X:?%&X\3M[
M")DLK;T/PF4Q3;) "#7F%! D+P]XCEH'(*;QO<-,^I#!<7>_1?\0<^=<EM+C
MN=7_J(+6T^0L@0)+V6BZL9N/V.5S$O!RJWW\PJ:U/1TFD#>>;-4Y,X-*F7:5
M/[HZ[#B<92\XB,Y!1-YMH,CR0I*<39S=@ O6C!8V,=7HS>24"9=R2XY/%?O1
M[(-4#KY(W2!<H?2-0ZXXP<&=7&KTAY.4.$@P3?,.<-$"BA< W\&5-;3V\+<I
ML/C5/V5R/4.Q9;@0>P%OL3Z&878$(A.#/7C#/N-AQ!O^.>,+Y7-M0](>OLZ7
MGAS_)-_VQ!CU,48QQN@ESMP[1:,1; ES[Y$\2%/ )R672BM2'*^K=@'\:]Y@
MWCBGS H6TBO_7-'WQ@N=._:US'&:<&MZ= ^8S.[6"*75W'8!F>*%=LVG_D4@
M/CZW52W-XQNF]Y.EWF%9;5E*@C(4[B$6+K03M^26]3*P9HB0+E\78;5$U]]9
M!+W O-,.HC8;PYR>,SZX-$S--IZ]_"%\P@?4,.A6T:U#N+,D]4[AGO^/_3C\
MC?C('>/N><)5#37L5C:,#:] #(Y&)X(WK_\Z$P/Q_I===WAI"+FD!$X2@M_(
MNK<Y$&^SPR=2RVL'NE4_ 1Z<B9#^;T7Y?[,_.3H]?3'[]G!?]J/A\/")U&>_
MA6[53X"%> ?/-5FZ,\8J=*LXK#WDMC'43K1>V[\'\W8,_C1O'Y,KZ5;*>-!8
MLFMV_/8D =<.Z%8@6\>AN+3$(S9NU_RFH0L&?%Y:2ULA!.A?R=E_4$L#!!0
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M8>7FQL,>3!IMY*)=3!XLRMK]BV]M'+86Y/X3"\)V06C]=H:LEZ^%$9?G2JY
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MI=PW*/=@Y-)^]QE+0W5KFW,4!2J>0.-3*<WZ@0UT'P(O_P%02P,$%     @
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ML\JR2W<'D_37=W;!R)7J7F"_WG>>F1W(>F.?78U(XJ51VBVBFJB]C6-7U-B
MNS0M:MZIC&V >&KWL6LM0AE$C8K3)+F)&Y ZRK.PMK%Y9CI24N/&"M<U#=C7
M)2K3+Z)9=%QXDON:_$*<9RWL<8OTM=U8GL632RD;U$X:+2Q6B^AN=KN<^_/A
MP#>)O3L9"Y_)SIAG/_E<+J+$ Z'"@KP#\.N *U3*&S'&K]$SFD)ZX>GXZ'X?
M<N=<=N!P9=1W65*]B-Y'HL0*.D5/IO^$8S[7WJ\PRH6GZ,>S222*SI%I1C$3
M-%(/;W@9ZW BF'TX(TA'01JXAT"!<@T$>69-+ZP_S6Y^$%(-:H:3VE_*EBSO
M2M91_@6HLRA,)9:=XSWG!.A2/+9HP9?-B3=K))#*O<UBXH!>%A>C^7(P3\^8
M;[&]%//D0J1).G,$A'][Q P[$:<3<1I,YV=,'^T>M/P=Z"[$BA&-DB4,=\SH
M&XL.-0T+G->]U* +"4IL/0$W%#GQXV[GR')+_/P/T7PBF@>BJW,U[)H=6A\K
MY.B$U**O95$+CB7I5;36'&3)&^N'CX&Q1E!4BP*X](S?A4K_J[Y#X.L0V']?
MA_SJ)HL/I[#QR>7[[^@![%[RO2FL6)1<OF.U'7ISF)!I0S_L#'%WA2'SE&C]
M =ZOC*'CQ+?8](/(_P!02P,$%     @ ?8UA4\6>)M+) @  60<  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&ULC57;;J,P$/T5"_6AE=IR"R&MDDBY
M[&KWH5+4;'>?'1C JK%9VR3MW]<VA$T3DNT+V,.<,V=FS'B\X^)5%@ *O964
MR8E3*%4]NJY,"BBQO.<5,/TEXZ+$2F]%[LI* $XMJ*1NX'E#M\2$.=.QM:W$
M=,QK10F#E4"R+DLLWN= ^6[B^,[>\$SR0AF#.QU7.(<UJ)=J)?3.[5A24@*3
MA#,D()LX,_]Q$1M_Z_";P$X>K)')9,/YJ]G\3">.9P0!A409!JQ?6U@ I89(
MR_C;<CI=2 ,\7._9O]O<=2X;+&'!Z1^2JF+BC!R40H9KJI[Y[@>T^42&+^%4
MVB?:M;Z>@Y):*EZV8*V@)*QYX[>V#@< S=,/"%I < P8G &$+2"TB3;*;%I+
MK/!T+/@.">.MV<S"UL:B=3:$F2ZNE=!?B<:IZ;KI'N(96I.<D8PDF"DT2Q)>
M,T58CE:<DH2 1->M4:)G2(!L\8;"+9I1?1 P2P#I(X66O-ZHK*9[ GF#KI>@
M,*%Z=8=>UDMT?76#KA!AZ%?!:XE9*L>NTID8/6[2JIXWJH,SJA_0$V>JD.@;
M2R']C'=U!;HR!/LRS(.+A&NH[E'HW:+ "_P>/8NOP[T+<L*N*Z'E"\_P_:>H
M%R(,N@@#&V%P)L(<4\-_BS:0$\9,H_41> <L^KK1< TMEYD+V^F#YX=C=WM8
MHE.G.!X%G=,GF5$G,[HH<U%@EH,Y+?A32=)]27!O21K5#75T("@*(N](]:E3
M[(5^O^IAIWIX4?6L;/Z3G2!* =.5S?KT#4]"W\7^8'0DL,=KZ 51O\*X4QA_
MK?W 4M/X"@3A:9_(^+2KOA\=:3QU&L6CT9%$]V!*E2!R.[PELOUK_M3.VMT/
M,SL6C^QS?6\T8_X?37/I/&&A3[-$%#)-Z=W'NFRB&>3-1O'*SL(-5WJRVF6A
M[SX0QD%_SSA7^XT)T-VFTP]02P,$%     @ ?8UA4[RH-P)V P  N1   !D
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MVS ,_2N"T4,+=/5GVJ9P#+3)ANTP+&C6[3#LH-AT+%267(E.VG\_27:]M/E
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M9(UWB7KDA[])Y9"7ZXMX(HN_X%!A[0F(=E+QM!+6)T@I*W_QKRH0+0&MQRR
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M;J;R08>8 LCY%:5BUU$"S1-Q]!M02P,$%     @ ?8UA4T:[TI+9 @  70@
M !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULC99=;YLP%(;_BH5ZT4I;
M ?,1J))(;:)IDS8I:MKM8MJ% R?!JL',=IKVW\\V!*6!9+D)-ISW/<\Q'#OC
M'1<OL@!0Z*UDE9PXA5+UG>O*K("2R%M>0Z6?K+DHB=)3L7%E+8#D5E0R%WM>
M[):$5LYT;.\MQ'3,MXK1"A8"R6U9$O'^ (SO)H[O[&\\TDVAS UW.J[)!I:@
MGNN%T#.W<\EI"96DO$("UA/GWK^;I2;>!ORDL),'8V0J67'^8B;?\HGC&2!@
MD"GC0/3E%6; F#'2&'];3Z=+:82'X[W[%UN[KF5%),PX^T5S54R<Q$$YK,F6
MJ4>^^PIM/9'QRSB3]A?MFM@H<E"VE8J7K5@3E+1JKN2M78<#@1^>$.!6@"\5
M!*T@L(4V9+:L.5%D.A9\AX2)UFYF8-?&JG4UM#)O<:F$?DJU3DUG6R&@4N@[
M)2O*J*(@T?4<%*%,WJ#/Z'DY1]=7-^@*T0H]%7PK297+L:MT;N/@9FV>AR8/
M/I%G"?4M"KQ/"'O8'Y#/SLOGD&FY;^7>1[FK*^[*QEW9V/H%)_P6Y)VLF*Y5
M5X/NLTQL"9/H]_U**J&_K#]G4@1=BL"F"$^DL*Z0(VV8 ZK;A$,KU_C$UL=T
MW>L4XS@:NZ^'Z],/\G&$NZ /B&&'&%Z$F/&RI-(TIMR##G$V9M$!0I D1YC]
M&#Q*ABFCCC*ZB'+%JZV$LX11/WOJXR/$?E#DI]XP8]PQQA<QOI*,--N3_JXT
MJ.",#8'&?5 /CXY ^T%)& YSCCK.T5G.?;O77%A,OD9U02J]RR!9$ &(M?O
M^Q#UJ ?D>][Q\O:#PC")AK&3#CNY:'FY*D!TC'2XG9(>0)RD1Y#]F"B,AQG3
MCC$]R_C$%6'Z6&I(_\.8]KHYQ4EP!-D/TBV?'B^E>[#YFX/W!Q$;JAN9P5KK
MO-N1KE(TAUDS4;RVY\&**_W>[;#0YS\($Z"?KSE7^XDY8KI_%--_4$L#!!0
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M3>6AL@&TGTEI]A.;H'EEXW]02P,$%     @ ?8UA4\IM)^8C P  M0H  !D
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MFR<=I=U@UI?"/&#%P!Y$RI-J]S=02P,$%     @ ?8UA4W)6+MR< @  W <
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M-W<[3/'X!6D ^'PKT'P],3M\<Z#'?P!02P,$%     @ ?8UA4[32@6U- @
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MNSZ:J/H2J3=&5FX.9]+@5+ME@?<N*%N [Y=2FMW&CG9[D^?_ %!+ P04
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ME"O],MMAHKLS%,9 [\\Y5]N)<5#V>X-_4$L#!!0    ( 'V-85.GLK,6: ,
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M4*LNBMEV<:+X)A\//W&E>)P?KH$M0&0&^OZ2<_5ZDDV<JW\89G\!4$L#!!0
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M)4"\WQ'"7QKR ^UM;_$W4$L#!!0    ( 'V-85/K.^KA;P0  *T2   9
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M->Y%/9"0!2Y2><<VOQ#C4*#Y8I:*\A=LC*W; W$A),L,6"G(:%[]XV>S$"T
M] \ D &@8P&> 7C' GP#\'<!T0% 8 #!L4\8&,#@6$!H &$9K&IUR]!,L<23
M$6<;P+6U8M,'97Q+M(H(S74JSB57=ZG"R<E\A3E9L30A7/P,KK\65+Z D[ED
M\>.Y#G$"KEBF\EY@G3FGX&1*)*:I. 7GX'X^!2<?3L$'0'/PQXH5 N>)&#E2
MZ=+L3FPT7%8:T $-OQ9Y'T!X!I"+W [XE1T^)^L^\-P2#CO@T^/A74^__KZG
MWWS?TV_M\"F)%;QSZ1R5"74ZH#H=4,GGV=+!!'Z&7U3/D>""<YPOB3X^ ]?/
M.AG4715J<(775.*4_D.2,W"1L4)9__6;H@2?),G$WQ9!7BW(*P7Y!P3]OM9Y
M)X#JHD*J9])\"4Y4N@DM5)QV94M%&)2$NA,_3;PP5*U9K<]3.ZY'VMUVV+E!
MV+;;\LRO/?.MGK5K+&[5V!D@U1IW^591#EI:H.>B;<'3#B/D^3O>[QMYD1]L
M&]UT& 41[/8[J/T.K'[?YYS$;)GKK %J?)Y+_ R$7@S RF#;_ _V8^$/=U1?
MOV&TI7I0JQ[8\S#+Z4,AP"S%N26MPYHN?!]U%M6"(JM_G_$SS8K,U)5NZ-K3
M-TKM,MI;Z3 ,(@0/I,BP%C.TBID1'NL580M A2C,*K1;0*6I2Y*=&;E]U_W)
MLE[0;0:G>W1&@'_UF,Q4[I95;>-O#6;X/E($-L,!HA^0)(:TG25HX+H'&RAL
M9@,\:CC8?&NZ,?3?R7(WC1+:.^4W30C#N=7]W0#NC BXWR.'N]W_NH/*@RC<
MF1$=5"@<# _$MNFWT-YPOY2;")*<XR?"U:8(K FG+-$]P<P/O12=[VMV8@1>
M".;6I&FZ. RM7'=$2$YC);,J?'"O9%FIFWX,HW>2CTU7AO;F>3>__U\O8H9N
M*S/@</]%[$B[VPZ[0>0?[".H:>7(WLJ_J= ,9[LZT%Z==1E%PQW_.XQ"&.V4
M68=1!-$!SYLA@^ /JK(WB*$+U#B4*P&0#Q+\8BL*U-J=V =0Y[MC.V*O 3M3
M\NO2K%XNB_W2-(%$^RL;H-T8V8TJ?YS6/EQ_R/F,^9*JS4M*%@KE]D.5NKSZ
M-E*=2+8NM^8/3*J-?GFX(ECMQ;6!NK]@3+Z>Z-U^_85J\A]02P,$%     @
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M5'W> -<+U/L=8_(XT ;:#Z;U_U!+ P04    " !]C6%3^^%O?((#  #%"@
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MJYSH)",*6XBZX!N-Q9:#ASC @<9_9O8?&OPM6;2B<O"C<A-H!%S@W0UP[2L
M;>AH^$S/=[=UZ?Q>](??B_YH=I_AE71W=.Y'M72++G13/+<%[P6%"09TG;4.
MP+(-WU"(8\$-X%X![J7@GJG%P9R1%>ZJOMUAEL6YU'5AAM5/L90LOXU[-[W>
MR'JKOIL31D<T>P7-GI'F-&%,9BRU=L42'("0H"4)B2!8.ULR,+]"P;%M6.-Y
MCM%CT\CS!BW)^$4ROKGF@JY>KY7D!V!%([D.<J16$ETF?I.D6R<YU1A!UZNE
MVS1R!U[MW3UHC'H#1Y]NOTBW;TQ7HY>&QAT4J /CK$C1\B).*T4$]XRA>(,C
MU2[+ ZC:S=$A';[?(Q: ?[]*2/ D<,3_,Q :%H2&QC1?,!<DWJ@91*A6@\W^
M+CA@Q$RE<>QRW;*-Q?D[B99R(DO-V.7%S[0C4<4'7=NVO_!+4Z3*"ND864_P
MAL2QRGN)0A2O,.C*I2Q;Y'02,LOQ>I46&[9-* >6-*"1QA/G2A9.Q8:-V.[0
M:XE=RK/CGGSQ9\1V&[&O_9[?$KR4;\>LWP_O.\)D= O(O>0:DW.8>$TFCCUL
M85(JM&.6:+EU.+\-)CE8E83OU"7KA-$QT5)]'?_/KZ=.J7:.6>X:,T+[#OH-
MH>W['FQ)K=1$9W#&-- &'#1;O^^WM5^I><YIT6L).-3T.QRTI A+:8/V9QM>
MNT&T->'MEI4,EG('S7)WW.2ZQLX!CI90S^[7.ALV5?#(ZIA>*8/0+(,_J$!A
ML3DZ:/DU-=#Q_/K>Z)35,;]2*J%9*C^YC8--S=3LXTY9'7,ME16:E?4KC3?7
M K/H;+9-7?5\NT[6;'3,M=1>>&)[C/@6<"Q$F.Y[M!-"HZ75Z9A_&#6M/-@Z
M;4K)A>8=KV8+"'Z!!0ZEX>8*;'",F6Q<^?$+4" _Y D7#*E3%=.G:*G(L/_G
M!1^6H@O-HON9[7P.=?0]X=1V\SJ;WK#>1TTCZ-EV_75JH.Q^O=VLR@E)A-DF
M/<OB,I<D%MEG:C%:G)?=IZ=$M?&)<SMU-.,SY_8A.PTKX;/#N6^(R=62@Q"O
M92C[IB\[CV7G7=F-H+OT?&9)A6R@]'*+48"9,I#/UY2*CQL5H#AU'/\/4$L#
M!!0    ( 'V-85.027V8=P(  )\&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0Y+GAM;)U576^;,!3]*Q;J0RMM0("D7460VM!IDU8M:M3M8=J#0VZ"56,S
MVS3-O]^U(2AJ25;M!?QUSKGWX'M)MU(]Z1+ D)>*"SWU2F/JZR#010D5U;ZL
M0>#.6JJ*&IRJ3:!K!73E0!4/HC"<!!5EPLM2MS9762H;PYF N2*ZJ2JJ=K?
MY7;JC;S]P@/;E,8N!%E:TPTLP#S6<X6SH&=9L0J$9E(0!>NI=S.ZOIO8\^[
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MD0Y<!ZCG*6/RL- "S9^$R6]02P,$%     @ ?8UA4\DWJW%J!   JA$  !D
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M(<E/S'7-8 .2'8@$LQV(!-,=A.S-=\0^RF3WRK34(GY#8E>&0R%S9D9";XU
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MH+FW-GZSK[7<-5\(V"X1MDOB6[$VQO=@"RE:F4FP8=X>8HE[2(LVA;5K0[8
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MF[HL;WS;2BVT* YO0AS>XOCT U!+ P04    " !]C6%3H9?JE,D!  "@'@
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MZEW_I]XIG_<QW7MN:WS^?U*=+_?&^^.OR]O)P4NXXAS@A_3+-U!+ P04
M" !]C6%3*+1H$\,!  ")'@  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-V<EN
MPC 4!=!?0=E6Q'B #@(V;;<MB_Z FSP@(HDMVU#X^SIAD%K1J(A*O9M$B>UW
M7VSI;#)^VUGRO6U5UGZ2+$.P#XSY;$F5]JFQ5,>1N7&5#O'1+9C5V4HOB(G!
M8,0R4P>J0S\T-9+I^(GF>EV&WO,VOO:%J2>)H](GO<?]Q"9KDFAKRR+3(8ZS
M39U_2^D?$M*XLIWCEX7U-W%"PLXF-",_!QS6O6[(N2*GWDR[\**K.(MM2^;#
MKB2?=I<XTZ.9SXN,<I.MJ[@D]=:1SOV2*%1ENB]ZTYT<X@[3_LJOSF_+= 7&
MF3-GK(\GYNCRN..1-*O[-A8B%XKN3SPEQM)7?Q\UIYU3_LOLN+T?QJW:\_"L
MO5V_QU_/^%3_PCX$2!\2I \%TL<0I(\12!^W('W<@?1Q#](''Z T@B(J1R&5
MHYC*45#E**IR%%8YBJL<!5:.(JM D56@R"I09!4HL@H4606*K )%5H$BJT"1
M5:#(*E%DE2BR2A19)8JL$D56B2*K1)%5HL@J4625*+(J%%D5BJP*15:%(JM"
MD56AR*I09%4HLBH4616*K$,468?_*>N[,:N__CG:W--*%_4QG[5_H*>?4$L!
M A0#%     @ ?8UA4P=!36*!    L0   !               ( !     &1O
M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !]C6%3WRN*A.X    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !]
MC6%3F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( 'V-85-H?',6) 4  $85   8
M  " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !]
MC6%3 -CC&9L&  #+&@  &               @(%G#0  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ ?8UA4Z,LX%;% @  KP<  !@
M         ("!.!0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( 'V-85-C)6"U_@8  "8=   8              " @3,7  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !]C6%3ZDN(S7\*  "110
M&               @(%G'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ ?8UA4\\>%4>+!P  &1\  !@              ("!'"D  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( 'V-85,07S'5L 0
M .L)   8              " @=TP  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " !]C6%3:KN);YHC  "-<@  &               @('#
M-0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ?8UA4WVD
MF/@7 P  TP8  !@              ("!DUD  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( 'V-85.)RT%KUP(  "@&   9
M  " @>!<  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M?8UA4\?M#%]!"@  /QT  !D              ("![E\  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " !]C6%3224'I"L(  #&%@  &0
M            @(%F:@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( 'V-85,Z[*P7Q0P  &\H   9              " @<AR  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ?8UA4X55M=)P#
MYAX  !D              ("!Q'\  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " !]C6%37=KU) \%  #%"P  &0              @(%K
MC   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( 'V-85,<
M^2/C7P0  )@*   9              " @;&1  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ ?8UA4W-&F=:R(0  9FX  !D
M     ("!1Y8  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'V-85/# /IL^ (  #$'   9              "
M@?'&  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ ?8UA
M4WEC%T_-!@  %!0  !D              ("!(,H  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " !]C6%3PR2BOE@#  #Y!P  &0
M        @($DT0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( 'V-85.=XD"T'P(  "P$   9              " @;/4  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ?8UA4\6>)M+) @  60<
M !D              ("!"=<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " !]C6%3O*@W G8#  "Y$   &0              @($)V@
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( 'V-85/T@M[_
M) (  * $   9              " @;;=  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ ?8UA4\P+J[18 @  TP4  !D
M ("!$>   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !]
MC6%3_Y(7N2L$  !E$   &0              @(&@X@  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( 'V-85.OJD10=P,   8.   9
M          " @0+G  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#
M%     @ ?8UA4RD'_]0" P  +@H  !D              ("!L.H  'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !]C6%31KO2DMD"  !=
M"   &0              @('I[0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;%!+ 0(4 Q0    ( 'V-85.3)^.VL (  '$'   9              " @?GP
M  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ ?8UA4\IM
M)^8C P  M0H  !D              ("!X/,  'AL+W=O<FMS:&5E=',O<VAE
M970S-2YX;6Q02P$"% ,4    " !]C6%3<E8NW)P"  #<!P  &0
M    @($Z]P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M 'V-85.TTH%M30(  -4%   9              " @0WZ  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ ?8UA4\H<HL;F @  ^PD  !D
M             ("!D?P  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " !]C6%3I[*S%F@#  "@"P  &0              @(&N_P  >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( 'V-85.@%N)1(@0
M &T8   9              " @4T# 0!X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ ?8UA4S*,>/QB @  004  !D              ("!
MI@<! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !]C6%3
M-2/'?L8#  #Y#0  &0              @($_"@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( 'V-85/K.^KA;P0  *T2   9
M      " @3P. 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ ?8UA4R%C(CW$ P  / T  !D              ("!XA(! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !]C6%3^^%O?((#  #%"@
M&0              @('=%@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( 'V-85-FP:D\C0,  +,-   9              " @98: 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ ?8UA4[[$>[>/
M!   A1(  !D              ("!6AX! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " !]C6%3]*Y-K@0%  "!%   &0
M@($@(P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( 'V-
M85.027V8=P(  )\&   9              " @5LH 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ ?8UA4^YH]%C/ @  , @  !D
M         ("!"2L! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
M    " !]C6%3R3>K<6H$  "J$0  &0              @($/+@$ >&PO=V]R
M:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( 'V-85/\F9 +#P,  "P1
M   -              "  ; R 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     [ #L %!    @_ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>196</ContextCount>
  <ElementCount>325</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Business and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/NatureofBusinessandOperations</Role>
      <ShortName>Nature of Business and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/CurrentLiabilities</Role>
      <ShortName>Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Debt and Lease Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/DebtandLeaseLiabilities</Role>
      <ShortName>Debt and Lease Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2130107 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2139108 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2141109 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2143110 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.viemed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viemed.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viemed.com/role/PropertyandEquipment</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/CurrentLiabilitiesTables</Role>
      <ShortName>Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viemed.com/role/CurrentLiabilities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Debt and Lease Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/DebtandLeaseLiabilitiesTables</Role>
      <ShortName>Debt and Lease Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viemed.com/role/DebtandLeaseLiabilities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viemed.com/role/FairValueMeasurement</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viemed.com/role/ShareholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2344307 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.viemed.com/role/EarningsPerShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Business and Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/NatureofBusinessandOperationsDetails</Role>
      <ShortName>Nature of Business and Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/NatureofBusinessandOperations</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies (Customer Percentages) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Customer Percentages) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies (Inventory and Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Inventory and Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies (Equity investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Equity investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies (Revenue Recognition) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Revenue Recognition) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Property and Equipment (Schedule of Fixed Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails</Role>
      <ShortName>Property and Equipment (Schedule of Fixed Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Property and Equipment (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/CurrentLiabilitiesDetails</Role>
      <ShortName>Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/CurrentLiabilitiesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Debt and Lease Liabilities (Line of Credit Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails</Role>
      <ShortName>Debt and Lease Liabilities (Line of Credit Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/DebtandLeaseLiabilitiesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Debt and Lease Liabilities (Commercial Term Notes Narrative) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails</Role>
      <ShortName>Debt and Lease Liabilities (Commercial Term Notes Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/DebtandLeaseLiabilitiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Debt and Lease Liabilities (Schedule of Notes Payable) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails</Role>
      <ShortName>Debt and Lease Liabilities (Schedule of Notes Payable) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/DebtandLeaseLiabilitiesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Debt and Lease Liabilities (Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/DebtandLeaseLiabilitiesLeaseLiabilitiesDetails</Role>
      <ShortName>Debt and Lease Liabilities (Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/DebtandLeaseLiabilitiesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - Debt and Lease Liabilities (Finance Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/DebtandLeaseLiabilitiesFinanceLeaseLiabilitiesDetails</Role>
      <ShortName>Debt and Lease Liabilities (Finance Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/DebtandLeaseLiabilitiesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2425415 - Disclosure - Debt and Lease Liabilities (Operating Lease Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Debt and Lease Liabilities (Operating Lease Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/DebtandLeaseLiabilitiesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Fair Value Measurement (Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement (Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/FairValueMeasurementTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - Fair Value Measurement (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/FairValueMeasurementNarrativeDetails</Role>
      <ShortName>Fair Value Measurement (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/FairValueMeasurementTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Shareholders' Equity (Issued and Outstanding Share Capital) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails</Role>
      <ShortName>Shareholders' Equity (Issued and Outstanding Share Capital) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/ShareholdersEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - Shareholders' Equity (Stock-based Compensation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails</Role>
      <ShortName>Shareholders' Equity (Stock-based Compensation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/ShareholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Shareholders' Equity (Options, Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails</Role>
      <ShortName>Shareholders' Equity (Options, Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/ShareholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2435421 - Disclosure - Shareholders' Equity (Options, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Options, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/ShareholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2436422 - Disclosure - Shareholders' Equity (Options, Fair Value Assumptions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails</Role>
      <ShortName>Shareholders' Equity (Options, Fair Value Assumptions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/ShareholdersEquityTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2437423 - Disclosure - Shareholders' Equity (Restricted Stock Units) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails</Role>
      <ShortName>Shareholders' Equity (Restricted Stock Units) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/ShareholdersEquityTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2438424 - Disclosure - Shareholders' Equity (Phantom Share Units) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails</Role>
      <ShortName>Shareholders' Equity (Phantom Share Units) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/ShareholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2440425 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/CommitmentsandContingencies</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2442426 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/IncomeTaxes</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="vmd-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.viemed.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.viemed.com/role/EarningsPerShareTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="vmd-20210930.htm">vmd-20210930.htm</File>
    <File>a101formofrestrictedstocku.htm</File>
    <File>a102non-employeedirectorsd.htm</File>
    <File>q32021exhibit311.htm</File>
    <File>q32021exhibit312.htm</File>
    <File>q32021exhibit321.htm</File>
    <File>q32021exhibit322.htm</File>
    <File>vmd-20210930.xsd</File>
    <File>vmd-20210930_cal.xml</File>
    <File>vmd-20210930_def.xml</File>
    <File>vmd-20210930_lab.xml</File>
    <File>vmd-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>71
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vmd-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 196,
   "dts": {
    "calculationLink": {
     "local": [
      "vmd-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vmd-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vmd-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vmd-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vmd-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vmd-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 410,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 7
   },
   "keyCustom": 17,
   "keyStandard": 308,
   "memberCustom": 14,
   "memberStandard": 29,
   "nsprefix": "vmd",
   "nsuri": "http://www.viemed.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.viemed.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - Current Liabilities",
     "role": "http://www.viemed.com/role/CurrentLiabilities",
     "shortName": "Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vmd:DebtandLeaseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Debt and Lease Liabilities",
     "role": "http://www.viemed.com/role/DebtandLeaseLiabilities",
     "shortName": "Debt and Lease Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vmd:DebtandLeaseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - Fair Value Measurement",
     "role": "http://www.viemed.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130107 - Disclosure - Shareholders' Equity",
     "role": "http://www.viemed.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139108 - Disclosure - Commitments and Contingencies",
     "role": "http://www.viemed.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141109 - Disclosure - Income Taxes",
     "role": "http://www.viemed.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143110 - Disclosure - Earnings Per Share",
     "role": "http://www.viemed.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.viemed.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Current Liabilities (Tables)",
     "role": "http://www.viemed.com/role/CurrentLiabilitiesTables",
     "shortName": "Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Debt and Lease Liabilities (Tables)",
     "role": "http://www.viemed.com/role/DebtandLeaseLiabilitiesTables",
     "shortName": "Debt and Lease Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.viemed.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.viemed.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344307 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.viemed.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Business and Operations (Details)",
     "role": "http://www.viemed.com/role/NatureofBusinessandOperationsDetails",
     "shortName": "Nature of Business and Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "state",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details)",
     "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails",
     "shortName": "Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iaeed513b2882441a875dcc01fbc0a501_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies (Customer Percentages) (Details)",
     "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails",
     "shortName": "Summary of Significant Accounting Policies (Customer Percentages) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iaeed513b2882441a875dcc01fbc0a501_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies (Inventory and Property and Equipment) (Details)",
     "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies (Inventory and Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies (Equity investments) (Details)",
     "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails",
     "shortName": "Summary of Significant Accounting Policies (Equity investments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LessorOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies (Revenue Recognition) (Details)",
     "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
     "shortName": "Summary of Significant Accounting Policies (Revenue Recognition) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "icd917d51157d466ba06d77882124fe90_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLeaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Property and Equipment (Schedule of Fixed Assets) (Details)",
     "role": "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails",
     "shortName": "Property and Equipment (Schedule of Fixed Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i156a988ddacc42c782d87dff13bbeafa_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i0f164680a52c4595a2825372313c0fdd_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Property and Equipment (Narrative) (Details)",
     "role": "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails",
     "shortName": "Property and Equipment (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i0f164680a52c4595a2825372313c0fdd_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vmd:AccruedTradePayablesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Current Liabilities (Details)",
     "role": "http://www.viemed.com/role/CurrentLiabilitiesDetails",
     "shortName": "Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vmd:AccruedTradePayablesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i87fcc673b3034eaa9412181d84c0c71e_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Debt and Lease Liabilities (Line of Credit Narrative) (Details)",
     "role": "http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails",
     "shortName": "Debt and Lease Liabilities (Line of Credit Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i87fcc673b3034eaa9412181d84c0c71e_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i62a32ca8e15648e9b1241a1aae489574_I20190530",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Debt and Lease Liabilities (Commercial Term Notes Narrative) (Details)",
     "role": "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails",
     "shortName": "Debt and Lease Liabilities (Commercial Term Notes Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i62a32ca8e15648e9b1241a1aae489574_I20190530",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Debt and Lease Liabilities (Schedule of Notes Payable) (Details)",
     "role": "http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails",
     "shortName": "Debt and Lease Liabilities (Schedule of Notes Payable) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "ie603f4248e314cdf811e9ec8560c574f_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vmd:LiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vmd:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Debt and Lease Liabilities (Lease Liabilities) (Details)",
     "role": "http://www.viemed.com/role/DebtandLeaseLiabilitiesLeaseLiabilitiesDetails",
     "shortName": "Debt and Lease Liabilities (Lease Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vmd:LiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vmd:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeaseDiscountRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - Debt and Lease Liabilities (Finance Lease Liabilities) (Details)",
     "role": "http://www.viemed.com/role/DebtandLeaseLiabilitiesFinanceLeaseLiabilitiesDetails",
     "shortName": "Debt and Lease Liabilities (Finance Lease Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i0f164680a52c4595a2825372313c0fdd_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425415 - Disclosure - Debt and Lease Liabilities (Operating Lease Liabilities) (Details)",
     "role": "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails",
     "shortName": "Debt and Lease Liabilities (Operating Lease Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i0f164680a52c4595a2825372313c0fdd_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i0f164680a52c4595a2825372313c0fdd_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME",
     "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i0f164680a52c4595a2825372313c0fdd_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i93444cef350340c49a0041603bff9d22_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Fair Value Measurement (Recurring Basis) (Details)",
     "role": "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails",
     "shortName": "Fair Value Measurement (Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "ic8854bc148dc4d52b425355b31c2508a_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "vmd:AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i93444cef350340c49a0041603bff9d22_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "interestrateswap",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - Fair Value Measurement (Narrative) (Details)",
     "role": "http://www.viemed.com/role/FairValueMeasurementNarrativeDetails",
     "shortName": "Fair Value Measurement (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i93444cef350340c49a0041603bff9d22_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "interestrateswap",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Shareholders' Equity (Issued and Outstanding Share Capital) (Details)",
     "role": "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails",
     "shortName": "Shareholders' Equity (Issued and Outstanding Share Capital) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iac9ff3e2056a4a5f880103fc4356cd36_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "vmd:NumberOfStockClasses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "classofstock",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - Shareholders' Equity (Stock-based Compensation) (Details)",
     "role": "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails",
     "shortName": "Shareholders' Equity (Stock-based Compensation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "ib6898be82ef3450d8af8019abc1d1fb6_I20200611",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i57eb5a8d21f149e7a7983aaf659b0c3a_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Shareholders' Equity (Options, Stock Option Activity) (Details)",
     "role": "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails",
     "shortName": "Shareholders' Equity (Options, Stock Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435421 - Disclosure - Shareholders' Equity (Options, Narrative) (Details)",
     "role": "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails",
     "shortName": "Shareholders' Equity (Options, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436422 - Disclosure - Shareholders' Equity (Options, Fair Value Assumptions) (Details)",
     "role": "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails",
     "shortName": "Shareholders' Equity (Options, Fair Value Assumptions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i795dccfd9203404ba393cb88b8244587_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i9dedb3f8a3514cc5a585e7453a724c8d_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437423 - Disclosure - Shareholders' Equity (Restricted Stock Units) (Details)",
     "role": "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails",
     "shortName": "Shareholders' Equity (Restricted Stock Units) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i9dedb3f8a3514cc5a585e7453a724c8d_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "if18d5f0f70ef493491936ce24033c80d_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438424 - Disclosure - Shareholders' Equity (Phantom Share Units) (Details)",
     "role": "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails",
     "shortName": "Shareholders' Equity (Phantom Share Units) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i5cfe44b7f4fb431ba471fa2580d58737_D20210101-20210930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "ic98b72a5b163495eb502663ae5631ff3_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440425 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.viemed.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "ic98b72a5b163495eb502663ae5631ff3_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i976c03ac317a4dad950efc53136ca1d4_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iae414ee27046452e85105a8bd614cf93_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i0f164680a52c4595a2825372313c0fdd_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442426 - Disclosure - Income Taxes (Details)",
     "role": "http://www.viemed.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i0f164680a52c4595a2825372313c0fdd_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - Earnings Per Share (Details)",
     "role": "http://www.viemed.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "i0f164680a52c4595a2825372313c0fdd_D20210701-20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Business and Operations",
     "role": "http://www.viemed.com/role/NatureofBusinessandOperations",
     "shortName": "Nature of Business and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Property and Equipment",
     "role": "http://www.viemed.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vmd-20210930.htm",
      "contextRef": "iebc24a7b66b14d3db48d231b8e32bc8c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 44,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.viemed.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r309",
      "r441",
      "r442",
      "r443",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r189",
      "r291",
      "r295",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r248",
      "r270",
      "r311",
      "r312",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r509",
      "r512",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r248",
      "r270",
      "r311",
      "r312",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r509",
      "r512",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r189",
      "r291",
      "r295",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r187",
      "r291",
      "r293",
      "r460",
      "r508",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r187",
      "r291",
      "r293",
      "r460",
      "r508",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r248",
      "r270",
      "r301",
      "r311",
      "r312",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r509",
      "r512",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r248",
      "r270",
      "r301",
      "r311",
      "r312",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r509",
      "r512",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.",
        "label": "Accounts Payable and Accrued Liabilities, Noncurrent",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r9",
      "r46"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r30",
      "r190",
      "r191"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $7,115 and $9,013 at September 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r50"
     ],
     "calculation": {
      "http://www.viemed.com/role/CurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonuses payable"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r24",
      "r476",
      "r491"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.viemed.com/role/CurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viemed.com/role/CurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalesCommissionCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r50"
     ],
     "calculation": {
      "http://www.viemed.com/role/CurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Sales Commission, Current",
        "terseLabel": "Accrued commissions payable"
       }
      }
     },
     "localname": "AccruedSalesCommissionCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r44",
      "r217"
     ],
     "calculation": {
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r33",
      "r70",
      "r71",
      "r72",
      "r493",
      "r517",
      "r518"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r69",
      "r72",
      "r80",
      "r81",
      "r82",
      "r125",
      "r126",
      "r127",
      "r386",
      "r513",
      "r514",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r346",
      "r347",
      "r348",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation - restricted stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation - options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments for:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r314",
      "r341",
      "r351"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation, expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME",
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r37",
      "r196",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of year",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedTerseLabel": "Amounts written off"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r118",
      "r175",
      "r179",
      "r185",
      "r203",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r382",
      "r387",
      "r417",
      "r444",
      "r446",
      "r474",
      "r490"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r64",
      "r118",
      "r203",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r382",
      "r387",
      "r417",
      "r444",
      "r446"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r118",
      "r203",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r382",
      "r387",
      "r417",
      "r444"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total long-term assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Long-term assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r315",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails",
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Principles of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "verboseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r40",
      "r108"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market mutual funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r102",
      "r108",
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r102",
      "r418"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r116",
      "r118",
      "r140",
      "r141",
      "r142",
      "r144",
      "r146",
      "r156",
      "r157",
      "r158",
      "r203",
      "r234",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r268",
      "r269",
      "r271",
      "r272",
      "r417",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails",
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r55",
      "r226",
      "r480",
      "r497"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r231",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r125",
      "r126",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails",
      "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails",
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r29",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Shareholders' equity, ending balance (in shares)",
        "periodStartLabel": "Shareholders' equity, beginning balance (in shares)",
        "terseLabel": "Outstanding (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r29",
      "r446"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock - No par value: unlimited authorized; 39,630,446 and 39,185,182 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r75",
      "r77",
      "r78",
      "r87",
      "r484",
      "r503"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r189",
      "r414",
      "r415",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r189",
      "r414",
      "r415",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r189",
      "r414",
      "r415",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r165",
      "r166",
      "r189",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r163",
      "r165",
      "r166",
      "r167",
      "r414",
      "r416",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r189",
      "r414",
      "r415",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r112",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r280",
      "r281",
      "r292"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r92",
      "r460"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciation": {
     "auth_ref": [
      "r90",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r164",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r117",
      "r123",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r266",
      "r267",
      "r427",
      "r475",
      "r477",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails",
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r245",
      "r264",
      "r265",
      "r426",
      "r427",
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r52",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails",
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r53",
      "r117",
      "r123",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r266",
      "r267",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Monthly principal payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r53",
      "r117",
      "r123",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r264",
      "r265",
      "r266",
      "r267",
      "r274",
      "r275",
      "r276",
      "r277",
      "r425",
      "r426",
      "r427",
      "r428",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails",
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.viemed.com/role/CurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current",
        "terseLabel": "Current portion of phantom share liability",
        "verboseLabel": "Current accrued liabilities"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CurrentLiabilitiesDetails",
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Long-term accrued liabilities"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent",
        "totalLabel": "Total liability"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r106",
      "r119",
      "r366",
      "r372",
      "r373",
      "r374"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssets": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.",
        "label": "Deposits Assets",
        "terseLabel": "Outstanding deposit"
       }
      }
     },
     "localname": "DepositsAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r106",
      "r215"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationNonproduction": {
     "auth_ref": [
      "r106",
      "r215"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.",
        "label": "Depreciation, Nonproduction",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationNonproduction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails",
      "http://www.viemed.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed interest rate related to the interest rate derivative.",
        "label": "Derivative, Fixed Interest Rate",
        "terseLabel": "Fixed interest rate"
       }
      }
     },
     "localname": "DerivativeFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r67",
      "r396",
      "r397",
      "r398",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails",
      "http://www.viemed.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r413"
     ],
     "calculation": {
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "negatedLabel": "Interest rate swap",
        "negatedTerseLabel": "Fair value"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r391",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r391",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of interest rate swaps"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r390",
      "r392",
      "r394",
      "r395",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Interest rate swaps"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Source"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r88",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r138",
      "r140",
      "r144",
      "r145",
      "r146",
      "r150",
      "r151",
      "r403",
      "r404",
      "r485",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic earnings per share (in dollars per share)",
        "verboseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME",
      "http://www.viemed.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r88",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r140",
      "r144",
      "r145",
      "r146",
      "r150",
      "r151",
      "r403",
      "r404",
      "r485",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings per share (in dollars per share)",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME",
      "http://www.viemed.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.viemed.com/role/CurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued vacation and payroll"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.",
        "label": "Share-based Payment Arrangement, Cash Used to Settle Award",
        "terseLabel": "Cash settlement"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period of recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized pre-tax compensation expense, restricted stock units"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized pre-tax stock option expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails",
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r80",
      "r81",
      "r82",
      "r125",
      "r126",
      "r127",
      "r129",
      "r135",
      "r137",
      "r155",
      "r205",
      "r273",
      "r278",
      "r346",
      "r347",
      "r348",
      "r368",
      "r369",
      "r402",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r513",
      "r514",
      "r515",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r41",
      "r176",
      "r201"
     ],
     "calculation": {
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Investments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r41",
      "r101",
      "r202",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r200",
      "r505"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedLabel": "Income from equity method investments"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r254",
      "r264",
      "r265",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r406",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r254",
      "r302",
      "r303",
      "r308",
      "r310",
      "r406",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r254",
      "r264",
      "r265",
      "r302",
      "r303",
      "r308",
      "r310",
      "r406",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r254",
      "r264",
      "r265",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r406",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r409",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r254",
      "r264",
      "r265",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r410",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r429",
      "r433",
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r435",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r434",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average lease term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r106",
      "r214",
      "r219"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Loss (gain) on disposal of property and equipment",
        "negatedTerseLabel": "Loss (gain) on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r91",
      "r118",
      "r175",
      "r178",
      "r181",
      "r184",
      "r186",
      "r203",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r417"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r84",
      "r175",
      "r178",
      "r181",
      "r184",
      "r186",
      "r473",
      "r482",
      "r486",
      "r506"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net income before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r85",
      "r106",
      "r173",
      "r201",
      "r481",
      "r501"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Income from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r220",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r120",
      "r360",
      "r361",
      "r365",
      "r370",
      "r375",
      "r377",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r121",
      "r136",
      "r137",
      "r174",
      "r358",
      "r371",
      "r376",
      "r507"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision (benefit) for income taxes",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME",
      "http://www.viemed.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r354",
      "r355",
      "r361",
      "r362",
      "r364",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Provisional income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid during the period for income taxes, net of refunds received"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r57",
      "r479",
      "r500"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Increase in trade payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Increase in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "(Decrease) increase in accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r105",
      "r457"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Increase in deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.",
        "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable",
        "terseLabel": "Change in income tax payable/receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net change in working capital"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Increase in prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "negatedTerseLabel": "Interest expense, net of interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r100",
      "r103",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails",
      "http://www.viemed.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryLIFOReservePeriodCharge": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r211"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.",
        "label": "Inventory, LIFO Reserve, Period Charge",
        "terseLabel": "Change in inventory reserve"
       }
      }
     },
     "localname": "InventoryLIFOReservePeriodCharge",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r59",
      "r446"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net of inventory reserve of $1,237 and $1,353 at September 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r60",
      "r113",
      "r153",
      "r209",
      "r210",
      "r213",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r59",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory reserve"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInventoryandPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "totalLabel": "Balance, end of period",
        "verboseLabel": "Equity investments"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r436",
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Operating rental expenses"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments.",
        "label": "Lessee, Finance Lease, Discount Rate",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LesseeFinanceLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Recognition period"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r49",
      "r118",
      "r180",
      "r203",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r383",
      "r387",
      "r388",
      "r417",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r36",
      "r118",
      "r203",
      "r417",
      "r446",
      "r478",
      "r495"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r51",
      "r118",
      "r203",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r383",
      "r387",
      "r388",
      "r417",
      "r444",
      "r445",
      "r446"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r25",
      "r26",
      "r118",
      "r203",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r383",
      "r387",
      "r388",
      "r417",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r25",
      "r477",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Borrowings against facility"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r47",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "ICE LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r25",
      "r253",
      "r263",
      "r264",
      "r265",
      "r477",
      "r492"
     ],
     "calculation": {
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Current portion of notes payable",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "verboseLabel": "Net long-term notes payable"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails",
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r53",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails",
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r226",
      "r227",
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r228",
      "r230",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss contingency"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r102",
      "r104",
      "r107"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r73",
      "r76",
      "r82",
      "r86",
      "r107",
      "r118",
      "r128",
      "r130",
      "r131",
      "r132",
      "r133",
      "r136",
      "r137",
      "r143",
      "r175",
      "r178",
      "r181",
      "r184",
      "r186",
      "r203",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r404",
      "r417",
      "r483",
      "r502"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to shareholders",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME",
      "http://www.viemed.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted accounting pronouncements and Recently issued accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash transactions"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income and expenses"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableToBanksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a bank.",
        "label": "Notes Payable to Banks [Member]",
        "terseLabel": "Notes Payable"
       }
      }
     },
     "localname": "NotesPayableToBanksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails",
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesScheduleofNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states in which entity provides DME and health care solutions"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/NatureofBusinessandOperationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r175",
      "r178",
      "r181",
      "r184",
      "r186"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncome": {
     "auth_ref": [
      "r154",
      "r438",
      "r440"
     ],
     "calculation": {
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.",
        "label": "Operating Lease, Lease Income",
        "terseLabel": "Revenue from rentals"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r434",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Business and Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/NatureofBusinessandOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r50"
     ],
     "calculation": {
      "http://www.viemed.com/role/CurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Change in unrealized gain/loss on derivative instruments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r74",
      "r77",
      "r380",
      "r381",
      "r385"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Change in accumulated other comprehensive loss, net of tax",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherInvestments": {
     "auth_ref": [
      "r41",
      "r498"
     ],
     "calculation": {
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Investments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments classified as other.",
        "label": "Other Investments",
        "terseLabel": "Other equity investments"
       }
      }
     },
     "localname": "OtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityinvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other expense (income)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Shares redeemed to pay income tax"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Investment in equity investments"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PhantomShareUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded as phantom share or unit.",
        "label": "Phantom Share Units (PSUs) [Member]",
        "terseLabel": "Phantom Share Units"
       }
      }
     },
     "localname": "PhantomShareUnitsPSUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r315",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r38",
      "r39"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r97",
      "r345"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r44",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r221",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r43",
      "r216"
     ],
     "calculation": {
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r218",
      "r446",
      "r487",
      "r496"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net of accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r42",
      "r218",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r18",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r18",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r89",
      "r207"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Change in allowance for doubtful accounts",
        "verboseLabel": "Change in allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r309",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r441",
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Rental payments"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r309",
      "r441",
      "r442",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Total rental payments"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r309",
      "r441",
      "r443",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfOtherLongTermDebt": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.",
        "label": "Repayments of Other Long-term Debt",
        "negatedLabel": "Principal payments on notes payable"
       }
      }
     },
     "localname": "RepaymentsOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedTerseLabel": "Principal payments on term note"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r353",
      "r459",
      "r528"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r32",
      "r278",
      "r349",
      "r446",
      "r494",
      "r516",
      "r518"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r125",
      "r126",
      "r127",
      "r129",
      "r135",
      "r137",
      "r205",
      "r346",
      "r347",
      "r348",
      "r368",
      "r369",
      "r402",
      "r513",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r171",
      "r172",
      "r177",
      "r182",
      "r183",
      "r187",
      "r188",
      "r189",
      "r290",
      "r291",
      "r460"
     ],
     "calculation": {
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue from sales and services"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r165",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Accounting under Topic 606"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionLeases": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue recognition for leases entered into by lessor.",
        "label": "Revenue Recognition, Leases [Policy Text Block]",
        "terseLabel": "Revenue Accounting under Topic 842"
       }
      }
     },
     "localname": "RevenueRecognitionLeases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r83",
      "r118",
      "r171",
      "r172",
      "r177",
      "r182",
      "r183",
      "r187",
      "r188",
      "r189",
      "r203",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r417",
      "r486"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      },
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME",
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r53",
      "r123",
      "r264",
      "r266",
      "r274",
      "r275",
      "r276",
      "r277",
      "r425",
      "r426",
      "r428",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Notes Payable"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r314",
      "r340",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r314",
      "r340",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r44",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails",
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r326",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of Phantom Share Units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r315",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails",
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails",
      "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails",
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r319",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r163",
      "r165",
      "r166",
      "r167",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of Revenue by Customer"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Expired / Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Expired / Forfeited (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Issued (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "RSUs outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs (000's)",
        "verboseLabel": "Number of phantom share units (000's)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (USD per share)",
        "periodStartLabel": "Beginning balance (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Value of share equivalents"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails",
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails",
      "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails",
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Maximum shares in Plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Expired / Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired / Forfeited (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value (USD per share)",
        "verboseLabel": "Aggregate intrinsic value (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails",
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r321",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails",
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options (000's)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (USD per share)",
        "periodStartLabel": "Beginning balance (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average grant price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r313",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails",
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Issued (USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r315",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share Price(USD per share)",
        "verboseLabel": "Fair value on date of grant (USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails",
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails",
      "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "negatedTerseLabel": "Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r335",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r279",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r111",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r116",
      "r118",
      "r140",
      "r141",
      "r142",
      "r144",
      "r146",
      "r156",
      "r157",
      "r158",
      "r203",
      "r234",
      "r238",
      "r239",
      "r240",
      "r243",
      "r244",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r417",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails",
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r56",
      "r80",
      "r81",
      "r82",
      "r125",
      "r126",
      "r127",
      "r129",
      "r135",
      "r137",
      "r155",
      "r205",
      "r273",
      "r278",
      "r346",
      "r347",
      "r348",
      "r368",
      "r369",
      "r402",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r513",
      "r514",
      "r515",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r155",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r273",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r29",
      "r273",
      "r278",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of options (in shares)",
        "verboseLabel": "Common stock issued pursuant to stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails",
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r28",
      "r29",
      "r273",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r56",
      "r273",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r28",
      "r29",
      "r273",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Shares redeemed to pay income tax (in shares)",
        "terseLabel": "Shares redeemed to pay income tax (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r28",
      "r29",
      "r273",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Shares redeemed to pay income tax",
        "verboseLabel": "Shares redeemed to pay income tax"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r29",
      "r34",
      "r35",
      "r118",
      "r198",
      "r203",
      "r417",
      "r446"
     ],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Shareholders' equity, ending balance",
        "periodStartLabel": "Shareholders' equity, beginning balance",
        "totalLabel": "TOTAL SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedTerseLabel": "Deferred tax assets, valuation allowance released"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails",
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails",
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.viemed.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Stock options and other dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Denominator calculation from basic to diluted:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r139",
      "r146"
     ],
     "calculation": {
      "http://www.viemed.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Diluted weighted-average number of shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME",
      "http://www.viemed.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r138",
      "r146"
     ],
     "calculation": {
      "http://www.viemed.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Basic weighted-average number of common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME",
      "http://www.viemed.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.viemed.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vmd_AccruedTradePayablesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.viemed.com/role/CurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Trade Payables, Current",
        "label": "Accrued Trade Payables, Current",
        "terseLabel": "Accrued trade payables"
       }
      }
     },
     "localname": "AccruedTradePayablesCurrent",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/CurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vmd_AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Fair Value Disclosure And Liabilities Fair Value Disclosure",
        "label": "Assets Fair Value Disclosure And Liabilities Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAndLiabilitiesFairValueDisclosure",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vmd_AssetsHeldUnderFinanceLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets Held Under Finance Leases [Member]",
        "label": "Assets Held Under Finance Leases [Member]",
        "terseLabel": "Capital lease"
       }
      }
     },
     "localname": "AssetsHeldUnderFinanceLeasesMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vmd_BuildingTermNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Building Term Note [Member]",
        "label": "Building Term Note [Member]",
        "terseLabel": "Building Term Note"
       }
      }
     },
     "localname": "BuildingTermNoteMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vmd_COVID19ResponseSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Response Sales [Member]",
        "label": "COVID-19 Response Sales [Member]",
        "terseLabel": "COVID-19 response sales and services"
       }
      }
     },
     "localname": "COVID19ResponseSalesMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vmd_DebtAndLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt And Leases [Abstract]",
        "label": "Debt And Leases [Abstract]",
        "terseLabel": "Debt And Leases [Abstract]"
       }
      }
     },
     "localname": "DebtAndLeasesAbstract",
     "nsuri": "http://www.viemed.com/20210930",
     "xbrltype": "stringItemType"
    },
    "vmd_DebtInstrumentCovenantLoanToValueRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Loan To Value Ratio",
        "label": "Debt Instrument, Covenant, Loan To Value Ratio",
        "terseLabel": "Required loan to value ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLoanToValueRatio",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vmd_DebtInstrumentInterestRateFloorRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Floor Rate",
        "label": "Debt Instrument, Interest Rate, Floor Rate",
        "terseLabel": "Floor rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateFloorRate",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLineofCreditNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vmd_DebtandLeaseDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt and Lease Disclosure [Text Block]",
        "label": "Debt and Lease Disclosure [Text Block]",
        "terseLabel": "Debt and Lease Liabilities"
       }
      }
     },
     "localname": "DebtandLeaseDisclosureTextBlock",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vmd_DistributionsOfEarningsReceivedFromEquityMethodInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributions Of Earnings Received From Equity Method Investments",
        "label": "Distributions Of Earnings Received From Equity Method Investments",
        "terseLabel": "Distributions of earnings received from equity method investments"
       }
      }
     },
     "localname": "DistributionsOfEarningsReceivedFromEquityMethodInvestments",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vmd_EquipmentMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment, Medical [Member]",
        "label": "Equipment, Medical [Member]",
        "terseLabel": "Medical equipment"
       }
      }
     },
     "localname": "EquipmentMedicalMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vmd_EquipmentSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment Sales [Member]",
        "label": "Equipment Sales [Member]",
        "terseLabel": "Equipment and supply sales"
       }
      }
     },
     "localname": "EquipmentSalesMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vmd_FurnitureAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture And Equipment [Member]",
        "label": "Furniture And Equipment [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndEquipmentMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vmd_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "totalLabel": "Lease liabilities"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vmd_LeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "vmd_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, Current",
        "label": "Lease, Liability, Current",
        "negatedTerseLabel": "Current portion of lease liabilities",
        "terseLabel": "Current portion of lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilityCurrent",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vmd_LeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "vmd_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability, Noncurrent",
        "label": "Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "verboseLabel": "Net long-term lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilityNoncurrent",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vmd_LeasePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Payments",
        "label": "Lease, Payments",
        "negatedTerseLabel": "Repayments of lease liabilities"
       }
      }
     },
     "localname": "LeasePayments",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vmd_LiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities, Lessee [Table Text Block]",
        "label": "Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Lease Liabilities"
       }
      }
     },
     "localname": "LiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vmd_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid [Member]",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid revenues"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vmd_MedicareAndMedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare And Medicaid [Member]",
        "label": "Medicare And Medicaid [Member]",
        "terseLabel": "Total Medicare and Medicaid"
       }
      }
     },
     "localname": "MedicareAndMedicaidMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vmd_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare [Member]",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare revenues"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vmd_MonthlyRentalPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly Rental Payments [Member]",
        "label": "Monthly Rental Payments [Member]",
        "terseLabel": "Monthly Rental Payments"
       }
      }
     },
     "localname": "MonthlyRentalPaymentsMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vmd_NetNonCashChangesToFinanceLeaseBalances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Non-Cash Changes To Finance Lease Balances",
        "label": "Net Non-Cash Changes To Finance Lease Balances",
        "terseLabel": "Net non-cash changes to finance lease balances"
       }
      }
     },
     "localname": "NetNonCashChangesToFinanceLeaseBalances",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vmd_NetNonCashChangesToOperatingLeaseBalances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Non-Cash Changes To Operating Lease Balances",
        "label": "Net Non-Cash Changes To Operating Lease Balances",
        "terseLabel": "Net non-cash changes to operating lease balances"
       }
      }
     },
     "localname": "NetNonCashChangesToOperatingLeaseBalances",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vmd_NumberOfStockClasses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Stock Classes",
        "label": "Number Of Stock Classes",
        "terseLabel": "Number of stock classes"
       }
      }
     },
     "localname": "NumberOfStockClasses",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vmd_OmnibusPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Plan",
        "label": "Omnibus Plan [Member]",
        "terseLabel": "Omnibus Plan"
       }
      }
     },
     "localname": "OmnibusPlanMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vmd_OtherDurableMedicalEquipmentRentalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Durable Medical Equipment Rentals [Member]",
        "label": "Other Durable Medical Equipment Rentals [Member]",
        "terseLabel": "Other durable medical equipment rentals"
       }
      }
     },
     "localname": "OtherDurableMedicalEquipmentRentalsMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited",
        "negatedTerseLabel": "Expired / Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Issued",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Issued",
        "terseLabel": "Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Grant, Percent Of Stock Outstanding",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Grant, Percent Of Stock Outstanding",
        "terseLabel": "Percent of issued and outstanding shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vmd_TermNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Note [Member]",
        "label": "Term Note [Member]",
        "terseLabel": "Term Note"
       }
      }
     },
     "localname": "TermNoteMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/DebtandLeaseLiabilitiesCommercialTermNotesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vmd_VentilatorRentalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ventilator Rental [Member]",
        "label": "Ventilator Rental [Member]",
        "terseLabel": "Ventilator rentals, non-invasive and invasive"
       }
      }
     },
     "localname": "VentilatorRentalMember",
     "nsuri": "http://www.viemed.com/20210930",
     "presentation": [
      "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.L)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e99989-122729"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(k)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123420820&loc=SL77919311-209978"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f,g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r529": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r531": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r532": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r533": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r534": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r535": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r536": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001729149-21-000137-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001729149-21-000137-xbrl.zip
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M3AR]Z( H129-2SR)YXL9'R"0ST*E.HMTI218S]#-X1,693R%_\M9K6:(7&-
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M.6CYX:.6?U1?FX*.C^KKT8._TX-__M?QX'=&)E[ 7],B3=[^%U!+ P04
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MN7./.ZBK\?0=J&!'C-2?C/HCEKE*K$*?Y-48M5/'+J3QV#L%^,[N?6=\I??
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M@S;8N(3=1V5OB\H^V$=EOT)!\P8ULX=;9!%YLB+?:$LUX[HQ-PI?W1:C188
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MT0W7@]!4?6$K'5R]*' R(!HSU07E&@AX0A"++PH%]*'2.KW7R#ID(/9P<,:
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M4V+@";.$9:66H*SQ8!\,C;@7ONQJDD2E4 "1J!$N?CCK[4FY';-,Z:F=P]3
M2%IG* ]S>ACL1BN;*VBS<V/6K'V&@.OO">!N[D7GQ<%Q-SXZM36DZN*!2$+7
M!1G%[9IA.O((P8C+! LQC"0#A&6BI!V3.(GE2)!$DG0OI$V5MA7V(^HT6@6H
ME$:G(/"Q92\1&0(0:B'\:]6>#>7>X"6\\EU]N4=WX592*58$B))^1M2U@MR
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MJ.<@>1E@1$!HCZ$0-M&% "UPHAF-RAB/!>CHB!$)G(J?4&B$J-]]/C2]\">
M2/^^VSX)G7X.6U=[@&(/0I+,/R^^W_+17*2?5K^9GL__^!+Z@V;G8"BW>+:4
MQ=OO==NU-SK;1[5V=:W5W&]7X3V;;+_^Z7S_Z)A5U]QE=:_!JNWUR_VC57C?
MIXLMNM,*?^U<[._Y$TN8J)+&M^V]O]M =Z#B8:NVMM$&>?T&_8 V#BX:]=3V
M.MY?^SO6UC8O:]^^4B24H=IE.G+0JP$\"QV#R8241'F)+#5\:>4C;I24G1_*
M)DV["C*\>[Z]MONM=O"5.(R35YX) X+,N- )&<D,C"KWQ$3BV3U4?GO3J>F%
M&$ ONM"_PQ5+'MV[?NX< Q]4<I?ZW0 <L'\M]9OMDU9R]?+?#GN)3:Y[76_.
M^QY:>'NSB>'KO[]SU(5^][27?\LC!N]&K#<D\E/4_KBAD+M6XV]-G[['9NA5
M\@Z%.[WT]YO_<]-3N/WPROBGFZV?Y*PY_M8?F-X@F9>5L;.+\/BY[]>NNNFO
MW:JSY+/>O#+^/G[)VQL3-6[GM-,<3EH_"5+_:AK:P?1/>V%E]/K\XKB)\;7Q
M]]3&W70@CG,+-EUKRB*3QJ3P$Q,R&.&1X5\W4_=!'] "3/\PDC,8SBA&&:%7
M#8VN/')&3W-NOCEEH\#8N]W/:X^>S8B5YV!L)0J1P81JK*EP@3!$J5/(#V>S
M(,Q\8S9O\.?C9O/&#' 9+#<@RSA"SX(T4BL*3"6XMLA1D\\ PB#JQ9H!-,9%
MSYX!%+%@0H'L$,>XYH8HPJF$$5.'HO<CS2:+K=GD-#3;3=G1W&E!M&',,^.8
M=CHZ@DE4."I.6#YO:#QOJ(CSAAX^;VAB\T:]!DOJL*,\,BZC1MRX #Z(M:"#
MN!S-&R[VO#W4DCYKWJ[K?<"<.3"]F@O?/(,Q7+\U!U=FT.T]T43\\'SZ<2UT
MNNUFYZYF'VK(;S3Q]F;O?V6AM!0.4>,HE@9<>:\YF"K'03D)9[!G23]C/0W]
M/!IM.$@NP?"KAY>=G[2:KCFHAK:%5_@F7!TNZUUY' ,@>'IF_=^G*<(.;D>W
M U_[J^=- $?CV^#W=K?S>=!UQ\.V_GA[YRNNINRJ)X\R'%A/S' X[BE1,/F
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MOZ!%TW.'%UOA++1NNE%7-VUV3DX'_?P./+%U8],_7.WX]%?*\C@SK<0X-SL
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M"0Z6(FM]6%KY'$X&0]^>HN5*FO?2\)>&?^$,?[T'W6^F&.3<6_[]HR3_7]J
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MOYG??QH6G45\?Y**33_HC3/7:^??#QP9GD,TETKM66N2EU]Q]-$PB3-*K<J
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M0]?2?X9O'[H<-7_X=KJV$&!MJ9@>IYBN^:$,"ZE%S(2T/F-2T4PQ%<&&.21
MN5"A#0C)LB!DIHLT3W-#2S$M#IHHQ?318OK=[42<1DL=RC@#@,F<YID-B&;2
M.(PICDZEXA?@=6)4(#%]P:308B?N;79<MQTJ W-^;=VT\'FB+Q:,*W2NR93
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MJOB*^2]W6Q<?>C>^G+:W&<(X^S_!E_K(W_FCO_S'R=8_K\S,<<7U^6BU>=9
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M!)-2!M11@E?% <L10W53K8JYX1DNB6>(9SK+,PON/A'/K(1GVB5JN-9>V6K
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M;SJ\>&XS"?-,?>']+W[X*V\:M8K[HKYX6!KPR@:\FANO:L :-VV&S_(!-F?
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M@B$DL"9R*!JK $U2F+$YG2SP>L\8@NQF0W;)&08$V55"]M*E%=8:FR."2UX
M1A1@FXRZ6%]&P7VPH70/LH^T;LK-S8)F)T#.F_/\HY=G[7GZO9=^'-_U)._W
M&C@]]-[O8BVHNMZ5Z;;C02ES'Z7BI:HZZ9A*WHMB.4>=;6D:,RU^*NCYZ/CX
MO(;SV4F@@]/I9.J'S832V9]YBC6_WIFV>*^:(M4@B1*41@XHO0+/2H8L34"I
MA>3!;VU+VT>K^\9<C^AUO4_3O,!\X"/5JR68;A#YW7O<S?W0F\2F-Q[&N@>5
M4H^[=?/G_J6KE[VLKCF38'3Q@#X5L#I)8)H%4XR)F'33"%[?T.28J).HDZAS
M.=2I>#!!L>IQ8\:D?"A<<NDK5P9DSBBBSHY0YZ7IF5$RDXT%99M"I55*$*SR
M$+0M6D63N,XSEUN1U4G42=0YU]/.DZ.C#6?5Q@PELH(,A35)>Z^U4FA82>%V
M[KPE-8=X<F&>/+@T,0M7F2>1(51E!LBC@.JR%S H2W73B[6QV4W0UWLHSYUM
M0WQ%?-5]4R]K;U'YV39:U,)R99TNPDD10DB23+UN4-CL_X<S&ONO2=6*R]$
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MR;;0GL3]6K*1;$@V)!N2S1UD,U>9-*>=Y=8XZYK\I^AXS"[P('C.7**[@R]
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M0B5=L-8B*N\]>E=$%E;$)*PI9T40N9"<>E%UH![B_NN7[5Y4G$6%SAIP+BO
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M2I[<W%%)ZH&Y3I,NMDOV5?,\1F\4&"4\H,X(/@8)7$HFA5.26[:U+1XV?8-
M3 2[\;)YR(PZ(MCU$FS;9Y;:5T9U"-GSRK#!>PB,"V"*B1(<0VFQ8PS[I%)9
M%FPU_ 1C@12G)=F0;$@V)!N23=<L9Y$,T\59PRTR%X-2U9)6LVA%RD$LMT@$
MM2V]OY'\]DKY;:E25(Q'B-XC8/5\F@:F!JJ@JN14MJ7)<N1]8Z]7WR;,;CAF
MUUK8A3"[&&8O'=LBL/JPI0!*Z0"+"> -&HB8!/>,&9U<]S#[2+>"YVDU?)A/
MIODXY/%B_8:7&,,[KW9[-D&?%[Q]<MV(?72ER"R8TAZ]*M8RSF2)*)6.2>KS
M*O@+'N6@;L1+X\4_VP<VBM36R*+!&F\ 30P0DA=0N(_*YA31JEDW8EW1A[AY
MK367B-D'/KC_8+34#>UP]S8DRYR/3:+GZ\;J_;B9.I2LFY#;1W"8#<:+ $X[
MW[1VRA"X*Z"#",%E[Y3(LS['3ET_04=D3&1,9-Q1,N;%(CI,/F/]+Y@0M$G<
M%#32FZB1R+@C9'QI'3.G>=;HP13& %44$)H,<A&R<5*HF'G39Z^OV/4-<>)B
MXF+BXG5.Q%R]F3/WSLM8DJUD;$6(5CB5HU,LVN3][61,O9E71;RM1$_.,A?E
M_V?O79OBR)FTX;]2P;/[[#BBQ>A8)7DVB& ,GO$^ W@,GGGM+PX=H>T^L%7=
MQOC7ORE5]0D:FS,-U!WW8.BN4JFDS$M7IC)3H4#>QD!/3P."Q9,B$O+<<N4,
MTWQM@['S!]=?/H6U!< 6 )\6 %XEW1_LR8)['*A3P&N\L:Q0KL"%YT%X+5LR
MNAJ8.+_M3"S,F+8,>2$$ C@T2&&?(^EE()93[WUDHZI#N6SI:(O&+1H_%C0.
M1#H1<"BP#UPQKHABN?648\:LQ*Y%XU5!X[GS7!Q,B5<!.4P<XC0&%+B<H< Y
MRYW,I7& QE)U6-'NFETW].'7E-D!_[KNUXW_AA^3+L^U93UH4MEH]L9_F_+7
MZ?"VM[6W7>.V1G.X6A>@7,?#*E7>?EGZGAYUO_K?3KIN=#1!^;G[&CW!LUNT
M :T8CRZ^95D/D\S/VDQ*!GK9T\>5?SGYY;=)5=?N(&E[NNFWOBX/NX.)PL;>
MG]&Q]+SZZUF?UG'=KZ9T<//DYNOU]-49Q&B^4^LYRR_\&J^3BV]],LU2M<Z%
MNO5F\W7"V*5:75KUF8@I@?U!W%<M<@\??[GO?2S_,>S# T]C7=[!<.2K;#3,
M1D<^4B7G!_6A7(.TRJ0:(:$[T ,+CX8NP@>I O_" G>#@?DAE;X$P-S+J+W5
MAS[+%U'L!TOGQ= W_S.^7.*"MF"%5H(IKVD\6$;)4 1'A";4%SH4GZA8F]QT
M5,[&]- C4WK]!>D X_%2]T[T:;7VZ\*P]0&CFE?)BP2RJXN/ GJ(<1UPN1P?
MEUE_DWO%Y-Z+ &#VY?)83ZI^%.LYQ\#B,,YQL"4T['XU/P:I7L)*^N?-]L[V
M5O;G]N9?!W^^VGRWW<G>[+Y:3U+Z:F]W:WMW'[Z&W_;W_GJSM7D ?^P?P#\[
MV[L'^]G>Z^S5YOZ?V>N_]O[=7Z;\9T>3_7PT&^&XXH N0PR8EWN!"X(G0YW:
M>1F/'.G:R^R8;'\[+GT5H;4[ *P=CJ%]5\4"2^_7]]>SK:A,9?7BR@3KP5[H
M_4"/71>6AQ>7P\5+O='C 1RP-=<+<4G N=*75-Q1PVR=WDF[!;L\]#ZZ#E^0
M%\!_@&X_C7R_FTO5:O!0=:G%:!<^R7;@LJ,JVP;2Z1:S#RZQP-SV%*SR8 %'
MOT0JQM-ZZ4OFGSRYE\8WE?U53$NZW-N_TM51%GK#DRH+Y;"?#8]]J=/I,=&9
M^[4[ZOKK'1>SZ&0][T:=9YR7$*3KYSP]WT[>BB _?.V8LX+\H+5C;M#&58;X
M0;9 +S?0E]\"7?9>][J5>;D7NL)6IC>6<EV8/#>$.^8,EXXR8J1G,<C.-OG1
MY"GG1^_N3[8SWWW9V]H^^7AP".UM<WC.EYWO'[L?OF^3CUL?OWSX]]WGG8/-
MTX^?=[],MS/[V]]W__W[9/?@'VAWD^X=0-_H>_'QX O?^?ZNM_/'ZZ/=?]]\
M__COZ][9[<P/!SO0[B:!^[_M;'T0NW]L?_]XT.OM'1Q^W_WC_<F'?[?)A\_P
M/O_^$W9.\?<4;+>/OWT2QGO.6$#",X&XX X9HC4"4;(J.$4HYFL;HH/9*B5'
MMZ#3@DX-.LPI !U++!.!BR(H++3U1&)C E>B2*"#)Z"#6]!Y.- A4]#1)&=>
M.(,($1+QW'FD=4Z1SJVRQ.62YCH>4]/A8I50YXG:/LMU<.YPZZ@A+^^T]$+;
MQIT:)/7219/W<O4D;<L?EP"WZ6#T535/+E4D9&5*'SUR:C\O$.TB>X5%=G=_
MCMGG3*>JZ$C%XV]XT!)IYB0R@CK*82)-7&1EARBZ0FMLJZ^/CQ6W^GI]?9V1
M8L,#=RI(I&P10%^M14IPB9APA +8PF31F'%<<+%"^GJ'G'BU6<O<Z56]WO!$
M#ZQ/Y\O',.E1&/=25-OX;&#:[5D)][]#M'P<Z$/79'N"\'V_=.MM.?S:K:!+
MKX?E5B.]FXWPMG!^%3COSM$O[3#U0AK$K":(<V:0QHP@+:T-G@M)XX$UHD/%
M^4SF^SQ1X4X2X9ZY_MXO_6KU]_;T=T;'8-*-+(1'C#LPG[3G2 97(,$<E3J0
M@FB@8T4'='J%]/?9.I%F=*P[^ K4:%B>9J6'MKZN[);W4[11KU*(Y198S@45
M6=Y,1."O-Z_WWM524)^Y#&)2'OH6%:^"BO/;Q5@(@$,M$?%>QD($&DE>>.2!
MWY#<B+PP;FV#D/-YKY>OSM)ZDYXVG;GXH/16;V]7;^=V7"TCA6(Y4CE5B,<S
M-$T.O";G@E/%;.&*QW0@^M-W+Z52Y\CH.O>Q?^P'U?4WR!Z/-ZEHO4F/W)N4
M!/?W*+>OYL2V1>XK(/?>JSG&%8+0! >.G!06<2\DTCP(1!C'2@=N#%%K&ZPC
M;[XMT/J15DQS[]>/U&KN;6CNC',)(%S!*(EDL'$#'AMD/%%(V,"#E]3G)FFN
MD*T':07T<JM;U2=*P_BG/&BORP'TOLI*;WWW:ZP[$9. ZM.)LKX?'0U=\C8U
M87*MGVDE0?06Z$^-DU_[[N6"D.R%[49$WC42\AH$I"ZPMI/$X\U,.EH<O0J.
MS@<RP8KGI<$6T5QAP%&*D5& J%1:)8$=Z:#BF8M%&\;TU%3WSAU/K4K?ITK/
MJ!$/FEF!<^1S 2H-DQP3 "S*<\*5"\$%:E;8'761?D_J@$!G_8^1X#%?^6Q]
M<G7JSUVPP/O,3WA"IO0][S8NFLOUHK#O[;A,A0!>?]WMOO,P%-^]^T-W!VV*
MV%53Q.+J<#H]",)P0IDE&%EJXPD\I$ *.QDCV;5Q.&AA8@"&/$_[KGP01.OQ
M6ADUO07*UZKIG:OI[O[LO!9-\L"]19H;4%-K/%)*2&2-L'G("RI#L;;!;A(0
MT'JW;JZ#4<RS7PY!X%]DH(&1UPTKW8M^KN,RUK4!,J,'+O&:XTAD6F_62IK$
M=Q<T-0'#O<%6$HY4QGHO;%:5;TW=*R+DFWDB$W01*!<485-XQ'.FD"F,0(J&
MW!FB<QE+;##,5\C0;95U5=C,%3;P6@V^30V>XSB6$U&0PB),G$*<>X<D*"[,
M&7 <!=P$YW9M@W8X/:_##Q+W^&Q=-%L^^+),18V3KV:DOV7^6]S,]MDOQ@]\
MZ([.S4CKHGDJU.9*2<NUI-1.O0/];;L6D]]K(6GA\DIPN3-/>'))I:56(/CI
M$,>>(B54@:0D5!<<X-+H!)>D37U[%$I\SY1G:J"TZOQ@ZCS'?K04*@ ((Z/C
M4>@,QZ/090!U#E;3PE!'7,R$$XH]>2?/ZC&>6-K53I/?3H;EEUB?V.KC>'+"
MRCMQ'GL;SY9H \Z67E=U 8PFV;@)E(NG7[04>S57Y_OEV!,AV?+UOV\&D[ST
M=U-):5?F*ZW,[^>)=B&DU2H09 J<(QZ<09KR.'5$*,,+YHM4O%<4*[(RMUJ\
M*AR[U>*'U>(Y?LT9$XYBB22(*N(^.*2=L,AZQPK+-:?,Q\)?2K:;J*M#>J9E
M)E:>8S_3O9=;#_@ZCX.3?/6N;[=7K@: 'Q8CO03%W!,D<E8@7BB-I%<"><^-
MP)1:(L+:!E%M48FGI)\/36):Y;V^\LZQEZ)P2L9T'&E,W!MEP%X$+Y"Q7!(2
M9 "K!)2WP_%- C7;O=';92_'I3_673?9&ZU2[-=P=.3+3*=P@=:!LYJH^= .
MG+>UX$RV6YI=ELV!VXO"TX::7 -.[3P7\M;AM'?*E&"(YX0@90%8O<%>*Z^)
MX#3NG=(E)Z.T+IW'J]</S89:O;X#O9X/(6-"$>X+I"UWB%-LD70!(T*)%,R*
M7 02:5)1G"\&T3IY'HHFC4KM?':L3Z./LRWPT,:-_<@;_K86DX,H,RU47@DJ
M#^<ID'+4:N^! AG@09SD!!F!,?(PS99CZPL87Z! .9-MQ/P3T^6'ID&M+M^"
M+L_1'L95B#6#D:*T0!P;C50N-!*.* ?P[)U*H:#%2ATOV[J(@/NX22A]Z;_Z
MP;@-Z5E-Q+R';:Y7\+S8DW^[HZ-7XPK&PI=_=;7I]KJCTQ8=KX2.7Q:8#BQA
MME &.9S;6"%0(,EYCHBFGK)@I6.Q0N"2??\V3/YQ:^VMESEHM?9NM7:.T^#"
M.L*"BP=7$\2U5DB!QB(=N)-&FKKB 57%"FGML_7F_#)1B!<Q)7 ^9+D< [?I
M-0K1;;T[J^H9O\V*!S>U#:/,_#43F19%KX*BGS?GN0_GI- QX+&0L3JRP0[I
MG MD ^?"J)R:Q'TZ!;F)0[QU\#P]XM,J\<,J\1P5\M82KB5!S.("<:4(,@H,
M&!RX#S)H)XF([AUV<S+4NG=N]Y"\:7F$9G?KUS9YJV5"EPZ=;)*L_<11ONM'
M>V'NXS8SY)KPNE "DQ?<>:8]<BK&5N;&@*69*R0!:;EV!M90FH(&\O.%%-I@
MH-52]-5R#K4:?(<:/%\[ 7NL!= B$-54.0HC*2SP)8-QK)P@N(P$:4D1VR?I
M*WI(2E1<7#Y!5T>Q"N;7KO,N,Z=9K(>I1[&.0IR,KROM'OK9?698.E^BT?#X
M912(:MCKNBP.YL^1<S5(ZW]<U42XY!L_[C7B?H.>0$M>@9*\;73D]]/W52RU
MLS?1D\VIFK2+Q946BX5"H2)X*4S!D3!!(DZ#0\I:BG*G"I<+28NXL4!81]Y:
MM,3E=.6!768MQ#U+B+M?5V$+<7<&<?-[IYX$&Y1'+,<&<299S!O4R'L)",>4
M\CF+>Z<=1AX'Q%U ENE-?(EWZCMKVWAF%DY$M2STAB=5?7)1?5;1HG&3K:IU
M\V3:>+9[#F_'I3V*41>W>])$N]WP&+8;KL"_WNK3='[:P7#3@F24_FTC+&][
M>C#:'+CMB;RT_.M*_&NA8EP ]D6)=LC96,M588]T$30B+I?$PS>V,3&Q;+<4
MGI(RWZ\QU2KSG2GS?/1%02EQ+$>YYP)Q&PM!2HE1$7PNN:$F.+ZV(3MTR=$R
M;4[Q_>;53,X'C<$7S=FA[='Q*X^:MYY<<PX84WD%0$<WCL:8;PLM7 ,4%XK)
M25PH2CU'TIF N!84&6<=(B$H9CT/A0MK&T+=I'Q*&U6Z:HIZZR$3K:+>B:+.
ML1=1*(4=QPBFB@![$1P4U1@D2>ZI ^G-"QJ/Q5L-/7V^_IMR"+UVC?.P FEO
M/3FK@(X/RF(:F7@-(K$/$K$76OON=A!RH19<(#G!)K?(&L,0CP7AE* Y4M3[
M@CLN@S9K&WQ)7=PV/?AQ:^P]>VM:=;XS=9ZO\X^]E'GAD,%.("YS"EQ'>B04
MEUKZPBN6Q],ZB'PFF<.KMU<ZC08=5^D,T:6;I:OJK+EV(,2SC)1Z#,%2CR Y
MZ(*PJ3<3O6G#IJZY="R4Q,N5SG'0&DEEP5:67B#EP6 .6A4^YQY^FK1M1^1-
M3GJZJLX\UKC0%O"> . ]T$&S+>#=&>#-<>4\%T0J+Q&C<6LS*()D017"CE#I
M@Q4AM[$Z!.;GN?+JX5T;)/H(VWA6AL_9(-'0'>B!?1QVSY-IHY&XBQISW>JX
MIT\CUOD?/_8Q7]ENM"0%]-]\:;MUV.SP.*YK[9$\J^FKO=O=E='0?MFKYW^[
M$0G7$LNK$,OO"SF6CCN#B94(!R*!6,)O1E*,-/9,!U<4,'E@29-52LAO]?21
M[ZFT2GP+2CQG'1*L";=>(,>8B%4UXB%9.D>:P_1)Z[0T1:J+LR2(_<%W4AZ:
M8*T$O7OH;K2#\.!7/MM@\+=E%TSK8]V+I?=2D&$&*]=@./+5I!C?;9C:2Q9M
M"P_SY<./@+A35\(S#8&]=3ODG9_(YUY(T:]_#0>'![[L;WG3!H)<C;XLA*A;
MJK55A4;!<X)XP1C2-F>(FCAI2@5!5;1!;F$K;X5VZYZ[?MYZB'JKG[>IG_-Y
M=;D7C!**B) 4P<P7<=]=(5O8W J'94Z Q9 ;9=6UH>EW1:2 X?03F[H-?^F3
M(U'/T$>TNC4/YA%\W]MQZ5V+W5?&[H68^4)ZE\?3M)2)@0-.%D@7%"-3. :S
M1H6Q.+J&J!"KD1/=*NZJL*M6<>]=<>=(ERHLP3:72&+J$0?]1%I[BD3("QRH
M,Y[;J+CD1IF[CR,P?K5IU_Z1+GV5@<Q[W_<N&PTC_YH[4N*)>Z^*UGOUV(G7
M)+O[]; $*&\JE.V%5\-^?SA(VW4ME%\)RA</<&?*20[T*U<L($X<V,]<>I1C
M!>+K<PJV=81RSE;$@FYU> 4WV$/WFW?HNR^'K?;>N?;.$3&+E=0JY(A1&<\X
MY01I7#A4Y,8QGANOG%[;^+__1X(6_[9ZIWH]]+;F$]A4?8R^P)E%%B,F>^F<
MUYL>[MK&3CX1VO>U[U[^%45BLG*TZ\,5UH?=K86#6XG/A13$HU#XZ&%S"DGC
M) H25GNOC9?.Q3,?VPJB3TM5[\?#UJKJ355UCLH%(5C!<X^, AN,.RN1XDPB
MG4L076R(L*"J1:? <C54M>5PSRWQ[%S%C<>4>7;MQ-+GEWW^I%+/5ZO6QNN)
MQK2IY]=<-!<RA&@ 6N,<0<HYCSAA'$F6YT@66A%OC9&"KFWP3E'<0FG*]ORU
M%N96%N96J\)&"W,WA[GY'*K@.652(L;CR<02+'A)K$&6,$$+9215*MH&L*ZM
M.LRUY34>81O/SLKYQ36GK[^(H1+IMVCO).,G5E%.O\12RE\!TMHS(59V57P@
M\A^7Q/C?]DQ"WOEJ5';MR+OXQ>; +7XP=^5;&)4AK*&UV&TU@@A_]\9Q?K:_
MV2,]./3O],AOA^!M&\EVM97U[WD#PKC<**4"LC*'E97( DFLX@$]BBD0&^TX
MB08$(6WXPZH#P\KYQULX>!1P,'_DL6&4Y\$A4/X8#<4#4EH5*##L8+T@@DBY
MMD%4!_/S3/O!PRGN(I)@]?C9JXM(6*9'F?&'W<$@>J2'(3OUNFR#"582@$7A
MC=! QD@@7/E"%THRK4,NE,&6Z4]O(NX2X&H/A;LMC%X)1A=.+I5&$"4E(*B(
M_@I.#9*<>Z2X*4(@ JM"QN.".DK>&$;;X(,54^U"$VVQ9D$(P54H))6"Y)1X
MA;W6A8VJ352KVH](M>=3?W"N5> &,19RQ+TKD/)6H8 #]S&&G/H\53=G2Y+V
M'KR>T_/P8/V0(7GX/!X*ELR*5?5;M;M83V<7ZPI+1R#2"4"2 GLPPQE71+'<
M>LHQ8U9BEUCA3?.)VJ7C_I:.A5(Z@G+&I.0HQ\XA8/T$26$PXI(&H@7'!L=@
MU+PC\QL?JM1NV;=@M^)@AWW!A!1%H)$G\P",&0?G34X(5;A@M0G<@MTC KLY
MGNRTE(0%CSB+8.>%1CKW8 P[S1P!K%,% 1.8=MC-CX1L-^X?L(VY46<PM&XX
M-CV_..R/K8O/REC:'Q\?]WQ,7]"]S'4KVQM6XU@S 8PD.SEI(^L.:M %[5Q5
MF^G)M/%L\R*3W7ZL ;7=N(Q[&*,CWQCJ<<T'(1QYD,R5/;K[QL[.U9B&R]/5
M9>_UN$GIK1>F?=/([%L0ZUW?;DY?C5)^6;"?P3R06@1D8YH8#\PA#103P6P1
M)H0@CEBPGXOS^6&/?DNE199'CRRW7E*W19:;(<N<L4H9S24K6../$U0B0[1
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M7?@U7B<7?O=0S?)+-;M4>]14UA[TJ$9YN:,JO<^TM<,^// TFE/Q7/!D8<4
M)UB/G!_$NO/P6TIMTB/XHZE KWO01?B@?ZX8X_7'Y8>TXQ)*>2^#]E8?^JQ8
MU/R+@&3^9^Q_6E-MP0JM!%->PQ)/G)*A" Z6"$)]H4/QB<JUR4U'Y6S8#H'
MEEY_03K *[_4O1-]6JW]NC R?5#K:6_9>E3MB\#FBLAVWX #'5['=:>OBCA*
MKBM\\=<_U>$YYGW9_+[[U>Z8 GB)O>-_WFSO;&]E?VYO_G7PYZO-=]N=[,WN
MJ_4TO[M[!]O[V<%>=O#G=O9J;W=K>W<?KH7?]O?^>K.U>0!_O'ZSN[G[ZLWF
M7]G^ 7RPL[U[L/]S36?71T 8YUL:(#P9H-3.R^X('F O,62_'&@S[NDR<U&>
MRTSW@7J-JLQ_.RY]U9S!,3H:CN&Q+FW"OU_?7\^VTM55!ZZS'@0%R'56Q7.
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M!!=+'8J53U*_-RWXSQ9([A=(&#642\V,(077.9><2"H)P[[ FA2V<3 7%T1
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MG',F6@_.0T'P0H4857AA.<M1D<<=,QP,4K!B(B(TH<HP;F%>-O+SY=A7O?+
MK<+@"JP5RW5R5?;O6LQ+^:S!&5+D>2%SRP,#:T<1K'UA!"N"P:+U3ST@YN$Y
M4]1)HKQ')F<6P>(DD2:%0GD>BV-J';.0 ?/.1PFTF+<*.MEBWBIA7I%++(RD
MP0?.A94&8RN5TY8Z+T"16O?; V+>S/T&\\. D$LPM>.!%-XJI%41D,^9@"7*
M:F$88-[C*P/88EZ+>?>->0+L6B)RX O<<(*] K;G."V,(PIKV09Q/23FS=R+
MKG">::V0\$+'+0>/M'7Q3U:(@F"JG&QYWB/!O)N7\7M41?M2,R^[(WB&_?%8
MT3G\NJL2.&\&7P&.AN7I6Q C>_JLZ]P<['S27C/. T6R,!QQKB62T@ND"\^P
MXECD0=9+1G<P]FXSEELM1&Z)#\Q:4W#&K.+22EP4A:#<PB2>K8LS'?)S8GYG
M990>6N9_6(DG2G@SHFF9K"7OIZ,Z&\=9#<HJ@^%,W8"W^>Y=JKC3A=4W7E6-
MCX][75]EHR,]BG-8=:M1+.KC_W?</>['$I;'NAQ5G?3=N)\*8-5U\715#6U7
MCZ#%XW+HQG8T:RU^WZTR_^W8#RJX -I.97RZ?1\;CZ5^LF&9C2N_GAW,R@=E
M7W4OEA_J3M^BN;$W//%EO-,.8_?*;.!'\![QA5)5GG3?>K9G /C]J-XG&0^:
M.D+IBDF3J7=E<T?JF(?)[:?76-IH$LCYJ=C(9H,,[]B,<G,[=%'' 88G^\S4
M!Q_$#_]CU4K23]_A'WC+FHG5O9X=58*?&=[M;GT1.YN?7,YS:KQ#V.8"<:4D
M,MA)I)F,!XP+'S1?VR =RHH.:/XY.I6$[RKS?2^'F;?SO72^=T\^>6#)-/@"
M%44N$3=,(Z-(0)(P'<^>43E)\\T$NV"^EQ<-!BE84C)RL;YH0MW2]P!^ (*'
MRZJB-9"Z_ECK";XMA\? K4_? A:.-@=N>[*PM.1J=\M^4C"\N2T*)')"$=>Y
M1HI[C0CG*E"-!:Q?9\F5PGE>$(:-)SDL$%;S(F?P'S6LP)+_L.C@JE'YB7@D
M?9F2CGMA?0_+\):_^"*C@'6C+JXX<#6/@M^2:9OH2G.N4K9_Y#VP/$"2(R!O
MPUJ)@28!4ZMBE?-Q?]Q+-[A("2-E ]A:SW;T9R!2I1_X$UA0:LK6!R;WU?<3
M:TS8!$,43VV*O0"R%H_"[G5#8C1 _])3@4N!K*7YCN020"Q>/(.Y2 Z;%VT*
MKG=BE73@5WW=A;<<I'>(3P?&JKME_;4]RMP0B.N/>G#F.76'.JE',^(9R:2-
M9S:X^,8#?9C>+CN"+V;$;Z'QKW55R]F4]+RNZC>S("9#@,EJ':!]-I9QTBPP
MV'%L:US%\I:QQ6I4ZCCAJ)=J5OK1T1"F]*NO2UK.GG[VR4O?:SV[0&":XO3E
M* T_=$:?>;#1P.FGS^V6%SSY;,7:I^QNN(;I]5/,W5B0")C&?HK3ZLU-%<@(
M_&M]-3%KHAXG>Z@V5#IGCP^H9E<E;8Q_)7%(\FN\'X!.Q]DK:_G48*R-NDDJ
M:@,,1#(>=0#SG#Z9+".QW7(X/CRZ2*W20RX4N9/N"-33ARYPVC.*$Z41N$P4
MKEB[%0 %5+J^Z0B0)@IA3"6$-X-O[9$>'"9S+[/=$G J5ENVZ8,X='-O#5)K
M=5F>1M6J3V( ]#A-^&"BLM@HWM%H6V:NG9?KA>_O2K(;H>)J/19\/1Y6J2KN
MR\3V8*QF=5[_<W&%GCQ\=HN.9BV RX6W/'RY6D'8.L9IO^6"<K7+SH!JOLS5
MY-Z+ZH9>]\O5:+D):CTC&(36P_4 !2<7+KV@=^)<[RY5_/.'8;,_$=E;@'AY
MJ0V(MT #,G4&%RYRN\_]/"IG(W#HD2F]_H)T@-Z_U+T3?5JM_;H()Z!%TP>S
MA -G5?@1U956<EWAB[^^0HW>:P5DWWW-R*B1E]BI^>?-]L[V5O;G]N9?!W^^
MVGRWW<G>[+Y:3ZO![M[!]GYVL)<=_+D-UOSNUO;N/EP+O^WO_?5F:_, _GC]
M9G=S]]6;S;^R_0/X8&=[]V#_.L5H+SU&,,ZWG?IW>2NO/L?Y0!LP0DH@];WX
MS^0T)>#IP'2J^D FX,=C>*Q+)/C]^CZ0['1U73?>@Z  &<FJH[GCF%ZD0?_E
M_4"/'7 1]^)*R00_VE"\(L350WSW^'8N^7+Y>/^@)OY54&\I$\;226$"R0W!
MW#-N?'1@&.6DP5H&==9;8:PB./B +0G<:RVEL509ZIP1WEE]Y]MYT>,T.MU)
M]E=T@U:C9.#6_J?GZ'8Z^/)):^$)%@)A023BWA DA0JH"-(&[& H:3@[D1*S
M6 #,P/QY'G(A":66*!P*+9Q2=.7.NKBB*ZJ6D[13U(C(,]U\/#\05_1$19_0
ML']<=N.5T5<TF&MLX@=J3,0QM-AX1.K'-HZ2M,4XF'PX=WNT/H=@U\9]-NW@
ME<$4!7P%KI6(5 "#L]ZZ:ZSI;G7A$_M>5^.R]@CI'C0R2*89-%C9LFOJ96ES
M_U7&*$$$(R807;\_-\F#P.)S=LCO?-_YY$116$PT"IXP0$8LD;1Y0#FL7EH7
MU"B5KQS2_5"=XP9[?0!.\DPF+0&5T=U>-7]VS__]/Y*2XK?JO,K]X-R<A_<\
M2!CB@E['GN'%>L[%G1R0DM_Z 2F4K4MR.>-K13K+5NTTET=U,L%Y!O_L#F<X
MMWO^W$]JV%X@2,MXZBV&R]_.."Z-@E^-T?R/NRE;N8HU%NXE^.Q2['(:;,0>
M)[VLP_O['_M[_[[__J'_/T<?^^_IS@'<T_^GN_O'N\\[?^S@W?[VM]T__C[9
MZ;\Y.1O>_['_07P\V.U^Z+_N?SSX\ TH*=#5-_CC'SLG'[[_33\<;../6YNG
M'S[_'G;VYU+7A1".40Y$%%N"N, %TC OB'+K=6"6,:/7-@K.5[U(:PM2+4C=
M$*2N'S'9@M0=@-0LUUQHS')**7+4.0"IF'=)<H:D%#R6UU"PE*QM$/8X0.K)
MUG7> [._7&+GM^795HA/72&X.\UG"V#7!+#Y0[Z,HD9::I 6/D<<Y!$I+'',
M(Z>ZH(42RL9@<*)6I$Y;JZHKQRI:;;R9-L[H!!&^H-AAY*4&FZ?@$FE7./A!
MG,R5(($7:QM"K4@=U5NL8,C@Z6XXCH[TQU["L-D<[&0QC'L88A!'=W@GU0OO
M8XA7PE9</M#7M15O-AXKF$J_:O2L70NNN1;,'[Y!B%?,ZQQ)Y?*X%@2D&"L0
ML9H1*:16)IJ6'<6?2/7&:R\!C\ AUT)P"\&W3;M;E+TVRLZ=3<LDY@9@51E)
M$0_&(DD,,.[<:6&UPSH'QEVP\Z=<MQA[.=/@_HKZ+(W>_6D0YXH',\UI^64#
M"4N_$,H8\^$&=CY\$3[NCF)AD)0D>7(TK'P6$]]@V&*^&9@MH1O35*'OV7&,
M&JX+ILS*EL1LO)0V9[J]^.31,//??&F[,8$?!JH;0"9B<N\@],8Q S SXU'*
M7HL35 Y[Z]F%>_M-_Z&#NM<[G80LILHE*<NW>Y7(S)2YIY>IZH4V\9W.YN ^
M42,],9:\,15(2(KY=%&"ZV'N:^<GV<MG<PV;K,BY(-0H<,MBYV*R<\S%'0YB
M^F*=JP!W=T'@^JGD36]858LU;Z+PQ Q&$).8P=N%OEQPWR0*]U##I/\2/WF1
MA7+8/R/P\\(3)QPNCA6 9A+=9$=7/Y&=_1'\TX3_ANQ-ZLK/!-5_3>5%;CG]
M<S8A=6#ON?FH4CIHS!)ILKEG4<#KV>YPR4./]%=HQ]:IX3%-'-I<DC61>G R
M'/?@FA"\O:@[%\[ Q74['F?9@HNVCL[![%7#M)MT__\=PZN%TZF"'2=^D?*H
M06I=2FYN@K(EQ>O9Z_JZ:N'AG7/H['LP=XUL7!3U7?>C^;8ZJ_$-WG::L@K0
M[DRZUZ$_[T%@B$*89[:G862G1;6Z*?X]K3%PCXN_I"^')J9]I\$XAK7?S^M#
MHB$P9*,29JHF6-5T2.HVXI# !QH6&)A;7<[WM=&/"OAQUJVJL2\[@"M9'\1E
M\GX)9\X'UT-_YV8&>A+7V-*E-20M'LW -QIS/CU][JWF.C_5M$7H.]%5FG1]
MTN#=XK#&][M@E!:@.SU\ *I?9\$;7X/YA4H=N="H.DL*FL&H//2TI@.7%N$E
M.0$7IIBO4 9 G(;2 S!7(/XUOM=)46UIGIWO?W]2C'$O10%F$(^%P()$*L\]
M_*:),;G'FORPU,YCR'E:$(&&;CR#XCO+7AN4/,15HD;^!F9FN) J^YE8W27B
M?PJ13@E.F0.XB%2QV=BH&=D"<$<+8EBOFS4/2;4X%BA/NBFQM)-!3'(=CDL;
M:[+LC<LZE>I\9V?E'?UH\FF-BE.#J"YF"']&QE@_-K)&GY@DK##=K_7*!U^"
M^#9+9U/&<*2_P;(V5SVH?H/%SB16NJQD45PV$L;'H;EDUAC\/S4_'#1K6*+!
M1\,>]+3ZKV8>SI:I>?2$:K.J*T:.>]-U.UH3%/\633)8&%T4)@OCF#XFOT4;
MXZAKNK5-7U.A@L/:9GTYBI8!3,;7[G!<S5N+YV2A,2DF3+CNP"0/.Q90ZH(<
M-<4KUV#]/X2>'ZY-$[<;NV*93'0;0^&LC3-/P2+#_]IUP/4FZ^UIIH_AQ30P
ML&D)J51XJ1D4^,4G @Y*\7YJZ?^HG4XVZ?:TUZDZ#0SFEVFEI.8F9$[1M(&Z
M8%+24>A!'+U( IJYN?B-I^4^QR#!38E3, SB&RWIYGJV5>-&(KD).>;4J!.Q
M8,[..7M[JF(ZJ[]:F_6S]YWTY,3#"X/"N9\G+3X4!WD7(7'LW]4&<)3IEGSL
M;GWYE!,AG!0>*<$<XM8$I&PH4(Z%LKF2G!;^;(*V\*:0VFJG8WE@3@QA1K/"
MQ9,P>([-,K+RH.RCF?R)^R/._C--N9Z,1.(!>EIH;E*1N9H81P TICN8UABK
MK;S>I'[>(!X6"1]O[6S'3WX%D)\4!)M4(VM*C0&*-H^L4=%T>[VFAEBJ$]:+
M8)W("\R-!Y!K>,WD),K.]!C*:&MW2X=BF>AH2L;UIDSUHE'Z8UK>K^D)7'@Z
M?7CD#G.^KX9Z)*<HD*<(>/-V7FS%Z%C'T(PB2M<HOG!U64;:-O- +'0.GCPL
M4_7JB9^J&<;H6DAKT^*+QR4QPFG-Z"*K&>C>::JF!YV,]FQ3:>U8@V'MQGZN
MQ&'Z:-9<>D3932LJK)MU$;#(E8;3Q:F9@AE9C O@U\9MG((-4MG&5Q<,3D,A
MIGUU75@NR[K<G/&CDU@L+BVKJ=8LT-ORL.&)$Y%HA*C;-^.RJMTC]<5@C\/
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M.OZN\>%$%]?,L9 B&P;^<#B*#G$0,S3PHY-A^27-5Q3@V=1W$G4YC%[Y[!
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M^/?CO^]/X;U.H:_P+E_8QX-WBU4@=4ZXRPN%@LP9XM)Z)'-LD17&.ZT#EJH
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M^O#V1[W33/?CG&?P1%U_!L"*TB^9@9>IUK,X"I,V,NB,+^%QI]D1C  \/DN
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MK%S']&V[1L6^I(J4H%5-&FBG)N[$FY), (+5F8=7BX%U<,4,854'=.+7GPS
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M(8!BQ3DH5DPA1@T6PJM"61$9MZ!TB1CWO@:RI1<W_@(IXRDL7W>"J#F+])-
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M!2?B<2-N\,?,USHN*QO#=@>XP"5*//1=WP=ZF:H8H(.<]@9^1KW8L</>]5P
M\GT_-G>_K&1,B'&B;BQ(CHY96 EJ)5:2AV -E06UCA?2!!#69"D9$_@7C7]Y
M4%YPG2S_!LSHN;;]NYS[W^.7>;5&O.WC==HZ/,BQ""*FRXD"M.*HKZ!HNT-8
M*X=9K@EQ,3V?J?F]W.^D<,[5,R]C,:4/US8O/^ZJ2I@$M,@6BZMU]\?2F^BR
M+J[L#F.!':#4:)G4AZ]9?#G>(JVS U8HJX0$\#2 "3RW%&D9#'*JL YC9ZC(
MD_@RSZ<TU>=^,D%F1COMIL9_P#<GP%L^C@WB.VA_-G*A[0V&47U-A9LF:HL!
M_7 JL)1^LH$'HBWK*%RYO^K7VQ^F4P9N+L68-$+%@)T48!2%F5)MF&@34^8[
M\<.CGKNT%W>-<%UH=ZK%XBI9Z>'P2S+<;VD98$I76GA/PH3+,& \O46;0:\S
M&EY_RX]OCB@(6\-EA_MKNB/.2^"HOLS5^-[K&@#>]\OE&+G*WKQ$&#$<>.7'
MM".<N?2:V8DKLU-WZ>EW8X;,T\>-RSN%Z?\-IUI&Q"(]K,N?1_WI$AQZ9/I>
M?T4ZP/1_TYTS?3Y8^=_9)J; 1I,GLP0$EWGXN3D5G@R4B^_3QU3)-84?I=OF
MO3*/G[Y=Y.T1^NGU_]G:W-[<R/[87/]K[X]WZQ\W5[.MUKNU=!RT=O8V=[.]
MG6SOC\WLW0Y(&*U=N!9^V]WY:VMC?0_^>+_56F^]VUK_*]O=@P^V-UM[NXNT
MG%QXC<JV\H^Q0/A6I_#\)?ME3YM11_<S%^FY/PG+\]]/X5@>)&,''-F]$3RV
M5#$_K>VN91OIZL$J7&=!4$_"5%D%KQK@U[3HOWSJZI%K@W3QZT*M.V?R;AZ6
M E\N\=,#W'0'%NSJFM2:F>:F=T"]N6D!=PCS?]H6Y+OVR+M1Q^^$625F\(K3
M52YV/AP0(:7!%B-)HY/9>8<D4PP%Z0OF@G!8JN7N0-[W-O*D&RON*8BN9]M)
M<1@[+09UM6$U.SMJVZ/L2%?:Q" [A%-YF+2#Z!@[\YUOE8L5+D[0,:CZCP_N
MW'U\''<3.?\W6N;7S,;BT"M)-S]($E=JC4IRG^,])VM2T$?O_(W7)&&/W_D[
M7^/D\=N4/^%D[[:R39ORIDWY<K0I7Z8B0//5N!19^)2-G1YG[9:BDD33S/?N
M#B*?8Q8X!;&6$6Y=D(1XY:T4.;:BX.%1BO?\U>L>1A=!%&&7ISS$_037LCS$
M\2$\X^L97'>V??SGR<[>![Y_\H&W-BS>V=L^_W+RY_&7S_^TMR^VR>7R$#L;
M\#Y[ZR#@KI]OG^R+UL91^\O&(6Y=?!#;%W^>[)^T.E\^;UUL7UQJ1&Y)3F7.
M/&(\F)BAS9!1C"(M1.&,\('16&9QE8JK]7J6L8-O UP-<-T?N(CWH%8[7CCG
M./568>LHC[7(N!>"A4<I<M, U_V!:UK7)F?*4N\,HI1ZQ+4,2$K)H\U#"HV5
M)+)8>5.LYJQI/?Y#V>\O/ZC9"9ZB3.Y+'^,UM6+I/K7*\3.V:OAEF67OI:O0
M]A).LIF2F51CSVA .2XDXD1'JW.@*#<42^."IWD>.ZLH?+6B\J^+'F)+)&._
M=DY]=F&SX=1[<>I4YE0%#CE1'AGO"\0%-T@%:9&V@>>YY-PH$SE5LB7AU/L*
ME3<65+RQIN*2V3WG&X);?IAU@#'0U WV()'D%@'Q^59[*0P.#ZVY^_BK\K(K
M[SZ[1-?JE=&HS5&QT%$QT[%7*N&%TAP)JF,H@9#(%,8@*04I7*X*;4WLK,7X
MU8Z]RUYU]RD.B1_9;Z?!YP:?7Y+1N,'G^^)S7917S&"L4![+UG&C-=+>2Y0S
M07SN5.Y];&*T6JBKHGR#SX]7&_WFVDQ+7-3IQE"\3PLD"<\F;<:\N6DMS8'_
MEM) 8^8-+%?*Q+%568A!JO*Y&@-YNX=5R\CA4:R^M9JU3V*N:!9K%^AA3.:)
ML:M5/E!]N%YW4-;SG$Q@+7L_N6SZI++XB\]T5O:-2C6W87[K+BZN=]GFVZV]
MC7683'HY("F4ZE5DJ6!%>KK.4EI_]NY(]P_C?V,"4DPC2)>LQJ!"YV&*XTAF
M/ZYM7*M'NC?GTPS0M)< .=7&M4"/L:R'A7GU3F(Y9EC"*L<5QM>CSK!6RV;^
MZ@7=[HSZOBP3\M5/\V3/CGPW<Z-4!ZCORTSPM++3&WH&* 9VJ=>/L=81X*=3
M&B_G;&&2,QW7%[X].>VT8\QF51ZS4]^ F[/.)\6A9U//R^RM^?76KD^F>R0V
MO+6*^E,?XV5UZ%@3_FKQM'NEICU=[X!:S?KH+?-^+T+F*P[&QJWU ZL-)@X.
M9T)8;#/(<Z2PM,@SF5LL@R^P7>Y@[#&''^E!"LP^[);Y_0E@?=9)_0IJK?=2
MYO\)P!N<I['(5?NT!#A F"F2I[O*2SL)5^%?4]5Q*8^$.X=R+Q[&O131V5+D
M]XK.QFN,R4</>"9K>7&_,.I; I[9$T1G/^%DF^CL)CJ[B<Y^W,"92^=#$Z'=
M!#H^4J#CD[9732)M)-ZQ7'O^D]BI]DGK\S\G7S;@^XM/I+7W@;4N_FEO_[Z)
MO^RMTWWXY\N>9?LG7XXOVZE:QY_(E\]?OH*L>]S:@WLW+&M]WCK;W_O8V=[X
M<@S_=%H7KOWEI#4;GUWH0@NE&=*$*9""98&DAS^QI$8*2YW!170Y,W*UW.$R
MACDVL-7 UI(V(6U@ZZ&P5>LZ"LJYQCP@#FH,XAYCI 27J.!.8!*T 5)8><-6
M!7X9:25-=/:+C*QNHK,7B\Z^8I)J(K0?/^[S_K+W=>?4SQ78^4S'53T$VW@&
MT_8>":8YXD(KI I;("$*;G*C@^%NY0V79#G".AM&?!1&?&9ILN'2>W%I+6:#
MV-P(JA%QQ$>A4B*CB$-,>(<+)C OV,H;NEKP)>'3)OSZ#N'7CR-S-"%^38C?
MTX7X/;[(]M/%\#W/>3 38YUC(25C$EE)).(.*R1E;$+K+6R%];FS(+5)QIL(
MOB;"^L?C30._SV_V;>#WL>%W*HYS00)W'K3D8!WBU@H$Z$L1"9[K7/ ",[GR
MILBOUM]HX/=) JB7M@U"&N;N#7#?7Q<@]Q,W@(@Q@K'+96\TF T0+$/]IM&
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M=#4<^/Y[M"1$73P;'&F0':L!?DV+_LNGK@8M&T367Q=9QUF3WL,J$)9+_/0
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M4 9;=DTP>\/O#Z.&G;UMW-H[Q#L;AWC[XM/W;:"&W%#M&>A?NHBG3HZ1=K0
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M@?V?7EJEPQC54@G?&X*Q>U)B=X#Y8CIJ>?QF:XWM+M ]W?0GDEEB8@J K15
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M*PV*5K^A.KUA=X"Z&&I%!6A;H"P-3GM#>!ZH2J!Z?01B(9+TBVW4V!RP\;C
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MUN6;_*X2QOF0>6)GNE*Z2>&S&#6($"4A'0Z'2,5)E-[>^O@\#QH!9Z#<YN*
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M!,39N\]U6$&ZB'&CD3<\'C/!34<RW++P-G(6,U1KZ,*BERKX #:% =<DR"#
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M@J?!?2\,W#?2X#X-[M/@/@WNT^ ^#>YK)KCOT)Y"32?I$_F::/Z_;*<HR.A
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M@I2MB?].UO"3+V;CU+_-F#$%+@_OL7JG.%;3.1R2, :(01H9$5\=81X3>#R
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MW TU19^Y::$>0X_QK&.<K/=^E?GI).?I8N$ON>"_!(>];[9[AZE3J^V,;;Z
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MR_B;8>M$!C^)@ZQTAE*I!6$TA[,KA)_$V&=!B5)_BVN)0(O"EV4[:-"X+KP
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M:/]Y*U3)1; E.SI588+@ :,$-[,+^FT%\Z;"3=!N^T%HQ5A-3I!QZ(= &E6
M*U8@C<LYO!KQ#*IB9[[8_!^=V#%MUQCL\*F7O"4S0UA&B?-#*79U-$38HT!P
M]T82:94T9!4YY$\606.90BDZH*][RA$E"*X:2)0[D\[3AX=X=Z::R$=#CD5S
M#E/E?N,\!%O.][XCZ(F@OT$H#KT)FS(R&6%E*&8,,W]A"F[F&"UC!\^W"1UV
M<V?"Z$R;X/9)/RXAX,7J&,:=XZ?B,/+]\-X)7*#*_<QS9T+:N<G)74])$NE2
M2U+D,!;\JWP*U80'9BLL$I;'YN#RX?'L!$&*MC!PUIS[K-,IXQAOG!:AGJ<$
M6&S;",[H=L!..'U1_T2*$7GW^):Z]Q..1!CEX;5RWV'M.(,3H%LXSX;V[I<A
M\N]LL,)RN!2-V>X#*]8"/!$ ![&C]5!6DPC$(4#TD%- 2ZV%4W(LI[)>#E.2
MLHH3+RA%@4CE42%.%[,D%K9'D?,F_^^5YPXZ V?4ZXR8T^XZ]F0TG ZF$[OG
MV&TV<*:#_[5;K5<'Y-ZUR#=P+X_43S @04KR'1G?^!2_D_#;Q<47?K+\Z@6@
M.^%KQD?8K#0ZI7/9;F,A'^7<2C&&<4''"W#+U2_7WSY<R%,#X73&-*/&G%.#
MGV%>3.?9(F+\T*7;/>@HX;'##<8\W B_H&1,)'8<CQ?@61AVX>=<_&?@X3,W
M"9F?9Z]P1UX1BM@)''_Y;SQZ8F4^_%#C(C/&,,@=(O!H<C0_6-HT]7-$3XA)
M(M(0=$^#R>/T3^O&,O!C<H5@Y7Z$3][R)[*A5Z@DPT7@W#%_@5_R@BE"H^D(
M)@I@/(A<W5"U%?[O_QFV[<'[6"*HD1@LHE>1=C##.X_=\ULN\VP>)DJ^.)H=
M>F(%2Y@-.TYCM.?CPD9-V )U%(;O.;4]>,E-JL9PG04==__FJXF3"*'DD0!0
MH@4@_'?X$_&!$U6.-7&6YTEX#O^C8,8+)"YC0N/,>RM#=4[$:A 0#2#5Y0!O
MW8.=/_/$@([OIJAR%2!HP97/L@PK7Y/A!#Z6Q\WWA0]&$,T@C19AC#_F^\1U
M,^.*/ RJ"$1.5$!@2[*G\F6-T\DM2_@]HS/OCN;/N)W'I-F6,TZ@&&#$ !7?
MRW8!OD6H3G;K(=-?Y)$.4^&\%>&J% ,A;ZH4@&23FHT3F!QQ+LY1&*J"0+MM
MJM 1L0-G'_P%- L*2CY)C8#3"#B-@'M1"+BV1L!I!)Q&P&D$G$; :03<:2/@
MMN36,I\&K>8U9U[BH+C;=C8/XP1\<KQNYSKQ["WY<!SF(X-C2N0N=V9DJL<4
ML2=^)P;8$I-$PKLIAU%9Q@VC2#.XQ.!+A/?T21ZC6O ;Q,)3R9U[Q<><.10#
M8T'U+ MNW:J#(D-J,B%E^-X<))%_>#7+E<;<+R&WF4>%2D(@*[<1\YFL*]>=
M? TA4^<H0._:@Z)4"9;B?_+(B7]W;@_)OGLV)B/WS,Z*SSW3=]\7"&-W<,T?
M5)Z;.TM,F@C7DR>-1*R'!P^"F& R8^8Z*09>DP(*#I4J 6N0/^[Q)BDQ"_Y+
M*$.KI<# 5*ABS(*H08W?PWOPE","/TU""HT([UG6,P"]? O2$S 7]#DO0A*Q
MJ<\1$?E5>/Q<&-R&R(THIMF+,EPLBNODWG+%13#-?WOF/XR>\G.55XQ928#?
M,PX),X@7Q8\R#<($]R5L9\[E:<"E3-@C:E.P"+&%%TQ!H<8&U69(Z-]+N3 ;
M+]D\_9)9PVQ@HDXN+DX6,PL# 0BFE.1:G&\U,,>!N#(^66V(%JC>'5CM7BE'
M[A;'T;R].V]7PIL>H&<]0F/)W+!D$FEV%-FG\"T"/M[Q^'=I/-F#)W@T/YQ.
M/3!OT/25P5D2&)P/2(N#99=R::@$?L%4QPRYM6A@%/5KAOB4:^1I>)?P"K%(
MF=RBK1)Y&00T5J_+,Q$LIZR^"G7+JZIA^A(+#[AD_<N,WCA-^-OT9E5\VH?S
MXAQ1"'G:_@Z+QP A,,\BBXU9QM\SC\(2//+KYHL $J5XVQG/PY"OP8OCM!QL
M)Z<##TW3B-#/2+!\%OD'PO$_>51:6(UAEGU C)\380 ]%F@XM+A,03IN!#H4
MTUY;A]",691:)#IDX0<X+X-;TF?B?75(-/60V,%2 A\>I3ZT(MJW(KK.LMS9
MR;1/4T] BDADQ;@+9TFL4P3$Y/EXSDX$V1;(FT(F/C^F)ZDKCE$AW<43=YJ2
MXX[R<H]ZPKES/#_[<HIE$.L<WVMD>O[3^K#>K]'0>:&9. T1B$4.)>VPQY&7
ML)FNY^=><PY@X9@R]-#%*4?@R0SYHB:I3=SI-5^?<I_*-1[*?:[P-"8<)_ K
MO/>NDG@B_HR1T5Y9V.R8HMOVR.IV>WL/0]LMJS/:+0Q=9]B!U1J.GF#4SF"P
M]U%'UJB___C^DQ&VUZ[^]>&CCGK5;SZ&L+MMUY9V8XWO*B8QA;+V'R'I=BCI
M?]# _FY+6P\TG\:Z_C,-V(DMZ2.5>>K8I[2F#^!'<^[CRVJ=QK+6D;FGL2Y5
MJDYD206I.I$UK4B5/7I<\T_1ZO1)@ C/1A-T8*Z+%QYV;/&Z\[H;T2RG'(VT
M>[.<VHMN8+-;VQP,1P_KYUN'R1_:^48SW.DQ7*_?UPRG&>[Y&*X_[&J&TPSW
M7*OMF:V!K1E.,]QSK;9M#EM:PVF&>[XC=61V[;;F.,UQS[7:KMGN=C3#:89[
MOC.U,QPVE.%J1R576@,WEL4N)A,#9_]NA]CRPQL@ZS%.:XR'!NG+1+%G]9HH
M&.HEB4K9V-38NV3)S6C07>G1] </T[[[;KE^4E0=V \,O6JJ;J!JO_7 #(JF
MZB8-T.EIJNZ=JMVVINK^J6J/6IJJ^Z=J1U-U_U1MM1X82&F0Z]ID6WVU-O:#
M[/6293>9JP9U#Y4-V_I4@GID)!W6E5)-TFTD'=7-RFJ2;LT$M>H>T9JF6VE:
MVTG7--U*T]K.I*;I5IKVZB9(-$VWFN>UT^I[I.D6XUQ>_0Q"++*]*7ZOGWSH
MDR\@E[&UB]<)>]^VV6D]$#>C8QH;J-KNZ+S&4_"JSL$]!54?" [65-VH 1Z(
M@-54W4!5>Z3UZA-0M:<UP-YC>ZT'HO5T5F/'K,9:::JL\>%+R'# N3W48;DG
M.+>[FJK[INI9N]U9$TI-ST<$.G7BZ FLH*ZFZMXEOV_VNWTM^WODTV'=&(BF
MZ3::'C)O],B*/J+$90>^/@E3+)@I:73<)7]6*H\^\,K3'JC3B MPY31ZZ 6X
M?5#EH%)<3HZ!V<VK93V;[GC4E;S]2.\37Q+50O2"A*AO#KL#+41:B+00/9P<
M/;/;'VHATD*DA>CAY!B9W9X6(BU$6H@>Y1,-\L+(6HBT$&DAJD\.NV^VA]HI
M:H04:1':0I(&RL_ '/9//S"G94?+SE.$$GI:=FIDTGZB!G _U^C6MZ6K9N5[
MC]R(U2Y_:]M/O<3^C*E1XB?9*O[7K%7\1]ZF+ZX_\88LN+RMX4K>SXAG8>I/
ML.6D;%')&Z,COU!_PR0T>5]6['T8IV.8<9(FU.W2Q#:9<4I="2-Z<)J13W0Y
MC W@)FR&FXAA71=XE/I38@]7ZHAH&==Y]U?YXERTNL06EOFH:G_+-&LW2\T[
MQ4)XQW9U,0[U,7;\A$4![Z69A%G'7IAWH'1OQ&<7"Q]$ )B<EH<M9JG99^';
MV>K@$]3JN&)I-$+9]ZF%,N_\S5L59RT\'6RT"Z3'GJ1Q3@_9]E,T#?Y';/C>
MOU(/-FEI9LU+L\5G'2>QRSS-/O: @YS(7QJP?S[,.%L"$ID>D9U"66RM-J8T
M9@Y^<.XE=',KEHL*''])"@,^%/J;]\'#/LVA+[IF1F4,Q0?$CI=BYW.R\/;I
M].&(+<((YY9SP/J$)R'C'!6QJ2_:!V==BZ>&"XK.P5[LU,IZYD2W+!;?P*_1
MGLR=!/8,^S[G[5MQ1-ZA5?3@Q/W$R0:W(;XH)@R/OR=J<,K2A@2XI?!)7!>\
M#+.-EK1KF82L+\*;3AGVBL=MFP'!J:&LR7<"/^<!17A#7=PX3E*Q^S0SL<D/
MZ/VZ18D)G=(=$7AY$<:D+-Y%S*</YST_L<^A\IXXNUKY*\X8F +VO_*5M1Y2
M\//SMB[MV1VKU:+ZDQ6M2POU+8L_]D?RW?+?-[Y\!",+?,T*8]AM3JZ-7<)V
M* SZV$<K9M=;F]WHT1TWM[#LL]F67YQ;9G0Z1=&M,N#4?^("O,G_>^6Y@\[
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MOPYY#7#K*<B%!VQ/.N(747CGH?",E\99RKWBMP]KR[529^5![9]VINQC1C_
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MF4:3:339$:/)ZC9QN>!WU&2JXP.W_=$\_\A[/AZMZU/1Q"'R>)=.9>%?>,A
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MD-VB;@Z1MTK./<Q+>6)(50^-"U,LRI9"0CZY58^]?-T[^.\B1+KN^WO3*I;
M0\KQP5^$P[AP6*V961JJJZ&Z&JK;%-Q4':ANOPY$2H-N->A6@VXUZ%:#;C7H
M]OE MXWV_'0"2"> #I\ >J'AYZ\,)"Z0064L[L0IC!$P$ -449,M$50E3LU!
MCUNCOVJ8C<)9QCWQ8+*6.N$152Q=(W0",'$ZQ=A!Q")$;MB#][%\>\GKB?&.
M7A@!H5 0SC>+1<B(6NZBY\M5PL].+/6!.E5^LS=8J@7U$.DT!3G"B$%I'+T
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M>(W_RR=9[;J"\_*RU'EXG;_)RXKRKM,+%0%-^^+Q?5'K%1?V9;5-9J9@)[)
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MV..X<-4"K_/CS8HP(+>>&]!P3"4,PX\^D4*]G\ O>B]RXA1]4$+B<@/<BS/
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MPJO$H0F&A35UCAK>:J'#/7FB3$/BND]+"V!ZU/!K%%2;>@*%*99CG>]))_=
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MZLMJHQ,A,5N"V//KSVH)L P2"*D;-DG%V(C-WE^O]>UUZ5Z]^A___'PZVKN
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MJ5'U\7%#MB=^<W;4_<VW85M9U^NI _.$\6?,$3H_*D5FZ70X'DYG99@75S-
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M@/8&218I<5IH$Y3FF;59REI]K,@6=N5J67:>V+V[;+PQ.85!2LIK X8$[DJ
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M@I7UNZ'7O/R\?"F1PX]_^W]02P,$%     @ ?8UA4P00H)1$.P  J< " !0
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MZ[,F\%I2W3,\!2^BA5#[\I52#H() K0PFD4=K=!M4+*4I'L&CFY$W\ (O^.
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M=#[X4#0XJ5+*(D9,C3>L70/HCJCR(>!G':7L"#>3\WUZ'AJU)101:=<MO)8
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M*A^,C;YV(=6[H(A+IWT"[E0H)H5H99NPX_&@]XXJP ,'[SH*;E$\NCB/?@2
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MM\('1YMRNR6[#Y:/:'EV>#0>/+@.Z5:]31F_L//T0D#TA5PEFQT'E:V&4$P
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M3Q]G\9?'62=K/5_>W)2U0^!JL2J+156()L1F31M"YCI6# +.D>WY30@@*L\
MS5@2(X)Q+KQVK:]FR=2FE(VZT4;?$^7H)_9F>'A+IC[>T_>B.'8_./I2#3*'
MO?K8AG>]O(HUX[MD7G/0#KIJ7E6A?G/RNI-FVV\52T4Q9!G0-*^/=U- (-%
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M@"_'1%V,/8?[GV;3<'1NNHAVH/F!_8P'!OC'=C7N&O3/[6T\,'2O[G \I--
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MDW,,.,3(C#H4A,-<I)ER;>=V1,;4UE:-FE&KYT5D-34X1E97]X9NQP#M9MM
M, W,E[T0\FKI=@*#7BW=CCUSM)9N)XS:;>EVZM*^3=]7K%@H^9Z5=GU9M9$
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M9E$*"$HIX%Q0E),\3U7J&@BU]_2I45:K8+T"<(_8V0>MFVO.AF)@+ME%H4<
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M4I T@SD$.1+([#]3#$A"),AUS%B2(H-WXK?]"(7X.)N%U\#<;7D?"L>!R?E
M(^^+Z&VI9+&*;,FE=>GHZ"?K<R@K-@]8.LL%H] ==8\+'+N7[DG3#W31/7U/
M3U(W+\4G\YI<?B^JF1:2Y%+%@)(, YR2##"J8R"5IDAB&X7K541Y]^%3(^VZ
M>:)5+OK-JN?;@GL7-D=>Z G&P#S@C(/_1W[ X+ ?]:Z <3_B Z;M?;2'KNGW
MD7Y<+FZN57GW3O'53$J8$H61F?F9 &;;A0#!F ",*,PTQ4PDPB=E?_?A7A_I
M"'GWGY8K547W[,E.3WY?Z#/,W+[0OD@,_(5:M8"AQ+O(*A;N^SQD;M#O\YF
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MG@]B4$;KH<:H1-<?II?\=\:3_/,R+IL]U'7)I/K2'']5FR,#JF&:"PR4T!G
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MG/AV4-3(.6]=YNZGNW5>W>_C7S?:^Z+*>CNT;6R<I)211#'SZ4,),.)FNY%
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M++*Z#I#'[HA+6$_W"9GC.K[= -CS@SO>UH]6ZF3$S_I%;M'3RXK:.J&8(Y0
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M;PHSHW9]NBI6KFIV=M3NF\RWW"?OFFS7]NQ3VSLQGN1_;#]-0_H_V.N_1PF
MV$Y(5@H@VG#2;<B9%U2&N>" 0U@"K/(<"*X,X%P*0I! L(A*4;Q@9VHC1+-?
M-D^\PWC=QN*$B#A^(S;5YN&8>X:3V"J,W"&\D@?>5AJ,^X./_0$=))A06R!
M(6$ &R: 5$(" Z'01!:*D2*&!R[8F1H/U&YFAX.\OL>@EW -(X0$: U,"'V
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MMQE^G@3Q "@NYHF'W-N/F$ZWV9[NQ.UVZ.H=VUDNA"""$U"6N5M96<F Q,0
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MNS%L)3QBYPP\;-1?T:.F9(^2<FZR]W57N";Y4]UUO28^:I6OR5:W*]WZ-A'
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MI@%N\$EA#\QZS/^ZP4@\XVLQ./(<K[OII[.Z@'NNKJ_L2[W4&^2S$BFNH*0
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MV+L861SR%E.,%<% F4H2""$@"D& ,&Z!FPLF-(4S]R2Y>G;LC[T8&OV_FD8
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M:>'?0YQQR,Y-IO,XJ),C3RVJ/_YI-I7 2'58G<\,*A5A!0)<J1)@4Y2 &2(
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M0UHLF'*LP3%& +.B )S4]5<845B691%9>N6"I:E-4HX=C2VO<@G,,*)( M'
M+''LXTWVR,N4=54Z@$A<7>62M9%KK'0T^K322M<-_42G1*/R<HA .!SJ*(-4
M*7D!+(808*7<ZH5+"S1B5GO!%B%(C/Q4BZWI\8+<UN<VU:K^:&\]3FRI#=YV
MGD@,VN!,\0BO@[-AL4;1V,5)5B7"<$SQJOY81@M9!:#3(6G5]H11Q:T"FO)4
MYBKDEKX[0YOM!_N/U4K[X[G/9OU]KLSFLULESH2"AA?<K92I0KZHB)MJ*:0
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M=,GB,R@S=33^O")3UTW]".53?4C]R:C5U^7</[:NB#6S%!N1YP0(R#G )8%
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M*Q:^83?9[9T__&@^Y<B#TV'>@%@^?:9^'6,*.6B77D') T ^$(NG]/29B'\
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M;USI[NZ&G^AV!]S2CSS>+K^[:>UJ_=-OWU33HD]F8];?S6:&((%4F!(PHG*
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MK'RI\"V!*_#OWE09!]6A]VFK1AQGGQ[<K.I!';7D_%6C]$;X)LXXO3+21L^
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M5[7Y;)%^F2\R+LA>;%X7%NF69J]C]?P3OWX/"WH0I*_3D[SYZVHXAM#5:CZ
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MW\]>3I??SW.\[\MYOUB5-)8@)/C*PKK5O5,L@D#. @^6L497UQ\D:]P"F3:
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MY-3LX>J]O^?='K+N "SW3%(Y9T;8+$@Z#ABM*MK/*93PP2APB+P(3[&,RDV
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M4J^.?YTD1Z)TME8 )E][/<DJ3 5>6B/0I^P;=;2\2L6X!G5\3#PPGW<G!74
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M@Q2Q")]DF_88^]';6_N8(\%S<%7VC-N-_?\0?JZO,2Q"Q@F+3D?M$9 S3SL
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M@3C(?& RQS:W^>ZG:3N8/;5S@(%TT &:+NXDWC+7(1:NG8;@ZK@:CN0X"%7
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MTMX=+$Z2C"P&AB!MJ>6*SH'3HH#.CLD<=&:VS0'Q0U2-'$D?%8"#:6=OO/W
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MAO%](2HP5W[>OGG^_N,FDO-,Q\(,%$W\D,G4$,AN5NN;2C3.:=8F\[85>?T
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M]60!E"1Q.*1?DLTE:I%1I$8AY;B$3-MUVIDZG L0,]"'9ZAT,5AK*:@WJ4X
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M<%=CSB01D%QZR!B5\<7&DIN7P?1PM9TJVV\6- ]A= =(&<=<W[UKL\@+9H[
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MIVFF]>(C:LWT4.GAHAD^$0"E93K&0C=Y+G23&P3OK #%558A9T;.ZM\#(#H
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M*:_2UHX43#%8[L&&6H'AZ7(.F1?PSJA0='!:3_1$>RIILZ\T[NX*.AHXO5Q
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M=&5D<W1O8VMU+FAT;5!+ 0(4 Q0    ( 'V-85./GN.!1R@  -PR 0 >
M          "  3H8  !A,3 R;F]N+65M<&QO>65E9&ER96-T;W)S9"YH=&U0
M2P$"% ,4    " !]C6%3W09</?0'  !Q)@  %               @ &]0
M<3,R,#(Q97AH:6)I=#,Q,2YH=&U02P$"% ,4    " !]C6%3@PR3HO\'  !S
M)@  %               @ 'C2   <3,R,#(Q97AH:6)I=#,Q,BYH=&U02P$"
M% ,4    " !]C6%3Q8/EL4,$   ($   %               @ $440  <3,R
M,#(Q97AH:6)I=#,R,2YH=&U02P$"% ,4    " !]C6%3/2_H'DL$  #N#P
M%               @ &)50  <3,R,#(Q97AH:6)I=#,R,BYH=&U02P$"% ,4
M    " !]C6%3P&EZ&C\7 @"(UQ@ $               @ $&6@  =FUD+3(P
M,C$P.3,P+FAT;5!+ 0(4 Q0    ( 'V-85-T16HSJPP  'Z"   0
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K '9M9"TR,#(Q,#DS,%]P<F4N>&UL4$L%!@     ,  P ) ,  +D#!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
